<SEC-DOCUMENT>0001213900-24-028003.txt : 20240329
<SEC-HEADER>0001213900-24-028003.hdr.sgml : 20240329
<ACCEPTANCE-DATETIME>20240329163210
ACCESSION NUMBER:		0001213900-24-028003
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240329
DATE AS OF CHANGE:		20240329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		24804473

	BUSINESS ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431
		BUSINESS PHONE:		561-961-1900

	MAIL ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ea0201465-10k_therapeu.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 29 20:06:18 UTC 2024 -->
<html xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:txmd="http://www.therapeuticsmd.com/20231231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-10859">10-K</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Mark One)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" id="ixv-10860">&#9746;</ix:nonNumeric>
</span><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-10861"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-10862">December
31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-10863">2023</ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-10864">&#9744;</ix:nonNumeric>
</span><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the transition period from
<span style="text-decoration:underline">_____</span> to <span style="text-decoration:underline">_____</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Commission File Number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-61"><b>001-00100</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; width: 100%"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-74"><b>THERAPEUTICSMD, INC.</b></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-size: 10pt">(Exact name of Registrant as specified in its Charter)</span></td></tr>
</table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-85"><span style="font-size: 10pt"><b>Nevada</b></span></ix:nonNumeric></td> <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-90"><span style="font-size: 10pt"><b>87-0233535</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction<br/>
of incorporation or organization)</span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">(I.R.S. Employer<br/> Identification No.)</span></td></tr>
</table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-10865">951 Yamato Road</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-10866">Suite 220</ix:nonNumeric></b></span></td> <td style="width: 1%">&#160;</td> <td style="width: 49%; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-10867">Boca Raton</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-10868">Florida</ix:nonNumeric></b></span></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-117"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>33431</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-10869">561</ix:nonNumeric>-<ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-10870">961-1900</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Securities registered pursuant to Section 12(b)
of the Act:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Each Class</span></td> <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading symbol</span></td> <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-153"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock, par value $0.001 per share</b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-158"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TXMD</b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-163"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The Nasdaq Stock Market
LLC</b></span></ix:nonNumeric></td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Securities registered pursuant to Section 12(g) of the
Act: None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-10871">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark if the registrant is not required to
file reports pursuant to Section 13 or Section 15(d) of the Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-10872">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the
past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-10873">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-10874">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>
No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging
growth company&#8221; in Rule 12b-2 of the Exchange Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 11%">&#160;</td> <td style="width: 25%"><span style="font-size: 10pt">Large Accelerated Filer</span></td> <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 22%"><span style="font-size: 10pt">Accelerated filer</span></td> <td style="width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-216"><span style="font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td><span style="font-size: 10pt">Smaller reporting company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-223"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td><span style="font-size: 10pt">Emerging growth company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-230"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td> <td>&#160;</td> <td>&#160;</td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant has filed a report
on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section
404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-243"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">If securities are registered pursuant to Section 12(b) of the
Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error
to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-249"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether
any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of
the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act). Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span> No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-261"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2023, the registrant&#8217;s most recently completed second
fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to
the market price at which the common equity was last sold was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityPublicFloat" scale="0" unitRef="usd" id="ixv-10875">34,439,072</ix:nonFraction>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of March 27, 2024, there were outstanding <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-10876">11,532,443</ix:nonFraction> shares of the registrant&#8217;s
common stock, par value $0.001 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Documents Incorporated by Reference</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="ixv-279"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Part III (Items 10, 11, 12, 13 and 14) of this annual report on Form
10-K is incorporated by reference from the definitive Proxy Statement for the 2024 Annual Meeting of Stockholders or an amendment to this
annual report on Form 10-K to be filed with the Securities and Exchange Commission no later than 120 days after the end of the registrant&#8217;s
fiscal year covered by this report.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 6%; text-align: center">&#160;</td>
    <td style="width: 8%; text-align: left">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 78%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part I</span></a></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    factors</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved
    staff comments</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1C.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#Kalai_001">Cybersecurity</a></td>
    <td style="vertical-align: bottom; text-align: center">31</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    proceedings</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine
    safety disclosures</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part II</span></a></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    for registrant&#8217;s common equity, related stockholder matters, and issuer purchases of equity securities</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserved</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s
    discussion and analysis of financial condition and results of operations</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative
    and qualitative disclosures about market risk</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial statements and supplementary data</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in and disagreements with accountants on accounting and financial disclosure</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls
    and procedures</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    information</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9C.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
    regarding foreign jurisdictions that prevent inspections</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part III</span></a></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors,
    executive officers and corporate governance</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    compensation</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security
    ownership of certain beneficial owners and management and related stockholder matters</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    relationships and related transactions, and director independence</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    accountant fees and services</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Part IV</span></a></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits
    and financial statement schedules</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    10-K summary</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Part I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 1. Business</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Throughout this Annual Report on Form 10-K (&#8220;2023
10-K Report&#8221;), the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;TherapeuticsMD,&#8221; &#8220;the Company,&#8221;
or &#8220;our company&#8221; refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly
owned subsidiaries vitaMedMD, LLC, a Delaware limited liability company (&#8220;vitaMed&#8221;), and BocaGreenMD, Inc., a Nevada corporation
(&#8220;BocaGreen&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">TherapeuticsMD owns or has rights to trademarks,
service marks, or trade names that were previously used in connection with the operation of its business, or are now licensed by another
party, including TherapeuticsMD&#174;, vitaMedMD&#174;, BocaGreenMD&#174;, vitaCareTM, BIJUVA&#174;, and IMVEXXY&#174;, which are protected
under applicable intellectual property laws and are the property of the Company. This 2023 10-K Report also contains trademarks, trade
names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade
names and service marks referred to in this 2023 10-K Report may appear without the &#174;, &#8482; or SM symbols, but such references
are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right
of the applicable licensor to these trademarks, trade names, and service marks. We do not intend our use or display of other parties&#8217;
trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement
or sponsorship of us by, these other parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">In addition, this 2023 10-K Report includes
market and industry data that we obtained from periodic industry publications, third-party studies and surveys, government-agency sources,
filings of public companies in our industry, and internal-company surveys. Industry publications and surveys generally state that their
information has been obtained from sources believed to be reliable. Although we believe that the industry and market data below is reliable
as of the date of this 2023 10-K Report, this information could prove to be inaccurate as a result of a variety of matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Forward-looking statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">This 2023 10-K Report contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial
risks and uncertainties. For example, statements regarding our operations, financial position, business strategy, and other plans and
objectives for future operations, and assumptions and predictions about future demand, marketing, expenses and sales are all forward-looking
statements. These statements may be found in the items of this 2023 10-K Report entitled &#8220;Business&#8221; and &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as in this 2023 10-K Report generally. These
statements are generally accompanied by words such as &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221;
&#8220;potential(ly),&#8221; &#8220;continue,&#8221; &#8220;forecast,&#8221; &#8220;predict,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; or the negative of such terms
or other comparable terminology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">We have based these forward-looking statements
on our current expectations and projections about future events. We believe that the assumptions and expectations reflected in such forward-looking
statements are reasonable, based on information available to us on the date of this 2023 10-K Report, but we cannot assure you that these
assumptions and expectations will prove to have been correct or that we will take any action that we may presently be planning. These
forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ
materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences
include, but are not limited to, competition from other businesses, market and general economic factors, and the other risks discussed
in Item 1A of this 2023 10-K Report. This discussion should be read in conjunction with the consolidated financial statements and notes
thereto included in this 2023 10-K Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">We have identified some of the important factors
that could cause future events to differ from our current expectations and they are described in this 2023 10-K Report in the section
entitled &#8220;Risk Factors&#8221; that you should review carefully. Please consider our forward-looking statements in light of those
risks as you read this 2023 10-K Report. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions
prove to be incorrect, actual results may vary materially from what we project. We do not undertake to update any forward-looking statements
or to publicly announce the results of any revisions to any statements to reflect new information or future events or developments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Our company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">TherapeuticsMD was previously a women&#8217;s
healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy
prevention through menopause. In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving
royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. On December
30, 2022 (the &#8220;Closing Date&#8221;), we completed a transaction (the &#8220;Mayne Transaction&#8221;) with Mayne Pharma LLC, a
Delaware limited liability company (&#8220;Mayne Pharma&#8221;) and subsidiary of Mayne Pharma Group Limited, an Australian public company,
in which we and our subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize our IMVEXXY, BIJUVA and prescription
prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the &#8220;Licensed Products&#8221;) in the
United States and its possessions and territories, (ii) assigned to Mayne Pharma our exclusive license to commercialize ANNOVERA&#174;
(together with the Licensed Products, collectively, the &#8220;Products&#8221;) in the United States and its possessions and territories,
and (iii) sold certain other assets to Mayne Pharma in connection therewith.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">In a License Agreement, dated December 4, 2022,
between TherapeuticsMD and Mayne Pharma (the &#8220;Mayne License Agreement&#8221;), we granted Mayne Pharma, on the Closing Date, (i)
an exclusive, sublicensable, perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell,
use, and commercialize the Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable,
perpetual, irrevocable license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States
for commercialization in the United States and its possessions and territories.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Under the Mayne License Agreement, Mayne
Pharma will pay us one-time milestone payments of each of (i) $5.0 million if aggregate net sales of all Products in the United
States during a calendar year reach $100.0 million, (ii) $10.0 million if aggregate net sales of all Products in the United States
during a calendar year reach $200.0 million and (iii) $15.0 million if aggregate net sales of all Products in the United States
during a calendar year reach $300.0 million. Further, Mayne Pharma will pay us royalties on net sales of all Products in the United
States at a royalty rate of 8.0% on the first $80.0 million in annual net sales and 7.5% on annual net sales above $80.0 million,
subject to certain adjustments, for a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a
Product-by-Product basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and
(ii) a generic version of a Product launching in the United States. Mayne Pharma will pay us minimum annual royalties of $3.0
million per year for 12 years, adjusted for inflation at an annual rate of 3%, subject to certain further adjustments, including as
described below (the &#8220;Minimum Annual Royalty&#8221;). Upon the expiry of the 20-year royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement
will become a fully paid-up and royalty free license for the Licensed Products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Under the Transaction Agreement, dated December
4, 2022, between TherapeuticsMD and Mayne Pharma (the &#8220;Transaction Agreement&#8221;), we sold to Mayne Pharma, at closing, certain
assets for Mayne Pharma to commercialize the Products in the United States, including, with the Population Council&#8217;s consent, our
exclusive license from the Population Council to commercialize ANNOVERA (the &#8220;Transferred Assets&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The total consideration from Mayne Pharma
to TherapeuticsMD for the purchase of the Transferred Assets under the Transaction Agreement and the grant of the licenses under the
Mayne  License Agreement was (i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million
at closing for the acquisition of net working capital as determined in accordance with the Transaction Agreement and subject to
certain adjustments, (iii) a cash payment of approximately $1.0 million at closing for prepaid royalties in connection with the
Mayne License Agreement Amendment (as defined below) and (iv) the right to receive the contingent consideration set forth in the
Mayne License Agreement, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On the Closing Date, TherapeuticsMD and Mayne Pharma entered into Amendment
No. 1 to the Mayne License Agreement (the &#8220;Mayne License Agreement Amendment&#8221;). Pursuant to the Mayne License Agreement Amendment,
Mayne Pharma agreed to pay us approximately $1.0 million in prepaid royalties on the Closing Date. The prepaid royalties reduced the first
four quarterly payments that would have otherwise been payable pursuant to the Mayne License Agreement by an amount equal to $257 thousand
per quarterly royalty payment plus interest calculated at 19% per annum accruing from the Closing Date until the date such quarterly royalty
payment was paid to us. We and Mayne Pharma settled the $1.5 million of consideration due to Mayne Pharma for the assumed obligations
under a long-term services agreement (see the section entitled &#8220;vitaCare divestiture&#8221; below for a discussion of the long-term
services agreement), including our minimum payment obligations thereunder. As the parties agreed, Mayne Pharma reduced the second quarterly
royalty payment otherwise payable to us by an additional $0.6 million, and in August 2023 we remitted the remaining consideration of
$0.9 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">Mayne Pharma paid us approximately $12.1 million at closing on the Closing Date for the acquisition of net working capital, subject to certain adjustments as determined in accordance with the Transaction
Agreement. While the Transaction Agreement calls for much of the net working capital to be trued-up shortly after the Closing Date in
2023, for a period of one year following the Closing Date in the case of payer rebates and wholesale distributor fees and two years
following the Closing Date in the case for allowance for returns, net working capital amounts will be adjusted to arrive at final net
working capital under the Transaction Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2023, we revised certain accrual estimates including increasing
our working capital adjustment accrual from $3.5 million to $5.5 million for amounts anticipated to be owed under the Transaction Agreement.
In December 2023, we made a $5.5 million payment to Mayne Pharma to settle certain working capital amounts that were required to be trued-up
shortly after the Closing Date, excluding the allowance for returns, allowance for payer rebates, and allowance for wholesale distributor
fees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2024, the Company received Mayne Pharma&#8217;s
                                                                                               calculation of allowance for payer rebates and wholesale distributor fees which differed significantly from the Company&#8217;s
                                                                                               estimate of the allowances. The Company believes its estimated allowances for payer rebates and wholesale distributor fees are
                                                                                               reasonable and intends to resolve this matter through the process outlined in the Transaction Agreement. Given the recent receipt of
                                                                                               Mayne Pharma&#8217;s allowance calculation and the nature of the estimates involved, the outcome of this matter is uncertain at this
                                                                                               point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any
                                                                                               additional liability associated with Mayne Pharma&#8217;s allowance calculation for payer rebates and wholesale distributor
                                                                                               fees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, the Company believes no additional accrual
is required for amounts that may be owed for the allowance for returns under the Transaction Agreement. The Company has not recorded any
contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital
items as changes to estimated amounts owed or amounts due from Mayne Pharma that may be material.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">As part of the transformation that included the Mayne License Agreement,
historical results of commercial operations for all periods prior to the Closing Date have been reflected as discontinued operations in
our consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities
of discontinued operations in our consolidated balance sheets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">See Note 2 - Discontinued Operations to the
consolidated financial statements included in this Annual Report on Form 10-K for further details.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The Company also has license agreements with
strategic partners to commercialize IMVEXXY and BIJUVA outside of the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: .25in"/><td style="width: .25in">&#9679;</td><td>In July 2018, we entered into a license and supply agreement (the
                                            &#8220;Knight License Agreement&#8221;) with Knight Therapeutics Inc. (&#8220;Knight&#8221;)
                                            pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA
                                            in Canada and Israel.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: .25in"/><td style="width: .25in">&#9679;</td><td>In June 2019, we entered into an exclusive license and supply
                                            agreement (the &#8220;Theramex License Agreement&#8221;) with Theramex HQ UK Limited (&#8220;Theramex&#8221;)
                                            to commercialize IMVEXXY and BIJUVA outside of the U.S., excluding Canada and Israel. In
                                            2021, Theramex secured regulatory approval for BIJUVA in certain European countries and began
                                            commercialization efforts in those countries.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">In connection with our transformation into a
pharmaceutical royalty company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel
and current Chief Executive Officer) and all other employees was completed by December 31, 2022. Severance obligations for all employees
other than executive officers were paid in full in January 2023 and severance obligations for terminated executive officers were paid
in accordance with their employment agreements and separation agreements as previously disclosed. As of December 31, 2023, we employed
one full-time employee primarily engaged in an executive position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">We have engaged external consultants who support our relationship with
current partners and assist with certain financial, legal, and regulatory matters and the continued wind-down of our historical business
operations. On August 15, 2023, we entered into a master services agreement with JZ Advisory Group, pursuant to which Joseph Ziegler would
serve as our Principal Financial and Accounting Officer. On August 17, 2023 Michael C. Donegan notified us of his decision to resign from
the positions of Principal Financial and Accounting Officer of our Company effective as of August 17, 2023. Mr. Ziegler succeeded Mr.
Donegan as Principal Financial and Accounting Officer as of the date of Mr. Donegan&#8217;s resignation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>vitaCare divestiture</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On April 14, 2022, we completed the divestiture
of our former subsidiary vitaCare Prescription Services, Inc. (&#8220;vitaCare&#8221;) with the sale of all of vitaCare&#8217;s issued
and outstanding capital stock (the &#8220;vitaCare Divestiture&#8221;). We received net proceeds of $142.6 million, after deducting transaction
costs of $7.2 million, and we recognized a gain on sale of business of $143.4 million. Included in the net proceeds amount was $11.3
million of customary holdbacks as provided in the stock purchase agreement (the &#8220;Purchase Agreement&#8221;) which we received in
2023. Additionally, the Purchase Agreement provides that we may receive up to an additional $7.0 million in earn-out consideration, contingent
upon vitaCare&#8217;s financial performance through 2023 as determined in accordance with the terms of the Purchase Agreement; however,
we do not believe this earnout will be realized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The Purchase Agreement contains customary representations
and warranties, covenants, and indemnities of the parties thereto. The commitments under a long-term services agreement related to vitaCare
were transferred to Mayne Pharma as part of the Mayne Transaction. </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The divestiture of vitaCare was determined to
be a component of discontinued operations in December 2022, when we changed our business by becoming a royalty company and as a result
vitaCare activities were reclassified to discontinued operations for the years ended December 31, 2023 and 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Going concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On the Closing Date of the
Mayne Transaction, we repaid all obligations under the Financing Agreement, dated as of April 24, 2019, as amended, with Sixth Street
Specialty Lending, Inc., as administrative agent, the various lenders from time-to-time party thereto, and certain of our subsidiaries
party thereto from time to time as guarantors (the &#8220;Financing Agreement&#8221;) and the Financing Agreement was terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Following the transaction with Mayne
Pharma, our primary source of revenue is from royalties on products licensed to pharmaceutical organizations that possess commercial
capabilities in the relevant territories. We may need to raise additional capital to provide additional liquidity to fund our
operations until we become cash flow positive. To address our capital needs, we may pursue various equity and debt financing and
other alternatives. The equity financing alternatives may include the private placement of equity, equity-linked, or other similar
instruments or obligations with one or more investors, lenders, or other institutional counterparties or an underwritten public
equity or equity-linked securities offering. Our ability to sell equity securities may be limited by market conditions, including
the market price of our common stock and our available authorized shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">To the extent that we raise additional capital
through the sale of such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new
securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we are not
successful in obtaining additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable
prices, or merge, consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable
to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On May 1, 2023, we entered into a
Subscription Agreement (the &#8220;Subscription Agreement&#8221;) with Rubric Capital Management LP (&#8220;Rubric&#8221;), pursuant
to which we agreed to sell to Rubric, or one or more of its affiliates, up to an aggregate of 5,000,000 shares of our common stock,
par value $0.001 per share (our &#8220;Common Stock&#8221;), from time to time during the term of the Subscription Agreement at a
purchase price of the five-day volume-weighted average price of the Common Stock at the time of the sale of such shares of Common
Stock, at an aggregate purchase price of up to $5,000,000. On June 29, 2023, we issued and sold 312,525 shares of Common Stock at a
price per share equal to $3.6797 pursuant to the Subscription Agreement. We received gross proceeds of $1.15 million from the draw
down, before expenses. On November 15, 2023 Rubric drew down an additional 877,192 shares of Common Stock at a price per share equal
to $2.2761. We received gross proceeds of $2.0 million from the drawdown, before expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2024, the Company received Mayne Pharma&#8217;s
                                                                                               calculation of allowance for payer rebates and wholesale distributor fees pursuant to the Transaction Agreement which differed
                                                                                               significantly from the Company&#8217;s estimate of the allowances. The Company believes its estimated allowances for payer rebates
                                                                                               and wholesale distributor fees are reasonable and intends to resolve this matter through the process outlined in the Transaction
                                                                                               Agreement. Given the recent receipt of Mayne Pharma&#8217;s allowance calculation and the nature of the estimates involved, the
                                                                                               outcome of this matter is uncertain at this point. As a result, the Company cannot reasonably estimate a range of loss, and
                                                                                               accordingly, the Company has not accrued any additional liability associated with Mayne Pharma&#8217;s allowance calculation for
                                                                                               payer rebates and wholesale distributor fees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, the Company believes no additional accrual
is required for amounts that may be owed for the allowance for returns under the Transaction Agreement. The Company has not recorded any
contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital
items as changes to estimated amounts owed or amounts due from Mayne Pharma may be material.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">If Mayne Pharma&#8217;s sales of Licensed
Products grow more slowly than expected or decline, if the net working capital settlement with Mayne Pharma under the Transaction
Agreement is greater than our current estimates, if we are unsuccessful with future financings or the supply chains related to the
third-party contract manufacturers are worse than we anticipate, our existing cash reserves may be insufficient to satisfy our
liquidity requirements. The potential impact of these factors in conjunction with the uncertainty of the capital markets raises
substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The accompanying consolidated financial statements
do not include any adjustments that might be necessary if we are unable to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Portfolio of our royalty-bearing products</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On December 30, 2022, we changed our
business to become a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical
organizations that possess commercial capabilities in the relevant territories. On December 30, 2022, we granted an exclusive
license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands
and assigned our exclusive license to commercialize ANNOVERA to Mayne Pharma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration:underline">IMVEXXY (estradiol vaginal inserts), 4-&#956;g
and 10-&#956;g</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">This pharmaceutical product is for the treatment
of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due to menopause.
As part of the FDA&#8217;s approval of IMVEXXY, we committed to conduct a post-approval observational study to evaluate the risk of endometrial
cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On December 30, 2022, we granted an exclusive
license to commercialize IMVEXXY in the United States and its possessions and territories to Mayne Pharma. We also have entered into
licensing agreements with third parties to market and sell IMVEXXY outside of the U.S. We entered into the Knight License Agreement,
with Knight pursuant to which, we granted Knight an exclusive license to commercialize IMVEXXY in Canada and Israel. We entered into
the Theramex License Agreement with Theramex pursuant to which we granted Theramex an exclusive
license to commercialize IMVEXXY for human use outside of the U.S., except for Canada and Israel. As of December 31, 2023, no IMVEXXY
sales had been made through the Theramex and Knight licensing agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The FDA has also asked the sponsors of other
vaginal estrogen products to participate in the observational study. In connection with the observational study, we would have been required
to provide progress reports to the FDA on an annual basis. The obligation to conduct this study was transferred to Mayne Pharma as part
of the Mayne License Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration:underline">BIJUVA (estradiol and progesterone) capsules,
1 mg/100 mg</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">This pharmaceutical product is the first and
only FDA approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment
of moderate-to-severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On December 30, 2022, we granted an exclusive
license to commercialize BIJUVA in the United States and its possessions and territories to Mayne Pharma. We also have entered into the
Knight License Agreement with Knight pursuant to which we granted Knight an exclusive license to commercialize BIJUVA in Canada and Israel.
We have entered into the Theramex License Agreement with Theramex pursuant to which we granted Theramex an exclusive license to commercialize
BIJUVA for human use outside of the U.S., except for Canada and Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration:underline">ANNOVERA (segesterone acetate (&#8220;SA&#8221;)
and ethinyl estradiol (&#8220;EE&#8221;) vaginal system)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On December 30, 2022, we assigned our exclusive
license to commercialize ANNOVERA to Mayne Pharma. This pharmaceutical product is a one-year ring-shaped contraceptive vaginal system
(&#8220;CVS&#8221;) and the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent
pregnancy for up to a total of 13 cycles (one year). ANNOVERA is commercially sold in the U.S. pursuant to the terms of the Population
Council License Agreement. As part of the approval of ANNOVERA, the FDA has required a post-approval observational study be performed
to measure the risk of venous thromboembolism. We agreed to perform and pay the costs and expenses associated with this post-approval
study, provided that if the costs and expenses associated with such post-approval study exceed $20.0 million, half of such excess will
offset against royalties or other payments owed by us under the Population Council License Agreement. In August 2021, we filed a supplemental
New Drug Application (&#8220;NDA&#8221;) with the FDA to modify the testing specifications for ANNOVERA to allow increased consistency
of supply of ANNOVERA. In May 2022, the FDA approved the supplemental NDA for ANNOVERA. Our obligations to perform the post-approval
study have been transferred to Mayne Pharma as part of the Mayne License Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration:underline">Prenatal vitamin products</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On December 30, 2022, we granted an exclusive
license to commercialize, in the United States and its possessions and territories, our prescription prenatal vitamin product lines under
our vitaMedMD brand name and authorized generic formulations of some of our prescription prenatal vitamin products under our BocaGreenMD
prenatal name to Mayne Pharma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Sales concentration</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Our business model is dependent on third parties
achieving specified milestones and product sales. For information on the concentration of licenses of our products, see &#8220;Note 10.
Revenue&#8221; to the consolidated financial statements included in this 2023 10-K Report. Currently, the Company collects license revenue
from two licensees.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Seasonality</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The pharmaceutical markets in which we license
our products are not subject to seasonal sales fluctuations. However, our license revenues for the first quarter of each year can be
negatively affected by the annual reset of high-deductible commercial insurance plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Manufacturing of our licensed products</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">As of December 30, 2022, we were no longer responsible for any manufacturing
and have no manufacturing contracts. All manufacturing responsibility of our licensed products has been transferred to our licensees.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Research and development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">As of December 30, 2022, we no longer
conduct any research and development activities. Historically, our product development programs were concentrated in advanced
hormone therapy pharmaceutical products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Intellectual property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Patents and trademarks</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Our success depends, in part, on our ability
to obtain patents, maintain trade-secret protection, and operate without infringing the proprietary rights of others. Our intellectual
property portfolio is one way we attempt to protect our competitive position. We rely primarily on a combination of know-how, trade secrets,
patents, trademarks, and contractual restrictions to protect our products and to maintain our competitive position. We are diligently
seeking ways to protect our intellectual property through various legal mechanisms in relevant jurisdictions. Where permitted, patents
for our hormone therapy drug products have been submitted to the Orange Book.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">As of December 31, 2023, we have many domestic and foreign patents that cover our licensed products,
including many for each of BIJUVA and IMVEXXY that are Orange Book listed for the licensed products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">We hold multiple U.S. trademark registrations
and have numerous pending trademark applications. Issuance of a federally registered trademark creates a rebuttable presumption of ownership
of the mark; however, it is subject to challenge by others claiming first use in the mark in some or all the areas in which it is used.
Federally registered trademarks have a perpetual life so long as they are maintained and renewed on a timely basis and used properly
as trademarks, subject to the rights of third parties to seek cancellation of the trademarks if they claim priority or confusion of usage.
We believe our patents and trademarks are valuable and provide us certain benefits in marketing our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">We intend to actively protect our intellectual
property with patents, trademarks, trade secrets, or other legal avenues for the protection of intellectual property and to aggressively
prosecute, enforce, and defend our patents, trademarks, and proprietary technology, including those licensed by Mayne Pharma, Knight
and Theramex with our licensees to the extent permitted under their respective license agreements. The loss, by expiration or otherwise,
of any one patent may have a material effect on our business. Defense and enforcement of our intellectual property rights can be expensive
and time consuming, even if the outcome is favorable to us. It is possible that the patents issued or licensed to us will be successfully
challenged, that a court may find that we are infringing on validly issued patents of third parties, or that we may have to alter or
discontinue the development of our products or pay licensing fees to account for patent rights of third parties. See &#8220;&#8211; Pharmaceutical
Regulation &#8211; Regulatory Exclusivity&#8221; below for information regarding our intellectual property and challenges to that intellectual
property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">While we seek broad coverage under our patent
applications, there is always a risk that an alteration to the process may provide sufficient basis for a competitor to avoid infringement
claims. In addition, patents expire, and we cannot provide any assurance that any patents will be issued from our pending application
or that any potentially issued patents will adequately protect our intellectual property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Mayne Pharma licensed US patents and trademarks
for our commercial products. Under the terms of the Mayne License Agreement, Mayne Pharma exclusively took over prosecution of our US
patent and trademark portfolio and enforcement of our licensed patents and trademarks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Government regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">In the U.S., the FDA regulates pharmaceuticals,
biologics, medical devices, dietary supplements, and cosmetics under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and
its implementing regulations. These products are also subject to other federal, state, and local statutes and regulations, including
federal and state consumer protection laws, laws regarding pricing transparency, laws requiring the implementation of compliance programs,
laws requiring the reporting of payments or other transfers of value to HCPs or other healthcare professionals, laws governing the financial
relationships between manufacturers and HCPs or other referral sources and industry stakeholders, laws protecting the privacy of health-related
information, laws restricting items and services of value provided to patients, and laws prohibiting unfair and deceptive acts and trade
practices. See also Item 1A. Risk Factors &#8211; &#8220;Risks related to our business&#8221; for a discussion, among other things, of
the extensive and costly governmental regulation we are subject to.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Pharmaceutical regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The process required by the FDA before a new
drug product may be marketed in the U.S. generally involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>completion of or reference to extensive preclinical laboratory
                                            tests and preclinical animal studies, all performed in accordance with the FDA&#8217;s Good
                                            Laboratory Practice, or GLP, regulations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>submission to the FDA of an investigational new drug (&#8220;IND&#8221;)
                                            application under which the holder may begin conducting human clinical trials, provided that
                                            the FDA does not object; the IND must be updated annually;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>performance of adequate and well-controlled human clinical trials
                                            to establish the safety and efficacy of the drug candidate for each proposed indication;
                                            and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>submission to the FDA of an NDA after completion of all pivotal
                                            clinical trials.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">An IND application is a request for authorization
from the FDA to administer an investigational drug product to humans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Post-Approval Regulation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Mayne Pharma is required to comply with several
post-approval requirements for our currently approved drug products. We no longer have responsibility for any post-approval requirements.
As the holder of an approved NDA, Mayne Pharma is required to report, among other things, certain adverse reactions and production problems
to the FDA, to provide updated safety and efficacy information, to adhere to product sampling and distribution requirements, fulfill
post-marketing study commitments, and to comply with requirements concerning advertising and promotional labeling for any of our drug
products, which include, among other things, standards for direct-to-consumer advertising, restrictions that prohibit promoting products
for certain uses or in patient populations that are not described in the product&#8217;s approved indications or that are not otherwise
consistent with the approved, FDA-required label (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific
and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally
available products for off-label use if they deem such use to be appropriate in their professional medical judgment, manufacturers may
not market or promote such off-label uses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Also, quality control and manufacturing procedures
must continue to conform to cGMPs to ensure and preserve the long-term stability of the drug product. cGMP regulations require among
other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation
to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of
approved products are, depending on the nature and scope of their activities, subject to FDA and certain state agency requirements relating
to establishing and maintaining product quality. Changes to the manufacturing process are strictly regulated, and, depending on the significance
of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of
any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide
to use. Accordingly, manufacturers must continue to expend time, money and effort in production and quality control to maintain compliance
with cGMP and other aspects of regulatory compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA periodically inspects manufacturing facilities to assess compliance
with cGMP, which imposes extensive procedural, substantive, and record keeping requirements. For example, Catalent, the CMO that contracted
for the commercial supply of the BIJUVA and IMVEXXY hormone therapy drug products, was issued a Form FDA 483 in 2019 with respect to its
soft gel manufacturing plant. The observations and associated corrective actions related to the BIJUVA product were identified in Catalent&#8217;s
response to the Form FDA 483. The current inspection classification status of that Form FDA 483 is that the response was adequate and
Voluntary Action Indicated. Voluntary Action Indicated status indicates that objectionable conditions or practices were found but the
FDA is not prepared to take or recommend any administrative or regulatory action.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Our licensees rely, and expect to continue to
rely, on third parties to produce commercial quantities of our licensed drugs. Future FDA and state inspections may identify compliance
issues at the facilities of the manufacturers of our licensed products that may disrupt production or distribution or require substantial
resources to correct. In addition, discovery of previously unknown problems (for example, through adverse events observed in the post-marketing
context, or in Phase 4/post-marketing studies) with a product or the failure to comply with applicable requirements may result in restrictions
on a product, manufacturer, or holder of an approved NDA, including withdrawal or recall of the product from the market or other voluntary,
FDA-initiated or judicial action that could delay or prohibit further marketing. Newly discovered or developed safety or effectiveness
data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and may
require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation,
may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Regulatory exclusivity</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">There are two types of NDAs available under
Section 505(b) of the FDCA. Section 505(b)(1) of the FDCA provides a marketing approval pathway that is known as the &#8220;traditional&#8221;
or &#8220;full&#8221; NDA process. Sponsors use 505(b)(1) applications to obtain marketing approval of a new drug with active ingredients
that have not previously been approved by FDA. The data package necessary for approval of this new drug requires demonstration of safety
and efficacy based on adequate and well controlled human clinical trials conducted by or for the sponsor, without allowance for reference
to third party data. In contrast, Section 505(b)(2) of the FDCA provides an alternative NDA process for approving a new drug that contains
the same active ingredient as a previously approved product but allows sponsors to rely on clinical trials not conducted by or for the
sponsor, as well as other clinical data or literature produced by other parties. In addition, Section 505(j) of the FDCA provides for
a significantly shortened regulatory pathway for approval of a &#8220;generic&#8221; version of a new drug, by way of an Abbreviated
New Drug Application or ANDA. Rather than demonstrating safety and effectiveness as required for an NDA, the ANDA requires proof that
the generic drug is the &#8220;same&#8221; as or &#8220;bioequivalent&#8221; to the new drug under the standard of &#8220;bioequivalence,&#8221;
often using pharmacokinetic, pharmacodynamic, and/or in vitro studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A Section 505(b) NDA applicant may be eligible
for its own regulatory exclusivity period, such as a five-year or three-year exclusivity. The first approved Section 505(b) NDA applicant
for a drug containing an active ingredient that has not previously been approved in any other 505(b) NDA (a &#8220;new chemical entity,&#8221;
or NCE), is eligible for a five-year NCE exclusivity period starting on the date of the NDA approval. An Abbreviated
New Drug Application (&#8220;ANDA&#8221;) or 505(b)(2) application for a drug containing the protected active ingredient of the NCE product
generally cannot be submitted to FDA until the end of the five-year exclusivity period, except that such applications can be submitted
at year four if the product is covered by an Orange Book listed patent and the ANDA or 505(b)(2) NDA includes a Paragraph IV Certification
challenging such patent. Additional exclusivities may also apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The first approved Section 505(b) NDA applicant
for a particular condition, or a supplemental NDA approval for a change to a marketed product, such as a new extended-release formulation
for a previously approved product, may be eligible for a three-year Hatch-Waxman exclusivity if one or more new clinical studies, other
than bioavailability or bioequivalence studies, was essential to the approval of the application and was conducted or sponsored by the
applicant. Should this occur, the FDA would be precluded from granting final approval to any ANDA or 505(b)(2) application for the same
condition of use or change to the marketed product that was granted exclusivity until after that three-year exclusivity period has run.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Additionally, any ANDA or 505(b)(2) NDA that
references the 505(b) product must include one of several types of patent certifications. If the Section 505(b) NDA drug has one or more
unexpired patents listed in the Orange Book, an ANDA or 505(b)(2) NDA must include either a &#8220;Paragraph III Certification&#8221;
or a &#8220;Paragraph IV Certification.&#8221; A Paragraph III Certification identifies the expiration date of the listed patent and
requires FDA to withhold final approval until that patent has expired. A &#8220;Paragraph IV Certification&#8221; states that, in the
applicant&#8217;s opinion, the relevant patent is invalid, unenforceable, or would not be infringed by the commercial marketing of the
proposed ANDA or 505(b)(2) NDA product. The sponsor of a Paragraph IV ANDA or 505(b)(2) NDA must also provide the holder of the marketed
product NDA, and the owner of the challenged patent, with notification of the Paragraph IV filing along with a detailed statement of
the reasons the applicant believes the patent is invalid, unenforceable, or would not be infringed. If the patent owner brings an infringement
action against the Paragraph IV applicant within 45 days of the notification, a statutory stay is imposed which prevents FDA from granting
final approval of the Paragraph IV application for 30 months from the date of the Paragraph IV Notification. Generally, no more than
one 30-month stay may be applied against any specific Paragraph IV ANDA or 505(b)(2) NDA. A 30-month stay can be terminated early, and
the Paragraph IV application can be immediately approved, if the district court rules in favor of the Paragraph IV applicant that the
patent is invalid, unenforceable, or would not be infringed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2020, we received a Paragraph IV certification notice letter
(the &#8220;IMVEXXY Notice Letter&#8221;) regarding an ANDA submitted to FDA by Teva Pharmaceuticals USA, Inc. (&#8220;Teva&#8221;). See
Legal Proceedings in Item 3 of this 2023 10-K Report for additional information.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">In March 2020, we received a Paragraph IV certification
notice letter (the &#8220;BIJUVA Notice Letter&#8221;) regarding an ANDA submitted to FDA by Amneal Pharmaceuticals (&#8220;Amneal&#8221;).
In April 2020, we filed a complaint for patent infringement against Amneal in the U.S. District Court for the District of New Jersey
arising from Amneal&#8217;s ANDA filing with FDA. In December 2021, we entered into a settlement agreement (the &#8220;Settlement Agreement&#8221;)
with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals of New York LLC (collectively &#8220;Amneal&#8221;)
to resolve the litigation over our patents listed in FDA&#8217;s Orange Book that claim compositions and methods of BIJUVA (the &#8220;BIJUVA
Patents&#8221;). Under the terms of the Settlement Agreement, the Company granted Amneal a non-exclusive, non-transferable, royalty-free
license to commercialize Amneal&#8217;s generic formulation of BIJUVA in the U.S. commencing in May 2032 (180 days before the current
expiration date in November 2032 for the last to expire of our BIJUVA Patents), or earlier under certain circumstances customary for
settlement agreements of this nature.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Other U.S. healthcare laws and compliance
requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain federal and state healthcare laws and
regulations pertaining to fraud and abuse and patients&#8217; rights, among other topics, are and will be applicable to our business.
Our licensees and the licensed products are subject to regulation by both the federal government and the states in which we or our partners
conduct our business. The healthcare laws and regulations that may affect our licensees&#8217; ability to operate and our ability to
receive licensing revenues include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the federal Anti-Kickback Statute, which prohibits, among other
                                            things, any person or entity from knowingly and willfully offering, soliciting, receiving
                                            or providing any remuneration (including any kickback, bribe or rebate), directly or indirectly,
                                            overtly or covertly, in cash or in kind, to induce either the referral of an individual or
                                            in return for the purchase, lease, or order of, or the arranging for, any good, facility
                                            item or service, for which payment may be made, in whole or in part, under federal healthcare
                                            programs such as the Medicare and Medicaid programs;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>federal civil and criminal false claims laws and civil monetary
                                            penalty laws, including, for example, the federal civil False Claims Act, which impose criminal
                                            and civil penalties, including civil whistleblower or qui tam actions, against individuals
                                            or entities for, among other things, knowingly presenting, or causing to be presented, to
                                            the federal government, including the Medicare and Medicaid programs, claims for payment
                                            that are false or fraudulent or making a false statement to avoid, decrease or conceal an
                                            obligation to pay money to the federal government;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the federal Health Insurance Portability and Accountability Act
                                            of 1996 (&#8220;HIPAA&#8221;), which created additional federal criminal statutes that prohibit
                                            knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
                                            benefit program or obtain, by means of false or fraudulent pretenses, representations or
                                            promises, any of the money or property owned by, or under the custody or control of, any
                                            healthcare benefit program, regardless of the payer (e.g., public or private), knowingly
                                            and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing
                                            a criminal investigation of a healthcare offense and knowingly and willfully falsifying,
                                            concealing or covering up by any trick or device a material fact or making any materially
                                            false statements in connection with the delivery of, or payment for, healthcare benefits,
                                            items or services relating to healthcare matters;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>HIPAA, as amended by the Health Information Technology for Economic
                                            and Clinical Health Act, and their implementing regulations, which impose obligations on
                                            covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses,
                                            as well as their respective business associates that create, receive, maintain or transmit
                                            individually identifiable health information for or on behalf of a covered entity, with respect
                                            to safeguarding the privacy, security and transmission of individually identifiable health
                                            information;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the federal physician sunshine requirements under the ACA, which
                                            require certain manufacturers of drugs, devices, biologics and medical supplies for which
                                            payment is available under Medicare or Medicaid to report annually to the Centers for Medicare
                                            &amp; Medicaid Services information related to payments and other transfers of value provided
                                            to physicians and teaching hospitals, and ownership and investment interests held by physicians
                                            and their immediate family members. In 2022, the Sunshine Act has been extended to payments
                                            and transfers of value to physician assistants, nurse practitioners, and other mid-level
                                            practitioners (with reporting requirements going into effect in 2022 for payments made in
                                            2021). In addition, Section 6004 of the ACA requires annual reporting of information about
                                            drug samples that manufacturers and authorized distributors provide to healthcare providers;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>federal and state laws requiring pricing transparency or limiting
                                            price increases, which are in existence today or are anticipated to be in existence in the
                                            near future, may limit the ability to raise prices, require disclosure of price increases
                                            or require disclosure of the wholesale acquisition cost of pharmaceutical products to governmental
                                            agencies and consumers; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>state law equivalents of each of the above federal laws, such
                                            as anti-kickback and false claims laws, which may apply to items or services reimbursed by
                                            any third-party payer, including commercial insurers or even self-pay; state laws that require
                                            pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance
                                            guidelines and the applicable compliance guidance promulgated by the federal government,
                                            or otherwise restrict payments that may be provided to healthcare providers and other potential
                                            referral sources; state laws that require drug manufacturers to report information related
                                            to payments and other transfers of value to healthcare providers or marketing expenditures;
                                            state laws requiring a license, registration or permit to engage in manufacturing and distribution
                                            of prescription products or to engage in the practice of pharmacy; and state laws governing
                                            the privacy and security of health information in certain circumstances, many of which differ
                                            from each other in significant ways and may not have the same effect, thus complicating compliance
                                            efforts.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Pharmaceutical company interactions with HCPs,
patient advocacy groups, and patients, including with respect to product and patient assistance programs and other education and support
initiatives, have been and continue to be, the subject of regulatory scrutiny for compliance with fraud and abuse laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Because of the breadth of these laws and the
narrowness of the statutory exceptions and safe harbors available, it is possible that some of the business activities of the entities
with whom we do business could be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements
with third parties comply with applicable healthcare laws and regulations could be costly. If our past operations, including activities
conducted by our sales team or agents, are found to be in violation of any of these laws or any other governmental regulations that may
apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from third-party
payer programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the HCPs, providers,
or entities with whom we do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil,
or administrative sanctions, including exclusion from government funded healthcare programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Many aspects of these laws have not been definitively
interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of subjective interpretations that
increases the risk of potential violations. In addition, these laws and their interpretations are subject to change. Any action against
us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert
our management&#8217;s attention from the operation of our business, and damage our reputation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">In addition to the fraud and abuse laws, we
continue to monitor the potential impact of proposals to lower prescription drug costs at the federal and state level. For example, in
November 2021, the Biden Administration announced several prescription drug pricing proposals as part of the Build Back Better legislation.
In particular, the plan would allow for Medicare to negotiate prices for high-cost prescription drugs, including for both Part D and
Part B drugs, after the drugs have been on the market for a fixed number of years: 9 years for small molecule drugs and 12 years for
biologics. Medicare will negotiate up to 10 drugs per year during 2023, with the negotiated prices taking effect in 2025, increasing
up to 20 drugs per year. Further, the plan imposes a tax penalty if drug manufacturers increase their prices faster than inflation. Finally,
the plan places a $2,000 per year cap on out-of-pocket drug costs under Medicare Part D. At the state level, legislatures have increasingly
passed legislation and implemented regulations designed to control pharmaceutical pricing, including price or patient reimbursement constraints,
discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed
to encourage importation from other countries and bulk purchasing. We are unable to predict the future course of federal or state healthcare
legislation in the U.S. directed at broadening the availability of healthcare and containing or lowering the cost of healthcare.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">In addition, from time to time in the future,
our licensees and the licensed products may become subject to additional laws or regulations administered by the FDA, the FTC, U.S. Department
of Health and Human Services (&#8220;HHS&#8221;), or by other federal, state, local, or foreign regulatory authorities, or the repeal
of laws or regulations that we generally consider favorable, such as DSHEA, or to more stringent interpretations of current laws or regulations.
We are not able to predict the nature of such future laws, regulations, repeals, or interpretations, and we cannot predict what effect
additional governmental regulation, if and when it occurs, would have on our business in the future. Such developments could, however,
require reformulation of certain products to meet new standards, recalls or discontinuance of certain products not able to be reformulated,
additional record-keeping requirements, increased documentation of the properties of certain products, additional or different labeling,
additional scientific substantiation, additional personnel, or other new requirements. Any such developments could have a material adverse
effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Available information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">We are a Nevada corporation, and we maintain
our principal executive offices at 951 Yamato Road, Suite 220, Boca Raton, Florida 33431. Our telephone number is (561) 961-1900. We
maintain a corporate website at www.therapeuticsmd.com. The information contained on our website or that can be accessed through our
website is not incorporated by reference into this 2023 10-K Report or in any other report or document we file with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 1A. Risk factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Investing in our common stock involves a high
degree of risk. You should carefully consider the following risk factors, together with all of the information included in this 2023
10-K Report and our other filings with the SEC, before you decide to purchase shares of our common stock. We believe the risks and uncertainties
described below are the most significant we face. Additional risks and uncertainties of which we are unaware, or that we currently deem
immaterial, also may become important factors that affect us. If any of the following risks occur, our business, financial condition,
or results of operations could be materially and adversely affected. In that case, the trading price of our common stock could decline,
and you may lose all or part of your investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Our business is subject to a number of risks
and uncertainties. The following is a summary of the principal risk factors described in this section:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>We currently derive all of our revenues from royalties related
                                            to sales of our products, and the failure of our licensees to maintain or increase sales
                                            of these products could have an adverse effect on our business, financial condition, results
                                            of operations, and growth prospects.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>We have incurred net losses in the past and there are no assurances
                                            we will be able to maintain or increase profitability in the future.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>There is substantial doubt about our ability to continue as a
                                            going concern.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>We could be affected by transitions in our senior management
                                            team.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>The dependence upon third parties for the manufacture and supply
                                            of our women&#8217;s healthcare products may cause delays in, or prevent our licensees from,
                                            successfully commercializing and marketing our products.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>The commercial success of our products will depend upon gaining
                                            and retaining significant market acceptance of these products among physicians and payers.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>Coverage and reimbursement may not be available for our products,
                                            which could make it difficult for our licensees to sell our products profitably.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>Time and costs associated with winding down our general and administrative,
                                            commercial, and research and development activities may be significant.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>Licensing of intellectual property involves complex legal, business
                                            and scientific issues, and disputes could jeopardize our rights under such agreements.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>Our products and our licensees are subject to extensive government
                                            regulation.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>We must rely on Mayne Pharma to prosecute, file lawsuits, or take other
actions to protect or enforce our intellectual property and there can be no assurance they will take such actions or be successful.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>If efforts to protect the proprietary nature of the intellectual
                                            property covering our hormone therapy pharmaceutical products and other products are not
                                            adequate, our licensees may not be able to compete effectively in the market, which would
                                            adversely affect our royalties.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>Our products face significant competition from branded and generic
                                            products, and our operating results will suffer if our products fail to compete effectively.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>Our success is tied to the distribution channels of our licensees.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>Any failure of our licensees to adequately maintain a sales force
                                            or effectively implement sales strategies will impede our growth.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>Our future success depends on our ability to attract and retain
                                            qualified personnel.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>Our failure to maintain compliance with Nasdaq&#8217;s continued
                                            listing requirements could result in the delisting of our common stock.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><i>Risks related to our business</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>We currently derive
all revenue from royalties related to sales of our licensed women&#8217;s healthcare products, and the failure of our licensees to maintain
or increase sales of these products could have an adverse effect on our business, financial condition, results of operations, and growth
prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Following the Mayne Transaction,
we derive all revenue from royalties related to sales of our women&#8217;s healthcare products, including patient-controlled, long-acting
contraceptive, hormone therapy pharmaceutical products, prenatal and women&#8217;s multi-vitamins, and iron supplements. We cannot assure
you that our licensees will be able to sustain such sales or that such sales will grow. In addition to other risks described herein,
the ability of our licensees to maintain or increase existing product sales is subject to several risks and uncertainties, including
the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">the
                                            presence of new or existing competing products, including non-authorized generic copies of
                                            our products;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">supply
                                            or distribution problems arising with any of their manufacturing and distribution partners;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">changed
                                            or increased regulatory restrictions or regulatory actions by the FDA;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">changes
                                            in healthcare laws and policy, including changes in requirements for drug pricing, rebates,
                                            reimbursement, and coverage by federal healthcare programs and commercial payers;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">the
                                            impact or efficacy of any price increases our licensees may implement in the future;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">changes
                                            to the licensed products&#8217; labels and labeling, including new safety warnings or changes
                                            to boxed warnings, that further restrict how our licensees market and sell our products;
                                            and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">acceptance
                                            of our products as safe and effective by physicians and patients.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If revenue from royalties
related to sales of our products does not increase, we may be required to seek to raise additional funds, which could have an adverse
effect on our business, financial condition, results of operations, and growth prospects. In addition, our revenue from royalties is
based on information compiled by, and received from, our licensees. If the sales information provided by our licensees is erroneous,
it could have an adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>We have incurred net
losses in the past and there are no assurances we will be able to maintain or increase profitability in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the past, we have incurred recurring net losses, including net losses
of $10.3 million and $172.4 million for 2023 and 2021, respectively. In 2022, we recognized net income of $112.0 million due to the net
proceeds from the Mayne  Transaction and vitaCare divestiture exceeding our costs and expenses. We utilized most of the net proceeds
to repay borrowings and redeem our preferred stock. As of December 31, 2023, our stockholders&#8217; equity was $29.3 million. We have
funded our operations to date primarily from public and private sales of equity and private sales of debt securities. We may incur substantial
additional losses over the next few years because of costs associated with the winddown of our historical business as well as the ongoing
costs of being a public company. As a result, we may not maintain or increase profitability. If we continue to incur substantial losses,
because the royalties of our products are insufficient or otherwise, and are unable to secure additional financing, we could be forced
to discontinue or curtail our business operations, merge, consolidate, or combine with a company with greater financial resources in a
transaction that might be unfavorable to us.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>There is substantial
doubt about our ability to continue as a going concern.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our current liquidity position raises substantial doubt about our
ability to continue as a going concern and Berkowitz Pollack Brant, Advisors + CPAs, our independent registered public accounting
firm for the fiscal year ended December 31, 2023, has included an explanatory paragraph in their opinion that accompanies our
audited consolidated financial statements as of and for the year ended December 31, 2023, indicating such. If Mayne Pharma&#8217;s
sales of IMVEXXY, BIJUVA, or ANNOVERA grow more slowly than expected or decline, if the net working capital settlement with Mayne
Pharma under the Transaction Agreement is greater than our current estimates, if we are unsuccessful with future financings or if
the supply chains related to the third-party contract manufacturers are worse than we anticipate, our existing cash reserves may be
insufficient to satisfy our liquidity requirements. Our ability to continue as a going concern may depend on our ability to obtain
additional capital as well as our ability to minimize operational expenses, including any potential net working capital adjustments
relating to the Mayne Transaction. As substantial doubt about our ability to continue as a going concern exists, our ability to
finance our operations through the sale and issuance of debt or equity securities or through bank or other financing could be
impaired. Our ability to obtain financing on reasonable terms is subject to factors beyond the Company&#8217;s control, including
general economic, political, and financial market conditions. The capital markets have in the past experienced, are currently
experiencing, and may in the future experience, periods of upheaval that could impact the availability and cost of equity and debt
financing and there can be no assurance that such financing will be available on terms commercially acceptable to the Company, or at
all. If we sell equity securities, convertible securities or other securities current investors may be materially diluted by
subsequent sales. If we are unable to improve our liquidity position, we may not be able to continue as a going concern.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>We have experienced
significant turnover in our top executives, and our business could be adversely affected by these and other transitions in our senior
management team.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We have experienced turnover
in our top executives and the replacement of these positions with new officers. In December 2022, following the Mayne Transaction, all
our top executives, except for our former General Counsel, were terminated, and our former General Counsel was appointed as Chief Executive
Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Management transition is often
difficult and inherently causes some loss of institutional knowledge, which could negatively affect the results of operations and financial
condition. Our ability to execute our business strategies may be adversely affected by the uncertainty associated with these transitions
and the time and attention of the board and management dedicated to management transitions could disrupt our business. Further, we cannot
guarantee that we will not face similar turnover in the future. Although we generally enter into employment agreements with our executives,
our executive officers may terminate their employment relationship with us at any time, and we cannot ensure that we will be able to
retain the services of any of them. Our senior management&#8217;s knowledge of our business and industry could be difficult to replace,
and management turnover could negatively affect our business, growth, financial conditions, results of operations and cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Our dependence upon
third parties for the manufacture and supply of our existing women&#8217;s healthcare products may cause delays in or prevent our licensees
from successfully commercializing and marketing our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We do not currently have,
nor do we currently plan to build or acquire, the infrastructure or capability to internally manufacture our existing women&#8217;s healthcare
products, IMVEXXY, BIJUVA, and ANNOVERA. We have relied, and will continue to rely, on third parties to manufacture these products in
accordance with specifications and in compliance with applicable regulatory requirements, including the FDA&#8217;s current Good Manufacturing
Practice (&#8220;cGMPs&#8221;). We entered into long-term supply agreements with Catalent Pharma Solutions, LLC for the commercial supply
of IMVEXXY and BIJUVA which have been assigned to Mayne Pharma. We also entered into a long-term supply contract with QPharma AB, now
known as Sever Pharma Solutions, for ANNOVERA, which contract was also assigned to Mayne Pharma. We depended on Lang, a full-service,
private label and corporate brand manufacturer, to supply our vitaMedMD and BocaGreen products. We do not have long-term contracts for
the commercial supply of our vitaMedMD and BocaGreen products. We believe that our licensees evolved these relationships based on the
products they licensed from us. We continue to provide support for the third party manufacturers and our licensees as needed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Regulatory requirements could
pose barriers to the manufacture of our women&#8217;s healthcare products. All of our existing products are manufactured by third-party
contract manufacturing organizations (&#8220;CMOs&#8221;). These CMOs are required to manufacture our products in compliance with the
applicable regulatory requirements. The CMO that manufactures IMVEXXY and BIJUVA has previously been inspected by the FDA and received
Form 483 observations with respect to its softgel manufacturing plant that is used for the manufacture of the commercial supply of IMVEXXY
and BIJUVA. The CMO that manufactures ANNOVERA has previously been inspected by the FDA and received Form 483 observations with respect
to its facility that is used for the commercial supply of ANNOVERA. We believe that corrective actions to address the compliance issues
identified in the referenced Forms 483 have been implemented by the CMOs and that the CMOs continue to have the right to manufacture
under current regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If the manufacturers of our
products cannot successfully manufacture material that conforms to specifications and the strict regulatory requirements of the FDA and
any applicable foreign regulatory authority, regulatory submissions related to our products may be delayed or disapproved, and our marketed
products may be affected. If these facilities are not in compliance for the manufacture of our products, our licensees may need to find
alternative manufacturing facilities, which would result in substantial disruptions of sales of our products. In addition, manufacturers
of our products will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for
compliance with cGMPs and similar regulatory requirements. Failure by any of the manufacturers of our products to comply with applicable
cGMP regulations or other applicable requirements could result in sanctions being imposed on us or our licensees, including fines, injunctions,
civil penalties, violation letters, delays, suspensions or withdrawals of approvals, operating restrictions, interruptions in supply,
recalls, withdrawals, issuance of safety alerts, and criminal prosecutions, any of which could have an adverse impact on our business,
financial condition, results of operations, and prospects. Our licensees may seek to enter into long-term agreements with alternative
manufacturers on commercially reasonable terms, and if they do enter into agreements with alternative manufacturers, those alternative
manufacturers may not be approved by the FDA or subsequently lose FDA approval to manufacture our drugs, any of which could have an adverse
impact on our business. We also could experience manufacturing delays if our CMOs give greater priority to the supply of other products
over our products to the delay or other detriment of our products, or otherwise do not satisfactorily perform according to the terms
of their agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We have also experienced a
greater than expected amount of raw materials for ANNOVERA being out of specification. If any of the third-party CMOs of our products
or any suppliers of raw materials or API experience further difficulties, do not comply with the terms of their agreements, or do not
devote sufficient time, energy, and care to providing our manufacturing needs, or if any manufacturing specification modifications that
we or Mayne Pharma have requested are not approved by the FDA, we could experience additional interruptions in the supply of our products,
which may have a material adverse impact on our revenue, results of operations, and financial position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Our licensees also do not
have long-term contracts for the supply of all the API used in BIJUVA, and ANNOVERA. If any supplier of the API or other products used
in our products experiences any significant difficulties in its respective manufacturing processes, chooses to cease supplying, or does
not devote sufficient time, energy, and care to providing our manufacturing needs, we could experience significant interruptions in the
supply of our products, which could impair our licensee&#8217;s ability to supply our products at the levels required for commercialization
and prevent or delay their successful commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>The commercial success
of our existing products will depend upon gaining and retaining significant market acceptance of these products among physicians and
payers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Physicians may not prescribe
our products, which would prevent us from generating revenue or becoming profitable. Market acceptance of our products, including our
hormone therapy pharmaceutical products and patient-controlled, long-acting contraceptive, by physicians, patients, and payers, will
depend on a number of factors, many of which are beyond our control, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the clinical indications for which our hormone therapy pharmaceutical
                                            products and patient-controlled, long-acting contraceptive are approved;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>acceptance by physicians and payers of each product as a safe
                                            and effective treatment;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the cost of treatment in relation to alternative treatments,
                                            including numerous generic pharmaceutical products;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the relative convenience and ease of administration of our products
                                            in the treatment of the symptoms for which they are intended;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the availability and efficacy of competitive drugs and devices;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the effectiveness of our licensee&#8217;s sales force and marketing
                                            efforts;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the extent to which the product is approved for inclusion on
                                            formularies of hospitals and managed care organizations, including any access barriers such
                                            as prior authorizations and step-edits;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the availability of coverage and adequate reimbursement by third
                                            parties, such as insurance companies and other healthcare payers, or by government healthcare
                                            programs, including Medicare and Medicaid;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>limitations or warnings contained in a product&#8217;s FDA-approved
                                            labeling; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>prevalence and severity of adverse side effects.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Even if the medical community
accepts that our products are safe and effective for their approved indications, physicians may not immediately be receptive to their
use or may be slow to adopt our products as an accepted treatment for the symptoms for which they are intended. Labeling approved by
the FDA may not permit our licensees to promote our products as being superior to competing products, because the FDA applies a heightened
level of scrutiny to comparative claims when applying its statutory standards for advertising and promotion, including with regard to
its requirements for supporting data and that promotional labeling be truthful and not misleading, and there is potential for differing
interpretations of whether certain communications are consistent with a product&#8217;s FDA-required labeling. If our products do not
achieve an adequate level of acceptance by physicians and payers, we may not generate sufficient or any revenue from royalties related
to sales of these products. In addition, the efforts of our licensees to educate the medical community and third-party payers on the
benefits of our products may require significant resources and may never be successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>Coverage and reimbursement
may not be available for our products, which could make it difficult for our licensees to sell our products profitably.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Market acceptance and sales
of our products, including IMVEXXY, BIJUVA, and ANNOVERA, and our prescription vitamins, will depend on coverage and reimbursement policies
and may be affected by healthcare reform measures. Government healthcare programs and third-party payers decide which prescription pharmaceutical
products they will pay for and establish reimbursement levels. Payers generally do not cover OTC products, and coverage for prescription
vitamins and dietary supplements varies. Many private third-party payers, such as managed care plans, manage access to pharmaceutical
products&#8217; coverage partly to control costs to their plans, and may use drug formularies and medical policies to limit their exposure.
Factors considered by these payers include product efficacy, cost effectiveness, and safety, as well as the availability of other treatments
including generic prescription drugs. The ability to commercialize IMVEXXY, BIJUVA, and ANNOVERA successfully depends on coverage and
reimbursement levels set by government healthcare programs and third-party private payers. Obtaining and maintaining favorable reimbursement
can be a time-consuming and expensive process, and our licensees may not be able to negotiate or continue to negotiate reimbursement
or pricing terms for our products with payers at levels that are profitable to them, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In both the U.S. and some foreign jurisdictions, there have been several
legislative and regulatory proposals to change the healthcare system in ways that could affect our licensees&#8217; ability to sell our
products profitably. Payment or reimbursement of prescription drugs by Medicaid or Medicare requires manufacturers of the drugs to submit
pricing information to CMS. The Medicaid Drug Rebate statute requires manufacturers to calculate and report price points, which are used
to determine Medicaid rebate payments shared between the states and the federal government and Medicaid payment rates for the drug. For
drugs paid under Medicare Part B, manufacturers must also calculate and report their Average Sales Price (&#8220;ASP&#8221;), which is
used to determine the Medicare Part B payment rate for the drug. The federal government sets general guidelines for Medicaid and requires
rebates on outpatient drugs. Each state creates specific regulations that govern its individual program, including supplemental rebate
programs that prioritize coverage for drugs on the state Preferred Drug List. In the United States, private health insurers and other
third-party payers often provide reimbursement for products and services based on the level at which the government provides reimbursement
through the Medicare or Medicaid programs for such products and services. In addition, government programs like Medicaid include substantial
penalties for increasing commercial prices over the rate of inflation which can affect realization and return on investment. The cost
of pharmaceuticals continues to generate substantial governmental and third-party payer interest and states have begun to take action
to increase transparency in drug pricing through mandatory reporting requirements. We expect that the pharmaceutical industry will experience
pricing pressures due to the trend toward managed healthcare, the increasing influence of managed care organizations, and additional legislative
proposals. Our results of operations could be adversely affected by current and future healthcare reforms. While we cannot predict whether
any proposed cost-containment measures will be adopted or otherwise implemented in the future, any such cost-reduction initiatives could
decrease the coverage and price that our licensees receive for our products from Medicare, if any, including IMVEXXY, BIJUVA, and ANNOVERA,
and could significantly harm our business. It was historically unclear whether products approved to treat moderate-to-severe dyspareunia,
a symptom of vulvar and vaginal atrophy due to menopause, such as IMVEXXY, were excluded under Medicare Part D, which resulted in limited
Medicare coverage for such products. A clarification issued by CMS in May 2018 indicated that drugs, such as IMVEXXY, that are approved
for the treatment of moderate-to-severe dyspareunia (as well as drugs approved for the treatment of moderate-to-severe symptoms of vulvar
and vaginal atrophy associated with menopause) are not excluded from Medicare Part D coverage. CMS&#8217;s clarification, however, is
no guarantee that such coverage will be obtained or maintained for IMVEXXY and obtaining Medicare or other government healthcare program
reimbursement for any new pharmaceutical products may take up to several years following FDA approval.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">

</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The ability of our licensees
to commercialize ANNOVERA depends on coverage and reimbursement levels set by government healthcare programs and third-party private
payers. Despite our licensees coverage with commercial payers, there is no guarantee that our licensees will be able to retain ours or
their agreements or obtain new agreements, or that they will be able to negotiate favorable reimbursement or pricing terms for our products
in the future. Healthcare reform implementation, additional legislation or regulations, and other changes in government policy or regulation
may affect our licensees&#8217; reimbursement or impose additional coverage limitations and/or cost-sharing obligations on patients,
any of which could have an adverse effect on coverage and reimbursement of our products, and our business, financial condition, results
of operations, and prospects could be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We expect that our licensees
will experience pricing pressures in connection with the sale of our products generally due to the trend toward managed healthcare, the
increasing influence of health maintenance organizations, the scrutiny of pharmaceutical pricing, the ongoing debates on reducing government
spending and additional legislative proposals. We cannot predict whether new proposals will be made or adopted, when they may be adopted,
or what impact they may have on us if they are adopted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The availability of generic
products at lower prices than branded products may substantially reduce the likelihood of reimbursement for branded products, such as
IMVEXXY, BIJUVA, and ANNOVERA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If our licensees fail to successfully
secure and maintain adequate coverage and reimbursement for our products or are significantly delayed in doing so, they could have difficulty
achieving market acceptance of our products and our business, financial condition, results of operations, and prospects could be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>Time and costs associated
with winding down our general and administrative, commercial, and research and development activities may be significant.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">There are significant costs
associated with winding down our normal historic operations, such as separation of employees, termination of contracts and engagement
of external consultants, all of which have and in the future will reduce our cash resources and take up large portions of our employees&#8217;
and consultants&#8217; time. We have received certain invoices related to our historic operations that
we are currently disputing. Our accruals related to such invoices reflect the amount we believe we will be responsible for based on the
current information we have. Any litigation related to such disputes or to the winding down of our operations, as well as any unforeseen
liabilities related to the same, could have a material impact on our business, growth, financial conditions, results of operations and
cash flows. There is no guarantee that our cash and cash equivalents on hand at any given time will be enough to cover
our liabilities associated with winding down our historic operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>Unfavorable global economic
conditions could harm our business, financial condition or results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Our results of operations
could be harmed by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn,
including the impact of increased interest rates and inflation, could result in a variety of risks to our business, including our ability
to raise additional capital when needed on acceptable terms, if at all. The foregoing could harm our business and we cannot anticipate
all the ways in which unfavorable economic conditions and financial market conditions could harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Licensing of intellectual
property involves complex legal, business, and scientific issues, and disputes could jeopardize our rights under such agreements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We are currently and may in
the future be a party to license agreements of importance to our business and to our products. Disputes may arise between us and any
of these counterparties regarding intellectual property subject to and each parties&#8217; obligations under such agreements, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">the
                                            scope of rights granted under the agreement and other interpretation-related issues;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">our
                                            or our licensees&#8217; obligations to make milestone, royalty, or other payments under those
                                            agreements, or the amount of any such payments;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">our
                                            or our licensees&#8217; obligations to prosecute existing and new patent applications;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">our
                                            or our licensees&#8217; obligations to enforce infringement of our intellectual property;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">whether
                                            and the extent to which the ANNOVERA technology and processes infringe on intellectual property
                                            of the Population Council that is not subject to the ANNOVERA license agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">the
                                            ownership of inventions and know-how arising under the agreement or resulting from the joint
                                            creation or use of intellectual property by our licensees and us and our partners;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>our right, or the right of our licensees, to transfer or assign
                                            the license; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the effects of termination.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">These or other disputes over
our obligations, our licensees&#8217; obligations, or intellectual property that we have licensed may prevent or impair our ability to
maintain our current arrangements on acceptable terms, or may impair the value of the arrangement to us. Any such dispute could have
an adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In July 2018, we entered into
the Population Council License Agreement to obtain exclusive U.S. rights to commercialize ANNOVERA. The agreement required us to commercialize
this product and enter into certain manufacturing agreements, make timely milestone and other payments, provide certain information regarding
our activities under the agreement, and indemnify the other party with respect to our development and commercialization activities under
the terms of the agreements. The Company&#8217;s license under the Population Council License Agreement was sold to Mayne Pharma as part
of the Mayne Transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If Mayne Pharma, with respect
to the ANNOVERA license agreement that we have assigned to Mayne Pharma, fails to meet obligations under that license agreement in a
material respect, the Population Council could have the right to terminate the agreement and upon the effective date of such termination,
have the right to re-obtain the related technology as well as, potentially, aspects of any intellectual property controlled by Mayne
Pharma and developed during the period the agreement was in force that relate to the applicable technology. This means that Population
Council could effectively take control of the development and commercialization of ANNOVERA after an uncured, material breach of the
agreement by us or Mayne Pharma. Any uncured, material breach under a license agreement could result in our loss of exclusive rights
and may lead to a complete termination of any commercialization efforts for the applicable product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In connection with the Mayne
Transaction, we granted a license to Mayne Pharma (i) to research, develop, register, manufacture, have manufactured, market, sell, use,
and commercialize the Licensed Products in the United States and its possessions and territories and (ii) to manufacture, have manufactured,
import and have imported the Licensed Products outside the United States for commercialization in the United States and its possessions
and territories. Any disputes arising under the agreements governing the Mayne Transaction may have a material adverse impact on our
revenue, results of operations and financial position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We have also entered into
licensing and supply agreements with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA
in Canada and Israel and with Theramex pursuant to which we granted Theramex an exclusive license to commercialize BIJUVA, and IMVEXXY
outside of the U.S., except for Canada and Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Sales of our products in the
U.S. and our rights to receive royalties with respect to such sales could be adversely affected if products manufactured outside of the
U.S. or for sale outside of the U.S. under the terms of these licensing and supply agreements are reimported and sold in the U.S. In
addition, our rights to receive royalties with respect to our products sold outside the U.S. could be adversely affected if our licensees
fail to diligently pursue approval of our products, or opt not to sell our products, in certain jurisdictions where they are not required
to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>We maintain our cash
at financial institutions, often in balances that exceed federally insured limits.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The majority of our cash is
held in accounts at U.S. banking institutions that we believe are of high quality. Cash held in depository accounts may exceed the $250,000
Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If such banking institutions were to fail, such as Silicon
Valley Bank when the FDIC took control in March 2023, we could lose all or a portion of those amounts held in excess of such insurance
limitations. In the future, our access to our cash in amounts adequate to finance our operations could be significantly impaired by the
financial institutions with which we have arrangements directly facing liquidity constraints or failures. Any material loss that we may
experience in the future could have a material adverse effect on our financial condition and could materially impact our ability to pay
our operational expenses or make other payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><i>Our products and our licensees are subject
to extensive and costly government regulation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Our products are subject to
extensive and rigorous domestic government regulation, including regulation by the FDA, the Centers for Medicare &amp; Medicaid Services
(&#8220;CMS&#8221;), other divisions of the U.S. Department of Health and Human Services, including its Office of Inspector General (&#8220;OIG&#8221;),
the U.S. Department of Justice (&#8220;DOJ&#8221;), the Departments of Defense and Veterans Affairs, to the extent our products are paid
for directly or indirectly by those departments, state and local governments, and their respective foreign equivalents. The FDA regulates
dietary supplements, cosmetics, and drugs under different regulatory schemes. For example, the FDA regulates the processing, formulation,
safety, manufacturing, packaging, labeling, and distribution of dietary supplements and cosmetics under its dietary supplement and cosmetic
authority, respectively. The FDA also regulates the research, development, pre-clinical and clinical testing, manufacture, safety, effectiveness,
record keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, import, and export of pharmaceutical
products under various regulatory provisions. If any of our products are marketed abroad, they will also be subject to extensive regulation
by foreign governments, whether or not we have obtained FDA approval for a given product and its uses. Such foreign regulation may be
equally or more demanding than corresponding U.S. regulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">We and our licensees are also
subject to additional healthcare regulation and enforcement by the federal government and the states in which we conduct our business.
Applicable federal and state healthcare laws and regulations include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">The
                                            federal Anti-Kickback Statute (&#8220;AKS&#8221;)</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">The
                                            Civil Monetary Penalties Law (&#8220;CMPL&#8221;)</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.4pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">The
                                            Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;)</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.4pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">HIPAA,
                                            as amended by the Health Information Technology for Economic and Clinical Health Act of 2009
                                            (&#8220;HITECH&#8221;)</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.4pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">Section
                                            5(a) of the Federal Trade Commission Act</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.4pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">The
                                            Physician Payments Sunshine Act</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.4pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">Analogous
                                            state laws and regulations</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Many aspects of these laws
have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of subjective
interpretations that increases the risk of potential violations. In addition, these laws and their interpretations are subject to change.
Many state laws differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance
efforts. Moreover, the number and complexity of both federal and state laws continues to increase, and additional governmental resources
are being used to enforce these laws and to prosecute companies and individuals who are believed to be violating them. We anticipate
that government scrutiny of pharmaceutical sales and marketing practices will continue for the foreseeable future and subject us to the
risk of government investigations and enforcement actions. For example, federal enforcement agencies recently have shown interest in
pharmaceutical companies&#8217; product and patient assistance programs, including manufacturer reimbursement support services and relationships
with specialty pharmacies. Some of these investigations have resulted in significant civil and criminal settlements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Efforts to ensure that our
operations, including our business arrangements with third parties including our licensees, comply with applicable healthcare laws and
regulations could be costly. Although effective compliance programs can help mitigate the risk of investigation, regulatory and enforcement
actions, and prosecution for violations of these laws, the risks cannot be entirely eliminated. Moreover, achieving and sustaining compliance
with applicable federal and state fraud, privacy, security, and reporting laws may prove costly. We cannot guarantee that a government
agency will agree with our interpretations, and it is possible that an enforcement authority may find or we may discover that one or
more of our business practices may not comply. If our past or present operations, including activities conducted by our sales team or
agents, are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject
to significant civil, criminal, and administrative penalties, damages, fines, and exclusion from government healthcare programs. Any
action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses,
divert our management&#8217;s attention from the operation of our business, and damage our reputation. In addition, even if we are not
determined to have violated these laws, government investigations into these issues typically require the expenditure of significant
resources and generate negative publicity, and could result in related stockholder suits, any of which could also have an adverse effect
on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In addition, from time to
time in the future, we or our licensees may become subject to additional laws or regulations issued by federal or state agencies, all
of which are subject to influence resulting from changes in political party control. We are uncertain of the impact or outcome of new
legislation, regulation, Executive Orders, rescission of rules and policy statements, or new agency priorities, especially any relative
impact on the healthcare regulatory and policy landscape, or the impact they may have on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Such developments could, however,
require reformulation of certain products to meet new standards, recalls or discontinuance of certain products not able to be reformulated,
additional record-keeping requirements, increased documentation of the properties of certain products, additional or different labeling,
additional scientific substantiation, additional personnel, or other new requirements. Any such developments could have an adverse effect
on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>Recently enacted or
future legislation or regulations may adversely affect reimbursement from government healthcare programs and third-party payers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">There have been efforts by
government officials and legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation
on drug importation, which could adversely affect our royalty revenues. Recently enacted federal and state laws have put considerable
pressure on the pricing of pharmaceutical products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We are unable to predict the
future course of federal or state healthcare legislation in the United States directed at broadening the availability of healthcare and
containing or lowering the cost of healthcare. The Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) and any further changes
in the law or regulatory framework could also have an adverse effect on our business, financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Further, if a federal government
shutdown were to occur for a prolonged period, federal government payment obligations, including its obligations under Medicaid and Medicare,
may be delayed. Similarly, if state government shutdowns were to occur, state payment obligations may be delayed. If the federal or state
governments fail to make payments under these programs on a timely basis, the ability of our licensees to sell our products to government
payers may be limited, thereby reducing anticipated revenues and profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Even after the approval
of IMVEXXY, BIJUVA, and ANNOVERA, the products and the holder of the marketing authorizations will still face extensive, ongoing regulatory
requirements and review, and the products may face future development and regulatory difficulties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">With respect to IMVEXXY, BIJUVA,
and ANNOVERA, the FDA may still impose significant restrictions on a product&#8217;s indicated uses or marketing or to the conditions
for approval or impose ongoing requirements for potentially costly post-approval studies, including phase 4 clinical trials or post-market
surveillance. As a condition to granting marketing approval of a product, the FDA may require additional clinical trials. The results
generated in these post-approval clinical trials could result in loss of marketing approval, changes in product labeling, or new or increased
concerns about side effects or efficacy of a product. For example, the labeling for IMVEXXY, BIJUVA, and ANNOVERA contains restrictions
on use and warnings. The Food and Drug Administration Amendments Act of 2007 gives the FDA enhanced post-market authority, including
the imposition of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) as well as explicit authority to require post-market
studies and clinical trials, labeling changes based on new safety information, and compliance with FDA-approved REMS programs. IMVEXXY,
BIJUVA, and ANNOVERA will also be subject to ongoing FDA requirements governing the manufacturing, labeling, packaging, storage, distribution,
safety surveillance and reporting, advertising, promotion, record keeping, and reporting of safety and other post-market information.
The FDA&#8217;s exercise of its authority could result in delays or increased costs during product development, clinical trials and regulatory
review, increased costs to comply with additional post-approval regulatory requirements, and potential restrictions on sales of approved
products. Foreign regulatory agencies often have similar authority and may impose comparable requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">As part of the FDA&#8217;s
approval of IMVEXXY, we committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal
women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen such as IMVEXXY, which study was assumed by Mayne
Pharma as the holder of the new drug application (&#8220;NDA&#8221;). As part of the FDA&#8217;s approval of ANNOVERA, the FDA has required
four non-closed post-marketing studies, including both post-marketing reviews and post-marketing commitments. Each study has a timeline
for completion and submission of a final report to the FDA. If a post-approval study is not fulfilled according to FDA requirements,
the FDA may impose certain further requirements and penalties against the holder of the NDA, which could include withdrawal of the NDA
approval and withdrawal of the product from the market. For ANNOVERA, post marketing studies are being performed by the Population Council
and Mayne Pharma as the NDA holder. In July 2021, we received a letter from the FDA indicating that the post-marketing commitment study
being conducted by the Population Council for ANNOVERA to characterize the in vivo release rate of ANNOVERA was not fulfilled to FDA&#8217;s
satisfaction. In addition, the final reports for the two post-marketing requirement studies being performed by the Population Council
for ANNOVERA were not submitted by the initial listed submission deadline, which deadlines have since been extended by FDA. To the extent
that Mayne Pharma or the Population Council, as applicable, does not fulfil these studies to the FDA&#8217;s satisfaction, the ability
of our licensees to sell the applicable product may be limited and there may be an adverse impact on our revenue and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Post-marketing studies, whether
conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other emerging data about marketed products,
such as adverse event reports, may also adversely affect sales of our pharmaceutical product candidates once approved, and potentially
our other marketed products. Further, the discovery of significant problems with a product similar to one of our products that implicate
(or are perceived to implicate) an entire class of products could have an adverse effect on sales of our approved products. Accordingly,
new data about our products could negatively affect demand because of real or perceived side effects or uncertainty regarding efficacy
and, in some cases, could result in product withdrawal or recall. Furthermore, new data and information, including information about
product misuse, may lead government agencies, professional societies, and practice management groups or organizations involved with various
diseases to publish guidelines or recommendations related to the use of our products or the use of related therapies or place restrictions
on sales. Such guidelines or recommendations may lead to lower sales of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Manufacturers of pharmaceutical
products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for
compliance with the FDA&#8217;s cGMP regulations and other regulatory requirements, such as adverse event reporting. Facilities for the
manufacturer of pharmaceutical products also undergo internal audits as well as external audits by third parties. If our licensees or
a regulatory agency discovers problems with a product, such as adverse events of unanticipated severity or frequency or problems with
the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility,
or our licensees, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, requiring new
warnings or other labeling changes to limit use of the drug, requiring that additional clinical trials be conducted, imposing new monitoring
requirements, or requiring the establishment of a REMS program. Advertising and promotional materials must comply with FDA rules in addition
to other potentially applicable federal and state laws and are subject to review by FDA. If the FDA raises concerns regarding our licensees&#8217;
promotional materials or messages, they may be required to modify or discontinue using them and may be required to provide corrective
information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Commercial products must now
meet the requirements of the Drug Supply Chain Security Act (&#8220;DSCSA&#8221;) which imposes obligations on manufacturers of prescription
pharmaceutical products for commercial distribution, regulating the distribution of the products at the federal level, and sets certain
standards for federal or state registration and compliance of entities in the supply chain (manufacturers and re-packagers, wholesale
distributors, third-party logistics providers, and dispensers). The DSCSA preempts previously enacted state pedigree laws and the pedigree
requirements of the Prescription Drug Marketing Act (&#8220;PDMA&#8221;) and its implementing regulations. Trading partners within the
drug supply chain must now ensure certain product tracing requirements are met that they are doing business with other authorized trading
partners; and they are required to exchange transaction information, transaction history, and transaction statements. Product identifier
information (an aspect of the product tracing scheme) is also now required. The DSCSA requirements, development of standards, and the
system for product tracing have been and will continue to be phased in over a period of years. The distribution of product samples continues
to be regulated under the PDMA, and some states also impose regulations on drug sample distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Our activities and the activities
of our licensees are also potentially subject to federal and state consumer protection and unfair competition laws. If we, our licensees
or our third-party suppliers fail to comply with applicable regulatory requirements, a regulatory agency may take any of the following
actions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">conduct
                                            an investigation into our or our licensees&#8217; practices and any alleged violation of
                                            law;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">seek
                                            an injunction or impose civil or criminal penalties or monetary fines;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">suspend
                                            or withdraw regulatory approval;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">suspend
                                            or impose restrictions on our licensees&#8217; operations, including costly new manufacturing
                                            requirements;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: left; width: 0.25in"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">seize
                                            or detain products, refuse to permit the import or export of products, or require our licensees
                                            to initiate a product recall; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">exclude our licensees
                                            from providing our products to those participating in government healthcare programs, such
                                            as Medicare and Medicaid, and refuse to allow our licensees to enter into supply contracts,
                                            including government contracts.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>Recent government enforcement
has targeted pharmaceutical companies for violations of fraud, abuse and other laws.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The federal government has
pursued actions against pharmaceutical companies for violations of fraud, abuse, and other laws, including, but not limited to the AKS, False Claims Act, FDCA, HIPAA, HITECH, Ryan Haight Act, and others, including marketing and promotional
compliance programs or codes of conduct, and law or rules requiring reporting of commercial activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We cannot ensure that ours
or our licensee&#8217;s compliance controls, policies, and procedures will be sufficient to protect against acts of ours or their employees,
business partners, licenses, or vendors that may violate federal or state fraud and abuse laws or other applicable requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The violations of any of these
law or rules may result in penalties that may force us to expend significant amounts of time and money and may significantly inhibit
our licensee&#8217;s ability to continue to market our products and generate revenue. Following the closing of the vitaCare Divestiture,
we may still be required to indemnify the buyer of vitaCare in the event any enforcement related to activities prior to the vitaCare
Divestiture. Similar regulations apply in foreign jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>If our dietary supplement</i></b>,
<b><i>hormone therapy pharmaceutical products or patient-controlled, long-acting contraceptive products do not have the effects intended
or cause undesirable side effects, our business may suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Although many of the ingredients
in our dietary supplement products are vitamins, minerals, and other substances for which there is a long history of human consumption,
they also contain innovative ingredients or combinations of ingredients. Furthermore, our hormone therapy or patient-controlled, long-acting
contraceptive pharmaceutical products have been approved by the FDA based on its assessment of the safety and efficacy of these products.
While we believe that all of these products and the combinations of ingredients in them are safe when taken as directed, the products
could have certain undesirable side effects if not taken as directed or if taken by a consumer who has certain medical conditions. In
addition, these products may not have the effect intended if they are not taken in accordance with certain instructions, which include
certain dietary or other labeling restrictions. Furthermore, there can be no assurance that any of the products, even when used as directed,
will have the effects intended or will not have harmful side effects in an unforeseen way or on an unforeseen cohort. If any of our are
shown to be harmful or generate negative publicity from perceived harmful effects, our business, financial condition, results of operations,
and prospects could be harmed significantly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>Our products face significant
competition from branded and generic products, and our operating results will suffer if we fail to compete effectively.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Development and awareness
of our products will depend largely upon our licensee&#8217;s success in increasing the consumer base for our products. The pharmaceutical
and dietary supplement industries are intensely competitive and subject to rapid and significant technological change. Our products face
intense competition, including from major multinational pharmaceutical and dietary supplement companies, established biotechnology companies,
specialty pharmaceutical, and generic drug companies. Many of these companies have greater financial and other resources, such as larger
R&amp;D staffs and more experienced marketing and manufacturing organizations. As a result, these companies may obtain regulatory approval
more rapidly and may be more effective in selling and marketing their products. They also may invest heavily to accelerate discovery
and development of novel compounds or to in-license novel compounds that could make the products that we sell or develop obsolete. Smaller
or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established
companies. If our licensees are unable to economically promote or maintain our brand, our business, results of operations and financial
condition could be severely harmed. In addition, loss of exclusivity may provide opportunity for competing products, particularly generics,
to siphon off our consumers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In February 2020, we received
a Paragraph IV certification notice letter (the &#8220;IMVEXXY Notice Letter&#8221;) regarding an ANDA submitted to the FDA by Teva Pharmaceuticals
USA, Inc. (&#8220;Teva&#8221;). See &#8220;If our efforts or the efforts of our licensees to protect the proprietary nature of the intellectual
property covering our hormone therapy pharmaceutical products and other products are not adequate, we may not be able to compete effectively
in our market&#8221; below for more information regarding the IMVEXXY Notice Letter. Additionally, on March 2020, we received a Paragraph
IV certification notice letter (the &#8220;BIJUVA Notice Letter&#8221;) regarding an ANDA submitted to FDA by Amneal Pharmaceuticals.
See Item 1. Business &#8211; Pharmaceutical Regulation &#8211; Regulatory Exclusivity for more information on the BIJUVA Notice Letter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In addition, we cannot predict
what additional ANDAs could be filed by Teva or other potential generic competitors requesting approval to market generic forms of our
products, which if approved, could result in significant decreases in the revenue derived from royalties sales of our marketed products
and thereby harm our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>Our future success depends
on our ability to attract and retain qualified personnel.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We have one employee and use
a limited number of external consultants for the operation of our company, any of whom may terminate their consultancy with us at any
time. We may not be able to attract and retain consultants on acceptable terms given the competition for similar personnel. Some of our
consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with
other entities that may limit their availability to us. We do not maintain &#8220;key person&#8221; insurance. If we are unable to continue
to use our current consultants, or if we are unable to recruit new consultants, then our ability to operate our business will be negatively
impacted and it could interfere with our ability to receive any potential royalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Our financial condition
and results of operations in 2021 and 2022 were, and our financial condition and results of operations in the future may be, adversely
affected by the COVID-19 pandemic and any future pandemics or epidemics.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Our business was impacted
by the COVID-19 pandemic and it may be impacted by any future pandemics or epidemics. The severity of the impact of any pandemic on our
business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">During the COVID-19 pandemic,
stay at home, quarantine, and social distancing orders and closures and restrictions on travel negatively affected the ability of our
sales force to access healthcare providers to promote our products and the ability of patients to visit their healthcare professionals
for non-emergent matters. The sales force of our licensees may continue to use a hybrid model of office visits when necessary and digital
engagement tools and tactics and virtual detailing, which may be less effective than their ordinary course sales and marketing programs.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Further. our future results
of operations and liquidity could be adversely affected during or following any future pandemics or epidemics by extended billing and
collection cycles at our company, our licensees, or otherwise; delays in payments of outstanding receivable amounts beyond normal payment
terms, including royalty payments; supply chain disruptions; and uncertain demand.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Also, disruptions have
occurred and may occur in the future that affect our licensees&#8217; ability to obtain supplies or other components for our products,
manufacture additional products, or deliver inventory in a timely manner. This would result in lost sales (and royalties) and damage
to our reputation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Our business may also be
affected by negative impacts of any future pandemic or epidemic on capital markets and economies worldwide, and it is possible that a
pandemic could cause a local and/or global economic recession. While policymakers globally have responded with fiscal policy actions
to support the healthcare industry and economy as a whole, the magnitude and overall effectiveness of these actions remains uncertain.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We may also experience
other unknown impacts from COVID-19 or any future pandemics or epidemics that cannot be predicted. Accordingly, disruptions to our business
as a result of COVID-19 and other pandemics or epidemics could continue to result in an adverse effect on our business, results of operations,
financial condition and prospects in the near-term and beyond 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Failure to obtain
regulatory approval outside the U.S. will prevent our licensees from marketing our hormone therapy pharmaceutical products in non-U.S.
markets.</i></b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We have entered into licensing
and supply agreements with Knight and Theramex to commercialize IMVEXXY and BIJUVA in non-U.S. markets. To market these products in the
European Union and many other non-U.S. jurisdictions, our licensees must obtain separate regulatory approvals. We have had limited interactions
with non-U.S. regulatory authorities, the approval procedures vary among countries and can involve additional testing, and the time required
to obtain approval may differ from that required to obtain FDA approval or clearance. Approval or clearance by the FDA does not ensure
approval by regulatory authorities in other countries, and approval by one or more non-U.S. regulatory authorities does not ensure approval
by other regulatory authorities in other countries or by the FDA. The non-U.S. regulatory approval process may include all risks associated
with obtaining FDA approval or clearance. For these non-U.S. regulatory approvals, our licensees may not obtain them on a timely basis,
if at all. Our licensees&#8217; failure to receive necessary non-U.S. regulatory approvals to commercialize IMVEXXY and BIJUVA in a given
market could have an adverse effect on our business, financial condition, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In addition, by seeking
to obtain approval to market IMVEXXY and BIJUVA in one or more non-U.S. markets, we or our licensees will be subject to rules and regulations
in those markets relating to our products. In some countries, particularly countries of the European Union, each of which has developed
its own rules and regulations, pricing is subject to governmental control. In these countries, pricing negotiations with governmental
authorities can take considerable time after the receipt of regulatory approval for a drug. To obtain reimbursement or pricing approval
in some countries, our licensees may be required to conduct a clinical trial that compares the cost-effectiveness of our pharmaceutical
product to other available products. If reimbursement of our pharmaceutical product is unavailable or limited in scope or amount, or
if pricing is set at unsatisfactory levels, our licensees may be unable to generate revenues and achieve or sustain profitability with
respect to any given market, which could have an adverse effect on our business, financial condition, results of operations, and prospects.
If our licensees obtain approval to market IMVEXXY or BIJUVA in one or more non-U.S. markets, there will be additional pharmacovigilance
reporting requirements for our products. To the extent that the non-U.S. markets in which our licensees distribute our products have
different pharmacovigilance reporting requirements than the U.S., there is a risk that the marketing of our drugs in those countries
may increase the number of adverse events reported for our products.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><i>Our success is tied to our licensees&#8217;
distribution channels.</i></b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Our revenue is dependent
on our licensees&#8217; distribution through wholesale distributors and retail pharmacy distributors. Our business would be harmed if
our licensees&#8217; customers refused to distribute our products and if our licensees were not able to replace such customers through
their distribution channels.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><i>Our ability to utilize net operating loss
carryforwards may be limited.</i></b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, we had federal net operating loss (&#8220;NOL&#8221;)
carryforwards of $577.0 million. Subject to applicable limitations, our NOL may be used to offset future taxable income, to the extent
we generate any taxable income, and thereby reduce our future federal income taxes otherwise payable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Section 382 of the Internal
Revenue Code of 1986, as amended, imposes limitations on a corporation&#8217;s ability to utilize NOL carryforwards if it experiences
an ownership change as defined in Section 382. In general terms, an ownership change may result from transactions increasing the ownership
of certain stockholders in the stock of a corporation by more than 50 percent over a three-year period. If an ownership change has occurred,
or were to occur, utilization of our NOL carryforwards would be subject to an annual limitation under Section 382 determined by multiplying
the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. Any unused annual limitation
may be carried over to later years. We may be found to have experienced an ownership change under Section 382 because of events in the
past or the issuance of shares of our common stock in the future. If so, the use of our NOL carryforwards, or a portion thereof, against
our future taxable income may be subject to an annual limitation under Section 382.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2017, the U.S. federal government enacted comprehensive tax legislation
commonly referred to as the Tax Cuts and Jobs Act (the &#8220;2017 Tax Act&#8221;). The 2017 Tax Act makes broad and complex changes to
the U.S. federal tax code, including, but not limited to reducing the U.S. federal corporate tax rate from 34 percent to 21 percent and
imposing new restrictions on the use of NOL carryforwards. The 2017 Tax Act reduced the corporate tax rate to 21 percent, effective January
1, 2018. Management assessed the valuation allowance analyses with respect to our NOL carryforwards as affected by various aspects of
the 2017 Tax Act and determined that a full valuation allowance continues to be appropriate. Additionally, to address the impact of the
COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, was enacted into law in March 2020. The CARES
Act includes several significant business tax provisions that, among other things, includes further statutory amendments to the rules
governing NOL carryforwards, as amended by the 2017 Tax Act. The CARES Act limits the NOL deduction in taxable years beginning in 2021
to the lesser of the NOL carryforwards or 80% of the taxpayer&#8217;s taxable income (after considering the deduction for NOL arising in tax
years beginning before January 1, 2018), which may restrict our ability to offset future taxable income with NOL carryforwards and increase
our future federal income taxes otherwise payable.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>Any failure of our licensees
to adequately maintain a sales force or adequately promote our products will impede our growth.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We are substantially dependent
on the sales forces of our licensees to attract new business and to manage existing customer relationships. There is significant competition
for qualified, productive direct sales personnel with advanced sales skills and technical knowledge. Our ability to achieve growth in
revenue in the future will depend, in large part, on our licensees&#8217; success in recruiting, training, and retaining direct sales
personnel, and their decision to adequately promote our products. If our licensees are unable to hire, engage, and develop enough productive
sales personnel or fail to adequately promote our products, our business prospects could suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>Risks related to our
intellectual property</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>If our efforts or the
efforts of our licensees to protect the proprietary nature of the intellectual property covering our hormone therapy pharmaceutical products
and other products are not adequate, we may not be able to compete effectively in our market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Our commercial success will
depend in part on ours and our licensees&#8217; ability to obtain additional patents and protect our existing patent positions as well
as our ability to maintain adequate protection of other intellectual property for our hormone therapy pharmaceutical products. If we
do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive
advantage we may have, which could harm our business and ability to achieve profitability. The patent positions of pharmaceutical companies
are highly uncertain. The legal principles applicable to patents are in transition due to changing court precedent and legislative action,
and we cannot be certain that the historical legal standards surrounding questions of validity will continue to be applied or that current
defenses relating to issued patents in these fields will be sufficient in the future. Changes in patent laws in the U.S., such as the
America Invents Act of 2011, may affect the scope, strength, and enforceability of our patent rights or the nature of proceedings that
may be brought by us related to our patent rights. In addition, the laws of some foreign countries do not protect proprietary rights
to the same extent as the laws of the U.S., and we may encounter significant problems in protecting our proprietary rights in these countries.
We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies
are covered by valid and enforceable patents or are effectively maintained as trade secrets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">These risks include the possibility of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td style="text-align: left">the patent applications that we or our
                                            licenses have filed may fail to result in issued patents in the U.S. or in foreign jurisdictions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">patents
                                            issued or licensed to us, or our partners, may be challenged or discovered to have been issued
                                            on the basis of insufficient, incomplete, or incorrect information, and thus held to be invalid
                                            or unenforceable;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">the
                                            scope of any patent protection may be too narrow to exclude competitors from developing or
                                            designing around these patents;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">we,
                                            the Population Council, or our licensees were not the first to make the inventions covered
                                            by each of our issued patents and pending patent applications, or may have created bars under
                                            U.S. or foreign laws that would preclude the issuance of patents;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>we, the Population Council, or our licensees may not have been
                                            the first inventors to invent or file patent applications for these technologies in the U.S.
                                            or were not the first to file patent applications directed to these technologies abroad;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>we may fail to comply with procedural, documentary, fee payment,
                                            and other similar provisions during the patent application process, which can result in abandonment
                                            or lapse of the patent or patent application, resulting in partial or complete loss of patent
                                            rights;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>future pharmaceutical product candidates may not be patentable;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>others may claim rights or ownership regarding patents and other
                                            proprietary rights that we hold or license;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>delays in development, testing, clinical trials, and regulatory
                                            review may reduce the period during which we could market our pharmaceutical products under
                                            patent protection; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>we or our licensees may fail to timely apply for patents on our
                                            technologies or products.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">While we apply for patents covering our technologies
and products, as we deem appropriate, many third parties may already have filed patent applications or have received patents in our areas
of product development. These entities&#8217; applications, patents, and other intellectual property rights may conflict with patent
applications to which we have rights and could prevent us from obtaining patents or could call into question the validity of any of our
patents, if issued, or could otherwise adversely affect our ability to develop, manufacture, or commercialize our pharmaceutical products.
In addition, if third parties file patent applications in the technologies that also claim technology to which we have rights, we may
have to participate in interference, derivation, or other proceedings with the USPTO or foreign patent regulatory authorities to determine
our rights in the technologies, which may be time-consuming and expensive. Moreover, issued patents may be challenged in the courts or
in post-grant proceedings at the USPTO, or in similar proceedings in foreign countries. These proceedings may result in loss of patent
claims or adverse changes to the scope of the claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If we, the Population Council,
our licensees, or our strategic partners fail to obtain and maintain patent protection for our products, or our proprietary technologies
and their uses, companies may be dissuaded from collaborating with us or our licensees. In such event, ours or our licensee&#8217;s ability
to commercialize our pharmaceutical products may be threatened, we could lose our competitive advantage, and the competition we face
could increase, all of which could adversely affect our business, financial condition, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In addition, mechanisms exist
in much of the world permitting some form of challenge by generic drug marketers to our patents before, or immediately following, the
expiration of any regulatory exclusivity, and generic companies are increasingly employing aggressive strategies, such as &#8220;at risk&#8221;
launches or the post-grant approval processes that exists in the U.S. and foreign jurisdictions to challenge relevant patent rights.
In February 2020, we received the IMVEXXY Notice Letter regarding an ANDA submitted to the FDA by Teva. The ANDA submitted by Teva seeks
approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In the IMVEXXY Notice Letter,
Teva alleges that IMVEXXY Patents listed in the FDA&#8217;s Orange Book that claim compositions and methods of IMVEXXY are invalid, unenforceable,
and/or will not be infringed by Teva&#8217;s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents
identified in the IMVEXXY Notice Letter expire in 2032 or 2033. In April 2020, we filed a complaint for patent infringement against Teva
in the United States District Court for the District of New Jersey arising from Teva&#8217;s ANDA filing with the FDA. We are seeking,
among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA would be a date no earlier than the expiration
of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim
to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. In September 2021, the District Court made available
a public version of the order following the parties&#8217; agreement to a consent motion to redact information Teva contended was confidential.
The order provides that the statutory stay that prevents FDA from granting final approval of the ANDA for 30 months from the date of
the Notice Letter will be extended for the number of days that the stay of the IMVEXXY litigation is in place. The length of the stay
of the IMVEXXY litigation is dependent on further action by Teva.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We cannot assure you that
any patent infringement lawsuit that we or our licensees may file will prevent the introduction of a generic version of IMVEXXY for
any particular length of time, or at all. If Teva&#8217;s ANDA is approved, and a generic version of IMVEXXY is introduced, the
sales of IMVEXXY could be adversely affected and our license revenue could be significantly decreased. In addition, we cannot
predict what additional ANDAs could be filed by Teva, or other potential generic competitors requesting approval to market generic
forms of our products, which could require us or our licensees to incur significant additional expense and result in distraction for
our management team, and if approved, result in significant decreases in the revenue derived from sales of our marketed products
and thereby harm our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Our business also may rely
on unpatented proprietary technology, know-how, and trade secrets. If the confidentiality of this intellectual property is breached,
it could adversely impact our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>We must rely on Mayne
Pharma to file lawsuits or take other actions to protect or enforce our patents and there can be no assurance they will take such actions
or be successful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Competitors may infringe our
patents or the patents of the ANNOVERA licensor. Following the Mayne Transaction, we no longer have the express right to enforce our
intellectual property. To counter infringement or unauthorized use, we must rely on Mayne Pharma to file infringement claims, including
with respect to Teva&#8217;s IMVEXXY Notice Letter. There can be no assurance that Mayne Pharma will have sufficient financial or other
resources to file and pursue such infringement claims in the United States, which typically last for years before they are concluded.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other
intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement
of our patents or marketing of competing products in violation of our proprietary rights generally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In addition, in an infringement
proceeding, a court may decide that a patent of ours or of the ANNOVERA licensor is not valid or is unenforceable or may refuse to stop
the other party from using the technology at issue on the grounds that our patents, or those of the ANNOVERA licensor, do not cover the
technology in question or on other grounds. An adverse result in any litigation or defense proceedings could put one or more of our patents,
or those of the ANNOVERA licensor, at risk of being invalidated, held unenforceable, or interpreted narrowly. Moreover, we may not be
able to prevent, alone or with our licensees, or the ANNOVERA licensor, misappropriation of our proprietary rights, particularly in countries
in which the laws may not protect those rights as fully as in the U.S. or in those countries in which we do not file national phase patent
applications. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation,
there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition,
if securities analysts or investors perceive public announcements of the results of hearings, motions, or other interim proceedings or
developments to be negative, the price of our common stock could be adversely affected. The occurrence of any of the above could adversely
affect our business, financial condition, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>Risks related to ownership
of our common stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>We may be treated as
a &#8220;public shell&#8221; company which could have negative consequences, including potential Nasdaq delisting of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Our common stock is currently
listed on the Nasdaq Global Select Market. We have no current plans to delist our common stock from Nasdaq. However, following the transaction
with Mayne Pharma, when we changed our business to become a royalty company, we may be treated as a &#8220;public shell&#8221; company
under the Nasdaq rules and the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act. Although Nasdaq evaluates
whether a listed company is a public shell company based on a facts and circumstances determination, a Nasdaq-listed company with no
or nominal operations and either no or nominal assets, assets consisting solely of cash and cash equivalents, or assets consisting of
any amount of cash and cash equivalents and nominal other assets is generally considered to be a public shell company. Listed companies
determined to be public shell companies by Nasdaq may be subject to delisting proceedings or additional and more stringent listing criteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If our common stock is delisted
from Nasdaq, or if in the future we determine to delist our common stock, we would expect that such securities would qualify for trading
over-the-counter, or OTC, in the United States on a market colloquially referred to as the &#8220;Pink Sheets.&#8221; Securities quoted
OTC are generally subject to lesser requirements than securities listed for trading on a U.S. national stock exchange, such as Nasdaq,
including reduced corporate governance and public reporting standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If Nasdaq should delist our
common stock from trading, or if in the future we determine to delist our common stock, a reduction in some or all of the following may
occur, each of which could have a material adverse effect on holders of our common stock: the liquidity of our common stock; the market
price of our common stock; the number of institutional and general investors that will consider investing in our common stock; the number
of investors in general that will consider investing in our common stock; the number of market makers in our common stock; the availability
of information concerning the trading prices and volume of our common stock; and the number of broker-dealers willing to execute trades
in our common stock. In addition to the foregoing, there are certain consequences under the Securities Act of being a public shell company,
including the unavailability of Rule 144 thereunder for the resale of restricted securities and the inability to utilize Form S-8 for
the registration of employee benefit plan securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Our principal stockholder
owns a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, Rubric Capital Management LP (&#8220;Rubric&#8221;)
and its affiliates beneficially owned approximately 25.6% of our common stock. Rubric may be able to largely determine the outcome of
all matters requiring stockholder approval. For example, Rubric may be able to largely control elections of directors, amendments of our
organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage
unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>If we fail to maintain
proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Pursuant to Section 404 of
the Sarbanes-Oxley Act, our management is required annually to deliver a report that assesses the effectiveness of our internal control
over financial reporting. Due to our current filing status, we are not required to have our independent registered public accounting
firm deliver an attestation report on the effectiveness of our internal control over financial reporting. If we are unable to maintain
effective internal control over financial reporting or our independent auditors are unwilling or unable to provide us with an attestation
report on the effectiveness of internal control over financial reporting for future periods as required by, or voluntarily followed under,
Section 404 of the Sarbanes-Oxley Act, we may not be able to produce accurate financial statements, and investors may therefore lose
confidence in our operating results, our stock price could decline and we may be subject to litigation or regulatory enforcement actions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>We do not currently
intend to pay dividends on our common stock so any returns may be limited to the value of our stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We have never declared or
paid any cash dividends on our common stock. We currently anticipate that we will retain any future earnings for the operation of our
business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of any future
debt agreements may also preclude us from paying dividends. Any return to stockholders may be limited to the capital appreciation, if
any, of their stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Some provisions of our
charter documents and Nevada law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition
would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Provisions in our articles
of incorporation and bylaws, as well as certain provisions of Nevada law, could make it more difficult for a third-party to acquire us
or increase the cost of acquiring us, even if an acquisition would benefit our stockholders, and could also make it more difficult to
remove our current management. These provisions in our articles of incorporation and bylaws include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>authorizing the issuance of &#8220;blank check&#8221; preferred
                                            stock that could be issued by our board of directors (the &#8220;Board&#8221;) to increase the number of outstanding
                                            shares and thwart a takeover attempt;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>prohibiting cumulative voting in the election of directors, which
                                            would otherwise allow less than a majority of stockholders to elect director candidates;
                                            and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td style="text-align: left">advance notice provisions in connection
                                            with stockholder proposals that may prevent or hinder any attempt by our stockholders to
                                            bring business to be considered by our stockholders at a meeting or replace our board of
                                            directors.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In addition, we are subject
to Nevada&#8217;s Combination with Interested Stockholders statute (Nevada Revised Statute Sections 78.411 &#8211; 78.444), which prohibits
an &#8220;interested stockholder&#8221; from entering into a &#8220;combination&#8221; with a company, unless certain conditions are
met. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, beneficially owns (or within the
prior two years, did beneficially own) 10% or more of the corporation&#8217;s capital stock entitled to vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>General risks related
to our business</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>Our business may be
affected by unfavorable publicity or lack of consumer acceptance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We are highly dependent upon
consumer acceptance of the safety and quality of our products, as well as similar products distributed by other companies. Consumer acceptance
of a product can be significantly influenced by scientific research or findings, national media attention, and other publicity about
product use, products themselves, or marketing campaigns for our products. A product may be received favorably, resulting in high sales
associated with that product that may not be sustainable as consumer preferences change. Future scientific research or publicity could
be unfavorable to our industry or any of our products and may not be consistent with earlier favorable research or publicity. A future
research report or publicity that is perceived by consumers as less than favorable or that may question earlier favorable research or
publicity could have an adverse effect on sales of our products and our ability to generate revenue. Adverse publicity in the form of
published scientific research, statements by regulatory authorities or otherwise, whether or not accurate, that associates use of our
products or any other similar products with illness or other adverse effects, or that questions the benefits of our products or similar
products, or that claims that such products do not have the effect intended, or that question the marketing of our products, could have
an adverse effect on our business, reputation, financial condition, or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><i>Our licensees may initiate product recalls
or withdrawals or may be subject to regulatory enforcement actions that could negatively affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Our products may be subject
to product recalls, withdrawals, or seizures if any of our products are believed to cause injury or illness or if our licensees are alleged
to have violated governmental regulations in the manufacture, labeling, promotion, sale, or distribution of any of our products. A recall,
withdrawal, or seizure of any of our products could adversely affect consumer confidence in our brands and lead to decreased demand for
our products, which could adversely affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>Product liability lawsuits
could divert our resources, result in substantial liabilities, and reduce the commercial potential of our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We face an inherent risk of
product liability claims because of the commercial availability of our current products. Additionally, considering the history of product
liability claims related to other hormone therapy products and contraceptives, we will face an even greater risk through commercialization
of our products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable
during manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects
in design, failures to warn of dangers associated with the use of the product, negligence, strict liability, or breaches of warranties.
Claims could also be asserted under state consumer fraud and protection statutes. If we cannot successfully defend ourselves against
product liability claims, we may incur substantial liabilities or be required to limit commercialization of our existing products or
pharmaceutical product candidates. Regardless of the merits or eventual outcome, product liability claims may result in any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the inability to commercialize our products;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>difficulty recruiting subjects for clinical trials or withdrawal
                                            of these subjects before a trial is completed;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>labeling, marketing, or promotional changes and/or restrictions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>product recalls or withdrawals;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>decreased demand for our products or products that we may develop
                                            in the future;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>loss of revenue;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>injury to our reputation;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>initiation of investigations by regulators or actions by state
                                            attorney generals or the U.S. Department of Justice;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>costs to defend the related litigation;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>a diversion of management&#8217;s time and our resources;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>substantial monetary awards to trial participants or patients;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>exhaustion of any available insurance and our capital resources;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the obligation to indemnify our licensees that would be a diversion
                                            of management&#8217;s time and resources; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>a decline in our stock price.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Although we maintain general
liability insurance and clinical trial liability insurance for our products and product candidates, this insurance may not fully cover
potential liabilities. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial.
In addition, our inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against
potential product liability claims could prevent or inhibit the development and commercial production and sale of our products, which
could adversely affect our business, financial condition, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>A failure to maintain
optimal inventory levels to meet commercial demand for our products could harm our and our licensees&#8217; reputation and subject us
to financial losses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Our licensees&#8217; ability to
maintain optimal inventory levels to meet commercial demand depends on the performance of third-party contract manufacturers. In some
instances, our products have unique ingredients used under license arrangements. One of our third-party contract manufacturers has in
the past experienced an increase in difficulties with manufacturing of ANNOVERA, resulting in intermittent supply of ANNOVERA for commercial
distribution. See &#8220;Our dependence upon third parties for the manufacture and supply of our existing women&#8217;s healthcare products
may cause delays in or prevent our licensees from successfully commercializing and marketing our products&#8221; above. If the manufacturers
of our products are unsuccessful in obtaining raw materials, if are licensees are unable to manufacture and release inventory on a timely
and consistent basis, if our licensees fail to maintain an adequate level of product inventory, if inventory is destroyed or damaged,
or if our licensees&#8217; inventory reaches its expiration date, patients might not have access to our products, our reputation and
brands could be harmed, and physicians may be less likely to recommend our products in the future, each of which could have an adverse
effect on our business, financial condition, results of operations, and cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Our business may be
impacted by new or changing tax laws or regulations and actions by federal, state, and/or local agencies, or how judicial authorities
apply tax laws.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In connection with the products
we previously sold and the royalties we receive, we calculate, collect, and remit various federal, state, and local taxes, surcharges
and regulatory fees, or taxes, to numerous federal, state and local governmental authorities. In addition, we incur and pay state and
local taxes and fees on purchases of goods and services used in our business. Tax laws are dynamic and subject to change as new laws
are passed and new interpretations of the law are issued or applied. In many cases, the application of tax laws is uncertain and subject
to differing interpretations, especially when evaluated against new technologies and services. The impact of tax reform on holders of
our common stock is also uncertain and could be adverse.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If we have incorrectly described,
disclosed, calculated, assessed, or remitted amounts that were due to governmental authorities, we could be subject to additional taxes,
fines, penalties, or other adverse actions, which could impact our business, results of operations, and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>We may not be able to
maintain effective and efficient information systems or properly safeguard our information systems.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Our operations are dependent
on uninterrupted performance of our information systems. Failure to maintain reliable information systems, disruptions in our existing
information systems or the implementation of new systems could cause disruptions in our business operations, including violations of
patient privacy and confidentiality requirements and other regulatory requirements, increased administrative expenses and other adverse
consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In addition, information security
risks have generally increased in recent years because of new technologies and the increased activities of perpetrators of cyber-attacks
resulting in the theft of protected health, business, or financial information. Despite our layered security controls, experienced computer
programmers and hackers may be able to penetrate our information systems or the information systems of our licensees and misappropriate
or compromise sensitive patient or personnel information or proprietary or confidential information, create system disruptions or cause
shutdowns. They also may be able to develop and deploy viruses, worms and other malicious software programs that disable our systems
or otherwise exploit any security vulnerabilities. Outside parties may also attempt to fraudulently induce employees to take actions,
including the release of confidential or sensitive information or to make fraudulent payments, through illegal electronic spamming, phishing,
or other tactics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">A failure in or breach of
our information systems or those of our licensees because of cyber-attacks or other tactics could disrupt our business, result in the
release or misuse of protected health information, or PHI, confidential or proprietary business information or financial loss, damage
our reputation, increase our administrative expenses, and expose us to additional risk of liability to federal or state governments or
individuals. Although we believe that we have robust information security procedures and other safeguards in place, as cyber threats
continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures or to
investigate and remediate any information security vulnerabilities. Our remediation efforts may not be successful and could result in
interruptions, delays or cessation of service and loss of existing or potential patients and disruption of our operations. In addition,
breaches of our security measures and the unauthorized dissemination of patient healthcare and other sensitive information, proprietary
or confidential information about us or other third-parties could expose such persons&#8217; private information to the risk of financial
or medical identity theft or expose us or such persons to a risk of loss or misuse of this information, result in litigation and potential
liability for us, damage our brand and reputation or otherwise harm our business. Any of these disruptions or breaches of security could
have an adverse effect on our business, financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Our failure to comply
with foreign data protection laws and regulations could lead to government enforcement actions and significant penalties against us,
and adversely impact our operating results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">European Union member states
and other foreign jurisdictions, including Switzerland, have adopted data protection laws and regulations which impose significant compliance
obligations. Moreover, the collection and use of personal health data in the European Union, which was formerly governed by the provisions
of the European Union Data Protection Directive, was replaced with the European Union General Data Protection Regulation the (&#8220;GDPR&#8221;)
in May 2018. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom
the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach
notification and the use of third-party processors in connection with the processing of personal data. The GDPR also imposes strict rules
on the transfer of personal data out of the European Union to the U.S., provides an enforcement authority and imposes large penalties
for noncompliance, including the potential for fines of up to &#8364;20 million or 4% of the annual global revenues of the non-compliant
company, whichever is greater. The implementation of the GDPR has increased our responsibility and liability in relation to personal
data that we process, and we may in the future be required to put in place additional mechanisms to ensure compliance with the GDPR,
which could divert management&#8217;s attention and increase our cost of doing business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In July 2020, the Court of
Justice of the European Union issued its long-awaited decision in the case Data Protection Commission v. Facebook Ireland, Schrems. The
decision on this case invalidated the European Commission&#8217;s adequacy decision for the EU-U.S. Privacy Shield Framework, calling
into question personal data transfers from the EU to the U.S. On October 7, 2022, President Biden introduced an Executive Order to
facilitate a new Trans-Atlantic Data Privacy Framework (the &#8220;DPF&#8221;), and on July 10, 2023, the European Commission adopted
its Final Implementing Decision granting the U.S. adequacy (Adequacy Decision) for EU-U.S. transfers of personal information for companies
that self-certify to the DPF. While we have yet to determine the full impact of the DPF on our business, any transfers by us or our vendors
or licensees of personal information subject to the GDPR may not comply with data protection law and may increase our exposure to the
GDPR&#8217;s heightened sanctions for violations of its cross-border data transfer restrictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In addition, new regulation
or legislative actions regarding data privacy and security (together with applicable industry standards) may increase our costs of doing
business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to
privacy and data protection in the U.S., the European Union and other jurisdictions, and we cannot determine the impact such future laws,
regulations and standards may have on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>Our employees and business
partners may not appropriately secure and protect confidential information in their possession.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Each of our employees and
business partners is responsible for the security of the information in our systems or under our control and to ensure that private and
financial information is kept confidential. Should an employee or business partner not follow appropriate security measures, including
those related to cyber threats or attacks or other tactics, as well as our privacy and security policies and procedures, the improper
release of personal information, including PHI, or confidential business or financial information, or misappropriation of assets could
result. The release of such information or misappropriation of assets could have an adverse effect on our business, financial condition,
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Employees may engage
in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We are exposed to the risk
of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to
provide accurate information to the FDA, to comply with federal and state healthcare fraud and abuse laws and regulations, to report
financial information or data accurately, or to disclose unauthorized activities to us. In particular, sales, marketing, and business
arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks,
self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs, and other business arrangements. We have adopted a Code of Conduct
and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent
this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations
or other actions or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted
against us or our licensees, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant
impact on our business, including the imposition of significant fines or other sanctions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>General risks related
to our intellectual property</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>If we are sued for infringing
intellectual property rights of third parties, litigation will be costly and time consuming and could prevent or delay us from developing
or commercializing our pharmaceutical product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Our commercial success depends,
in part, on our not infringing the patents and proprietary rights of other parties and not breaching any collaboration or other agreements
we entered with regard to our technologies and products. We are aware of numerous third-party U.S. and non-U.S. issued patents and pending
applications that exist in the technical areas of our pharmaceutical products, including compounds, formulations, treatment methods,
and synthetic processes, which may be applied towards the synthesis of hormones, for example. Patent applications are confidential when
filed and remain confidential until publication, approximately 18 months after initial filing, while some patent applications remain
unpublished until issuance. As such, there may be other third-party patents and pending applications of which we are currently unaware
with claims directed towards composition of matter, formulations, methods of manufacture, or methods for treatment related to the use
or manufacture of our products or product candidates. Therefore, we cannot ever know with certainty the nature or existence of every
third-party patent filing. We cannot provide assurances that our licensees or their partners will be free to manufacture or market our
products as planned or that we or the ANNOVERA licensors&#8217; and partners&#8217; patents will not be opposed or litigated by third
parties. If any third-party patent was held by a court of competent jurisdiction to cover aspects of our materials, formulations, methods
of manufacture, or methods of treatment related to the use or manufacture of any of our products, the holders of any such patent may
be able to block our ability to commercialize the applicable product unless we obtained a license or until such patent expires or is
finally determined to be held invalid or unenforceable. There can be no assurances that we will be able to obtain a license to such patent
on favorable terms or at all. Failure to obtain such license may have an adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">There is a substantial amount
of litigation involving intellectual property in the pharmaceutical industry generally. If a third-party asserts that we infringe its
patents or other proprietary rights, we could face many risks that could adversely affect our business, financial condition, results
of operations, and prospects, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">infringement
                                            and other intellectual property claims, which would be costly and time-consuming to defend,
                                            whether or not we are ultimately successful, which in turn could delay the regulatory approval
                                            process, consume our capital, and divert management&#8217;s attention from our business;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">substantial
                                            damages for past infringement, which we may have to pay if a court determines that our products
                                            or technologies infringe a competitor&#8217;s patent or other proprietary rights;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">a
                                            court prohibiting us from selling or licensing our technologies or future products unless
                                            the third-party licenses its patents or other proprietary rights to us on commercially reasonable
                                            terms, which it is not required to do;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">if
                                            a license is available from a third-party, we may have to pay substantial royalties or lump
                                            sum payments or grant cross licenses to our patents or other proprietary rights to obtain
                                            that license; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: left; width: 18.6pt"/><td style="text-align: left; width: 0.25in">&#9679;</td><td style="text-align: left">redesigning
                                            our products so they do not infringe, which may not be possible or may require substantial
                                            monetary expenditures and time.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We are party from time to
time to legal proceedings relating to our intellectual property, and third parties in the future may file claims asserting that our technologies,
processes, or products infringe on their intellectual property. We cannot predict whether third parties will assert these claims against
us or our strategic partners or against the licensors of technology licensed to us or our licensees, or whether those claims will harm
our business. In addition, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified
in advance. If we or our partners were to face infringement claims or challenges by third parties relating to our pharmaceutical product
candidates, an adverse outcome could subject us to significant liabilities to such third parties, and force us or our partners to curtail
or cease the development of some or all of our pharmaceutical product candidates, which could adversely affect our business, financial
condition, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>If we are unable to
protect the confidentiality of certain information, the value of our products and technology could be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We rely and previously relied
on trade secrets, know-how, and continuing technological advancement to develop and maintain our competitive position. To protect this
competitive position, we regularly enter into confidentiality and proprietary information agreements with third parties, including employees,
independent contractors, suppliers, and collaborators. We cannot, however, ensure that these protective arrangements will be honored
by third parties, and we may not have adequate remedies if these arrangements are breached. In addition, enforcement of claims that a
third-party has illegally obtained and is using trade secrets, know-how, or technological advancements is expensive, time-consuming,
and uncertain. Non-U.S. courts are sometimes less willing than U.S. courts to protect this information. Moreover, our trade secrets,
know-how, and technological advancements may otherwise become known or be independently developed by competitors in a manner providing
us with no practical recourse against the competing parties. If any such events were to occur, they could adversely affect our business,
financial condition, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>We may be subject to
claims that our former employees wrongfully used or disclosed alleged trade secrets of their former employers or of other third parties
with whom we have obligations of confidentiality.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">As is common in the pharmaceutical
industry, we employ and previously employed individuals who were previously employed at other biotechnology or pharmaceutical companies,
including our competitors or potential competitors. We may be subject to claims that these former employees, or we, have inadvertently
or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary
to defend against these claims. Such claims may lead to material costs for us, or an inability to protect or use valuable intellectual
property rights, which could adversely affect our business, financial condition, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>General risks related
to ownership of our Common Stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b><i>The market price of
our common stock may be highly volatile, and you could lose all or part of your investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The trading price of our common
stock on Nasdaq is likely to be volatile. This volatility may prevent you from being able to sell your shares at or above the price you
paid for your shares. Our stock price could be subject to wide fluctuations in response to a variety of factors, which include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>changes in laws or regulations applicable to our products;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>unanticipated serious safety concerns related to the use of our
                                            products;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the inability for our licensees to obtain adequate supply for
                                            our products or the inability to do so at acceptable prices;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>adverse regulatory decisions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the introduction of new products or technologies offered by our
                                            competitors;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the effectiveness of our licensees&#8217; commercialization efforts;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the perception of the pharmaceutical industry by the public,
                                            legislatures, regulators, and the investment community;</td></tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>disputes or other developments relating to proprietary rights,
                                            including patents, litigation matters, and our ability to obtain patent protection for our
                                            technologies;</td></tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>actual or anticipated variations in quarterly operating results;</td></tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the failure to meet or exceed the estimates and projections of
                                            the investment community;</td></tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the overall performance of the U.S. equity markets and general
                                            political and economic conditions;</td></tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>announcements of significant acquisitions, strategic partnerships,
                                            joint ventures, or capital commitments by us or our competitors;</td></tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>additions or departures of key management personnel;</td></tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>adverse market reaction to any indebtedness we may incur or securities
                                            we may issue in the future;</td></tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>sales of our common stock by us or our stockholders in the future;</td></tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>significant lawsuits, including patent or stockholder litigation;</td></tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>changes in the market valuations of similar companies;</td></tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>the trading volume of our common stock;</td></tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>increases in our common stock available for sale upon expiration
                                            of lock-up agreements;</td></tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>effects of natural or man-made catastrophic events or other business
                                            interruptions; and</td></tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: .25in">&#9679;</td><td>other events or factors, many of which are beyond our control.</td></tr></table><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">In addition, the stock market
in general, and the stock of biotechnology companies in particular, have experienced extreme price and volume fluctuations that have
often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively
affect the market price of our common stock, regardless of our actual operating performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>If securities or industry
analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume
could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The trading market for our
common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If
one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock
price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could
lose visibility in the financial markets, which might cause our stock price and trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>Future sales and issuances
of equity securities, convertible securities or other securities could result in additional dilution of the percentage ownership of holders
of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Our stockholders may experience
dilution upon future equity issuances, including convertible debt or equity securities we may issue in the future, the exercise of stock
options to purchase common stock granted to our employees, consultants and directors, including options to purchase common stock granted
under our stock option and equity incentive plans or the issuance of common stock in settlement of previously issued awards under our
stock option and equity incentive plans that may vest in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">We expect that additional
capital will be needed in the future to continue our planned operations. To raise capital, we may sell equity securities, convertible
securities or other securities in one or more transactions at prices and in a manner we determine from time to time. If we sell equity
securities, convertible securities or other securities current investors may be materially diluted by subsequent sales. We may also need
our stockholders to authorize the issuance of additional shares of common stock under our articles of incorporation if we do not have
sufficient authorized shares to raise such additional capital or issue future awards under our stock option and equity incentive plans.
New investors could also gain rights, preferences, and privileges senior to those of holders of our existing equity securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 1B. Unresolved staff comments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="Kalai_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 1C. Cybersecurity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cybersecurity Risk Management and Strategy</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have implemented and maintain various information security processes
designed to assess, identify and manage material risks from cybersecurity threats to our critical systems and information. Such processes
are integrated into our overall risk management processes. For example, cybersecurity risk is addressed as a component of our enterprise
risk management program and has historically been included as part of compliance reports provided to our audit committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our officers, contractors and third-party IT vendors help assess, identify
and manage our cybersecurity threats and risks by monitoring and evaluating our threat environment and risk profile using various methods
including, for example: through the use of automated tools; conducting audits and threat assessments for internal and external threats;
analyzing reports of threats and actors; conducting vulnerability assessments to identify vulnerabilities; evaluating our and our industry&#8217;s
risk profile; and evaluating threats reported to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We implement and maintain various technical, physical, and organizational
measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our critical
systems and information, including, for example: multi-factor authentication, encryption, anti-malware functionality, access controls
and systems monitoring.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We use third-party service providers to perform a variety of functions
throughout our business, including but not limited to application providers and hosting companies. All of our critical information is
hosted by a third-party service provider. We have a vendor management program to assess cybersecurity risks associated with our use of
these providers. Further, we also rely upon such third-party service providers to both assist us in identifying cybersecurity threats,
as well as to review and notify us of any data breach on their systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">For a description of the risks from cybersecurity threats that may
materially affect us and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this 2023 10-K Report, including
the risk factor captioned &#8220;We may not be able to maintain effective and efficient information systems or properly safeguard our
information systems.&#8221; While to date we have not identified any breaches from known cybersecurity threats, including as a result
of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our business
strategy, results of operations, or financial condition, the sophistication of cybersecurity threats continues to increase, and the preventative
actions we take to reduce the risk of cybersecurity incidents and protect our systems and information may be insufficient. Accordingly,
no matter how well our program is designed or implemented, we will not be able to anticipate all security breaches, and we may not be
able to implement effective preventive measures against such security breaches in a timely manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cybersecurity Governance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board of directors considers cybersecurity risk as part of its
risk oversight function. The audit committee of our board of directors bears primary responsibility for the board&#8217;s oversight of
our cybersecurity risk. Periodically management updates our audit committee about various risks facing the Company, of which cybersecurity
may be included.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our cybersecurity risk assessment and management processes are implemented
and maintained by management and IT consultants. The IT consultants have relevant expertise, experience, education and training as well
as knowledge of our company&#8217;s critical systems and information technology policies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our cybersecurity incident response processes are designed to escalate
certain cybersecurity incidents to our chief executive officer, who would be responsible, along with third parties including our IT consultants,
for assessing the materiality of, and mitigating and remediating, any cybersecurity incidents of which we are notified. In addition, our
incident response processes include a procedure for reporting certain cybersecurity incidents to the board of directors.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 2. Properties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our headquarters are in Boca Raton, Florida. We operate from a fully
remote environment. We have a lease that includes 62,748 rentable square feet, or the full premises, of which the lease of 7,561 square
feet commenced in 2018 and the lease of 55,187 square feet commenced in August of 2019, or the full premises commencement date. In June
2019, we entered into an agreement with the same lessors to lease an additional 6,536 square feet of administrative office space in the
same location, pursuant to an addendum to such lease, which commenced in May 2020. The lease will expire 11 years after the full premises
commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term of the lease
for two additional consecutive periods of five years. The extension option is not included in the determination of the lease term as it
is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent periods. We are also responsible
for certain other operating costs under the lease, including electricity and utility expenses. We have sublet 41,418 square feet and are
in the process of subletting the remaining 21,330 square feet of our headquarters in Boca Raton as a result of shifting our business to
become a pharmaceutical royalty company and terminating our employees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 3. Legal proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">In February 2020, we received a Paragraph IV
certification notice letter (the &#8220;IMVEXXY Notice Letter&#8221;) regarding an Abbreviated New Drug Application (&#8220;ANDA&#8221;)
submitted to the FDA by Teva Pharmaceuticals USA, Inc. (&#8220;Teva&#8221;). The ANDA seeks approval from the FDA to commercially manufacture,
use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the IMVEXXY Notice Letter, Teva alleges that TherapeuticsMD
patents listed in the FDA&#8217;s Orange Book that claim compositions and methods of IMVEXXY (the &#8220;IMVEXXY Patents&#8221;) are
invalid, unenforceable, and/or will not be infringed by Teva&#8217;s commercial manufacture, use, or sale of its proposed generic drug
product. The IMVEXXY Patents identified in the IMVEXXY Notice Letter expire in 2032 or 2033. In April 2020, we filed a complaint for
patent infringement against Teva in the United States District Court for the District of New Jersey arising from Teva&#8217;s ANDA filing
with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA would be
a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents.
Teva has filed its answer and counterclaim to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. In July
2021, following a proposal by Teva, the District Court entered an order temporarily staying all proceedings in the IMVEXXY litigation,
which order was filed under seal. In September 2021, the District Court made available a public version of the order following the parties&#8217;
agreement to a consent motion to redact information Teva contended was confidential. The order provides that the statutory stay that
prevents the FDA from granting final approval of the ANDA for 30 months from the date of the IMVEXXY Notice Letter will be extended for
the number of days that the stay of the IMVEXXY litigation is in place. The length of the stay of the IMVEXXY litigation is dependent
on further action by Teva. As of December 31, 2022, for the IMVEXXY Paragraph IV legal proceeding, we had incurred and recorded legal
costs amounting to $2.3 million in prepaid expenses and other current assets since we believe that we will successfully prevail in this
legal proceeding. Upon the successful conclusion of the legal proceeding, the related capitalized legal costs will be reclassified to
patents, in license rights and other intangible assets, net, in the accompanying consolidated balance sheets, and such costs will be
amortized over the remaining useful life of the patents. If we are unsuccessful in this legal proceeding, then the related capitalized
legal costs for this legal preceding and any unamortized IMVEXXY patent costs that were previously capitalized will be immediately expensed
in the period in which we become aware of an unsuccessful legal proceeding. As of December 30, 2022, and per the Mayne License Agreement,
Mayne Pharma is responsible for all enforcement of our patents, including this litigation with Teva.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">From time to time, we are involved in other
litigations and proceedings in the ordinary course of business. We are currently not involved in any other litigations and proceedings
that we believe would have a material effect on our consolidated financial condition, results of operations, or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 4. Mine safety disclosures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 5. Market for registrant&#8217;s common
equity, related stockholder matters, and issuer purchases of equity securities market information on common stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Since October 2017, our common stock has been
listed on the Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;TXMD.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 29, 2023, the closing price of our common stock on Nasdaq
was $2.25 per share. As of March 29, 2024, there were 80 stockholders of record of our common stock.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Performance graph</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">As a &#8220;smaller reporting company,&#8221;
as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and pursuant to Instruction
6 to Item 201(e) of Regulation S-K, we are not required to provide this information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Historically, we have not paid dividends on
our common stock, and we currently do not intend to pay any dividends on our common stock in the foreseeable future. We currently plan
to retain any earnings for the operation of our business rather than to pay cash dividends. Payments of any cash dividends in the future
will depend on our financial condition, results of operations, and capital requirements as well as other factors deemed relevant by our
board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 6. Reserved</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 7. Management&#8217;s discussion and
analysis of financial condition and results of operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">You should read the following discussion and
analysis in conjunction with the information set forth under our consolidated financial statements and the notes to those financial statements
included elsewhere in this 2023 10-K Report. This discussion contains forward-looking statements based upon current expectations that
involve risks and uncertainties. See &#8220;Statement Regarding Forward-Looking Information.&#8221; Our actual results may differ materially
from those contained in or implied by any forward-looking statements as a result of various factors, including, but not limited to, the
risks and uncertainties described under &#8220;Risk Factors&#8221; elsewhere in this 2023 10-K Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Certain amounts in the Management&#8217;s discussion
and analysis of financial condition and results of operations may not add due to rounding, and all percentages have been calculated using
unrounded amounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Business overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">TherapeuticsMD was previously a women&#8217;s
healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy
prevention through menopause. In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving
royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in relevant territories. On December
30, 2022 (the &#8220;Closing Date&#8221;), we completed a transaction (the &#8220;Mayne Transaction&#8221;) with Mayne Pharma LLC, a
Delaware limited liability company (&#8220;Mayne Pharma&#8221;) and subsidiary of Mayne Pharma Group Limited, an Australian public company,
in which we and our subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize our IMVEXXY, BIJUVA and prescription
prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the &#8220;Licensed Products&#8221;) in the
United States and its possessions and territories, (ii) assigned to Mayne Pharma our exclusive license to commercialize ANNOVERA&#174;
(together with the Licensed Products, collectively, the &#8220;Products&#8221;) in the United States and its possessions and territories,
and (iii) sold certain other assets to Mayne Pharma in connection therewith.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">In a License Agreement, dated December 4, 2022,
between TherapeuticsMD and Mayne Pharma (the &#8220;Mayne License Agreement&#8221;), we granted Mayne Pharma, on the Closing Date, (i)
an exclusive, sublicensable, perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell,
use, and commercialize the Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable,
perpetual, irrevocable license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States
for commercialization in the United States and its possessions and territories.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Under the Mayne License Agreement, Mayne
Pharma will pay us one-time milestone payments of each of (i) $5.0 million if aggregate net sales of all Products in the United
States during a calendar year reach $100.0 million, (ii) $10.0 million if aggregate net sales of all Products in the United States
during a calendar year reach $200.0 million and (iii) $15.0 million if aggregate net sales of all Products in the United States
during a calendar year reach $300.0 million. Further, Mayne Pharma will pay us royalties on net sales of all Products in the United
States at a royalty rate of 8.0% on the first $80.0 million in annual net sales and 7.5% on annual net sales above $80.0 million,
subject to certain adjustments, for a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a
Product-by-Product basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and
(ii) a generic version of a Product launching in the United States. Mayne Pharma will pay us minimum annual royalties of $3.0
million per year for 12 years, adjusted for inflation at an annual rate of 3%, subject to certain further adjustments, including as
described below. Upon the expiry of the 20-year royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement
will become a fully paid-up and royalty free license for the Licensed Products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Under the Transaction Agreement, dated December
4, 2022, between TherapeuticsMD and Mayne Pharma (the &#8220;Transaction Agreement&#8221;), we sold to Mayne Pharma, at closing, certain
assets for Mayne Pharma to commercialize the Products in the United States, including, with the Population Council&#8217;s consent, our
exclusive license from the Population Council to commercialize ANNOVERA (the &#8220;Transferred Assets&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The total consideration from Mayne Pharma
to TherapeuticsMD for the purchase of the Transferred Assets under the Transaction Agreement and the grant of the licenses under the
Mayne License Agreement was (i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million
at closing for the acquisition of net working capital as determined in accordance with the Transaction Agreement and subject to
certain adjustments, (iii) a cash payment of approximately $1.0 million at closing for prepaid royalties in connection with the
Mayne License Agreement Amendment (as defined below) and (iv) the right to receive the contingent consideration set forth in the
Mayne License Agreement, as amended. The acquisition of net working capital was determined in accordance with the Transaction
Agreement and included significant estimates which could change materially for a period of up to two years following the Closing
Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On the Closing Date, TherapeuticsMD and Mayne Pharma entered into Amendment
No. 1 to the Mayne License Agreement (the &#8220;Mayne License Agreement Amendment&#8221;). Pursuant to the Mayne License Agreement Amendment,
Mayne Pharma agreed to pay us approximately $1.0 million in prepaid royalties on the Closing Date. The prepaid royalties reduced the first
four quarterly payments that would have otherwise been payable pursuant to the Mayne License Agreement by an amount equal to $257 thousand
per quarterly royalty payment plus interest calculated at 19% per annum accruing from the Closing Date until the date such quarterly royalty
payment was paid to us. We and Mayne Pharma settled the $1.5 million of consideration due to Mayne for the assumed obligations under a
long-term services agreement (see the section entitled &#8220;vitaCare divestiture&#8221; below for a discussion of the long-term services
agreement), including our minimum payment obligations thereunder. As the parties agreed, during the second quarter of 2023, Mayne Parma
held back our royalty payment of $0.6 million and we funded an additional $0.9 million in August 2023 to settle the original $1.5 million
payable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As part of the transformation that included the Mayne License Agreement,
historical results of commercial operations for all periods prior to the Closing Date have been reflected as discontinued operations in
our consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities
of discontinued operations in our consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in
Note 2 of our consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The Company also has license agreements with
strategic partners to commercialize IMVEXXY and BIJUVA outside of the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">In July 2018, we entered into the &#8220;Knight License Agreement&#8221;
with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">In June 2019, we entered into the &#8220;Theramex License
Agreement&#8221; with Theramex to commercialize IMVEXXY and BIJUVA outside of the U.S., excluding Canada and Israel. In 2021, Theramex secured
regulatory approval for BIJUVA in certain European countries and began commercialization efforts in those countries.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">In connection with our transformation into a
pharmaceutical royalty company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel
and current Chief Executive Officer) and all other employees was completed by December 31, 2022. Severance obligations for all employees
other than executive officers were paid in full in January 2023 and severance obligations for terminated executive officers were paid
in accordance with their employment agreements and separation agreements as previously disclosed. As of December 31,  2023,
we employed one full-time employee primarily engaged in an executive position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">We have engaged external consultants who support our relationship with
current partners and assist with certain financial, legal, and regulatory matters and the continued wind-down of our historical business
operations. On August 15, 2023, we entered into a master services agreement with JZ Advisory Group, pursuant to which Joseph Ziegler would
serve as our Principal Financial and Accounting Officer. On August 17, 2023 Michael C. Donegan notified us of his decision to resign from
the positions of Principal Financial and Accounting Officer of our Company effective as of August 17, 2023. Mr. Ziegler succeeded Mr.
Donegan as Principal Financial and Accounting Officer as of the date of Mr. Donegan&#8217;s resignation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>vitaCare divestiture</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On April&#160;14, 2022, we completed the divestiture of vitaCare Prescription
Services, Inc. (&#8220;vitaCare&#8221;) with the sale of all vitaCare&#8217;s issued and outstanding capital stock (the &#8220;vitaCare
Divestiture&#8221;). We received net proceeds of $142.6&#160;million, net of transaction costs of $7.2&#160;million, and we recognized
a gain on sale of business of $143.4&#160;million. Included in the net proceeds amount was $11.3&#160;million of customary holdbacks as
provided in the stock purchase agreement between us and GoodRx, Inc. (the &#8220;Purchase Agreement&#8221;), which was recorded as restricted
cash in the consolidated balance sheets until the cash was released to us. The restricted cash was held by an escrow agent and was released
to us in March 2023. Additionally, we may receive up to an additional $7.0&#160;million in earn-out consideration, contingent upon vitaCare&#8217;s
financial performance through 2023 as determined in accordance with the terms of the Purchase Agreement, however we do not believe this
earnout will be realized. We will record the contingent consideration at the settlement amount when the consideration is realized or realizable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The Purchase Agreement contains customary representations and warranties,
covenants, and indemnities of the parties thereto. Our commitments under a long-term services agreement related to vitaCare were transferred
to Mayne Pharma as part of the Mayne Transaction. In addition, under the Mayne License Agreement Amendment, we owed Mayne Pharma $1.5
million payable from one royalty payment. During the second quarter of 2023, Mayne Pharma held back our royalty payment of $0.6 million
and we funded an additional $0.9 million in August 2023 to settle the original $1.5 million payable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The pre-divesture operations
of vitaCare were reclassified to discontinued operations in December 2022 when we transitioned to becoming a royalty company and licensed
our products to Mayne Pharma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Portfolio of our licensed products</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">In December 2022, we changed our business to
become a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess
commercial capabilities in the relevant territories. On December&#160;30, 2022, we granted an exclusive license to commercialize IMVEXXY,
BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigning our exclusive license
to commercialize ANNOVERA to Mayne Pharma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration:underline">IMVEXXY (estradiol vaginal inserts), 4-&#956;g
and 10-&#956;g</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">This pharmaceutical product is for the treatment
of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due to menopause.
As part of the FDA&#8217;s approval of IMVEXXY, we committed to conduct a post-approval observational study to evaluate the risk of endometrial
cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On December&#160;30, 2022, we granted an exclusive
license to commercialize IMVEXXY in the United States and its possessions and territories to Mayne Pharma. We also have entered into
licensing agreements with third parties to market and sell IMVEXXY outside of the U.S. We entered into the Knight License Agreement,
with Knight pursuant to which, we granted Knight an exclusive license to commercialize IMVEXXY in Canada and Israel. We entered into
the Theramex License Agreement with Theramex HQ UK Limited (&#8220;Theramex&#8221;) pursuant to which we granted Theramex an exclusive
license to commercialize IMVEXXY for human use outside of the U.S., except for Canada and Israel. As of December 31, 2023, no IMVEXXY
sales had been made through the Theramex and Knight licensing agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The FDA has also asked the sponsors of other
vaginal estrogen products to participate in the observational study. In connection with the observational study, we would have been required
to provide progress reports to the FDA on an annual basis. The obligation to conduct this study was transferred to Mayne Pharma as part
of the Mayne License Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration:underline">BIJUVA (estradiol and progesterone) capsules,
1 mg/100 mg</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">This pharmaceutical product is the first and
only FDA approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment
of moderate-to-severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On December&#160;30, 2022, we granted an exclusive
license to commercialize BIJUVA in the United States and its possessions and territories to Mayne Pharma. We also have entered into the
Knight License Agreement with Knight pursuant to which we granted Knight an exclusive license to commercialize BIJUVA in Canada and Israel.
We have entered into the Theramex License Agreement with Theramex pursuant to which we granted Theramex an exclusive license to commercialize
BIJUVA for human use outside of the U.S., except for Canada and Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration:underline">ANNOVERA (segesterone acetate (&#8220;SA&#8221;)
and ethinyl estradiol (&#8220;EE&#8221;) vaginal system)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On December&#160;30, 2022, we assigned our exclusive
license to commercialize ANNOVERA to Mayne Pharma. This pharmaceutical product is a one-year ring-shaped contraceptive vaginal system
(&#8220;CVS&#8221;) and the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent
pregnancy for up to a total of 13 cycles (one year). ANNOVERA is commercially sold in the U.S. pursuant to the terms of the Population
Council License Agreement. As part of the approval of ANNOVERA, the FDA has required a post-approval observational study be performed
to measure the risk of venous thromboembolism. We agreed to perform and pay the costs and expenses associated with this post-approval
study, provided that if the costs and expenses associated with such post-approval study exceed $20.0&#160;million, half of such excess
will offset against royalties or other payments owed by us under the Population Council License Agreement. In August 2021, we filed a
supplemental New Drug Application (&#8220;NDA&#8221;) with the FDA to modify the testing specifications for ANNOVERA to allow increased
consistency of supply of ANNOVERA. In May 2022, the FDA approved the supplemental NDA for ANNOVERA. Our obligations to perform the post-approval
study have been transferred to Mayne Pharma as part of the Mayne License Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration:underline">Prenatal vitamin products</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On December&#160;30, 2022, we granted an exclusive
license to commercialize, in the United States and its possessions and territories, our prescription prenatal vitamin product lines under
our vitaMedMD brand name and authorized generic formulations of some of our prescription prenatal vitamin products under our BocaGreenMD
Prenatal name to Mayne Pharma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Results of operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">In December 2022, we granted an exclusive license
to commercialize our IMVEXXY, BIJUVA, and prescription prenatal vitamin products and assigned our exclusive license to commercialize
ANNOVERA to Mayne Pharma, which resulted in a business shift that had a major effect on our operations and financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As part of the transformation that included the Mayne License Agreement,
historical results of commercial operations have been reflected as discontinued operations in the Company&#8217;s consolidated financial
statements for all periods prior to the Closing Date. Assets and liabilities associated with the commercial business are classified as
assets and liabilities of discontinued operations in the Company&#8217;s consolidated balance sheets. Additional disclosures regarding
discontinued operations are provided in Note 2 to the consolidated financial statements included in this 2023 10-K Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The following table sets forth the results of
our operations (in thousands):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">Revenue, net:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">License and service revenue</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,302</td><td style="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">69,963</td><td style="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Total revenue, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,302</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">69,963</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Cost of revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,397</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Gross profit</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,302</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">68,566</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Selling, general and administrative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,903</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">56,710</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Depreciation &amp; amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">922</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,193</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Restructuring</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,472</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,825</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">67,375</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Income (loss) from operations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,523</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,191</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Miscellaneous income (expense)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">781</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(117</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total other income (loss), net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">781</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(117</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Income (loss) from continuing operations before income taxes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(7,742</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,074</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Benefit (provision) for income
    taxes</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">43</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net income (loss) from continuing operations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(7,699</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,074</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Income (loss) from discontinued operations, net of income taxes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,579</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">110,923</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Net income (loss)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(10,278</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">111,997</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Revenue. </i>As part of our transformation
and the Mayne License Agreement, historical results of commercial operations have been reflected as discontinued operations in the Company&#8217;s
consolidated financial statements for all periods presented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded $1.3 million in license revenue during the year ended December
31, 2023 primarily from the Mayne License Agreement, a decrease of $68.7 million, compared to $70.0 million in license revenue recorded
for the allocation of the initial upfront payment and guaranteed minimum royalties from the Mayne License Agreement during the year ended
December 31, 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Gross profit. </i>Our gross profit for 2023 was $1.3 million, a decrease
of $67.3 million, compared to $68.6 million for 2022. This decrease in our gross profit was primarily a result of the license revenue
related to the initial upfront payment and guaranteed minimums from the Mayne Transaction that was recognized during the year ended December
31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Operating expenses. </i>Total operating expenses for 2023 were $9.8
million, a decrease of $57.6 million, compared to the $67.4 million we had for 2022. Total operating expenses decreased primarily due
to lower general and administrative expenses due to the transition of our business from a manufacturing and commercialization business
to a royalty- based business with limited infrastructure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Income (loss) from operations. </i>For 2023, we had a loss from operations
of $8.5 million, a decrease of $9.7 million, compared to income from operations of $1.2 million for 2022. This change was primarily attributable
to the transition of our business from a manufacturing and commercialization business to a royalty-based business and the revenue related
to the allocation of the initial upfront payment and guaranteed minimum royalties from the Mayne License Agreement during the year ended
December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Other income (expense), net. </i>In 2023, we had other income of
$0.8 million, an increase of $0.9 million, compared to other expense of $0.1 million in 2022. Other income (expense), net represents interest
income from bank accounts as well the present value of the minimum royalty receivables recorded compared to actual minimum royalties received
and other miscellaneous items. The year ended December 31, 2023 also includes $0.5 million in other income pertaining to royalty sales
of ANNOVERA.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Benefit (provision) for income taxes</i>. In 2023, the Company recognized
an immaterial benefit for income taxes from continuing operations, while no provision for income taxes was recognized in 2022 from continuing
operations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Net income (loss) from continuing operations</i>. For 2023, we had net
loss from continuing operations of $7.7 million, or $0.74 per basic and diluted common share, a decrease of $8.8 million, compared to
net income from continuing operations of $1.1 million, or $0.12 per basic and $0.11 per diluted common share, for 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Discontinued Operations &#8212; </i>For 2023 revenues from discontinued
operations were $(0.8) million, a decrease of $81.5 million, as compared to $80.7 million in 2022. Revenue in 2023 reflected adjustments
to earnings under the Mayne Agreement. In 2023, operating expenses from discontinued operations were $0.5 million, a decrease of $97.1
million, compared to $97.6 million in 2022. For 2023, net loss from discontinued operations was $2.6 million, a decrease of $113.5 million,
compared to net income from discontinued operations of $110.9 million for 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">For additional information, see Note 2 &#8211; Discontinued
Operations, in the notes to the consolidated financial statements appearing elsewhere in this 2023 10-K Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Liquidity and capital resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Our primary use of cash is to fund our continuing
operations. We have funded our operations primarily through public offerings of our common stock and private placements of equity and
debt securities, the divestiture of our former subsidiary vitaCare, and the transactions with Mayne Pharma. As of December 31, 2023,
we had cash and cash equivalents totaling $4.3 million. We maintain cash at financial institutions that at times may exceed the Federal
Deposit Insurance Corporation insured limits of $0.25 million per bank. We have never experienced any losses related to these funds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>vitaCare Divestiture</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On April 14, 2022, we completed the vitaCare
Divestiture. We may receive up to an additional $7.0 million in earn-out consideration, contingent upon vitaCare&#8217;s financial performance
through 2023 as determined in accordance with the terms of the Purchase Agreement, however we do not believe this earnout will be realized.
We utilized $120.0 million of net proceeds from the vitaCare Divestiture to make a prepayment of the loans under the Financing Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Mayne Pharma License Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 30, 2022, we granted Mayne Pharma (i) an exclusive, sublicensable,
perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell, use, and commercialize the
Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable
license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States for commercialization
in the United States and its possessions and territories. The total consideration from Mayne Pharma to us under the Mayne License Agreement
consisted of (i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million at closing for the acquisition
of net working capital as determined in accordance with the Transaction Agreement, and subject to certain adjustments,
(iii) a cash payment of approximately $1.0 million at closing for prepaid royalties in connection with the Mayne License Agreement Amendment
and (iv) the right to receive the contingent consideration set forth in the Mayne License Agreement, as amended.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Pursuant to the Mayne License
Agreement, Mayne Pharma will pay us one-time, milestone payments of each of (i) $5.0 million if aggregate net sales of all Products in
the United States during a calendar year reach $100.0 million, (ii) $10.0 million if aggregate net sales of all Products in the United
States during a calendar year reach $200.0 million and (iii) $15.0 million if aggregate net sales of all Products in the United States
during a calendar year reach $300.0 million. Further, Mayne Pharma will pay us royalties on net sales of all Products in the United States
at a royalty rate of 8.0% on the first $80 million in annual net sales and 7.5% on annual net sales above $80.0 million, subject to certain
adjustments, for a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product basis
upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version of a Product
launching in the United States. Mayne Pharma will pay us minimum annual royalties of $3.0 million per year for 12 years, adjusted for
inflation at an annual rate of 3%, subject to certain further adjustments, including as described below. Upon the expiry of the 20-year
royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully paid-up and royalty free license
for the Licensed Products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mayne Pharma paid us approximately $12.1 million at closing on the Closing Date for the acquisition of net working capital, subject to certain adjustments as determined in accordance with the Transaction
Agreement. While the Transaction Agreement calls for much of the net working capital to be trued-up shortly after the Closing Date in
2023, for a period of one year following the Closing Date in the case of payer rebates and wholesale distributor fees and two years
following the Closing Date in the case for allowance for returns, net working capital amounts will be adjusted to arrive at final net
working capital under the Transaction Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2023, we revised certain accrual estimates including increasing
our working capital adjustment accrual from $3.5 million to $5.5 million for amounts anticipated to be owed under the Transaction Agreement.&#160;
In December 2023, we made a $5.5 million payment to Mayne Pharma to settle certain working capital amounts that were required to be trued-up
shortly after the Closing Date, excluding the allowance for returns, allowance for payer rebates, and allowance for wholesale distributor
fees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2024, the Company received Mayne Pharma&#8217;s
                                                                         calculation of allowance for payer rebates and wholesale distributor fees which differed significantly from the Company&#8217;s
                                                                         estimate of the allowances. The Company believes its estimated allowances for payer rebates and wholesale distributor fees are
                                                                         reasonable and intends to resolve this matter through the process outlined in the Transaction Agreement. Given the recent receipt of
                                                                         Mayne Pharma&#8217;s allowance calculation and the nature of the estimates involved, the outcome of this matter is uncertain at this
                                                                         point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any
                                                                         additional liability associated with Mayne Pharma&#8217;s allowance calculation for payer rebates and wholesale distributor
                                                                         fees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, the Company believes no additional accrual
is required for amounts that may be owed for the allowance for returns. The Company has not recorded any contingent gains or receivables
for any such allowances. Management continues to monitor the unresolved and pending net working capital items as changes to estimated
amounts owed or amounts due from Mayne Pharma that may be material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Subscription Agreement with Rubric Capital
Management LP</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On May 1, 2023, we entered into the Subscription
Agreement with Rubric, pursuant to which we agreed to sell to Rubric, or one or more of its affiliates, up to an aggregate of 5,000,000
shares of Common Stock, from time to time during the term of the Subscription Agreement in separate draw downs at our election, at a
purchase price of the five-day volume-weighted average price of our common stock at the time of the sale of such shares, at an aggregate
purchase price of up to $5,000,000 (collectively, the &#8220;Private Placement&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The initial draw down occurred on June 29, 2023 consisting of a sale of
312,525 shares of Common Stock at a price per share equal to $3.6797. We received gross proceeds of $1.15 million from the drawdown, before
expenses. On November 15, 2023 Rubric drew down an additional 877,192 shares of Common Stock at a price per share equal to $2.2761. We
received gross proceeds of $2.0 million from the drawdown, before expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Going concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On the Closing Date of the
Mayne Transaction, we repaid all obligations under the Financing Agreement, dated as of April 24, 2019, as amended, with Sixth Street
Specialty Lending, Inc., as administrative agent, the various lenders from time-to-time party thereto, and certain of our subsidiaries
party thereto from time to time as guarantors (the &#8220;Financing Agreement&#8221;) and the Financing Agreement was terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Following the transaction with Mayne
Pharma, our primary source of revenue is from royalties on products licensed to pharmaceutical organizations that possess commercial
capabilities in the relevant territories. We may need to raise additional capital to provide additional liquidity to fund our
operations until we become cash flow positive. To address our capital needs, we may pursue various equity and debt financing and
other alternatives. The equity financing alternatives may include the private placement of equity, equity-linked, or other similar
instruments or obligations with one or more investors, lenders, or other institutional counterparties or an underwritten public
equity or equity-linked securities offering. Our ability to sell equity securities may be limited by market conditions, including
the market price of our common stock and our available authorized shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">To the extent that we raise additional capital
through the sale of such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new
securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we are not
successful in obtaining additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable
prices, or merge, consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable
to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On May 1, 2023, we entered into a
Subscription Agreement (the &#8220;Subscription Agreement&#8221;) with Rubric Capital Management LP (&#8220;Rubric&#8221;), pursuant
to which we agreed to sell to Rubric, or one or more of its affiliates, up to an aggregate of 5,000,000 shares of our common stock,
par value $0.001 per share (our &#8220;Common Stock&#8221;), from time to time during the term of the Subscription Agreement at a
purchase price of the five-day volume-weighted average price of the Common Stock at the time of the sale of such shares of Common
Stock, at an aggregate purchase price of up to $5,000,000. On June 29, 2023, we issued and sold 312,525 shares of Common Stock at a
price per share equal to $3.6797 pursuant to the Subscription Agreement. We received gross proceeds of $1.15 million from the draw
down, before expenses. On November 15, 2023 Rubric drew down an additional 877,192 shares of Common Stock at a price per share equal
to $2.2761. We received gross proceeds of $2.0 million from the drawdown, before expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2024, the Company received Mayne Pharma&#8217;s
                                                                                               calculation of allowance for payer rebates and wholesale distributor fees pursuant to the Transaction Agreement which differed
                                                                                               significantly from the Company&#8217;s estimate of the allowances. The Company believes its estimated allowances for payer rebates
                                                                                               and wholesale distributor fees are reasonable and intends to resolve this matter through the process outlined in the Transaction
                                                                                               Agreement. Given the recent receipt of Mayne Pharma&#8217;s allowance calculation and the nature of the estimates involved, the
                                                                                               outcome of this matter is uncertain at this point. As a result, the Company cannot reasonably estimate a range of loss, and
                                                                                               accordingly, the Company has not accrued any additional liability associated with Mayne Pharma&#8217;s allowance calculation for
                                                                                               payer rebates and wholesale distributor fees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, the Company believes no additional accrual
is required for amounts that may be owed for the allowance for returns under the Transaction Agreement. The Company has not recorded any
contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital
items as changes to estimated amounts owed or amounts due from Mayne Pharma may be material.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">If Mayne Pharma&#8217;s sales of Licensed
Products grow more slowly than expected or decline, if the net working capital settlement with Mayne Pharma under the Transaction
Agreement is greater than our current estimates, if we are unsuccessful with future financings or the supply chains related to the
third-party contract manufacturers are worse than we anticipate, our existing cash reserves may be insufficient to satisfy our
liquidity requirements. The potential impact of these factors in conjunction with the uncertainty of the capital markets raises
substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The accompanying consolidated financial statements
do not include any adjustments that might be necessary if we are unable to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Cash flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The following table reflects the major categories
of cash flows from continuing operations for each of the periods (in thousands).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Years ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Cash flow from continuing operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net cash provided by (used in) operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(23,081</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,359</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net cash (used in) investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(355</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by (used in) financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(235,206</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,060</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">210,397</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net decrease in cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(44,990</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(15,805</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Operating Activities from continuing operations. </i>Net cash used
in operating activities in 2023 was $23.1 million, a decrease of $32.4 million, compared to net cash provided by operating activities
of $9.4 million for 2022. This change was due our transition from a manufacturing and commercialization business to a royalty-based business.
Cash outflows in 2023 primarily related to maintaining our operating activities as a royalty company and paying down commercial amounts
accrued for at December 31, 2022.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Investing Activities from continuing operations. </i>Net cash used
in investing activities for 2023 was $0.0 million, a decrease of $0.4 million, compared to net cash used in investing activities of
$0.4 million for 2022. This change was due our transition from a manufacturing and commercialization business to a royalty-based
business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Financing Activities from continuing operations. </i>Net cash provided
by financing activities for 2023 was $3.2 million, a decrease of $238.4 million, compared to net cash used by financing activities of
$235.2 million for 2022. Cash proceeds in 2023 are from stock sales to Rubric Capital Management and cash outflows during 2022 reflect
our paydowns of debt.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Discontinued operations. </i>Net cash used in discontinued operations
for 2023 was $25.1 million, a decrease of $235.5 million, as compared to net cash provided by discontinued operations of $210.4 million
for 2022. This change was due to our transition from a manufacturing and commercialization business to a royalty-based business as well
as proceeds from the divesture of vitaCare of $142.6 million and proceeds from the sale of ANNOVERA of $81.2 million which occurred during
2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt">For additional details, see the consolidated statements of
cash flows included in our consolidated financial statements in this 2023 10-K Report.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Other liquidity measure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Receivable
from Mayne.</i> On December 30, 2022, Mayne Pharma acquired our accounts receivable balance of approximately $29.3 million which is subject
to certain working capital adjustments. As of December 31, 2023, we had a royalty receivable of $3.1 million relating to the short-term
portion of receivable from Mayne Pharma and $18.5 million relating to the long-term portion of royalty receivable which includes royalties
recognized from the Minimum Annual Royalty. See Note 1 Business, basis of presentation, new accounting standards and summary of significant
accounting policies (Revenue Recognition) to the consolidated financial statements included in this 2023 10-K Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Contractual obligations, off-balance sheet
arrangements, purchase commitments and employment agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our contractual obligations and off-balance sheet arrangements are
discussed below. For additional information on any of the following and other obligations and arrangements, see &#8220;Note 8. Commitments
and Contingencies&#8221; to the consolidated financial statements included in this 2023 10-K Report.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the normal course of business, we may be confronted with issues
or events that may result in contingent liability. These generally relate to lawsuits, claims, environmental actions, or the actions of
various regulatory agencies. We consult with counsel and other appropriate experts to assess the claim. If, in our opinion, we have incurred
a probable loss as set forth by U.S. GAAP, an estimate is made of the loss and the appropriate accounting entries are reflected in our
consolidated financial statements.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Commitments</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Information regarding commitments is in &#8220;Note
8. Commitments and contingencies&#8221; to the consolidated financial statements included in this 2023 10-K Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Employment agreements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Information regarding employment agreements
is in &#8220;Note 8. Commitments and contingencies&#8221; to the consolidated financial statements included in this 2023 10-K Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Critical accounting policies and estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Management&#8217;s discussion and analysis of our
financial condition and results of operations are based upon our consolidated financial statements included elsewhere in this 2023 10-K
Report, which has been prepared in accordance with U.S. GAAP (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements
requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and
related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to unbilled
revenue, identifiable intangible assets, certain accrued liabilities, and income taxes. We base our estimates on historical experience
and on other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from
these estimates under different assumptions or conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">We have identified the areas described below
as critical to our business operations and the understanding of our results of operations given the uncertainties associated with the
assumptions underlying each estimate. For a detailed discussion on the application of these and other significant accounting policies,
see &#8220;Note 1. Basis of presentation, new accounting standards and summary of significant accounting policies&#8221; to the consolidated
financial statements included in this 2023 10-K Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Discontinued Operations</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Discontinued operations comprise activities
that were disposed of at the end of the period, represent a separate major line of business that can be clearly distinguished for operational
and financial reporting purposes and represent a business shift having a major effect on the Company&#8217;s operations and financial
results according to Accounting Standard Codification (&#8220;ASC&#8221;) Topic 205, Presentation of Financial Statements. An adjustment
has been made to the consolidated statements of operations for the twelve months ended December 31, 2023 and 2022 to reclassify commercial
activities and vitaCare activities to discontinued operations as the cessation of these operations, in the aggregate, represented a business
shift that will have a major effect on the Company&#8217;s operations and financial results. For additional information, see Note 2 &#8211;
Discontinued Operations, in the notes to the consolidated financial statements appearing elsewhere in this Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>&#160;</i></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Loss contingencies &#8211;
Mayne Pharma</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In determining whether an accrual for a loss contingency is required,
we first assess the likelihood of occurrence of the future event or events that will confirm the loss. When a loss is probable (the future
event or events are likely to occur) and the amount of the loss can be reasonably estimated, the estimated loss is accrued. If the reasonable
estimate of the loss is a range and an amount within the range appears to be a better estimate than any other amount within the range,
that amount should be accrued. However, if no amount within the range is a better estimate, the minimum amount in the range should be
accrued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2024, the Company received Mayne Pharma&#8217;s
                                                                         calculation of allowance for payer rebates and wholesale distributor fees which differed significantly from the Company&#8217;s
                                                                         estimate of the allowances. The Company believes its estimated allowances for payer rebates and wholesale distributor fees are
                                                                         reasonable and intends to resolve this matter through the process outlined in the Transaction Agreement. Given the recent receipt of
                                                                         Mayne Pharma&#8217;s allowance calculation and the nature of the estimates involved, the outcome of this matter is uncertain at this
                                                                         point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any
                                                                         additional liability associated with Mayne Pharma&#8217;s allowance calculation for payer rebates and wholesale distributor
                                                                         fees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The Company believes no additional accrual is required for amounts
that may be owed for the allowance for returns. The Company has not recorded any contingent gains or receivables for any such allowances.
Management continues to monitor the unresolved and pending net working capital items as changes to estimated amounts owed or amounts due
from Mayne Pharma that may be material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>License revenue</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">License arrangements may consist of non-refundable
upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones
and future product royalty payments. Some of these arrangements may include multiple performance obligations. Non-refundable up-front
fees that are not contingent on any future performance by us, and do not require continuing involvement on our part, are recognized as
revenue when the right to use functional intellectual property is transferred to the customer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 30, 2022, we closed a License Agreement with Mayne Pharma
pursuant to which we sold to Mayne Pharma the exclusive license rights in our product ANNOVERA and granted an exclusive license in other
products, including IMVEXXY and BIJUVA. Under the terms of the License Agreement, we received $140 million at closing and we are eligible
to receive additional payments in the aggregate of up to an additional $30 million based on the achievement of sales milestones (collectively,
the &#8220;Milestone Amounts&#8221;). The proceeds at closing were allocated between consideration for the sale of ANNOVERA and the initial
license fee for the Licensed Products, as the sale of ANNOVERA was accounted for under ASC 610-20, Gains and Losses from Derecognition
of Nonfinancial Assets in arriving at the gain on disposal (see Note 2 to the consolidated financial statements included in this 2023
10-K Report), while the license grant of the other products were recognized under the provisions of ASC 606, Revenue from Contracts with
Customers, as a license of functional intellectual asset. The proceeds were allocated among the Licensed Products on the relative net
present value of forecasted future product sales from those products. The Milestone Amounts will be recognized, as applicable, in subsequent
periods based on actual product sales that exceed the respective net sales milestones as such variable consideration is constrained by
the occurrence of the subsequent sales.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our royalty revenue recognized in 2023 primarily related to royalties
provided for under the Mayne License Agreement based on Mayne Pharma&#8217;s sales of the Licensed Products subject to that agreement.
Under the Mayne License Agreement, the Company is entitled to earn royalties on net sales of all of the Licensed Products at a royalty
rate of (i) 8% on the first $80 million of net sales of the Licensed Products and (ii) 7.5% on net sales of all of the Licensed Products
after the first $80 million of net sales. The royalty rate is subject to a 2% reduction upon the earlier to occur of (i) the expiration
or revocation of the last valid claim covering a Licensed Product, and (ii) a generic product launch (a &#8220;LOE&#8221;). We are entitled
to minimum annual royalties beginning with the year ending December 31, 2023 ($3 million annual minimum) and continuing with 3% annual
increases through the year ending December 31, 2034 (the &#8220;Minimum Annual Royalty&#8221;). The Minimum Annual Royalty originally
totaled $42.6 million, and this total amount was allocated among the Licensed Products on the relative net present value of forecasted
future product sales from those products. The portion allocated to consideration for the sale of ANNOVERA was attributed towards the gain
on disposal of that asset. For the remaining portion allocated to the license grants for the other products, we determined that the minimum
guarantee underlying the Minimum Annual Royalty should be treated as fixed consideration and recognized under ASC 606 at the point in
time when the license was transferred. Since the Minimum Annual Royalty will be received in annual installments through 2034, we determined
the transaction price allocated under ASC 606 contained a significant financing component, and we therefore determined the initial royalty
revenue and corresponding receivable based on the present value of the allocated Minimum Annual Royalty. The present value was calculated
using a discount rate of 10.45%, based on the credit characteristics of Mayne Pharma and the timing of future payments, and the value
will be accreted to full value through the earlier of January 1, 2034 or a LOE. This royalty receivable is a contract asset as of December
31, 2023, and is further subject to offset by Mayne Pharma.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Royalty revenue earned in excess of the Minimum
Annual Royalty will be recognized under ASC 606, which provides revenue recognition constraints by requiring the recognition of revenue
at the later of the following: 1) when the subsequent sale occurs or 2) when the performance obligation to which some or all of the sales-based
royalty has been allocated has been satisfied (or partially satisfied). We applied the royalty recognition constraint required under
the guidance for sales-based royalties, which requires a sales-based royalty to be recorded no sooner than the underlying sale. Therefore,
royalties on sales of products commercialized by Mayne Pharma will be recognized in the subsequent periods that the Licensed Products
are sold.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">For additional discussion on revenue, see &#8220;J.
Revenue recognition&#8221; in Note 1. Basis of presentation, new accounting standards and summary of significant accounting policies
to the consolidated financial statements included in this 2023 10-K Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Restructuring Costs.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our restructuring costs consist primarily of severance, employee termination
costs, contract termination costs, and write off of fixed assets related to restructuring activities.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Recent accounting pronouncements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Information regarding accounting standards issued
or effective in 2023 is included in &#8220;Note 1. Basis of Presentation, New Accounting Standards and Significant Accounting Policies&#8221;
to the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 7A. Quantitative and qualitative disclosures
about market risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">As a &#8220;smaller reporting company,&#8221;
as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and pursuant to Instruction
6 to Item 201(e) of Regulation S-K, we are not required to provide this information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 8. Financial statements and supplementary
data</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Reference is made to the financial statements,
the notes thereto, and the report thereon, commencing on page F-1 of this 2023 10-K Report, which financial statements, notes, and reports
are incorporated herein by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 9. Change in and disagreements with
accountants on accounting and financial disclosure </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 9A. Controls and procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Evaluation of disclosure controls and procedures</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Our management evaluated the effectiveness of
our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) or 15d-15(e)) as of the end
of the period covered by this 2023 10-K Report. Based on that evaluation, our Principal Executive Officer and Principal Financial Officer
concluded that, as of December 31, 2023, our disclosure controls and procedures were effective to ensure that information required to
be disclosed by us in the reports we file or submit under the Exchange Act is (i) recorded, processed, summarized, and reported within
the time periods specified in the SEC rules and forms, and (ii) is accumulated and communicated to our management, including our Principal
Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Changes in internal control over financial
reporting</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">There was no change in our internal control
over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect,
our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Inherent limitations on effectiveness of
controls</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Our management does not expect that our disclosure
controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived
and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design
of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative
to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that all control issues, misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented or
detected. Further, internal controls may become inadequate because of changes in conditions, or through the deterioration of the degree
of compliance with policies or procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Management&#8217;s report on internal control
over financial reporting</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting, as defined under Exchange Act Rules 13a-15(f) and 15d-15(f). Our
internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Internal control over financial
reporting includes those policies and procedures that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">pertain to the maintenance of records that in reasonable
detail accurately and fairly reflect the transactions and dispositions of our assets;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">provide reasonable assurance that transactions are recorded
as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our
receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Our management assessed the effectiveness
of our internal control over financial reporting as of December 31, 2023. In making this assessment, our management used the
criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control &#8212;
Integrated Framework (2013). Management&#8217;s assessment included an evaluation of the design of our internal control over
financial reporting and testing of the operational effectiveness of its internal control over financial reporting. Based on
management&#8217;s assessment, we believe that our internal controls over financial reporting were effective as of December 31,
2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">This 2023 10-K Report does not include an attestation
report of the Company&#8217;s registered public accounting firm regarding internal control over financial reporting. Management&#8217;s
report was not subject to attestation by the Company&#8217;s registered public accounting firm pursuant to the rules of the SEC that
permit the Company to provide only management&#8217;s report in this 2023 10-K Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 9B. <ix:nonNumeric contextRef="c24" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-10877"><ix:nonNumeric contextRef="c24" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-10878"><ix:nonNumeric contextRef="c24" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-10879"><ix:nonNumeric contextRef="c24" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-10880">Other information</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Effective March 22, 2024, Tommy G. Thompson resigned as the Company&#8217;s
Executive Chairman of the Board and was reappointed as the Company&#8217;s Chairman of the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 9C. Disclosure regarding foreign jurisdictions
that prevent inspections </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 10. Directors, executive officers, and
corporate governance</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">This information will be contained in our definitive proxy statement for
our 2024 Annual Meeting of Stockholders, to be filed with the SEC not later than 120 days after the end of our fiscal year covered by
this report, and incorporated herein by reference or, alternatively, by amendment to this Form 10-K under cover of Form 10-K/A no later
than the end of such 120 day period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 11. Executive compensation</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">This information will be contained in our definitive proxy statement for
our 2024 Annual Meeting of Stockholders, to be filed with the SEC not later than 120 days after the end of our fiscal year covered by
this report, and incorporated herein by reference or, alternatively, by amendment to this Form 10-K under cover of Form 10-K/A no later
than the end of such 120 day period.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 12. Security ownership of certain beneficial
owners and management and related stockholder matters</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">This information will be contained in our definitive proxy statement for
our 2024 Annual Meeting of Stockholders, to be filed with the SEC not later than 120 days after the end of our fiscal year covered by
this report, and incorporated herein by reference or, alternatively, by amendment to this Form 10-K under cover of Form 10-K/A no later
than the end of such 120 day period.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 13. Certain relationships and related
transactions, and director independence</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">This information will be contained in our definitive proxy statement for
our 2024 Annual Meeting of Stockholders, to be filed with the SEC not later than 120 days after the end of our fiscal year covered by
this report, and incorporated herein by reference or, alternatively, by amendment to this Form 10-K under cover of Form 10-K/A no later
than the end of such 120 day period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 14. Principal accountant fees and services</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">This information will be contained in our definitive proxy statement
for our 2024 Annual Meeting of Stockholders, to be filed with the SEC not later than 120 days after the end of our fiscal year covered
by this report, and incorporated herein by reference or, alternatively, by amendment to this Form 10-K under cover of Form 10-K/A no
later than the end of such 120 day period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_024"></a></div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>PART IV</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 15. Exhibits and financial statement
schedules</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(a)</td><td><b>Financial statements and financial statements schedules</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">(1)</td><td>Financial Statements are listed in the Index to Financial Statements
                                            on page F-1 of this 2023 10-K Report.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">(2)</td><td>No financial statement schedules are included because such schedules
                                            are not applicable, are not required, or because required information is included in the
                                            consolidated financial statements or notes thereto.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(b)</td><td><b>Exhibits</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 9%"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%"><b>&#160;</b></td>
    <td style="text-align: left; border-bottom: Black 1.5pt solid; width: 90%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">2.1</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000101968709002459/croff_8k-ex0201.htm">Agreement and Plan of Reorganization, dated July 6, 2009, among Croff Enterprises, Inc., AMHN Acquisition Corp., America&#8217;s Minority Health Network, Inc., and the Major Shareholders(1)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">2.2</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312510138955/dex101.htm">Agreement and Plan of Reorganization, dated June 11, 2010, among AMHN, Inc., SHN Acquisition Corp., Spectrum Health Network, Inc., and the Sole Shareholder of Spectrum Health Network, Inc.(2)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">2.3</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000135601808000256/ex332.htm">Croff Enterprises, Inc. Plan of Corporate Division and Reorganization, dated October 25, 2007 (3)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">2.4</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713111001316/ex-10_01.htm">Agreement and Plan of Merger, dated July 18, 2011, among vitaMedMD, LLC, AMHN, Inc., and vitaMed Acquisition, LLC(4)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">2.5***+</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000156459022009476/txmd-ex21_221.htm">Stock Purchase Agreement, dated March 6, 2022, by and between TherapeuticsMD, Inc. and GoodRx, Inc. (5)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex34.htm"><span style="font-size: 10pt">Articles of Conversion of AMHN, Inc. filed in the State of Nevada, dated July 20, 2010 (6)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex35.htm"><span style="font-size: 10pt">Articles of Incorporation of AMHN, Inc. filed in the State of Nevada, dated July 20, 2010 (6)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312523211458/d499757dex31.htm">Composite Amended and Restated Articles of Incorporation of the Company, as amended (7)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">3.4</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312510149198/ddef14c.htm">Bylaws of the AMHN, Inc. (8)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">3.5</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex3-1.htm">First Amendment to Bylaws of the Company, dated December 17, 2015 (9)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">3.6</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459022022465/txmd-ex31_10.htm">Second Amendment to Bylaws of the Company, adopted May 27, 2022 (10)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">3.7</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312522207645/d356180dex32.htm" style="-sec-extract: exhibit">Third Amendment to Bylaws of the Company, dated July 29, 2022 (11)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">3.8</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000156459022018687/txmd-ex31_8.htm">Certificate of Change to Articles of Incorporation of the Company (12)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">3.9</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312522207645/d356180dex31.htm"><span style="font-size: 10pt">Certificate of Designation, Preferences and Rights of Series A Preferred Stock (11)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify"><span style="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</span></td>
    <td style="font-size: 10pt"><span style="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt"><span style="text-decoration: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312523182808/d816117dex31.htm">Fourth Amendment to Bylaws of the Company, dated June 29, 2023 (13)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113000166/ex4-2.htm">Form of Certificate of Common Stock (14)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex42_160.htm">Description of Securities of the Company (15)</a> </span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_3.htm">Form of Common Stock Purchase Warrant (16)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_2.htm">Form of Non-Qualified Stock Option Agreement (16)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.3*</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119004545/ex99-1.htm">TherapeuticsMD, Inc. 2019 Stock Incentive Plan (17)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.4*</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312521116458/d152560ddef14a.htm">First Amendment to the TherapeuticsMD, Inc. 2019 Stock Incentive Plan (18)</a></span></td></tr>

<tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.5*</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713113003145/ex10-34.htm">Amended and Restated 2012 Stock Incentive Plan (19)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.6*</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312513399924/d611784dex991.htm">2009 Long Term Incentive Compensation Plan, as amended (20)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.7*</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120004409/txmd-def14a_061820.htm#txmd_027">TherapeuticsMD, Inc. 2020 Employee Stock Purchase Plan (21)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.8</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713112000490/ex-10_3.htm">Form of Common Stock Purchase Warrant, dated February 24, 2012 (22)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713113000292/ex10_1.htm">Common Stock Purchase Warrant, issued to Plato &amp; Associates, LLC, dated January 31, 2013 (23)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex4-1.htm">Form of Warrant to Purchase Common Stock, dated August 5, 2020 (24)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex4-2.htm"><span style="font-size: 10pt">Amendment to Company Warrant issued by the Company to the Subscribers party to that certain Subscription Agreement, dated as of August 5, 2020, dated November 8, 2020 (25)</span></a></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-size: 10pt">10.12</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 90%"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713121003140/ex10-12.htm"><span style="font-size: 10pt">Second Amendment to Company Warrant issued by the Company to the Subscribers party to that certain Subscription Agreement, dated as of August 5, 2020 (26)</span>&#160;</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.13</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713121003140/ex10-13.htm">Warrant issued by the Company to Robert Finizio (26)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.14</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713121003140/ex10-14.htm">Amendment to Warrant issued by the Company to Robert Finizio (26)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.15*</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713121003140/ex10-15.htm">Warrant issued by the Company to John C.K. Milligan, IV (26)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.16*</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713121003140/ex10-16.htm">Amendment to Warrant issued by the Company to John C.K. Milligan, IV (26)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.17</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-5.htm">Subscription Agreement, dated August 5, 2020, by and among TherapeuticsMD, Inc. and the Subscribers identified on the Schedule of Subscribers attached thereto (24)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.18***</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713118005976/ex10-1.htm">License Agreement, dated July 30, 2018, by and between TherapeuticsMD, Inc. and The Population Council, Inc. (27)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">10.19***</td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713119008469/ex10-2.htm">Lease, dated October 5, 2018, by and between 951 Yamato Acquisition Company, LLC and TherapeuticsMD, Inc. (28)</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.20***</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713119005935/ex10-3.htm">License and Supply Agreement, dated June 6, 2019, by and between TherapeuticsMD, Inc. and Theramex HQ UK Limited (29)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.21*</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex10-3.htm">Form of Indemnification Agreement between TherapeuticsMD, Inc. and each of its executive officers and directors (25)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.22*</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000156459022011525/txmd-ex1055_277.htm">2022 Executive Retention and Performance Bonus Plan. (ERB-Plan) (30)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.23</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312522207645/d356180dex101.htm">Subscription Agreement between TherapeuticsMD, Inc. and Rubric Capital Management LP, dated July 29, 2022 (11)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.24</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312522207645/d356180dex102.htm">Subscription Agreement by and among TherapeuticsMD, Inc., Sixth Street Specialty Lending, Inc., TOP IV Talents, LLC and TOA Talents, LLC, dated July 29, 2022 (11)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.25</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312522256102/d378570dex101.htm">Subscription Agreement between TherapeuticsMD, Inc. and Rubric Capital Management LP, dated September 30, 2022 (31)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.26</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312522256102/d378570dex102.htm">Subscription Agreement by and among TherapeuticsMD, Inc., Sixth Street Specialty Lending, Inc., TOP IV Talents, LLC and TAO Talents, LLC, dated September 30, 2022 (31)</a></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-size: 10pt">10.27</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 90%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522273110/d394277dex101.htm">Subscription Agreement between TherapeuticsMD, Inc. and Rubric Capital Management LP, dated October 28, 2022 (32)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.28</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522273110/d394277dex102.htm">Subscription Agreement by and among TherapeuticsMD, Inc., Sixth Street Specialty Lending, Inc., TOP IV Talents, LLC and TAO Talents, LLC, dated October 28, 2022 (32)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.29***+</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312522298002/d409080dex101.htm">License Agreement by and between TherapeuticsMD, Inc. and Mayne Pharma LLC, dated December 4, 2022 (33)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.30***+</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522298002/d409080dex102.htm">Transaction Agreement by and between TherapeuticsMD, Inc. and Mayne Pharma LLC, dated December 4, 2022 (33)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.31**</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex1045_158.htm">Amendment No. 1 to the License Agreement between TherapeuticsMD, Inc. and Mayne Pharma LLC, dated as of December 30, 2022 (15)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.32</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex1046_159.htm">Amendment No. 1 to the Transaction Agreement between TherapeuticsMD, Inc. and Mayne Pharma LLC, dated as of December 30, 2022 (15)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.33*</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex1047_471.htm">Amended and Restated Employment Agreement, dated as of December 18, 2018, by and between TherapeuticsMD, Inc. and Marlan Walker (15)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.34*</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex1048_439.htm">Amendment, effective October 15, 2021, to the Employment Agreement, dated as of December 18, 2018, by and between TherapeuticsMD, Inc. and Marlan Walker (15)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.35*</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312523050813/d372195dex101.htm">Amendment, dated February 21, 2023, to the Employment Agreement, dated as of December 18, 2018, as extended effective October 15, 2021, by and between TherapeuticsMD, Inc. and Marlan Walker (34)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">10.36*</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312523050813/d372195dex102.htm">General Consulting and Services Agreement by and between TherapeuticsMD, Inc. and MCD Consulting Management Services, LLC, dated February 21, 2023 (34)</a></span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312523147098/d256418ddef14a.htm">Subscription Agreement, dated May 1, 2023, between TherapeuticsMD, Inc. and Rubric Capital Management LP (35)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/25743/000119312523277143/d569965dex101.htm">Master Services Agreement, dated August 15, 2023, between TherapeuticsMD, Inc. and JZ Advisory Group (36)</a></span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">21.1&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="ea020146501ex21-1_therapeu.htm">Subsidiaries of the Company</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">23.1&#8224;</td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="ea020146501ex23-1_therapeu.htm">Consent of Berkowitz Pollack Brant</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">23.2&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt"><a href="ea020146501ex23-2_therapeu.htm">Consent of Grant Thornton LLP</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">31.1&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="ea020146501ex31-1_therapeu.htm"><span style="font-size: 10pt">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">31.2&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="ea020146501ex31-2_therapeu.htm"><span style="font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">32.1&#8224;&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="ea020146501ex32-1_therapeu.htm"><span style="font-size: 10pt">Section 1350 Certification of Chief Executive Officer</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">32.2&#8224;&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="ea020146501ex32-2_therapeu.htm"><span style="font-size: 10pt">Section 1350 Certification of Chief Financial Officer</span></a></td></tr>

<tr style="vertical-align: top; ">
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">97.1&#8224;</span></td>
    <td style="font-size: 10pt"><span style="text-decoration: none">&#160;</span></td>
    <td style="font-size: 10pt"><a href="ea020146501ex97-1_therapeu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">TherapeuticsMD, Inc. Policy on Recoupment of Incentive Compensation</span></a></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%"><span style="font-size: 10pt">101&#8224;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 90%"><span style="font-size: 10pt">Inline XBRL Document Set for the consolidated financial statements and accompanying notes in Part IV, Item 15(a), &#8220;Financial Statements and Financial Statements Schedules&#8221; of this Annual Report on Form 10-K</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">104&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Inline XBRL for the cover page of this Annual Report on Form 10-K, included in the Exhibit 101 Inline XBRL Document Set</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">*</td><td>Indicates a contract with management or compensatory plan or arrangement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">**</td><td>Certain confidential material contained in the document has been omitted
                                            and filed separately with the Securities and Exchange Commission. Confidential treatment
                                            has been granted with respect to this omitted information.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">***</td><td>Portions of this exhibit have been redacted in compliance with Regulation
                                            S-K Item 601(b)(2). The omitted information is not material and would likely cause competitive
                                            harm to the Company if publicly disclosed.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left">+</td><td style="text-align: left">Certain of the exhibits and
                                            schedules to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation
                                            S-K. The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC
                                            upon its request.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">&#8224;</td><td>Filed herewith.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">&#8224;&#8224;</td><td>Furnished herewith.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(1)</td><td>Filed as an exhibit to Form 8-K filed with the Commission on July
                                            10, 2009 and incorporated herein by reference (SEC File No. 000-16731).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(2)</td><td style="text-align: left">Filed as an exhibit to Form 8-K filed with
                                            the Commission on June 14, 2010 and incorporated herein by reference (SEC File No. 000-16731).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(3)</td><td>Filed as an exhibit to Form 10-K for the year ended December 31,
                                            2007 filed with the Commission on May 1, 2008 and incorporated herein by reference (SEC File
                                            No. 000-16731).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(4)</td><td>Filed as an exhibit to Form 8-K filed with the Commission on July
                                            21, 2011 and incorporated herein by reference (SEC File No. 000-16731).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0in"/>
    <td style="font-size: 10pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to Form
    8-K filed with the Commission on March 10, 2022 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(6)</td><td>Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2010
                                            filed with the Commission on August 3, 2010 and incorporated herein by reference (SEC File
                                            No. 000-16731).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(7)</td><td>Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2023
                                            filed with the Commission on August 14, 2023 and incorporated herein by reference (SEC File
                                            No. 001-00100).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(8)</td><td>Filed as an exhibit to Definitive 14C Information Statement filed
                                            with the Commission on June 29, 2010 and incorporated herein by reference (SEC File No. 000-16731).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(9)</td><td>Filed as an exhibit to Form 8-K filed with the Commission on December
                                            22, 2015 and incorporated herein by reference (SEC File No. 001-00100).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(10)</td><td>Filed as an exhibit to Form 8-K filed with the Commission on June 3,
2022 and incorporated herein by reference (SEC File No. 001-00100).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(11)</td><td>Filed as an exhibit to Form 8-K filed with the Commission on August
1, 2022 and incorporated herein by reference (SEC File No. 001-00100).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(12)</td><td>Filed as an exhibit to Form 8-K filed with the Commission on May 9, 2022 and incorporated herein by reference (SEC File No.
                                                              001-00100).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(13)</td><td>Filed as an exhibit to Form 8-K filed with the Commission on July 6, 2023 and incorporated herein by reference (SEC File No.
                                                              001-00100).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(14)</td><td>Filed as an exhibit to  Form S-3 filed
                                            with the Commission on January 25, 2013 and incorporated hereby by reference (SEC File No.
                                            333-186189).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0in; font-size: 10pt"/>
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to Form 10-K for the year ended December 31, 2022 filed with the Commission on April 7, 2023 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0in"/>
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to Form 8-K filed with the Commission on October 11, 2011 and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0in"/>
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to Form S-8 filed with the Commission on June 21, 2019 and incorporated herein by reference (SEC File No. 333-232268).</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(18)</td><td>Filed as an appendix to the Definitive Proxy Statement filed with the Commission on April 14, 2021 and incorporated herein by
                                                              reference (SEC File No. 001-00100).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(19)</td><td>Filed as an exhibit to Form 8-K filed with the Commission on August 22, 2013 and incorporated herein by reference (SEC File No. 001-00100).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(20)</td><td>Filed as an exhibit to Registration Statement on Form S-8 filed
                                            with the Commission on October 15, 2013 and incorporated herein by reference (SEC File No. 333-191730).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0in"/><td style="width: 0.5in">(21)</td><td>Filed as an appendix to the Definitive Proxy Statement filed with
                                            the Commission on May 4, 2020 and incorporated herein by reference (SEC File No. 001-00100).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to Form 8-K filed with the Commission on February 24, 2012 and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to Form 8-K filed with the Commission on February 6, 2013 and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2020 filed with the Commission on August 7, 2020 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to Form 10-Q filed with the Commission on November 9, 2020 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to Form 10-K for the year ended December 31, 2020 filed with the Commission on March 4, 2021 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2018 filed with the Commission on November 8, 2018 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2019 filed with the Commission on November 8, 2019 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2019 filed with the Commission on August 9, 2019 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed as an exhibit to Form
    10-K for the year ended December 31, 2021, filed with the Commission on March 23, 2022 and incorporated herein by reference (SEC
    File No. 001-00100).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(31)</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed as an exhibit to Form 8-K filed with the Commission on October
3, 2022 and incorporated herein by reference (SEC File No. 001-00100).</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32)</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed as an exhibit to Form 8-K filed with the Commission on October
31, 2022 and incorporated herein by reference (SEC File No. 001-00100).</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(33)</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed as an exhibit to Form 8-K filed with the Commission on December
5, 2022 and incorporated herein by reference (SEC File No. 001-00100).</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(34)</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed as an exhibit to Form 8-K filed with the Commission on February
27, 2023 and incorporated herein by reference (SEC SEC File No. 001-00100).</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(35)</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed as an appendix to the Definitive Proxy Statement filed with
the Commission on May 17, 2023 and incorporated herein by reference (SEC File No. 001-00100).</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(36)</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed as an exhibit to Form 10-Q for the quarter ended September
    30, 2023, filed with the Commission on November 14, 2023 and incorporated herein by reference (SEC File No. 001-00100).</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>Item 16. Form 10-K summary</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Signatures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this 2023 10-K Report to be signed on its behalf by the undersigned, thereunto duly
authorized, on March 29, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 40%">THERAPEUTICSMD, INC.</td><td style="width: 60%; text-align: left">&#160;</td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td style="border-bottom: Black 1.5pt solid">/s/ Marlan D. Walker</td><td style="text-align: left">&#160;</td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td>Marlan D. Walker</td><td style="text-align: left">&#160;</td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td>Chief Executive Officer</td><td style="text-align: left">&#160;</td></tr>
     </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this 2023 10-K Report to be signed on its behalf by the undersigned, thereunto duly
authorized, on March 29, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 26%"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 4%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 70%"><span style="font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">/s/ Marlan D. Walker</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Marlan D. Walker</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Executive Officer)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">/s/ Joseph Ziegler</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Principal Financial and Accounting Officer</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Joseph Ziegler</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">/s/ Tommy G. Thompson</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chairman</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Tommy G. Thompson</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">/s/ Cooper C. Collins</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Cooper C. Collins</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">/s/ Gail K. Naughton, Ph.D.</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Gail K. Naughton, Ph.D.</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">/s/ Justin Roberts</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Justin Roberts</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 95%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 5%; text-align: center"><span style="font-size: 10pt">Page</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><a href="#a_027"><span style="font-size: 10pt">Report of Independent Registered Public Accounting Firm (PCAOB ID Number 52)</span></a></td> <td style="text-align: center">F-2</td></tr> <tr style="vertical-align: top; "> <td><a href="#rep_002">Report of Independent Registered Public Accounting Firm (PCAOB ID Number
<ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-10881">248</ix:nonNumeric>)</a></td> <td style="text-align: center">F-4</td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><a href="#a_028"><span style="font-size: 10pt">Consolidated Balance Sheets</span></a></td> <td style="text-align: center"><span style="font-size: 10pt">F-5</span></td></tr> <tr style="vertical-align: top; "> <td><a href="#a_029"><span style="font-size: 10pt">Consolidated Statements of Operations</span></a></td> <td style="text-align: center"><span style="font-size: 10pt">F-6</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><a href="#a_030"><span style="font-size: 10pt">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></a></td> <td style="text-align: center"><span style="font-size: 10pt">F-7</span></td></tr> <tr style="vertical-align: top; "> <td><a href="#a_031"><span style="font-size: 10pt">Consolidated Statements of Cash Flows</span></a></td> <td style="text-align: center"><span style="font-size: 10pt">F-8</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><a href="#a_032"><span style="font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td> <td style="text-align: center"><span style="font-size: 10pt">F-9</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 52; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span><b>REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">To the Board of Directors and<br/>
Stockholders of TherapeuticsMD, Inc. and Subsidiaries</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We have audited the accompanying consolidated
balance sheet of TherapeuticsMD, Inc. and Subsidiaries (the &#8220;Company&#8221;) as of December 31, 2023, and the related consolidated
statement of operations, stockholders&#8217; equity, and cash flows for the year then ended, and the related notes (collectively referred
to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all
material respects, the financial position of the Company as of December 31, 2023, and the results of its operations and its cash flows
for the year then ended, in conformity with accounting principles generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Substantial Doubt about the Company&#8217;s
Ability to Continue as a Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The accompanying consolidated financial statements
have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements,
the recent change in operations and negative cash flow position along with other conditions as set forth in Note 1, raise substantial
doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described
in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">These consolidated financial statements are the
responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial
statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Our audit included performing procedures to assess
the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides
a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 53; Options: NewSection; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Audit Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The critical audit matters communicated below
are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated
to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and
(2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter
in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit
matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Acquisition of Net Working Capital</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As described further in Note 1 to the consolidated
financial statements, the Company determined the acquisition of net working capital by Mayne Pharma, LLC in accordance with the Transaction
Agreement. The Transaction Agreement included significant estimates, which are subject to change for a period of up to two years. The
Company received financial claims from Mayne Pharma, LLC related to this agreement for amounts owed under the provisions of the Transaction
Agreement related to distributor fees, rebates and returns of licensed products. The Company does not believe these claims are substantiated
and thus, did not record an amount due to the licensee as of December 31, 2023. We identified the acquisition of net working capital as
a critical audit matter. The principal consideration for our determination that the acquisition of net working capital pursuant to the
provisions of the Transaction Agreement as a critical audit matter is due to the significant estimates and judgements required by management
when determining the inputs and assumptions utilized in the development of the initial net working capital calculation included in the
Transaction Agreement. The subjectivity of the estimates increases the level of estimation uncertainty, auditor judgement and level of
effort required to evaluate management&#8217;s evidence supporting the projected final net working capital acquisition amount as it relates
to the allowance for returns, rebates and distributor fees, including assumptions that no further liability will be incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit procedures perform<span style="font-family: Times New Roman, Times, Serif">ed
to address the critical matter included, among others:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Review
the letter sent to the licensee in response to financial claims.</span></td>
</tr></table><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Review
                                            original Transaction Agreement and subsequent amendments.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Review
                                            the rebates and returns analysis performed by the Company, assess method utilized, calculation,
                                            and conclusion reached for reasonableness.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Berkowitz Pollack Brant, Advisors + CPAs</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">West Palm Beach, FL</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 29, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 54 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><div><a id="rep_002"></a></div><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>REPORT
    OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p><div>

</div><p style="margin: 0pt 0">&#160;</p><div>

</div><p style="margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; ">Board of Directors and Shareholders</span><span style="font-family: Times New Roman, Times, Serif"><br/>
TherapeuticsMD, Inc.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Opinion
on the financial statements</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We have audited
the accompanying consolidated balance sheet of TherapeuticsMD, Inc. (a Nevada corporation) and subsidiaries (the &#8220;Company&#8221;)
as of December 31, 2022, the related consolidated statements of operations, stockholders&#8217; (deficit) equity, and cash flows for
the year then ended, and the related notes collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of
its operations and its cash flows for the year ended December 31, 2022, in conformity with accounting principles generally accepted in
the United States of America.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Going
concern</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The accompanying
consolidated financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 1 to
the financial statements, the Company has recently changed its business strategy to become a royalty company. The Company has limited
experience operating as a royalty company and may need to raise additional capital to fund its operations until the Company becomes cash
flow positive. These conditions, along with other matters as set forth in Note 1, raise substantial doubt about the Company&#8217;s ability
to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Basis
for opinion</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">These financial
statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We conducted
our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we
are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Our audit
included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud,
and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts
and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a
reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">/S/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-10882">GRANT
THORNTON LLP</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We served
as the Company&#8217;s auditor from 2015 to 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-10883">Miami, Florida</ix:nonNumeric><br/>
April 7, 2023</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TherapeuticsMD, Inc. and Subsidiaries</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Consolidated Balance Sheets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In thousands, except per share amounts)</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd" id="ixv-10884">4,327</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd" id="ixv-10885">38,067</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd" id="ixv-10886">11,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Royalty receivable, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="txmd:RoyaltyReceivableCurrentPortion" scale="3" unitRef="usd" id="ixv-10887">3,090</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Prepaid and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-10888">4,035</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-10889">6,034</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Current assets of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" unitRef="usd" id="ixv-10890">344</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-10891">11,796</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-10892">55,351</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Fixed assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-10893">78</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">License rights and other intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-10894">6,098</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-10895">6,943</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Royalty receivable, long term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="txmd:RoyaltyReceivableLongTerm" scale="3" unitRef="usd" id="ixv-10896">18,484</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="txmd:RoyaltyReceivableLongTerm" scale="3" unitRef="usd" id="ixv-10897">20,253</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-10898">58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-10899">253</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Right of use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-10900">6,873</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-10901">7,580</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-10902">43,309</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-10903">90,458</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Liabilities and stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-10904">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-10905">2,162</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-10906">3,133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-10907">18,846</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" unitRef="usd" id="ixv-10908">3,694</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" unitRef="usd" id="ixv-10909">25,831</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-10910">6,854</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-10911">46,839</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating lease liabilities, non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="3" unitRef="usd" id="ixv-10912">6,532</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="3" unitRef="usd" id="ixv-10913">7,369</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Other non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-10914">636</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-10915">1,107</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-10916">14,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-10917">55,315</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Commitments and contingencies (Note 8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stockholders&#8217; equity (deficit):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Common stock, par value $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-10918"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-10919">0.001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" unitRef="shares" id="ixv-10920">32,000</ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" unitRef="shares" id="ixv-10921">12,000</ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" unitRef="shares" id="ixv-10922"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" unitRef="shares" id="ixv-10923">11,532</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" unitRef="shares" id="ixv-10924"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" unitRef="shares" id="ixv-10925">9,498</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-10926">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-10927">9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-10928">978,917</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-10929">974,497</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-10930">949,641</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-10931">939,363</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-10932">29,287</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-10933">35,143</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-10934">43,309</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-10935">90,458</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 56 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TherapeuticsMD, Inc. and Subsidiaries</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Consolidated Statements of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center">(In thousands, except per share amounts)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Years ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue, net:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">License and service revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-10936">1,302</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-10937">69,963</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total revenue, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-10938">1,302</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-10939">69,963</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Cost of revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" unitRef="usd" id="ixv-10940">1,397</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross profit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" unitRef="usd" id="ixv-10941">1,302</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" unitRef="usd" id="ixv-10942">68,566</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Selling, general and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-10943">8,903</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-10944">56,710</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation &amp; amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-10945">922</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-10946">1,193</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Restructuring</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" unitRef="usd" id="ixv-10947">9,472</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-10948">9,825</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-10949">67,375</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income (loss) from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-10950">8,523</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" unitRef="usd" id="ixv-10951">1,191</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Miscellaneous income (expense)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="txmd:MiscellaneousIncomeexpense" scale="3" sign="-" unitRef="usd" id="ixv-10952">781</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="txmd:MiscellaneousIncomeexpense" scale="3" unitRef="usd" id="ixv-10953">117</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other income (loss), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-10954">781</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-10955">117</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Income (loss) from continuing operations before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-10956">7,742</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-10957">1,074</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Benefit (provision) for income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd" id="ixv-10958">43</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net income (loss) from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" sign="-" unitRef="usd" id="ixv-10959">7,699</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" unitRef="usd" id="ixv-10960">1,074</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Income (loss) from discontinued operations, net of income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-10961">2,579</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" unitRef="usd" id="ixv-10962">110,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net income (loss)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-10963">10,278</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-10964">111,997</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income (loss) per common share, basic:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt">Continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-10965">0.74</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-9; font-family: Times New Roman, Times, Serif; font-size: 10pt">0. 12</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Discontinued operations, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-10966">0.25</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" unitRef="usdPershares" id="ixv-10967">12.29</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net income (loss) per common share, basic</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-10968">0.98</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares" id="ixv-10969">12.41</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income (loss) per common share, diluted:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt">Continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-10970">0.74</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" unitRef="usdPershares" id="ixv-10971">0.11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Discontinued operations, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-10972">0.25</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" unitRef="usdPershares" id="ixv-10973">11.84</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net income (loss) per common share, diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-10974">0.98</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" unitRef="usdPershares" id="ixv-10975">11.96</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average common shares, basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" unitRef="shares" id="ixv-10976">10,441</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" unitRef="shares" id="ixv-10977">9,028</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average common shares, diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" unitRef="shares" id="ixv-10978">10,441</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" unitRef="shares" id="ixv-10979">9,366</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net income (loss)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-10980">10,278</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-10981">111,997</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive income (loss):</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-10982">10,278</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" unitRef="usd" id="ixv-10983">111,997</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 57 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TherapeuticsMD, Inc.
and Subsidiaries</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Consolidated Statements of Stockholders&#8217; (Deficit)
Equity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In thousands)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Common Stock</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Additional<br/> Paid in</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Accumulated</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Deficit</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%">Balance, December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="3" unitRef="shares" id="ixv-10984">8,597</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-10985">9</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-10986">957,730</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-10987">1,051,360</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-10988">93,621</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued for sale of common stock, net of cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" unitRef="shares" id="ixv-10989">565</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-10990">2,454</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-10991">2,454</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Lender warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="txmd:AdjustmentsToAdditionalPaidInCapitalLenderWarrants" scale="3" unitRef="usd" id="ixv-10992">2,727</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="txmd:AdjustmentsToAdditionalPaidInCapitalLenderWarrants" scale="3" unitRef="usd" id="ixv-10993">2,727</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Rounding for fractional shares in connection with the reverse stock split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="3" unitRef="shares" id="ixv-10994">142</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued for vested restricted and performance stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" unitRef="shares" id="ixv-10995">189</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued for sale of common stock related to employee stock purchase plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" unitRef="shares" id="ixv-10996">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" unitRef="usd" id="ixv-10997">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" unitRef="usd" id="ixv-10998">14</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share-based payment award compensation costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" unitRef="usd" id="ixv-10999">11,572</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" unitRef="usd" id="ixv-11000">11,572</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11001">111,997</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11002">111,997</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Balance, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="3" unitRef="shares" id="ixv-11003">9,498</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11004">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11005">974,497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11006">939,363</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11007">35,143</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued for vested restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" unitRef="shares" id="ixv-11008">844</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-11009">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-11010">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd" id="ixv-11011">1,271</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd" id="ixv-11012">1,271</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Shares issued for sale of common stock related to private placement sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="3" unitRef="shares" id="ixv-11013">1,190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-11014">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-11015">3,149</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-11016">3,150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11017">10,278</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11018">10,278</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">Balance, December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="3" unitRef="shares" id="ixv-11019">11,532</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11020">11</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11021">978,917</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-11022">949,641</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-11023">29,287</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 58 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TherapeuticsMD, Inc. and Subsidiaries</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Consolidated Statements of Cash Flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In thousands)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Years ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net income (loss)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11024">10,278</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11025">111,997</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Less: Income (loss) from discontinued operations, net of tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-11026">2,579</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" unitRef="usd" id="ixv-11027">110,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net income (loss) from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" sign="-" unitRef="usd" id="ixv-11028">7,699</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" unitRef="usd" id="ixv-11029">1,074</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Adjustments to reconcile net income (loss) to net cash provided by (used in) continuing operating
    activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="txmd:WriteoffOfPatentAndTrademark" scale="3" unitRef="usd" id="ixv-11030">922</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="txmd:WriteoffOfPatentAndTrademark" scale="3" unitRef="usd" id="ixv-11031">1,193</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Share-based payment compensation costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-11032">1,271</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-11033">11,572</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Make-whole payment accretion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="txmd:MakeWholePaymentAccretion" scale="3" unitRef="usd" id="ixv-11034">354</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" sign="-" unitRef="usd" id="ixv-11035">129</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" sign="-" unitRef="usd" id="ixv-11036">40</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Prepaid and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd" id="ixv-11037">1,999</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd" id="ixv-11038">620</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" unitRef="usd" id="ixv-11039">1,126</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" unitRef="usd" id="ixv-11040">7,636</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" sign="-" unitRef="usd" id="ixv-11041">2,135</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" sign="-" unitRef="usd" id="ixv-11042">1,211</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-11043">15,713</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" unitRef="usd" id="ixv-11044">4,262</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-11045">471</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-11046">121</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-11047">15,382</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="3" unitRef="usd" id="ixv-11048">8,285</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) continuing operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="3" sign="-" unitRef="usd" id="ixv-11049">23,081</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="3" unitRef="usd" id="ixv-11050">9,359</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from continuing investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Receipts (payment) for patents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" unitRef="usd" id="ixv-11051">355</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in continuing investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" scale="3" sign="-" unitRef="usd" id="ixv-11052">355</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash flows from continuing financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Proceeds from sale of common stock, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-11053">3,151</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-11054">2,454</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Proceeds from sale of common stock related to employee stock purchase plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="txmd:ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan" scale="3" unitRef="usd" id="ixv-11055">14</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Repayments of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="3" unitRef="usd" id="ixv-11056">219,432</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Proceeds from Series A Preferred Stock, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="3" unitRef="usd" id="ixv-11057">21,684</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Repurchase of Preferred Stock at liquidation preference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" scale="3" unitRef="usd" id="ixv-11058">38,657</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Proceeds from make-whole derivative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" scale="3" unitRef="usd" id="ixv-11059">3,322</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Repayment of make-whole derivative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" scale="3" unitRef="usd" id="ixv-11060">2,969</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Payment of debt financing fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" unitRef="usd" id="ixv-11061">1,622</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) continuing financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" scale="3" unitRef="usd" id="ixv-11062">3,151</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" scale="3" sign="-" unitRef="usd" id="ixv-11063">235,206</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Discontinued operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="3" sign="-" unitRef="usd" id="ixv-11064">25,060</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="3" sign="-" unitRef="usd" id="ixv-11065">13,437</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Net cash provided by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="3" unitRef="usd" id="ixv-11066">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="3" unitRef="usd" id="ixv-11067">223,834</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" scale="3" unitRef="usd" id="ixv-11068">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" scale="3" unitRef="usd" id="ixv-11069">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInDiscontinuedOperations" scale="3" sign="-" unitRef="usd" id="ixv-11070">25,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInDiscontinuedOperations" scale="3" unitRef="usd" id="ixv-11071">210,397</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net decrease in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-11072">44,990</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-11073">15,805</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash and restricted cash - continuing operations, beginning of period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-11074">49,317</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-11075">64,907</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and restricted cash - discontinued operations, beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="3" unitRef="usd" id="ixv-11076">215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total cash and restricted cash, end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd" id="ixv-11077">4,327</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd" id="ixv-11078">49,317</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Interest paid</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-11079">13,545</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Supplemental disclosure of noncash financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Warrants issued in relation to debt financing agreement</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="txmd:WarrantsIssuedInRelationToDebtFinancingAgreement" scale="3" unitRef="usd" id="ixv-11080">2,727</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 59 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>TherapeuticsMD, Inc. and Subsidiaries</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="ixv-7342"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>1. Business, basis of presentation, new accounting standards and summary of significant accounting policies</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="txmd_GeneralInformationPolicyTextBlock-c0_cont_1" escape="true" name="txmd:GeneralInformationPolicyTextBlock" id="ixv-7346"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GeneralInformationPolicyTextBlock-c0_cont_2" id="txmd_GeneralInformationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TherapeuticsMD, Inc. (the &#8220;Company&#8221;), a Nevada
corporation, and its consolidated subsidiaries are referred to collectively in this Annual Report on Form 10-K (&#8220;2023 10-K
Report&#8221;) as &#8220;TherapeuticsMD,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us.&#8221; This 2023 10-K Report
includes trademarks, trade names and service marks, such as TherapeuticsMD<sup>&#174;</sup>, vitaMedMD<sup>&#174;</sup>,
BocaGreenMD<sup>&#174;</sup>, vitaCareTM, IMVEXXY<sup>&#174;</sup>, and BIJUVA<sup>&#174;</sup>, which are protected under applicable
intellectual property laws and are the property of, or licensed by or to, us. Solely for convenience, trademarks, trade names and
service marks referred to in this 2023 10-K Report may appear without the <sup>&#174;</sup>, TM or SM symbols, but such references
are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the
right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other
parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a
relationship with, or endorsement or sponsorship of us by, these other parties.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GeneralInformationPolicyTextBlock-c0_cont_3" id="txmd_GeneralInformationPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TherapeuticsMD was previously a women&#8217;s healthcare company with
a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause.
In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed
to pharmaceutical organizations that possess commercial capabilities in the relevant territories. On December 30, 2022 (the &#8220;Closing
Date&#8221;), we completed a transaction (the &#8220;Mayne Transaction&#8221;) with Mayne Pharma LLC, a Delaware limited liability company
(&#8220;Mayne Pharma&#8221;) and subsidiary of Mayne Pharma Group Limited, an Australian public company, in which we and our subsidiaries
(i) granted Mayne Pharma an exclusive license to commercialize our IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under
the BocaGreenMD and vitaMedMD brands (collectively, the &#8220;Licensed Products&#8221;) in the United States and its possessions and
territories, (ii) assigned to Mayne Pharma our exclusive license to commercialize ANNOVERA<sup>&#174;</sup> (together with the Licensed
Products, collectively, the &#8220;Products&#8221;) in the United States and its possessions and territories, and (iii) sold certain
other assets to Mayne Pharma in connection therewith.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GeneralInformationPolicyTextBlock-c0_cont_4" id="txmd_GeneralInformationPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In a License Agreement, dated December 4, 2022, between TherapeuticsMD
and Mayne Pharma (the &#8220;Mayne License Agreement&#8221;), we granted Mayne Pharma, on the Closing Date, (i) an exclusive, sublicensable,
perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell, use, and commercialize the
Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable
license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States for commercialization
in the United States and its possessions and territories.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GeneralInformationPolicyTextBlock-c0_cont_5" id="txmd_GeneralInformationPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Mayne License Agreement, Mayne Pharma will pay us
one-time milestone payments of each of (i) $<ix:nonFraction contextRef="c25" decimals="-5" format="ixt:num-dot-decimal" name="txmd:OneTimeMilestonePayments" scale="6" unitRef="usd" id="ixv-11081">5.0</ix:nonFraction> million if aggregate net sales of all Products in the United States during a
calendar year reach $<ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" scale="6" unitRef="usd" id="ixv-11082">100.0</ix:nonFraction> million, (ii) $<ix:nonFraction contextRef="c26" decimals="-5" format="ixt:num-dot-decimal" name="txmd:OneTimeMilestonePayments" scale="6" unitRef="usd" id="ixv-11083">10.0</ix:nonFraction> million if aggregate net sales of all Products in the United States during a calendar
year reach $<ix:nonFraction contextRef="c26" decimals="INF" format="ixt:num-dot-decimal" name="txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" scale="6" unitRef="usd" id="ixv-11084">200.0</ix:nonFraction> million and (iii) $<ix:nonFraction contextRef="c27" decimals="-5" format="ixt:num-dot-decimal" name="txmd:OneTimeMilestonePayments" scale="6" unitRef="usd" id="ixv-11085">15.0</ix:nonFraction> million if aggregate net sales of all Products in the United States during a calendar year
reach $<ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" scale="6" unitRef="usd" id="ixv-11086">300.0</ix:nonFraction> million. Further, Mayne Pharma will pay us royalties on net sales of all Products in the United States at a royalty
rate of <ix:nonFraction contextRef="c28" decimals="3" format="ixt:num-dot-decimal" name="txmd:RoyaltyRateAsPercentageOnNetSales" scale="-2" unitRef="pure" id="ixv-11087">8.0</ix:nonFraction>% on the first $<ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate" scale="6" unitRef="usd" id="ixv-11088">80.0</ix:nonFraction> million in annual net sales and <ix:nonFraction contextRef="c29" decimals="3" format="ixt:num-dot-decimal" name="txmd:RoyaltyRateAsPercentageOnNetSales" scale="-2" unitRef="pure" id="ixv-11089">7.5</ix:nonFraction>% on annual net sales above $<ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate" scale="6" unitRef="usd" id="ixv-11090">80.0</ix:nonFraction> million, subject to certain
adjustments, for a period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="txmd:TermOfRoyaltyPayments" id="ixv-11091">20</ix:nonNumeric> years following the Closing Date. The royalty rate will decrease to <ix:nonFraction contextRef="c30" decimals="3" format="ixt:num-dot-decimal" name="txmd:DecreaseInRoyaltyRateOnProductByProductBasis" scale="-2" unitRef="pure" id="ixv-11092">2.0</ix:nonFraction>% on a Product-by-Product
basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version
of a Product launching in the United States. Mayne Pharma will pay us minimum annual royalties of $<ix:nonFraction contextRef="c30" decimals="-5" format="ixt:num-dot-decimal" name="txmd:MinimumAnnualRoyaltyPayment" scale="6" unitRef="usd" id="ixv-11093">3.0</ix:nonFraction> million per year for <ix:nonNumeric contextRef="c30" format="ixt-sec:duryear" name="txmd:PeriodOfMinimumAnnualRoyaltyPayment" id="ixv-11094">12</ix:nonNumeric>
years, adjusted for inflation at an annual rate of <ix:nonFraction contextRef="c30" decimals="2" format="ixt:num-dot-decimal" name="txmd:InflationRateAdjustedForMinimalAnnualRoyaltyPayment" scale="-2" unitRef="pure" id="ixv-11095">3</ix:nonFraction>%, subject to certain further adjustments, including as described below. Upon
the expiry of the <ix:nonNumeric contextRef="c30" format="ixt-sec:duryear" name="txmd:TermOfRoyaltyPayments" id="ixv-11096">20</ix:nonNumeric>-year royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully
paid-up and royalty free license for the Licensed Products.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GeneralInformationPolicyTextBlock-c0_cont_6" id="txmd_GeneralInformationPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Transaction Agreement, dated December 4, 2022, between TherapeuticsMD
and Mayne Pharma (the &#8220;Transaction Agreement&#8221;), we sold to Mayne Pharma, at closing, certain assets for Mayne Pharma to commercialize
the Products in the United States, including, with the Population Council&#8217;s consent, our exclusive license from the Population Council
to commercialize ANNOVERA (the &#8220;Transferred Assets&#8221;).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GeneralInformationPolicyTextBlock-c0_cont_7" id="txmd_GeneralInformationPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total consideration from Mayne Pharma to TherapeuticsMD for
the purchase of the Transferred Assets under the Transaction Agreement and the grant of the licenses under the Mayne License
Agreement was (i) a cash payment of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="txmd:PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment" scale="6" unitRef="usd" id="ixv-11097">140.0</ix:nonFraction> million at closing, (ii) a cash payment of approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="txmd:PaymentsToAcquireNetWorkingCapital" scale="6" unitRef="usd" id="ixv-11098">12.1</ix:nonFraction> million at closing for the
acquisition of net working capital as determined in accordance with the Transaction Agreement and subject to certain adjustments,
(iii) a cash payment of approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="6" unitRef="usd" id="ixv-11099">1.0</ix:nonFraction> million at closing for prepaid royalties in connection with the Mayne License Agreement
Amendment (as defined below) and (iv) the right to receive the contingent consideration set forth in the Mayne License Agreement, as
amended. The acquisition of net working capital was determined in accordance with the Transaction Agreement and included significant
estimates which could change materially for a period of up to two years following the Closing Date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 60 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_2" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation continuedAt="txmd_GeneralInformationPolicyTextBlock-c0_cont_8" id="txmd_GeneralInformationPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On the Closing Date, TherapeuticsMD and Mayne Pharma entered into Amendment
No. 1 to the Mayne License Agreement (the &#8220;Mayne License Agreement Amendment&#8221;). Pursuant to the Mayne License Agreement Amendment,
Mayne Pharma agreed to pay us approximately $<ix:nonFraction contextRef="c31" decimals="-5" format="ixt:num-dot-decimal" name="txmd:PrepaidRoyaltyLiabilities" scale="6" unitRef="usd" id="ixv-11100">1.0</ix:nonFraction> million in prepaid royalties on the Closing Date. The prepaid royalties reduced the first
four quarterly payments that would have otherwise been payable pursuant to the Mayne License Agreement by an amount equal to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="txmd:QuarterlyRoyaltyPayment" scale="0" unitRef="usd" id="ixv-11101">257</ix:nonFraction> thousand
per quarterly royalty payment plus interest calculated at <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="txmd:QuarterlyRoyaltyInterest" scale="-2" unitRef="pure" id="ixv-11102">19</ix:nonFraction>% per annum accruing from the Closing Date until the date such quarterly royalty
payment was paid to us. We and Mayne Pharma settled the $<ix:nonFraction contextRef="c30" decimals="-5" format="ixt:num-dot-decimal" name="txmd:RoyaltyPaymentPayableUnderLongTermServiceAgreement" scale="6" unitRef="usd" id="ixv-11103">1.5</ix:nonFraction> million of consideration due to Mayne for the assumed obligations under a
long-term services agreement (see the section entitled &#8220;vitaCare Divestiture&#8221; below for a discussion of the long-term services
agreement), including our minimum payment obligations thereunder. As the parties agreed, during the second quarter of 2023, Mayne Parma
held back our royalty payment of $<ix:nonFraction contextRef="c32" decimals="-5" format="ixt:num-dot-decimal" name="txmd:RoyaltyPayment" scale="6" unitRef="usd" id="ixv-11104">0.6</ix:nonFraction> million and we funded an additional $<ix:nonFraction contextRef="c33" decimals="-5" format="ixt:num-dot-decimal" name="txmd:AdditionalFund" scale="6" unitRef="usd" id="ixv-11105">0.9</ix:nonFraction> million in August 2023 to settle the original $<ix:nonFraction contextRef="c34" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="6" unitRef="usd" id="ixv-11106">1.5</ix:nonFraction> million
payable.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GeneralInformationPolicyTextBlock-c0_cont_9" id="txmd_GeneralInformationPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As part of the transformation that included the Mayne License Agreement,
historical results of commercial operations for all periods prior to the Closing Date have been reflected as discontinued operations in
our consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities
of discontinued operations in our consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in
Note 2.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GeneralInformationPolicyTextBlock-c0_cont_10" id="txmd_GeneralInformationPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also have license agreements with strategic partners to commercialize
IMVEXXY and BIJUVA outside of the U.S.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&#160;</p>

<ix:continuation continuedAt="txmd_GeneralInformationPolicyTextBlock-c0_cont_11" id="txmd_GeneralInformationPolicyTextBlock-c0_cont_10"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">In July 2018, we entered into a license and supply agreement
(the &#8220;Knight License Agreement&#8221;) with Knight Therapeutics Inc. (&#8220;Knight&#8221;) pursuant to which we granted Knight
an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel.</td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<ix:continuation continuedAt="txmd_GeneralInformationPolicyTextBlock-c0_cont_12" id="txmd_GeneralInformationPolicyTextBlock-c0_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            September 2019, we entered into an exclusive license and supply agreement (the &#8220;Theramex
                                            License Agreement&#8221;) with Theramex HQ UK Limited (&#8220;Theramex&#8221;) to commercialize
                                            IMVEXXY and BIJUVA outside of the U.S., excluding Canada and Israel. In 2021, Theramex secured
                                            regulatory approval for BIJUVA in certain European countries and began commercialization
                                            efforts in those countries.</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GeneralInformationPolicyTextBlock-c0_cont_13" id="txmd_GeneralInformationPolicyTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our transformation into a pharmaceutical royalty
company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief
Executive Officer) and all other employees was completed by December 31, 2022. Severance obligations for all employees other than executive
officers were paid in full in January 2023 and severance obligations for terminated executive officers were paid in accordance with their
employment agreements and separation agreements as previously disclosed. As of December 31, 2022 and 2023, we employed one full-time employee
primarily engaged in an executive position.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="txmd_GeneralInformationPolicyTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have engaged external consultants who support our relationship with
current partners and assist with certain financial, legal, and regulatory matters and the continued wind-down of our historical business
operations. On August 15, 2023, we entered into a master services agreement with JZ Advisory Group, pursuant to which Joseph Ziegler would
serve as our Principal Financial and Accounting Officer. On August 17, 2023 Michael C. Donegan notified us of his decision to resign from
the positions of Principal Financial and Accounting Officer of our Company effective as of August 17, 2023. Mr. Ziegler succeeded Mr.
Donegan as Principal Financial and Accounting Officer as of the date of Mr. Donegan&#8217;s resignation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="txmd_DivestitureOfBusinessPolicyPolicyTextBlock-c0_cont_1" escape="true" name="txmd:DivestitureOfBusinessPolicyPolicyTextBlock" id="ixv-7421"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>vitaCare Divestiture</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_DivestitureOfBusinessPolicyPolicyTextBlock-c0_cont_2" id="txmd_DivestitureOfBusinessPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 14, 2022, we completed the divestiture of our former subsidiary
vitaCare Prescription Services, Inc. (&#8220;vitaCare&#8221;) with the sale of all of vitaCare&#8217;s issued and outstanding capital
stock (the &#8220;vitaCare Divestiture&#8221;). We received net proceeds of $<ix:nonFraction contextRef="c35" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" unitRef="usd" id="ixv-11107">142.6</ix:nonFraction> million, after deducting transaction costs of $<ix:nonFraction contextRef="c35" decimals="-5" format="ixt:num-dot-decimal" name="txmd:TransactionCostsRelatedToDivestitureOfBusiness" scale="6" unitRef="usd" id="ixv-11108">7.2</ix:nonFraction>
million, and we recognized a gain on sale of business of $<ix:nonFraction contextRef="c35" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" unitRef="usd" id="ixv-11109">143.4</ix:nonFraction> million. Included in the net proceeds amount was $<ix:nonFraction contextRef="c36" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="6" unitRef="usd" id="ixv-11110">11.3</ix:nonFraction> million of customary
holdbacks as provided in the stock purchase agreement (the &#8220;Purchase Agreement&#8221;) which we received in 2023. Additionally,
the Purchase Agreement provides that we may receive up to an additional $<ix:nonFraction contextRef="c37" decimals="-5" format="ixt:num-dot-decimal" name="txmd:ContingentCashConsiderationFromSaleOfBusiness" scale="6" unitRef="usd" id="ixv-11111">7.0</ix:nonFraction> million in earn-out consideration, contingent upon vitaCare&#8217;s
financial performance through 2023 as determined in accordance with the terms of the Purchase Agreement; however, we do not believe this
earnout will be realized. We will record the contingent consideration at the settlement amount if and when the consideration is realized
or realizable.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_DivestitureOfBusinessPolicyPolicyTextBlock-c0_cont_3" id="txmd_DivestitureOfBusinessPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Purchase Agreement contains customary representations and warranties,
covenants, and indemnities of the parties thereto. The commitments under a long-term services agreement related to vitaCare were transferred
to Mayne Pharma as part of the Mayne Transaction. </p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="txmd_DivestitureOfBusinessPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The divestiture of vitaCare was determined to be a component of discontinued
operations in December 2022, when we changed our business by becoming a royalty company and as a result vitaCare activities were reclassified
to discontinued operations for 2023 and 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 61 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_3" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="txmd_GoingConcernPolicyTextBlock-c0_cont_1" escape="true" name="txmd:GoingConcernPolicyTextBlock" id="ixv-7449"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Going concern</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GoingConcernPolicyTextBlock-c0_cont_2" id="txmd_GoingConcernPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 4, 2022, we entered into agreements with Mayne Pharma pursuant
to which we granted Mayne Pharma an exclusive license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products (in
the United States and its possessions and territories), (ii) assign to Mayne Pharma our exclusive license to commercialize ANNOVERA in
the United States and its possessions and territories, and (iii) sell certain other assets to Mayne Pharma.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GoingConcernPolicyTextBlock-c0_cont_3" id="txmd_GoingConcernPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total consideration from Mayne Pharma to the TherapeuticsMD for
the purchase of the Transferred Assets under the Transaction Agreement and the grant of the licenses under the Mayne License Agreement
consisted of (i) a cash payment of $<ix:nonFraction contextRef="c30" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAcquiredFromAcquisition" scale="6" unitRef="usd" id="ixv-11112">140.0</ix:nonFraction> million at closing, (ii) a cash payment of approximately $<ix:nonFraction contextRef="c30" decimals="-5" format="ixt:num-dot-decimal" name="txmd:ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments" scale="6" unitRef="usd" id="ixv-11113">12.1</ix:nonFraction> million at closing for the acquisition
of net working capital subject to certain adjustments, (iii) a cash payment of approximately $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="txmd:PrepaidRoyaltyLiabilities" scale="6" unitRef="usd" id="ixv-11114">1.0</ix:nonFraction> million at closing for prepaid royalties
in connection with the Mayne License Agreement Amendment and (iv) the right to receive the contingent consideration set forth in the Mayne
License Agreement, as amended.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GoingConcernPolicyTextBlock-c0_cont_4" id="txmd_GoingConcernPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On the Closing Date, we repaid all obligations under the Financing
Agreement, dated as of April 24, 2019, as amended, with Sixth Street Specialty Lending, Inc., as administrative agent, the various lenders
from time-to-time party thereto, and certain of our subsidiaries party thereto from time to time as guarantors (the &#8220;Financing Agreement&#8221;)
and the Financing Agreement was terminated.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GoingConcernPolicyTextBlock-c0_cont_5" id="txmd_GoingConcernPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the transaction with Mayne Pharma, our primary source of
revenue is from royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories.
We may need to raise additional capital to provide additional liquidity to fund our operations until we become cash flow positive. To
address our capital needs, we may pursue various equity and debt financing and other alternatives. The equity financing alternatives may
include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders,
or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity
securities may be limited by market conditions, including the market price of our common stock, and our available authorized shares.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GoingConcernPolicyTextBlock-c0_cont_6" id="txmd_GoingConcernPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent that we raise additional capital through the sale of
such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include
liquidation or other preferences that adversely affect the rights of our existing stockholders. If we are not successful in obtaining
additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, or merge,
consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GoingConcernPolicyTextBlock-c0_cont_7" id="txmd_GoingConcernPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 1, 2023, we entered into a Subscription Agreement (the &#8220;Subscription
Agreement&#8221;) with Rubric Capital Management LP (&#8220;Rubric&#8221;), pursuant to which we agreed to sell to Rubric, or one or more
of its affiliates, up to an aggregate of <ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-11115">5,000,000</ix:nonFraction> shares of our common stock, par value $<ix:nonFraction contextRef="c38" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-11116">0.001</ix:nonFraction> per share (our &#8220;Common Stock&#8221;),
from time to time during the term of the Subscription Agreement in separate draw-downs at our election. On June 29, 2023, we issued and
sold <ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-11117">312,525</ix:nonFraction> shares of Common Stock at a price per share equal to $<ix:nonFraction contextRef="c39" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-11118">3.6797</ix:nonFraction> pursuant to the Subscription Agreement. We received gross proceeds
of $<ix:nonFraction contextRef="c40" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="6" unitRef="usd" id="ixv-11119">1.15</ix:nonFraction> million from the draw down, before expenses. On November 15,
2023 Rubric drew down an additional <ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-11120">1,000,000</ix:nonFraction> shares of Common Stock at a price per share equal to $<ix:nonFraction contextRef="c41" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-11121">2.28</ix:nonFraction>. We received gross proceeds of
$<ix:nonFraction contextRef="c42" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="6" unitRef="usd" id="ixv-11122">2.0</ix:nonFraction> million from the drawdown, before expenses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:continuation continuedAt="txmd_GoingConcernPolicyTextBlock-c0_cont_8" id="txmd_GoingConcernPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2024, the Company received Mayne Pharma&#8217;s
                                                                         calculation of allowance for payer rebates and wholesale distributor fees which differed significantly from the Company&#8217;s
                                                                         estimate of the allowances. The Company believes its estimated allowances for payer rebates and wholesale distributor fees are
                                                                         reasonable and intends to resolve this matter through the process outlined in the Transaction Agreement. Given the recent receipt of
                                                                         Mayne Pharma&#8217;s allowance calculation and the nature of the estimates involved, the outcome of this matter is uncertain at this
                                                                         point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any
                                                                         additional liability associated with Mayne Pharma&#8217;s allowance calculation for payer rebates and wholesale distributor
                                                                         fees.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GoingConcernPolicyTextBlock-c0_cont_9" id="txmd_GoingConcernPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, the Company believes no additional accrual
is required for amounts that may be owed for the allowance for returns under the Transaction Agreement. The Company has not recorded any
contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital
items as changes to estimated amounts owed or amounts due from Mayne Pharma that may be material.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="txmd_GoingConcernPolicyTextBlock-c0_cont_10" id="txmd_GoingConcernPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If Mayne Pharma&#8217;s sales of IMVEXXY, BIJUVA, or ANNOVERA
grow more slowly than expected or decline, if the net working capital settlement with Mayne Pharma under the Transaction Agreement
is greater than our current estimates, if we are unsuccessful with future financings or if the supply chains related to the
third-party contract manufacturers are worse than we anticipate, our existing cash reserves may be insufficient to satisfy our
liquidity requirements. The potential impact of these factors in conjunction with the uncertainty of the capital markets raises
substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial
statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="txmd_GoingConcernPolicyTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying consolidated financial statements do not include any
adjustments that might be necessary if we are unable to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 62 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_4" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-7499"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A.&#160;Basis of presentation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2" id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements and related notes include our
parent company and all wholly owned subsidiaries. The consolidated financial statements are prepared in accordance with accounting principles
generally accepted in the Unites States of America (&#8220;U.S. GAAP&#8221;). Our fiscal year-end is as of and for the year ended December
31st for each year presented. All intercompany transactions among our businesses have been eliminated.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_3" id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As part of the transformation and as a result of the vitaCare divestiture
and the Mayne Transaction, historical results of commercial operations for all periods prior to the Closing Date have been reflected as
discontinued operations in the consolidated financial statements. Assets and liabilities associated with the commercial business are classified
as assets and liabilities of discontinued operations in the consolidated balance sheet. Additional disclosures regarding discontinued
operations are provided in Note 2 of these consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain amounts in the notes to the consolidated financial statements
may not add due to rounding. Certain prior period amounts have been reclassified to conform to current-period presentation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-7512"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B.&#160;New accounting standards</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Adoption of new accounting standards</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;)
issued ASU 2023-09, &#8220;Income Taxes (Topic 740) - Improvements to Income Tax Disclosures.&#8221; ASU 2023-09 enhances the transparency
and decision usefulness of income tax disclosures by requiring consistent categories and greater disaggregation of information in the
rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 will be effective for the Company in its income tax
disclosure included in its 2025 Annual Report on Form 10-K and will be applied on a prospective basis. However, retrospective application
is permitted. Early adoption is also permitted. The Company is evaluating the impact of ASU 2023-09 on the Company's income tax disclosures
and on its consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DiscontinuedOperationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DiscontinuedOperationsPolicyTextBlock" id="ixv-7523"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>C. Discontinued Operations</b></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_DiscontinuedOperationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Discontinued operations comprise activities that were disposed of at
the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting
purposes and represent a business shift having a major effect on the Company&#8217;s operations and financial results according to Accounting
Standard Codification (&#8220;ASC&#8221;) Topic 205, Presentation of Financial Statements. An adjustment has been made to the consolidated
statements of operations for the twelve months ended December 31, 2023 and 2022 to reclassify commercial activities and vitaCare activities
to discontinued operations as both components, in the aggregate, represented a business shift that will have a major effect on the Company&#8217;s
operations and financial results. <ix:nonFraction contextRef="c43" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-11123">No</ix:nonFraction> amounts for shared general and administrative operating support expense were allocated to discontinued
operations. As required by the terms of the Financing Agreement, the proceeds from both transactions were used to fully repay our outstanding
debt borrowings. As a result, interest expense and amortization of deferred financing costs as well as expense for accretion of Series
A Preferred Stock and loss on extinguishment of debt are included within income (loss) from discontinued operations, net of tax. Additionally,
the related assets and liabilities have been reported as assets and liabilities of discontinued operations in the Company&#8217;s consolidated
balance sheet as of December 31, 2023 and 2022. For additional information, see Note 2 - Discontinued Operations.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-7530"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>D. Estimates and assumptions</b></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of consolidated financial statements in conformity
to U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the
reporting period. We evaluate our estimated assumptions based on historical experience and on various other assumptions that are believed
to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different
assumptions or conditions.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="ixv-7537"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>E. Cash and Restricted Cash</b></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">For the purpose of the statements of cash flows, all highly liquid
investments with an original maturity of three months or less are considered to be&#160;cash&#160;equivalents. The carrying value of these
investments approximates fair value.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We maintain cash at financial institutions that at times may exceed
the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits of $<ix:nonFraction contextRef="c3" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="6" unitRef="usd" id="ixv-11124">0.25</ix:nonFraction> million per bank. We have never experienced any
losses related to these funds.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restricted cash was comprised of escrowed funds deposited with a bank
relating to the vitaCare Divestiture. All restrictions were lifted in March 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 63 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_5" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-7565"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>F.</b>&#160;<b>Fair Value Measurements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fair value is the price to sell an asset or transfer a liability and
therefore represents an exit price in the principal market (or in the absence of a principal market, the most advantageous market). It
represents a market-based measurement that contemplates a hypothetical transaction between market participants at the measurement date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The unique characteristics of an asset or liability and the availability
of observable prices affect the number of valuation approaches and/or techniques used in a fair value analysis. We measure fair value
using observable and unobservable inputs. We give the highest priority to quoted prices (unadjusted) in active markets for identical assets
or liabilities (Level 1 inputs) and the lowest priority to unobservable inputs (Level 3 inputs).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We apply the following fair value hierarchy:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">Level 1 - Quoted prices (unadjusted) in active markets for
identical assets and liabilities.</td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">Level 2 - Quoted prices in non-active markets or in active
markets for similar assets or liabilities, observable inputs other than quoted prices; and inputs that are not directly observable but
are corroborated by observable market data.</td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">Level 3 - Inputs that are unobservable.</td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amount of our cash, restricted cash, accounts receivable,
accounts payable and accrued expenses approximate their fair value because of the short-term maturity of such instruments, which are considered
Level 1 under the fair value hierarchy.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-7603"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>G.&#160;Fixed assets</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fixed assets are carried at cost less accumulated depreciation and
amortization. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs
to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related
assets, which range from <ix:nonNumeric contextRef="c44" continuedAt="_PropertyPlantAndEquipmentUsefulLife-c44_cont_1" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-11125">three</ix:nonNumeric> to <ix:nonNumeric contextRef="c45" continuedAt="_PropertyPlantAndEquipmentUsefulLife-c45_cont_1" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-11126">seven</ix:nonNumeric><ix:continuation id="_PropertyPlantAndEquipmentUsefulLife-c45_cont_1"><ix:continuation id="_PropertyPlantAndEquipmentUsefulLife-c44_cont_1"> years</ix:continuation></ix:continuation>. Leasehold improvements are depreciated over the shorter of their useful life or the term
of the lease. Long-lived assets held and used by us, including fixed assets, are assessed for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be recoverable.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We capitalize software and software development costs incurred to create
and acquire computer software for internal use, principally related to software coding and application development. We begin to capitalize
software development costs when both the preliminary project stage is completed, and it is probable that the software will be used as
intended. Capitalized software costs include only external direct costs and services utilized in developing or obtaining computer software.
Capitalized software costs are amortized on a straight-line basis when placed into service over the estimated useful life, generally <ix:nonNumeric contextRef="c46" continuedAt="_PropertyPlantAndEquipmentUsefulLife-c46_cont_1" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-11129">five</ix:nonNumeric>
to <ix:nonNumeric contextRef="c47" continuedAt="_PropertyPlantAndEquipmentUsefulLife-c47_cont_1" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-11130">seven</ix:nonNumeric><ix:continuation id="_PropertyPlantAndEquipmentUsefulLife-c47_cont_1"><ix:continuation id="_PropertyPlantAndEquipmentUsefulLife-c46_cont_1"> years</ix:continuation></ix:continuation>.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="ixv-7613"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>H.&#160;License rights and other
intangibles assets</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-c0_cont_2" id="_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We record license rights and other intangible assets at cost, which
includes external costs, consisting primary of legal costs, incurred in securing our patents and trademarks.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-c0_cont_3" id="_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">License rights costs related to ANNOVERA were amortized until December
30, 2022 over the useful life over which the license rights would contribute directly or indirectly to our cash flows. The cost was amortized
using the straight-line method as the pattern of economic benefit could not be reliably determined. On December 30, 2022, we assigned
our ANNOVERA license to Mayne Pharma and included the remaining ANNOVERA license cost of $<ix:nonFraction contextRef="c48" decimals="-5" format="ixt:num-dot-decimal" name="txmd:WriteOffOfAsset" scale="6" unitRef="usd" id="ixv-11133">30.2</ix:nonFraction> million in our calculation of the gain
on sale of assets. In addition, amortization of license rights of $<ix:nonFraction contextRef="c49" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" unitRef="usd" id="ixv-11134">3.0</ix:nonFraction> million for 2022 was reclassified to discontinued operations.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-c0_cont_4" id="_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intangible assets subject to amortization, such as patents, are amortized
over the useful life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs
at that time. Intangible assets not subject to amortization, such as trademarks, are perpetual and have indefinite lives.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We review license rights and other intangible assets subject to amortization
on a periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision to their remaining useful
lives. We assess other intangible assets not subject to amortization for potential impairment at least annually during the fourth quarter
of each year, or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the
intangible assets below their carrying value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_6" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-7644"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>I.</b>&#160;<b>Segment reporting</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We manage and operate as one business, which prior to December 2022
was focused on creating and commercializing products targeted exclusively for women and after we signed Mayne License Agreement, is focused
on collecting royalties from licensing our products. Our business is led by our chief executive officer. We do not operate separate lines
of business with respect to any of our products, and we do not prepare discrete financial information with respect to separate products.
Accordingly, we view our business as <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="pure" id="ixv-11135"><ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure" id="ixv-11136">one</ix:nonFraction></ix:nonFraction> reportable operating segment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-7652"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>J.&#160;Revenue recognition</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We determine the amount of revenue to be recognized through application
of the following steps:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: 0.25in">&#9679;</td><td>Identification of the contract with a customer;</td></tr></table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_4" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: 0.25in">&#9679;</td><td>Identification of the performance obligations in the contract;</td></tr></table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_5" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: 0.25in">&#9679;</td><td>Determination of the transaction price;</td></tr></table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_6" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: 0.25in">&#9679;</td><td>Allocation of the transaction price to the performance obligations in the contract; and</td></tr></table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_7" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"/><td style="width: 0.25in">&#9679;</td><td>Recognition of revenue when or as we satisfy the performance obligations.</td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_8" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A performance obligation is a promise in a contract to transfer a product
or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains
control, and we treat shipping as a fulfillment activity rather than as a separate obligation. We generally recognize revenue at a point
in time when all of our performance obligations under the terms of a contract are satisfied. Revenue is recognized upon transfer of control
of promised products or services in an amount that reflects the consideration we expect to receive in exchange for those products or services.
The collectability of consideration on the contract is reasonably assured before revenue is recognized. To the extent that customer payment
has been received before all recognition criteria are met, these revenues are initially deferred in other accruals on the balance sheet
and the revenue is recognized in the period that all recognition criteria have been met.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_9" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>License revenue</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_10" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">License arrangements may consist of non-refundable upfront license
fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones and future product
royalty payments. Some of these arrangements may include multiple performance obligations. Non-refundable up-front fees that are not contingent
on any future performance by us, and do not require continuing involvement on our part, are recognized as revenue when the right to use
functional intellectual property is transferred to the customer.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_11" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 30, 2022, we granted an exclusive license to commercialize
our prescription products and assigning the Company&#8217;s exclusive license to commercialize ANNOVERA to Mayne Pharma, which resulted
in a business shift that had a major effect on our operations and financial results. As part of the transformation that included the Mayne
License Agreement, historical results of commercial operations have been reflected as discontinued operations in the Company&#8217;s consolidated
financial statements for all periods prior to the Closing Date. As of December 31, 2022, we are no longer directly engaged in the sale
of prescription products.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_12" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the Mayne License Agreement, we received $<ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" unitRef="usd" id="ixv-11137">140</ix:nonFraction> million
at closing and we are eligible to receive additional payments in the aggregate of up to an additional $<ix:nonFraction contextRef="c50" decimals="-6" format="ixt:num-dot-decimal" name="txmd:AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments" scale="6" unitRef="usd" id="ixv-11138">30</ix:nonFraction> million, based on the achievement
of sales milestones (collectively, the &#8220;Milestone Amounts&#8221;). The proceeds at closing were allocated between consideration
for the sale of ANNOVERA and the initial license fee for the Licensed Products, as the sale of ANNOVERA was accounted for under ASC 610-20,
Gains and Losses from Derecognition of Nonfinancial Assets in arriving at the gain on disposal (see Note 2), while the license grant of
the other products were recognized under the provisions of ASC 606, Revenue from Contracts with Customers, as a license of functional
intellectual property. The proceeds were allocated among the Licensed Products on the relative net present value of forecasted future
product sales from those products. The Milestone Amounts will be recognized, as applicable, in subsequent periods based on actual product
sales that exceed the respective net sales milestones as such variable consideration is constrained by the occurrence of the subsequent
sales.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 65 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_7" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_13" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our royalty revenue in 2023 primarily related to royalties provided
for under the Mayne License Agreement based on Mayne Pharma&#8217;s sales of the licensed products subject to that agreement. Under the
Mayne License Agreement, the Company is entitled to earn royalties on net sales of all of the Licensed Products at a royalty rate of (i)
<ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="txmd:RoyaltyRateAsPercentageOnNetSales" scale="-2" unitRef="pure" id="ixv-11139">8</ix:nonFraction>% on the first $<ix:nonFraction contextRef="c51" decimals="-6" format="ixt:num-dot-decimal" name="txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate" scale="6" unitRef="usd" id="ixv-11140">80</ix:nonFraction> million of net sales of the Licensed Products and (ii) <ix:nonFraction contextRef="c52" decimals="3" format="ixt:num-dot-decimal" name="txmd:RoyaltyRateAsPercentageOnNetSales" scale="-2" unitRef="pure" id="ixv-11141">7.5</ix:nonFraction>% on net sales of all of the Licensed Products after the
first $<ix:nonFraction contextRef="c53" decimals="-6" format="ixt:num-dot-decimal" name="txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate" scale="6" unitRef="usd" id="ixv-11142">80</ix:nonFraction> million of net sales. The royalty rate is subject to a <ix:nonFraction contextRef="c54" decimals="2" format="ixt:num-dot-decimal" name="txmd:DecreaseInRoyaltyRateOnProductByProductBasis" scale="-2" unitRef="pure" id="ixv-11143">2</ix:nonFraction>% reduction upon the earlier to occur of (i) the expiration or revocation
of the last valid claim covering a Licensed Product, and (ii) a generic product launch (a &#8220;LOE&#8221;). We are entitled to minimum
annual royalties beginning with the year ending December 31, 2023 ($<ix:nonFraction contextRef="c54" decimals="-6" format="ixt:num-dot-decimal" name="txmd:MinimumAnnualRoyaltyPayment" scale="6" unitRef="usd" id="ixv-11144">3</ix:nonFraction> million annual minimum) and continuing with <ix:nonFraction contextRef="c54" decimals="2" format="ixt:num-dot-decimal" name="txmd:InflationRateAdjustedForMinimalAnnualRoyaltyPayment" scale="-2" unitRef="pure" id="ixv-11145">3</ix:nonFraction>% annual increases
through the year ending December 31, 2034 (the &#8220;Minimum Annual Royalty&#8221;). The total Minimum Annual Royalty we are entitled
to is $<ix:nonFraction contextRef="c55" decimals="-5" format="ixt:num-dot-decimal" name="txmd:AggregateMinimumAnnualRoyaltyPaymentsDue" scale="6" unitRef="usd" id="ixv-11146">42.6</ix:nonFraction> million, and this total amount was allocated among the Licensed Products on the relative net present value of forecasted future
product sales from those products. The portion allocated to consideration for the sale of ANNOVERA was attributed towards the gain on
disposal of that asset. For the remaining portion allocated to the license grants for the other products, we determined that the minimum
guarantee underlying the Minimum Annual Royalty should be treated as fixed consideration and recognized under ASC 606 at the point in
time when the license was transferred. Since the Minimum Annual Royalty will be received in annual installments through 2034, we determined
the transaction price allocated under ASC 606 contained a significant financing component, and we therefore determined the initial royalty
revenue and corresponding receivable based on the present value of the allocated Minimum Annual Royalty. The present value was calculated
using a discount rate of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="txmd:PresentValueOfAnnualMinimumRoyaltyDiscountRate" scale="-2" unitRef="pure" id="ixv-11147">10.45</ix:nonFraction>%, based on the credit characteristics of Mayne Pharma and the timing of future payments, and the value
will be accreted to full value through the earlier of January 1, 2034 or a LOE. This royalty receivable is a contract asset as of December
31, 2022 and 2023, and is further subject to offset by Mayne Pharma (see L. Contract Assets and Liabilities below).</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_14" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Royalty revenue earned in excess of the Minimum Annual Royalty will
be recognized under ASC 606, which provides revenue recognition constraints by requiring the recognition of revenue at the later of the
following: 1) when the subsequent sale occurs or 2) when the performance obligation to which some or all of the sales-based royalty has
been allocated has been satisfied (or partially satisfied). We applied the royalty recognition constraint required under the guidance
for sales-based royalties, which requires a sales-based royalty to be recorded no sooner than the underlying sale. Therefore, royalties
on sales of products commercialized by Mayne Pharma will be recognized in the subsequent periods that the Licensed Products are sold.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2023, we recorded BIJUVA license sales of $<ix:nonFraction contextRef="c56" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" unitRef="usd" id="ixv-11148">0.3</ix:nonFraction> million made through
the Theramex License Agreement and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="txmd:LicenseRevenue" scale="6" unitRef="usd" id="ixv-11149">1.0</ix:nonFraction> million pertaining to our licensed products with Mayne Pharma, which was recognized as license
revenue. Additionally, we recognized $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" unitRef="usd" id="ixv-11150">0.5</ix:nonFraction> million in other income pertaining to royalty sales of ANNOVERA.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CostOfSalesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock" id="ixv-7737"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>K.</b>&#160;<b>Cost of revenue</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_CostOfSalesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenue includes the cost of inventory, manufacturing, manufacturing
overhead and supply chain costs and product shipping and handling costs. Costs related to the Population Council License Agreement, which
were based on our net sales of ANNOVERA, and amortization of license rights were reclassified to discontinued operations for 2022 as a
result of the transaction with Mayne Pharma.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="txmd_ContractAssetsAndLiabilitiesPolicyTextBlock-c0_cont_1" escape="true" name="txmd:ContractAssetsAndLiabilitiesPolicyTextBlock" id="ixv-7745"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>L.&#160;Contract Assets and
Liabilities</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:continuation id="txmd_ContractAssetsAndLiabilitiesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contract assets totaling $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DepositContractsAssets" scale="6" unitRef="usd" id="ixv-11151">21.6</ix:nonFraction> million as of December 31, 2023, include
royalties recognized from the Minimum Annual Royalty (see J. Revenue Recognition above).</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-7753"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>M.&#160;Share-based payment
awards</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We account for share-based payment awards on a fair value basis of
the equity instrument issued. Under fair value accounting, the grant-date fair value of the share-based payment award is amortized as
compensation expense, on a straight-line basis, over the service period (generally, the vesting period) for both graded and cliff vesting
awards. We have elected to account for forfeitures as they occur.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Common stock reverse stock split</b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 6, 2022, we completed a reverse stock split of our Common Stock.
As a result, <ix:nonNumeric contextRef="c57" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-11152">shares of our outstanding Common Stock were split at a ratio of 50-for-1</ix:nonNumeric> (the &#8220;Reverse Stock Split&#8221;) with any
fractional shares resulting from the Reserve Stock Split rounded up to the next whole share of Common Stock. The number of authorized
shares of Common Stock was also correspondingly reduced from <ix:nonFraction contextRef="c58" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-11153">600.0</ix:nonFraction> million shares to <ix:nonFraction contextRef="c59" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-11154">12.0</ix:nonFraction> million shares to give effect to the Reverse
Stock Split. Additionally, all rights to receive shares of Common Stock under outstanding warrants, options, restricted stock units (&#8220;RSUs&#8221;)
and performance stock units (&#8220;PSUs&#8221;) were adjusted to give effect of the Reverse Stock Split. Furthermore, remaining shares
of Common Stock available for future issuance under share-based payment award plans and our employee stock purchase plan were adjusted
to give effect of the Reverse Stock Split. Pursuant to Section 78.209 of the Nevada Revised Statutes, the approval of our stockholders
was not required for our Board of Directors (the &#8220;Board&#8221;) to effectuate the Reverse Stock Split.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All historical numbers of shares of Common Stock and per share data
have been adjusted to give effect to the Reverse Stock Split. Additionally, since the Common Stock par value was unchanged, historical
amounts for Common Stock and additional paid-in capital have been adjusted to give effect to the Reverse Stock Split.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 66 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_8" id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_6" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Increase of authorized shares</b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 26, 2023, at our combined 2022 and 2023 Annual Meeting, our
stockholders approved an amendment to our Amended and Restated Articles of Incorporation to increase the number of authorized shares of
Common Stock from <ix:nonFraction contextRef="c60" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-11155">12</ix:nonFraction> million shares to <ix:nonFraction contextRef="c61" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-11156">32</ix:nonFraction> million shares.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-7793"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>N.&#160;Income taxes</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income taxes are accounted for under the asset and liability method.
Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and income
tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in income tax rates is recorded as a component of the income tax provision in the period that includes the enactment
date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_3" id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regular assessments are made on the likelihood that our deferred tax
assets will be recovered from our future taxable income. Our evaluation is based on estimates, assumptions, and includes an analysis of
available positive and negative evidence, giving weight based on the evidence&#8217;s relative objectivity. Sources of positive evidence
include estimates of future taxable income, future reversal of existing taxable temporary differences, taxable income in carryback years,
and available tax planning strategies. Sources of negative evidence include current and cumulative losses in recent years, losses expected
in early future years, any history of operating losses or tax credit carryforwards expiring unused, and unsettled circumstances that,
if unfavorably resolved, would adversely affect future profit levels.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_4" id="_IncomeTaxPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The remaining carrying value of our deferred tax assets, after recording
the valuation allowance on our deferred tax assets, is based on our present belief that it is more likely than not that we will be able
to generate sufficient future taxable income to utilize such deferred tax assets. The amount of the remaining deferred tax assets considered
recoverable could be adjusted if our estimates of future taxable income during the carryforward period change favorably or unfavorably.
To the extent we believe that it is more likely than not that some or all the remaining deferred tax assets will not be realized, we must
establish a valuation allowance against those deferred tax assets, resulting in additional income tax expense in the period such determination
is made. To the extent a valuation allowance currently exists, we will continue to monitor all positive and negative evidence until we
believe it is more likely than not that it is no longer necessary, resulting in an income tax benefit in the period such determination
is made.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our policy is to recognize both interest and penalties related to uncertain
tax positions as part of the income tax provision. Significant judgment is required in evaluating our tax positions, and in determining
our provisions for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred
tax assets. We establish reserves when, despite our belief that the income tax return positions are fully supportable, certain positions
are likely to be challenged and we may ultimately not prevail in defending those positions.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-7809"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>O.&#160;Earnings per common
share</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic earnings or loss per common share is computed by dividing net
income or loss available to common stockholders by the sum of the weighted average number of shares of common stock. Diluted earnings
per common share is computed by dividing net income available to common stockholders by the sum of the weighted average number of shares
of common stock and the number of additional shares of common stock that would have been outstanding if our outstanding potentially dilutive
securities had been issued. Potentially dilutive securities include awards of non-vested or vested and not settled restricted stock units,
performance stock units where the performance requirements have been met and not settled, warrants and options. The dilutive effect of
potentially dilutive securities is reflected in diluted earnings per common share by application of the treasury stock method, except
if its impact is anti-dilutive. Under the treasury stock method, an increase in the fair market value of our common stock can result in
a greater dilutive effect from potentially dilutive securities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-7816"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>P.&#160;Leases</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We determine if an arrangement is a lease at inception. Determining
whether a contract contains a lease includes judgment regarding whether the contract conveys the right to control the use of identified
property or equipment for a period of time in exchange for consideration.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We account for our lease-related assets and liabilities based on their
classification as operating leases or finance leases, following the relevant accounting guidance. For all the lessee arrangements, we
have elected an accounting policy to combine non-lease components with the related-lease components and treat the combined items as a
lease for accounting purposes. We measure lease related assets and liabilities based on the present value of lease payments, including
in-substance fixed payments, variable payments that depend on an index or rate measured at the commencement date, and the amount we believe
is probable we will pay the lessor under residual value guarantees when applicable. We discount lease payments based on our estimated
incremental borrowing rate at lease commencement (or modification), which is primarily based on our estimated credit rating, the lease
term at commencement, and the contract currency of the lease arrangement. We have elected to exclude short-term leases (leases with an
original lease term less than one year) from the measurement of lease-related assets and liabilities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_4" id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We test right-of-use assets in an operating or finance lease at the asset group level (because these assets are long-lived nonfinancial
assets and should be accounted for the same way as other long-lived nonfinancial assets) whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 67 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We sublease our unoccupied facilities to third parties. Any impairment
to the associated right-of-use asset, leasehold improvements, or other assets as a result of the sublease is recognized in the period
when a decision to sublease is made and recorded in our consolidated statement of operations. We recognize sublease income on a straight-line
basis over the sublease term.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-7848"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Q.&#160;Loss Contingencies</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In determining whether an accrual for a loss contingency is required,
we first assess the likelihood of occurrence of the future event or events that will confirm the loss. When a loss is probable (the future
event or events are likely to occur) and the amount of the loss can be reasonably estimated, the estimated loss is accrued. If the reasonable
estimate of the loss is a range and an amount within the range appears to be a better estimate than any other amount within the range,
that amount should be accrued. However, if no amount within the range is a better estimate, the minimum amount in the range should be
accrued. When a loss is reasonably possible (the chance of the future event or events occurring is more than remote but less than likely),
<ix:nonFraction contextRef="c3" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="0" unitRef="usd" id="ixv-11157">no</ix:nonFraction> accrual is recognized. See Note 8 for more information.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy-c0_cont_1" escape="true" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" id="ixv-7855"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>R.&#160;Restructuring charges</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy-c0_cont_2" id="_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2022, the Company initiated and
completed a restructuring plan that resulted in a reduction of its workforce to <ix:nonFraction contextRef="c7" decimals="0" format="ixt-sec:numwordsen" name="txmd:NumberOfEmployeesAfterWorkforceReduction" scale="0" unitRef="pure" id="ixv-11158">one</ix:nonFraction> employee. One-time termination benefits include severance,
continuation of health insurance coverage, and other benefits for a specified period of time, as well as contract terminations and fixed
assets write-downs, which resulted in $<ix:nonFraction contextRef="c7" decimals="-5" format="ixt:num-dot-decimal" name="txmd:RestructuringChargesIncludingDiscontinuedOperations" scale="6" unitRef="usd" id="ixv-11159">15.7</ix:nonFraction> million of restructuring costs for the year ended December 31, 2022. There were no restructuring
costs incurred during the year ended December 31, 2023. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRestructuringAndRelatedCostsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="ixv-11160">Restructuring costs have been recognized in the accompanying consolidated statement
of operations as follows (in thousands):</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfRestructuringAndRelatedCostsTextBlock-c0_cont_1"><ix:continuation continuedAt="_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy-c0_cont_3" id="_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Year ended<br/> December&#160;31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Executive termination benefits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" unitRef="usd" id="ixv-11161">3,897</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Consulting and legal expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" unitRef="usd" id="ixv-11162">3,060</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other contract termination costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" unitRef="usd" id="ixv-11163">2,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total restructuring expenses - general and administrative expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="3" unitRef="usd" id="ixv-11164">9,472</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employee termination benefits</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" scale="3" unitRef="usd" id="ixv-11165">4,813</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other contract termination costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" scale="3" unitRef="usd" id="ixv-11166">1,367</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total restructuring expenses - discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" scale="3" unitRef="usd" id="ixv-11167">6,180</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At December 31, 2023 and 2022 respectively, $<ix:nonFraction contextRef="c62" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringReserve" scale="6" unitRef="usd" id="ixv-11168">2.5</ix:nonFraction> million and $<ix:nonFraction contextRef="c63" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringReserve" scale="6" unitRef="usd" id="ixv-11169">6.2</ix:nonFraction> million
of restructuring costs were included in current liabilities of discontinued operations in the accompanying consolidated balance sheets.
At December 31, 2022, $<ix:nonFraction contextRef="c63" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" unitRef="usd" id="ixv-11170">9.3</ix:nonFraction> million related to restructuring costs was included in accrued expenses and other current liabilities.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_PriorPeriodReclassificationAdjustmentDescription-c0_cont_1" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="ixv-7928"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>S. Reclassification of prior year presentation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_PriorPeriodReclassificationAdjustmentDescription-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain prior year amounts have been reclassified for consistency with
the current year presentation.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="ixv-7937"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>2. Discontinued Operations</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt">As discussed in Note 1, we changed our business in 2022 by
licensing our products to receive royalties and future sales related milestone payments, after granting an exclusive license to commercialize
our IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands in the United States and
assigning our exclusive license to commercialize ANNOVERA to Mayne Pharma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt">This plan represented a strategic shift having a major effect
on our operations and financial results. Upon our conversion from a commercial pharmaceutical company to a licensing only company with
the consummation of the Mayne Transaction, we classified all direct revenues, costs and expenses related to commercial operations, within
income (loss) from discontinued operations, net of tax, in the consolidated statements of operations for all periods presented. We have
<ix:nonFraction contextRef="c43" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-11171">no</ix:nonFraction>t allocated any amounts for shared general and administrative operating support expense to discontinued operations. As required by the
terms of the Financing Agreement, proceeds from the Mayne Transaction and the vitaCare Divestiture were used to fully repay our outstanding
debt borrowings, and as a result interest expense and amortization of deferred financing costs as well as expense for accretion of Series
A Preferred Stock and loss on extinguishment of debt are included within income (loss) from discontinued operations, net of tax (as disclosed
below).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt">Additionally, the related assets and liabilities have been
reported as assets and liabilities of discontinued operations in our consolidated balance sheet as of December 31, 2023 and 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 68 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt">The total consideration from Mayne Pharma consisted of (i)
a cash payment of $<ix:nonFraction contextRef="c43" decimals="-5" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived" scale="6" unitRef="usd" id="ixv-11172">140.0</ix:nonFraction> million at closing, (ii) a cash payment of $<ix:nonFraction contextRef="c68" decimals="-5" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments" scale="6" unitRef="usd" id="ixv-11173">12.1</ix:nonFraction> million for the acquisition of net working capital subject to
certain adjustments, (iii) a cash payment of approximately $<ix:nonFraction contextRef="c43" decimals="-5" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties" scale="6" unitRef="usd" id="ixv-11174">1.0</ix:nonFraction> million for prepaid royalties in connection with the Mayne License Agreement
Amendment and (iv) the right to receive the contingent consideration set forth in the Mayne License Agreement, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt">Our estimate of net working capital at closing was determined in accordance
with the Transaction Agreement which establishes the process for the determination of final net working capital. The determination of
final net working capital includes significant estimates which could change materially for a period of up to two years following the Closing
Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt"><ix:nonNumeric contextRef="c0" continuedAt="txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock-c0_cont_1" escape="true" name="txmd:ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock" id="ixv-11175">The following table presents results of discontinued operations
(in thousands):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Years ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Product revenue, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" sign="-" unitRef="usd" id="ixv-11176">833</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" unitRef="usd" id="ixv-11177">80,749</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" unitRef="usd" id="ixv-11178">15,640</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross profit (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-11179">833</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" unitRef="usd" id="ixv-11180">65,109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing" scale="3" unitRef="usd" id="ixv-11181">75,208</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-11182">481</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-11183">11,301</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-11184">4,942</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Restructuring charges</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" scale="3" unitRef="usd" id="ixv-11185">6,180</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" unitRef="usd" id="ixv-11186">481</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" unitRef="usd" id="ixv-11187">97,631</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss from discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11188">1,314</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11189">32,522</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gain on sale of vitaCare</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness" scale="3" unitRef="usd" id="ixv-11190">143,384</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on ANNOVERA sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationGainOnSale" scale="3" unitRef="usd" id="ixv-11191">62,031</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on the extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" sign="-" unitRef="usd" id="ixv-11192">8,380</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense and other financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts" scale="3" unitRef="usd" id="ixv-11193">36,065</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expense for accretion of Series A Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock" scale="3" unitRef="usd" id="ixv-11194">16,973</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss on disposal of assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" sign="-" unitRef="usd" id="ixv-11195">1,150</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-11196">115</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" scale="3" sign="-" unitRef="usd" id="ixv-11197">1,265</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" scale="3" unitRef="usd" id="ixv-11198">143,997</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss before from income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes" scale="3" sign="-" unitRef="usd" id="ixv-11199">2,579</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes" scale="3" unitRef="usd" id="ixv-11200">111,475</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Benefit (provision) for income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" scale="3" unitRef="usd" id="ixv-11201">552</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net income (loss) from discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-11202">2,579</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" unitRef="usd" id="ixv-11203">110,923</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="ixv-11204">The following table presents the carrying amounts of the classes of
assets and liabilities of discontinued operations (in thousands):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationRentReceivable" scale="3" unitRef="usd" id="ixv-11205">344</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="3" unitRef="usd" id="ixv-11206">344</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-11207">12,243</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities" scale="3" unitRef="usd" id="ixv-11208">3,694</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities" scale="3" unitRef="usd" id="ixv-11209">13,588</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="3" unitRef="usd" id="ixv-11210">3,694</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="3" unitRef="usd" id="ixv-11211">25,831</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 69 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-8336"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3.&#160;Prepaid and other current
assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfOtherCurrentAssetsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ixv-11212">Our prepaid and other current assets consisted of the following
(in thousands):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:continuation id="_ScheduleOfOtherCurrentAssetsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" unitRef="usd" id="ixv-11213">253</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" unitRef="usd" id="ixv-11214">1,167</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Capitalized legal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AcquisitionCostsCumulative" scale="3" unitRef="usd" id="ixv-11215">2,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AcquisitionCostsCumulative" scale="3" unitRef="usd" id="ixv-11216">2,334</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-11217">1,448</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-11218">2,533</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Prepaid and other current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-11219">4,035</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-11220">6,034</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-8401"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-size: 10pt"><b>4. Fixed assets</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-11221">Our fixed assets, net consisted of the following (in thousands):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Furniture and fixtures</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-11222">931</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-11223">931</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Computer and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-11224">1,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-11225">1,168</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-11226">375</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-11227">375</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-11228">49</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-11229">49</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-11230">2,522</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-11231">2,523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-11232">2,522</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-11233">2,445</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Fixed assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-11234">78</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded in continuing operations, depreciation expense of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" unitRef="usd" id="ixv-11235">0.1</ix:nonFraction>
million for 2023 and $<ix:nonFraction contextRef="c7" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" unitRef="usd" id="ixv-11236">0.6</ix:nonFraction> million for 2022.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="ixv-8500"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>5. Licensed rights and other intangible assets</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock-c0_cont_1" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="ixv-11237">The following provides information about our license rights and other
intangible assets, net (in thousands):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:continuation id="_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Gross</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Gross</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Carrying</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Carrying</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Net</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Net</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Intangible assets subject to amortization:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Hormone therapy drug patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11238">6,818</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" unitRef="usd" id="ixv-11239">1,871</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11240">4,947</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11241">6,225</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" unitRef="usd" id="ixv-11242">1,598</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11243">4,627</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Hormone therapy drug patents applied and pending approval</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11244">842</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11245">842</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11246">1,995</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11247">1,995</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Intangible assets subject to amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11248">7,660</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" unitRef="usd" id="ixv-11249">1,871</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11250">5,789</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11251">8,220</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" unitRef="usd" id="ixv-11252">1,598</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11253">6,622</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Intangible assets not subject to amortization:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Trademarks/trade name rights</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11254">309</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11255">309</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11256">321</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11257">321</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Intangible assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11258">7,969</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" unitRef="usd" id="ixv-11259">1,871</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11260">6,098</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11261">8,541</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" unitRef="usd" id="ixv-11262">1,598</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd" id="ixv-11263">6,943</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded, in continuing operations, amortization expense related
to patents of $<ix:nonFraction contextRef="c78" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" unitRef="usd" id="ixv-11264">0.8</ix:nonFraction> million for 2023, of which $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" unitRef="usd" id="ixv-11265">0.5</ix:nonFraction> million is accelerated amortization as a result of a review of our intangible assets,
and $<ix:nonFraction contextRef="c79" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" unitRef="usd" id="ixv-11266">0.6</ix:nonFraction> million for 2022. We recorded amortization expense related to the exclusive license rights agreement with Population Council
of $<ix:nonFraction contextRef="c49" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" unitRef="usd" id="ixv-11267">3.0</ix:nonFraction> million for 2022, which was reclassified to discontinued operations after we completed transaction with Mayne Pharma in December
2022, and excluded from the table above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="ixv-11268">Our intangible assets subject to amortization are expected to be amortized
as follows (in thousands):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">Year ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" unitRef="usd" id="ixv-11269">533</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" unitRef="usd" id="ixv-11270">445</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" unitRef="usd" id="ixv-11271">445</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" unitRef="usd" id="ixv-11272">445</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" unitRef="usd" id="ixv-11273">445</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" unitRef="usd" id="ixv-11274">5,347</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" unitRef="usd" id="ixv-11275">7,660</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:nonNumeric><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation id="_IntangibleAssetsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We use a combination of qualitative and quantitative factors to assess
licensed rights and intangible assets for impairment. In the year ending December 31, 2023, we have not impaired any of our hormone therapy
drug patent assets.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="ixv-8831"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>6. Accrued expenses and other current liabilities</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="txmd:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" id="ixv-11276">Other accrued expenses and other current liabilities consisted of the
following (in thousands):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Payroll and related costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11277">762</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11278">8,748</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued contract termination costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="txmd:AccruedContractTerminationCosts" scale="3" unitRef="usd" id="ixv-11279">4,700</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="txmd:AccruedResearchAndDevelopmentExpenses" scale="3" unitRef="usd" id="ixv-11280">978</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" unitRef="usd" id="ixv-11281">489</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" unitRef="usd" id="ixv-11282">415</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-11283">1,473</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-11284">1,390</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid royalty</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="txmd:AccruedPrepaidRoyalty" scale="3" unitRef="usd" id="ixv-11285">1,011</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other accrued expenses and current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11286">409</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-11287">1,604</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="txmd:AccruedExpensesAndOtherCurrentLiabilities" scale="3" unitRef="usd" id="ixv-11288">3,133</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="txmd:AccruedExpensesAndOtherCurrentLiabilities" scale="3" unitRef="usd" id="ixv-11289">18,846</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expense advertising costs when incurred, which amounted to
$<ix:nonFraction contextRef="c7" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdvertisingExpense" scale="6" unitRef="usd" id="ixv-11290">13.2</ix:nonFraction> million for 2022, which was reclassified to discontinued operations as a result of our business shift following the Mayne
Transaction. We incurred no advertising costs in 2023.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LongTermDebtTextBlock" id="ixv-8940"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>7. Debt</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Financing agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We were party to the Financing Agreement with Sixth Street
Specialty Lending, Inc., as administrative agent, various lenders from time-to-time party thereto, and certain of our subsidiaries
party thereto from time to time as guarantors. On December 30, 2022, we repaid all obligations under the Financing Agreement and the
Financing Agreement was terminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Interest and financing costs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Included in miscellaneous income in 2023 is $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="6" unitRef="usd" id="ixv-11291">0.3</ix:nonFraction> million of interest
income and $<ix:nonFraction contextRef="c7" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="6" unitRef="usd" id="ixv-11292">0.2</ix:nonFraction> million of interest expense. In 2022 and recorded in discontinued operations, we recognized $<ix:nonFraction contextRef="c7" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" unitRef="usd" id="ixv-11293">13.5</ix:nonFraction> million of debt-related
interest expense and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" scale="6" unitRef="usd" id="ixv-11294">22.5</ix:nonFraction> million of financing fees amortization.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-8957"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8.&#160;Commitments and contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2018, we entered into a lease for executive, administrative,
operations and sales offices in Boca Raton, Florida. The lease includes <ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfLand" scale="0" unitRef="sqm" id="ixv-11295">62,748</ix:nonFraction> rentable square feet, or the full premises, of which the
lease on <ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfLand" scale="0" unitRef="sqm" id="ixv-11296">7,561</ix:nonFraction> square feet commenced in 2018 and the lease on <ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfLand" scale="0" unitRef="sqm" id="ixv-11297">48,651</ix:nonFraction> square feet commenced in August 2019, or the full premises
commencement date. In June 2019, we entered into an agreement with the same lessors to
lease additional <ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfLand" scale="0" unitRef="sqm" id="ixv-11298">6,536</ix:nonFraction> square feet of administrative office space in the same location, pursuant to an addendum to such lease, which commenced
in May 2020. The lease will expire <ix:nonNumeric contextRef="c90" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-11299">11</ix:nonNumeric> years after the full premises commencement date, unless terminated earlier in accordance with
the terms of the lease. We have the option to extend the term of the lease for <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="ixv-11300">two</ix:nonNumeric> additional consecutive periods of <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="txmd:LeaseConsecutivePeriods" id="ixv-11301">five years</ix:nonNumeric>. The extension
option is not included in the determination of the lease term as it is not reasonably certain to be exercised. The term of the lease includes
escalating rent and free rent periods. We are also responsible for certain other operating costs under the lease, including electricity
and utility expenses. As a result of shifting our business
to become a license company and terminating our employees, we have sublet the majority of our headquarters and are in the process of subleasing
the remainder. We anticipate that sublease income will approximate the amounts due under our existing leases, therefore no impairment
of the right of use asset was recorded in 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 71 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For 2023 and 2022, operating <span style="-sec-ix-hidden: hidden-fact-75"><span style="-sec-ix-hidden: hidden-fact-76">lease expense</span></span> (including all variable
costs) related to our real estate leases was $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="6" unitRef="usd" id="ixv-11302">2.3</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="6" unitRef="usd" id="ixv-11303">2.1</ix:nonFraction> million, respectively. In 2023 and 2022, our rental income on sublease of our
three suites which were subleased following the vitaCare transaction was $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RentalIncomeNonoperating" scale="6" unitRef="usd" id="ixv-11304">1.3</ix:nonFraction> million and $<ix:nonFraction contextRef="c7" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RentalIncomeNonoperating" scale="6" unitRef="usd" id="ixv-11305">0.0</ix:nonFraction> million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-11306">As of December 31, 2023, our remaining lease payments were as follows
(in thousands):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Year ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-11307">1,477</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-11308">1,513</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd" id="ixv-11309">1,551</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" unitRef="usd" id="ixv-11310">1,590</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" unitRef="usd" id="ixv-11311">1,630</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" unitRef="usd" id="ixv-11312">2,664</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-11313">10,425</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-11314">2,420</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Present value of lease payments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-11315">8,005</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCondensedBalanceSheetTableTextBlock-c0_cont_1" escape="true" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock" id="ixv-11316">The following table sets forth supplemental balance sheet information
related to leases (in thousands):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfCondensedBalanceSheetTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31,</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease right-of-use assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-11317">6,873</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-11318">7,580</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease liabilities current (included in accrued expenses and other current liabilities)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-11319">1,473</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-11320">1,390</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-11321">6,532</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-11322">7,369</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-11323">8,005</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-11324">8,759</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-11325">The following table presents other information related to leases:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_LeaseCostTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Weighted average remaining term (years) - operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-11326">6.7</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-11327">7.7</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Weighted average discount rate - operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-11328">8.3</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-11329">8.3</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cash paid for amounts included in the measurement of lease liabilities from operating lease (in thousands)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="3" unitRef="usd" id="ixv-11330">1,443</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="3" unitRef="usd" id="ixv-11331">1,413</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Right-of-use assets obtained in exchange for new operating lease obligations (non-cash in thousands)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Mayne Pharma Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mayne Pharma paid us approximately $<ix:nonFraction contextRef="c92" decimals="-5" format="ixt:num-dot-decimal" name="txmd:CashReceivedForNetWorkingCapital" scale="6" unitRef="usd" id="ixv-11332">12.1</ix:nonFraction> million at closing on December
30, 2022, for the acquisition of net working capital, subject to certain adjustments as determined in accordance with the Transaction
Agreement. While the Transaction Agreement calls for much of the net working capital to be trued-up shortly after the Closing Date in
2023, for a period of one year following the Closing Date in the case of payer rebates and wholesale distributor fees and two years
following the Closing Date in the case for allowance for returns, net working capital amounts will be adjusted to arrive at final net
working capital under the Transaction Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2023, we revised certain accrual estimates including increasing our working capital adjustment accrual from $<ix:nonFraction contextRef="c93" decimals="-5" format="ixt:num-dot-decimal" name="txmd:IncrementalAccrualForNetWorkingCapital" scale="6" unitRef="usd" id="ixv-11333">3.5</ix:nonFraction> million to $<ix:nonFraction contextRef="c94" decimals="-5" format="ixt:num-dot-decimal" name="txmd:IncrementalAccrualForNetWorkingCapital" scale="6" unitRef="usd" id="ixv-11334">5.5</ix:nonFraction> million for amounts anticipated to be owed under the Transaction Agreement. In December 2023, we made a $<ix:nonFraction contextRef="c95" decimals="-5" format="ixt:num-dot-decimal" name="txmd:WorkingCapitalAmounts" scale="6" unitRef="usd" id="ixv-11335">5.5</ix:nonFraction> million payment to Mayne Pharma to settle certain working capital amounts that were required to be trued-up shortly after the Closing Date, excluding the allowance for returns, allowance for payer rebates, and allowance for wholesale distributor fees.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2024, the Company received Mayne Pharma&#8217;s
                                                                                                             calculation of allowance for payer rebates and wholesale distributor fees which differed significantly from the Company&#8217;s
                                                                                                             estimate of the allowances. The Company believes its estimated allowances for payer rebates and wholesale distributor fees are
                                                                                                             reasonable and intends to resolve this matter through the process outlined in the Transaction Agreement. Given the recent receipt of
                                                                                                             Mayne Pharma&#8217;s allowance calculation and the nature of the estimates involved, the outcome of this matter is uncertain at this
                                                                                                             point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any
                                                                                                             additional liability associated with Mayne Pharma&#8217;s allowance calculation for payer rebates and wholesale distributor
                                                                                                             fees.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Additionally and as of December 31, 2023, the Company believes no additional
accrual is required for amounts that may be owed for the allowance for returns. The Company has not recorded any contingent gains or receivables
for any such allowances. Management continues to monitor the unresolved and pending net working capital items as changes to estimated
amounts owed or amounts due from Mayne Pharma that may be material.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 72 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Population Council License Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of our license agreement with the Population Council,
Inc. (the &#8220;Population Council License Agreement&#8221;), we paid the Population Council a milestone payment of $<ix:nonFraction contextRef="c96" decimals="-5" format="ixt:num-dot-decimal" name="txmd:MilestonePayment" scale="6" unitRef="usd" id="ixv-11336">20.0</ix:nonFraction> million in
2018, which was within 30 days following the approval by the FDA of the New Drug Application (&#8220;NDA&#8221;) for ANNOVERA, and $<ix:nonFraction contextRef="c97" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DirectTaxesAndLicensesCosts" scale="6" unitRef="usd" id="ixv-11337">20.0</ix:nonFraction>
million in 2019 following the first commercial batch release of ANNOVERA. The aggregate $<ix:nonFraction contextRef="c98" decimals="-5" format="ixt:num-dot-decimal" name="txmd:MilestonePaymentsRecordedAsLicenseRights" scale="6" unitRef="usd" id="ixv-11338">40.0</ix:nonFraction> million of milestone payments were recorded
as license rights. The Population Council was also eligible to receive future payments upon the achievement of certain commercial sales
milestones of ANNOVERA. On December 30, 2022, we assigned the ANNOVERA license to Mayne Pharma. Our rights and obligations under the Population
Council License Agreement have been transferred to Mayne Pharma and may revert back to us upon the occurrence of certain events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2020, we received a Paragraph IV certification notice letter
(the &#8220;IMVEXXY Notice Letter&#8221;) regarding an Abbreviated New Drug Application (&#8220;ANDA&#8221;) submitted to the FDA by Teva
Pharmaceuticals USA, Inc. (&#8220;Teva&#8221;). The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic
version of the 4 mcg and 10 mcg doses of IMVEXXY. In the IMVEXXY Notice Letter, Teva alleges that TherapeuticsMD patents listed in the
FDA&#8217;s Orange Book that claim compositions and methods of IMVEXXY (the &#8220;IMVEXXY Patents&#8221;) are invalid, unenforceable,
and/or will not be infringed by Teva&#8217;s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents
identified in the IMVEXXY Notice Letter expire in 2032 or 2033. In April 2020, we filed a complaint for patent infringement against Teva
in the United States District Court for the District of New Jersey arising from Teva&#8217;s ANDA filing with the FDA. We are seeking,
among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA would be a date no earlier than the expiration
of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim
to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. In July 2021, following a proposal by Teva, the District
Court entered an order temporarily staying all proceedings in the IMVEXXY litigation, which order was filed under seal. In September 2021,
the District Court made available a public version of the order following the parties&#8217; agreement to a consent motion to redact information
Teva contended was confidential. The order provides that the statutory stay that prevents the FDA from granting final approval of the
ANDA for 30 months from the date of the IMVEXXY Notice Letter will be extended for the number of days that the stay of the IMVEXXY litigation
is in place. The length of the stay of the IMVEXXY litigation is dependent on further action by Teva. We have incurred and recorded legal
costs amounting to $<ix:nonFraction contextRef="c99" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="6" unitRef="usd" id="ixv-11339">2.3</ix:nonFraction> million in prepaid expenses and other current assets as of December 31, 2023, for the IMVEXXY Paragraph IV legal
proceeding since we believe that we will successfully prevail in this legal proceeding. Upon the successful conclusion of the legal proceeding,
the related capitalized legal costs will be reclassified to patents, in license rights and other intangible assets, net, in the accompanying
consolidated balance sheets, and such costs will be amortized over the remaining useful life of the patents. If we are unsuccessful in
this legal proceeding, then the related capitalized legal costs for this legal preceding and any unamortized IMVEXXY patent costs that
were previously capitalized will be immediately expensed in the period in which we become aware of an unsuccessful legal proceeding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beginning on December 30, 2022 and per the Mayne License Agreement,
Mayne Pharma is responsible for all enforcement of our patents, including the litigation discussed above with respect to Teva.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2023, one of our former contractors retained to market
ANNOVERA under Title X, filed a lawsuit that accused us of breach of contract. We answered their complaint and filed breach of contract
counterclaims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, we are involved in other litigations and proceedings
in the ordinary course of business. We are not currently involved in any other litigations and proceedings that we believe would have
a material effect on our consolidated financial condition, results of operations, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Off-balance sheet arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023 and 2022 we had no off-balance sheet arrangements
that have had or are reasonably likely to have current or future effects on our financial condition, changes in financial condition, revenues
or expenses, results of operations, liquidity, capital expenditures or capital resources that we consider material.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employment agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our transformation into a pharmaceutical royalty
company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief
Executive Officer) and all other employees was completed by December 30, 2022. Severance obligations for all employees other than executive
officers were paid in full in the first quarter of 2023. As of December 31, 2023, we employ one full-time employee primarily engaged in
an executive position. We have engaged external consultants who support our relationship with current partners and assist with certain
financial, legal, and regulatory matters and the continued wind-down of our historical business operations. The separation of our former
Interim Co-Chief Executive Officers, former Interim Chief Financial Officer and other executives from TherapeuticsMD was each a termination
without &#8220;Good Cause,&#8221; as defined in their respective employment agreements. In the aggregate, as of December 31, 2023, we
have accrued severance liabilities for executive termination obligations of $<ix:nonFraction contextRef="c100" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="6" unitRef="usd" id="ixv-11340">0.4</ix:nonFraction> million.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 73 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-9270"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>9. Stockholders&#8217; Equity</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt"><b>Increase of authorized shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">On June 26, 2023, at our combined 2022
and 2023 Annual Meeting, our stockholders approved an amendment to our Amended and Restated Articles of Incorporation to increase the
number of authorized shares of Common Stock from <ix:nonFraction contextRef="c101" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" scale="6" unitRef="shares" id="ixv-11341">12</ix:nonFraction> million shares to <ix:nonFraction contextRef="c102" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" scale="6" unitRef="shares" id="ixv-11342">32</ix:nonFraction> million shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="txmd_ScheduleOfWarrantRollForwardTableTextBlock-c0_cont_1" escape="true" name="txmd:ScheduleOfWarrantRollForwardTableTextBlock" id="ixv-11343">As of December 31, 2023, the following table summarizes the status
of our outstanding and exercisable warrants and related transactions since December 31, 2021 (in thousands, except weighted average exercise
price and weighted average remaining contractual life data):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="txmd_ScheduleOfWarrantRollForwardTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">Warrants outstanding and exercisable</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in&#160;Years)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance, December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrants" scale="3" unitRef="shares" id="ixv-11344">103</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c106" decimals="2" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-11345">76.19</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c107" format="ixt-sec:duryear" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife" id="ixv-11346">8.3</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c107" decimals="-3" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted" scale="3" unitRef="shares" id="ixv-11347">436</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c107" decimals="2" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted" scale="0" unitRef="usdPershares" id="ixv-11348">0.14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c107" decimals="-3" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired" scale="3" sign="-" unitRef="shares" id="ixv-11349">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c107" decimals="1" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired" scale="0" unitRef="usdPershares" id="ixv-11350">341.5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrants" scale="3" unitRef="shares" id="ixv-11351">536</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="2" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-11352">13.10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue" scale="3" unitRef="usd" id="ixv-11353">2,427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c107" format="ixt-sec:duryear" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife" id="ixv-11354">9.3</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised" scale="3" sign="-" unitRef="shares" id="ixv-11355">435</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c109" decimals="2" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised" scale="0" unitRef="usdPershares" id="ixv-11356">0.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised" scale="3" sign="-" unitRef="usd" id="ixv-11357">2,270</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired" scale="3" sign="-" unitRef="shares" id="ixv-11358">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c109" decimals="2" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired" scale="0" unitRef="usdPershares" id="ixv-11359">0.89</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance, December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrants" scale="3" unitRef="shares" id="ixv-11360">99</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-11361">66.61</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue" scale="3" unitRef="usd" id="ixv-11362">1,793</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonNumeric contextRef="c109" format="ixt-sec:duryear" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife" id="ixv-11363">6.5</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We used the Black Scholes option pricing model to estimate the fair
value of the warrants issued. The weighted average fair value of the warrants issued in 2022 was $<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-11364">0.13</ix:nonFraction> per warrant and the assumptions
used to determine such fair value were as follows: expected term of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-11365">10</ix:nonNumeric> years, volatility of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-11366">69.4</ix:nonFraction>%, dividend yields of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-11367">0</ix:nonFraction>% and risk-free
interest rates of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-11368">2.9</ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Share-based compensation payment plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, <ix:nonFraction contextRef="c103" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="3" unitRef="shares" id="ixv-11369">126,573</ix:nonFraction> shares of common stock were subject
to outstanding awards under our share-based payment award plans and inducement grants (calculated using the base number of PSUs that may
vest). As of December 31, 2023, <ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" unitRef="shares" id="ixv-11370">394,669</ix:nonFraction> shares of common stock were available for future grants of share-based payment awards under the
TherapeuticsMD, Inc. 2019 Stock Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-11371">The following table summarizes the status of our outstanding and exercisable
options and related transactions (each adjusted to account for the Reverse Stock Split) since December 31, 2022 (in thousands, except
weighed average exercise price and weighted average remaining contractual life data):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">Outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">Exercisable</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Options<br/> Awards</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise<br/> Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life<br/> (in&#160;Years)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Options<br/> Awards</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life (in&#160;Years)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-indent: -9pt; padding-left: 9pt">As of January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" unitRef="shares" id="ixv-11372">353</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-11373">225.98</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c111" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-11374">3.8</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" unitRef="shares" id="ixv-11375">336</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-11376">230.93</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c111" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-11377">3.6</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Cancelled/Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" unitRef="shares" id="ixv-11378">4</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-11379">94.99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" unitRef="shares" id="ixv-11380">177</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-11381">226.56</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">As of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" unitRef="shares" id="ixv-11382">172</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-11383">228.28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="txmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" id="ixv-11384">3.6</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" unitRef="shares" id="ixv-11385">170</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-11386">229.43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-11387">3.6</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Cancelled/Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" unitRef="shares" id="ixv-11388">100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-11389">206.15</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">As of December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" unitRef="shares" id="ixv-11390">72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-11391">258.55</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="txmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" id="ixv-11392">3.0</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" unitRef="shares" id="ixv-11393">73</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-11394">258.46</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-11395">3.0</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:nonNumeric><div>



</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 74 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="ixv-11396">The following table summarizes the status of our RSUs and related transactions
(each adjusted to account for the Reverse Stock Split) (in thousands, except weighed average grant date fair value):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:continuation continuedAt="_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock-c0_cont_2" id="_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">RSUs awards outstanding</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
 Average<br/>
 Grant Date<br/>
 Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/>
 Intrinsic<br/>
 Value</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance, January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c112" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-11397">272</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11398">58.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" unitRef="usdPershares" id="ixv-11399">4,890.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c113" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-11400">170</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c113" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11401">16.05</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c113" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-11402">327</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c113" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11403">48.20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cancelled/Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c113" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-11404">58</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11405">37</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c114" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-11406">57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11407">14.57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" unitRef="usdPershares" id="ixv-11408">318.63</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-11409">163</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11410">4.82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c115" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-11411">180</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11412">6.83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cancelled/Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance, as of December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c116" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-11413">40</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c116" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11414">9.67</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c116" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" unitRef="usdPershares" id="ixv-11415">89.6</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:continuation continuedAt="_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock-c0_cont_3" id="_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock-c0_cont_2">The following table summarizes the status of our PSUs and related transactions
for each for the following years (each adjusted to account for the Reverse Stock Split) (in thousands, except weighed average grant date
fair value):</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">PSUs</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Grant Date<br/> Fair Value</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2021</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c117" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-11417">164</ix:nonFraction></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11418">51.50</ix:nonFraction></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" unitRef="usdPershares" id="ixv-11419">2,953</ix:nonFraction></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c105" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-11420">63</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c105" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11421">34.50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vested and settled</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c105" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-11422">133</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c105" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11423">47.12</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c105" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" scale="0" sign="-" unitRef="usdPershares" id="ixv-11424">2,382.98</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Cancelled/Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c105" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-11425">75</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c105" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11426">44.85</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Unvested, as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c118" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-11427">19</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11428">52.15</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" unitRef="usdPershares" id="ixv-11429">107.55</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">&#8212;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Vested</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c119" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-11430">5</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11431">56.05</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" scale="0" sign="-" unitRef="usdPershares" id="ixv-11432">10.72</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Cancelled/Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Unvested, as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c120" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-11433">14</ix:nonFraction></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-11434">50.87</ix:nonFraction></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" unitRef="usdPershares" id="ixv-11435">33</ix:nonFraction></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Share-based payment compensation cost</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Share-based payment compensation expense for PSUs is based on <ix:nonFraction contextRef="c105" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" unitRef="pure" id="ixv-11436">100</ix:nonFraction>%
vesting which was a part of the termination benefits for all employees who were terminated in 2022. We recorded share-based payment award
compensation costs related to previously issued options, RSU and PSUs, as well as shares of common stock issued under our employee stock
purchase plan (&#8220;ESPP&#8221;) totaling $<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-11437">1.3</ix:nonFraction> million for 2023 and $<ix:nonFraction contextRef="c7" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-11438">11.6</ix:nonFraction> million for 2022.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2023, we had $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" unitRef="usd" id="ixv-11439">0.3</ix:nonFraction> million of unrecognized share-based
payment award compensation cost related to unvested options, RSUs and PSUs as well as shares issuable under our ESPP, which may be adjusted
for future changes in forfeitures and is included as additional paid-in capital in the accompanying consolidated balance sheets. No tax
benefit was realized due to a continued pattern of net losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The unrecognized compensation cost as of December 31, 2023 of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-11440">0.3</ix:nonFraction>
million is expected to be recognized as share-based payment award compensation over a weighted average period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-11441">0.8</ix:nonNumeric> years.</p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 75 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="ixv-10235"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>10. Revenue </b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the Mayne License Agreement, the Company granted Mayne
Pharma, on the Closing Date, (i) an exclusive, sublicensable, perpetual, irrevocable license to research, develop, register, manufacture,
have manufactured, market, sell, use, and commercialize the Licensed Products in the United States and its possessions and territories
and (ii) an exclusive, sublicensable, perpetual, irrevocable license to manufacture, have manufactured, import and have imported the Licensed
Products outside the United States for commercialization in the United States and its possessions and territories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the Mayne License Agreement, Mayne Pharma will make one-time,
milestone payments to the Company of each of (i) $<ix:nonFraction contextRef="c25" decimals="-5" format="ixt:num-dot-decimal" name="txmd:OneTimeMilestonePayments" scale="6" unitRef="usd" id="ixv-11442">5.0</ix:nonFraction> million if aggregate net sales of all Products in the United States during a calendar
year reach $<ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" scale="6" unitRef="usd" id="ixv-11443">100.0</ix:nonFraction> million, (ii) $<ix:nonFraction contextRef="c26" decimals="-5" format="ixt:num-dot-decimal" name="txmd:OneTimeMilestonePayments" scale="6" unitRef="usd" id="ixv-11444">10.0</ix:nonFraction> million if aggregate net sales of all Products in the United States during a calendar year reach
$<ix:nonFraction contextRef="c26" decimals="INF" format="ixt:num-dot-decimal" name="txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" scale="6" unitRef="usd" id="ixv-11445">200.0</ix:nonFraction> million and (iii) $<ix:nonFraction contextRef="c27" decimals="-5" format="ixt:num-dot-decimal" name="txmd:OneTimeMilestonePayments" scale="6" unitRef="usd" id="ixv-11446">15.0</ix:nonFraction> million if aggregate net sales of all Products in the United States during a calendar year reach $<ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" scale="6" unitRef="usd" id="ixv-11447">300.0</ix:nonFraction>
million. Further, Mayne Pharma will pay to the Company royalties on net sales of all Products in the United States at a royalty rate of
<ix:nonFraction contextRef="c28" decimals="3" format="ixt:num-dot-decimal" name="txmd:RoyaltyRateAsPercentageOnNetSales" scale="-2" unitRef="pure" id="ixv-11448">8.0</ix:nonFraction>% on the first $<ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate" scale="6" unitRef="usd" id="ixv-11449">80</ix:nonFraction> million in annual net sales and <ix:nonFraction contextRef="c29" decimals="3" format="ixt:num-dot-decimal" name="txmd:RoyaltyRateAsPercentageOnNetSales" scale="-2" unitRef="pure" id="ixv-11450">7.5</ix:nonFraction>% on annual net sales above $<ix:nonFraction contextRef="c29" decimals="INF" format="ixt:num-dot-decimal" name="txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate" scale="6" unitRef="usd" id="ixv-11451">80.0</ix:nonFraction> million, subject to certain adjustments, for
a period of <ix:nonNumeric contextRef="c30" format="ixt-sec:duryear" name="txmd:TermOfRoyaltyPayments" id="ixv-11452">20</ix:nonNumeric> years following the Closing Date. The royalty rate will decrease to <ix:nonFraction contextRef="c30" decimals="3" format="ixt:num-dot-decimal" name="txmd:DecreaseInRoyaltyRateOnProductByProductBasis" scale="-2" unitRef="pure" id="ixv-11453">2.0</ix:nonFraction>% on a Product-by-Product basis upon the earlier
to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version of a Product launching in
the United States. Mayne Pharma will pay to the Company minimum annual royalties of $<ix:nonFraction contextRef="c30" decimals="-5" format="ixt:num-dot-decimal" name="txmd:MinimumAnnualRoyaltyPayment" scale="6" unitRef="usd" id="ixv-11454">3.0</ix:nonFraction> million per year for <ix:nonNumeric contextRef="c30" format="ixt-sec:duryear" name="txmd:PeriodOfMinimumAnnualRoyaltyPayment" id="ixv-11455">12</ix:nonNumeric> years, adjusted for inflation
at an annual rate of <ix:nonFraction contextRef="c30" decimals="2" format="ixt:num-dot-decimal" name="txmd:InflationRateAdjustedForMinimalAnnualRoyaltyPayment" scale="-2" unitRef="pure" id="ixv-11456">3</ix:nonFraction>%, subject to certain further adjustments, including as described below. Upon the expiry of the <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="txmd:TermOfRoyaltyPayments" id="ixv-11457">20</ix:nonNumeric>-year royalty
term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully paid-up and royalty free license for
the Licensed Products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2023, we recorded BIJUVA license sales of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" unitRef="usd" id="ixv-11458">0.3</ix:nonFraction> million made through
the Theramex License Agreement and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="txmd:LicenseRevenue" scale="6" unitRef="usd" id="ixv-11459">1.0</ix:nonFraction> million pertaining to our licensed products with Mayne Pharma, which was recorded as license revenue.
Additionally, we recognized $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" unitRef="usd" id="ixv-11460">0.5</ix:nonFraction> million in other income pertaining to royalty sales of ANNOVERA.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-10247"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>11. Income
taxes</b></span> </p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="ixv-11461">Our income (loss) from continuing operations before income taxes is
as follows (in thousands):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:continuation id="_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Year Ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">United States</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-11462">7,742</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-11463">1,074</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">For the year ended December 31, 2023, there was no provision for income
taxes in discontinued operations, current or deferred. For the year ended, December 31, 2023, we recorded a benefit of <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-11464">0.5</ix:nonFraction>% in continuing
operations. For the year ended December 31, 2022, there was <ix:nonFraction contextRef="c121" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-11465">0</ix:nonFraction>% and <ix:nonFraction contextRef="c122" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-11466">0.5</ix:nonFraction>% provision for income taxes in continuing and discontinued operations,
respectively, current or deferred.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, we had federal net operating loss (&#8220;NOL&#8221;)
carryforwards of $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd" id="ixv-11467">577.0</ix:nonFraction> million, which is available to offset future taxable income. Approximately $<ix:nonFraction contextRef="c123" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd" id="ixv-11468">19.2</ix:nonFraction> million of the federal NOLs can
be carried forward for <ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="txmd:NetOperatingLossCarryforwardsTerm" id="ixv-11469">20</ix:nonNumeric> years and will begin to expire in 2035. The remaining $<ix:nonFraction contextRef="c124" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd" id="ixv-11470">557.8</ix:nonFraction> million can be carried forward indefinitely. In
the event of future income, the NOL deduction arising from NOLs generated in taxable years beginning in 2021 will be limited to <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="txmd:PercentageOfFutureTaxableIncome" scale="-2" unitRef="pure" id="ixv-11471">80</ix:nonFraction>% of
the excess taxable income. The Company experienced an ownership change pursuant to IRC Sec. 382. As a result, our NOLs carryforward as
of December 31, 2023 will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-11472">A reconciliation between taxes computed at the federal statutory rate
and the consolidated effective tax rate is as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal statutory tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-11473">1,626</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-11474">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-11475">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State tax rate, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure" id="ixv-11476">0.0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure" id="ixv-11477">3.9</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustment in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" sign="-" unitRef="usd" id="ixv-11478">22,173</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-11479">286.4</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure" id="ixv-11480">3,228.6</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Excess stock benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" unitRef="usd" id="ixv-11481">2,460</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" sign="-" unitRef="pure" id="ixv-11482">31.8</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" unitRef="pure" id="ixv-11483">835.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense accretion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="txmd:EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars" scale="3" unitRef="usd" id="ixv-11484">35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="txmd:EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars" scale="-2" sign="-" unitRef="pure" id="ixv-11485">0.5</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="txmd:EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars" scale="-2" unitRef="pure" id="ixv-11486">0.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Permanent and other differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" unitRef="usd" id="ixv-11487">21,261</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" sign="-" unitRef="pure" id="ixv-11488">274.6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" unitRef="pure" id="ixv-11489">2,368.5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">(Benefit) provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd" id="ixv-11490">43</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="txmd:EffectiveIncomeTaxRateDiscontinuedOperations" scale="-2" unitRef="pure" id="ixv-11491">0.5</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="txmd:EffectiveIncomeTaxRateDiscontinuedOperations" scale="-2" unitRef="pure" id="ixv-11492">0.0</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:nonNumeric><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not expect to pay any significant federal or state income taxes
as a result of (i) the losses recorded during 2023, (ii) net operating losses carry forwards from prior years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: left; margin: 0; font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-11493">Deferred income taxes result from temporary differences between the amount
of assets and liabilities recognized for financial reporting and tax purposes. The components of the net deferred tax assets as of December
31, 2023 and 2022 are as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0">&#160;</p>

<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred income tax assets (liabilities):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-11494">158,040</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-11495">176,631</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payment compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd" id="ixv-11496">3,339</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd" id="ixv-11497">8,590</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense limitation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="3" unitRef="usd" id="ixv-11498">19,547</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="3" unitRef="usd" id="ixv-11499">19,707</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gain on sale of ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DeferredTaxAssetGainOnSaleOfIntellectualProperty" scale="3" sign="-" unitRef="usd" id="ixv-11500">3,401</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DeferredTaxAssetGainOnSaleOfIntellectualProperty" scale="3" sign="-" unitRef="usd" id="ixv-11501">3,624</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrual for sales returns and coupons</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="3" unitRef="usd" id="ixv-11502">288</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">R&amp;D credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-11503">186</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-11504">186</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" unitRef="usd" id="ixv-11505">256</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" sign="-" unitRef="usd" id="ixv-11506">1,062</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred income tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DeferredTaxAssetsLiabilitiesGross" scale="3" unitRef="usd" id="ixv-11507">178,255</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DeferredTaxAssetsLiabilitiesGross" scale="3" sign="-" unitRef="usd" id="ixv-11508">200,428</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DeferredTaxAssetsLiabilitiesNetOfValuationAllowance" scale="3" sign="-" unitRef="usd" id="ixv-11509">178,255</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="txmd:DeferredTaxAssetsLiabilitiesNetOfValuationAllowance" scale="3" unitRef="usd" id="ixv-11510">200,428</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Deferred income tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that it is more likely than not that we will not generate
sufficient future taxable income to realize tax benefits related to our deferred tax assets and as such, a valuation allowance has been
established against all the deferred tax assets as of both December 31, 2023 and 2022.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since our first year of operations in 2011, we generated net operating
losses, and our U.S. federal and state tax returns remain open to examination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023 and 2022, we had <span style="-sec-ix-hidden: hidden-fact-99"><span style="-sec-ix-hidden: hidden-fact-100">no</span></span> tax positions relating
to open tax returns that were considered to be uncertain, and we had no unrecognized tax benefits.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-10557"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. Income (loss) per common share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-11511">The following table sets forth the computation of basic and diluted
income (loss) per common share (each adjusted to account for the Reverse Stock Split) for the periods presented (in thousands, except
per share amounts):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Years Ending December 31,</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Net income (loss) from continuing operations</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" sign="-" unitRef="usd" id="ixv-11512">7,699</ix:nonFraction></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="3" unitRef="usd" id="ixv-11513">1,074</ix:nonFraction></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net income (loss) from discontinued operations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-11514">2,579</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" unitRef="usd" id="ixv-11515">110,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net income (loss)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-11516">10,278</ix:nonFraction></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-11517">111,997</ix:nonFraction></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Weighted average common shares for basic income (loss) per common share</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" unitRef="shares" id="ixv-11518">10,441</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" unitRef="shares" id="ixv-11519">9,028</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Effect of dilutive securities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" unitRef="shares" id="ixv-11520">338</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Weighted average common shares for diluted income (loss) per common share</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" unitRef="shares" id="ixv-11521">10,441</ix:nonFraction></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" unitRef="shares" id="ixv-11522">9,366</ix:nonFraction></td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss) per common share, continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Basic</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-11523">0.74</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" unitRef="usdPershares" id="ixv-11524">0.12</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-11525">0.74</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" unitRef="usdPershares" id="ixv-11526">0.11</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss) per common share, discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Basic</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-11527">0.25</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" unitRef="usdPershares" id="ixv-11528">12.29</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" sign="-" unitRef="usdPershares" id="ixv-11529">0.25</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" unitRef="usdPershares" id="ixv-11530">11.84</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since we reported a net loss from continuing operations for 2023, our potentially
dilutive securities are deemed to be anti-dilutive, accordingly, there was no effect of dilutive securities. Therefore, our basic and
diluted loss per common share and our basic and diluted weighted average common shares are the same for 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 77 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_EarningsPerShareTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-11531">The following table sets forth the outstanding securities as of the
periods presented which were not included in the calculation of diluted earnings per common share during 2023 and 2022 (in thousands):</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-11532">72</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c128" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-11533">172</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-11534">40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>PSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-11535">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-11536">99</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c132" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-11537">101</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-11538">225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-11539">273</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-10818"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>13. Related parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 23, 2022, we appointed Mr. Justin Roberts as a director to
fill a newly created vacancy on our Board of Directors. Mr. Roberts was elected to serve as a director at our combined 2022 and 2023 Annual
Meeting held on June 26, 2023. Mr. Roberts will serve until our next Annual Meeting of Stockholders or until his successor is duly elected
or appointed or his earlier death or resignation. As a director of our Company, Mr. Roberts is entitled to receive compensation in the
same manner as our other non-employee directors, described in the section entitled &#8220;Director Compensation&#8221; in our Amendment
No. 1 to Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on May 1, 2023, but
he has elected not to receive any compensation for his service as a non-employee director at this time. Mr. Roberts currently serves as
a Partner of Rubric. On July 29, 2022, September 30, 2022, October 28, 2022, and May 1, 2023, we entered into subscription agreements
with Rubric. On December 30, 2022, in accordance with the terms of the Certificate of Designation, we redeemed all <ix:nonFraction contextRef="c133" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" scale="3" unitRef="shares" id="ixv-11540">29,000</ix:nonFraction> outstanding
shares of Series A Preferred Stock previously issued to affiliates of Rubric at a purchase price of $<ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-11541">1,333</ix:nonFraction> per share. also paid certain
affiliates of Rubric approximately $<ix:nonFraction contextRef="c133" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" scale="6" unitRef="usd" id="ixv-11542">3.0</ix:nonFraction> million as a make-whole payment pursuant to the subscription agreements previously entered into
between us and Rubric. On June 29, 2023, we issued and sold <ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" unitRef="shares" id="ixv-11543">312,525</ix:nonFraction> shares of Common Stock to Rubric at a price per share equal to $<ix:nonFraction contextRef="c135" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-11544">3.6797</ix:nonFraction>
pursuant to the Subscription Agreement and received gross proceeds of $<ix:nonFraction contextRef="c136" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="6" unitRef="usd" id="ixv-11545">1.15</ix:nonFraction> million, before expenses. On November 15, 2023 Rubric drew
down an additional <ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="3" unitRef="shares" id="ixv-11546">877,192</ix:nonFraction> shares of Common Stock at a price per share equal to $<ix:nonFraction contextRef="c137" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-11547">2.2761</ix:nonFraction>. We received gross proceeds of $<ix:nonFraction contextRef="c138" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="6" unitRef="usd" id="ixv-11548">2.0</ix:nonFraction> million from
the drawdown, before expenses.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="ixv-10827"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>14. Business concentrations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">TherapeuticsMD was previously a women&#8217;s healthcare company with a
mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause.
In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed
to pharmaceutical organizations that possess commercial capabilities in the relevant territories. As part of the transformation that included
the Mayne License Agreement, historical results of commercial operations for all periods prior to the Closing Date have been reflected
as discontinued operations in our consolidated financial statements. Assets and liabilities associated with the commercial business are
classified as assets and liabilities of discontinued operations in our consolidated balance sheets. Additional disclosures regarding discontinued
operations are provided in Note 2.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For the year ended December 31, 2023, <ix:nonFraction contextRef="c139" decimals="INF" format="ixt:num-dot-decimal" name="txmd:CustomerLicenseRevenuePercentage" scale="-2" unitRef="pure" id="ixv-11549">100</ix:nonFraction>% of license revenue related to
Mayne Pharma and Theramex.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, we had a royalty receivable of $<ix:nonFraction contextRef="c140" decimals="-5" format="ixt:num-dot-decimal" name="txmd:RoyaltyReceivableShortTermPortion" scale="6" unitRef="usd" id="ixv-11550">3.1</ix:nonFraction> million
relating to the short-term portion of receivable from Mayne Pharma and Theramex and $<ix:nonFraction contextRef="c140" decimals="-5" format="ixt:num-dot-decimal" name="txmd:RoyaltyReceivableLongTermPortion" scale="6" unitRef="usd" id="ixv-11551">18.5</ix:nonFraction> million relating to the long-term portion of
royalty receivable which includes royalties recognized from the minimum annual royalty that Mayne Pharma is obligated to pay to us under
the Mayne License Agreement.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-10841"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>15. Subsequent Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective March 22, 2024, Tommy G. Thompson resigned as the Company&#8217;s
Executive Chairman of the Board and was reappointed as the Company&#8217;s Chairman of the Board.</p></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 78; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="us-gaap:RestrictedCashCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-1" name="txmd:RoyaltyReceivableCurrentPortion" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-2" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-5" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-6" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-7" name="us-gaap:RestructuringCharges" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-8" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" decimals="2" id="hidden-fact-9" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" unitRef="usdPershares">0.12</ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-10" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-11" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-12" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-13" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-14" name="txmd:AdjustmentsToAdditionalPaidInCapitalLenderWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-15" name="txmd:AdjustmentsToAdditionalPaidInCapitalLenderWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-16" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-17" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-18" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-19" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-23" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-24" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-25" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-26" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c14" id="hidden-fact-27" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-28" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-29" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-30" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-32" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-33" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-34" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-35" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-36" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-37" name="txmd:MakeWholePaymentAccretion" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-38" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-39" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-40" name="txmd:ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-41" name="us-gaap:RepaymentsOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-42" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-43" name="us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-44" name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-45" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-46" name="us-gaap:PaymentsOfFinancingCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-47" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-48" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-49" name="txmd:WarrantsIssuedInRelationToDebtFinancingAgreement" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-50" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-51" name="txmd:DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-52" name="txmd:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-53" name="txmd:DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-54" name="txmd:DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-55" name="txmd:DisposalGroupIncludingDiscontinuedOperationGainOnSale" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-56" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-57" name="txmd:DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-58" name="txmd:DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c69" id="hidden-fact-59" name="us-gaap:GainLossOnDispositionOfAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c69" id="hidden-fact-60" name="txmd:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-61" name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-62" name="txmd:DisposalGroupIncludingDiscontinuedOperationRentReceivable" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-63" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-64" name="txmd:DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-65" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c82" id="hidden-fact-66" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c83" id="hidden-fact-67" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c86" id="hidden-fact-68" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c87" id="hidden-fact-69" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-70" name="txmd:AccruedContractTerminationCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-71" name="txmd:AccruedResearchAndDevelopmentExpenses" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-72" name="txmd:AccruedPrepaidRoyalty" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-73" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-74" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c3" id="hidden-fact-75" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">http://fasb.org/us-gaap/2023#Liabilities</ix:nonNumeric>
<ix:nonNumeric contextRef="c4" id="hidden-fact-76" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">http://fasb.org/us-gaap/2023#Liabilities</ix:nonNumeric>
<ix:nonFraction contextRef="c106" id="hidden-fact-77" name="txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-79" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-81" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-83" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c115" id="hidden-fact-84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c115" id="hidden-fact-85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c115" id="hidden-fact-86" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c115" id="hidden-fact-87" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c115" id="hidden-fact-88" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c119" id="hidden-fact-89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c119" id="hidden-fact-90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c119" id="hidden-fact-91" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c119" id="hidden-fact-92" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c119" id="hidden-fact-93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c119" id="hidden-fact-94" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-95" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-96" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-97" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-98" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-99" name="us-gaap:UnrecognizedTaxBenefits" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-100" name="us-gaap:UnrecognizedTaxBenefits" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-101" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c130" id="hidden-fact-102" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c105" id="hidden-fact-103" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-11658">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-11659">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-11660">0000025743</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="txmd-20231231.xsd" xlink:type="simple"/></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:MilestonePaymentsOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:MilestonePaymentsTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:MilestonePaymentsThreeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:RoyaltyRateOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:RoyaltyRateTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-01</xbrli:startDate>
    <xbrli:endDate>2023-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">txmd:VitaCareDivestitureMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-14</xbrli:startDate>
    <xbrli:endDate>2022-04-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">txmd:VitaCareDivestitureMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:StockPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">txmd:VitaCareDivestitureMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-14</xbrli:startDate>
    <xbrli:endDate>2022-04-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-09</xbrli:startDate>
    <xbrli:endDate>2023-06-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-15</xbrli:startDate>
    <xbrli:endDate>2023-11-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">txmd:AnnoverasMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">txmd:AnnoverasMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:RoyaltyRateOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:RoyaltyRateTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:MilestonePaymentsOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2034-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvasMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:TheramexLicenseAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-06</xbrli:startDate>
    <xbrli:endDate>2022-05-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">txmd:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">txmd:CurrentLiabilitiesForDiscontinuedOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">txmd:ExecutiveTerminationBenefitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">txmd:ConsultingAndLegalExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbcL4qf5LvDZDepCbNlW2HHdtTp8h/JBPAKml91Z9+QS2gjfdoyURiOQgrxFESWde/Q+Ash/YJdGlbG5QR3nEMXflGmqnNLFtFl1nIAPLFlMWnSI/b92PyAqBFuykXvgMcnlPm3rTC5y1gsY+iS9+gbk0SFpyt2CDowYCrPhIqMSfw/7Rr70FR899kUalV/joGETyJd8o2qqQ==] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">txmd:OtherContractTerminationCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">txmd:EmployeeTerminationBenefitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">txmd:AnnoverasMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">txmd:AnnoverasMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugPatentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugPatentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:IntangibleAssetsSubjectToAmortizationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:IntangibleAssetsSubjectToAmortizationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MaynePharmaAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MaynePharmaAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MaynePharmaAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MaynePharmaAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:PopulationCouncilLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-01-01</xbrli:startDate>
    <xbrli:endDate>2018-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">txmd:AnnoverasMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:PopulationCouncilLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="txmd:LegalProceedingAxis">txmd:ParagraphFourCertificationNoticeLetterMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-26</xbrli:startDate>
    <xbrli:endDate>2023-01-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-26</xbrli:startDate>
    <xbrli:endDate>2023-01-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriod20YearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriodIndefiniteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:SubscriptionAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-30</xbrli:startDate>
    <xbrli:endDate>2022-12-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:SubscriptionAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-28</xbrli:startDate>
    <xbrli:endDate>2023-06-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-15</xbrli:startDate>
    <xbrli:endDate>2023-11-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:TheramexMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:MaynePharmaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="sqm">
  <xbrli:measure>utr:sqm</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>ea020146501ex21-1_therapeu.htm
<DESCRIPTION>SUBSIDIARIES OF THE COMPANY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><U>Subsidiaries of
the Company</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: top; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>State or Jurisdiction of Incorporation or Organization</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">VitaMedMD, LLC</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">BocagreenMD, Inc.</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Nevada</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ea020146501ex23-1_therapeu.htm
<DESCRIPTION>CONSENT OF BERKOWITZ POLLACK BRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSENT OF INDEPENDENT ACCOUNTANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We consent to the incorporation by reference in
the Registration Statements on Forms S-8 (File No. 333-191730, File No. 333-232268, File No. 333-242363, File No. 333-256879, File No.
333-259221 and File No. 333-260295) of TherapeuticsMD, Inc. of our report dated March 29, 2024 on the consolidated statements of financial
position of TherapeuticsMD, Inc. and Subsidiaries as of December 31, 2023, and the related consolidated statements of operations, changes
in stockholders&rsquo; equity and cash flows for the year ended December 31, 2023, included herein on the annual report of TherapeuticsMD,
Inc. on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Berkowitz Pollack Brant, Advisors + CPAs</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">West Palm Beach, FL</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 29, 2024</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>ea020146501ex23-2_therapeu.htm
<DESCRIPTION>CONSENT OF GRANT THORNTON LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 23.2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We have issued our report dated April 7, 2023,
with respect to the consolidated financial statements included in the Annual Report of TherapeuticsMD, Inc. on Form 10-K for the year
ended December 31, 2023. We consent to the incorporation by reference of said report in the Registration Statements of TherapeuticsMD,
Inc. on  Form S-8 (File No. 333-191730, File No. 333-232268, File No. 333-242363, File No. 333-256879, File No. 333-259221 and File No. 333-260295).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/S/ GRANT THORNTON LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Miami, Florida</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 29, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ea020146501ex31-1_therapeu.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Marlan D. Walker, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">(1)</TD><TD>I have reviewed this Annual Report on Form 10-K of TherapeuticsMD, Inc. (the &ldquo;10-K Report&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">(2)</TD><TD>Based on my knowledge, this 10-K Report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">(3)</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">(4)</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this 10-K Report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(c)</TD><TD>evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this 10-K Report based on such evaluation;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(d)</TD><TD>disclosed in this 10-K Report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">(5)</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; width: 60%; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Date: March 29, 2024</FONT></TD>
    <TD STYLE="padding: 0pt; width: 40%; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; border-bottom: Black 1.5pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">/s/ Marlan D. Walker</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Marlan D. Walker</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 338pt">&nbsp;</P>






</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ea020146501ex31-2_therapeu.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>CERTIFICATION OF PRINCIPAL
FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Joseph Ziegler, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.4in">(1)</TD>
    <TD>I have reviewed this Annual Report on Form 10-K of TherapeuticsMD, Inc. (the &ldquo;10-K Report&rdquo;);</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.4in">(2)</TD>
    <TD>Based on my knowledge, this 10-K Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.4in">(3)</TD>
    <TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.4in">(4)</TD>
    <TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.4in">&nbsp;</TD>
    <TD STYLE="width: 0.4in">(a)</TD>
    <TD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this 10-K Report is being prepared;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.4in">&nbsp;</TD>
    <TD STYLE="width: 0.4in">(b)</TD>
    <TD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.4in">&nbsp;</TD>
    <TD STYLE="width: 0.4in">(c)</TD>
    <TD>evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this 10-K Report based on such evaluation; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.4in">&nbsp;</TD>
    <TD STYLE="width: 0.4in">(d)</TD>
    <TD>disclosed in this 10-K Report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.4in">(5)</TD>
    <TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.4in">&nbsp;</TD>
    <TD STYLE="width: 0.4in">(a)</TD>
    <TD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.4in">&nbsp;</TD>
    <TD STYLE="width: 0.4in">(b)</TD>
    <TD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Date: March 29, 2024</FONT></TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Joseph Ziegler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Joseph Ziegler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Principal Financial and<BR>
 Accounting Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ea020146501ex32-1_therapeu.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Annual Report on Form 10-K of TherapeuticsMD,
Inc. (the &ldquo;Company&rdquo;) for the year ended December 31, 2023 (the &ldquo;10-K Report&rdquo;), as filed with the Securities and
Exchange Commission on the date hereof, I, Marlan D. Walker, Chief Executive Officer of the Company, certify, to my best knowledge and
belief, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(1)</TD><TD STYLE="text-align: left">The 10-K Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C.78m(a)
or 78o(d)); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(2)</TD><TD STYLE="text-align: left">The information contained in the 10-K Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0pt; width: 60%; padding-bottom: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-size: 10pt">March 29, 2024</FONT></TD>
    <TD STYLE="padding-top: 0pt; width: 40%; padding-bottom: 0pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0pt; padding-bottom: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-size: 10pt">/s/ Marlan D. Walker</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; padding-top: 0pt; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Marlan D. Walker</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0pt; padding-bottom: 0pt; padding-left: 0pt; text-indent: 0pt">Chief <FONT STYLE="font-size: 10pt">
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0">A signed original of this certification has been provided to
the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ea020146501ex32-2_therapeu.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>SECTION 1350 CERTIFICATION
OF PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Annual Report on Form 10-K of TherapeuticsMD,
Inc. (the &ldquo;Company&rdquo;) for the year ended December 31, 2023 (the &ldquo;10-K Report&rdquo;), as filed with the Securities and
Exchange Commission on the date hereof, I, Joseph Ziegler, Principal Financial Officer of the Company, certify, to my best knowledge and
belief, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.4in">&nbsp;</TD>
    <TD STYLE="width: 0.4in">(1)</TD>
    <TD STYLE="text-align: left">The 10-K Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.4in">&nbsp;</TD>
    <TD STYLE="width: 0.4in">(2)</TD>
    <TD STYLE="text-align: left">The information contained in the 10-K Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">March 29, 2024</FONT></TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Joseph Ziegler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Joseph Ziegler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Principal Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0">A signed original of this certification has been provided to
the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>ea020146501ex97-1_therapeu.htm
<DESCRIPTION>THERAPEUTICSMD, INC. POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 97.1</B></P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman, Times, Serif"><B>THERAPEUTICSMD, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Introduction</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors (the &ldquo;<U>Board</U>&rdquo;) of TherapeuticsMD,
Inc. (the &ldquo;<U>Company</U>&rdquo;) has adopted this Policy on Recoupment of Incentive Compensation (this &ldquo;<U>Policy</U>&rdquo;),
which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by the Company.
This Policy shall be interpreted to comply with the requirements of U.S. Securities and Exchange Commission (&ldquo;<U>SEC</U>&rdquo;)
rules and Nasdaq Stock Market (&ldquo;<U>Nasdaq</U>&rdquo;) listing standards implementing Section 954 of the Dodd-Frank Wall Street Reform
and Consumer Protection Act of 2010 (the &ldquo;<U>Dodd-Frank Act</U>&rdquo;) and, to the extent this Policy is in any manner deemed inconsistent
with such rules, this Policy shall be treated as retroactively amended to be compliant with such rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Administration</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Policy shall be administered by the Compensation Committee (the
&ldquo;<U>Compensation Committee</U>&rdquo;) of the Board. Any determinations made by the Compensation Committee shall be final and binding
on all affected individuals. The Compensation Committee is authorized to interpret and construe this Policy and to make all determinations
necessary, appropriate or advisable for the administration of this Policy, in all cases consistent with the Dodd-Frank Act. The Board
or Compensation Committee may amend this Policy from time to time in its discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Covered Executives</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Policy applies to any current or former &ldquo;executive officer,&rdquo;
within the meaning of Rule 10D-1 under the Securities Exchange Act of 1934, as amended, of the Company or a subsidiary of the Company
(each such individual, an &ldquo;<U>Executive</U>&rdquo;). This Policy shall be binding and enforceable against all Executives and their
beneficiaries, executors, administrators, and other legal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Recoupment Upon Financial Restatement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the Company is required to prepare an accounting restatement due
to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required
accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial
statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the
current period (a &ldquo;<U>Financial Restatement</U>&rdquo;), the Compensation Committee shall cause the Company to recoup from each
Executive, as promptly as reasonably possible, any erroneously awarded Incentive-Based Compensation, as defined below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>No-Fault Recovery</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recoupment under this Policy shall be required regardless of whether
the Executive or any other person was at fault or responsible for accounting errors that contributed to the need for the Financial Restatement
or engaged in any misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Compensation Subject to Recovery; Enforcement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Policy applies to all compensation granted, earned or vested based
wholly or in part upon the attainment of any financial reporting measure determined and presented in accordance with the accounting principles
used in preparing the Company&rsquo;s financial statements, and any measure that is derived wholly or in part from such measures, whether
or not presented within the Company&rsquo;s financial statements or included in a filing with the SEC, including stock price and total
shareholder return (&ldquo;<U>TSR</U>&rdquo;), including but not limited to performance-based cash, stock, options or other equity-based
awards paid or granted to the Executive (&ldquo;<U>Incentive-Based Compensation</U>&rdquo;). Compensation that is granted, vests or is
earned based solely upon the occurrence of non-financial events, such as base salary, restricted stock or options with time-based vesting,
or a bonus awarded solely at the discretion of the Board or Compensation Committee and not based on the attainment of any financial measure,
is not subject to this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event of a Financial Restatement, the amount to be recovered
will be the excess of (i) the Incentive-Based Compensation received by the Executive during the Recovery Period (as defined below) based
on the erroneous data and calculated without regard to any taxes paid or withheld, over (ii) the Incentive-Based Compensation that would
have been received by the Executive had it been calculated based on the restated financial information, as determined by the Compensation
Committee. For purposes of this Policy, &ldquo;<U>Recovery Period</U>&rdquo; means the three completed fiscal years immediately preceding
the date on which the Company is required to prepare the Financial Restatement, as determined in accordance with the last sentence of
this paragraph, or any transition period that results from a change in the Company&rsquo;s fiscal year (as set forth in Section 5608(b)(i)(D)
of the Nasdaq Listing Rules). The date on which the Company is required to prepare a Financial Restatement is the earlier to occur of
(A) the date the Board or a Board committee (or authorized officers of the Company if Board action is not required) concludes, or reasonably
should have concluded, that the Company is required to prepare a Financial Restatement or (B) the date a court, regulator, or other legally
authorized body directs the Company to prepare a Financial Restatement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For Incentive-Based Compensation based on stock price or TSR, where
the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Financial
Restatement, then the Compensation Committee shall determine the amount to be recovered based on a reasonable estimate of the effect of
the Financial Restatement on the stock price or TSR upon which the Incentive-Based Compensation was received and the Company shall document
the determination of that estimate and provide it to Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Incentive-Based Compensation is considered to have been received by
an Executive in the fiscal year during which the applicable financial reporting measure was attained or purportedly attained, even if
the payment or grant of such Incentive-Based Compensation occurs after the end of that period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company may use any legal or equitable remedies that are available
to the Company to recoup any erroneously awarded Incentive-Based Compensation, including but not limited to by collecting from the Executive
cash payments or shares of Company common stock from or by forfeiting any amounts that the Company owes to the Executive. Executives shall
be solely responsible for any tax consequences to them that result from the recoupment or recovery of any amount pursuant to this Policy,
and the Company shall have no obligation to administer the Policy in a manner that avoids or minimizes any such tax consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>No Indemnification</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company shall not indemnify any Executive or pay or reimburse the
premium for any insurance policy to cover any losses incurred by such Executive under this Policy or any claims relating to the Company&rsquo;s
enforcement of rights under this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Exceptions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The compensation recouped under this Policy shall not include Incentive-Based
Compensation received by an Executive (i) prior to beginning service as an Executive or (ii) if he or she did not serve as an Executive
at any time during the performance period applicable to the Incentive-Based Compensation in question. The Compensation Committee (or a
majority of independent directors serving on the Board) may determine not to seek recovery from an Executive in whole or part to the extent
it determines in its sole discretion that such recovery would be impracticable because (A) the direct expense paid to a third party to
assist in enforcing recovery would exceed the recoverable amount (after having made a reasonable attempt to recover the erroneously awarded
Incentive-Based Compensation and providing corresponding documentation of such attempt to Nasdaq), (B) recovery would violate the home
country law that was adopted prior to November 28, 2022, as determined by an opinion of counsel licensed in the applicable jurisdiction
that is acceptable to and provided to Nasdaq, or (C) recovery would likely cause the Company&rsquo;s 401(k) plan or any other tax-qualified
retirement plan to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended,
and the regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Other Remedies Not Precluded</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The exercise by the Compensation Committee of any rights pursuant to
this Policy shall be without prejudice to any other rights or remedies that the Company, the Board or the Compensation Committee may have
with respect to any Executive subject to this Policy, whether arising under applicable law (including pursuant to Section 304 of the Sarbanes-Oxley
Act of 2002), regulation or pursuant to the terms of any other policy of the Company, employment agreement, equity award, cash incentive
award or other agreement applicable to an Executive. Notwithstanding the foregoing, there shall be no duplication of recovery of the same
Incentive-Based Compensation under this Policy and any other such rights or remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Acknowledgment</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent required by the Compensation Committee, each Executive
shall be required to sign and return to the Company the acknowledgement form attached hereto as Exhibit A pursuant to which such Executive
will agree to be bound by the terms of, and comply with, this Policy. For the avoidance of doubt, each Executive shall be fully bound
by, and must comply with, the Policy, whether or not such Executive has executed and returned such acknowledgment form to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Effective Date and Applicability</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Policy has been adopted by the Board on December 1, 2023, and
shall apply to any Incentive-Based Compensation that is received by an Executive on or after October 2, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">EXHIBIT A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">DODD-FRANK COMPENSATION
CLAWBACK POLICY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">ACKNOWLEDGEMENT
FORM</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Capitalized terms used but not otherwise defined
in this Acknowledgement Form (this &ldquo;<B><I>Acknowledgement Form</I></B>&rdquo;) shall have the meanings ascribed to such terms in
the Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">By signing this Acknowledgement Form, the undersigned
acknowledges, confirms and agrees that the undersigned: (i) has received and reviewed a copy of the Policy; (ii) is and will continue
to be subject to the Policy and that the Policy will apply both during and after the undersigned&rsquo;s employment with the Company;
and (iii) will abide by the terms of the Policy, including, without limitation, by reasonably promptly returning any recoverable compensation
to the Company as required by the Policy, as determined by the Compensation Committee in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sign:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp; </FONT></TD>
    <TD STYLE="text-align: justify">[Employee]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ; ,@# 2(  A$! Q$!_\0
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KG%6](T$V=U)?WETUY?R#:TS+@*O]U1V%;8IQI\S)5"*=W=@!12T5)N?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>txmd-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 29 20:06:18 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" targetNamespace="http://www.therapeuticsmd.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:txmd="http://www.therapeuticsmd.com/20231231" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="txmd-20231231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="txmd-20231231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="txmd-20231231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="txmd-20231231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet" id="txmd_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals" id="txmd_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement" id="txmd_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatementAlt0" id="txmd_r_ConsolidatedIncomeStatementAlt0">
        <link:definition>995303 - Statement - Consolidated Statements of Operations Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3" id="txmd_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Consolidated Statements of Stockholders&#8217; (Deficit) Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ConsolidatedCashFlow" id="txmd_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies" id="txmd_r_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies">
        <link:definition>995306 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/DiscontinuedOperations" id="txmd_r_DiscontinuedOperations">
        <link:definition>995307 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssets" id="txmd_r_PrepaidandOtherCurrentAssets">
        <link:definition>995308 - Disclosure - Prepaid and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/FixedAssets" id="txmd_r_FixedAssets">
        <link:definition>995309 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssets" id="txmd_r_LicensedRightsandOtherIntangibleAssets">
        <link:definition>995310 - Disclosure - Licensed Rights and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilities" id="txmd_r_AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>995311 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/Debt" id="txmd_r_Debt">
        <link:definition>995312 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/CommitmentsandContingencies" id="txmd_r_CommitmentsandContingencies">
        <link:definition>995313 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/StockholdersEquityDeficit" id="txmd_r_StockholdersEquityDeficit">
        <link:definition>995314 - Disclosure - Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/Revenue" id="txmd_r_Revenue">
        <link:definition>995315 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/IncomeTaxes" id="txmd_r_IncomeTaxes">
        <link:definition>995316 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/IncomeLossPerCommonShare" id="txmd_r_IncomeLossPerCommonShare">
        <link:definition>995317 - Disclosure - Income (Loss) Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/Relatedparties" id="txmd_r_Relatedparties">
        <link:definition>995318 - Disclosure - Related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/BusinessConcentrations" id="txmd_r_BusinessConcentrations">
        <link:definition>995319 - Disclosure - Business Concentrations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/SubsequentEvents" id="txmd_r_SubsequentEvents">
        <link:definition>995320 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy" id="txmd_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesTables" id="txmd_r_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables" id="txmd_r_DiscontinuedOperationsTables">
        <link:definition>996002 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssetsTables" id="txmd_r_PrepaidandOtherCurrentAssetsTables">
        <link:definition>996003 - Disclosure - Prepaid and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/FixedAssetsTables" id="txmd_r_FixedAssetsTables">
        <link:definition>996004 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables" id="txmd_r_LicensedRightsandOtherIntangibleAssetsTables">
        <link:definition>996005 - Disclosure - Licensed Rights and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" id="txmd_r_AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>996006 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/CommitmentsandContingenciesTables" id="txmd_r_CommitmentsandContingenciesTables">
        <link:definition>996007 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/StockholdersEquityDeficitTables" id="txmd_r_StockholdersEquityDeficitTables">
        <link:definition>996008 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/IncomeTaxesTables" id="txmd_r_IncomeTaxesTables">
        <link:definition>996009 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTables" id="txmd_r_IncomeLossPerCommonShareTables">
        <link:definition>996010 - Disclosure - Income (Loss) Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails" id="txmd_r_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996011 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable" id="txmd_r_SummaryofRestructuringCostRecognitionTable">
        <link:definition>996012 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details) - Summary of Restructuring Cost Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails" id="txmd_r_DiscontinuedOperationsDetails">
        <link:definition>996013 - Disclosure - Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable" id="txmd_r_ScheduleofDiscontinuedOperationsTable">
        <link:definition>996014 - Disclosure - Discontinued Operations (Details) - Schedule of Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable" id="txmd_r_ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable">
        <link:definition>996015 - Disclosure - Discontinued Operations (Details) - Schedule of Classes of Liabilities of Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable" id="txmd_r_ScheduleofPrepaidandOtherCurrentAssetsTable">
        <link:definition>996016 - Disclosure - Prepaid and Other Current Assets (Details) - Schedule of Prepaid and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/FixedAssetsDetails" id="txmd_r_FixedAssetsDetails">
        <link:definition>996017 - Disclosure - Fixed Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable" id="txmd_r_ScheduleofFixedAssetsNetTable">
        <link:definition>996018 - Disclosure - Fixed Assets (Details) - Schedule of Fixed Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails" id="txmd_r_LicensedRightsandOtherIntangibleAssetsDetails">
        <link:definition>996019 - Disclosure - Licensed Rights and Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable" id="txmd_r_ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable">
        <link:definition>996020 - Disclosure - Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable" id="txmd_r_ScheduleofIntangibleAssetsSubjectToAmortizationTable">
        <link:definition>996021 - Disclosure - Licensed Rights and Other Intangible Assets (Details) - Schedule of Intangible Assets Subject To Amortization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" id="txmd_r_AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>996022 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable" id="txmd_r_ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable">
        <link:definition>996023 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of Other Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/DebtDetails" id="txmd_r_DebtDetails">
        <link:definition>996024 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails" id="txmd_r_CommitmentsandContingenciesDetails">
        <link:definition>996025 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbcL4qf5LvDZDepCbNlW2HHdtTp8h/JBPAKml91Z9+QS2gjfdoyURiOQgrxFESWde/Q+Ash/YJdGlbG5QR3nEMXflGmqnNLFtFl1nIAPLFlMWnSI/b92PyAqBFuykXvgMcnlPm3rTC5y1gsY+iS9+gbk0SFpyt2CDowYCrPhIqMSfw/7Rr70FR8ovgRBFDLXcezaethdJMOgHg8+qsZZUFU] CSR-->
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable" id="txmd_r_ScheduleofRemainingLeasePaymentsTable">
        <link:definition>996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Remaining Lease Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable" id="txmd_r_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable">
        <link:definition>996027 - Disclosure - Commitments and Contingencies (Details) - Schedule of Supplemental Balance Sheet Information Related to Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofOtherInformationRelatedtoLeasesTable" id="txmd_r_ScheduleofOtherInformationRelatedtoLeasesTable">
        <link:definition>996028 - Disclosure - Commitments and Contingencies (Details) - Schedule of Other Information Related to Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails" id="txmd_r_StockholdersEquityDeficitDetails">
        <link:definition>996029 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable" id="txmd_r_ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable">
        <link:definition>996030 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details) - Schedule of Outstanding and Exercisable Warrants and Related Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable" id="txmd_r_ScheduleofStockOptionsActivityTable">
        <link:definition>996031 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details) - Schedule of Stock Options Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable" id="txmd_r_ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable">
        <link:definition>996032 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details) - Schedule of the Status of our Unvested and Related Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/RevenueDetails" id="txmd_r_RevenueDetails">
        <link:definition>996033 - Disclosure - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/IncomeTaxesDetails" id="txmd_r_IncomeTaxesDetails">
        <link:definition>996034 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable" id="txmd_r_ScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable">
        <link:definition>996035 - Disclosure - Income Taxes (Details) - Schedule of Income (Loss) from Continuing Operations Before Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable" id="txmd_r_ScheduleofEffectiveIncomeTaxRateReconciliationTable">
        <link:definition>996036 - Disclosure - Income Taxes (Details) - Schedule of Effective Income Tax Rate Reconciliation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable" id="txmd_r_ScheduleofComponentsofNetDeferredIncomeTaxAssetTable">
        <link:definition>996037 - Disclosure - Income Taxes (Details) - Schedule of Components of Net Deferred Income Tax Asset</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable" id="txmd_r_ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable">
        <link:definition>996038 - Disclosure - Income (Loss) Per Common Share (Details) - Schedule of Computation of Basic and Diluted Income (Loss) Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable" id="txmd_r_ScheduleofOutstandingSecuritiesTable">
        <link:definition>996039 - Disclosure - Income (Loss) Per Common Share (Details) - Schedule of Outstanding Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/RelatedpartiesDetails" id="txmd_r_RelatedpartiesDetails">
        <link:definition>996040 - Disclosure - Related parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails" id="txmd_r_BusinessConcentrationsDetails">
        <link:definition>996041 - Disclosure - Business Concentrations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd"/>
  <xs:element name="SummaryOfRestructuringCostRecognitionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_SummaryOfRestructuringCostRecognitionAbstract"/>
  <xs:element name="ScheduleOfDiscontinuedOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfDiscontinuedOperationsAbstract"/>
  <xs:element name="ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract"/>
  <xs:element name="ScheduleOfPrepaidAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract"/>
  <xs:element name="ScheduleOfFixedAssetsNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfFixedAssetsNetAbstract"/>
  <xs:element name="ScheduleOfLicenseRightsAndOtherIntangibleAssetsNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfLicenseRightsAndOtherIntangibleAssetsNetAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract"/>
  <xs:element name="ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract"/>
  <xs:element name="ScheduleOfOutstandingAndExercisableWarrantsAndRelatedTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfOutstandingAndExercisableWarrantsAndRelatedTransactionsAbstract"/>
  <xs:element name="ScheduleOfStockOptionsActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfStockOptionsActivityAbstract"/>
  <xs:element name="ScheduleOfTheStatusOfOurUnvestedAndRelatedTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfTheStatusOfOurUnvestedAndRelatedTransactionsAbstract"/>
  <xs:element name="ScheduleOfIncomeLossFromContinuingOperationsBeforeIncomeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfIncomeLossFromContinuingOperationsBeforeIncomeTaxesAbstract"/>
  <xs:element name="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract"/>
  <xs:element name="ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract"/>
  <xs:element name="ScheduleOfComputationOfBasicAndDilutedIncomeLossPerCommonShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfComputationOfBasicAndDilutedIncomeLossPerCommonShareAbstract"/>
  <xs:element name="ScheduleOfOutstandingSecuritiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfOutstandingSecuritiesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_UnlabeledAbstract0"/>
  <xs:element name="IntangibleAssetsSubjectToAmortizationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_IntangibleAssetsSubjectToAmortizationAbstract"/>
  <xs:element name="IntangibleAssetsNotSubjectToAmortizationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_IntangibleAssetsNotSubjectToAmortizationAbstract"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_UnlabeledAbstract1"/>
  <xs:element name="DeferredIncomeTaxAssetsLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_UnlabeledAbstract2"/>
  <xs:element name="RoyaltyReceivableCurrentPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_RoyaltyReceivableCurrentPortion"/>
  <xs:element name="RoyaltyReceivableLongTerm" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_RoyaltyReceivableLongTerm"/>
  <xs:element name="MiscellaneousIncomeexpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_MiscellaneousIncomeexpense"/>
  <xs:element name="AdjustmentsToAdditionalPaidInCapitalLenderWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants"/>
  <xs:element name="WriteoffOfPatentAndTrademark" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_WriteoffOfPatentAndTrademark"/>
  <xs:element name="MakeWholePaymentAccretion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_MakeWholePaymentAccretion"/>
  <xs:element name="ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan"/>
  <xs:element name="WarrantsIssuedInRelationToDebtFinancingAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_WarrantsIssuedInRelationToDebtFinancingAgreement"/>
  <xs:element name="GeneralInformationPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_GeneralInformationPolicyTextBlock"/>
  <xs:element name="DivestitureOfBusinessPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_DivestitureOfBusinessPolicyPolicyTextBlock"/>
  <xs:element name="GoingConcernPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_GoingConcernPolicyTextBlock"/>
  <xs:element name="ContractAssetsAndLiabilitiesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ContractAssetsAndLiabilitiesPolicyTextBlock"/>
  <xs:element name="ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock"/>
  <xs:element name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
  <xs:element name="ScheduleOfWarrantRollForwardTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ScheduleOfWarrantRollForwardTableTextBlock"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges"/>
  <xs:element name="DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable"/>
  <xs:element name="DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationGainOnSale" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationRentReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities"/>
  <xs:element name="LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"/>
  <xs:element name="LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems"/>
  <xs:element name="AccruedContractTerminationCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_AccruedContractTerminationCosts"/>
  <xs:element name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_AccruedResearchAndDevelopmentExpenses"/>
  <xs:element name="AccruedPrepaidRoyalty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_AccruedPrepaidRoyalty"/>
  <xs:element name="AccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_AccruedExpensesAndOtherCurrentLiabilities"/>
  <xs:element name="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"/>
  <xs:element name="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems"/>
  <xs:element name="WarrantsOutstandingAndExercisableOtherThanOptionsWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants"/>
  <xs:element name="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice"/>
  <xs:element name="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue"/>
  <xs:element name="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife"/>
  <xs:element name="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted"/>
  <xs:element name="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted"/>
  <xs:element name="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired"/>
  <xs:element name="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired"/>
  <xs:element name="WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife"/>
  <xs:element name="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised"/>
  <xs:element name="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised"/>
  <xs:element name="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2"/>
  <xs:element name="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"/>
  <xs:element name="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems"/>
  <xs:element name="IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable"/>
  <xs:element name="IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems"/>
  <xs:element name="EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars"/>
  <xs:element name="EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars"/>
  <xs:element name="EffectiveIncomeTaxRateDiscontinuedOperations" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_EffectiveIncomeTaxRateDiscontinuedOperations"/>
  <xs:element name="DeferredTaxAssetGainOnSaleOfIntellectualProperty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty"/>
  <xs:element name="DeferredTaxAssetsLiabilitiesGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DeferredTaxAssetsLiabilitiesGross"/>
  <xs:element name="DeferredTaxAssetsLiabilitiesNetOfValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance"/>
  <xs:element name="IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"/>
  <xs:element name="IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems"/>
  <xs:element name="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="OneTimeMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_OneTimeMilestonePayments"/>
  <xs:element name="ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment"/>
  <xs:element name="RoyaltyRateAsPercentageOnNetSales" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_RoyaltyRateAsPercentageOnNetSales"/>
  <xs:element name="ThresholdAnnualNetSalesToDetermineRoyaltyRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate"/>
  <xs:element name="TermOfRoyaltyPayments" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_TermOfRoyaltyPayments"/>
  <xs:element name="DecreaseInRoyaltyRateOnProductByProductBasis" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_DecreaseInRoyaltyRateOnProductByProductBasis"/>
  <xs:element name="MinimumAnnualRoyaltyPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_MinimumAnnualRoyaltyPayment"/>
  <xs:element name="PeriodOfMinimumAnnualRoyaltyPayment" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_PeriodOfMinimumAnnualRoyaltyPayment"/>
  <xs:element name="InflationRateAdjustedForMinimalAnnualRoyaltyPayment" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment"/>
  <xs:element name="PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment"/>
  <xs:element name="PaymentsToAcquireNetWorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_PaymentsToAcquireNetWorkingCapital"/>
  <xs:element name="PrepaidRoyaltyLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_PrepaidRoyaltyLiabilities"/>
  <xs:element name="QuarterlyRoyaltyPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_QuarterlyRoyaltyPayment"/>
  <xs:element name="QuarterlyRoyaltyInterest" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_QuarterlyRoyaltyInterest"/>
  <xs:element name="RoyaltyPaymentPayableUnderLongTermServiceAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement"/>
  <xs:element name="RoyaltyPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_RoyaltyPayment"/>
  <xs:element name="AdditionalFund" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_AdditionalFund"/>
  <xs:element name="TransactionCostsRelatedToDivestitureOfBusiness" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_TransactionCostsRelatedToDivestitureOfBusiness"/>
  <xs:element name="ContingentCashConsiderationFromSaleOfBusiness" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_ContingentCashConsiderationFromSaleOfBusiness"/>
  <xs:element name="ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments"/>
  <xs:element name="WriteOffOfAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_WriteOffOfAsset"/>
  <xs:element name="AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments"/>
  <xs:element name="AggregateMinimumAnnualRoyaltyPaymentsDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_AggregateMinimumAnnualRoyaltyPaymentsDue"/>
  <xs:element name="PresentValueOfAnnualMinimumRoyaltyDiscountRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate"/>
  <xs:element name="LicenseRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_LicenseRevenue"/>
  <xs:element name="NumberOfEmployeesAfterWorkforceReduction" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_NumberOfEmployeesAfterWorkforceReduction"/>
  <xs:element name="RestructuringChargesIncludingDiscontinuedOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_RestructuringChargesIncludingDiscontinuedOperations"/>
  <xs:element name="DiscontinuedOperationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="txmd_DiscontinuedOperationsDetailsTable"/>
  <xs:element name="DiscontinuedOperationsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_DiscontinuedOperationsDetailsLineItems"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties"/>
  <xs:element name="LicensedRightsandOtherIntangibleAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="txmd_LicensedRightsandOtherIntangibleAssetsDetailsTable"/>
  <xs:element name="LicensedRightsandOtherIntangibleAssetsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems"/>
  <xs:element name="LegalProceedingDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_LegalProceedingDomainDomain"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="txmd_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_CommitmentsandContingenciesDetailsLineItems"/>
  <xs:element name="LeaseConsecutivePeriods" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_LeaseConsecutivePeriods"/>
  <xs:element name="CashReceivedForNetWorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_CashReceivedForNetWorkingCapital"/>
  <xs:element name="IncrementalAccrualForNetWorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_IncrementalAccrualForNetWorkingCapital"/>
  <xs:element name="WorkingCapitalAmounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_WorkingCapitalAmounts"/>
  <xs:element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_MilestonePayment"/>
  <xs:element name="MilestonePaymentsRecordedAsLicenseRights" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="txmd_MilestonePaymentsRecordedAsLicenseRights"/>
  <xs:element name="StockholdersEquityDeficitDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="txmd_StockholdersEquityDeficitDetailsTable"/>
  <xs:element name="StockholdersEquityDeficitDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_StockholdersEquityDeficitDetailsLineItems"/>
  <xs:element name="RevenueDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="txmd_RevenueDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="txmd_IncomeTaxesDetailsTable"/>
  <xs:element name="NetOperatingLossCarryforwardsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_NetOperatingLossCarryforwardsTerm"/>
  <xs:element name="PercentageOfFutureTaxableIncome" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_PercentageOfFutureTaxableIncome"/>
  <xs:element name="RelatedpartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="txmd_RelatedpartiesDetailsTable"/>
  <xs:element name="BusinessConcentrationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="txmd_BusinessConcentrationsDetailsTable"/>
  <xs:element name="BusinessConcentrationsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_BusinessConcentrationsDetailsLineItems"/>
  <xs:element name="CustomerLicenseRevenuePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_CustomerLicenseRevenuePercentage"/>
  <xs:element name="RoyaltyReceivableShortTermPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_RoyaltyReceivableShortTermPortion"/>
  <xs:element name="RoyaltyReceivableLongTermPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="txmd_RoyaltyReceivableLongTermPortion"/>
  <xs:element name="LegalProceedingAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="txmd_LegalProceedingAxis"/>
  <xs:element name="AccruedExpensesAndOtherCurrentLiabilitiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember"/>
  <xs:element name="AnnoverasMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_AnnoverasMember"/>
  <xs:element name="BijuvasMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_BijuvasMember"/>
  <xs:element name="ConsultingAndLegalExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ConsultingAndLegalExpensesMember"/>
  <xs:element name="CurrentLiabilitiesForDiscontinuedOperationsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_CurrentLiabilitiesForDiscontinuedOperationsMember"/>
  <xs:element name="EmployeeTerminationBenefitsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_EmployeeTerminationBenefitsMember"/>
  <xs:element name="ExecutiveTerminationBenefitsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ExecutiveTerminationBenefitsMember"/>
  <xs:element name="ExpirationPeriod20YearsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ExpirationPeriod20YearsMember"/>
  <xs:element name="ExpirationPeriodIndefiniteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ExpirationPeriodIndefiniteMember"/>
  <xs:element name="HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember"/>
  <xs:element name="HormoneTherapyDrugPatentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_HormoneTherapyDrugPatentsMember"/>
  <xs:element name="IntangibleAssetsSubjectToAmortizationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_IntangibleAssetsSubjectToAmortizationMember"/>
  <xs:element name="MayneLicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_MayneLicenseAgreementMember"/>
  <xs:element name="MaynePharmaAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_MaynePharmaAgreementMember"/>
  <xs:element name="MaynePharmaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_MaynePharmaMember"/>
  <xs:element name="MilestonePaymentsOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_MilestonePaymentsOneMember"/>
  <xs:element name="MilestonePaymentsThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_MilestonePaymentsThreeMember"/>
  <xs:element name="MilestonePaymentsTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_MilestonePaymentsTwoMember"/>
  <xs:element name="OtherContractTerminationCostsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_OtherContractTerminationCostsMember"/>
  <xs:element name="ParagraphFourCertificationNoticeLetterMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_ParagraphFourCertificationNoticeLetterMember"/>
  <xs:element name="PopulationCouncilLicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_PopulationCouncilLicenseAgreementMember"/>
  <xs:element name="RoyaltyRateOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_RoyaltyRateOneMember"/>
  <xs:element name="RoyaltyRateTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_RoyaltyRateTwoMember"/>
  <xs:element name="RubricCapitalManagementLPMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_RubricCapitalManagementLPMember"/>
  <xs:element name="StockOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_StockOptionsMember"/>
  <xs:element name="StockPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_StockPurchaseAgreementMember"/>
  <xs:element name="SubscriptionAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_SubscriptionAgreementMember"/>
  <xs:element name="TheramexLicenseAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_TheramexLicenseAgreementsMember"/>
  <xs:element name="TheramexMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_TheramexMember"/>
  <xs:element name="TwoThousandNineteenStockIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_TwoThousandNineteenStockIncentivePlanMember"/>
  <xs:element name="VitaCareDivestitureMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_VitaCareDivestitureMember"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract"/>
  <xs:element name="FixedAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_FixedAssetsAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>txmd-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 29 20:06:18 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ConsolidatedBalanceSheet" roleURI="http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ConsolidatedIncomeStatement" roleURI="http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ConsolidatedCashFlow" roleURI="http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofDiscontinuedOperationsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofPrepaidandOtherCurrentAssetsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofFixedAssetsNetTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofIntangibleAssetsSubjectToAmortizationTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofRemainingLeasePaymentsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofEffectiveIncomeTaxRateReconciliationTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyReceivableCurrentPortion" xlink:href="txmd-20231231.xsd#txmd_RoyaltyReceivableCurrentPortion"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="txmd_RoyaltyReceivableCurrentPortion" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyReceivableLongTerm" xlink:href="txmd-20231231.xsd#txmd_RoyaltyReceivableLongTerm"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="txmd_RoyaltyReceivableLongTerm" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringCharges" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="txmd_MiscellaneousIncomeexpense" xlink:href="txmd-20231231.xsd#txmd_MiscellaneousIncomeexpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="txmd_MiscellaneousIncomeexpense" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="txmd_WriteoffOfPatentAndTrademark" xlink:href="txmd-20231231.xsd#txmd_WriteoffOfPatentAndTrademark"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="txmd_WriteoffOfPatentAndTrademark" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_MakeWholePaymentAccretion" xlink:href="txmd-20231231.xsd#txmd_MakeWholePaymentAccretion"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="txmd_MakeWholePaymentAccretion" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan" xlink:href="txmd-20231231.xsd#txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_RepaymentsOfDebt" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbcL4qf5LvDZDepCbNlW2HHdtTp8h/JBPAKml91Z9+QS2gjfdoyURiOQgrxFESWde/Q+Ash/YJdGlbG5QR3nEMXflGmqnNLFtFl1nIAPLFlMWnSI/b92PyAqBFuykXvgMcnlPm3rTC5y1gsY+iS9+gbk0SFpyt2CDowYCrPhIqMSfw/7Rr70FR84Ai2/77thUO3D1Vf2VkDwMJLe1P3/QuU] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="3" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcquisitionCostsCumulative" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquisitionCostsCumulative"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AcquisitionCostsCumulative" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="txmd_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="txmd-20231231.xsd#txmd_AccruedExpensesAndOtherCurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_AccruedContractTerminationCosts" xlink:href="txmd-20231231.xsd#txmd_AccruedContractTerminationCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="txmd_AccruedContractTerminationCosts" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_AccruedResearchAndDevelopmentExpenses" xlink:href="txmd-20231231.xsd#txmd_AccruedResearchAndDevelopmentExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="txmd_AccruedResearchAndDevelopmentExpenses" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_AccruedPrepaidRoyalty" xlink:href="txmd-20231231.xsd#txmd_AccruedPrepaidRoyalty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="txmd_AccruedPrepaidRoyalty" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars" xlink:href="txmd-20231231.xsd#txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_EffectiveIncomeTaxRateDiscontinuedOperations" xlink:href="txmd-20231231.xsd#txmd_EffectiveIncomeTaxRateDiscontinuedOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_EffectiveIncomeTaxRateDiscontinuedOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_EffectiveIncomeTaxRateDiscontinuedOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_EffectiveIncomeTaxRateDiscontinuedOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars" xlink:href="txmd-20231231.xsd#txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_EffectiveIncomeTaxRateDiscontinuedOperations" xlink:to="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_EffectiveIncomeTaxRateDiscontinuedOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="txmd_EffectiveIncomeTaxRateDiscontinuedOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>txmd-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 29 20:06:18 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ConsolidatedBalanceSheet" roleURI="http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ConsolidatedIncomeStatement" roleURI="http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ShareholdersEquityType2or3" roleURI="http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ConsolidatedCashFlow" roleURI="http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies" roleURI="http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_DiscontinuedOperations" roleURI="http://www.therapeuticsmd.com/role/DiscontinuedOperations"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_PrepaidandOtherCurrentAssets" roleURI="http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_FixedAssets" roleURI="http://www.therapeuticsmd.com/role/FixedAssets"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_LicensedRightsandOtherIntangibleAssets" roleURI="http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_Debt" roleURI="http://www.therapeuticsmd.com/role/Debt"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_CommitmentsandContingencies" roleURI="http://www.therapeuticsmd.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_StockholdersEquityDeficit" roleURI="http://www.therapeuticsmd.com/role/StockholdersEquityDeficit"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_Revenue" roleURI="http://www.therapeuticsmd.com/role/Revenue"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_IncomeTaxes" roleURI="http://www.therapeuticsmd.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_IncomeLossPerCommonShare" roleURI="http://www.therapeuticsmd.com/role/IncomeLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_Relatedparties" roleURI="http://www.therapeuticsmd.com/role/Relatedparties"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_BusinessConcentrations" roleURI="http://www.therapeuticsmd.com/role/BusinessConcentrations"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_SubsequentEvents" roleURI="http://www.therapeuticsmd.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_AccountingPoliciesByPolicy" roleURI="http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_DiscontinuedOperationsTables" roleURI="http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_PrepaidandOtherCurrentAssetsTables" roleURI="http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_FixedAssetsTables" roleURI="http://www.therapeuticsmd.com/role/FixedAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_LicensedRightsandOtherIntangibleAssetsTables" roleURI="http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_CommitmentsandContingenciesTables" roleURI="http://www.therapeuticsmd.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_StockholdersEquityDeficitTables" roleURI="http://www.therapeuticsmd.com/role/StockholdersEquityDeficitTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_IncomeTaxesTables" roleURI="http://www.therapeuticsmd.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_IncomeLossPerCommonShareTables" roleURI="http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_SummaryofRestructuringCostRecognitionTable" roleURI="http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofDiscontinuedOperationsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofPrepaidandOtherCurrentAssetsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofFixedAssetsNetTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofIntangibleAssetsSubjectToAmortizationTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofRemainingLeasePaymentsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofOtherInformationRelatedtoLeasesTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofOtherInformationRelatedtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofStockOptionsActivityTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofEffectiveIncomeTaxRateReconciliationTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofComponentsofNetDeferredIncomeTaxAssetTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofOutstandingSecuritiesTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_DiscontinuedOperationsDetails" roleURI="http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_FixedAssetsDetails" roleURI="http://www.therapeuticsmd.com/role/FixedAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_LicensedRightsandOtherIntangibleAssetsDetails" roleURI="http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_DebtDetails" roleURI="http://www.therapeuticsmd.com/role/DebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_CommitmentsandContingenciesDetails" roleURI="http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_StockholdersEquityDeficitDetails" roleURI="http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_RevenueDetails" roleURI="http://www.therapeuticsmd.com/role/RevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_IncomeTaxesDetails" roleURI="http://www.therapeuticsmd.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_RelatedpartiesDetails" roleURI="http://www.therapeuticsmd.com/role/RelatedpartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_BusinessConcentrationsDetails" roleURI="http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#DocumentAndEntityInformation" roleURI="http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyReceivableCurrentPortion" xlink:href="txmd-20231231.xsd#txmd_RoyaltyReceivableCurrentPortion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="txmd_RoyaltyReceivableCurrentPortion" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyReceivableLongTerm" xlink:href="txmd-20231231.xsd#txmd_RoyaltyReceivableLongTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="txmd_RoyaltyReceivableLongTerm" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MiscellaneousIncomeexpense" xlink:href="txmd-20231231.xsd#txmd_MiscellaneousIncomeexpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="txmd_MiscellaneousIncomeexpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants" xlink:href="txmd-20231231.xsd#txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WriteoffOfPatentAndTrademark" xlink:href="txmd-20231231.xsd#txmd_WriteoffOfPatentAndTrademark"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="txmd_WriteoffOfPatentAndTrademark" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MakeWholePaymentAccretion" xlink:href="txmd-20231231.xsd#txmd_MakeWholePaymentAccretion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="txmd_MakeWholePaymentAccretion" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan" xlink:href="txmd-20231231.xsd#txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsIssuedInRelationToDebtFinancingAgreement" xlink:href="txmd-20231231.xsd#txmd_WarrantsIssuedInRelationToDebtFinancingAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="txmd_WarrantsIssuedInRelationToDebtFinancingAgreement" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/DiscontinuedOperations">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/FixedAssets">
    <loc xlink:type="locator" xlink:label="txmd_FixedAssetsAbstract" xlink:href="txmd-20231231.xsd#txmd_FixedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_FixedAssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/Debt">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/StockholdersEquityDeficit">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/Revenue">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/IncomeLossPerCommonShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/Relatedparties">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/BusinessConcentrations">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="txmd_GeneralInformationPolicyTextBlock" xlink:href="txmd-20231231.xsd#txmd_GeneralInformationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="txmd_GeneralInformationPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DivestitureOfBusinessPolicyPolicyTextBlock" xlink:href="txmd-20231231.xsd#txmd_DivestitureOfBusinessPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="txmd_DivestitureOfBusinessPolicyPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_GoingConcernPolicyTextBlock" xlink:href="txmd-20231231.xsd#txmd_GoingConcernPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="txmd_GoingConcernPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DiscontinuedOperationsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:href="txmd-20231231.xsd#txmd_ContractAssetsAndLiabilitiesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="txmd_ContractAssetsAndLiabilitiesPolicyTextBlock" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/FixedAssetsTables">
    <loc xlink:type="locator" xlink:label="txmd_FixedAssetsAbstract" xlink:href="txmd-20231231.xsd#txmd_FixedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_FixedAssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/StockholdersEquityDeficitTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfWarrantRollForwardTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="txmd_ScheduleOfWarrantRollForwardTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable">
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_ExecutiveTerminationBenefitsMember" xlink:href="txmd-20231231.xsd#txmd_ExecutiveTerminationBenefitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="txmd_ExecutiveTerminationBenefitsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_ConsultingAndLegalExpensesMember" xlink:href="txmd-20231231.xsd#txmd_ConsultingAndLegalExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="txmd_ConsultingAndLegalExpensesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_OtherContractTerminationCostsMember" xlink:href="txmd-20231231.xsd#txmd_OtherContractTerminationCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="txmd_OtherContractTerminationCostsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_EmployeeTerminationBenefitsMember" xlink:href="txmd-20231231.xsd#txmd_EmployeeTerminationBenefitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="txmd_EmployeeTerminationBenefitsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable">
    <loc xlink:type="locator" xlink:label="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" xlink:href="txmd-20231231.xsd#txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems"/>
    <loc xlink:type="locator" xlink:label="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable" xlink:href="txmd-20231231.xsd#txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" xlink:to="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_AnnoverasMember" xlink:href="txmd-20231231.xsd#txmd_AnnoverasMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="txmd_AnnoverasMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable">
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcquisitionCostsCumulative" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquisitionCostsCumulative"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_AcquisitionCostsCumulative" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable">
    <loc xlink:type="locator" xlink:label="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems" xlink:href="txmd-20231231.xsd#txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems"/>
    <loc xlink:type="locator" xlink:label="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable" xlink:href="txmd-20231231.xsd#txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems" xlink:to="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_HormoneTherapyDrugPatentsMember" xlink:href="txmd-20231231.xsd#txmd_HormoneTherapyDrugPatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="txmd_HormoneTherapyDrugPatentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember" xlink:href="txmd-20231231.xsd#txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_IntangibleAssetsSubjectToAmortizationMember" xlink:href="txmd-20231231.xsd#txmd_IntangibleAssetsSubjectToAmortizationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="txmd_IntangibleAssetsSubjectToAmortizationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksAndTradeNamesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable">
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_AccruedContractTerminationCosts" xlink:href="txmd-20231231.xsd#txmd_AccruedContractTerminationCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="txmd_AccruedContractTerminationCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_AccruedResearchAndDevelopmentExpenses" xlink:href="txmd-20231231.xsd#txmd_AccruedResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="txmd_AccruedResearchAndDevelopmentExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_AccruedPrepaidRoyalty" xlink:href="txmd-20231231.xsd#txmd_AccruedPrepaidRoyalty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="txmd_AccruedPrepaidRoyalty" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="txmd-20231231.xsd#txmd_AccruedExpensesAndOtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="txmd_AccruedExpensesAndOtherCurrentLiabilities" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_OperatingLeaseLiability" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable">
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofOtherInformationRelatedtoLeasesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable">
    <loc xlink:type="locator" xlink:label="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable">
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfStockOptionsActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:href="txmd-20231231.xsd#txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:to="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" order="12" xbrldt:closed="true"/>
  </definitionLink>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbcL4qf5LvDZDepCbNlW2HHdtTp8h/JBPAKml91Z9+QS2gjfdoyURiOQgrxFESWde/Q+Ash/YJdGlbG5QR3nEMXflGmqnNLFtFl1nIAPLFlMWnSI/b92PyAqBFuykXvgMcnlPm3rTC5y1gsY+iS9+gbk0SFpyt2CDowYCrPhIqMSfw/7Rr70FR8L4VxF6KA5BYfUyYcDSO31bkyCqwtBXZG] CSR-->
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable">
    <loc xlink:type="locator" xlink:label="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable">
    <loc xlink:type="locator" xlink:label="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems" xlink:href="txmd-20231231.xsd#txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems"/>
    <loc xlink:type="locator" xlink:label="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable" xlink:href="txmd-20231231.xsd#txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems" xlink:to="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable">
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars" xlink:href="txmd-20231231.xsd#txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars" xlink:href="txmd-20231231.xsd#txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_EffectiveIncomeTaxRateDiscontinuedOperations" xlink:href="txmd-20231231.xsd#txmd_EffectiveIncomeTaxRateDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="txmd_EffectiveIncomeTaxRateDiscontinuedOperations" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable">
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:href="txmd-20231231.xsd#txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract" xlink:to="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty" xlink:href="txmd-20231231.xsd#txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DeferredTaxAssetsLiabilitiesGross" xlink:href="txmd-20231231.xsd#txmd_DeferredTaxAssetsLiabilitiesGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="txmd_DeferredTaxAssetsLiabilitiesGross" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance" xlink:href="txmd-20231231.xsd#txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract" xlink:to="txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable">
    <loc xlink:type="locator" xlink:label="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems" xlink:href="txmd-20231231.xsd#txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems"/>
    <loc xlink:type="locator" xlink:label="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable" xlink:href="txmd-20231231.xsd#txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems" xlink:to="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_StockOptionsMember" xlink:href="txmd-20231231.xsd#txmd_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="txmd_StockOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="txmd-20231231.xsd#txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_StatementScenarioAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MayneLicenseAgreementMember" xlink:href="txmd-20231231.xsd#txmd_MayneLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="txmd_MayneLicenseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_StockPurchaseAgreementMember" xlink:href="txmd-20231231.xsd#txmd_StockPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="txmd_StockPurchaseAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_RubricCapitalManagementLPMember" xlink:href="txmd-20231231.xsd#txmd_RubricCapitalManagementLPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="txmd_RubricCapitalManagementLPMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_TheramexLicenseAgreementsMember" xlink:href="txmd-20231231.xsd#txmd_TheramexLicenseAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="txmd_TheramexLicenseAgreementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_RoyaltyAgreementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MilestonePaymentsOneMember" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="txmd_MilestonePaymentsOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MilestonePaymentsTwoMember" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="txmd_MilestonePaymentsTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MilestonePaymentsThreeMember" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="txmd_MilestonePaymentsThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyRateOneMember" xlink:href="txmd-20231231.xsd#txmd_RoyaltyRateOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="txmd_RoyaltyRateOneMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyRateTwoMember" xlink:href="txmd-20231231.xsd#txmd_RoyaltyRateTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="txmd_RoyaltyRateTwoMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_BijuvasMember" xlink:href="txmd-20231231.xsd#txmd_BijuvasMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="txmd_BijuvasMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:href="txmd-20231231.xsd#txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_CurrentLiabilitiesForDiscontinuedOperationsMember" xlink:href="txmd-20231231.xsd#txmd_CurrentLiabilitiesForDiscontinuedOperationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="txmd_CurrentLiabilitiesForDiscontinuedOperationsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandAndBuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandAndBuildingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandAndBuildingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_VitaCareDivestitureMember" xlink:href="txmd-20231231.xsd#txmd_VitaCareDivestitureMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="txmd_VitaCareDivestitureMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_AnnoverasMember" xlink:href="txmd-20231231.xsd#txmd_AnnoverasMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="txmd_AnnoverasMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_OneTimeMilestonePayments" xlink:href="txmd-20231231.xsd#txmd_OneTimeMilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_OneTimeMilestonePayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" xlink:href="txmd-20231231.xsd#txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyRateAsPercentageOnNetSales" xlink:href="txmd-20231231.xsd#txmd_RoyaltyRateAsPercentageOnNetSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_RoyaltyRateAsPercentageOnNetSales" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate" xlink:href="txmd-20231231.xsd#txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_TermOfRoyaltyPayments" xlink:href="txmd-20231231.xsd#txmd_TermOfRoyaltyPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_TermOfRoyaltyPayments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DecreaseInRoyaltyRateOnProductByProductBasis" xlink:href="txmd-20231231.xsd#txmd_DecreaseInRoyaltyRateOnProductByProductBasis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_DecreaseInRoyaltyRateOnProductByProductBasis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MinimumAnnualRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_MinimumAnnualRoyaltyPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_MinimumAnnualRoyaltyPayment" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_PeriodOfMinimumAnnualRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_PeriodOfMinimumAnnualRoyaltyPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_PeriodOfMinimumAnnualRoyaltyPayment" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment" xlink:href="txmd-20231231.xsd#txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_PaymentsToAcquireNetWorkingCapital" xlink:href="txmd-20231231.xsd#txmd_PaymentsToAcquireNetWorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_PaymentsToAcquireNetWorkingCapital" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_PrepaidRoyaltyLiabilities" xlink:href="txmd-20231231.xsd#txmd_PrepaidRoyaltyLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_PrepaidRoyaltyLiabilities" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_QuarterlyRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_QuarterlyRoyaltyPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_QuarterlyRoyaltyPayment" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_QuarterlyRoyaltyInterest" xlink:href="txmd-20231231.xsd#txmd_QuarterlyRoyaltyInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_QuarterlyRoyaltyInterest" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement" xlink:href="txmd-20231231.xsd#txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_RoyaltyPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_RoyaltyPayment" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_AdditionalFund" xlink:href="txmd-20231231.xsd#txmd_AdditionalFund"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_AdditionalFund" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinesses" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_TransactionCostsRelatedToDivestitureOfBusiness" xlink:href="txmd-20231231.xsd#txmd_TransactionCostsRelatedToDivestitureOfBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_TransactionCostsRelatedToDivestitureOfBusiness" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_ContingentCashConsiderationFromSaleOfBusiness" xlink:href="txmd-20231231.xsd#txmd_ContingentCashConsiderationFromSaleOfBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_ContingentCashConsiderationFromSaleOfBusiness" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments" xlink:href="txmd-20231231.xsd#txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WriteOffOfAsset" xlink:href="txmd-20231231.xsd#txmd_WriteOffOfAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_WriteOffOfAsset" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments" xlink:href="txmd-20231231.xsd#txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments" order="41" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_AggregateMinimumAnnualRoyaltyPaymentsDue" xlink:href="txmd-20231231.xsd#txmd_AggregateMinimumAnnualRoyaltyPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_AggregateMinimumAnnualRoyaltyPaymentsDue" order="42" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate" xlink:href="txmd-20231231.xsd#txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate" order="43" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="44" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_LicenseRevenue" xlink:href="txmd-20231231.xsd#txmd_LicenseRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_LicenseRevenue" order="45" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RoyaltyIncomeNonoperating" order="46" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositContractsAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DepositContractsAssets" order="47" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="48" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="49" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" order="50" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_NumberOfEmployeesAfterWorkforceReduction" xlink:href="txmd-20231231.xsd#txmd_NumberOfEmployeesAfterWorkforceReduction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_NumberOfEmployeesAfterWorkforceReduction" order="51" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_RestructuringChargesIncludingDiscontinuedOperations" xlink:href="txmd-20231231.xsd#txmd_RestructuringChargesIncludingDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_RestructuringChargesIncludingDiscontinuedOperations" order="52" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RestructuringReserve" order="53" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="54" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails">
    <loc xlink:type="locator" xlink:label="txmd_DiscontinuedOperationsDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_DiscontinuedOperationsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="txmd_DiscontinuedOperationsDetailsTable" xlink:href="txmd-20231231.xsd#txmd_DiscontinuedOperationsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="txmd_DiscontinuedOperationsDetailsLineItems" xlink:to="txmd_DiscontinuedOperationsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_DiscontinuedOperationsDetailsTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_DiscontinuedOperationsDetailsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_AnnoverasMember" xlink:href="txmd-20231231.xsd#txmd_AnnoverasMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="txmd_AnnoverasMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DiscontinuedOperationsDetailsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DiscontinuedOperationsDetailsLineItems" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DiscontinuedOperationsDetailsLineItems" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_DiscontinuedOperationsDetailsLineItems" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/FixedAssetsDetails">
    <loc xlink:type="locator" xlink:label="txmd_FixedAssetsAbstract" xlink:href="txmd-20231231.xsd#txmd_FixedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_FixedAssetsAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="txmd_LicensedRightsandOtherIntangibleAssetsDetailsTable" xlink:href="txmd-20231231.xsd#txmd_LicensedRightsandOtherIntangibleAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems" xlink:to="txmd_LicensedRightsandOtherIntangibleAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_LicensedRightsandOtherIntangibleAssetsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_AdvertisingExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/DebtDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_CommitmentsandContingenciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="txmd_CommitmentsandContingenciesDetailsTable" xlink:href="txmd-20231231.xsd#txmd_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="txmd_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_LegalProceedingAxis" xlink:href="txmd-20231231.xsd#txmd_LegalProceedingAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_CommitmentsandContingenciesDetailsTable" xlink:to="txmd_LegalProceedingAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_LegalProceedingDomainDomain" xlink:href="txmd-20231231.xsd#txmd_LegalProceedingDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="txmd_LegalProceedingAxis" xlink:to="txmd_LegalProceedingDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_LegalProceedingDomainDomain_0" xlink:href="txmd-20231231.xsd#txmd_LegalProceedingDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="txmd_LegalProceedingAxis" xlink:to="txmd_LegalProceedingDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_CommitmentsandContingenciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_CommitmentsandContingenciesDetailsTable" xlink:to="srt_RangeAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MaynePharmaAgreementMember" xlink:href="txmd-20231231.xsd#txmd_MaynePharmaAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="txmd_MaynePharmaAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_PopulationCouncilLicenseAgreementMember" xlink:href="txmd-20231231.xsd#txmd_PopulationCouncilLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="txmd_PopulationCouncilLicenseAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_ParagraphFourCertificationNoticeLetterMember" xlink:href="txmd-20231231.xsd#txmd_ParagraphFourCertificationNoticeLetterMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_LegalProceedingDomainDomain" xlink:to="txmd_ParagraphFourCertificationNoticeLetterMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_AnnoverasMember" xlink:href="txmd-20231231.xsd#txmd_AnnoverasMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="txmd_AnnoverasMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_AreaOfLand" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_LeaseConsecutivePeriods" xlink:href="txmd-20231231.xsd#txmd_LeaseConsecutivePeriods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="txmd_LeaseConsecutivePeriods" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RentalIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RentalIncomeNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RentalIncomeNonoperating" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_CashReceivedForNetWorkingCapital" xlink:href="txmd-20231231.xsd#txmd_CashReceivedForNetWorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="txmd_CashReceivedForNetWorkingCapital" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_IncrementalAccrualForNetWorkingCapital" xlink:href="txmd-20231231.xsd#txmd_IncrementalAccrualForNetWorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="txmd_IncrementalAccrualForNetWorkingCapital" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_WorkingCapitalAmounts" xlink:href="txmd-20231231.xsd#txmd_WorkingCapitalAmounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="txmd_WorkingCapitalAmounts" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MilestonePayment" xlink:href="txmd-20231231.xsd#txmd_MilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="txmd_MilestonePayment" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DirectTaxesAndLicensesCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DirectTaxesAndLicensesCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_DirectTaxesAndLicensesCosts" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MilestonePaymentsRecordedAsLicenseRights" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsRecordedAsLicenseRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="txmd_MilestonePaymentsRecordedAsLicenseRights" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LegalFees" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SeveranceCosts1" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails">
    <loc xlink:type="locator" xlink:label="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="txmd_StockholdersEquityDeficitDetailsTable" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:to="txmd_StockholdersEquityDeficitDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_StockholdersEquityDeficitDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_StockholdersEquityDeficitDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_StockholdersEquityDeficitDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_TwoThousandNineteenStockIncentivePlanMember" xlink:href="txmd-20231231.xsd#txmd_TwoThousandNineteenStockIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="txmd_TwoThousandNineteenStockIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PhantomShareUnitsPSUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PhantomShareUnitsPSUsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/RevenueDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="txmd_RevenueDetailsTable" xlink:href="txmd-20231231.xsd#txmd_RevenueDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="txmd_RevenueDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_RevenueDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_RevenueDetailsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MayneLicenseAgreementMember" xlink:href="txmd-20231231.xsd#txmd_MayneLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="txmd_MayneLicenseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MilestonePaymentsOneMember" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="txmd_MilestonePaymentsOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MilestonePaymentsTwoMember" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="txmd_MilestonePaymentsTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MilestonePaymentsThreeMember" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="txmd_MilestonePaymentsThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyRateOneMember" xlink:href="txmd-20231231.xsd#txmd_RoyaltyRateOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="txmd_RoyaltyRateOneMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyRateTwoMember" xlink:href="txmd-20231231.xsd#txmd_RoyaltyRateTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="txmd_RoyaltyRateTwoMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_OneTimeMilestonePayments" xlink:href="txmd-20231231.xsd#txmd_OneTimeMilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="txmd_OneTimeMilestonePayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" xlink:href="txmd-20231231.xsd#txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyRateAsPercentageOnNetSales" xlink:href="txmd-20231231.xsd#txmd_RoyaltyRateAsPercentageOnNetSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="txmd_RoyaltyRateAsPercentageOnNetSales" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate" xlink:href="txmd-20231231.xsd#txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_TermOfRoyaltyPayments" xlink:href="txmd-20231231.xsd#txmd_TermOfRoyaltyPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="txmd_TermOfRoyaltyPayments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_DecreaseInRoyaltyRateOnProductByProductBasis" xlink:href="txmd-20231231.xsd#txmd_DecreaseInRoyaltyRateOnProductByProductBasis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="txmd_DecreaseInRoyaltyRateOnProductByProductBasis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MinimumAnnualRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_MinimumAnnualRoyaltyPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="txmd_MinimumAnnualRoyaltyPayment" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_PeriodOfMinimumAnnualRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_PeriodOfMinimumAnnualRoyaltyPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="txmd_PeriodOfMinimumAnnualRoyaltyPayment" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_LicenseRevenue" xlink:href="txmd-20231231.xsd#txmd_LicenseRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="txmd_LicenseRevenue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RoyaltyIncomeNonoperating" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <loc xlink:type="locator" xlink:label="txmd_IncomeTaxesDetailsTable" xlink:href="txmd-20231231.xsd#txmd_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="txmd_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_IncomeTaxesDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_ExpirationPeriod20YearsMember" xlink:href="txmd-20231231.xsd#txmd_ExpirationPeriod20YearsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="txmd_ExpirationPeriod20YearsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_ExpirationPeriodIndefiniteMember" xlink:href="txmd-20231231.xsd#txmd_ExpirationPeriodIndefiniteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="txmd_ExpirationPeriodIndefiniteMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_NetOperatingLossCarryforwardsTerm" xlink:href="txmd-20231231.xsd#txmd_NetOperatingLossCarryforwardsTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="txmd_NetOperatingLossCarryforwardsTerm" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_PercentageOfFutureTaxableIncome" xlink:href="txmd-20231231.xsd#txmd_PercentageOfFutureTaxableIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="txmd_PercentageOfFutureTaxableIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/RelatedpartiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="txmd_RelatedpartiesDetailsTable" xlink:href="txmd-20231231.xsd#txmd_RelatedpartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="txmd_RelatedpartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_RelatedpartiesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_RelatedpartiesDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_RelatedpartiesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_SubscriptionAgreementMember" xlink:href="txmd-20231231.xsd#txmd_SubscriptionAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="txmd_SubscriptionAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_RubricCapitalManagementLPMember" xlink:href="txmd-20231231.xsd#txmd_RubricCapitalManagementLPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="txmd_RubricCapitalManagementLPMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails">
    <loc xlink:type="locator" xlink:label="txmd_BusinessConcentrationsDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_BusinessConcentrationsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="txmd_BusinessConcentrationsDetailsTable" xlink:href="txmd-20231231.xsd#txmd_BusinessConcentrationsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="txmd_BusinessConcentrationsDetailsLineItems" xlink:to="txmd_BusinessConcentrationsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="txmd_BusinessConcentrationsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_TheramexMember" xlink:href="txmd-20231231.xsd#txmd_TheramexMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="txmd_TheramexMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_MaynePharmaMember" xlink:href="txmd-20231231.xsd#txmd_MaynePharmaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="txmd_MaynePharmaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_CustomerLicenseRevenuePercentage" xlink:href="txmd-20231231.xsd#txmd_CustomerLicenseRevenuePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessConcentrationsDetailsLineItems" xlink:to="txmd_CustomerLicenseRevenuePercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyReceivableShortTermPortion" xlink:href="txmd-20231231.xsd#txmd_RoyaltyReceivableShortTermPortion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessConcentrationsDetailsLineItems" xlink:to="txmd_RoyaltyReceivableShortTermPortion" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyReceivableLongTermPortion" xlink:href="txmd-20231231.xsd#txmd_RoyaltyReceivableLongTermPortion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="txmd_BusinessConcentrationsDetailsLineItems" xlink:to="txmd_RoyaltyReceivableLongTermPortion" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_Liabilities" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="39" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>txmd-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 29 20:06:18 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Income (loss) from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (loss), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (loss) from continuing operations before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">United States</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Net income (loss) from continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl0" xml:lang="en-US">Net income (loss) from continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl1" xml:lang="en-US">Net income (loss) from continuing operations (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net income (loss) (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net income (loss) per common share, basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net income (loss) per common share, diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive income (loss):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Total adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash provided by (used in) continuing operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in continuing investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash provided by (used in) continuing financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_lbl" xml:lang="en-US">Net cash provided by (used in) discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and restricted cash - continuing operations, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_lbl" xml:lang="en-US">Cash and restricted cash - discontinued operations, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Total cash and restricted cash, end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US">Restructuring Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Discontinued Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" xml:lang="en-US">Gross profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet_lbl" xml:lang="en-US">Total other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">Net income (loss) from discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl0" xml:lang="en-US">Income (loss) from discontinued operations, net of income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl1" xml:lang="en-US">Less: Income (loss) from discontinued operations, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl2" xml:lang="en-US">Net income (loss) from discontinued operations (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xml:lang="en-US">Disposal Group Classification [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xml:lang="en-US">Disposal Group Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Prepaid and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Schedule of Prepaid and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract" xlink:to="txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_FixedAssetsAbstract" xlink:href="txmd-20231231.xsd#txmd_FixedAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FixedAssetsAbstract_lbl" xml:lang="en-US">Fixed Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FixedAssetsAbstract" xlink:to="txmd_FixedAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfFixedAssetsNetAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfFixedAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfFixedAssetsNetAbstract_lbl" xml:lang="en-US">Schedule of Fixed Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfFixedAssetsNetAbstract" xlink:to="txmd_ScheduleOfFixedAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Fixed assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Licensed Rights and Other Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfLicenseRightsAndOtherIntangibleAssetsNetAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfLicenseRightsAndOtherIntangibleAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfLicenseRightsAndOtherIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Schedule of License Rights and Other Intangible Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfLicenseRightsAndOtherIntangibleAssetsNetAbstract" xlink:to="txmd_ScheduleOfLicenseRightsAndOtherIntangibleAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract_lbl" xml:lang="en-US">Schedule of Intangible Assets Subject To Amortization [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:to="txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Other Accrued Expenses and Other Current Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="txmd-20231231.xsd#txmd_AccruedExpensesAndOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="txmd_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="txmd_AccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Remaining Lease Payments [Abstarct]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Present value of lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Schedule of Other Information Related to Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfOutstandingAndExercisableWarrantsAndRelatedTransactionsAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfOutstandingAndExercisableWarrantsAndRelatedTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfOutstandingAndExercisableWarrantsAndRelatedTransactionsAbstract_lbl" xml:lang="en-US">Schedule of Outstanding and Exercisable Warrants and Related Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfOutstandingAndExercisableWarrantsAndRelatedTransactionsAbstract" xlink:to="txmd_ScheduleOfOutstandingAndExercisableWarrantsAndRelatedTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants_lbl" xml:lang="en-US">Beginning balance, Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants_lbl0" xml:lang="en-US">Ending balance, Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Beginning balance, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Ending balance, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue_lbl" xml:lang="en-US">Warrants, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue_lbl0" xml:lang="en-US">Warrants, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfStockOptionsActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfStockOptionsActivityAbstract_lbl" xml:lang="en-US">Schedule of Stock Options Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfStockOptionsActivityAbstract" xlink:to="txmd_ScheduleOfStockOptionsActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options awards outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Options awards outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options awards outstanding, weighted average exercise price, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Options awards outstanding, weighted average exercise price, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options awards outstanding, aggregate intrinsic value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Options awards outstanding, aggregate intrinsic value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options awards exercisable, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Options awards exercisable, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options awards exercisable, weighted average exercise price, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Options awards exercisable, weighted average exercise price, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Options awards exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Options awards exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfTheStatusOfOurUnvestedAndRelatedTransactionsAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfTheStatusOfOurUnvestedAndRelatedTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfTheStatusOfOurUnvestedAndRelatedTransactionsAbstract_lbl" xml:lang="en-US">Schedule of the Status of our Unvested and Related Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfTheStatusOfOurUnvestedAndRelatedTransactionsAbstract" xlink:to="txmd_ScheduleOfTheStatusOfOurUnvestedAndRelatedTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Unvested, Beginning balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Unvested Ending balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xml:lang="en-US">Revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfIncomeLossFromContinuingOperationsBeforeIncomeTaxesAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfIncomeLossFromContinuingOperationsBeforeIncomeTaxesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfIncomeLossFromContinuingOperationsBeforeIncomeTaxesAbstract_lbl" xml:lang="en-US">Schedule of Income (Loss) from Continuing Operations Before Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfIncomeLossFromContinuingOperationsBeforeIncomeTaxesAbstract" xlink:to="txmd_ScheduleOfIncomeLossFromContinuingOperationsBeforeIncomeTaxesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract_lbl" xml:lang="en-US">Schedule of Components of Net Deferred Income Tax Asset [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract" xlink:to="txmd_ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Income (loss) per common share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Business Concentrations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyReceivableCurrentPortion" xlink:href="txmd-20231231.xsd#txmd_RoyaltyReceivableCurrentPortion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_RoyaltyReceivableCurrentPortion_lbl" xml:lang="en-US">Royalty receivable, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyReceivableCurrentPortion" xlink:to="txmd_RoyaltyReceivableCurrentPortion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Current assets of discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">License rights and other intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyReceivableLongTerm" xlink:href="txmd-20231231.xsd#txmd_RoyaltyReceivableLongTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_RoyaltyReceivableLongTerm_lbl" xml:lang="en-US">Royalty receivable, long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyReceivableLongTerm" xlink:to="txmd_RoyaltyReceivableLongTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Current liabilities of discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 8)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity (deficit):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.001; 32,000 and 12,000 shares authorized, 11,532 and 9,498 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share | $ / shares (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Par value per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Number of authorized shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common stock shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue, net:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenue, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative operating support expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation &amp; amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US">Restructuring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestructuringCharges_lbl0" xml:lang="en-US">Total restructuring expenses - general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Income (loss) per common share, basic:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl0" xml:lang="en-US">Income (loss) per common share, continuing operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Continuing operations (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl0" xml:lang="en-US">Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xml:lang="en-US">Discontinued operations, net (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl0" xml:lang="en-US">Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xml:lang="en-US">Income (loss) per common share, diluted:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl0" xml:lang="en-US">Income (loss) per common share, discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Continuing operations (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl0" xml:lang="en-US">Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xml:lang="en-US">Discontinued operations, net (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl0" xml:lang="en-US">Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares, basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted average common shares for basic income (loss) per common share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares, diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted average common shares for diluted income (loss) per common share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_UnlabeledAbstract" xlink:href="txmd-20231231.xsd#txmd_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnlabeledAbstract" xlink:to="txmd_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued for sale of common stock, net of cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued for sale of common stock, net of cost (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants" xlink:href="txmd-20231231.xsd#txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants_lbl" xml:lang="en-US">Lender warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants" xlink:to="txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US">Rounding for fractional shares in connection with the reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Rounding for fractional shares in connection with the reverse stock split (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Shares issued for vested restricted and performance stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Shares issued for vested restricted and performance stock units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Shares issued for sale of common stock related to employee stock purchase plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Shares issued for sale of common stock related to employee stock purchase plan (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Share-based payment award compensation costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Shares issued for vested restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Shares issued for vested restricted stock units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued for sale of common stock related to private placement sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued for sale of common stock related to private placement sale (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by (used in) continuing operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_WriteoffOfPatentAndTrademark" xlink:href="txmd-20231231.xsd#txmd_WriteoffOfPatentAndTrademark"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_WriteoffOfPatentAndTrademark_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WriteoffOfPatentAndTrademark" xlink:to="txmd_WriteoffOfPatentAndTrademark_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based payment compensation costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Other non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from continuing investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from continuing financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net of costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan" xlink:href="txmd-20231231.xsd#txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Proceeds from sale of common stock related to employee stock purchase plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan" xlink:to="txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from Series A Preferred Stock, net of transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_lbl" xml:lang="en-US">Proceeds from make-whole derivative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:to="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" xml:lang="en-US">Discontinued operations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Net cash provided by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of noncash financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsIssuedInRelationToDebtFinancingAgreement" xlink:href="txmd-20231231.xsd#txmd_WarrantsIssuedInRelationToDebtFinancingAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_WarrantsIssuedInRelationToDebtFinancingAgreement_lbl" xml:lang="en-US">Warrants issued in relation to debt financing agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedInRelationToDebtFinancingAgreement" xlink:to="txmd_WarrantsIssuedInRelationToDebtFinancingAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_MiscellaneousIncomeexpense" xlink:href="txmd-20231231.xsd#txmd_MiscellaneousIncomeexpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="txmd_MiscellaneousIncomeexpense_lbl" xml:lang="en-US">Miscellaneous income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MiscellaneousIncomeexpense" xlink:to="txmd_MiscellaneousIncomeexpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Benefit (provision) for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">(Benefit) provision for income taxes (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_MakeWholePaymentAccretion" xlink:href="txmd-20231231.xsd#txmd_MakeWholePaymentAccretion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="txmd_MakeWholePaymentAccretion_lbl" xml:lang="en-US">Make-whole payment accretion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MakeWholePaymentAccretion" xlink:to="txmd_MakeWholePaymentAccretion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Receipts (payment) for patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Repurchase of Preferred Stock at liquidation preference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_lbl" xml:lang="en-US">Repayment of make-whole derivative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:to="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payment of debt financing fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License and service revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Business, basis of presentation, new accounting standards and summary of significant accounting policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xml:lang="en-US">Summary of Restructuring Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_UnlabeledAbstract0" xlink:href="txmd-20231231.xsd#txmd_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnlabeledAbstract0" xlink:to="txmd_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges_lbl" xml:lang="en-US">Total restructuring expenses - discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges_lbl0" xml:lang="en-US">Restructuring charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock_lbl" xml:lang="en-US">Schedule of Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock" xlink:to="txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Product revenue, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing_lbl" xml:lang="en-US">Selling and marketing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_lbl" xml:lang="en-US">Loss from discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract_lbl" xml:lang="en-US">Other income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness_lbl" xml:lang="en-US">Gain on sale of vitaCare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale_lbl" xml:lang="en-US">Gain on ANNOVERA sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on the extinguishment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Loss on disposal of assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_lbl" xml:lang="en-US">Other expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes_lbl" xml:lang="en-US">Loss before from income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">Schedule of Classes of Liabilities of Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">Prepaid and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcquisitionCostsCumulative" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquisitionCostsCumulative"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcquisitionCostsCumulative_lbl" xml:lang="en-US">Capitalized legal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquisitionCostsCumulative" xlink:to="us-gaap_AcquisitionCostsCumulative_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Fixed Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Licensed rights and other intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of License Rights and Other Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_IntangibleAssetsSubjectToAmortizationAbstract" xlink:href="txmd-20231231.xsd#txmd_IntangibleAssetsSubjectToAmortizationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_IntangibleAssetsSubjectToAmortizationAbstract_lbl" xml:lang="en-US">Intangible assets subject to amortization:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IntangibleAssetsSubjectToAmortizationAbstract" xlink:to="txmd_IntangibleAssetsSubjectToAmortizationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_IntangibleAssetsNotSubjectToAmortizationAbstract" xlink:href="txmd-20231231.xsd#txmd_IntangibleAssetsNotSubjectToAmortizationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_IntangibleAssetsNotSubjectToAmortizationAbstract_lbl" xml:lang="en-US">Intangible assets not subject to amortization:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IntangibleAssetsNotSubjectToAmortizationAbstract" xlink:to="txmd_IntangibleAssetsNotSubjectToAmortizationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets Subject To Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Accrued Expenses and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Payroll and related costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_AccruedContractTerminationCosts" xlink:href="txmd-20231231.xsd#txmd_AccruedContractTerminationCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_AccruedContractTerminationCosts_lbl" xml:lang="en-US">Accrued contract termination costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedContractTerminationCosts" xlink:to="txmd_AccruedContractTerminationCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_AccruedResearchAndDevelopmentExpenses" xlink:href="txmd-20231231.xsd#txmd_AccruedResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedResearchAndDevelopmentExpenses" xlink:to="txmd_AccruedResearchAndDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating lease liabilities current (included in accrued expenses and other current liabilities)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_AccruedPrepaidRoyalty" xlink:href="txmd-20231231.xsd#txmd_AccruedPrepaidRoyalty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_AccruedPrepaidRoyalty_lbl" xml:lang="en-US">Prepaid royalty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedPrepaidRoyalty" xlink:to="txmd_AccruedPrepaidRoyalty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses and current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Remaining Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_UnlabeledAbstract1" xlink:href="txmd-20231231.xsd#txmd_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnlabeledAbstract1" xlink:to="txmd_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Information Related to Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining term (years) - operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate - operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities from operating lease (in thousands)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease obligations (non-cash in thousands)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfWarrantRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Outstanding and Exercisable Warrants and Related Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:to="txmd_ScheduleOfWarrantRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US">Warrants, Weighted Average Remaining Contractual Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted_lbl" xml:lang="en-US">Granted, Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted_lbl" xml:lang="en-US">Granted, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired_lbl" xml:lang="en-US">Expired, Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired_lbl" xml:lang="en-US">Expired, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US">Warrants, Weighted Average Remaining Contractual Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised_lbl" xml:lang="en-US">Exercised, Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised_lbl" xml:lang="en-US">Exercised, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised_lbl" xml:lang="en-US">Exercised, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Options Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options awards outstanding, Weighted Average Remaining Contractual Life (in Years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options awards exercisable, Weighted Average Remaining Contractual Life (in Years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options awards outstanding Weighted Average Exercise Price, Cancelled/Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options awards outstanding Weighted Average Exercise Price, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:href="txmd-20231231.xsd#txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl" xml:lang="en-US">Options awards outstanding, Weighted Average Remaining Contractual Life (in Years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:to="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of the Status of our Unvested and Related Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Unvested, Granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Cancelled/Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant Date Fair Value, Cancelled/Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Cancelled/Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of Income (Loss) from Continuing Operations Before Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory tax rate (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory tax rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal tax benefit (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal tax benefit, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Adjustment in valuation allowances (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US">Excess stock benefits (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US">Excess stock benefits, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars" xlink:href="txmd-20231231.xsd#txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars_lbl" xml:lang="en-US">Interest expense accretion (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars" xlink:to="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars" xlink:href="txmd-20231231.xsd#txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars_lbl" xml:lang="en-US">Interest expense accretion, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars" xlink:to="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent and other differences (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent and other differences, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_EffectiveIncomeTaxRateDiscontinuedOperations" xlink:href="txmd-20231231.xsd#txmd_EffectiveIncomeTaxRateDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="txmd_EffectiveIncomeTaxRateDiscontinuedOperations_lbl" xml:lang="en-US">(Benefit) provision for income taxes, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectiveIncomeTaxRateDiscontinuedOperations" xlink:to="txmd_EffectiveIncomeTaxRateDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Net Deferred Income Tax Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:href="txmd-20231231.xsd#txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred income tax assets (liabilities):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Share-based payment compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xml:lang="en-US">Interest expense limitation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty" xlink:href="txmd-20231231.xsd#txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty_lbl" xml:lang="en-US">Gain on sale of ANNOVERA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty" xlink:to="txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xml:lang="en-US">Accrual for sales returns and coupons</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DeferredTaxAssetsLiabilitiesGross" xlink:href="txmd-20231231.xsd#txmd_DeferredTaxAssetsLiabilitiesGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DeferredTaxAssetsLiabilitiesGross_lbl" xml:lang="en-US">Deferred income tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredTaxAssetsLiabilitiesGross" xlink:to="txmd_DeferredTaxAssetsLiabilitiesGross_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance" xlink:href="txmd-20231231.xsd#txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance" xlink:to="txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred income tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Income (Loss) Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Summary of Computation of Basic and Diluted Income (Loss) Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US">Effect of dilutive securities (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_UnlabeledAbstract2" xlink:href="txmd-20231231.xsd#txmd_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnlabeledAbstract2" xlink:to="txmd_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Outstanding Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">Business Concentrations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts_lbl" xml:lang="en-US">Interest expense and other financing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock_lbl" xml:lang="en-US">Expense for accretion of Series A Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_lbl" xml:lang="en-US">Benefit (provision) for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options awards outstanding, Cancelled/Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Options awards outstanding, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Unvested, Vested (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Unvested, Cancelled/Forfeited (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Adjustment in valuation allowances, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ExecutiveTerminationBenefitsMember" xlink:href="txmd-20231231.xsd#txmd_ExecutiveTerminationBenefitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_ExecutiveTerminationBenefitsMember_lbl" xml:lang="en-US">Executive Termination Benefits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExecutiveTerminationBenefitsMember" xlink:to="txmd_ExecutiveTerminationBenefitsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ConsultingAndLegalExpensesMember" xlink:href="txmd-20231231.xsd#txmd_ConsultingAndLegalExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_ConsultingAndLegalExpensesMember_lbl" xml:lang="en-US">Consulting And Legal Expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ConsultingAndLegalExpensesMember" xlink:to="txmd_ConsultingAndLegalExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_OtherContractTerminationCostsMember" xlink:href="txmd-20231231.xsd#txmd_OtherContractTerminationCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_OtherContractTerminationCostsMember_lbl" xml:lang="en-US">Other Contract Termination Costs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OtherContractTerminationCostsMember" xlink:to="txmd_OtherContractTerminationCostsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_EmployeeTerminationBenefitsMember" xlink:href="txmd-20231231.xsd#txmd_EmployeeTerminationBenefitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_EmployeeTerminationBenefitsMember_lbl" xml:lang="en-US">Employee Termination Benefits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EmployeeTerminationBenefitsMember" xlink:to="txmd_EmployeeTerminationBenefitsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_lbl" xml:lang="en-US">Discontinued Operations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_AnnoverasMember" xlink:href="txmd-20231231.xsd#txmd_AnnoverasMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_AnnoverasMember_lbl" xml:lang="en-US">Annoveras [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnoverasMember" xlink:to="txmd_AnnoverasMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer and office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Computer software	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl0" xml:lang="en-US">Software and Software Development Costs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_HormoneTherapyDrugPatentsMember" xlink:href="txmd-20231231.xsd#txmd_HormoneTherapyDrugPatentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_HormoneTherapyDrugPatentsMember_lbl" xml:lang="en-US">Hormone Therapy Drug Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugPatentsMember" xlink:to="txmd_HormoneTherapyDrugPatentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember" xlink:href="txmd-20231231.xsd#txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember_lbl" xml:lang="en-US">Hormone therapy drug patents applied and pending approval [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember" xlink:to="txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_IntangibleAssetsSubjectToAmortizationMember" xlink:href="txmd-20231231.xsd#txmd_IntangibleAssetsSubjectToAmortizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_IntangibleAssetsSubjectToAmortizationMember_lbl" xml:lang="en-US">Intangible Assets Subject to Amortization [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IntangibleAssetsSubjectToAmortizationMember" xlink:to="txmd_IntangibleAssetsSubjectToAmortizationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TrademarksAndTradeNamesMember_lbl" xml:lang="en-US">Trademarks and Trade Names [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksAndTradeNamesMember" xlink:to="us-gaap_TrademarksAndTradeNamesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl0" xml:lang="en-US">PSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_StockOptionsMember" xlink:href="txmd-20231231.xsd#txmd_StockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_StockOptionsMember_lbl" xml:lang="en-US">Stock options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockOptionsMember" xlink:to="txmd_StockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xml:lang="en-US">Contingent Consideration by Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Balance Sheet Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US">Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_LegalProceedingAxis" xlink:href="txmd-20231231.xsd#txmd_LegalProceedingAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_LegalProceedingAxis_lbl" xml:lang="en-US">Legal Proceeding [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LegalProceedingAxis" xlink:to="txmd_LegalProceedingAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_OneTimeMilestonePayments" xlink:href="txmd-20231231.xsd#txmd_OneTimeMilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_OneTimeMilestonePayments_lbl" xml:lang="en-US">One-time milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OneTimeMilestonePayments" xlink:to="txmd_OneTimeMilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" xlink:href="txmd-20231231.xsd#txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment_lbl" xml:lang="en-US">Threshold net sales amount to determine one-time milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" xlink:to="txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyRateAsPercentageOnNetSales" xlink:href="txmd-20231231.xsd#txmd_RoyaltyRateAsPercentageOnNetSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_RoyaltyRateAsPercentageOnNetSales_lbl" xml:lang="en-US">Royalty rate as percentage on net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyRateAsPercentageOnNetSales" xlink:to="txmd_RoyaltyRateAsPercentageOnNetSales_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate" xlink:href="txmd-20231231.xsd#txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate_lbl" xml:lang="en-US">Threshold annual net sales to determine royalty rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate" xlink:to="txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_TermOfRoyaltyPayments" xlink:href="txmd-20231231.xsd#txmd_TermOfRoyaltyPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_TermOfRoyaltyPayments_lbl" xml:lang="en-US">Period of royalty payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TermOfRoyaltyPayments" xlink:to="txmd_TermOfRoyaltyPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_TermOfRoyaltyPayments_lbl0" xml:lang="en-US">Period of minimal annual royalty payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TermOfRoyaltyPayments" xlink:to="txmd_TermOfRoyaltyPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_DecreaseInRoyaltyRateOnProductByProductBasis" xlink:href="txmd-20231231.xsd#txmd_DecreaseInRoyaltyRateOnProductByProductBasis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DecreaseInRoyaltyRateOnProductByProductBasis_lbl" xml:lang="en-US">Decrease in royalty rate on product-by-product basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DecreaseInRoyaltyRateOnProductByProductBasis" xlink:to="txmd_DecreaseInRoyaltyRateOnProductByProductBasis_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_MinimumAnnualRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_MinimumAnnualRoyaltyPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_MinimumAnnualRoyaltyPayment_lbl" xml:lang="en-US">Minimal annual royalty payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumAnnualRoyaltyPayment" xlink:to="txmd_MinimumAnnualRoyaltyPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_PeriodOfMinimumAnnualRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_PeriodOfMinimumAnnualRoyaltyPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_PeriodOfMinimumAnnualRoyaltyPayment_lbl" xml:lang="en-US">Period of minimal annual royalty payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PeriodOfMinimumAnnualRoyaltyPayment" xlink:to="txmd_PeriodOfMinimumAnnualRoyaltyPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment_lbl" xml:lang="en-US">Inflation rate adjusted for minimal annual royalty payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment" xlink:to="txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment" xlink:href="txmd-20231231.xsd#txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment_lbl" xml:lang="en-US">General</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment" xlink:to="txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_PaymentsToAcquireNetWorkingCapital" xlink:href="txmd-20231231.xsd#txmd_PaymentsToAcquireNetWorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_PaymentsToAcquireNetWorkingCapital_lbl" xml:lang="en-US">Acquisition of net working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaymentsToAcquireNetWorkingCapital" xlink:to="txmd_PaymentsToAcquireNetWorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived_lbl" xml:lang="en-US">Cash received for prepaid royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_PrepaidRoyaltyLiabilities" xlink:href="txmd-20231231.xsd#txmd_PrepaidRoyaltyLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_PrepaidRoyaltyLiabilities_lbl" xml:lang="en-US">Prepaid royalty liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidRoyaltyLiabilities" xlink:to="txmd_PrepaidRoyaltyLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_QuarterlyRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_QuarterlyRoyaltyPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_QuarterlyRoyaltyPayment_lbl" xml:lang="en-US">Quarterly royalty payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_QuarterlyRoyaltyPayment" xlink:to="txmd_QuarterlyRoyaltyPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_QuarterlyRoyaltyInterest" xlink:href="txmd-20231231.xsd#txmd_QuarterlyRoyaltyInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_QuarterlyRoyaltyInterest_lbl" xml:lang="en-US">Quarterly royalty payment, interest per annum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_QuarterlyRoyaltyInterest" xlink:to="txmd_QuarterlyRoyaltyInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement" xlink:href="txmd-20231231.xsd#txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement_lbl" xml:lang="en-US">Royalty payment payable under long term service agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement" xlink:to="txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_RoyaltyPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_RoyaltyPayment_lbl" xml:lang="en-US">Royalty payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPayment" xlink:to="txmd_RoyaltyPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_AdditionalFund" xlink:href="txmd-20231231.xsd#txmd_AdditionalFund"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_AdditionalFund_lbl" xml:lang="en-US">Additional fund</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalFund" xlink:to="txmd_AdditionalFund_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" xml:lang="en-US">Proceeds from sale of business, net of transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_TransactionCostsRelatedToDivestitureOfBusiness" xlink:href="txmd-20231231.xsd#txmd_TransactionCostsRelatedToDivestitureOfBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_TransactionCostsRelatedToDivestitureOfBusiness_lbl" xml:lang="en-US">Transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TransactionCostsRelatedToDivestitureOfBusiness" xlink:to="txmd_TransactionCostsRelatedToDivestitureOfBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xml:lang="en-US">Gain on sale of business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfBusiness" xlink:to="us-gaap_GainLossOnSaleOfBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ContingentCashConsiderationFromSaleOfBusiness" xlink:href="txmd-20231231.xsd#txmd_ContingentCashConsiderationFromSaleOfBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_ContingentCashConsiderationFromSaleOfBusiness_lbl" xml:lang="en-US">Contingent cash consideration from sale of business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ContingentCashConsiderationFromSaleOfBusiness" xlink:to="txmd_ContingentCashConsiderationFromSaleOfBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US">Cash received in acquire businesses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments" xlink:href="txmd-20231231.xsd#txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments_lbl" xml:lang="en-US">Proceeds from acquire businesses net of working capital adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments" xlink:to="txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares, Issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Preferred stock at a purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl0" xml:lang="en-US">Additional shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC insured amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful life of assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_WriteOffOfAsset" xlink:href="txmd-20231231.xsd#txmd_WriteOffOfAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_WriteOffOfAsset_lbl" xml:lang="en-US">Gain on intangible assets write off</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WriteOffOfAsset" xlink:to="txmd_WriteOffOfAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Payments to acquire businesses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments" xlink:href="txmd-20231231.xsd#txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments_lbl" xml:lang="en-US">Additional milestone payments to be received on achievement of sales milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments" xlink:to="txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_AggregateMinimumAnnualRoyaltyPaymentsDue" xlink:href="txmd-20231231.xsd#txmd_AggregateMinimumAnnualRoyaltyPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_AggregateMinimumAnnualRoyaltyPaymentsDue_lbl" xml:lang="en-US">Aggregate minimum annual royalty Payments due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AggregateMinimumAnnualRoyaltyPaymentsDue" xlink:to="txmd_AggregateMinimumAnnualRoyaltyPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate" xlink:href="txmd-20231231.xsd#txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate_lbl" xml:lang="en-US">Present value of annual minimum royalty discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate" xlink:to="txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">License sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0" xml:lang="en-US">License sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_LicenseRevenue" xlink:href="txmd-20231231.xsd#txmd_LicenseRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_LicenseRevenue_lbl" xml:lang="en-US">License revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseRevenue" xlink:to="txmd_LicenseRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyIncomeNonoperating_lbl" xml:lang="en-US">Royalty sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyIncomeNonoperating" xlink:to="us-gaap_RoyaltyIncomeNonoperating_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositContractsAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositContractsAssets_lbl" xml:lang="en-US">Contract assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsAssets" xlink:to="us-gaap_DepositContractsAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xml:lang="en-US">Loss contingency accrual</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_NumberOfEmployeesAfterWorkforceReduction" xlink:href="txmd-20231231.xsd#txmd_NumberOfEmployeesAfterWorkforceReduction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_NumberOfEmployeesAfterWorkforceReduction_lbl" xml:lang="en-US">Employees after workforce reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfEmployeesAfterWorkforceReduction" xlink:to="txmd_NumberOfEmployeesAfterWorkforceReduction_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_RestructuringChargesIncludingDiscontinuedOperations" xlink:href="txmd-20231231.xsd#txmd_RestructuringChargesIncludingDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_RestructuringChargesIncludingDiscontinuedOperations_lbl" xml:lang="en-US">Restructuring charges including discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RestructuringChargesIncludingDiscontinuedOperations" xlink:to="txmd_RestructuringChargesIncludingDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US">Restructuring costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived_lbl" xml:lang="en-US">Cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments_lbl" xml:lang="en-US">Net working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties_lbl" xml:lang="en-US">Prepaid royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Deb interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl" xml:lang="en-US">Financing fees amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Rentable square feet (in Square Meters)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease expiry year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Lease extend term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_LeaseConsecutivePeriods" xlink:href="txmd-20231231.xsd#txmd_LeaseConsecutivePeriods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_LeaseConsecutivePeriods_lbl" xml:lang="en-US">Lease consecutive periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LeaseConsecutivePeriods" xlink:to="txmd_LeaseConsecutivePeriods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RentalIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RentalIncomeNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RentalIncomeNonoperating_lbl" xml:lang="en-US">Rental income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RentalIncomeNonoperating" xlink:to="us-gaap_RentalIncomeNonoperating_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_CashReceivedForNetWorkingCapital" xlink:href="txmd-20231231.xsd#txmd_CashReceivedForNetWorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_CashReceivedForNetWorkingCapital_lbl" xml:lang="en-US">Acquisition of net working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CashReceivedForNetWorkingCapital" xlink:to="txmd_CashReceivedForNetWorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_IncrementalAccrualForNetWorkingCapital" xlink:href="txmd-20231231.xsd#txmd_IncrementalAccrualForNetWorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_IncrementalAccrualForNetWorkingCapital_lbl" xml:lang="en-US">Incremental accrual for net working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IncrementalAccrualForNetWorkingCapital" xlink:to="txmd_IncrementalAccrualForNetWorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_WorkingCapitalAmounts" xlink:href="txmd-20231231.xsd#txmd_WorkingCapitalAmounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_WorkingCapitalAmounts_lbl" xml:lang="en-US">Working capital amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WorkingCapitalAmounts" xlink:to="txmd_WorkingCapitalAmounts_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_MilestonePayment" xlink:href="txmd-20231231.xsd#txmd_MilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePayment" xlink:to="txmd_MilestonePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DirectTaxesAndLicensesCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DirectTaxesAndLicensesCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DirectTaxesAndLicensesCosts_lbl" xml:lang="en-US">Commercial batch release amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectTaxesAndLicensesCosts" xlink:to="us-gaap_DirectTaxesAndLicensesCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_MilestonePaymentsRecordedAsLicenseRights" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsRecordedAsLicenseRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_MilestonePaymentsRecordedAsLicenseRights_lbl" xml:lang="en-US">Aggregate of milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsRecordedAsLicenseRights" xlink:to="txmd_MilestonePaymentsRecordedAsLicenseRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Executive termination obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" xml:lang="en-US">Common stock shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Percentage of volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Percentage of risk free interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Remaining shares of common stock available for future issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based payment arrangement, expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Total unrecognized share based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-based compensation over a weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Provision for income taxes continuing and discontinued operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss (&#8220;NOL&#8221;) carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_NetOperatingLossCarryforwardsTerm" xlink:href="txmd-20231231.xsd#txmd_NetOperatingLossCarryforwardsTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_NetOperatingLossCarryforwardsTerm_lbl" xml:lang="en-US">Carried forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetOperatingLossCarryforwardsTerm" xlink:to="txmd_NetOperatingLossCarryforwardsTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_PercentageOfFutureTaxableIncome" xlink:href="txmd-20231231.xsd#txmd_PercentageOfFutureTaxableIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_PercentageOfFutureTaxableIncome_lbl" xml:lang="en-US">Excess taxable income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PercentageOfFutureTaxableIncome" xlink:to="txmd_PercentageOfFutureTaxableIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xml:lang="en-US">Outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xml:lang="en-US">Preferred stock investor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_CustomerLicenseRevenuePercentage" xlink:href="txmd-20231231.xsd#txmd_CustomerLicenseRevenuePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_CustomerLicenseRevenuePercentage_lbl" xml:lang="en-US">Customer license revenue percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerLicenseRevenuePercentage" xlink:to="txmd_CustomerLicenseRevenuePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyReceivableShortTermPortion" xlink:href="txmd-20231231.xsd#txmd_RoyaltyReceivableShortTermPortion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_RoyaltyReceivableShortTermPortion_lbl" xml:lang="en-US">Royalty receivable short term portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyReceivableShortTermPortion" xlink:to="txmd_RoyaltyReceivableShortTermPortion_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyReceivableLongTermPortion" xlink:href="txmd-20231231.xsd#txmd_RoyaltyReceivableLongTermPortion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_RoyaltyReceivableLongTermPortion_lbl" xml:lang="en-US">Royalty receivable long term portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyReceivableLongTermPortion" xlink:to="txmd_RoyaltyReceivableLongTermPortion_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_GeneralInformationPolicyTextBlock" xlink:href="txmd-20231231.xsd#txmd_GeneralInformationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_GeneralInformationPolicyTextBlock_lbl" xml:lang="en-US">General</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GeneralInformationPolicyTextBlock" xlink:to="txmd_GeneralInformationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DivestitureOfBusinessPolicyPolicyTextBlock" xlink:href="txmd-20231231.xsd#txmd_DivestitureOfBusinessPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_DivestitureOfBusinessPolicyPolicyTextBlock_lbl" xml:lang="en-US">vitaCare Divestiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DivestitureOfBusinessPolicyPolicyTextBlock" xlink:to="txmd_DivestitureOfBusinessPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_GoingConcernPolicyTextBlock" xlink:href="txmd-20231231.xsd#txmd_GoingConcernPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_GoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GoingConcernPolicyTextBlock" xlink:to="txmd_GoingConcernPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New accounting standards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xml:lang="en-US">Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Estimates and assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed assets</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbcL4qf5LvDZDepCbNlW2HHdtTp8h/JBPAKml91Z9+QS2gjfdoyURiOQgrxFESWde/Q+Ash/YJdGlbG5QR3nEMXflGmqnNLFtFl1nIAPLFlMWnSI/b92PyAqBFuykXvgMcnlPm3rTC5y1gsY+iS9+gbk0SFpyt2CDowYCrPhIqMSfw/7Rr70FR8H9oR8eW+fUCTlfU8J42Qvg==] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">License rights and other intangibles assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based payment awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Loss Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_lbl" xml:lang="en-US">Restructuring charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification of prior year presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:href="txmd-20231231.xsd#txmd_ContractAssetsAndLiabilitiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_ContractAssetsAndLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Contract Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:to="txmd_ContractAssetsAndLiabilitiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_MilestonePaymentsOneMember" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_MilestonePaymentsOneMember_lbl" xml:lang="en-US">Milestone Payments One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsOneMember" xlink:to="txmd_MilestonePaymentsOneMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_MilestonePaymentsOneMember_lbl0" xml:lang="en-US">Milestone Payments 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsOneMember" xlink:to="txmd_MilestonePaymentsOneMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_MayneLicenseAgreementMember" xlink:href="txmd-20231231.xsd#txmd_MayneLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_MayneLicenseAgreementMember_lbl" xml:lang="en-US">Mayne License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MayneLicenseAgreementMember" xlink:to="txmd_MayneLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_MilestonePaymentsTwoMember" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_MilestonePaymentsTwoMember_lbl" xml:lang="en-US">Milestone Payments Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsTwoMember" xlink:to="txmd_MilestonePaymentsTwoMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_MilestonePaymentsTwoMember_lbl0" xml:lang="en-US">Milestone Payments 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsTwoMember" xlink:to="txmd_MilestonePaymentsTwoMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_MilestonePaymentsThreeMember" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_MilestonePaymentsThreeMember_lbl" xml:lang="en-US">Milestone Payments Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsThreeMember" xlink:to="txmd_MilestonePaymentsThreeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_MilestonePaymentsThreeMember_lbl0" xml:lang="en-US">Milestone Payments 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsThreeMember" xlink:to="txmd_MilestonePaymentsThreeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyRateOneMember" xlink:href="txmd-20231231.xsd#txmd_RoyaltyRateOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_RoyaltyRateOneMember_lbl" xml:lang="en-US">Royalty Rate One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyRateOneMember" xlink:to="txmd_RoyaltyRateOneMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_RoyaltyRateOneMember_lbl0" xml:lang="en-US">Royalty Rate 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyRateOneMember" xlink:to="txmd_RoyaltyRateOneMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_RoyaltyRateTwoMember" xlink:href="txmd-20231231.xsd#txmd_RoyaltyRateTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_RoyaltyRateTwoMember_lbl" xml:lang="en-US">Royalty Rate Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyRateTwoMember" xlink:to="txmd_RoyaltyRateTwoMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_RoyaltyRateTwoMember_lbl0" xml:lang="en-US">Royalty Rate 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyRateTwoMember" xlink:to="txmd_RoyaltyRateTwoMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_VitaCareDivestitureMember" xlink:href="txmd-20231231.xsd#txmd_VitaCareDivestitureMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_VitaCareDivestitureMember_lbl" xml:lang="en-US">Vita Care Divestiture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VitaCareDivestitureMember" xlink:to="txmd_VitaCareDivestitureMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_StockPurchaseAgreementMember" xlink:href="txmd-20231231.xsd#txmd_StockPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockPurchaseAgreementMember" xlink:to="txmd_StockPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_RubricCapitalManagementLPMember" xlink:href="txmd-20231231.xsd#txmd_RubricCapitalManagementLPMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_RubricCapitalManagementLPMember_lbl" xml:lang="en-US">Rubric Capital Management L P [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RubricCapitalManagementLPMember" xlink:to="txmd_RubricCapitalManagementLPMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandAndBuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandAndBuildingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandAndBuildingMember_lbl" xml:lang="en-US">Land and Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandAndBuildingMember" xlink:to="us-gaap_LandAndBuildingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xml:lang="en-US">Licensing Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyAgreementsMember_lbl" xml:lang="en-US">Royalty Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementsMember" xlink:to="us-gaap_RoyaltyAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_BijuvasMember" xlink:href="txmd-20231231.xsd#txmd_BijuvasMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_BijuvasMember_lbl" xml:lang="en-US">Bijuvas [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvasMember" xlink:to="txmd_BijuvasMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_TheramexLicenseAgreementsMember" xlink:href="txmd-20231231.xsd#txmd_TheramexLicenseAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_TheramexLicenseAgreementsMember_lbl" xml:lang="en-US">Theramex License Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TheramexLicenseAgreementsMember" xlink:to="txmd_TheramexLicenseAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:href="txmd-20231231.xsd#txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember_lbl" xml:lang="en-US">Accrued Expenses And Other Current Liabilities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:to="txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_CurrentLiabilitiesForDiscontinuedOperationsMember" xlink:href="txmd-20231231.xsd#txmd_CurrentLiabilitiesForDiscontinuedOperationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_CurrentLiabilitiesForDiscontinuedOperationsMember_lbl" xml:lang="en-US">Current Liabilities For Discontinued Operations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CurrentLiabilitiesForDiscontinuedOperationsMember" xlink:to="txmd_CurrentLiabilitiesForDiscontinuedOperationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_MaynePharmaAgreementMember" xlink:href="txmd-20231231.xsd#txmd_MaynePharmaAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_MaynePharmaAgreementMember_lbl" xml:lang="en-US">Mayne Pharma Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaynePharmaAgreementMember" xlink:to="txmd_MaynePharmaAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_PopulationCouncilLicenseAgreementMember" xlink:href="txmd-20231231.xsd#txmd_PopulationCouncilLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_PopulationCouncilLicenseAgreementMember_lbl" xml:lang="en-US">Population Council License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PopulationCouncilLicenseAgreementMember" xlink:to="txmd_PopulationCouncilLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ParagraphFourCertificationNoticeLetterMember" xlink:href="txmd-20231231.xsd#txmd_ParagraphFourCertificationNoticeLetterMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_ParagraphFourCertificationNoticeLetterMember_lbl" xml:lang="en-US">Paragraph Four Certification Notice Letter [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ParagraphFourCertificationNoticeLetterMember" xlink:to="txmd_ParagraphFourCertificationNoticeLetterMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PhantomShareUnitsPSUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PhantomShareUnitsPSUsMember_lbl" xml:lang="en-US">Phantom Share Units (PSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PhantomShareUnitsPSUsMember" xlink:to="us-gaap_PhantomShareUnitsPSUsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_TwoThousandNineteenStockIncentivePlanMember" xlink:href="txmd-20231231.xsd#txmd_TwoThousandNineteenStockIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_TwoThousandNineteenStockIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Nineteen Stock Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TwoThousandNineteenStockIncentivePlanMember" xlink:to="txmd_TwoThousandNineteenStockIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ExpirationPeriod20YearsMember" xlink:href="txmd-20231231.xsd#txmd_ExpirationPeriod20YearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_ExpirationPeriod20YearsMember_lbl" xml:lang="en-US">Expiration Period 20 Years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriod20YearsMember" xlink:to="txmd_ExpirationPeriod20YearsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_ExpirationPeriodIndefiniteMember" xlink:href="txmd-20231231.xsd#txmd_ExpirationPeriodIndefiniteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_ExpirationPeriodIndefiniteMember_lbl" xml:lang="en-US">Expiration Period Indefinite [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriodIndefiniteMember" xlink:to="txmd_ExpirationPeriodIndefiniteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_SubscriptionAgreementMember" xlink:href="txmd-20231231.xsd#txmd_SubscriptionAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_SubscriptionAgreementMember_lbl" xml:lang="en-US">Subscription Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SubscriptionAgreementMember" xlink:to="txmd_SubscriptionAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_TheramexMember" xlink:href="txmd-20231231.xsd#txmd_TheramexMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_TheramexMember_lbl" xml:lang="en-US">Theramex [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TheramexMember" xlink:to="txmd_TheramexMember_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_MaynePharmaMember" xlink:href="txmd-20231231.xsd#txmd_MaynePharmaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_MaynePharmaMember_lbl" xml:lang="en-US">Mayne Pharma [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaynePharmaMember" xlink:to="txmd_MaynePharmaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US">Type of Restructuring [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xml:lang="en-US">Disposal Group Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xml:lang="en-US">Disposal Group Classification [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupClassificationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable" xlink:href="txmd-20231231.xsd#txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable_lbl" xml:lang="en-US">Discontinued Operations (Details) - Schedule of Discontinued Operations [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable" xlink:to="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" xlink:href="txmd-20231231.xsd#txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems_lbl" xml:lang="en-US">Discontinued Operations (Details) - Schedule of Discontinued Operations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" xlink:to="txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable" xlink:href="txmd-20231231.xsd#txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable_lbl" xml:lang="en-US">Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable" xlink:to="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems" xlink:href="txmd-20231231.xsd#txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems_lbl" xml:lang="en-US">Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems" xlink:to="txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit) (Details) - Schedule of Outstanding and Exercisable Warrants and Related Transactions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable" xlink:to="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit) (Details) - Schedule of Outstanding and Exercisable Warrants and Related Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit) (Details) - Schedule of the Status of our Unvested and Related Transactions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable" xlink:to="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit) (Details) - Schedule of the Status of our Unvested and Related Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable" xlink:href="txmd-20231231.xsd#txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable_lbl" xml:lang="en-US">Income Taxes (Details) - Schedule of Income (Loss) from Continuing Operations Before Income Taxes [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable" xlink:to="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems" xlink:href="txmd-20231231.xsd#txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems_lbl" xml:lang="en-US">Income Taxes (Details) - Schedule of Income (Loss) from Continuing Operations Before Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems" xlink:to="txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable" xlink:href="txmd-20231231.xsd#txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable_lbl" xml:lang="en-US">Schedule of Computation of Basic and Diluted Income (Loss) Per Common Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable" xlink:to="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems" xlink:href="txmd-20231231.xsd#txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems_lbl" xml:lang="en-US">Schedule of Computation of Basic and Diluted Income (Loss) Per Common Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems" xlink:to="txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Outstanding Securities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Outstanding Securities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xml:lang="en-US">Contingent Consideration Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US">Balance Sheet Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="txmd-20231231.xsd#txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DiscontinuedOperationsDetailsTable" xlink:href="txmd-20231231.xsd#txmd_DiscontinuedOperationsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DiscontinuedOperationsDetailsTable_lbl" xml:lang="en-US">Discontinued Operations (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DiscontinuedOperationsDetailsTable" xlink:to="txmd_DiscontinuedOperationsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_DiscontinuedOperationsDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_DiscontinuedOperationsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DiscontinuedOperationsDetailsLineItems_lbl" xml:lang="en-US">Discontinued Operations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DiscontinuedOperationsDetailsLineItems" xlink:to="txmd_DiscontinuedOperationsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_LicensedRightsandOtherIntangibleAssetsDetailsTable" xlink:href="txmd-20231231.xsd#txmd_LicensedRightsandOtherIntangibleAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicensedRightsandOtherIntangibleAssetsDetailsTable_lbl" xml:lang="en-US">Licensed Rights and Other Intangible Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicensedRightsandOtherIntangibleAssetsDetailsTable" xlink:to="txmd_LicensedRightsandOtherIntangibleAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems_lbl" xml:lang="en-US">Licensed Rights and Other Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems" xlink:to="txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_lbl" xml:lang="en-US">Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_LegalProceedingDomainDomain" xlink:href="txmd-20231231.xsd#txmd_LegalProceedingDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LegalProceedingDomainDomain_lbl" xml:lang="en-US">LegalProceedingDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LegalProceedingDomainDomain" xlink:to="txmd_LegalProceedingDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_CommitmentsandContingenciesDetailsTable" xlink:href="txmd-20231231.xsd#txmd_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CommitmentsandContingenciesDetailsTable" xlink:to="txmd_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_CommitmentsandContingenciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CommitmentsandContingenciesDetailsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CommitmentsandContingenciesDetailsLineItems" xlink:to="txmd_CommitmentsandContingenciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_StockholdersEquityDeficitDetailsTable" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockholdersEquityDeficitDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit) (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockholdersEquityDeficitDetailsTable" xlink:to="txmd_StockholdersEquityDeficitDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockholdersEquityDeficitDetailsLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockholdersEquityDeficitDetailsLineItems" xlink:to="txmd_StockholdersEquityDeficitDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_RevenueDetailsTable" xlink:href="txmd-20231231.xsd#txmd_RevenueDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RevenueDetailsTable_lbl" xml:lang="en-US">Revenue (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RevenueDetailsTable" xlink:to="txmd_RevenueDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Revenue [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US">Tax Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_IncomeTaxesDetailsTable" xlink:href="txmd-20231231.xsd#txmd_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IncomeTaxesDetailsTable" xlink:to="txmd_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_IncomeTaxExaminationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_RelatedpartiesDetailsTable" xlink:href="txmd-20231231.xsd#txmd_RelatedpartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RelatedpartiesDetailsTable_lbl" xml:lang="en-US">Related parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RelatedpartiesDetailsTable" xlink:to="txmd_RelatedpartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_BusinessConcentrationsDetailsTable" xlink:href="txmd-20231231.xsd#txmd_BusinessConcentrationsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BusinessConcentrationsDetailsTable_lbl" xml:lang="en-US">Business Concentrations (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BusinessConcentrationsDetailsTable" xlink:to="txmd_BusinessConcentrationsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="txmd_BusinessConcentrationsDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_BusinessConcentrationsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BusinessConcentrationsDetailsLineItems_lbl" xml:lang="en-US">Business Concentrations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BusinessConcentrationsDetailsLineItems" xlink:to="txmd_BusinessConcentrationsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedContractTerminationCosts_lbl0" xml:lang="en-US">Accrued contract termination costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedContractTerminationCosts" xlink:to="txmd_AccruedContractTerminationCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedExpensesAndOtherCurrentLiabilities_lbl0" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="txmd_AccruedExpensesAndOtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedPrepaidRoyalty_lbl0" xml:lang="en-US">Accrued prepaid royalty.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedPrepaidRoyalty" xlink:to="txmd_AccruedPrepaidRoyalty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedResearchAndDevelopmentExpenses_lbl0" xml:lang="en-US">Accrued research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedResearchAndDevelopmentExpenses" xlink:to="txmd_AccruedResearchAndDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdditionalFund_lbl0" xml:lang="en-US">Amount of additional fund paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalFund" xlink:to="txmd_AdditionalFund_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments_lbl0" xml:lang="en-US">Additional milestone payments to be received on achievement of sales milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments" xlink:to="txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants_lbl0" xml:lang="en-US">Lender warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants" xlink:to="txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AggregateMinimumAnnualRoyaltyPaymentsDue_lbl0" xml:lang="en-US">Aggregate minimum annual royalty payments due.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AggregateMinimumAnnualRoyaltyPaymentsDue" xlink:to="txmd_AggregateMinimumAnnualRoyaltyPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CashReceivedForNetWorkingCapital_lbl0" xml:lang="en-US">Cash received for net working capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CashReceivedForNetWorkingCapital" xlink:to="txmd_CashReceivedForNetWorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ContingentCashConsiderationFromSaleOfBusiness_lbl0" xml:lang="en-US">Contingent cash consideration from sale of business.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ContingentCashConsiderationFromSaleOfBusiness" xlink:to="txmd_ContingentCashConsiderationFromSaleOfBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ContractAssetsAndLiabilitiesPolicyTextBlock_lbl0" xml:lang="en-US">Contract assets and liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:to="txmd_ContractAssetsAndLiabilitiesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerLicenseRevenuePercentage_lbl0" xml:lang="en-US">Customer license revenue percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerLicenseRevenuePercentage" xlink:to="txmd_CustomerLicenseRevenuePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DecreaseInRoyaltyRateOnProductByProductBasis_lbl0" xml:lang="en-US">Decrease in royalty rate on product-by-product basis.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DecreaseInRoyaltyRateOnProductByProductBasis" xlink:to="txmd_DecreaseInRoyaltyRateOnProductByProductBasis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty_lbl0" xml:lang="en-US">Deferred tax asset gain on sale of intellectual property.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty" xlink:to="txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DeferredTaxAssetsLiabilitiesGross_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset (liabilities) attributable to deductible temporary differences and carryforwards.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredTaxAssetsLiabilitiesGross" xlink:to="txmd_DeferredTaxAssetsLiabilitiesGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance_lbl0" xml:lang="en-US">Amount after allocation of valuation allowances of deferred tax asset (liabilities) attributable to deductible temporary differences and carryforwards.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance" xlink:to="txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities_lbl0" xml:lang="en-US">Disposal group, including discontinued operation, accrued expenses and other current liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments_lbl0" xml:lang="en-US">Disposal group including discontinued operation cash received for acquisition of networking capital subject to certain adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties_lbl0" xml:lang="en-US">Disposal group including discontinued operation cash received for prepaid royalties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock_lbl0" xml:lang="en-US">Disposal group including discontinued operation expense for accretion of series a preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale_lbl0" xml:lang="en-US">Disposal group including discontinued operation gain on sale.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness_lbl0" xml:lang="en-US">Disposal group including discontinued operation gain on sale of business.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts_lbl0" xml:lang="en-US">Disposal group including discontinued operation interest expense and other financing costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived_lbl0" xml:lang="en-US">Disposal group including discontinued operation license payment received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes_lbl0" xml:lang="en-US">Disposal group, including discontinued operation, loss before from income taxes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_lbl0" xml:lang="en-US">Disposal group including discontinued operation other income (expense).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable_lbl0" xml:lang="en-US">Amount classified as rent receivable attributable to disposal group held for sale or disposed of,  expected to be disposed of after one year or the normal operating cycle, if longer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_lbl0" xml:lang="en-US">Disposal group, including discontinued operation,research and development.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges_lbl1" xml:lang="en-US">Disposal group, including discontinued operation, restructuring charges.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing_lbl0" xml:lang="en-US">Disposal group, including discontinued operation, selling and marketing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet_lbl0" xml:lang="en-US">Disposal group including discontinued operation total other income expense net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent_lbl0" xml:lang="en-US">Represent the amount of accounts payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DivestitureOfBusinessPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Divestiture of business policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DivestitureOfBusinessPolicyPolicyTextBlock" xlink:to="txmd_DivestitureOfBusinessPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EffectiveIncomeTaxRateDiscontinuedOperations_lbl0" xml:lang="en-US">Effective income tax rate discontinued operations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectiveIncomeTaxRateDiscontinuedOperations" xlink:to="txmd_EffectiveIncomeTaxRateDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars_lbl0" xml:lang="en-US">Interest expense accretion, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars" xlink:to="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars_lbl0" xml:lang="en-US">Interest expense accretion.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars" xlink:to="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_GeneralInformationPolicyTextBlock_lbl0" xml:lang="en-US">General information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GeneralInformationPolicyTextBlock" xlink:to="txmd_GeneralInformationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_GoingConcernPolicyTextBlock_lbl0" xml:lang="en-US">Going concern.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GoingConcernPolicyTextBlock" xlink:to="txmd_GoingConcernPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IncrementalAccrualForNetWorkingCapital_lbl0" xml:lang="en-US">Incremental accrual for net working capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IncrementalAccrualForNetWorkingCapital" xlink:to="txmd_IncrementalAccrualForNetWorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment_lbl0" xml:lang="en-US">Inflation rate adjusted for minimal annual royalty payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment" xlink:to="txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LeaseConsecutivePeriods_lbl0" xml:lang="en-US">Lease consecutive periods.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LeaseConsecutivePeriods" xlink:to="txmd_LeaseConsecutivePeriods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LicenseRevenue_lbl0" xml:lang="en-US">Amount of license revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseRevenue" xlink:to="txmd_LicenseRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MakeWholePaymentAccretion_lbl0" xml:lang="en-US">Make-whole payment accretion.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MakeWholePaymentAccretion" xlink:to="txmd_MakeWholePaymentAccretion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePayment_lbl0" xml:lang="en-US">Milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePayment" xlink:to="txmd_MilestonePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentsRecordedAsLicenseRights_lbl0" xml:lang="en-US">Milestone payments recorded as license rights.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsRecordedAsLicenseRights" xlink:to="txmd_MilestonePaymentsRecordedAsLicenseRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MinimumAnnualRoyaltyPayment_lbl0" xml:lang="en-US">Minimum annual royalty payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumAnnualRoyaltyPayment" xlink:to="txmd_MinimumAnnualRoyaltyPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MiscellaneousIncomeexpense_lbl0" xml:lang="en-US">Miscellaneous income (expense).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MiscellaneousIncomeexpense" xlink:to="txmd_MiscellaneousIncomeexpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NetOperatingLossCarryforwardsTerm_lbl0" xml:lang="en-US">Net operating loss carryforwards term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetOperatingLossCarryforwardsTerm" xlink:to="txmd_NetOperatingLossCarryforwardsTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfEmployeesAfterWorkforceReduction_lbl0" xml:lang="en-US">Number of employees after workforce reduction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfEmployeesAfterWorkforceReduction" xlink:to="txmd_NumberOfEmployeesAfterWorkforceReduction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OneTimeMilestonePayments_lbl0" xml:lang="en-US">One-time milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OneTimeMilestonePayments" xlink:to="txmd_OneTimeMilestonePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PaymentsToAcquireNetWorkingCapital_lbl0" xml:lang="en-US">Payments to acquire net working capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaymentsToAcquireNetWorkingCapital" xlink:to="txmd_PaymentsToAcquireNetWorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PercentageOfFutureTaxableIncome_lbl0" xml:lang="en-US">Percentage of future taxable Income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PercentageOfFutureTaxableIncome" xlink:to="txmd_PercentageOfFutureTaxableIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PeriodOfMinimumAnnualRoyaltyPayment_lbl0" xml:lang="en-US">Period of minimum annual royalty payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PeriodOfMinimumAnnualRoyaltyPayment" xlink:to="txmd_PeriodOfMinimumAnnualRoyaltyPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidRoyaltyLiabilities_lbl0" xml:lang="en-US">Prepaid royalty liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidRoyaltyLiabilities" xlink:to="txmd_PrepaidRoyaltyLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate_lbl0" xml:lang="en-US">Present value of annual minimum royalty discount rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate" xlink:to="txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments_lbl0" xml:lang="en-US">Proceeds from acquire businesses net of working capital adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments" xlink:to="txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan_lbl0" xml:lang="en-US">Proceeds from sale of common stock related to employee stock purchase plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan" xlink:to="txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment_lbl0" xml:lang="en-US">Purchase of transferred assets and grant of licenses cash payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment" xlink:to="txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_QuarterlyRoyaltyInterest_lbl0" xml:lang="en-US">Quarterly royalty interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_QuarterlyRoyaltyInterest" xlink:to="txmd_QuarterlyRoyaltyInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_QuarterlyRoyaltyPayment_lbl0" xml:lang="en-US">Quarterly royalty payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_QuarterlyRoyaltyPayment" xlink:to="txmd_QuarterlyRoyaltyPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RestructuringChargesIncludingDiscontinuedOperations_lbl0" xml:lang="en-US">Restructuring charges including discontinued operations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RestructuringChargesIncludingDiscontinuedOperations" xlink:to="txmd_RestructuringChargesIncludingDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyPayment_lbl0" xml:lang="en-US">Royalty payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPayment" xlink:to="txmd_RoyaltyPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement_lbl0" xml:lang="en-US">Royalty payment payable under long term service agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement" xlink:to="txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyRateAsPercentageOnNetSales_lbl0" xml:lang="en-US">Royalty rate as percentage on net sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyRateAsPercentageOnNetSales" xlink:to="txmd_RoyaltyRateAsPercentageOnNetSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyReceivableCurrentPortion_lbl0" xml:lang="en-US">Royalty receivable, current portion.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyReceivableCurrentPortion" xlink:to="txmd_RoyaltyReceivableCurrentPortion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyReceivableLongTerm_lbl0" xml:lang="en-US">Royalty receivable, long term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyReceivableLongTerm" xlink:to="txmd_RoyaltyReceivableLongTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyReceivableLongTermPortion_lbl0" xml:lang="en-US">Royalty receivable, long term portion.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyReceivableLongTermPortion" xlink:to="txmd_RoyaltyReceivableLongTermPortion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyReceivableShortTermPortion_lbl0" xml:lang="en-US">Royalty receivable short term portion.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyReceivableShortTermPortion" xlink:to="txmd_RoyaltyReceivableShortTermPortion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Accrued Expenses And Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of warrants that were granted, exercised, forfeited, and expired during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:to="txmd_ScheduleOfWarrantRollForwardTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:to="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TermOfRoyaltyPayments_lbl1" xml:lang="en-US">Term of royalty payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TermOfRoyaltyPayments" xlink:to="txmd_TermOfRoyaltyPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate_lbl0" xml:lang="en-US">Threshold annual net sales to determine royalty rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate" xlink:to="txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment_lbl0" xml:lang="en-US">Threshold net sales amount to determine one-time milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" xlink:to="txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TransactionCostsRelatedToDivestitureOfBusiness_lbl0" xml:lang="en-US">Transaction costs related to divestiture of business.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TransactionCostsRelatedToDivestitureOfBusiness" xlink:to="txmd_TransactionCostsRelatedToDivestitureOfBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedInRelationToDebtFinancingAgreement_lbl0" xml:lang="en-US">Warrants issued in relation to debt financing agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedInRelationToDebtFinancingAgreement" xlink:to="txmd_WarrantsIssuedInRelationToDebtFinancingAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife_lbl0" xml:lang="en-US">Warrants outstanding and exercisable other than options warrants weighted average remaining contractual life.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants_lbl1" xml:lang="en-US">Warrants outstanding and exercisable other than options warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue_lbl1" xml:lang="en-US">Warrants outstanding and exercisable other than options warrants aggregate intrinsic value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised_lbl0" xml:lang="en-US">Warrants outstanding and exercisable other than options warrants aggregate intrinsic value exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised_lbl0" xml:lang="en-US">Warrants outstanding and exercisable other than options warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired_lbl0" xml:lang="en-US">Warrants outstanding and exercisable other than options warrants expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted_lbl0" xml:lang="en-US">Warrants outstanding and exercisable other than options warrants granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Warrants outstanding and exercisable other than options warrants weighted average exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised_lbl0" xml:lang="en-US">Warrants outstanding and exercisable other than options warrants weighted average exercise price exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired_lbl0" xml:lang="en-US">Warrants outstanding and exercisable other than options warrants weighted average exercise price expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted_lbl0" xml:lang="en-US">Warrants outstanding and exercisable other than options warrants weighted average exercise price granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife_lbl0" xml:lang="en-US">Warrants outstanding and exercisable other than options warrants weighted average remaining contractual life.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WorkingCapitalAmounts_lbl0" xml:lang="en-US">Working capital amounts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WorkingCapitalAmounts" xlink:to="txmd_WorkingCapitalAmounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WriteOffOfAsset_lbl0" xml:lang="en-US">Write off of asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WriteOffOfAsset" xlink:to="txmd_WriteOffOfAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WriteoffOfPatentAndTrademark_lbl0" xml:lang="en-US">Represent the amount of write-off of patent and trademark.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WriteoffOfPatentAndTrademark" xlink:to="txmd_WriteoffOfPatentAndTrademark_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LegalProceedingAxis_lbl0" xml:lang="en-US">Legal Proceedings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LegalProceedingAxis" xlink:to="txmd_LegalProceedingAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember_lbl0" xml:lang="en-US">Accrued expenses and other current liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:to="txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnoverasMember_lbl0" xml:lang="en-US">Annovera.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnoverasMember" xlink:to="txmd_AnnoverasMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_BijuvasMember_lbl0" xml:lang="en-US">BIJUVA.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvasMember" xlink:to="txmd_BijuvasMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ConsultingAndLegalExpensesMember_lbl0" xml:lang="en-US">Consulting and legal expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ConsultingAndLegalExpensesMember" xlink:to="txmd_ConsultingAndLegalExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CurrentLiabilitiesForDiscontinuedOperationsMember_lbl0" xml:lang="en-US">Current liabilities for discontinued operations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CurrentLiabilitiesForDiscontinuedOperationsMember" xlink:to="txmd_CurrentLiabilitiesForDiscontinuedOperationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EmployeeTerminationBenefitsMember_lbl0" xml:lang="en-US">Employee termination benefits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EmployeeTerminationBenefitsMember" xlink:to="txmd_EmployeeTerminationBenefitsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ExecutiveTerminationBenefitsMember_lbl0" xml:lang="en-US">Executive termination benefits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExecutiveTerminationBenefitsMember" xlink:to="txmd_ExecutiveTerminationBenefitsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ExpirationPeriod20YearsMember_lbl0" xml:lang="en-US">Expiration Period 20 Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriod20YearsMember" xlink:to="txmd_ExpirationPeriod20YearsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ExpirationPeriodIndefiniteMember_lbl0" xml:lang="en-US">Expiration Period Indefinite</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriodIndefiniteMember" xlink:to="txmd_ExpirationPeriodIndefiniteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_HormoneTherapyDrugPatentsMember_lbl0" xml:lang="en-US">Hormone Therapy Drug Patents Member.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugPatentsMember" xlink:to="txmd_HormoneTherapyDrugPatentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MayneLicenseAgreementMember_lbl0" xml:lang="en-US">Mayne License Agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MayneLicenseAgreementMember" xlink:to="txmd_MayneLicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MaynePharmaAgreementMember_lbl0" xml:lang="en-US">Mayne Pharma Agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaynePharmaAgreementMember" xlink:to="txmd_MaynePharmaAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MaynePharmaMember_lbl0" xml:lang="en-US">Mayne Pharma.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaynePharmaMember" xlink:to="txmd_MaynePharmaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentsOneMember_lbl1" xml:lang="en-US">Milestone payments one.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsOneMember" xlink:to="txmd_MilestonePaymentsOneMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentsThreeMember_lbl1" xml:lang="en-US">Milestone payments three.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsThreeMember" xlink:to="txmd_MilestonePaymentsThreeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentsTwoMember_lbl1" xml:lang="en-US">Milestone payments two.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsTwoMember" xlink:to="txmd_MilestonePaymentsTwoMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OtherContractTerminationCostsMember_lbl0" xml:lang="en-US">Other contract termination costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OtherContractTerminationCostsMember" xlink:to="txmd_OtherContractTerminationCostsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PopulationCouncilLicenseAgreementMember_lbl0" xml:lang="en-US">Population council license agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PopulationCouncilLicenseAgreementMember" xlink:to="txmd_PopulationCouncilLicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyRateOneMember_lbl1" xml:lang="en-US">Royalty rate one.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyRateOneMember" xlink:to="txmd_RoyaltyRateOneMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyRateTwoMember_lbl1" xml:lang="en-US">Royalty rate two.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyRateTwoMember" xlink:to="txmd_RoyaltyRateTwoMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RubricCapitalManagementLPMember_lbl0" xml:lang="en-US">Rubric capital management LP.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RubricCapitalManagementLPMember" xlink:to="txmd_RubricCapitalManagementLPMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockOptionsMember_lbl0" xml:lang="en-US">The member represent stock options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockOptionsMember" xlink:to="txmd_StockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockPurchaseAgreementMember_lbl0" xml:lang="en-US">Stock purchase agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockPurchaseAgreementMember" xlink:to="txmd_StockPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SubscriptionAgreementMember_lbl0" xml:lang="en-US">Subscription agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SubscriptionAgreementMember" xlink:to="txmd_SubscriptionAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TheramexLicenseAgreementsMember_lbl0" xml:lang="en-US">Theramex license agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TheramexLicenseAgreementsMember" xlink:to="txmd_TheramexLicenseAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TheramexMember_lbl0" xml:lang="en-US">Theramex.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TheramexMember" xlink:to="txmd_TheramexMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TwoThousandNineteenStockIncentivePlanMember_lbl0" xml:lang="en-US">Two Thousand Nineteen Stock Incentive Plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TwoThousandNineteenStockIncentivePlanMember" xlink:to="txmd_TwoThousandNineteenStockIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_VitaCareDivestitureMember_lbl0" xml:lang="en-US">vitaCare divestiture.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VitaCareDivestitureMember" xlink:to="txmd_VitaCareDivestitureMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operation Loss Before From Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_VitaCareDivestitureMember_lbl1" xml:lang="en-US">Vita Care Divestiture Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VitaCareDivestitureMember" xlink:to="txmd_VitaCareDivestitureMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OtherContractTerminationCostsMember_lbl1" xml:lang="en-US">Other Contract Termination Costs Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OtherContractTerminationCostsMember" xlink:to="txmd_OtherContractTerminationCostsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired_lbl1" xml:lang="en-US">Warrants Outstanding And Exercisable Other Than Options Warrants Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl0" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived_lbl0" xml:lang="en-US">Proceeds from Royalties Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerLicenseRevenuePercentage_lbl1" xml:lang="en-US">Customer License Revenue Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerLicenseRevenuePercentage" xlink:to="txmd_CustomerLicenseRevenuePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl0" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ExpirationPeriod20YearsMember_lbl1" xml:lang="en-US">Expiration Period20 Years Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriod20YearsMember" xlink:to="txmd_ExpirationPeriod20YearsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants_lbl1" xml:lang="en-US">Adjustments To Additional Paid In Capital Lender Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants" xlink:to="txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectTaxesAndLicensesCosts_lbl0" xml:lang="en-US">Cost, Direct Tax and License</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectTaxesAndLicensesCosts" xlink:to="us-gaap_DirectTaxesAndLicensesCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RubricCapitalManagementLPMember_lbl1" xml:lang="en-US">Rubric Capital Management LPMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RubricCapitalManagementLPMember" xlink:to="txmd_RubricCapitalManagementLPMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RestructuringChargesIncludingDiscontinuedOperations_lbl1" xml:lang="en-US">Restructuring Charges Including Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RestructuringChargesIncludingDiscontinuedOperations" xlink:to="txmd_RestructuringChargesIncludingDiscontinuedOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan_lbl1" xml:lang="en-US">Proceeds From Sale Of Common Stock Related To Employee Stock Purchase Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan" xlink:to="txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock_lbl0" xml:lang="en-US">Schedule Of Classes Of Assets And Liabilities Of Discontinued Operations Table Test Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock" xlink:to="txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gross Profit (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operation Expense For Accretion Of Series APreferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MinimumAnnualRoyaltyPayment_lbl1" xml:lang="en-US">Minimum Annual Royalty Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumAnnualRoyaltyPayment" xlink:to="txmd_MinimumAnnualRoyaltyPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MiscellaneousIncomeexpense_lbl1" xml:lang="en-US">Miscellaneous Incomeexpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MiscellaneousIncomeexpense" xlink:to="txmd_MiscellaneousIncomeexpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment_lbl1" xml:lang="en-US">Inflation Rate Adjusted For Minimal Annual Royalty Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment" xlink:to="txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment_lbl1"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfOutstandingSecuritiesAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfOutstandingSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfOutstandingSecuritiesAbstract_lbl" xml:lang="en-US">Schedule Of Outstanding Securities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfOutstandingSecuritiesAbstract" xlink:to="txmd_ScheduleOfOutstandingSecuritiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RoyaltyRateAsPercentageOnNetSales_lbl1" xml:lang="en-US">Royalty Rate As Percentage On Net Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyRateAsPercentageOnNetSales" xlink:to="txmd_RoyaltyRateAsPercentageOnNetSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl0" xml:lang="en-US">Repayments of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AggregateMinimumAnnualRoyaltyPaymentsDue_lbl1" xml:lang="en-US">Aggregate Minimum Annual Royalty Payments Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AggregateMinimumAnnualRoyaltyPaymentsDue" xlink:to="txmd_AggregateMinimumAnnualRoyaltyPaymentsDue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_QuarterlyRoyaltyPayment_lbl1" xml:lang="en-US">Quarterly Royalty Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_QuarterlyRoyaltyPayment" xlink:to="txmd_QuarterlyRoyaltyPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl1" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl1" xml:lang="en-US">Performance Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments_lbl1" xml:lang="en-US">Additional Milestone Payments To Be Received On Achievement Of Sales Milestone Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments" xlink:to="txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl1" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MaynePharmaAgreementMember_lbl1" xml:lang="en-US">Mayne Pharma Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaynePharmaAgreementMember" xlink:to="txmd_MaynePharmaAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl0" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Accrued Expenses And Other Current Liabilities Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl2" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment_lbl1" xml:lang="en-US">Purchase Of Transferred Assets And Grant Of Licenses Cash Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment" xlink:to="txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised_lbl1" xml:lang="en-US">Warrants Outstanding And Exercisable Other Than Options Warrants Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfEmployeesAfterWorkforceReduction_lbl1" xml:lang="en-US">Number Of Employees After Workforce Reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfEmployeesAfterWorkforceReduction" xlink:to="txmd_NumberOfEmployeesAfterWorkforceReduction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract_lbl0" xml:lang="en-US">Deferred Income Tax Assets Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CurrentLiabilitiesForDiscontinuedOperationsMember_lbl1" xml:lang="en-US">Current Liabilities For Discontinued Operations Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CurrentLiabilitiesForDiscontinuedOperationsMember" xlink:to="txmd_CurrentLiabilitiesForDiscontinuedOperationsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance_lbl1" xml:lang="en-US">Deferred Tax Assets Liabilities Net Of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance" xlink:to="txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TheramexMember_lbl1" xml:lang="en-US">Theramex Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TheramexMember" xlink:to="txmd_TheramexMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicenseRevenue_lbl1" xml:lang="en-US">License Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseRevenue" xlink:to="txmd_LicenseRevenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_lbl0" xml:lang="en-US">Payments for Derivative Instrument, Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:to="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnoverasMember_lbl1" xml:lang="en-US">Annoveras Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnoverasMember" xlink:to="txmd_AnnoverasMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operations Accounts Payable Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl0" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty_lbl1" xml:lang="en-US">Deferred Tax Asset Gain On Sale Of Intellectual Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty" xlink:to="txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RoyaltyReceivableShortTermPortion_lbl1" xml:lang="en-US">Royalty Receivable Short Term Portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyReceivableShortTermPortion" xlink:to="txmd_RoyaltyReceivableShortTermPortion_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RoyaltyRateOneMember_lbl2" xml:lang="en-US">Royalty Rate One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyRateOneMember" xlink:to="txmd_RoyaltyRateOneMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl1" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl1"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfDiscontinuedOperationsAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfDiscontinuedOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfDiscontinuedOperationsAbstract_lbl" xml:lang="en-US">Schedule Of Discontinued Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfDiscontinuedOperationsAbstract" xlink:to="txmd_ScheduleOfDiscontinuedOperationsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl0" xml:lang="en-US">Prepaid Insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl1" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl0" xml:lang="en-US">Stock Redeemed or Called During Period, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl1" xml:lang="en-US">Software and Software Development Costs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfBusiness" xlink:to="us-gaap_GainLossOnSaleOfBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl0" xml:lang="en-US">Number of Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedPrepaidRoyalty_lbl1" xml:lang="en-US">Accrued Prepaid Royalty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedPrepaidRoyalty" xlink:to="txmd_AccruedPrepaidRoyalty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MayneLicenseAgreementMember_lbl1" xml:lang="en-US">Mayne License Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MayneLicenseAgreementMember" xlink:to="txmd_MayneLicenseAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl0" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised_lbl1" xml:lang="en-US">Warrants Outstanding And Exercisable Other Than Options Warrants Aggregate Intrinsic Value Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RentalIncomeNonoperating_lbl0" xml:lang="en-US">Rental Income, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RentalIncomeNonoperating" xlink:to="us-gaap_RentalIncomeNonoperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentsOneMember_lbl2" xml:lang="en-US">Milestone Payments One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsOneMember" xlink:to="txmd_MilestonePaymentsOneMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl0" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnlabeledAbstract2" xlink:to="txmd_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnlabeledAbstract1" xlink:to="txmd_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnlabeledAbstract0" xlink:to="txmd_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RoyaltyReceivableCurrentPortion_lbl1" xml:lang="en-US">Royalty Receivable Current Portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyReceivableCurrentPortion" xlink:to="txmd_RoyaltyReceivableCurrentPortion_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl0" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:to="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl0" xml:lang="en-US">License [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PaymentsToAcquireNetWorkingCapital_lbl1" xml:lang="en-US">Payments To Acquire Net Working Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaymentsToAcquireNetWorkingCapital" xlink:to="txmd_PaymentsToAcquireNetWorkingCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_lbl0" xml:lang="en-US">Proceeds from Derivative Instrument, Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:to="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentsRecordedAsLicenseRights_lbl1" xml:lang="en-US">Milestone Payments Recorded As License Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsRecordedAsLicenseRights" xlink:to="txmd_MilestonePaymentsRecordedAsLicenseRights_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted_lbl1" xml:lang="en-US">Warrants Outstanding And Exercisable Other Than Options Warrants Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Lease Income, Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredTaxAssetsLiabilitiesGross_lbl1" xml:lang="en-US">Deferred Tax Assets Liabilities Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredTaxAssetsLiabilitiesGross" xlink:to="txmd_DeferredTaxAssetsLiabilitiesGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnlabeledAbstract" xlink:to="txmd_UnlabeledAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_SummaryOfRestructuringCostRecognitionAbstract" xlink:href="txmd-20231231.xsd#txmd_SummaryOfRestructuringCostRecognitionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SummaryOfRestructuringCostRecognitionAbstract_lbl" xml:lang="en-US">Summary Of Restructuring Cost Recognition Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SummaryOfRestructuringCostRecognitionAbstract" xlink:to="txmd_SummaryOfRestructuringCostRecognitionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife_lbl1" xml:lang="en-US">Warrants Outstanding And Exercisable Other Than Options Warrants Weighted Average Remaining Contractual Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl0" xml:lang="en-US">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife_lbl1" xml:lang="en-US">Warrants Outstanding And Exercisable Other Than Option Warrants Weighted Average Remaining Contractual Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ContractAssetsAndLiabilitiesPolicyTextBlock_lbl1" xml:lang="en-US">Contract Assets And Liabilities Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:to="txmd_ContractAssetsAndLiabilitiesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedInRelationToDebtFinancingAgreement_lbl1" xml:lang="en-US">Warrants Issued In Relation To Debt Financing Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedInRelationToDebtFinancingAgreement" xlink:to="txmd_WarrantsIssuedInRelationToDebtFinancingAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PercentageOfFutureTaxableIncome_lbl1" xml:lang="en-US">Percentage Of Future Taxable Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PercentageOfFutureTaxableIncome" xlink:to="txmd_PercentageOfFutureTaxableIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract_lbl0" xml:lang="en-US">Disposal Group Including Discontinued Operation Other Expense Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MaynePharmaMember_lbl1" xml:lang="en-US">Mayne Pharma Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaynePharmaMember" xlink:to="txmd_MaynePharmaMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IntangibleAssetsSubjectToAmortizationMember_lbl0" xml:lang="en-US">Intangible Assets Subject To Amortization Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IntangibleAssetsSubjectToAmortizationMember" xlink:to="txmd_IntangibleAssetsSubjectToAmortizationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl1" xml:lang="en-US">Restructuring Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract_lbl" xml:lang="en-US">Schedule Of Classes Of Liabilities Of Discontinued Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract" xlink:to="txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockPurchaseAgreementMember_lbl1" xml:lang="en-US">Stock Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockPurchaseAgreementMember" xlink:to="txmd_StockPurchaseAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ExpirationPeriodIndefiniteMember_lbl1" xml:lang="en-US">Expiration Period Indefinite Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriodIndefiniteMember" xlink:to="txmd_ExpirationPeriodIndefiniteMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidRoyaltyLiabilities_lbl1" xml:lang="en-US">Prepaid Royalty Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidRoyaltyLiabilities" xlink:to="txmd_PrepaidRoyaltyLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Warrant Roll Forward Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:to="txmd_ScheduleOfWarrantRollForwardTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IntangibleAssetsNotSubjectToAmortizationAbstract_lbl0" xml:lang="en-US">Intangible Assets Not Subject To Amortization Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IntangibleAssetsNotSubjectToAmortizationAbstract" xlink:to="txmd_IntangibleAssetsNotSubjectToAmortizationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_GeneralInformationPolicyTextBlock_lbl1" xml:lang="en-US">General Information Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GeneralInformationPolicyTextBlock" xlink:to="txmd_GeneralInformationPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl0" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PopulationCouncilLicenseAgreementMember_lbl1" xml:lang="en-US">Population Council License Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PopulationCouncilLicenseAgreementMember" xlink:to="txmd_PopulationCouncilLicenseAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedExpensesAndOtherCurrentLiabilities_lbl1" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="txmd_AccruedExpensesAndOtherCurrentLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl0" xml:lang="en-US">Payments of Financing Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl0" xml:lang="en-US">Severance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted_lbl1" xml:lang="en-US">Warrants Outstanding And Exercisable Other Than Options Warrants Weighted Average Exercise Price Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IncrementalAccrualForNetWorkingCapital_lbl1" xml:lang="en-US">Incremental Accrual For Net Working Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IncrementalAccrualForNetWorkingCapital" xlink:to="txmd_IncrementalAccrualForNetWorkingCapital_lbl1"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfComputationOfBasicAndDilutedIncomeLossPerCommonShareAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfComputationOfBasicAndDilutedIncomeLossPerCommonShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfComputationOfBasicAndDilutedIncomeLossPerCommonShareAbstract_lbl" xml:lang="en-US">Schedule Of Computation Of Basic And Diluted Income Loss Per Common Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfComputationOfBasicAndDilutedIncomeLossPerCommonShareAbstract" xlink:to="txmd_ScheduleOfComputationOfBasicAndDilutedIncomeLossPerCommonShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RoyaltyPayment_lbl1" xml:lang="en-US">Royalty Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPayment" xlink:to="txmd_RoyaltyPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedContractTerminationCosts_lbl1" xml:lang="en-US">Accrued Contract Termination Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedContractTerminationCosts" xlink:to="txmd_AccruedContractTerminationCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl0" xml:lang="en-US">Cash Acquired from Acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_lbl0" xml:lang="en-US">Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SubscriptionAgreementMember_lbl1" xml:lang="en-US">Subscription Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SubscriptionAgreementMember" xlink:to="txmd_SubscriptionAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operation License Payment Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ConsultingAndLegalExpensesMember_lbl1" xml:lang="en-US">Consulting And Legal Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ConsultingAndLegalExpensesMember" xlink:to="txmd_ConsultingAndLegalExpensesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdditionalFund_lbl1" xml:lang="en-US">Additional Fund</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalFund" xlink:to="txmd_AdditionalFund_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl0" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_EmployeeTerminationBenefitsMember_lbl1" xml:lang="en-US">Employee Termination Benefits Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EmployeeTerminationBenefitsMember" xlink:to="txmd_EmployeeTerminationBenefitsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LegalProceedingAxis_lbl1" xml:lang="en-US">Legal Proceeding Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LegalProceedingAxis" xlink:to="txmd_LegalProceedingAxis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyAgreementsMember_lbl0" xml:lang="en-US">Royalty Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementsMember" xlink:to="us-gaap_RoyaltyAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_EffectiveIncomeTaxRateDiscontinuedOperations_lbl1" xml:lang="en-US">Effective Income Tax Rate Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectiveIncomeTaxRateDiscontinuedOperations" xlink:to="txmd_EffectiveIncomeTaxRateDiscontinuedOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RoyaltyRateTwoMember_lbl2" xml:lang="en-US">Royalty Rate Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyRateTwoMember" xlink:to="txmd_RoyaltyRateTwoMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BijuvasMember_lbl1" xml:lang="en-US">Bijuvas Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvasMember" xlink:to="txmd_BijuvasMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TransactionCostsRelatedToDivestitureOfBusiness_lbl1" xml:lang="en-US">Transaction Costs Related To Divestiture Of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TransactionCostsRelatedToDivestitureOfBusiness" xlink:to="txmd_TransactionCostsRelatedToDivestitureOfBusiness_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised_lbl1" xml:lang="en-US">Warrants Outstanding And Exercisable Other Than Options Warrants Weighted Average Exercise Price Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MakeWholePaymentAccretion_lbl1" xml:lang="en-US">Make Whole Payment Accretion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MakeWholePaymentAccretion" xlink:to="txmd_MakeWholePaymentAccretion_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_lbl0" xml:lang="en-US">Payments for Repurchase of Preferred Stock and Preference Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DivestitureOfBusinessPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Divestiture Of Business Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DivestitureOfBusinessPolicyPolicyTextBlock" xlink:to="txmd_DivestitureOfBusinessPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PhantomShareUnitsPSUsMember_lbl0" xml:lang="en-US">Phantom Share Units (PSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PhantomShareUnitsPSUsMember" xlink:to="us-gaap_PhantomShareUnitsPSUsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operation Accrued Expenses And Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl0" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl0" xml:lang="en-US">Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePayment_lbl1" xml:lang="en-US">Milestone Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePayment" xlink:to="txmd_MilestonePayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operation Interest Expense And Other Financing Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl0" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TwoThousandNineteenStockIncentivePlanMember_lbl1" xml:lang="en-US">Two Thousand Nineteen Stock Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TwoThousandNineteenStockIncentivePlanMember" xlink:to="txmd_TwoThousandNineteenStockIncentivePlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Warrants Outstanding And Exercisable Other Than Options Warrants Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TrademarksAndTradeNamesMember_lbl0" xml:lang="en-US">Trademarks and Trade Names [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksAndTradeNamesMember" xlink:to="us-gaap_TrademarksAndTradeNamesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl0" xml:lang="en-US">Restricted Cash, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl1" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ExecutiveTerminationBenefitsMember_lbl1" xml:lang="en-US">Executive Termination Benefits Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExecutiveTerminationBenefitsMember" xlink:to="txmd_ExecutiveTerminationBenefitsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyIncomeNonoperating_lbl0" xml:lang="en-US">Royalty Income, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyIncomeNonoperating" xlink:to="us-gaap_RoyaltyIncomeNonoperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl0" xml:lang="en-US">Stock Redeemed or Called During Period, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl3" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges_lbl2" xml:lang="en-US">Disposal Group Including Discontinued Operation Restructuring Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue_lbl2" xml:lang="en-US">Warrants Outstanding And Exercisable Other Than Options Warrants Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement_lbl1" xml:lang="en-US">Royalty Payment Payable Under Long Term Service Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement" xlink:to="txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PeriodOfMinimumAnnualRoyaltyPayment_lbl1" xml:lang="en-US">Period Of Minimum Annual Royalty Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PeriodOfMinimumAnnualRoyaltyPayment" xlink:to="txmd_PeriodOfMinimumAnnualRoyaltyPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NetOperatingLossCarryforwardsTerm_lbl1" xml:lang="en-US">Net Operating Loss Carryforwards Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetOperatingLossCarryforwardsTerm" xlink:to="txmd_NetOperatingLossCarryforwardsTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserve_lbl0" xml:lang="en-US">Restructuring Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquisitionCostsCumulative_lbl0" xml:lang="en-US">Acquisition Costs, Cumulative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquisitionCostsCumulative" xlink:to="us-gaap_AcquisitionCostsCumulative_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TermOfRoyaltyPayments_lbl2" xml:lang="en-US">Term Of Royalty Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TermOfRoyaltyPayments" xlink:to="txmd_TermOfRoyaltyPayments_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentsThreeMember_lbl2" xml:lang="en-US">Milestone Payments Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsThreeMember" xlink:to="txmd_MilestonePaymentsThreeMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment_lbl1" xml:lang="en-US">Threshold Net Sales Amount To Determine One Time Milestone Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" xlink:to="txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl0" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operation Selling And Marketing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl0" xml:lang="en-US">Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember_lbl0" xml:lang="en-US">Hormone Therapy Drug Patents Applied And Pending Approval Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember" xlink:to="txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operation Research And Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operation Rent Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate_lbl1" xml:lang="en-US">Threshold Annual Net Sales To Determine Royalty Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate" xlink:to="txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operation Cash Received For Prepaid Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RoyaltyReceivableLongTerm_lbl1" xml:lang="en-US">Royalty Receivable Long Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyReceivableLongTerm" xlink:to="txmd_RoyaltyReceivableLongTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_GoingConcernPolicyTextBlock_lbl1" xml:lang="en-US">Going Concern Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GoingConcernPolicyTextBlock" xlink:to="txmd_GoingConcernPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentsTwoMember_lbl2" xml:lang="en-US">Milestone Payments Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsTwoMember" xlink:to="txmd_MilestonePaymentsTwoMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositContractsAssets_lbl0" xml:lang="en-US">Deposit Contracts, Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsAssets" xlink:to="us-gaap_DepositContractsAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WorkingCapitalAmounts_lbl1" xml:lang="en-US">Working Capital Amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WorkingCapitalAmounts" xlink:to="txmd_WorkingCapitalAmounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RoyaltyReceivableLongTermPortion_lbl1" xml:lang="en-US">Royalty Receivable Long Term Portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyReceivableLongTermPortion" xlink:to="txmd_RoyaltyReceivableLongTermPortion_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operation Gain On Sale Of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl1" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IntangibleAssetsSubjectToAmortizationAbstract_lbl0" xml:lang="en-US">Intangible Assets Subject To Amortization Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IntangibleAssetsSubjectToAmortizationAbstract" xlink:to="txmd_IntangibleAssetsSubjectToAmortizationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl0" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl0" xml:lang="en-US">Advertising Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operation Total Other Income Expense Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl0" xml:lang="en-US">Legal Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl1" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operation Cash Received For Acquisition Of Networking Capital Subject To Certain Adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember_lbl1" xml:lang="en-US">Accrued Expenses And Other Current Liabilities Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:to="txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract_lbl" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information Related To Leases Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:to="txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl0" xml:lang="en-US">Area of Land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operation Other Income Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl0" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation Interest Expense Accretionin Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars" xlink:to="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_HormoneTherapyDrugPatentsMember_lbl1" xml:lang="en-US">Hormone Therapy Drug Patents Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugPatentsMember" xlink:to="txmd_HormoneTherapyDrugPatentsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl1" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockOptionsMember_lbl1" xml:lang="en-US">Stock Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockOptionsMember" xlink:to="txmd_StockOptionsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CashReceivedForNetWorkingCapital_lbl1" xml:lang="en-US">Cash Received For Net Working Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CashReceivedForNetWorkingCapital" xlink:to="txmd_CashReceivedForNetWorkingCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WriteoffOfPatentAndTrademark_lbl1" xml:lang="en-US">Writeoff Of Patent And Trademark</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WriteoffOfPatentAndTrademark" xlink:to="txmd_WriteoffOfPatentAndTrademark_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OneTimeMilestonePayments_lbl1" xml:lang="en-US">One Time Milestone Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OneTimeMilestonePayments" xlink:to="txmd_OneTimeMilestonePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl0" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ParagraphFourCertificationNoticeLetterMember_lbl0" xml:lang="en-US">Paragraph Four Certification Notice Letter Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ParagraphFourCertificationNoticeLetterMember" xlink:to="txmd_ParagraphFourCertificationNoticeLetterMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation Interest Expense Accretion Percentagein Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars" xlink:to="txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_QuarterlyRoyaltyInterest_lbl1" xml:lang="en-US">Quarterly Royalty Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_QuarterlyRoyaltyInterest" xlink:to="txmd_QuarterlyRoyaltyInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LeaseConsecutivePeriods_lbl1" xml:lang="en-US">Lease Consecutive Periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LeaseConsecutivePeriods" xlink:to="txmd_LeaseConsecutivePeriods_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operation Gain On Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale" xlink:to="txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WriteOffOfAsset_lbl1" xml:lang="en-US">Write Off Of Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WriteOffOfAsset" xlink:to="txmd_WriteOffOfAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate_lbl1" xml:lang="en-US">Present Value Of Annual Minimum Royalty Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate" xlink:to="txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired_lbl1" xml:lang="en-US">Warrants Outstanding And Exercisable Other Than Options Warrants Weighted Average Exercise Price Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensingAgreementsMember_lbl0" xml:lang="en-US">Licensing Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl2" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DecreaseInRoyaltyRateOnProductByProductBasis_lbl1" xml:lang="en-US">Decrease In Royalty Rate On Product By Product Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DecreaseInRoyaltyRateOnProductByProductBasis" xlink:to="txmd_DecreaseInRoyaltyRateOnProductByProductBasis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ContingentCashConsiderationFromSaleOfBusiness_lbl1" xml:lang="en-US">Contingent Cash Consideration From Sale Of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ContingentCashConsiderationFromSaleOfBusiness" xlink:to="txmd_ContingentCashConsiderationFromSaleOfBusiness_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl2" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants_lbl2" xml:lang="en-US">Warrants Outstanding And Exercisable Other Than Options Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants" xlink:to="txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl2" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl0" xml:lang="en-US">Cash, FDIC Insured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl0" xml:lang="en-US">Long-Term Debt [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments_lbl1" xml:lang="en-US">Proceeds From Acquire Businesses Net Of Working Capital Adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments" xlink:to="txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_lbl0" xml:lang="en-US">Discontinued Operations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_lbl0" xml:lang="en-US">Discontinued Operation, Provision for Loss (Gain) on Disposal, before Income Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl1" xml:lang="en-US">Excess Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TheramexLicenseAgreementsMember_lbl1" xml:lang="en-US">Theramex License Agreements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TheramexLicenseAgreementsMember" xlink:to="txmd_TheramexLicenseAgreementsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandAndBuildingMember_lbl0" xml:lang="en-US">Land and Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandAndBuildingMember" xlink:to="us-gaap_LandAndBuildingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedResearchAndDevelopmentExpenses_lbl1" xml:lang="en-US">Accrued Research And Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedResearchAndDevelopmentExpenses" xlink:to="txmd_AccruedResearchAndDevelopmentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl0" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>txmd-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 29 20:06:18 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ConsolidatedBalanceSheet" roleURI="http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ConsolidatedIncomeStatement" roleURI="http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ShareholdersEquityType2or3" roleURI="http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ConsolidatedCashFlow" roleURI="http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies" roleURI="http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_DiscontinuedOperations" roleURI="http://www.therapeuticsmd.com/role/DiscontinuedOperations"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_PrepaidandOtherCurrentAssets" roleURI="http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_FixedAssets" roleURI="http://www.therapeuticsmd.com/role/FixedAssets"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_LicensedRightsandOtherIntangibleAssets" roleURI="http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_Debt" roleURI="http://www.therapeuticsmd.com/role/Debt"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_CommitmentsandContingencies" roleURI="http://www.therapeuticsmd.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_StockholdersEquityDeficit" roleURI="http://www.therapeuticsmd.com/role/StockholdersEquityDeficit"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_Revenue" roleURI="http://www.therapeuticsmd.com/role/Revenue"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_IncomeTaxes" roleURI="http://www.therapeuticsmd.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_IncomeLossPerCommonShare" roleURI="http://www.therapeuticsmd.com/role/IncomeLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_Relatedparties" roleURI="http://www.therapeuticsmd.com/role/Relatedparties"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_BusinessConcentrations" roleURI="http://www.therapeuticsmd.com/role/BusinessConcentrations"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_SubsequentEvents" roleURI="http://www.therapeuticsmd.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_AccountingPoliciesByPolicy" roleURI="http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_DiscontinuedOperationsTables" roleURI="http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_PrepaidandOtherCurrentAssetsTables" roleURI="http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_FixedAssetsTables" roleURI="http://www.therapeuticsmd.com/role/FixedAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_LicensedRightsandOtherIntangibleAssetsTables" roleURI="http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_CommitmentsandContingenciesTables" roleURI="http://www.therapeuticsmd.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_StockholdersEquityDeficitTables" roleURI="http://www.therapeuticsmd.com/role/StockholdersEquityDeficitTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_IncomeTaxesTables" roleURI="http://www.therapeuticsmd.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_IncomeLossPerCommonShareTables" roleURI="http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_SummaryofRestructuringCostRecognitionTable" roleURI="http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofDiscontinuedOperationsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofPrepaidandOtherCurrentAssetsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofFixedAssetsNetTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofIntangibleAssetsSubjectToAmortizationTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofRemainingLeasePaymentsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofOtherInformationRelatedtoLeasesTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofOtherInformationRelatedtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofStockOptionsActivityTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofEffectiveIncomeTaxRateReconciliationTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofComponentsofNetDeferredIncomeTaxAssetTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_ScheduleofOutstandingSecuritiesTable" roleURI="http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_DiscontinuedOperationsDetails" roleURI="http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_FixedAssetsDetails" roleURI="http://www.therapeuticsmd.com/role/FixedAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_LicensedRightsandOtherIntangibleAssetsDetails" roleURI="http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_DebtDetails" roleURI="http://www.therapeuticsmd.com/role/DebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_CommitmentsandContingenciesDetails" roleURI="http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_StockholdersEquityDeficitDetails" roleURI="http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_RevenueDetails" roleURI="http://www.therapeuticsmd.com/role/RevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_IncomeTaxesDetails" roleURI="http://www.therapeuticsmd.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_RelatedpartiesDetails" roleURI="http://www.therapeuticsmd.com/role/RelatedpartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#txmd_r_BusinessConcentrationsDetails" roleURI="http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyReceivableCurrentPortion" xlink:href="txmd-20231231.xsd#txmd_RoyaltyReceivableCurrentPortion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="RoyaltyReceivableCurrentPortion" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyReceivableLongTerm" xlink:href="txmd-20231231.xsd#txmd_RoyaltyReceivableLongTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="RoyaltyReceivableLongTerm" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_LicenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MiscellaneousIncomeexpense" xlink:href="txmd-20231231.xsd#txmd_MiscellaneousIncomeexpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="MiscellaneousIncomeexpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToAdditionalPaidInCapitalLenderWarrants" xlink:href="txmd-20231231.xsd#txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalLenderWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WriteoffOfPatentAndTrademark" xlink:href="txmd-20231231.xsd#txmd_WriteoffOfPatentAndTrademark"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="WriteoffOfPatentAndTrademark" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MakeWholePaymentAccretion" xlink:href="txmd-20231231.xsd#txmd_MakeWholePaymentAccretion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="MakeWholePaymentAccretion" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan" xlink:href="txmd-20231231.xsd#txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperations" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssuedInRelationToDebtFinancingAgreement" xlink:href="txmd-20231231.xsd#txmd_WarrantsIssuedInRelationToDebtFinancingAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="WarrantsIssuedInRelationToDebtFinancingAgreement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/DiscontinuedOperations">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/FixedAssets">
    <loc xlink:type="locator" xlink:label="FixedAssetsAbstract" xlink:href="txmd-20231231.xsd#txmd_FixedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FixedAssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/Debt">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/StockholdersEquityDeficit">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/Revenue">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/IncomeLossPerCommonShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/Relatedparties">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/BusinessConcentrations">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralInformationPolicyTextBlock" xlink:href="txmd-20231231.xsd#txmd_GeneralInformationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GeneralInformationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DivestitureOfBusinessPolicyPolicyTextBlock" xlink:href="txmd-20231231.xsd#txmd_DivestitureOfBusinessPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DivestitureOfBusinessPolicyPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GoingConcernPolicyTextBlock" xlink:href="txmd-20231231.xsd#txmd_GoingConcernPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GoingConcernPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DiscontinuedOperationsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContractAssetsAndLiabilitiesPolicyTextBlock" xlink:href="txmd-20231231.xsd#txmd_ContractAssetsAndLiabilitiesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ContractAssetsAndLiabilitiesPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/FixedAssetsTables">
    <loc xlink:type="locator" xlink:label="FixedAssetsAbstract" xlink:href="txmd-20231231.xsd#txmd_FixedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FixedAssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/StockholdersEquityDeficitTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantRollForwardTableTextBlock" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfWarrantRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ScheduleOfWarrantRollForwardTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable">
    <loc xlink:type="locator" xlink:label="SummaryOfRestructuringCostRecognitionAbstract" xlink:href="txmd-20231231.xsd#txmd_SummaryOfRestructuringCostRecognitionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryOfRestructuringCostRecognitionAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExecutiveTerminationBenefitsMember" xlink:href="txmd-20231231.xsd#txmd_ExecutiveTerminationBenefitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="ExecutiveTerminationBenefitsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultingAndLegalExpensesMember" xlink:href="txmd-20231231.xsd#txmd_ConsultingAndLegalExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="ConsultingAndLegalExpensesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherContractTerminationCostsMember" xlink:href="txmd-20231231.xsd#txmd_OtherContractTerminationCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="OtherContractTerminationCostsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeTerminationBenefitsMember" xlink:href="txmd-20231231.xsd#txmd_EmployeeTerminationBenefitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="EmployeeTerminationBenefitsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDiscontinuedOperationsAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfDiscontinuedOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable" xlink:href="txmd-20231231.xsd#txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable"/>
    <loc xlink:type="locator" xlink:label="DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" xlink:href="txmd-20231231.xsd#txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDiscontinuedOperationsAbstract" xlink:to="DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AnnoverasMember" xlink:href="txmd-20231231.xsd#txmd_AnnoverasMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="AnnoverasMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable" xlink:to="DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationRestructuringCharges" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationGainOnSale" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationGainOnSale" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationRentReceivable" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationRentReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrepaidAndOtherCurrentAssetsAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcquisitionCostsCumulative" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquisitionCostsCumulative"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_AcquisitionCostsCumulative" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFixedAssetsNetAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfFixedAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFixedAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLicenseRightsAndOtherIntangibleAssetsNetAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfLicenseRightsAndOtherIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable" xlink:href="txmd-20231231.xsd#txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"/>
    <loc xlink:type="locator" xlink:label="LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems" xlink:href="txmd-20231231.xsd#txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLicenseRightsAndOtherIntangibleAssetsNetAbstract" xlink:to="LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HormoneTherapyDrugPatentsMember" xlink:href="txmd-20231231.xsd#txmd_HormoneTherapyDrugPatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="HormoneTherapyDrugPatentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember" xlink:href="txmd-20231231.xsd#txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsSubjectToAmortizationMember" xlink:href="txmd-20231231.xsd#txmd_IntangibleAssetsSubjectToAmortizationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="IntangibleAssetsSubjectToAmortizationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_TrademarksAndTradeNamesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable" xlink:to="LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedContractTerminationCosts" xlink:href="txmd-20231231.xsd#txmd_AccruedContractTerminationCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="AccruedContractTerminationCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedResearchAndDevelopmentExpenses" xlink:href="txmd-20231231.xsd#txmd_AccruedResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="AccruedResearchAndDevelopmentExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedPrepaidRoyalty" xlink:href="txmd-20231231.xsd#txmd_AccruedPrepaidRoyalty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="AccruedPrepaidRoyalty" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedExpensesAndOtherCurrentLiabilities" xlink:href="txmd-20231231.xsd#txmd_AccruedExpensesAndOtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="AccruedExpensesAndOtherCurrentLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofOtherInformationRelatedtoLeasesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingAndExercisableWarrantsAndRelatedTransactionsAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfOutstandingAndExercisableWarrantsAndRelatedTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingAndExercisableWarrantsAndRelatedTransactionsAbstract" xlink:to="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable" xlink:to="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbcL4qf5LvDZDepCbNlW2HHdtTp8h/JBPAKml91Z9+QS2gjfdoyURiOQgrxFESWde/Q+Ash/YJdGlbG5QR3nEMXflGmqnNLFtFl1nIAPLFlMWnSI/b92PyAqBFuykXvgMcnlPm3rTC5y1gsY+iS9+gbk0SFpyt2CDowYCrPhIqMSfw/7Rr70FR804RnNZ8+uUnx+iI7cIQ0CrLS5Z/Ucu+B] CSR-->
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingAndExercisableOtherThanOptionsWarrants" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="WarrantsOutstandingAndExercisableOtherThanOptionsWarrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingAndExercisableOtherThanOptionsWarrants_0" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="WarrantsOutstandingAndExercisableOtherThanOptionsWarrants_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice_0" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue_0" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife" xlink:href="txmd-20231231.xsd#txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems" xlink:to="WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionsActivityAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfStockOptionsActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" xlink:href="txmd-20231231.xsd#txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheStatusOfOurUnvestedAndRelatedTransactionsAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfTheStatusOfOurUnvestedAndRelatedTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheStatusOfOurUnvestedAndRelatedTransactionsAbstract" xlink:to="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable" xlink:to="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_0" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeLossFromContinuingOperationsBeforeIncomeTaxesAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfIncomeLossFromContinuingOperationsBeforeIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable" xlink:href="txmd-20231231.xsd#txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems" xlink:href="txmd-20231231.xsd#txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeLossFromContinuingOperationsBeforeIncomeTaxesAbstract" xlink:to="IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable" xlink:to="IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars" xlink:href="txmd-20231231.xsd#txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars" xlink:href="txmd-20231231.xsd#txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateDiscontinuedOperations" xlink:href="txmd-20231231.xsd#txmd_EffectiveIncomeTaxRateDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateDiscontinuedOperations" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:href="txmd-20231231.xsd#txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract" xlink:to="DeferredIncomeTaxAssetsLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetGainOnSaleOfIntellectualProperty" xlink:href="txmd-20231231.xsd#txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="DeferredTaxAssetGainOnSaleOfIntellectualProperty" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsLiabilitiesGross" xlink:href="txmd-20231231.xsd#txmd_DeferredTaxAssetsLiabilitiesGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxAssetsLiabilitiesAbstract" xlink:to="DeferredTaxAssetsLiabilitiesGross" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsLiabilitiesNetOfValuationAllowance" xlink:href="txmd-20231231.xsd#txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract" xlink:to="DeferredTaxAssetsLiabilitiesNetOfValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComputationOfBasicAndDilutedIncomeLossPerCommonShareAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfComputationOfBasicAndDilutedIncomeLossPerCommonShareAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable" xlink:href="txmd-20231231.xsd#txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"/>
    <loc xlink:type="locator" xlink:label="IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems" xlink:href="txmd-20231231.xsd#txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComputationOfBasicAndDilutedIncomeLossPerCommonShareAbstract" xlink:to="IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable" xlink:to="IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingSecuritiesAbstract" xlink:href="txmd-20231231.xsd#txmd_ScheduleOfOutstandingSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="txmd-20231231.xsd#txmd_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="StockOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_WarrantMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="txmd-20231231.xsd#txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandAndBuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandAndBuildingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandAndBuildingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MayneLicenseAgreementMember" xlink:href="txmd-20231231.xsd#txmd_MayneLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="MayneLicenseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockPurchaseAgreementMember" xlink:href="txmd-20231231.xsd#txmd_StockPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="StockPurchaseAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RubricCapitalManagementLPMember" xlink:href="txmd-20231231.xsd#txmd_RubricCapitalManagementLPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="RubricCapitalManagementLPMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TheramexLicenseAgreementsMember" xlink:href="txmd-20231231.xsd#txmd_TheramexLicenseAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="TheramexLicenseAgreementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_StatementScenarioAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BijuvasMember" xlink:href="txmd-20231231.xsd#txmd_BijuvasMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="BijuvasMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsOneMember" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="MilestonePaymentsOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsTwoMember" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="MilestonePaymentsTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsThreeMember" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="MilestonePaymentsThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyRateOneMember" xlink:href="txmd-20231231.xsd#txmd_RoyaltyRateOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="RoyaltyRateOneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyRateTwoMember" xlink:href="txmd-20231231.xsd#txmd_RoyaltyRateTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="RoyaltyRateTwoMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LicensingAgreementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_RoyaltyAgreementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="VitaCareDivestitureMember" xlink:href="txmd-20231231.xsd#txmd_VitaCareDivestitureMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="VitaCareDivestitureMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AnnoverasMember" xlink:href="txmd-20231231.xsd#txmd_AnnoverasMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="AnnoverasMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:href="txmd-20231231.xsd#txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="AccruedExpensesAndOtherCurrentLiabilitiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentLiabilitiesForDiscontinuedOperationsMember" xlink:href="txmd-20231231.xsd#txmd_CurrentLiabilitiesForDiscontinuedOperationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="CurrentLiabilitiesForDiscontinuedOperationsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OneTimeMilestonePayments" xlink:href="txmd-20231231.xsd#txmd_OneTimeMilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="OneTimeMilestonePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" xlink:href="txmd-20231231.xsd#txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyRateAsPercentageOnNetSales" xlink:href="txmd-20231231.xsd#txmd_RoyaltyRateAsPercentageOnNetSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="RoyaltyRateAsPercentageOnNetSales" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThresholdAnnualNetSalesToDetermineRoyaltyRate" xlink:href="txmd-20231231.xsd#txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ThresholdAnnualNetSalesToDetermineRoyaltyRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TermOfRoyaltyPayments" xlink:href="txmd-20231231.xsd#txmd_TermOfRoyaltyPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="TermOfRoyaltyPayments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecreaseInRoyaltyRateOnProductByProductBasis" xlink:href="txmd-20231231.xsd#txmd_DecreaseInRoyaltyRateOnProductByProductBasis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="DecreaseInRoyaltyRateOnProductByProductBasis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumAnnualRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_MinimumAnnualRoyaltyPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="MinimumAnnualRoyaltyPayment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PeriodOfMinimumAnnualRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_PeriodOfMinimumAnnualRoyaltyPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="PeriodOfMinimumAnnualRoyaltyPayment" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InflationRateAdjustedForMinimalAnnualRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="InflationRateAdjustedForMinimalAnnualRoyaltyPayment" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment" xlink:href="txmd-20231231.xsd#txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsToAcquireNetWorkingCapital" xlink:href="txmd-20231231.xsd#txmd_PaymentsToAcquireNetWorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="PaymentsToAcquireNetWorkingCapital" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidRoyaltyLiabilities" xlink:href="txmd-20231231.xsd#txmd_PrepaidRoyaltyLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="PrepaidRoyaltyLiabilities" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="QuarterlyRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_QuarterlyRoyaltyPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="QuarterlyRoyaltyPayment" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="QuarterlyRoyaltyInterest" xlink:href="txmd-20231231.xsd#txmd_QuarterlyRoyaltyInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="QuarterlyRoyaltyInterest" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPaymentPayableUnderLongTermServiceAgreement" xlink:href="txmd-20231231.xsd#txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="RoyaltyPaymentPayableUnderLongTermServiceAgreement" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_RoyaltyPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="RoyaltyPayment" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalFund" xlink:href="txmd-20231231.xsd#txmd_AdditionalFund"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="AdditionalFund" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinesses" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransactionCostsRelatedToDivestitureOfBusiness" xlink:href="txmd-20231231.xsd#txmd_TransactionCostsRelatedToDivestitureOfBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="TransactionCostsRelatedToDivestitureOfBusiness" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentCashConsiderationFromSaleOfBusiness" xlink:href="txmd-20231231.xsd#txmd_ContingentCashConsiderationFromSaleOfBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ContingentCashConsiderationFromSaleOfBusiness" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments" xlink:href="txmd-20231231.xsd#txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WriteOffOfAsset" xlink:href="txmd-20231231.xsd#txmd_WriteOffOfAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="WriteOffOfAsset" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments" xlink:href="txmd-20231231.xsd#txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateMinimumAnnualRoyaltyPaymentsDue" xlink:href="txmd-20231231.xsd#txmd_AggregateMinimumAnnualRoyaltyPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="AggregateMinimumAnnualRoyaltyPaymentsDue" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PresentValueOfAnnualMinimumRoyaltyDiscountRate" xlink:href="txmd-20231231.xsd#txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="PresentValueOfAnnualMinimumRoyaltyDiscountRate" order="42.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="43.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseRevenue" xlink:href="txmd-20231231.xsd#txmd_LicenseRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="LicenseRevenue" order="44.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RoyaltyIncomeNonoperating" order="45.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositContractsAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositContractsAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DepositContractsAssets" order="46.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="47.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="48.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" order="49.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfEmployeesAfterWorkforceReduction" xlink:href="txmd-20231231.xsd#txmd_NumberOfEmployeesAfterWorkforceReduction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="NumberOfEmployeesAfterWorkforceReduction" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestructuringChargesIncludingDiscontinuedOperations" xlink:href="txmd-20231231.xsd#txmd_RestructuringChargesIncludingDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="RestructuringChargesIncludingDiscontinuedOperations" order="51.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RestructuringReserve" order="52.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="53.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <loc xlink:type="locator" xlink:label="DiscontinuedOperationsDetailsTable" xlink:href="txmd-20231231.xsd#txmd_DiscontinuedOperationsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="DiscontinuedOperationsDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_DiscontinuedOperationsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="DiscontinuedOperationsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsDetailsTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsDetailsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AnnoverasMember" xlink:href="txmd-20231231.xsd#txmd_AnnoverasMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="AnnoverasMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsDetailsTable" xlink:to="DiscontinuedOperationsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsDetailsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsDetailsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsDetailsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties" xlink:href="txmd-20231231.xsd#txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DiscontinuedOperationsDetailsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/FixedAssetsDetails">
    <loc xlink:type="locator" xlink:label="FixedAssetsAbstract" xlink:href="txmd-20231231.xsd#txmd_FixedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FixedAssetsAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="LicensedRightsandOtherIntangibleAssetsDetailsTable" xlink:href="txmd-20231231.xsd#txmd_LicensedRightsandOtherIntangibleAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LicensedRightsandOtherIntangibleAssetsDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="LicensedRightsandOtherIntangibleAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensedRightsandOtherIntangibleAssetsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LicensingAgreementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensedRightsandOtherIntangibleAssetsDetailsTable" xlink:to="LicensedRightsandOtherIntangibleAssetsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensedRightsandOtherIntangibleAssetsDetailsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_AdvertisingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/DebtDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="txmd-20231231.xsd#txmd_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_CommitmentsandContingenciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MaynePharmaAgreementMember" xlink:href="txmd-20231231.xsd#txmd_MaynePharmaAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="MaynePharmaAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PopulationCouncilLicenseAgreementMember" xlink:href="txmd-20231231.xsd#txmd_PopulationCouncilLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="PopulationCouncilLicenseAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AnnoverasMember" xlink:href="txmd-20231231.xsd#txmd_AnnoverasMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="AnnoverasMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LegalProceedingAxis" xlink:href="txmd-20231231.xsd#txmd_LegalProceedingAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="LegalProceedingAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LegalProceedingDomainDomain" xlink:href="txmd-20231231.xsd#txmd_LegalProceedingDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalProceedingAxis" xlink:to="LegalProceedingDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ParagraphFourCertificationNoticeLetterMember" xlink:href="txmd-20231231.xsd#txmd_ParagraphFourCertificationNoticeLetterMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalProceedingAxis" xlink:to="ParagraphFourCertificationNoticeLetterMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="CommitmentsandContingenciesDetailsLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_AreaOfLand" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseConsecutivePeriods" xlink:href="txmd-20231231.xsd#txmd_LeaseConsecutivePeriods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="LeaseConsecutivePeriods" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RentalIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RentalIncomeNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RentalIncomeNonoperating" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashReceivedForNetWorkingCapital" xlink:href="txmd-20231231.xsd#txmd_CashReceivedForNetWorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="CashReceivedForNetWorkingCapital" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncrementalAccrualForNetWorkingCapital" xlink:href="txmd-20231231.xsd#txmd_IncrementalAccrualForNetWorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="IncrementalAccrualForNetWorkingCapital" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapitalAmounts" xlink:href="txmd-20231231.xsd#txmd_WorkingCapitalAmounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="WorkingCapitalAmounts" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePayment" xlink:href="txmd-20231231.xsd#txmd_MilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="MilestonePayment" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DirectTaxesAndLicensesCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DirectTaxesAndLicensesCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_DirectTaxesAndLicensesCosts" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsRecordedAsLicenseRights" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsRecordedAsLicenseRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="MilestonePaymentsRecordedAsLicenseRights" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LegalFees" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SeveranceCosts1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDeficitDetailsTable" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDeficitDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_StockholdersEquityDeficitDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="StockholdersEquityDeficitDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PhantomShareUnitsPSUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PhantomShareUnitsPSUsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandNineteenStockIncentivePlanMember" xlink:href="txmd-20231231.xsd#txmd_TwoThousandNineteenStockIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandNineteenStockIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsTable" xlink:to="StockholdersEquityDeficitDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/RevenueDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="RevenueDetailsTable" xlink:href="txmd-20231231.xsd#txmd_RevenueDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="RevenueDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MayneLicenseAgreementMember" xlink:href="txmd-20231231.xsd#txmd_MayneLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="MayneLicenseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueDetailsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsOneMember" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="MilestonePaymentsOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsTwoMember" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="MilestonePaymentsTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsThreeMember" xlink:href="txmd-20231231.xsd#txmd_MilestonePaymentsThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="MilestonePaymentsThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyRateOneMember" xlink:href="txmd-20231231.xsd#txmd_RoyaltyRateOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="RoyaltyRateOneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyRateTwoMember" xlink:href="txmd-20231231.xsd#txmd_RoyaltyRateTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="RoyaltyRateTwoMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueDetailsTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OneTimeMilestonePayments" xlink:href="txmd-20231231.xsd#txmd_OneTimeMilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="OneTimeMilestonePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" xlink:href="txmd-20231231.xsd#txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyRateAsPercentageOnNetSales" xlink:href="txmd-20231231.xsd#txmd_RoyaltyRateAsPercentageOnNetSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="RoyaltyRateAsPercentageOnNetSales" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThresholdAnnualNetSalesToDetermineRoyaltyRate" xlink:href="txmd-20231231.xsd#txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="ThresholdAnnualNetSalesToDetermineRoyaltyRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TermOfRoyaltyPayments" xlink:href="txmd-20231231.xsd#txmd_TermOfRoyaltyPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="TermOfRoyaltyPayments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DecreaseInRoyaltyRateOnProductByProductBasis" xlink:href="txmd-20231231.xsd#txmd_DecreaseInRoyaltyRateOnProductByProductBasis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="DecreaseInRoyaltyRateOnProductByProductBasis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumAnnualRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_MinimumAnnualRoyaltyPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="MinimumAnnualRoyaltyPayment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PeriodOfMinimumAnnualRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_PeriodOfMinimumAnnualRoyaltyPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="PeriodOfMinimumAnnualRoyaltyPayment" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InflationRateAdjustedForMinimalAnnualRoyaltyPayment" xlink:href="txmd-20231231.xsd#txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="InflationRateAdjustedForMinimalAnnualRoyaltyPayment" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseRevenue" xlink:href="txmd-20231231.xsd#txmd_LicenseRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="LicenseRevenue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RoyaltyIncomeNonoperating" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="txmd-20231231.xsd#txmd_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExpirationPeriod20YearsMember" xlink:href="txmd-20231231.xsd#txmd_ExpirationPeriod20YearsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="ExpirationPeriod20YearsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpirationPeriodIndefiniteMember" xlink:href="txmd-20231231.xsd#txmd_ExpirationPeriodIndefiniteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="ExpirationPeriodIndefiniteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxExaminationLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetOperatingLossCarryforwardsTerm" xlink:href="txmd-20231231.xsd#txmd_NetOperatingLossCarryforwardsTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="NetOperatingLossCarryforwardsTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfFutureTaxableIncome" xlink:href="txmd-20231231.xsd#txmd_PercentageOfFutureTaxableIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="PercentageOfFutureTaxableIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/RelatedpartiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedpartiesDetailsTable" xlink:href="txmd-20231231.xsd#txmd_RelatedpartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedpartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedpartiesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementMember" xlink:href="txmd-20231231.xsd#txmd_SubscriptionAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SubscriptionAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedpartiesDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RubricCapitalManagementLPMember" xlink:href="txmd-20231231.xsd#txmd_RubricCapitalManagementLPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="RubricCapitalManagementLPMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedpartiesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedpartiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="BusinessConcentrationsDetailsTable" xlink:href="txmd-20231231.xsd#txmd_BusinessConcentrationsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="BusinessConcentrationsDetailsLineItems" xlink:href="txmd-20231231.xsd#txmd_BusinessConcentrationsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="BusinessConcentrationsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessConcentrationsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TheramexMember" xlink:href="txmd-20231231.xsd#txmd_TheramexMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="TheramexMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaynePharmaMember" xlink:href="txmd-20231231.xsd#txmd_MaynePharmaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="MaynePharmaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessConcentrationsDetailsTable" xlink:to="BusinessConcentrationsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CustomerLicenseRevenuePercentage" xlink:href="txmd-20231231.xsd#txmd_CustomerLicenseRevenuePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessConcentrationsDetailsLineItems" xlink:to="CustomerLicenseRevenuePercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyReceivableShortTermPortion" xlink:href="txmd-20231231.xsd#txmd_RoyaltyReceivableShortTermPortion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessConcentrationsDetailsLineItems" xlink:to="RoyaltyReceivableShortTermPortion" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyReceivableLongTermPortion" xlink:href="txmd-20231231.xsd#txmd_RoyaltyReceivableLongTermPortion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessConcentrationsDetailsLineItems" xlink:to="RoyaltyReceivableLongTermPortion" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/dei/role/document/Cover"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824844455056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Part III (Items 10, 11, 12, 13 and 14) of this annual report on Form
10-K is incorporated by reference from the definitive Proxy Statement for the 2024 Annual Meeting of Stockholders or an amendment to this
annual report on Form 10-K to be filed with the Securities and Exchange Commission no later than 120 days after the end of the registrant&#8217;s
fiscal year covered by this report.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">THERAPEUTICSMD, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-00100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0233535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,439,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">951 Yamato Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">961-1900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TXMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,532,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824961511360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">GRANT
THORNTON LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Miami, Florida<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824847140880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,327<span></span>
</td>
<td class="nump">$ 38,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_RoyaltyReceivableCurrentPortion', window );">Royalty receivable, current portion</a></td>
<td class="nump">3,090<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">4,035<span></span>
</td>
<td class="nump">6,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="nump">344<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">11,796<span></span>
</td>
<td class="nump">55,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">License rights and other intangible assets, net</a></td>
<td class="nump">6,098<span></span>
</td>
<td class="nump">6,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_RoyaltyReceivableLongTerm', window );">Royalty receivable, long term</a></td>
<td class="nump">18,484<span></span>
</td>
<td class="nump">20,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">6,873<span></span>
</td>
<td class="nump">7,580<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">43,309<span></span>
</td>
<td class="nump">90,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">2,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,133<span></span>
</td>
<td class="nump">18,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="nump">3,694<span></span>
</td>
<td class="nump">25,831<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,854<span></span>
</td>
<td class="nump">46,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">6,532<span></span>
</td>
<td class="nump">7,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">636<span></span>
</td>
<td class="nump">1,107<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,022<span></span>
</td>
<td class="nump">55,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001; 32,000 and 12,000 shares authorized, 11,532 and 9,498 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">978,917<span></span>
</td>
<td class="nump">974,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(949,641)<span></span>
</td>
<td class="num">(939,363)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">29,287<span></span>
</td>
<td class="nump">35,143<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 43,309<span></span>
</td>
<td class="nump">$ 90,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyReceivableCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty receivable, current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyReceivableCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyReceivableLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty receivable, long term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyReceivableLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824962573136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">32,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">11,532,000<span></span>
</td>
<td class="nump">9,498,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">11,532,000<span></span>
</td>
<td class="nump">9,498,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824843934416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue, net</a></td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="nump">$ 69,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,397<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">68,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">8,903<span></span>
</td>
<td class="nump">56,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation &amp; amortization</a></td>
<td class="nump">922<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,472<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">9,825<span></span>
</td>
<td class="nump">67,375<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(8,523)<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_MiscellaneousIncomeexpense', window );">Miscellaneous income (expense)</a></td>
<td class="nump">781<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (loss), net</a></td>
<td class="nump">781<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) from continuing operations before income taxes</a></td>
<td class="num">(7,742)<span></span>
</td>
<td class="nump">1,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (provision) for income taxes</a></td>
<td class="nump">43<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(7,699)<span></span>
</td>
<td class="nump">1,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (loss) from discontinued operations, net of income taxes</a></td>
<td class="num">(2,579)<span></span>
</td>
<td class="nump">110,923<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (10,278)<span></span>
</td>
<td class="nump">$ 111,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Income (loss) per common share, basic:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in Dollars per share)</a></td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations, net (in Dollars per share)</a></td>
<td class="num">(0.25)<span></span>
</td>
<td class="nump">12.29<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per common share, basic (in Dollars per share)</a></td>
<td class="num">(0.98)<span></span>
</td>
<td class="nump">12.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Income (loss) per common share, diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in Dollars per share)</a></td>
<td class="num">(0.74)<span></span>
</td>
<td class="nump">0.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations, net (in Dollars per share)</a></td>
<td class="num">(0.25)<span></span>
</td>
<td class="nump">11.84<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per common share, diluted (in Dollars per share)</a></td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="nump">$ 11.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares, basic (in Shares)</a></td>
<td class="nump">10,441<span></span>
</td>
<td class="nump">9,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares, diluted (in Shares)</a></td>
<td class="nump">10,441<span></span>
</td>
<td class="nump">9,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (10,278)<span></span>
</td>
<td class="nump">$ 111,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss):</a></td>
<td class="num">(10,278)<span></span>
</td>
<td class="nump">111,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License and service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue, net</a></td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="nump">$ 69,963<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MiscellaneousIncomeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MiscellaneousIncomeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824843253440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; (Deficit) Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 957,730<span></span>
</td>
<td class="num">$ (1,051,360)<span></span>
</td>
<td class="num">$ (93,621)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">8,597,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued for sale of common stock, net of cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,454<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued for sale of common stock, net of cost (in Shares)</a></td>
<td class="nump">565,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants', window );">Lender warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,727<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Rounding for fractional shares in connection with the reverse stock split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Rounding for fractional shares in connection with the reverse stock split (in Shares)</a></td>
<td class="nump">142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vested restricted and performance stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Shares issued for vested restricted and performance stock units (in Shares)</a></td>
<td class="nump">189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued for sale of common stock related to employee stock purchase plan</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued for sale of common stock related to employee stock purchase plan (in Shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Share-based payment award compensation costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,572<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">111,997<span></span>
</td>
<td class="nump">111,997<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">974,497<span></span>
</td>
<td class="num">(939,363)<span></span>
</td>
<td class="nump">35,143<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">9,498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Shares issued for vested restricted stock units</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vested restricted stock units (in Shares)</a></td>
<td class="nump">844,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,271<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued for sale of common stock related to private placement sale</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,149<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued for sale of common stock related to private placement sale (in Shares)</a></td>
<td class="nump">1,190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,278)<span></span>
</td>
<td class="num">(10,278)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 978,917<span></span>
</td>
<td class="num">$ (949,641)<span></span>
</td>
<td class="nump">$ 29,287<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">11,532,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lender warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824843661392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (10,278)<span></span>
</td>
<td class="nump">$ 111,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Less: Income (loss) from discontinued operations, net of tax</a></td>
<td class="num">(2,579)<span></span>
</td>
<td class="nump">110,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(7,699)<span></span>
</td>
<td class="nump">1,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) continuing operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WriteoffOfPatentAndTrademark', window );">Depreciation and amortization</a></td>
<td class="nump">922<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based payment compensation costs</a></td>
<td class="nump">1,271<span></span>
</td>
<td class="nump">11,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_MakeWholePaymentAccretion', window );">Make-whole payment accretion</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="nump">1,999<span></span>
</td>
<td class="nump">620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(1,126)<span></span>
</td>
<td class="num">(7,636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,135)<span></span>
</td>
<td class="num">(1,211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(15,713)<span></span>
</td>
<td class="nump">4,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(471)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="num">(15,382)<span></span>
</td>
<td class="nump">8,285<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by (used in) continuing operating activities</a></td>
<td class="num">(23,081)<span></span>
</td>
<td class="nump">9,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from continuing investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Receipts (payment) for patents</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in continuing investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from continuing financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="nump">3,151<span></span>
</td>
<td class="nump">2,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan', window );">Proceeds from sale of common stock related to employee stock purchase plan</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(219,432)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Series A Preferred Stock, net of transaction costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock', window );">Repurchase of Preferred Stock at liquidation preference</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(38,657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities', window );">Proceeds from make-whole derivative</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities', window );">Repayment of make-whole derivative</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of debt financing fees</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,622)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by (used in) continuing financing activities</a></td>
<td class="nump">3,151<span></span>
</td>
<td class="num">(235,206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract', window );"><strong>Discontinued operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(25,060)<span></span>
</td>
<td class="num">(13,437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash provided by investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">223,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations', window );">Net cash provided by (used in) discontinued operations</a></td>
<td class="num">(25,060)<span></span>
</td>
<td class="nump">210,397<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash</a></td>
<td class="num">(44,990)<span></span>
</td>
<td class="num">(15,805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash - continuing operations, beginning of period</a></td>
<td class="nump">49,317<span></span>
</td>
<td class="nump">64,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations', window );">Cash and restricted cash - discontinued operations, beginning of period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash and restricted cash, end of period</a></td>
<td class="nump">4,327<span></span>
</td>
<td class="nump">49,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsIssuedInRelationToDebtFinancingAgreement', window );">Warrants issued in relation to debt financing agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MakeWholePaymentAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Make-whole payment accretion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MakeWholePaymentAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of common stock related to employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsIssuedInRelationToDebtFinancingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued in relation to debt financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsIssuedInRelationToDebtFinancingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WriteoffOfPatentAndTrademark">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of write-off of patent and trademark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WriteoffOfPatentAndTrademark</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in cash associated with the entity's discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824840212048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Business, basis of presentation, new accounting standards and summary of significant accounting policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>1. Business, basis of presentation, new accounting standards and summary of significant accounting policies</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TherapeuticsMD, Inc. (the &#8220;Company&#8221;), a Nevada
corporation, and its consolidated subsidiaries are referred to collectively in this Annual Report on Form 10-K (&#8220;2023 10-K
Report&#8221;) as &#8220;TherapeuticsMD,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us.&#8221; This 2023 10-K Report
includes trademarks, trade names and service marks, such as TherapeuticsMD<sup>&#174;</sup>, vitaMedMD<sup>&#174;</sup>,
BocaGreenMD<sup>&#174;</sup>, vitaCareTM, IMVEXXY<sup>&#174;</sup>, and BIJUVA<sup>&#174;</sup>, which are protected under applicable
intellectual property laws and are the property of, or licensed by or to, us. Solely for convenience, trademarks, trade names and
service marks referred to in this 2023 10-K Report may appear without the <sup>&#174;</sup>, TM or SM symbols, but such references
are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the
right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other
parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a
relationship with, or endorsement or sponsorship of us by, these other parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TherapeuticsMD was previously a women&#8217;s healthcare company with
a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause.
In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed
to pharmaceutical organizations that possess commercial capabilities in the relevant territories. On December 30, 2022 (the &#8220;Closing
Date&#8221;), we completed a transaction (the &#8220;Mayne Transaction&#8221;) with Mayne Pharma LLC, a Delaware limited liability company
(&#8220;Mayne Pharma&#8221;) and subsidiary of Mayne Pharma Group Limited, an Australian public company, in which we and our subsidiaries
(i) granted Mayne Pharma an exclusive license to commercialize our IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under
the BocaGreenMD and vitaMedMD brands (collectively, the &#8220;Licensed Products&#8221;) in the United States and its possessions and
territories, (ii) assigned to Mayne Pharma our exclusive license to commercialize ANNOVERA<sup>&#174;</sup> (together with the Licensed
Products, collectively, the &#8220;Products&#8221;) in the United States and its possessions and territories, and (iii) sold certain
other assets to Mayne Pharma in connection therewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In a License Agreement, dated December 4, 2022, between TherapeuticsMD
and Mayne Pharma (the &#8220;Mayne License Agreement&#8221;), we granted Mayne Pharma, on the Closing Date, (i) an exclusive, sublicensable,
perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell, use, and commercialize the
Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable
license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States for commercialization
in the United States and its possessions and territories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Mayne License Agreement, Mayne Pharma will pay us
one-time milestone payments of each of (i) $5.0 million if aggregate net sales of all Products in the United States during a
calendar year reach $100.0 million, (ii) $10.0 million if aggregate net sales of all Products in the United States during a calendar
year reach $200.0 million and (iii) $15.0 million if aggregate net sales of all Products in the United States during a calendar year
reach $300.0 million. Further, Mayne Pharma will pay us royalties on net sales of all Products in the United States at a royalty
rate of 8.0% on the first $80.0 million in annual net sales and 7.5% on annual net sales above $80.0 million, subject to certain
adjustments, for a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product
basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version
of a Product launching in the United States. Mayne Pharma will pay us minimum annual royalties of $3.0 million per year for 12
years, adjusted for inflation at an annual rate of 3%, subject to certain further adjustments, including as described below. Upon
the expiry of the 20-year royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully
paid-up and royalty free license for the Licensed Products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Transaction Agreement, dated December 4, 2022, between TherapeuticsMD
and Mayne Pharma (the &#8220;Transaction Agreement&#8221;), we sold to Mayne Pharma, at closing, certain assets for Mayne Pharma to commercialize
the Products in the United States, including, with the Population Council&#8217;s consent, our exclusive license from the Population Council
to commercialize ANNOVERA (the &#8220;Transferred Assets&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total consideration from Mayne Pharma to TherapeuticsMD for
the purchase of the Transferred Assets under the Transaction Agreement and the grant of the licenses under the Mayne License
Agreement was (i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million at closing for the
acquisition of net working capital as determined in accordance with the Transaction Agreement and subject to certain adjustments,
(iii) a cash payment of approximately $1.0 million at closing for prepaid royalties in connection with the Mayne License Agreement
Amendment (as defined below) and (iv) the right to receive the contingent consideration set forth in the Mayne License Agreement, as
amended. The acquisition of net working capital was determined in accordance with the Transaction Agreement and included significant
estimates which could change materially for a period of up to two years following the Closing Date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On the Closing Date, TherapeuticsMD and Mayne Pharma entered into Amendment
No. 1 to the Mayne License Agreement (the &#8220;Mayne License Agreement Amendment&#8221;). Pursuant to the Mayne License Agreement Amendment,
Mayne Pharma agreed to pay us approximately $1.0 million in prepaid royalties on the Closing Date. The prepaid royalties reduced the first
four quarterly payments that would have otherwise been payable pursuant to the Mayne License Agreement by an amount equal to $257 thousand
per quarterly royalty payment plus interest calculated at 19% per annum accruing from the Closing Date until the date such quarterly royalty
payment was paid to us. We and Mayne Pharma settled the $1.5 million of consideration due to Mayne for the assumed obligations under a
long-term services agreement (see the section entitled &#8220;vitaCare Divestiture&#8221; below for a discussion of the long-term services
agreement), including our minimum payment obligations thereunder. As the parties agreed, during the second quarter of 2023, Mayne Parma
held back our royalty payment of $0.6 million and we funded an additional $0.9 million in August 2023 to settle the original $1.5 million
payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As part of the transformation that included the Mayne License Agreement,
historical results of commercial operations for all periods prior to the Closing Date have been reflected as discontinued operations in
our consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities
of discontinued operations in our consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in
Note 2.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also have license agreements with strategic partners to commercialize
IMVEXXY and BIJUVA outside of the U.S.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">In July 2018, we entered into a license and supply agreement
(the &#8220;Knight License Agreement&#8221;) with Knight Therapeutics Inc. (&#8220;Knight&#8221;) pursuant to which we granted Knight
an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            September 2019, we entered into an exclusive license and supply agreement (the &#8220;Theramex
                                            License Agreement&#8221;) with Theramex HQ UK Limited (&#8220;Theramex&#8221;) to commercialize
                                            IMVEXXY and BIJUVA outside of the U.S., excluding Canada and Israel. In 2021, Theramex secured
                                            regulatory approval for BIJUVA in certain European countries and began commercialization
                                            efforts in those countries.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our transformation into a pharmaceutical royalty
company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief
Executive Officer) and all other employees was completed by December 31, 2022. Severance obligations for all employees other than executive
officers were paid in full in January 2023 and severance obligations for terminated executive officers were paid in accordance with their
employment agreements and separation agreements as previously disclosed. As of December 31, 2022 and 2023, we employed one full-time employee
primarily engaged in an executive position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have engaged external consultants who support our relationship with
current partners and assist with certain financial, legal, and regulatory matters and the continued wind-down of our historical business
operations. On August 15, 2023, we entered into a master services agreement with JZ Advisory Group, pursuant to which Joseph Ziegler would
serve as our Principal Financial and Accounting Officer. On August 17, 2023 Michael C. Donegan notified us of his decision to resign from
the positions of Principal Financial and Accounting Officer of our Company effective as of August 17, 2023. Mr. Ziegler succeeded Mr.
Donegan as Principal Financial and Accounting Officer as of the date of Mr. Donegan&#8217;s resignation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>vitaCare Divestiture</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 14, 2022, we completed the divestiture of our former subsidiary
vitaCare Prescription Services, Inc. (&#8220;vitaCare&#8221;) with the sale of all of vitaCare&#8217;s issued and outstanding capital
stock (the &#8220;vitaCare Divestiture&#8221;). We received net proceeds of $142.6 million, after deducting transaction costs of $7.2
million, and we recognized a gain on sale of business of $143.4 million. Included in the net proceeds amount was $11.3 million of customary
holdbacks as provided in the stock purchase agreement (the &#8220;Purchase Agreement&#8221;) which we received in 2023. Additionally,
the Purchase Agreement provides that we may receive up to an additional $7.0 million in earn-out consideration, contingent upon vitaCare&#8217;s
financial performance through 2023 as determined in accordance with the terms of the Purchase Agreement; however, we do not believe this
earnout will be realized. We will record the contingent consideration at the settlement amount if and when the consideration is realized
or realizable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Purchase Agreement contains customary representations and warranties,
covenants, and indemnities of the parties thereto. The commitments under a long-term services agreement related to vitaCare were transferred
to Mayne Pharma as part of the Mayne Transaction. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The divestiture of vitaCare was determined to be a component of discontinued
operations in December 2022, when we changed our business by becoming a royalty company and as a result vitaCare activities were reclassified
to discontinued operations for 2023 and 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Going concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 4, 2022, we entered into agreements with Mayne Pharma pursuant
to which we granted Mayne Pharma an exclusive license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products (in
the United States and its possessions and territories), (ii) assign to Mayne Pharma our exclusive license to commercialize ANNOVERA in
the United States and its possessions and territories, and (iii) sell certain other assets to Mayne Pharma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total consideration from Mayne Pharma to the TherapeuticsMD for
the purchase of the Transferred Assets under the Transaction Agreement and the grant of the licenses under the Mayne License Agreement
consisted of (i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million at closing for the acquisition
of net working capital subject to certain adjustments, (iii) a cash payment of approximately $1.0 million at closing for prepaid royalties
in connection with the Mayne License Agreement Amendment and (iv) the right to receive the contingent consideration set forth in the Mayne
License Agreement, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On the Closing Date, we repaid all obligations under the Financing
Agreement, dated as of April 24, 2019, as amended, with Sixth Street Specialty Lending, Inc., as administrative agent, the various lenders
from time-to-time party thereto, and certain of our subsidiaries party thereto from time to time as guarantors (the &#8220;Financing Agreement&#8221;)
and the Financing Agreement was terminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the transaction with Mayne Pharma, our primary source of
revenue is from royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories.
We may need to raise additional capital to provide additional liquidity to fund our operations until we become cash flow positive. To
address our capital needs, we may pursue various equity and debt financing and other alternatives. The equity financing alternatives may
include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders,
or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity
securities may be limited by market conditions, including the market price of our common stock, and our available authorized shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent that we raise additional capital through the sale of
such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include
liquidation or other preferences that adversely affect the rights of our existing stockholders. If we are not successful in obtaining
additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, or merge,
consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 1, 2023, we entered into a Subscription Agreement (the &#8220;Subscription
Agreement&#8221;) with Rubric Capital Management LP (&#8220;Rubric&#8221;), pursuant to which we agreed to sell to Rubric, or one or more
of its affiliates, up to an aggregate of 5,000,000 shares of our common stock, par value $0.001 per share (our &#8220;Common Stock&#8221;),
from time to time during the term of the Subscription Agreement in separate draw-downs at our election. On June 29, 2023, we issued and
sold 312,525 shares of Common Stock at a price per share equal to $3.6797 pursuant to the Subscription Agreement. We received gross proceeds
of $1.15 million from the draw down, before expenses. On November 15,
2023 Rubric drew down an additional 1,000,000 shares of Common Stock at a price per share equal to $2.28. We received gross proceeds of
$2.0 million from the drawdown, before expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2024, the Company received Mayne Pharma&#8217;s
                                                                         calculation of allowance for payer rebates and wholesale distributor fees which differed significantly from the Company&#8217;s
                                                                         estimate of the allowances. The Company believes its estimated allowances for payer rebates and wholesale distributor fees are
                                                                         reasonable and intends to resolve this matter through the process outlined in the Transaction Agreement. Given the recent receipt of
                                                                         Mayne Pharma&#8217;s allowance calculation and the nature of the estimates involved, the outcome of this matter is uncertain at this
                                                                         point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any
                                                                         additional liability associated with Mayne Pharma&#8217;s allowance calculation for payer rebates and wholesale distributor
                                                                         fees.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, the Company believes no additional accrual
is required for amounts that may be owed for the allowance for returns under the Transaction Agreement. The Company has not recorded any
contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital
items as changes to estimated amounts owed or amounts due from Mayne Pharma that may be material.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If Mayne Pharma&#8217;s sales of IMVEXXY, BIJUVA, or ANNOVERA
grow more slowly than expected or decline, if the net working capital settlement with Mayne Pharma under the Transaction Agreement
is greater than our current estimates, if we are unsuccessful with future financings or if the supply chains related to the
third-party contract manufacturers are worse than we anticipate, our existing cash reserves may be insufficient to satisfy our
liquidity requirements. The potential impact of these factors in conjunction with the uncertainty of the capital markets raises
substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying consolidated financial statements do not include any
adjustments that might be necessary if we are unable to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A.&#160;Basis of presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements and related notes include our
parent company and all wholly owned subsidiaries. The consolidated financial statements are prepared in accordance with accounting principles
generally accepted in the Unites States of America (&#8220;U.S. GAAP&#8221;). Our fiscal year-end is as of and for the year ended December
31st for each year presented. All intercompany transactions among our businesses have been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As part of the transformation and as a result of the vitaCare divestiture
and the Mayne Transaction, historical results of commercial operations for all periods prior to the Closing Date have been reflected as
discontinued operations in the consolidated financial statements. Assets and liabilities associated with the commercial business are classified
as assets and liabilities of discontinued operations in the consolidated balance sheet. Additional disclosures regarding discontinued
operations are provided in Note 2 of these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain amounts in the notes to the consolidated financial statements
may not add due to rounding. Certain prior period amounts have been reclassified to conform to current-period presentation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B.&#160;New accounting standards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Adoption of new accounting standards</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;)
issued ASU 2023-09, &#8220;Income Taxes (Topic 740) - Improvements to Income Tax Disclosures.&#8221; ASU 2023-09 enhances the transparency
and decision usefulness of income tax disclosures by requiring consistent categories and greater disaggregation of information in the
rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 will be effective for the Company in its income tax
disclosure included in its 2025 Annual Report on Form 10-K and will be applied on a prospective basis. However, retrospective application
is permitted. Early adoption is also permitted. The Company is evaluating the impact of ASU 2023-09 on the Company's income tax disclosures
and on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>C. Discontinued Operations</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Discontinued operations comprise activities that were disposed of at
the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting
purposes and represent a business shift having a major effect on the Company&#8217;s operations and financial results according to Accounting
Standard Codification (&#8220;ASC&#8221;) Topic 205, Presentation of Financial Statements. An adjustment has been made to the consolidated
statements of operations for the twelve months ended December 31, 2023 and 2022 to reclassify commercial activities and vitaCare activities
to discontinued operations as both components, in the aggregate, represented a business shift that will have a major effect on the Company&#8217;s
operations and financial results. No amounts for shared general and administrative operating support expense were allocated to discontinued
operations. As required by the terms of the Financing Agreement, the proceeds from both transactions were used to fully repay our outstanding
debt borrowings. As a result, interest expense and amortization of deferred financing costs as well as expense for accretion of Series
A Preferred Stock and loss on extinguishment of debt are included within income (loss) from discontinued operations, net of tax. Additionally,
the related assets and liabilities have been reported as assets and liabilities of discontinued operations in the Company&#8217;s consolidated
balance sheet as of December 31, 2023 and 2022. For additional information, see Note 2 - Discontinued Operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>D. Estimates and assumptions</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of consolidated financial statements in conformity
to U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the
reporting period. We evaluate our estimated assumptions based on historical experience and on various other assumptions that are believed
to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different
assumptions or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>E. Cash and Restricted Cash</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">For the purpose of the statements of cash flows, all highly liquid
investments with an original maturity of three months or less are considered to be&#160;cash&#160;equivalents. The carrying value of these
investments approximates fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We maintain cash at financial institutions that at times may exceed
the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits of $0.25 million per bank. We have never experienced any
losses related to these funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restricted cash was comprised of escrowed funds deposited with a bank
relating to the vitaCare Divestiture. All restrictions were lifted in March 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>F.</b>&#160;<b>Fair Value Measurements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fair value is the price to sell an asset or transfer a liability and
therefore represents an exit price in the principal market (or in the absence of a principal market, the most advantageous market). It
represents a market-based measurement that contemplates a hypothetical transaction between market participants at the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The unique characteristics of an asset or liability and the availability
of observable prices affect the number of valuation approaches and/or techniques used in a fair value analysis. We measure fair value
using observable and unobservable inputs. We give the highest priority to quoted prices (unadjusted) in active markets for identical assets
or liabilities (Level 1 inputs) and the lowest priority to unobservable inputs (Level 3 inputs).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We apply the following fair value hierarchy:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">Level 1 - Quoted prices (unadjusted) in active markets for
identical assets and liabilities.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">Level 2 - Quoted prices in non-active markets or in active
markets for similar assets or liabilities, observable inputs other than quoted prices; and inputs that are not directly observable but
are corroborated by observable market data.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">Level 3 - Inputs that are unobservable.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amount of our cash, restricted cash, accounts receivable,
accounts payable and accrued expenses approximate their fair value because of the short-term maturity of such instruments, which are considered
Level 1 under the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>G.&#160;Fixed assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fixed assets are carried at cost less accumulated depreciation and
amortization. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs
to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related
assets, which range from three to seven years. Leasehold improvements are depreciated over the shorter of their useful life or the term
of the lease. Long-lived assets held and used by us, including fixed assets, are assessed for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be recoverable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We capitalize software and software development costs incurred to create
and acquire computer software for internal use, principally related to software coding and application development. We begin to capitalize
software development costs when both the preliminary project stage is completed, and it is probable that the software will be used as
intended. Capitalized software costs include only external direct costs and services utilized in developing or obtaining computer software.
Capitalized software costs are amortized on a straight-line basis when placed into service over the estimated useful life, generally five
to seven years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>H.&#160;License rights and other
intangibles assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We record license rights and other intangible assets at cost, which
includes external costs, consisting primary of legal costs, incurred in securing our patents and trademarks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">License rights costs related to ANNOVERA were amortized until December
30, 2022 over the useful life over which the license rights would contribute directly or indirectly to our cash flows. The cost was amortized
using the straight-line method as the pattern of economic benefit could not be reliably determined. On December 30, 2022, we assigned
our ANNOVERA license to Mayne Pharma and included the remaining ANNOVERA license cost of $30.2 million in our calculation of the gain
on sale of assets. In addition, amortization of license rights of $3.0 million for 2022 was reclassified to discontinued operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intangible assets subject to amortization, such as patents, are amortized
over the useful life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs
at that time. Intangible assets not subject to amortization, such as trademarks, are perpetual and have indefinite lives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We review license rights and other intangible assets subject to amortization
on a periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision to their remaining useful
lives. We assess other intangible assets not subject to amortization for potential impairment at least annually during the fourth quarter
of each year, or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the
intangible assets below their carrying value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>I.</b>&#160;<b>Segment reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We manage and operate as one business, which prior to December 2022
was focused on creating and commercializing products targeted exclusively for women and after we signed Mayne License Agreement, is focused
on collecting royalties from licensing our products. Our business is led by our chief executive officer. We do not operate separate lines
of business with respect to any of our products, and we do not prepare discrete financial information with respect to separate products.
Accordingly, we view our business as one reportable operating segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>J.&#160;Revenue recognition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We determine the amount of revenue to be recognized through application
of the following steps:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"></td><td style="width: 0.25in">&#9679;</td><td>Identification of the contract with a customer;</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"></td><td style="width: 0.25in">&#9679;</td><td>Identification of the performance obligations in the contract;</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"></td><td style="width: 0.25in">&#9679;</td><td>Determination of the transaction price;</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"></td><td style="width: 0.25in">&#9679;</td><td>Allocation of the transaction price to the performance obligations in the contract; and</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"></td><td style="width: 0.25in">&#9679;</td><td>Recognition of revenue when or as we satisfy the performance obligations.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A performance obligation is a promise in a contract to transfer a product
or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains
control, and we treat shipping as a fulfillment activity rather than as a separate obligation. We generally recognize revenue at a point
in time when all of our performance obligations under the terms of a contract are satisfied. Revenue is recognized upon transfer of control
of promised products or services in an amount that reflects the consideration we expect to receive in exchange for those products or services.
The collectability of consideration on the contract is reasonably assured before revenue is recognized. To the extent that customer payment
has been received before all recognition criteria are met, these revenues are initially deferred in other accruals on the balance sheet
and the revenue is recognized in the period that all recognition criteria have been met.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>License revenue</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">License arrangements may consist of non-refundable upfront license
fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones and future product
royalty payments. Some of these arrangements may include multiple performance obligations. Non-refundable up-front fees that are not contingent
on any future performance by us, and do not require continuing involvement on our part, are recognized as revenue when the right to use
functional intellectual property is transferred to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 30, 2022, we granted an exclusive license to commercialize
our prescription products and assigning the Company&#8217;s exclusive license to commercialize ANNOVERA to Mayne Pharma, which resulted
in a business shift that had a major effect on our operations and financial results. As part of the transformation that included the Mayne
License Agreement, historical results of commercial operations have been reflected as discontinued operations in the Company&#8217;s consolidated
financial statements for all periods prior to the Closing Date. As of December 31, 2022, we are no longer directly engaged in the sale
of prescription products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the Mayne License Agreement, we received $140 million
at closing and we are eligible to receive additional payments in the aggregate of up to an additional $30 million, based on the achievement
of sales milestones (collectively, the &#8220;Milestone Amounts&#8221;). The proceeds at closing were allocated between consideration
for the sale of ANNOVERA and the initial license fee for the Licensed Products, as the sale of ANNOVERA was accounted for under ASC 610-20,
Gains and Losses from Derecognition of Nonfinancial Assets in arriving at the gain on disposal (see Note 2), while the license grant of
the other products were recognized under the provisions of ASC 606, Revenue from Contracts with Customers, as a license of functional
intellectual property. The proceeds were allocated among the Licensed Products on the relative net present value of forecasted future
product sales from those products. The Milestone Amounts will be recognized, as applicable, in subsequent periods based on actual product
sales that exceed the respective net sales milestones as such variable consideration is constrained by the occurrence of the subsequent
sales.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our royalty revenue in 2023 primarily related to royalties provided
for under the Mayne License Agreement based on Mayne Pharma&#8217;s sales of the licensed products subject to that agreement. Under the
Mayne License Agreement, the Company is entitled to earn royalties on net sales of all of the Licensed Products at a royalty rate of (i)
8% on the first $80 million of net sales of the Licensed Products and (ii) 7.5% on net sales of all of the Licensed Products after the
first $80 million of net sales. The royalty rate is subject to a 2% reduction upon the earlier to occur of (i) the expiration or revocation
of the last valid claim covering a Licensed Product, and (ii) a generic product launch (a &#8220;LOE&#8221;). We are entitled to minimum
annual royalties beginning with the year ending December 31, 2023 ($3 million annual minimum) and continuing with 3% annual increases
through the year ending December 31, 2034 (the &#8220;Minimum Annual Royalty&#8221;). The total Minimum Annual Royalty we are entitled
to is $42.6 million, and this total amount was allocated among the Licensed Products on the relative net present value of forecasted future
product sales from those products. The portion allocated to consideration for the sale of ANNOVERA was attributed towards the gain on
disposal of that asset. For the remaining portion allocated to the license grants for the other products, we determined that the minimum
guarantee underlying the Minimum Annual Royalty should be treated as fixed consideration and recognized under ASC 606 at the point in
time when the license was transferred. Since the Minimum Annual Royalty will be received in annual installments through 2034, we determined
the transaction price allocated under ASC 606 contained a significant financing component, and we therefore determined the initial royalty
revenue and corresponding receivable based on the present value of the allocated Minimum Annual Royalty. The present value was calculated
using a discount rate of 10.45%, based on the credit characteristics of Mayne Pharma and the timing of future payments, and the value
will be accreted to full value through the earlier of January 1, 2034 or a LOE. This royalty receivable is a contract asset as of December
31, 2022 and 2023, and is further subject to offset by Mayne Pharma (see L. Contract Assets and Liabilities below).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Royalty revenue earned in excess of the Minimum Annual Royalty will
be recognized under ASC 606, which provides revenue recognition constraints by requiring the recognition of revenue at the later of the
following: 1) when the subsequent sale occurs or 2) when the performance obligation to which some or all of the sales-based royalty has
been allocated has been satisfied (or partially satisfied). We applied the royalty recognition constraint required under the guidance
for sales-based royalties, which requires a sales-based royalty to be recorded no sooner than the underlying sale. Therefore, royalties
on sales of products commercialized by Mayne Pharma will be recognized in the subsequent periods that the Licensed Products are sold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2023, we recorded BIJUVA license sales of $0.3 million made through
the Theramex License Agreement and $1.0 million pertaining to our licensed products with Mayne Pharma, which was recognized as license
revenue. Additionally, we recognized $0.5 million in other income pertaining to royalty sales of ANNOVERA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>K.</b>&#160;<b>Cost of revenue</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenue includes the cost of inventory, manufacturing, manufacturing
overhead and supply chain costs and product shipping and handling costs. Costs related to the Population Council License Agreement, which
were based on our net sales of ANNOVERA, and amortization of license rights were reclassified to discontinued operations for 2022 as a
result of the transaction with Mayne Pharma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>L.&#160;Contract Assets and
Liabilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contract assets totaling $21.6 million as of December 31, 2023, include
royalties recognized from the Minimum Annual Royalty (see J. Revenue Recognition above).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>M.&#160;Share-based payment
awards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We account for share-based payment awards on a fair value basis of
the equity instrument issued. Under fair value accounting, the grant-date fair value of the share-based payment award is amortized as
compensation expense, on a straight-line basis, over the service period (generally, the vesting period) for both graded and cliff vesting
awards. We have elected to account for forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Common stock reverse stock split</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 6, 2022, we completed a reverse stock split of our Common Stock.
As a result, shares of our outstanding Common Stock were split at a ratio of 50-for-1 (the &#8220;Reverse Stock Split&#8221;) with any
fractional shares resulting from the Reserve Stock Split rounded up to the next whole share of Common Stock. The number of authorized
shares of Common Stock was also correspondingly reduced from 600.0 million shares to 12.0 million shares to give effect to the Reverse
Stock Split. Additionally, all rights to receive shares of Common Stock under outstanding warrants, options, restricted stock units (&#8220;RSUs&#8221;)
and performance stock units (&#8220;PSUs&#8221;) were adjusted to give effect of the Reverse Stock Split. Furthermore, remaining shares
of Common Stock available for future issuance under share-based payment award plans and our employee stock purchase plan were adjusted
to give effect of the Reverse Stock Split. Pursuant to Section 78.209 of the Nevada Revised Statutes, the approval of our stockholders
was not required for our Board of Directors (the &#8220;Board&#8221;) to effectuate the Reverse Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All historical numbers of shares of Common Stock and per share data
have been adjusted to give effect to the Reverse Stock Split. Additionally, since the Common Stock par value was unchanged, historical
amounts for Common Stock and additional paid-in capital have been adjusted to give effect to the Reverse Stock Split.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Increase of authorized shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 26, 2023, at our combined 2022 and 2023 Annual Meeting, our
stockholders approved an amendment to our Amended and Restated Articles of Incorporation to increase the number of authorized shares of
Common Stock from 12 million shares to 32 million shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>N.&#160;Income taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income taxes are accounted for under the asset and liability method.
Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and income
tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in income tax rates is recorded as a component of the income tax provision in the period that includes the enactment
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regular assessments are made on the likelihood that our deferred tax
assets will be recovered from our future taxable income. Our evaluation is based on estimates, assumptions, and includes an analysis of
available positive and negative evidence, giving weight based on the evidence&#8217;s relative objectivity. Sources of positive evidence
include estimates of future taxable income, future reversal of existing taxable temporary differences, taxable income in carryback years,
and available tax planning strategies. Sources of negative evidence include current and cumulative losses in recent years, losses expected
in early future years, any history of operating losses or tax credit carryforwards expiring unused, and unsettled circumstances that,
if unfavorably resolved, would adversely affect future profit levels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The remaining carrying value of our deferred tax assets, after recording
the valuation allowance on our deferred tax assets, is based on our present belief that it is more likely than not that we will be able
to generate sufficient future taxable income to utilize such deferred tax assets. The amount of the remaining deferred tax assets considered
recoverable could be adjusted if our estimates of future taxable income during the carryforward period change favorably or unfavorably.
To the extent we believe that it is more likely than not that some or all the remaining deferred tax assets will not be realized, we must
establish a valuation allowance against those deferred tax assets, resulting in additional income tax expense in the period such determination
is made. To the extent a valuation allowance currently exists, we will continue to monitor all positive and negative evidence until we
believe it is more likely than not that it is no longer necessary, resulting in an income tax benefit in the period such determination
is made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our policy is to recognize both interest and penalties related to uncertain
tax positions as part of the income tax provision. Significant judgment is required in evaluating our tax positions, and in determining
our provisions for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred
tax assets. We establish reserves when, despite our belief that the income tax return positions are fully supportable, certain positions
are likely to be challenged and we may ultimately not prevail in defending those positions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>O.&#160;Earnings per common
share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic earnings or loss per common share is computed by dividing net
income or loss available to common stockholders by the sum of the weighted average number of shares of common stock. Diluted earnings
per common share is computed by dividing net income available to common stockholders by the sum of the weighted average number of shares
of common stock and the number of additional shares of common stock that would have been outstanding if our outstanding potentially dilutive
securities had been issued. Potentially dilutive securities include awards of non-vested or vested and not settled restricted stock units,
performance stock units where the performance requirements have been met and not settled, warrants and options. The dilutive effect of
potentially dilutive securities is reflected in diluted earnings per common share by application of the treasury stock method, except
if its impact is anti-dilutive. Under the treasury stock method, an increase in the fair market value of our common stock can result in
a greater dilutive effect from potentially dilutive securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>P.&#160;Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We determine if an arrangement is a lease at inception. Determining
whether a contract contains a lease includes judgment regarding whether the contract conveys the right to control the use of identified
property or equipment for a period of time in exchange for consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We account for our lease-related assets and liabilities based on their
classification as operating leases or finance leases, following the relevant accounting guidance. For all the lessee arrangements, we
have elected an accounting policy to combine non-lease components with the related-lease components and treat the combined items as a
lease for accounting purposes. We measure lease related assets and liabilities based on the present value of lease payments, including
in-substance fixed payments, variable payments that depend on an index or rate measured at the commencement date, and the amount we believe
is probable we will pay the lessor under residual value guarantees when applicable. We discount lease payments based on our estimated
incremental borrowing rate at lease commencement (or modification), which is primarily based on our estimated credit rating, the lease
term at commencement, and the contract currency of the lease arrangement. We have elected to exclude short-term leases (leases with an
original lease term less than one year) from the measurement of lease-related assets and liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We test right-of-use assets in an operating or finance lease at the asset group level (because these assets are long-lived nonfinancial
assets and should be accounted for the same way as other long-lived nonfinancial assets) whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We sublease our unoccupied facilities to third parties. Any impairment
to the associated right-of-use asset, leasehold improvements, or other assets as a result of the sublease is recognized in the period
when a decision to sublease is made and recorded in our consolidated statement of operations. We recognize sublease income on a straight-line
basis over the sublease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Q.&#160;Loss Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In determining whether an accrual for a loss contingency is required,
we first assess the likelihood of occurrence of the future event or events that will confirm the loss. When a loss is probable (the future
event or events are likely to occur) and the amount of the loss can be reasonably estimated, the estimated loss is accrued. If the reasonable
estimate of the loss is a range and an amount within the range appears to be a better estimate than any other amount within the range,
that amount should be accrued. However, if no amount within the range is a better estimate, the minimum amount in the range should be
accrued. When a loss is reasonably possible (the chance of the future event or events occurring is more than remote but less than likely),
no accrual is recognized. See Note 8 for more information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>R.&#160;Restructuring charges</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2022, the Company initiated and
completed a restructuring plan that resulted in a reduction of its workforce to one employee. One-time termination benefits include severance,
continuation of health insurance coverage, and other benefits for a specified period of time, as well as contract terminations and fixed
assets write-downs, which resulted in $15.7 million of restructuring costs for the year ended December 31, 2022. There were no restructuring
costs incurred during the year ended December 31, 2023. Restructuring costs have been recognized in the accompanying consolidated statement
of operations as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Year ended<br/> December&#160;31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Executive termination benefits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,897</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Consulting and legal expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,060</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other contract termination costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,515</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total restructuring expenses - general and administrative expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,472</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employee termination benefits</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,813</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other contract termination costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,367</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total restructuring expenses - discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,180</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At December 31, 2023 and 2022 respectively, $2.5 million and $6.2 million
of restructuring costs were included in current liabilities of discontinued operations in the accompanying consolidated balance sheets.
At December 31, 2022, $9.3 million related to restructuring costs was included in accrued expenses and other current liabilities.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>S. Reclassification of prior year presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain prior year amounts have been reclassified for consistency with
the current year presentation.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824844165296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>2. Discontinued Operations</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt">As discussed in Note 1, we changed our business in 2022 by
licensing our products to receive royalties and future sales related milestone payments, after granting an exclusive license to commercialize
our IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands in the United States and
assigning our exclusive license to commercialize ANNOVERA to Mayne Pharma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt">This plan represented a strategic shift having a major effect
on our operations and financial results. Upon our conversion from a commercial pharmaceutical company to a licensing only company with
the consummation of the Mayne Transaction, we classified all direct revenues, costs and expenses related to commercial operations, within
income (loss) from discontinued operations, net of tax, in the consolidated statements of operations for all periods presented. We have
not allocated any amounts for shared general and administrative operating support expense to discontinued operations. As required by the
terms of the Financing Agreement, proceeds from the Mayne Transaction and the vitaCare Divestiture were used to fully repay our outstanding
debt borrowings, and as a result interest expense and amortization of deferred financing costs as well as expense for accretion of Series
A Preferred Stock and loss on extinguishment of debt are included within income (loss) from discontinued operations, net of tax (as disclosed
below).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt">Additionally, the related assets and liabilities have been
reported as assets and liabilities of discontinued operations in our consolidated balance sheet as of December 31, 2023 and 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt">The total consideration from Mayne Pharma consisted of (i)
a cash payment of $140.0 million at closing, (ii) a cash payment of $12.1 million for the acquisition of net working capital subject to
certain adjustments, (iii) a cash payment of approximately $1.0 million for prepaid royalties in connection with the Mayne License Agreement
Amendment and (iv) the right to receive the contingent consideration set forth in the Mayne License Agreement, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt">Our estimate of net working capital at closing was determined in accordance
with the Transaction Agreement which establishes the process for the determination of final net working capital. The determination of
final net working capital includes significant estimates which could change materially for a period of up to two years following the Closing
Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt">The following table presents results of discontinued operations
(in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Years ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Product revenue, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(833</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">80,749</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,640</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross profit (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(833</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65,109</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,208</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">481</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,301</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,942</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Restructuring charges</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">481</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">97,631</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss from discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,314</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(32,522</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gain on sale of vitaCare</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">143,384</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on ANNOVERA sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,031</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on the extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,380</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense and other financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36,065</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expense for accretion of Series A Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,973</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss on disposal of assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,150</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(115</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,265</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">143,997</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss before from income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,579</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,475</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Benefit (provision) for income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(552</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net income (loss) from discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,579</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">110,923</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents the carrying amounts of the classes of
assets and liabilities of discontinued operations (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">344</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">344</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,243</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,694</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,588</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,694</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,831</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824840123216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid and other current assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3.&#160;Prepaid and other current
assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our prepaid and other current assets consisted of the following
(in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">253</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,167</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Capitalized legal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,334</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,448</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,533</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Prepaid and other current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,035</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,034</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824843962592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_FixedAssetsAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-size: 10pt"><b>4. Fixed assets</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our fixed assets, net consisted of the following (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Furniture and fixtures</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">931</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">931</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Computer and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,168</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,522</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,523</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,522</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,445</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Fixed assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded in continuing operations, depreciation expense of $0.1
million for 2023 and $0.6 million for 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_FixedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_FixedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824843382864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensed Rights and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Licensed Rights and Other Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Licensed rights and other intangible assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>5. Licensed rights and other intangible assets</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following provides information about our license rights and other
intangible assets, net (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Gross</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Gross</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Carrying</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Carrying</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Net</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Net</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Intangible assets subject to amortization:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Hormone therapy drug patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,818</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,871</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,947</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,225</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,598</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,627</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Hormone therapy drug patents applied and pending approval</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">842</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">842</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,995</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,995</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Intangible assets subject to amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,660</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,871</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,789</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,220</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,598</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,622</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Intangible assets not subject to amortization:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Trademarks/trade name rights</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">309</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">309</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">321</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">321</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Intangible assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,969</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,871</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,098</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,541</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,598</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,943</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded, in continuing operations, amortization expense related
to patents of $0.8 million for 2023, of which $0.5 million is accelerated amortization as a result of a review of our intangible assets,
and $0.6 million for 2022. We recorded amortization expense related to the exclusive license rights agreement with Population Council
of $3.0 million for 2022, which was reclassified to discontinued operations after we completed transaction with Mayne Pharma in December
2022, and excluded from the table above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our intangible assets subject to amortization are expected to be amortized
as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">Year ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">533</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,347</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,660</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We use a combination of qualitative and quantitative factors to assess
licensed rights and intangible assets for impairment. In the year ending December 31, 2023, we have not impaired any of our hormone therapy
drug patent assets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824842103008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued expenses and other current liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>6. Accrued expenses and other current liabilities</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other accrued expenses and other current liabilities consisted of the
following (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Payroll and related costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">762</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,748</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued contract termination costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,700</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">978</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">489</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">415</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,473</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,390</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid royalty</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,011</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other accrued expenses and current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,604</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,133</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,846</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expense advertising costs when incurred, which amounted to
$13.2 million for 2022, which was reclassified to discontinued operations as a result of our business shift following the Mayne
Transaction. We incurred no advertising costs in 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824840072096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debt</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>7. Debt</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Financing agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We were party to the Financing Agreement with Sixth Street
Specialty Lending, Inc., as administrative agent, various lenders from time-to-time party thereto, and certain of our subsidiaries
party thereto from time to time as guarantors. On December 30, 2022, we repaid all obligations under the Financing Agreement and the
Financing Agreement was terminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Interest and financing costs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Included in miscellaneous income in 2023 is $0.3 million of interest
income and $0.2 million of interest expense. In 2022 and recorded in discontinued operations, we recognized $13.5 million of debt-related
interest expense and $22.5 million of financing fees amortization.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824844014240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8.&#160;Commitments and contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2018, we entered into a lease for executive, administrative,
operations and sales offices in Boca Raton, Florida. The lease includes 62,748 rentable square feet, or the full premises, of which the
lease on 7,561 square feet commenced in 2018 and the lease on 48,651 square feet commenced in August 2019, or the full premises
commencement date. In June 2019, we entered into an agreement with the same lessors to
lease additional 6,536 square feet of administrative office space in the same location, pursuant to an addendum to such lease, which commenced
in May 2020. The lease will expire 11 years after the full premises commencement date, unless terminated earlier in accordance with
the terms of the lease. We have the option to extend the term of the lease for two additional consecutive periods of five years. The extension
option is not included in the determination of the lease term as it is not reasonably certain to be exercised. The term of the lease includes
escalating rent and free rent periods. We are also responsible for certain other operating costs under the lease, including electricity
and utility expenses. As a result of shifting our business
to become a license company and terminating our employees, we have sublet the majority of our headquarters and are in the process of subleasing
the remainder. We anticipate that sublease income will approximate the amounts due under our existing leases, therefore no impairment
of the right of use asset was recorded in 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For 2023 and 2022, operating <span style="-sec-ix-hidden: hidden-fact-75"><span style="-sec-ix-hidden: hidden-fact-76">lease expense</span></span> (including all variable
costs) related to our real estate leases was $2.3 and $2.1 million, respectively. In 2023 and 2022, our rental income on sublease of our
three suites which were subleased following the vitaCare transaction was $1.3 million and $0.0 million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, our remaining lease payments were as follows
(in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Year ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,477</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,513</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,551</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,590</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,630</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,664</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,425</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,420</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Present value of lease payments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,005</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth supplemental balance sheet information
related to leases (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31,</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease right-of-use assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">6,873</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">7,580</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease liabilities current (included in accrued expenses and other current liabilities)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,473</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,390</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,369</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,005</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,759</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents other information related to leases:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Weighted average remaining term (years) - operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.7</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Weighted average discount rate - operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cash paid for amounts included in the measurement of lease liabilities from operating lease (in thousands)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,413</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Right-of-use assets obtained in exchange for new operating lease obligations (non-cash in thousands)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Mayne Pharma Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mayne Pharma paid us approximately $12.1 million at closing on December
30, 2022, for the acquisition of net working capital, subject to certain adjustments as determined in accordance with the Transaction
Agreement. While the Transaction Agreement calls for much of the net working capital to be trued-up shortly after the Closing Date in
2023, for a period of one year following the Closing Date in the case of payer rebates and wholesale distributor fees and two years
following the Closing Date in the case for allowance for returns, net working capital amounts will be adjusted to arrive at final net
working capital under the Transaction Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2023, we revised certain accrual estimates including increasing our working capital adjustment accrual from $3.5 million to $5.5 million for amounts anticipated to be owed under the Transaction Agreement. In December 2023, we made a $5.5 million payment to Mayne Pharma to settle certain working capital amounts that were required to be trued-up shortly after the Closing Date, excluding the allowance for returns, allowance for payer rebates, and allowance for wholesale distributor fees.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2024, the Company received Mayne Pharma&#8217;s
                                                                                                             calculation of allowance for payer rebates and wholesale distributor fees which differed significantly from the Company&#8217;s
                                                                                                             estimate of the allowances. The Company believes its estimated allowances for payer rebates and wholesale distributor fees are
                                                                                                             reasonable and intends to resolve this matter through the process outlined in the Transaction Agreement. Given the recent receipt of
                                                                                                             Mayne Pharma&#8217;s allowance calculation and the nature of the estimates involved, the outcome of this matter is uncertain at this
                                                                                                             point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any
                                                                                                             additional liability associated with Mayne Pharma&#8217;s allowance calculation for payer rebates and wholesale distributor
                                                                                                             fees.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Additionally and as of December 31, 2023, the Company believes no additional
accrual is required for amounts that may be owed for the allowance for returns. The Company has not recorded any contingent gains or receivables
for any such allowances. Management continues to monitor the unresolved and pending net working capital items as changes to estimated
amounts owed or amounts due from Mayne Pharma that may be material.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Population Council License Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of our license agreement with the Population Council,
Inc. (the &#8220;Population Council License Agreement&#8221;), we paid the Population Council a milestone payment of $20.0 million in
2018, which was within 30 days following the approval by the FDA of the New Drug Application (&#8220;NDA&#8221;) for ANNOVERA, and $20.0
million in 2019 following the first commercial batch release of ANNOVERA. The aggregate $40.0 million of milestone payments were recorded
as license rights. The Population Council was also eligible to receive future payments upon the achievement of certain commercial sales
milestones of ANNOVERA. On December 30, 2022, we assigned the ANNOVERA license to Mayne Pharma. Our rights and obligations under the Population
Council License Agreement have been transferred to Mayne Pharma and may revert back to us upon the occurrence of certain events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2020, we received a Paragraph IV certification notice letter
(the &#8220;IMVEXXY Notice Letter&#8221;) regarding an Abbreviated New Drug Application (&#8220;ANDA&#8221;) submitted to the FDA by Teva
Pharmaceuticals USA, Inc. (&#8220;Teva&#8221;). The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic
version of the 4 mcg and 10 mcg doses of IMVEXXY. In the IMVEXXY Notice Letter, Teva alleges that TherapeuticsMD patents listed in the
FDA&#8217;s Orange Book that claim compositions and methods of IMVEXXY (the &#8220;IMVEXXY Patents&#8221;) are invalid, unenforceable,
and/or will not be infringed by Teva&#8217;s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents
identified in the IMVEXXY Notice Letter expire in 2032 or 2033. In April 2020, we filed a complaint for patent infringement against Teva
in the United States District Court for the District of New Jersey arising from Teva&#8217;s ANDA filing with the FDA. We are seeking,
among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA would be a date no earlier than the expiration
of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim
to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. In July 2021, following a proposal by Teva, the District
Court entered an order temporarily staying all proceedings in the IMVEXXY litigation, which order was filed under seal. In September 2021,
the District Court made available a public version of the order following the parties&#8217; agreement to a consent motion to redact information
Teva contended was confidential. The order provides that the statutory stay that prevents the FDA from granting final approval of the
ANDA for 30 months from the date of the IMVEXXY Notice Letter will be extended for the number of days that the stay of the IMVEXXY litigation
is in place. The length of the stay of the IMVEXXY litigation is dependent on further action by Teva. We have incurred and recorded legal
costs amounting to $2.3 million in prepaid expenses and other current assets as of December 31, 2023, for the IMVEXXY Paragraph IV legal
proceeding since we believe that we will successfully prevail in this legal proceeding. Upon the successful conclusion of the legal proceeding,
the related capitalized legal costs will be reclassified to patents, in license rights and other intangible assets, net, in the accompanying
consolidated balance sheets, and such costs will be amortized over the remaining useful life of the patents. If we are unsuccessful in
this legal proceeding, then the related capitalized legal costs for this legal preceding and any unamortized IMVEXXY patent costs that
were previously capitalized will be immediately expensed in the period in which we become aware of an unsuccessful legal proceeding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beginning on December 30, 2022 and per the Mayne License Agreement,
Mayne Pharma is responsible for all enforcement of our patents, including the litigation discussed above with respect to Teva.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2023, one of our former contractors retained to market
ANNOVERA under Title X, filed a lawsuit that accused us of breach of contract. We answered their complaint and filed breach of contract
counterclaims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, we are involved in other litigations and proceedings
in the ordinary course of business. We are not currently involved in any other litigations and proceedings that we believe would have
a material effect on our consolidated financial condition, results of operations, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Off-balance sheet arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023 and 2022 we had no off-balance sheet arrangements
that have had or are reasonably likely to have current or future effects on our financial condition, changes in financial condition, revenues
or expenses, results of operations, liquidity, capital expenditures or capital resources that we consider material.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employment agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our transformation into a pharmaceutical royalty
company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief
Executive Officer) and all other employees was completed by December 30, 2022. Severance obligations for all employees other than executive
officers were paid in full in the first quarter of 2023. As of December 31, 2023, we employ one full-time employee primarily engaged in
an executive position. We have engaged external consultants who support our relationship with current partners and assist with certain
financial, legal, and regulatory matters and the continued wind-down of our historical business operations. The separation of our former
Interim Co-Chief Executive Officers, former Interim Chief Financial Officer and other executives from TherapeuticsMD was each a termination
without &#8220;Good Cause,&#8221; as defined in their respective employment agreements. In the aggregate, as of December 31, 2023, we
have accrued severance liabilities for executive termination obligations of $0.4 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824843843232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity (Deficit)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>9. Stockholders&#8217; Equity</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt"><b>Increase of authorized shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt">On June 26, 2023, at our combined 2022
and 2023 Annual Meeting, our stockholders approved an amendment to our Amended and Restated Articles of Incorporation to increase the
number of authorized shares of Common Stock from 12 million shares to 32 million shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, the following table summarizes the status
of our outstanding and exercisable warrants and related transactions since December 31, 2021 (in thousands, except weighted average exercise
price and weighted average remaining contractual life data):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">Warrants outstanding and exercisable</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in&#160;Years)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance, December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">103</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">76.19</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.3</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">436</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">341.5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,427</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(435</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,270</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.89</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance, December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">99</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">66.61</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,793</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We used the Black Scholes option pricing model to estimate the fair
value of the warrants issued. The weighted average fair value of the warrants issued in 2022 was $0.13 per warrant and the assumptions
used to determine such fair value were as follows: expected term of 10 years, volatility of 69.4%, dividend yields of 0% and risk-free
interest rates of 2.9%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Share-based compensation payment plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, 126,573 shares of common stock were subject
to outstanding awards under our share-based payment award plans and inducement grants (calculated using the base number of PSUs that may
vest). As of December 31, 2023, 394,669 shares of common stock were available for future grants of share-based payment awards under the
TherapeuticsMD, Inc. 2019 Stock Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the status of our outstanding and exercisable
options and related transactions (each adjusted to account for the Reverse Stock Split) since December 31, 2022 (in thousands, except
weighed average exercise price and weighted average remaining contractual life data):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">Outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">Exercisable</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Options<br/> Awards</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise<br/> Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life<br/> (in&#160;Years)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Options<br/> Awards</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life (in&#160;Years)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-indent: -9pt; padding-left: 9pt">As of January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">353</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">225.98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.8</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">336</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">230.93</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.6</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Cancelled/Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(177</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">226.56</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">As of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Cancelled/Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">206.15</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">As of December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">258.55</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.0</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">73</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">258.46</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.0</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the status of our RSUs and related transactions
(each adjusted to account for the Reverse Stock Split) (in thousands, except weighed average grant date fair value):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">RSUs awards outstanding</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
 Average<br/>
 Grant Date<br/>
 Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/>
 Intrinsic<br/>
 Value</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance, January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">272</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">58.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,890.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(327</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cancelled/Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(58</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">318.63</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">163</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(180</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cancelled/Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance, as of December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9.67</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">89.6</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the status of our PSUs and related transactions
for each for the following years (each adjusted to account for the Reverse Stock Split) (in thousands, except weighed average grant date
fair value):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">PSUs</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Grant Date<br/> Fair Value</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2021</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">164</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">51.50</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,953</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">63</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">34.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vested and settled</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(133</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">47.12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,382.98</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Cancelled/Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(75</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(44.85</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Unvested, as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">52.15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">107.55</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">&#8212;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Vested</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">56.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(10.72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Cancelled/Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Unvested, as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">14</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">50.87</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Share-based payment compensation cost</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Share-based payment compensation expense for PSUs is based on 100%
vesting which was a part of the termination benefits for all employees who were terminated in 2022. We recorded share-based payment award
compensation costs related to previously issued options, RSU and PSUs, as well as shares of common stock issued under our employee stock
purchase plan (&#8220;ESPP&#8221;) totaling $1.3 million for 2023 and $11.6 million for 2022.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2023, we had $0.3 million of unrecognized share-based
payment award compensation cost related to unvested options, RSUs and PSUs as well as shares issuable under our ESPP, which may be adjusted
for future changes in forfeitures and is included as additional paid-in capital in the accompanying consolidated balance sheets. No tax
benefit was realized due to a continued pattern of net losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The unrecognized compensation cost as of December 31, 2023 of $0.3
million is expected to be recognized as share-based payment award compensation over a weighted average period of 0.8 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824843309344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>10. Revenue </b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the Mayne License Agreement, the Company granted Mayne
Pharma, on the Closing Date, (i) an exclusive, sublicensable, perpetual, irrevocable license to research, develop, register, manufacture,
have manufactured, market, sell, use, and commercialize the Licensed Products in the United States and its possessions and territories
and (ii) an exclusive, sublicensable, perpetual, irrevocable license to manufacture, have manufactured, import and have imported the Licensed
Products outside the United States for commercialization in the United States and its possessions and territories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the Mayne License Agreement, Mayne Pharma will make one-time,
milestone payments to the Company of each of (i) $5.0 million if aggregate net sales of all Products in the United States during a calendar
year reach $100.0 million, (ii) $10.0 million if aggregate net sales of all Products in the United States during a calendar year reach
$200.0 million and (iii) $15.0 million if aggregate net sales of all Products in the United States during a calendar year reach $300.0
million. Further, Mayne Pharma will pay to the Company royalties on net sales of all Products in the United States at a royalty rate of
8.0% on the first $80 million in annual net sales and 7.5% on annual net sales above $80.0 million, subject to certain adjustments, for
a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product basis upon the earlier
to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version of a Product launching in
the United States. Mayne Pharma will pay to the Company minimum annual royalties of $3.0 million per year for 12 years, adjusted for inflation
at an annual rate of 3%, subject to certain further adjustments, including as described below. Upon the expiry of the 20-year royalty
term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully paid-up and royalty free license for
the Licensed Products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2023, we recorded BIJUVA license sales of $0.3 million made through
the Theramex License Agreement and $1.0 million pertaining to our licensed products with Mayne Pharma, which was recorded as license revenue.
Additionally, we recognized $0.5 million in other income pertaining to royalty sales of ANNOVERA.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824846548192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>11. Income
taxes</b></span> </p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our income (loss) from continuing operations before income taxes is
as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Year Ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">United States</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(7,742</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">1,074</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">For the year ended December 31, 2023, there was no provision for income
taxes in discontinued operations, current or deferred. For the year ended, December 31, 2023, we recorded a benefit of 0.5% in continuing
operations. For the year ended December 31, 2022, there was 0% and 0.5% provision for income taxes in continuing and discontinued operations,
respectively, current or deferred.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, we had federal net operating loss (&#8220;NOL&#8221;)
carryforwards of $577.0 million, which is available to offset future taxable income. Approximately $19.2 million of the federal NOLs can
be carried forward for 20 years and will begin to expire in 2035. The remaining $557.8 million can be carried forward indefinitely. In
the event of future income, the NOL deduction arising from NOLs generated in taxable years beginning in 2021 will be limited to 80% of
the excess taxable income. The Company experienced an ownership change pursuant to IRC Sec. 382. As a result, our NOLs carryforward as
of December 31, 2023 will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A reconciliation between taxes computed at the federal statutory rate
and the consolidated effective tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal statutory tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,626</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State tax rate, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustment in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,173</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">286.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,228.6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Excess stock benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,460</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(31.8</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">835.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense accretion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.5</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Permanent and other differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,261</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(274.6</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,368.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">(Benefit) provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(43</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.5</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.0</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not expect to pay any significant federal or state income taxes
as a result of (i) the losses recorded during 2023, (ii) net operating losses carry forwards from prior years.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: left; margin: 0; font: 10pt Times New Roman, Times, Serif">Deferred income taxes result from temporary differences between the amount
of assets and liabilities recognized for financial reporting and tax purposes. The components of the net deferred tax assets as of December
31, 2023 and 2022 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred income tax assets (liabilities):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">158,040</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">176,631</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payment compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,339</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,590</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense limitation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,547</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,707</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gain on sale of ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,401</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,624</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrual for sales returns and coupons</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">R&amp;D credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">256</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,062</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred income tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,255</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(200,428</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(178,255</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,428</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Deferred income tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that it is more likely than not that we will not generate
sufficient future taxable income to realize tax benefits related to our deferred tax assets and as such, a valuation allowance has been
established against all the deferred tax assets as of both December 31, 2023 and 2022.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since our first year of operations in 2011, we generated net operating
losses, and our U.S. federal and state tax returns remain open to examination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023 and 2022, we had <span style="-sec-ix-hidden: hidden-fact-99"><span style="-sec-ix-hidden: hidden-fact-100">no</span></span> tax positions relating
to open tax returns that were considered to be uncertain, and we had no unrecognized tax benefits.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824840238864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Income (loss) per common share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Income (Loss) Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. Income (loss) per common share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following table sets forth the computation of basic and diluted
income (loss) per common share (each adjusted to account for the Reverse Stock Split) for the periods presented (in thousands, except
per share amounts):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Years Ending December 31,</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Net income (loss) from continuing operations</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,699</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,074</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net income (loss) from discontinued operations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,579</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">110,923</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net income (loss)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(10,278</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">111,997</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Weighted average common shares for basic income (loss) per common share</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,441</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,028</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Effect of dilutive securities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">338</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Weighted average common shares for diluted income (loss) per common share</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,441</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,366</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss) per common share, continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Basic</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.74</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.74</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss) per common share, discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Basic</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.25</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12.29</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.25</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11.84</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since we reported a net loss from continuing operations for 2023, our potentially
dilutive securities are deemed to be anti-dilutive, accordingly, there was no effect of dilutive securities. Therefore, our basic and
diluted loss per common share and our basic and diluted weighted average common shares are the same for 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the outstanding securities as of the
periods presented which were not included in the calculation of diluted earnings per common share during 2023 and 2022 (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">72</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">172</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>PSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">99</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">101</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">273</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824961500832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related parties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>13. Related parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 23, 2022, we appointed Mr. Justin Roberts as a director to
fill a newly created vacancy on our Board of Directors. Mr. Roberts was elected to serve as a director at our combined 2022 and 2023 Annual
Meeting held on June 26, 2023. Mr. Roberts will serve until our next Annual Meeting of Stockholders or until his successor is duly elected
or appointed or his earlier death or resignation. As a director of our Company, Mr. Roberts is entitled to receive compensation in the
same manner as our other non-employee directors, described in the section entitled &#8220;Director Compensation&#8221; in our Amendment
No. 1 to Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on May 1, 2023, but
he has elected not to receive any compensation for his service as a non-employee director at this time. Mr. Roberts currently serves as
a Partner of Rubric. On July 29, 2022, September 30, 2022, October 28, 2022, and May 1, 2023, we entered into subscription agreements
with Rubric. On December 30, 2022, in accordance with the terms of the Certificate of Designation, we redeemed all 29,000 outstanding
shares of Series A Preferred Stock previously issued to affiliates of Rubric at a purchase price of $1,333 per share. also paid certain
affiliates of Rubric approximately $3.0 million as a make-whole payment pursuant to the subscription agreements previously entered into
between us and Rubric. On June 29, 2023, we issued and sold 312,525 shares of Common Stock to Rubric at a price per share equal to $3.6797
pursuant to the Subscription Agreement and received gross proceeds of $1.15 million, before expenses. On November 15, 2023 Rubric drew
down an additional 877,192 shares of Common Stock at a price per share equal to $2.2761. We received gross proceeds of $2.0 million from
the drawdown, before expenses.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824840242704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Concentrations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Business Concentrations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Business Concentrations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>14. Business concentrations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">TherapeuticsMD was previously a women&#8217;s healthcare company with a
mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause.
In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed
to pharmaceutical organizations that possess commercial capabilities in the relevant territories. As part of the transformation that included
the Mayne License Agreement, historical results of commercial operations for all periods prior to the Closing Date have been reflected
as discontinued operations in our consolidated financial statements. Assets and liabilities associated with the commercial business are
classified as assets and liabilities of discontinued operations in our consolidated balance sheets. Additional disclosures regarding discontinued
operations are provided in Note 2.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For the year ended December 31, 2023, 100% of license revenue related to
Mayne Pharma and Theramex.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, we had a royalty receivable of $3.1 million
relating to the short-term portion of receivable from Mayne Pharma and Theramex and $18.5 million relating to the long-term portion of
royalty receivable which includes royalties recognized from the minimum annual royalty that Mayne Pharma is obligated to pay to us under
the Mayne License Agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824840107792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>15. Subsequent Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective March 22, 2024, Tommy G. Thompson resigned as the Company&#8217;s
Executive Chairman of the Board and was reappointed as the Company&#8217;s Chairman of the Board.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824847041712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (10,278)<span></span>
</td>
<td class="nump">$ 111,997<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824942067600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824843187056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_GeneralInformationPolicyTextBlock', window );">General</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TherapeuticsMD, Inc. (the &#8220;Company&#8221;), a Nevada
corporation, and its consolidated subsidiaries are referred to collectively in this Annual Report on Form 10-K (&#8220;2023 10-K
Report&#8221;) as &#8220;TherapeuticsMD,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us.&#8221; This 2023 10-K Report
includes trademarks, trade names and service marks, such as TherapeuticsMD<sup>&#174;</sup>, vitaMedMD<sup>&#174;</sup>,
BocaGreenMD<sup>&#174;</sup>, vitaCareTM, IMVEXXY<sup>&#174;</sup>, and BIJUVA<sup>&#174;</sup>, which are protected under applicable
intellectual property laws and are the property of, or licensed by or to, us. Solely for convenience, trademarks, trade names and
service marks referred to in this 2023 10-K Report may appear without the <sup>&#174;</sup>, TM or SM symbols, but such references
are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the
right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other
parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a
relationship with, or endorsement or sponsorship of us by, these other parties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TherapeuticsMD was previously a women&#8217;s healthcare company with
a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause.
In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed
to pharmaceutical organizations that possess commercial capabilities in the relevant territories. On December 30, 2022 (the &#8220;Closing
Date&#8221;), we completed a transaction (the &#8220;Mayne Transaction&#8221;) with Mayne Pharma LLC, a Delaware limited liability company
(&#8220;Mayne Pharma&#8221;) and subsidiary of Mayne Pharma Group Limited, an Australian public company, in which we and our subsidiaries
(i) granted Mayne Pharma an exclusive license to commercialize our IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under
the BocaGreenMD and vitaMedMD brands (collectively, the &#8220;Licensed Products&#8221;) in the United States and its possessions and
territories, (ii) assigned to Mayne Pharma our exclusive license to commercialize ANNOVERA<sup>&#174;</sup> (together with the Licensed
Products, collectively, the &#8220;Products&#8221;) in the United States and its possessions and territories, and (iii) sold certain
other assets to Mayne Pharma in connection therewith.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In a License Agreement, dated December 4, 2022, between TherapeuticsMD
and Mayne Pharma (the &#8220;Mayne License Agreement&#8221;), we granted Mayne Pharma, on the Closing Date, (i) an exclusive, sublicensable,
perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell, use, and commercialize the
Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable
license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States for commercialization
in the United States and its possessions and territories.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Mayne License Agreement, Mayne Pharma will pay us
one-time milestone payments of each of (i) $5.0 million if aggregate net sales of all Products in the United States during a
calendar year reach $100.0 million, (ii) $10.0 million if aggregate net sales of all Products in the United States during a calendar
year reach $200.0 million and (iii) $15.0 million if aggregate net sales of all Products in the United States during a calendar year
reach $300.0 million. Further, Mayne Pharma will pay us royalties on net sales of all Products in the United States at a royalty
rate of 8.0% on the first $80.0 million in annual net sales and 7.5% on annual net sales above $80.0 million, subject to certain
adjustments, for a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product
basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version
of a Product launching in the United States. Mayne Pharma will pay us minimum annual royalties of $3.0 million per year for 12
years, adjusted for inflation at an annual rate of 3%, subject to certain further adjustments, including as described below. Upon
the expiry of the 20-year royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully
paid-up and royalty free license for the Licensed Products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Transaction Agreement, dated December 4, 2022, between TherapeuticsMD
and Mayne Pharma (the &#8220;Transaction Agreement&#8221;), we sold to Mayne Pharma, at closing, certain assets for Mayne Pharma to commercialize
the Products in the United States, including, with the Population Council&#8217;s consent, our exclusive license from the Population Council
to commercialize ANNOVERA (the &#8220;Transferred Assets&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total consideration from Mayne Pharma to TherapeuticsMD for
the purchase of the Transferred Assets under the Transaction Agreement and the grant of the licenses under the Mayne License
Agreement was (i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million at closing for the
acquisition of net working capital as determined in accordance with the Transaction Agreement and subject to certain adjustments,
(iii) a cash payment of approximately $1.0 million at closing for prepaid royalties in connection with the Mayne License Agreement
Amendment (as defined below) and (iv) the right to receive the contingent consideration set forth in the Mayne License Agreement, as
amended. The acquisition of net working capital was determined in accordance with the Transaction Agreement and included significant
estimates which could change materially for a period of up to two years following the Closing Date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On the Closing Date, TherapeuticsMD and Mayne Pharma entered into Amendment
No. 1 to the Mayne License Agreement (the &#8220;Mayne License Agreement Amendment&#8221;). Pursuant to the Mayne License Agreement Amendment,
Mayne Pharma agreed to pay us approximately $1.0 million in prepaid royalties on the Closing Date. The prepaid royalties reduced the first
four quarterly payments that would have otherwise been payable pursuant to the Mayne License Agreement by an amount equal to $257 thousand
per quarterly royalty payment plus interest calculated at 19% per annum accruing from the Closing Date until the date such quarterly royalty
payment was paid to us. We and Mayne Pharma settled the $1.5 million of consideration due to Mayne for the assumed obligations under a
long-term services agreement (see the section entitled &#8220;vitaCare Divestiture&#8221; below for a discussion of the long-term services
agreement), including our minimum payment obligations thereunder. As the parties agreed, during the second quarter of 2023, Mayne Parma
held back our royalty payment of $0.6 million and we funded an additional $0.9 million in August 2023 to settle the original $1.5 million
payable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As part of the transformation that included the Mayne License Agreement,
historical results of commercial operations for all periods prior to the Closing Date have been reflected as discontinued operations in
our consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities
of discontinued operations in our consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in
Note 2.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also have license agreements with strategic partners to commercialize
IMVEXXY and BIJUVA outside of the U.S.</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">In July 2018, we entered into a license and supply agreement
(the &#8220;Knight License Agreement&#8221;) with Knight Therapeutics Inc. (&#8220;Knight&#8221;) pursuant to which we granted Knight
an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel.</td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            September 2019, we entered into an exclusive license and supply agreement (the &#8220;Theramex
                                            License Agreement&#8221;) with Theramex HQ UK Limited (&#8220;Theramex&#8221;) to commercialize
                                            IMVEXXY and BIJUVA outside of the U.S., excluding Canada and Israel. In 2021, Theramex secured
                                            regulatory approval for BIJUVA in certain European countries and began commercialization
                                            efforts in those countries.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our transformation into a pharmaceutical royalty
company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief
Executive Officer) and all other employees was completed by December 31, 2022. Severance obligations for all employees other than executive
officers were paid in full in January 2023 and severance obligations for terminated executive officers were paid in accordance with their
employment agreements and separation agreements as previously disclosed. As of December 31, 2022 and 2023, we employed one full-time employee
primarily engaged in an executive position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have engaged external consultants who support our relationship with
current partners and assist with certain financial, legal, and regulatory matters and the continued wind-down of our historical business
operations. On August 15, 2023, we entered into a master services agreement with JZ Advisory Group, pursuant to which Joseph Ziegler would
serve as our Principal Financial and Accounting Officer. On August 17, 2023 Michael C. Donegan notified us of his decision to resign from
the positions of Principal Financial and Accounting Officer of our Company effective as of August 17, 2023. Mr. Ziegler succeeded Mr.
Donegan as Principal Financial and Accounting Officer as of the date of Mr. Donegan&#8217;s resignation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DivestitureOfBusinessPolicyPolicyTextBlock', window );">vitaCare Divestiture</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>vitaCare Divestiture</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 14, 2022, we completed the divestiture of our former subsidiary
vitaCare Prescription Services, Inc. (&#8220;vitaCare&#8221;) with the sale of all of vitaCare&#8217;s issued and outstanding capital
stock (the &#8220;vitaCare Divestiture&#8221;). We received net proceeds of $142.6 million, after deducting transaction costs of $7.2
million, and we recognized a gain on sale of business of $143.4 million. Included in the net proceeds amount was $11.3 million of customary
holdbacks as provided in the stock purchase agreement (the &#8220;Purchase Agreement&#8221;) which we received in 2023. Additionally,
the Purchase Agreement provides that we may receive up to an additional $7.0 million in earn-out consideration, contingent upon vitaCare&#8217;s
financial performance through 2023 as determined in accordance with the terms of the Purchase Agreement; however, we do not believe this
earnout will be realized. We will record the contingent consideration at the settlement amount if and when the consideration is realized
or realizable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Purchase Agreement contains customary representations and warranties,
covenants, and indemnities of the parties thereto. The commitments under a long-term services agreement related to vitaCare were transferred
to Mayne Pharma as part of the Mayne Transaction. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The divestiture of vitaCare was determined to be a component of discontinued
operations in December 2022, when we changed our business by becoming a royalty company and as a result vitaCare activities were reclassified
to discontinued operations for 2023 and 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Going concern</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 4, 2022, we entered into agreements with Mayne Pharma pursuant
to which we granted Mayne Pharma an exclusive license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products (in
the United States and its possessions and territories), (ii) assign to Mayne Pharma our exclusive license to commercialize ANNOVERA in
the United States and its possessions and territories, and (iii) sell certain other assets to Mayne Pharma.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The total consideration from Mayne Pharma to the TherapeuticsMD for
the purchase of the Transferred Assets under the Transaction Agreement and the grant of the licenses under the Mayne License Agreement
consisted of (i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million at closing for the acquisition
of net working capital subject to certain adjustments, (iii) a cash payment of approximately $1.0 million at closing for prepaid royalties
in connection with the Mayne License Agreement Amendment and (iv) the right to receive the contingent consideration set forth in the Mayne
License Agreement, as amended.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On the Closing Date, we repaid all obligations under the Financing
Agreement, dated as of April 24, 2019, as amended, with Sixth Street Specialty Lending, Inc., as administrative agent, the various lenders
from time-to-time party thereto, and certain of our subsidiaries party thereto from time to time as guarantors (the &#8220;Financing Agreement&#8221;)
and the Financing Agreement was terminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the transaction with Mayne Pharma, our primary source of
revenue is from royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories.
We may need to raise additional capital to provide additional liquidity to fund our operations until we become cash flow positive. To
address our capital needs, we may pursue various equity and debt financing and other alternatives. The equity financing alternatives may
include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders,
or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity
securities may be limited by market conditions, including the market price of our common stock, and our available authorized shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent that we raise additional capital through the sale of
such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include
liquidation or other preferences that adversely affect the rights of our existing stockholders. If we are not successful in obtaining
additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, or merge,
consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 1, 2023, we entered into a Subscription Agreement (the &#8220;Subscription
Agreement&#8221;) with Rubric Capital Management LP (&#8220;Rubric&#8221;), pursuant to which we agreed to sell to Rubric, or one or more
of its affiliates, up to an aggregate of 5,000,000 shares of our common stock, par value $0.001 per share (our &#8220;Common Stock&#8221;),
from time to time during the term of the Subscription Agreement in separate draw-downs at our election. On June 29, 2023, we issued and
sold 312,525 shares of Common Stock at a price per share equal to $3.6797 pursuant to the Subscription Agreement. We received gross proceeds
of $1.15 million from the draw down, before expenses. On November 15,
2023 Rubric drew down an additional 1,000,000 shares of Common Stock at a price per share equal to $2.28. We received gross proceeds of
$2.0 million from the drawdown, before expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2024, the Company received Mayne Pharma&#8217;s
                                                                         calculation of allowance for payer rebates and wholesale distributor fees which differed significantly from the Company&#8217;s
                                                                         estimate of the allowances. The Company believes its estimated allowances for payer rebates and wholesale distributor fees are
                                                                         reasonable and intends to resolve this matter through the process outlined in the Transaction Agreement. Given the recent receipt of
                                                                         Mayne Pharma&#8217;s allowance calculation and the nature of the estimates involved, the outcome of this matter is uncertain at this
                                                                         point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any
                                                                         additional liability associated with Mayne Pharma&#8217;s allowance calculation for payer rebates and wholesale distributor
                                                                         fees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2023, the Company believes no additional accrual
is required for amounts that may be owed for the allowance for returns under the Transaction Agreement. The Company has not recorded any
contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital
items as changes to estimated amounts owed or amounts due from Mayne Pharma that may be material.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If Mayne Pharma&#8217;s sales of IMVEXXY, BIJUVA, or ANNOVERA
grow more slowly than expected or decline, if the net working capital settlement with Mayne Pharma under the Transaction Agreement
is greater than our current estimates, if we are unsuccessful with future financings or if the supply chains related to the
third-party contract manufacturers are worse than we anticipate, our existing cash reserves may be insufficient to satisfy our
liquidity requirements. The potential impact of these factors in conjunction with the uncertainty of the capital markets raises
substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial
statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying consolidated financial statements do not include any
adjustments that might be necessary if we are unable to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A.&#160;Basis of presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements and related notes include our
parent company and all wholly owned subsidiaries. The consolidated financial statements are prepared in accordance with accounting principles
generally accepted in the Unites States of America (&#8220;U.S. GAAP&#8221;). Our fiscal year-end is as of and for the year ended December
31st for each year presented. All intercompany transactions among our businesses have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As part of the transformation and as a result of the vitaCare divestiture
and the Mayne Transaction, historical results of commercial operations for all periods prior to the Closing Date have been reflected as
discontinued operations in the consolidated financial statements. Assets and liabilities associated with the commercial business are classified
as assets and liabilities of discontinued operations in the consolidated balance sheet. Additional disclosures regarding discontinued
operations are provided in Note 2 of these consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain amounts in the notes to the consolidated financial statements
may not add due to rounding. Certain prior period amounts have been reclassified to conform to current-period presentation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting standards</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B.&#160;New accounting standards</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Adoption of new accounting standards</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;)
issued ASU 2023-09, &#8220;Income Taxes (Topic 740) - Improvements to Income Tax Disclosures.&#8221; ASU 2023-09 enhances the transparency
and decision usefulness of income tax disclosures by requiring consistent categories and greater disaggregation of information in the
rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 will be effective for the Company in its income tax
disclosure included in its 2025 Annual Report on Form 10-K and will be applied on a prospective basis. However, retrospective application
is permitted. Early adoption is also permitted. The Company is evaluating the impact of ASU 2023-09 on the Company's income tax disclosures
and on its consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>C. Discontinued Operations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Discontinued operations comprise activities that were disposed of at
the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting
purposes and represent a business shift having a major effect on the Company&#8217;s operations and financial results according to Accounting
Standard Codification (&#8220;ASC&#8221;) Topic 205, Presentation of Financial Statements. An adjustment has been made to the consolidated
statements of operations for the twelve months ended December 31, 2023 and 2022 to reclassify commercial activities and vitaCare activities
to discontinued operations as both components, in the aggregate, represented a business shift that will have a major effect on the Company&#8217;s
operations and financial results. No amounts for shared general and administrative operating support expense were allocated to discontinued
operations. As required by the terms of the Financing Agreement, the proceeds from both transactions were used to fully repay our outstanding
debt borrowings. As a result, interest expense and amortization of deferred financing costs as well as expense for accretion of Series
A Preferred Stock and loss on extinguishment of debt are included within income (loss) from discontinued operations, net of tax. Additionally,
the related assets and liabilities have been reported as assets and liabilities of discontinued operations in the Company&#8217;s consolidated
balance sheet as of December 31, 2023 and 2022. For additional information, see Note 2 - Discontinued Operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Estimates and assumptions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>D. Estimates and assumptions</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of consolidated financial statements in conformity
to U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the
reporting period. We evaluate our estimated assumptions based on historical experience and on various other assumptions that are believed
to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different
assumptions or conditions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>E. Cash and Restricted Cash</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">For the purpose of the statements of cash flows, all highly liquid
investments with an original maturity of three months or less are considered to be&#160;cash&#160;equivalents. The carrying value of these
investments approximates fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We maintain cash at financial institutions that at times may exceed
the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits of $0.25 million per bank. We have never experienced any
losses related to these funds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restricted cash was comprised of escrowed funds deposited with a bank
relating to the vitaCare Divestiture. All restrictions were lifted in March 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>F.</b>&#160;<b>Fair Value Measurements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fair value is the price to sell an asset or transfer a liability and
therefore represents an exit price in the principal market (or in the absence of a principal market, the most advantageous market). It
represents a market-based measurement that contemplates a hypothetical transaction between market participants at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The unique characteristics of an asset or liability and the availability
of observable prices affect the number of valuation approaches and/or techniques used in a fair value analysis. We measure fair value
using observable and unobservable inputs. We give the highest priority to quoted prices (unadjusted) in active markets for identical assets
or liabilities (Level 1 inputs) and the lowest priority to unobservable inputs (Level 3 inputs).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We apply the following fair value hierarchy:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">Level 1 - Quoted prices (unadjusted) in active markets for
identical assets and liabilities.</td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">Level 2 - Quoted prices in non-active markets or in active
markets for similar assets or liabilities, observable inputs other than quoted prices; and inputs that are not directly observable but
are corroborated by observable market data.</td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">Level 3 - Inputs that are unobservable.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amount of our cash, restricted cash, accounts receivable,
accounts payable and accrued expenses approximate their fair value because of the short-term maturity of such instruments, which are considered
Level 1 under the fair value hierarchy.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>G.&#160;Fixed assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fixed assets are carried at cost less accumulated depreciation and
amortization. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs
to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related
assets, which range from three to seven years. Leasehold improvements are depreciated over the shorter of their useful life or the term
of the lease. Long-lived assets held and used by us, including fixed assets, are assessed for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be recoverable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We capitalize software and software development costs incurred to create
and acquire computer software for internal use, principally related to software coding and application development. We begin to capitalize
software development costs when both the preliminary project stage is completed, and it is probable that the software will be used as
intended. Capitalized software costs include only external direct costs and services utilized in developing or obtaining computer software.
Capitalized software costs are amortized on a straight-line basis when placed into service over the estimated useful life, generally five
to seven years.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">License rights and other intangibles assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>H.&#160;License rights and other
intangibles assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We record license rights and other intangible assets at cost, which
includes external costs, consisting primary of legal costs, incurred in securing our patents and trademarks.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">License rights costs related to ANNOVERA were amortized until December
30, 2022 over the useful life over which the license rights would contribute directly or indirectly to our cash flows. The cost was amortized
using the straight-line method as the pattern of economic benefit could not be reliably determined. On December 30, 2022, we assigned
our ANNOVERA license to Mayne Pharma and included the remaining ANNOVERA license cost of $30.2 million in our calculation of the gain
on sale of assets. In addition, amortization of license rights of $3.0 million for 2022 was reclassified to discontinued operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intangible assets subject to amortization, such as patents, are amortized
over the useful life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs
at that time. Intangible assets not subject to amortization, such as trademarks, are perpetual and have indefinite lives.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We review license rights and other intangible assets subject to amortization
on a periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision to their remaining useful
lives. We assess other intangible assets not subject to amortization for potential impairment at least annually during the fourth quarter
of each year, or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the
intangible assets below their carrying value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>I.</b>&#160;<b>Segment reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We manage and operate as one business, which prior to December 2022
was focused on creating and commercializing products targeted exclusively for women and after we signed Mayne License Agreement, is focused
on collecting royalties from licensing our products. Our business is led by our chief executive officer. We do not operate separate lines
of business with respect to any of our products, and we do not prepare discrete financial information with respect to separate products.
Accordingly, we view our business as one reportable operating segment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>J.&#160;Revenue recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We determine the amount of revenue to be recognized through application
of the following steps:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"></td><td style="width: 0.25in">&#9679;</td><td>Identification of the contract with a customer;</td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"></td><td style="width: 0.25in">&#9679;</td><td>Identification of the performance obligations in the contract;</td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"></td><td style="width: 0.25in">&#9679;</td><td>Determination of the transaction price;</td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"></td><td style="width: 0.25in">&#9679;</td><td>Allocation of the transaction price to the performance obligations in the contract; and</td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.6pt"></td><td style="width: 0.25in">&#9679;</td><td>Recognition of revenue when or as we satisfy the performance obligations.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A performance obligation is a promise in a contract to transfer a product
or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains
control, and we treat shipping as a fulfillment activity rather than as a separate obligation. We generally recognize revenue at a point
in time when all of our performance obligations under the terms of a contract are satisfied. Revenue is recognized upon transfer of control
of promised products or services in an amount that reflects the consideration we expect to receive in exchange for those products or services.
The collectability of consideration on the contract is reasonably assured before revenue is recognized. To the extent that customer payment
has been received before all recognition criteria are met, these revenues are initially deferred in other accruals on the balance sheet
and the revenue is recognized in the period that all recognition criteria have been met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>License revenue</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">License arrangements may consist of non-refundable upfront license
fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones and future product
royalty payments. Some of these arrangements may include multiple performance obligations. Non-refundable up-front fees that are not contingent
on any future performance by us, and do not require continuing involvement on our part, are recognized as revenue when the right to use
functional intellectual property is transferred to the customer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December 30, 2022, we granted an exclusive license to commercialize
our prescription products and assigning the Company&#8217;s exclusive license to commercialize ANNOVERA to Mayne Pharma, which resulted
in a business shift that had a major effect on our operations and financial results. As part of the transformation that included the Mayne
License Agreement, historical results of commercial operations have been reflected as discontinued operations in the Company&#8217;s consolidated
financial statements for all periods prior to the Closing Date. As of December 31, 2022, we are no longer directly engaged in the sale
of prescription products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the Mayne License Agreement, we received $140 million
at closing and we are eligible to receive additional payments in the aggregate of up to an additional $30 million, based on the achievement
of sales milestones (collectively, the &#8220;Milestone Amounts&#8221;). The proceeds at closing were allocated between consideration
for the sale of ANNOVERA and the initial license fee for the Licensed Products, as the sale of ANNOVERA was accounted for under ASC 610-20,
Gains and Losses from Derecognition of Nonfinancial Assets in arriving at the gain on disposal (see Note 2), while the license grant of
the other products were recognized under the provisions of ASC 606, Revenue from Contracts with Customers, as a license of functional
intellectual property. The proceeds were allocated among the Licensed Products on the relative net present value of forecasted future
product sales from those products. The Milestone Amounts will be recognized, as applicable, in subsequent periods based on actual product
sales that exceed the respective net sales milestones as such variable consideration is constrained by the occurrence of the subsequent
sales.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our royalty revenue in 2023 primarily related to royalties provided
for under the Mayne License Agreement based on Mayne Pharma&#8217;s sales of the licensed products subject to that agreement. Under the
Mayne License Agreement, the Company is entitled to earn royalties on net sales of all of the Licensed Products at a royalty rate of (i)
8% on the first $80 million of net sales of the Licensed Products and (ii) 7.5% on net sales of all of the Licensed Products after the
first $80 million of net sales. The royalty rate is subject to a 2% reduction upon the earlier to occur of (i) the expiration or revocation
of the last valid claim covering a Licensed Product, and (ii) a generic product launch (a &#8220;LOE&#8221;). We are entitled to minimum
annual royalties beginning with the year ending December 31, 2023 ($3 million annual minimum) and continuing with 3% annual increases
through the year ending December 31, 2034 (the &#8220;Minimum Annual Royalty&#8221;). The total Minimum Annual Royalty we are entitled
to is $42.6 million, and this total amount was allocated among the Licensed Products on the relative net present value of forecasted future
product sales from those products. The portion allocated to consideration for the sale of ANNOVERA was attributed towards the gain on
disposal of that asset. For the remaining portion allocated to the license grants for the other products, we determined that the minimum
guarantee underlying the Minimum Annual Royalty should be treated as fixed consideration and recognized under ASC 606 at the point in
time when the license was transferred. Since the Minimum Annual Royalty will be received in annual installments through 2034, we determined
the transaction price allocated under ASC 606 contained a significant financing component, and we therefore determined the initial royalty
revenue and corresponding receivable based on the present value of the allocated Minimum Annual Royalty. The present value was calculated
using a discount rate of 10.45%, based on the credit characteristics of Mayne Pharma and the timing of future payments, and the value
will be accreted to full value through the earlier of January 1, 2034 or a LOE. This royalty receivable is a contract asset as of December
31, 2022 and 2023, and is further subject to offset by Mayne Pharma (see L. Contract Assets and Liabilities below).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Royalty revenue earned in excess of the Minimum Annual Royalty will
be recognized under ASC 606, which provides revenue recognition constraints by requiring the recognition of revenue at the later of the
following: 1) when the subsequent sale occurs or 2) when the performance obligation to which some or all of the sales-based royalty has
been allocated has been satisfied (or partially satisfied). We applied the royalty recognition constraint required under the guidance
for sales-based royalties, which requires a sales-based royalty to be recorded no sooner than the underlying sale. Therefore, royalties
on sales of products commercialized by Mayne Pharma will be recognized in the subsequent periods that the Licensed Products are sold.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2023, we recorded BIJUVA license sales of $0.3 million made through
the Theramex License Agreement and $1.0 million pertaining to our licensed products with Mayne Pharma, which was recognized as license
revenue. Additionally, we recognized $0.5 million in other income pertaining to royalty sales of ANNOVERA.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>K.</b>&#160;<b>Cost of revenue</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenue includes the cost of inventory, manufacturing, manufacturing
overhead and supply chain costs and product shipping and handling costs. Costs related to the Population Council License Agreement, which
were based on our net sales of ANNOVERA, and amortization of license rights were reclassified to discontinued operations for 2022 as a
result of the transaction with Mayne Pharma.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based payment awards</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>M.&#160;Share-based payment
awards</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We account for share-based payment awards on a fair value basis of
the equity instrument issued. Under fair value accounting, the grant-date fair value of the share-based payment award is amortized as
compensation expense, on a straight-line basis, over the service period (generally, the vesting period) for both graded and cliff vesting
awards. We have elected to account for forfeitures as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Common stock reverse stock split</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 6, 2022, we completed a reverse stock split of our Common Stock.
As a result, shares of our outstanding Common Stock were split at a ratio of 50-for-1 (the &#8220;Reverse Stock Split&#8221;) with any
fractional shares resulting from the Reserve Stock Split rounded up to the next whole share of Common Stock. The number of authorized
shares of Common Stock was also correspondingly reduced from 600.0 million shares to 12.0 million shares to give effect to the Reverse
Stock Split. Additionally, all rights to receive shares of Common Stock under outstanding warrants, options, restricted stock units (&#8220;RSUs&#8221;)
and performance stock units (&#8220;PSUs&#8221;) were adjusted to give effect of the Reverse Stock Split. Furthermore, remaining shares
of Common Stock available for future issuance under share-based payment award plans and our employee stock purchase plan were adjusted
to give effect of the Reverse Stock Split. Pursuant to Section 78.209 of the Nevada Revised Statutes, the approval of our stockholders
was not required for our Board of Directors (the &#8220;Board&#8221;) to effectuate the Reverse Stock Split.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All historical numbers of shares of Common Stock and per share data
have been adjusted to give effect to the Reverse Stock Split. Additionally, since the Common Stock par value was unchanged, historical
amounts for Common Stock and additional paid-in capital have been adjusted to give effect to the Reverse Stock Split.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Increase of authorized shares</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 26, 2023, at our combined 2022 and 2023 Annual Meeting, our
stockholders approved an amendment to our Amended and Restated Articles of Incorporation to increase the number of authorized shares of
Common Stock from 12 million shares to 32 million shares.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>N.&#160;Income taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income taxes are accounted for under the asset and liability method.
Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and income
tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in income tax rates is recorded as a component of the income tax provision in the period that includes the enactment
date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regular assessments are made on the likelihood that our deferred tax
assets will be recovered from our future taxable income. Our evaluation is based on estimates, assumptions, and includes an analysis of
available positive and negative evidence, giving weight based on the evidence&#8217;s relative objectivity. Sources of positive evidence
include estimates of future taxable income, future reversal of existing taxable temporary differences, taxable income in carryback years,
and available tax planning strategies. Sources of negative evidence include current and cumulative losses in recent years, losses expected
in early future years, any history of operating losses or tax credit carryforwards expiring unused, and unsettled circumstances that,
if unfavorably resolved, would adversely affect future profit levels.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The remaining carrying value of our deferred tax assets, after recording
the valuation allowance on our deferred tax assets, is based on our present belief that it is more likely than not that we will be able
to generate sufficient future taxable income to utilize such deferred tax assets. The amount of the remaining deferred tax assets considered
recoverable could be adjusted if our estimates of future taxable income during the carryforward period change favorably or unfavorably.
To the extent we believe that it is more likely than not that some or all the remaining deferred tax assets will not be realized, we must
establish a valuation allowance against those deferred tax assets, resulting in additional income tax expense in the period such determination
is made. To the extent a valuation allowance currently exists, we will continue to monitor all positive and negative evidence until we
believe it is more likely than not that it is no longer necessary, resulting in an income tax benefit in the period such determination
is made.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our policy is to recognize both interest and penalties related to uncertain
tax positions as part of the income tax provision. Significant judgment is required in evaluating our tax positions, and in determining
our provisions for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred
tax assets. We establish reserves when, despite our belief that the income tax return positions are fully supportable, certain positions
are likely to be challenged and we may ultimately not prevail in defending those positions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per common share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>O.&#160;Earnings per common
share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic earnings or loss per common share is computed by dividing net
income or loss available to common stockholders by the sum of the weighted average number of shares of common stock. Diluted earnings
per common share is computed by dividing net income available to common stockholders by the sum of the weighted average number of shares
of common stock and the number of additional shares of common stock that would have been outstanding if our outstanding potentially dilutive
securities had been issued. Potentially dilutive securities include awards of non-vested or vested and not settled restricted stock units,
performance stock units where the performance requirements have been met and not settled, warrants and options. The dilutive effect of
potentially dilutive securities is reflected in diluted earnings per common share by application of the treasury stock method, except
if its impact is anti-dilutive. Under the treasury stock method, an increase in the fair market value of our common stock can result in
a greater dilutive effect from potentially dilutive securities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>P.&#160;Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We determine if an arrangement is a lease at inception. Determining
whether a contract contains a lease includes judgment regarding whether the contract conveys the right to control the use of identified
property or equipment for a period of time in exchange for consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We account for our lease-related assets and liabilities based on their
classification as operating leases or finance leases, following the relevant accounting guidance. For all the lessee arrangements, we
have elected an accounting policy to combine non-lease components with the related-lease components and treat the combined items as a
lease for accounting purposes. We measure lease related assets and liabilities based on the present value of lease payments, including
in-substance fixed payments, variable payments that depend on an index or rate measured at the commencement date, and the amount we believe
is probable we will pay the lessor under residual value guarantees when applicable. We discount lease payments based on our estimated
incremental borrowing rate at lease commencement (or modification), which is primarily based on our estimated credit rating, the lease
term at commencement, and the contract currency of the lease arrangement. We have elected to exclude short-term leases (leases with an
original lease term less than one year) from the measurement of lease-related assets and liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We test right-of-use assets in an operating or finance lease at the asset group level (because these assets are long-lived nonfinancial
assets and should be accounted for the same way as other long-lived nonfinancial assets) whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We sublease our unoccupied facilities to third parties. Any impairment
to the associated right-of-use asset, leasehold improvements, or other assets as a result of the sublease is recognized in the period
when a decision to sublease is made and recorded in our consolidated statement of operations. We recognize sublease income on a straight-line
basis over the sublease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Loss Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Q.&#160;Loss Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In determining whether an accrual for a loss contingency is required,
we first assess the likelihood of occurrence of the future event or events that will confirm the loss. When a loss is probable (the future
event or events are likely to occur) and the amount of the loss can be reasonably estimated, the estimated loss is accrued. If the reasonable
estimate of the loss is a range and an amount within the range appears to be a better estimate than any other amount within the range,
that amount should be accrued. However, if no amount within the range is a better estimate, the minimum amount in the range should be
accrued. When a loss is reasonably possible (the chance of the future event or events occurring is more than remote but less than likely),
no accrual is recognized. See Note 8 for more information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy', window );">Restructuring charges</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>R.&#160;Restructuring charges</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2022, the Company initiated and
completed a restructuring plan that resulted in a reduction of its workforce to one employee. One-time termination benefits include severance,
continuation of health insurance coverage, and other benefits for a specified period of time, as well as contract terminations and fixed
assets write-downs, which resulted in $15.7 million of restructuring costs for the year ended December 31, 2022. There were no restructuring
costs incurred during the year ended December 31, 2023. Restructuring costs have been recognized in the accompanying consolidated statement
of operations as follows (in thousands):</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Year ended<br/> December&#160;31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Executive termination benefits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,897</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Consulting and legal expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,060</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other contract termination costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,515</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total restructuring expenses - general and administrative expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,472</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employee termination benefits</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,813</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other contract termination costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,367</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total restructuring expenses - discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,180</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At December 31, 2023 and 2022 respectively, $2.5 million and $6.2 million
of restructuring costs were included in current liabilities of discontinued operations in the accompanying consolidated balance sheets.
At December 31, 2022, $9.3 million related to restructuring costs was included in accrued expenses and other current liabilities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification of prior year presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>S. Reclassification of prior year presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain prior year amounts have been reclassified for consistency with
the current year presentation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ContractAssetsAndLiabilitiesPolicyTextBlock', window );">Contract Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>L.&#160;Contract Assets and
Liabilities</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contract assets totaling $21.6 million as of December 31, 2023, include
royalties recognized from the Minimum Annual Royalty (see J. Revenue Recognition above).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ContractAssetsAndLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ContractAssetsAndLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DivestitureOfBusinessPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Divestiture of business policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DivestitureOfBusinessPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_GeneralInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_GeneralInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480598/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480781/205-20-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824844013184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring Cost Recognition</a></td>
<td class="text">Restructuring costs have been recognized in the accompanying consolidated statement
of operations as follows (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Year ended<br/> December&#160;31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Executive termination benefits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,897</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Consulting and legal expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,060</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other contract termination costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,515</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total restructuring expenses - general and administrative expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,472</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employee termination benefits</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,813</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other contract termination costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,367</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total restructuring expenses - discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,180</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824840277440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock', window );">Schedule of Discontinued Operations</a></td>
<td class="text">The following table presents results of discontinued operations
(in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Years ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Product revenue, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(833</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">80,749</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,640</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gross profit (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(833</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65,109</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,208</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">481</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,301</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,942</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Restructuring charges</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,180</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">481</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">97,631</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss from discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,314</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(32,522</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gain on sale of vitaCare</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">143,384</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on ANNOVERA sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,031</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on the extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,380</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense and other financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36,065</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expense for accretion of Series A Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,973</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss on disposal of assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,150</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(115</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,265</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">143,997</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss before from income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,579</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,475</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Benefit (provision) for income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(552</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net income (loss) from discontinued operations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,579</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">110,923</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Classes of Liabilities of Discontinued Operations</a></td>
<td class="text">The following table presents the carrying amounts of the classes of
assets and liabilities of discontinued operations (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">344</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">344</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,243</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,694</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,588</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,694</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,831</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824842133568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid and Other Current Assets</a></td>
<td class="text">Our prepaid and other current assets consisted of the following
(in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">253</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,167</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Capitalized legal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,334</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,448</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,533</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Prepaid and other current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,035</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,034</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824842828848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_FixedAssetsAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Fixed Assets, Net</a></td>
<td class="text">Our fixed assets, net consisted of the following (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Furniture and fixtures</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">931</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">931</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Computer and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,168</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,522</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,523</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,522</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,445</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Fixed assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_FixedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_FixedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824844569808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensed Rights and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Licensed Rights and Other Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of License Rights and Other Intangible Assets, Net</a></td>
<td class="text">The following provides information about our license rights and other
intangible assets, net (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Gross</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Gross</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Carrying</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Carrying</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Net</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Net</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Intangible assets subject to amortization:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Hormone therapy drug patents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,818</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,871</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,947</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,225</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,598</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,627</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Hormone therapy drug patents applied and pending approval</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">842</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">842</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,995</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,995</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Intangible assets subject to amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,660</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,871</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,789</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,220</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,598</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,622</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Intangible assets not subject to amortization:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Trademarks/trade name rights</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">309</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">309</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">321</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">321</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Intangible assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,969</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,871</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,098</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,541</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,598</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,943</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Intangible Assets Subject To Amortization</a></td>
<td class="text">Our intangible assets subject to amortization are expected to be amortized
as follows (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">Year ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">533</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,347</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,660</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824844374912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Other accrued expenses and other current liabilities consisted of the
following (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Payroll and related costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">762</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,748</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued contract termination costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,700</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">978</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">489</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">415</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,473</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,390</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid royalty</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,011</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other accrued expenses and current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,604</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,133</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,846</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Accrued Expenses And Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824844422656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Remaining Lease Payments</a></td>
<td class="text">As of December 31, 2023, our remaining lease payments were as follows
(in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Year ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,477</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,513</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,551</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,590</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,630</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,664</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,425</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,420</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Present value of lease payments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,005</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related to Leases</a></td>
<td class="text">The following table sets forth supplemental balance sheet information
related to leases (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31,</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease right-of-use assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">6,873</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">7,580</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease liabilities current (included in accrued expenses and other current liabilities)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,473</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,390</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,532</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,369</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,005</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,759</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Other Information Related to Leases</a></td>
<td class="text">The following table presents other information related to leases:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Weighted average remaining term (years) - operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.7</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Weighted average discount rate - operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cash paid for amounts included in the measurement of lease liabilities from operating lease (in thousands)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,413</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Right-of-use assets obtained in exchange for new operating lease obligations (non-cash in thousands)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824840276304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ScheduleOfWarrantRollForwardTableTextBlock', window );">Schedule of Outstanding and Exercisable Warrants and Related Transactions</a></td>
<td class="text">As of December 31, 2023, the following table summarizes the status
of our outstanding and exercisable warrants and related transactions since December 31, 2021 (in thousands, except weighted average exercise
price and weighted average remaining contractual life data):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">Warrants outstanding and exercisable</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in&#160;Years)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance, December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">103</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">76.19</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.3</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">436</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">341.5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,427</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(435</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,270</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.89</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Balance, December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">99</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">66.61</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,793</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text">The following table summarizes the status of our outstanding and exercisable
options and related transactions (each adjusted to account for the Reverse Stock Split) since December 31, 2022 (in thousands, except
weighed average exercise price and weighted average remaining contractual life data):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">Outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">Exercisable</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Options<br/> Awards</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise<br/> Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life<br/> (in&#160;Years)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Options<br/> Awards</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life (in&#160;Years)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; text-indent: -9pt; padding-left: 9pt">As of January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">353</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">225.98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.8</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">336</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">230.93</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.6</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Cancelled/Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(177</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">226.56</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">As of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Cancelled/Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">206.15</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">As of December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">258.55</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.0</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">73</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">258.46</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.0</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of the Status of our Unvested and Related Transactions</a></td>
<td class="text">The following table summarizes the status of our RSUs and related transactions
(each adjusted to account for the Reverse Stock Split) (in thousands, except weighed average grant date fair value):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">RSUs awards outstanding</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
 Average<br/>
 Grant Date<br/>
 Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/>
 Intrinsic<br/>
 Value</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance, January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">272</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">58.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,890.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(327</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cancelled/Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(58</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">318.63</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">163</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(180</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cancelled/Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Balance, as of December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9.67</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">89.6</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>The following table summarizes the status of our PSUs and related transactions
for each for the following years (each adjusted to account for the Reverse Stock Split) (in thousands, except weighed average grant date
fair value):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">PSUs</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Grant Date<br/> Fair Value</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font: 10pt Times New Roman, Times, Serif">Balance, December 31, 2021</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">164</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">51.50</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,953</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">63</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">34.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vested and settled</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(133</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">47.12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,382.98</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Cancelled/Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(75</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(44.85</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Unvested, as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">52.15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">107.55</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">&#8212;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Vested</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">56.05</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(10.72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Cancelled/Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Unvested, as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">14</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">50.87</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">33</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfWarrantRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of warrants that were granted, exercised, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfWarrantRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824840249968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income (Loss) from Continuing Operations Before Income Taxes</a></td>
<td class="text">Our income (loss) from continuing operations before income taxes is
as follows (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Year Ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">United States</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(7,742</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">1,074</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text">A reconciliation between taxes computed at the federal statutory rate
and the consolidated effective tax rate is as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal statutory tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,626</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State tax rate, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustment in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,173</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">286.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,228.6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Excess stock benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,460</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(31.8</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">835.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense accretion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.5</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Permanent and other differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,261</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(274.6</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,368.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">(Benefit) provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(43</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.5</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.0</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Net Deferred Income Tax Asset</a></td>
<td class="text">Deferred income taxes result from temporary differences between the amount
of assets and liabilities recognized for financial reporting and tax purposes. The components of the net deferred tax assets as of December
31, 2023 and 2022 are as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred income tax assets (liabilities):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">158,040</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">176,631</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payment compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,339</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,590</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense limitation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,547</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,707</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gain on sale of ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,401</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,624</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrual for sales returns and coupons</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">R&amp;D credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">256</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,062</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred income tax asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,255</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(200,428</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(178,255</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,428</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Deferred income tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824846594816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Income (loss) per common share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Computation of Basic and Diluted Income (Loss) Per Common Share</a></td>
<td class="text">The following table sets forth the computation of basic and diluted
income (loss) per common share (each adjusted to account for the Reverse Stock Split) for the periods presented (in thousands, except
per share amounts):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Years Ending December 31,</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Net income (loss) from continuing operations</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,699</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,074</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net income (loss) from discontinued operations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,579</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">110,923</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net income (loss)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(10,278</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">111,997</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Weighted average common shares for basic income (loss) per common share</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,441</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,028</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Effect of dilutive securities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">338</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Weighted average common shares for diluted income (loss) per common share</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,441</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,366</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss) per common share, continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Basic</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.74</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.74</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Income (loss) per common share, discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Basic</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.25</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12.29</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.25</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11.84</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Outstanding Securities</a></td>
<td class="text">The following table sets forth the outstanding securities as of the
periods presented which were not included in the calculation of diluted earnings per common share during 2023 and 2022 (in thousands):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">72</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">172</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>PSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">99</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">101</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">273</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824827481552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 15, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 09, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 06, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2034 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 01, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_TermOfRoyaltyPayments', window );">Period of royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment', window );">General</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_PaymentsToAcquireNetWorkingCapital', window );">Acquisition of net working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Cash received for prepaid royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_PrepaidRoyaltyLiabilities', window );">Prepaid royalty liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_QuarterlyRoyaltyPayment', window );">Quarterly royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_QuarterlyRoyaltyInterest', window );">Quarterly royalty payment, interest per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_RoyaltyPayment', window );">Royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,532,000<span></span>
</td>
<td class="nump">9,498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative operating support expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,903,000<span></span>
</td>
<td class="nump">$ 56,710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate', window );">Present value of annual minimum royalty discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_LicenseRevenue', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalty sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositContractsAssets', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">shares of our outstanding Common Stock were split at a ratio of 50-for-1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Number of authorized shares of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_NumberOfEmployeesAfterWorkforceReduction', window );">Employees after workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_RestructuringChargesIncludingDiscontinuedOperations', window );">Restructuring charges including discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,000<span></span>
</td>
<td class="nump">1,604,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember', window );">Accrued Expenses And Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=txmd_CurrentLiabilitiesForDiscontinuedOperationsMember', window );">Current Liabilities For Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments', window );">Additional milestone payments to be received on achievement of sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Number of authorized shares of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">32,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Number of authorized shares of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=txmd_VitaCareDivestitureMember', window );">Vita Care Divestiture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from sale of business, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_TransactionCostsRelatedToDivestitureOfBusiness', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=txmd_VitaCareDivestitureMember', window );">Vita Care Divestiture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ContingentCashConsiderationFromSaleOfBusiness', window );">Contingent cash consideration from sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=txmd_AnnoverasMember', window );">Annoveras [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WriteOffOfAsset', window );">Gain on intangible assets write off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=txmd_AnnoverasMember', window );">Annoveras [Member] | Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative operating support expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DecreaseInRoyaltyRateOnProductByProductBasis', window );">Decrease in royalty rate on product-by-product basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_MinimumAnnualRoyaltyPayment', window );">Minimal annual royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment', window );">Inflation rate adjusted for minimal annual royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsOneMember', window );">Milestone Payments One [Member] | Royalty Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate', window );">Threshold annual net sales to determine royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=txmd_RoyaltyRateOneMember', window );">Royalty Rate One [Member] | Royalty Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_RoyaltyRateAsPercentageOnNetSales', window );">Royalty rate as percentage on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate', window );">Threshold annual net sales to determine royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=txmd_RoyaltyRateTwoMember', window );">Royalty Rate Two [Member] | Royalty Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_RoyaltyRateAsPercentageOnNetSales', window );">Royalty rate as percentage on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Number of authorized shares of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_AggregateMinimumAnnualRoyaltyPaymentsDue', window );">Aggregate minimum annual royalty Payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember', window );">Mayne License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_TermOfRoyaltyPayments', window );">Period of royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DecreaseInRoyaltyRateOnProductByProductBasis', window );">Decrease in royalty rate on product-by-product basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_MinimumAnnualRoyaltyPayment', window );">Minimal annual royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_PeriodOfMinimumAnnualRoyaltyPayment', window );">Period of minimal annual royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment', window );">Inflation rate adjusted for minimal annual royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_PrepaidRoyaltyLiabilities', window );">Prepaid royalty liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement', window );">Royalty payment payable under long term service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_AdditionalFund', window );">Additional fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accounts Payable and Other Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash received in acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments', window );">Proceeds from acquire businesses net of working capital adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember', window );">Mayne License Agreement [Member] | Milestone Payments One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_OneTimeMilestonePayments', window );">One-time milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment', window );">Threshold net sales amount to determine one-time milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember', window );">Mayne License Agreement [Member] | Milestone Payments Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_OneTimeMilestonePayments', window );">One-time milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment', window );">Threshold net sales amount to determine one-time milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember', window );">Mayne License Agreement [Member] | Milestone Payments Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_OneTimeMilestonePayments', window );">One-time milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment', window );">Threshold net sales amount to determine one-time milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember', window );">Mayne License Agreement [Member] | Royalty Rate One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_RoyaltyRateAsPercentageOnNetSales', window );">Royalty rate as percentage on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate', window );">Threshold annual net sales to determine royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember', window );">Mayne License Agreement [Member] | Royalty Rate Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_RoyaltyRateAsPercentageOnNetSales', window );">Royalty rate as percentage on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate', window );">Threshold annual net sales to determine royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_StockPurchaseAgreementMember', window );">Stock Purchase Agreement [Member] | Vita Care Divestiture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_RubricCapitalManagementLPMember', window );">Rubric Capital Management L P [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, Issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.6797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Gross proceeds</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Shares of common stock (in Shares) | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_TheramexLicenseAgreementsMember', window );">Theramex License Agreements [Member] | Bijuvas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember', window );">Land and Building [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember', window );">Land and Building [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software and Software Development Costs [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software and Software Development Costs [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdditionalFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional fund paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdditionalFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payments to be received on achievement of sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AggregateMinimumAnnualRoyaltyPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate minimum annual royalty payments due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AggregateMinimumAnnualRoyaltyPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ContingentCashConsiderationFromSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent cash consideration from sale of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ContingentCashConsiderationFromSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DecreaseInRoyaltyRateOnProductByProductBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in royalty rate on product-by-product basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DecreaseInRoyaltyRateOnProductByProductBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inflation rate adjusted for minimal annual royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of license revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumAnnualRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum annual royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumAnnualRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfEmployeesAfterWorkforceReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of employees after workforce reduction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfEmployeesAfterWorkforceReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OneTimeMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>One-time milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_OneTimeMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PaymentsToAcquireNetWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire net working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PaymentsToAcquireNetWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PeriodOfMinimumAnnualRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of minimum annual royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PeriodOfMinimumAnnualRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidRoyaltyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid royalty liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidRoyaltyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of annual minimum royalty discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from acquire businesses net of working capital adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of transferred assets and grant of licenses cash payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_QuarterlyRoyaltyInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Quarterly royalty interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_QuarterlyRoyaltyInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_QuarterlyRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Quarterly royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_QuarterlyRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RestructuringChargesIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring charges including discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RestructuringChargesIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payment payable under long term service agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyRateAsPercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty rate as percentage on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyRateAsPercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_TermOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_TermOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold annual net sales to determine royalty rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold net sales amount to determine one-time milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_TransactionCostsRelatedToDivestitureOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs related to divestiture of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_TransactionCostsRelatedToDivestitureOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WriteOffOfAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WriteOffOfAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(10)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of assets as of the balance sheet date pertaining to amounts paid by the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483081/340-30-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483054/340-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a),(c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=txmd_CurrentLiabilitiesForDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=txmd_CurrentLiabilitiesForDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=txmd_VitaCareDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=txmd_VitaCareDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=txmd_AnnoverasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=txmd_AnnoverasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=txmd_RoyaltyRateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=txmd_RoyaltyRateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=txmd_RoyaltyRateTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=txmd_RoyaltyRateTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_RubricCapitalManagementLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_RubricCapitalManagementLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_TheramexLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_TheramexLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_BijuvasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_BijuvasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824843791648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details) - Summary of Restructuring Cost Recognition - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring expenses - general and administrative expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges', window );">Total restructuring expenses - discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=txmd_ExecutiveTerminationBenefitsMember', window );">Executive Termination Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring expenses - general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=txmd_ConsultingAndLegalExpensesMember', window );">Consulting And Legal Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring expenses - general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=txmd_OtherContractTerminationCostsMember', window );">Other Contract Termination Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring expenses - general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges', window );">Total restructuring expenses - discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=txmd_EmployeeTerminationBenefitsMember', window );">Employee Termination Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges', window );">Total restructuring expenses - discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group, including discontinued operation, restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=txmd_ExecutiveTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=txmd_ExecutiveTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=txmd_ConsultingAndLegalExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=txmd_ConsultingAndLegalExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=txmd_OtherContractTerminationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=txmd_OtherContractTerminationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=txmd_EmployeeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=txmd_EmployeeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139825020458528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Details) - Discontinued Operations [Member] - Annoveras [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DiscontinuedOperationsDetailsLineItems', window );"><strong>Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived', window );">Cash payment</a></td>
<td class="nump">140,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments', window );">Net working capital</a></td>
<td class="nump">12,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties', window );">Prepaid royalties</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DiscontinuedOperationsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DiscontinuedOperationsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation cash received for acquisition of networking capital subject to certain adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation cash received for prepaid royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation license payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=txmd_AnnoverasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=txmd_AnnoverasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824851064384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Details) - Schedule of Discontinued Operations - Discontinued Operations [Member] - Annoveras [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems', window );"><strong>Discontinued Operations (Details) - Schedule of Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Product revenue, net</a></td>
<td class="num">$ (833)<span></span>
</td>
<td class="nump">$ 80,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,640<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss', window );">Gross profit (loss)</a></td>
<td class="num">(833)<span></span>
</td>
<td class="nump">65,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing', window );">Selling and marketing</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">11,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment', window );">Research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges', window );">Restructuring charges</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,180<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">97,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Loss from discontinued operations</a></td>
<td class="num">(1,314)<span></span>
</td>
<td class="num">(32,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness', window );">Gain on sale of vitaCare</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">143,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale', window );">Gain on ANNOVERA sale</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">62,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on the extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(8,380)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts', window );">Interest expense and other financing costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(36,065)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock', window );">Expense for accretion of Series A Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(16,973)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of assets</a></td>
<td class="num">(1,150)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(115)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet', window );">Total other income (expense), net</a></td>
<td class="num">(1,265)<span></span>
</td>
<td class="nump">143,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes', window );">Loss before from income taxes</a></td>
<td class="num">(2,579)<span></span>
</td>
<td class="nump">111,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax', window );">Benefit (provision) for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(552)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net income (loss) from discontinued operations</a></td>
<td class="num">$ (2,579)<span></span>
</td>
<td class="nump">$ 110,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation expense for accretion of series a preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation gain on sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation gain on sale of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation interest expense and other financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group, including discontinued operation, loss before from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation other income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group, including discontinued operation,research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group, including discontinued operation, restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group, including discontinued operation, selling and marketing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation total other income expense net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=txmd_AnnoverasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=txmd_AnnoverasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824846817824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations (Details) - Schedule of Classes of Liabilities of Discontinued Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract', window );"><strong>Schedule Of Classes Of Liabilities Of Discontinued Operations Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable', window );">Accounts receivable</a></td>
<td class="nump">$ 344<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets</a></td>
<td class="nump">344<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,694<span></span>
</td>
<td class="nump">13,588<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities</a></td>
<td class="nump">$ 3,694<span></span>
</td>
<td class="nump">$ 25,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group, including discontinued operation, accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as rent receivable attributable to disposal group held for sale or disposed of,  expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824843931008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid and Other Current Assets (Details) - Schedule of Prepaid and Other Current Assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract', window );"><strong>Schedule of Prepaid and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 1,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquisitionCostsCumulative', window );">Capitalized legal</a></td>
<td class="nump">2,334<span></span>
</td>
<td class="nump">2,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">2,533<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">$ 4,035<span></span>
</td>
<td class="nump">$ 6,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquisitionCostsCumulative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The capitalized costs incurred (excluded from amortization), as of the date of the balance sheet, to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10.(c)(7)(ii))<br> -SubTopic 10<br> -Topic 932<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479664/932-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquisitionCostsCumulative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824846622688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_FixedAssetsAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_FixedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_FixedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824827356864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed Assets (Details) - Schedule of Fixed Assets, Net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets</a></td>
<td class="nump">$ 2,522<span></span>
</td>
<td class="nump">$ 2,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="nump">2,522<span></span>
</td>
<td class="nump">2,445<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets</a></td>
<td class="nump">1,167<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824942161840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensed Rights and Other Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems', window );"><strong>Licensed Rights and Other Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems', window );"><strong>Licensed Rights and Other Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems', window );"><strong>Licensed Rights and Other Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824843530096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems', window );"><strong>Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 7,969<span></span>
</td>
<td class="nump">$ 8,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,871<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">6,098<span></span>
</td>
<td class="nump">6,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugPatentsMember', window );">Hormone Therapy Drug Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems', window );"><strong>Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">6,818<span></span>
</td>
<td class="nump">6,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,871<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">4,947<span></span>
</td>
<td class="nump">4,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember', window );">Hormone therapy drug patents applied and pending approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems', window );"><strong>Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">1,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">1,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_IntangibleAssetsSubjectToAmortizationMember', window );">Intangible Assets Subject to Amortization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems', window );"><strong>Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">7,660<span></span>
</td>
<td class="nump">8,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,871<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">5,789<span></span>
</td>
<td class="nump">6,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems', window );"><strong>Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_IntangibleAssetsSubjectToAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_IntangibleAssetsSubjectToAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824962599424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Licensed Rights and Other Intangible Assets (Details) - Schedule of Intangible Assets Subject To Amortization<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract', window );"><strong>Schedule of Intangible Assets Subject To Amortization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">5,347<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 7,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824840344272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 13.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824851111088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - Schedule of Other Accrued Expenses and Other Current Liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract', window );"><strong>Schedule of Other Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related costs</a></td>
<td class="nump">$ 762<span></span>
</td>
<td class="nump">$ 8,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_AccruedContractTerminationCosts', window );">Accrued contract termination costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_AccruedResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,473<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_AccruedPrepaidRoyalty', window );">Prepaid royalty</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses and current liabilities</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">1,604<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 3,133<span></span>
</td>
<td class="nump">$ 18,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedContractTerminationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued contract termination costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedContractTerminationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedPrepaidRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued prepaid royalty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedPrepaidRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824847370320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Deb interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Financing fees amortization</a></td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824839323984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>m&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Rentable square feet (in Square Meters) | m&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,651<span></span>
</td>
<td class="nump">7,561<span></span>
</td>
<td class="nump">6,536<span></span>
</td>
<td class="nump">62,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease expiry year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease extend term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">two<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_LeaseConsecutivePeriods', window );">Lease consecutive periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">lease expense<span></span>
</td>
<td class="text">lease expense<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RentalIncomeNonoperating', window );">Rental income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectTaxesAndLicensesCosts', window );">Commercial batch release amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Executive termination obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_LegalProceedingAxis=txmd_ParagraphFourCertificationNoticeLetterMember', window );">Paragraph Four Certification Notice Letter [Member] | Prepaid Expenses and Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MaynePharmaAgreementMember', window );">Mayne Pharma Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_CashReceivedForNetWorkingCapital', window );">Acquisition of net working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WorkingCapitalAmounts', window );">Working capital amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MaynePharmaAgreementMember', window );">Mayne Pharma Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_IncrementalAccrualForNetWorkingCapital', window );">Incremental accrual for net working capital</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MaynePharmaAgreementMember', window );">Mayne Pharma Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_IncrementalAccrualForNetWorkingCapital', window );">Incremental accrual for net working capital</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_PopulationCouncilLicenseAgreementMember', window );">Population Council License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_PopulationCouncilLicenseAgreementMember', window );">Population Council License Agreement [Member] | Annoveras [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_MilestonePaymentsRecordedAsLicenseRights', window );">Aggregate of milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CashReceivedForNetWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for net working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CashReceivedForNetWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IncrementalAccrualForNetWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental accrual for net working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_IncrementalAccrualForNetWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LeaseConsecutivePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease consecutive periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LeaseConsecutivePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentsRecordedAsLicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments recorded as license rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentsRecordedAsLicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WorkingCapitalAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WorkingCapitalAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectTaxesAndLicensesCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax incurred and cost of license directly related to good produced or service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectTaxesAndLicensesCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RentalIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RentalIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LegalProceedingAxis=txmd_ParagraphFourCertificationNoticeLetterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LegalProceedingAxis=txmd_ParagraphFourCertificationNoticeLetterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_MaynePharmaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_MaynePharmaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_PopulationCouncilLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_PopulationCouncilLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_AnnoverasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_AnnoverasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824942100368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Remaining Lease Payments - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Remaining Lease Payments [Abstarct]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">1,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">1,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">10,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">2,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease payments</a></td>
<td class="nump">$ 8,005<span></span>
</td>
<td class="nump">$ 8,759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824843750736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Supplemental Balance Sheet Information Related to Leases - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract', window );"><strong>Schedule Of Supplemental Balance Sheet Information Related To Leases Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 6,873<span></span>
</td>
<td class="nump">$ 7,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities current (included in accrued expenses and other current liabilities)</a></td>
<td class="nump">1,473<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">6,532<span></span>
</td>
<td class="nump">7,369<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 8,005<span></span>
</td>
<td class="nump">$ 8,759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824846555840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Other Information Related to Leases - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Schedule of Other Information Related to Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term (years) - operating leases</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - operating leases</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities from operating lease (in thousands)</a></td>
<td class="nump">$ 1,443<span></span>
</td>
<td class="nump">$ 1,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease obligations (non-cash in thousands)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824834108320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 26, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_StockholdersEquityDeficitDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Percentage of volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Percentage of risk free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based compensation over a weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_TwoThousandNineteenStockIncentivePlanMember', window );">Two Thousand Nineteen Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_StockholdersEquityDeficitDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Remaining shares of common stock available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_StockholdersEquityDeficitDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease', window );">Common stock shares authorized</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_StockholdersEquityDeficitDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease', window );">Common stock shares authorized</a></td>
<td class="nump">32,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember', window );">Phantom Share Units (PSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_StockholdersEquityDeficitDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_StockholdersEquityDeficitDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockholdersEquityDeficitDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_StockholdersEquityDeficitDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_TwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_TwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824847138976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of Outstanding and Exercisable Warrants and Related Transactions - Warrant [Member] - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of Outstanding and Exercisable Warrants and Related Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants', window );">Beginning balance, Warrants</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice', window );">Beginning balance, Weighted Average Exercise Price</a></td>
<td class="nump">$ 13.1<span></span>
</td>
<td class="nump">$ 76.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue', window );">Warrants, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 2,427<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife', window );">Warrants, Weighted Average Remaining Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised', window );">Exercised, Warrants</a></td>
<td class="num">(435)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised', window );">Exercised, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised', window );">Exercised, Weighted Average Exercise Price</a></td>
<td class="num">$ (2,270)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted', window );">Granted, Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted', window );">Granted, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired', window );">Expired, Warrants</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired', window );">Expired, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="nump">$ 341.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants', window );">Ending balance, Warrants</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice', window );">Ending balance, Weighted Average Exercise Price</a></td>
<td class="nump">$ 66.61<span></span>
</td>
<td class="nump">$ 13.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue', window );">Warrants, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 1,793<span></span>
</td>
<td class="nump">$ 2,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife', window );">Warrants, Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants outstanding and exercisable other than options warrants weighted average remaining contractual life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants outstanding and exercisable other than options warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants outstanding and exercisable other than options warrants aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants outstanding and exercisable other than options warrants aggregate intrinsic value exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants outstanding and exercisable other than options warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants outstanding and exercisable other than options warrants expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants outstanding and exercisable other than options warrants granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants outstanding and exercisable other than options warrants weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants outstanding and exercisable other than options warrants weighted average exercise price exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants outstanding and exercisable other than options warrants weighted average exercise price expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants outstanding and exercisable other than options warrants weighted average exercise price granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants outstanding and exercisable other than options warrants weighted average remaining contractual life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824851062336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of Stock Options Activity - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ScheduleOfStockOptionsActivityAbstract', window );"><strong>Schedule of Stock Options Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options awards outstanding, Beginning balance</a></td>
<td class="nump">353,000<span></span>
</td>
<td class="nump">172,000<span></span>
</td>
<td class="nump">353,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options awards outstanding, weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 225.98<span></span>
</td>
<td class="nump">$ 228.28<span></span>
</td>
<td class="nump">$ 225.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options awards outstanding, aggregate intrinsic value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options awards outstanding, Weighted Average Remaining Contractual Life (in Years)</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options awards exercisable, Beginning balance</a></td>
<td class="nump">336,000<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="nump">336,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options awards exercisable, weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 230.93<span></span>
</td>
<td class="nump">$ 229.43<span></span>
</td>
<td class="nump">$ 230.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options awards exercisable, Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options awards exercisable, Weighted Average Remaining Contractual Life (in Years)</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options awards outstanding, Cancelled/Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options awards outstanding Weighted Average Exercise Price, Cancelled/Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options awards outstanding, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="num">(177,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options awards outstanding Weighted Average Exercise Price, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206.15<span></span>
</td>
<td class="nump">$ 226.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options awards outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">172,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options awards outstanding, weighted average exercise price, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258.55<span></span>
</td>
<td class="nump">$ 228.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options awards outstanding, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2', window );">Options awards outstanding, Weighted Average Remaining Contractual Life (in Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options awards exercisable, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,000<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options awards exercisable, weighted average exercise price, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258.46<span></span>
</td>
<td class="nump">$ 229.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options awards exercisable, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfStockOptionsActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfStockOptionsActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824850534304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of the Status of our Unvested and Related Transactions - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of the Status of our Unvested and Related Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, Beginning balance (in Shares)</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning balance</a></td>
<td class="nump">$ 14.57<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
<td class="nump">$ 318.63<span></span>
</td>
<td class="nump">$ 4,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Unvested, Granted (in Shares)</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="nump">$ 4.82<span></span>
</td>
<td class="nump">$ 16.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Aggregate Intrinsic Value, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Unvested, Vested (in Shares)</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="nump">$ 6.83<span></span>
</td>
<td class="nump">$ 48.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue', window );">Aggregate Intrinsic Value, Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Unvested, Cancelled/Forfeited (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Cancelled/Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Cancelled/Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Aggregate Intrinsic Value, Cancelled/Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested Ending balance (in Shares)</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending balance</a></td>
<td class="nump">$ 9.67<span></span>
</td>
<td class="nump">$ 14.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">$ 89.6<span></span>
</td>
<td class="nump">$ 318.63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of the Status of our Unvested and Related Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, Beginning balance (in Shares)</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning balance</a></td>
<td class="nump">$ 52.15<span></span>
</td>
<td class="nump">$ 51.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
<td class="nump">$ 107.55<span></span>
</td>
<td class="nump">$ 2,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Unvested, Granted (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 34.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Aggregate Intrinsic Value, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Unvested, Vested (in Shares)</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="nump">$ 56.05<span></span>
</td>
<td class="nump">$ 47.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue', window );">Aggregate Intrinsic Value, Vested</a></td>
<td class="num">$ (10.72)<span></span>
</td>
<td class="num">$ (2,382.98)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Unvested, Cancelled/Forfeited (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Cancelled/Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (44.85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Cancelled/Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 44.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Aggregate Intrinsic Value, Cancelled/Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested Ending balance (in Shares)</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending balance</a></td>
<td class="nump">$ 50.87<span></span>
</td>
<td class="nump">$ 52.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 107.55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824827411600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_TermOfRoyaltyPayments', window );">Period of minimal annual royalty payment</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License sale</a></td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_LicenseRevenue', window );">License revenue</a></td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalty sales</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember', window );">Mayne License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_TermOfRoyaltyPayments', window );">Period of minimal annual royalty payment</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DecreaseInRoyaltyRateOnProductByProductBasis', window );">Decrease in royalty rate on product-by-product basis</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_MinimumAnnualRoyaltyPayment', window );">Minimal annual royalty payment</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_PeriodOfMinimumAnnualRoyaltyPayment', window );">Period of minimal annual royalty payment</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment', window );">Inflation rate adjusted for minimal annual royalty payment</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember', window );">Mayne License Agreement [Member] | Milestone Payments 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_OneTimeMilestonePayments', window );">One-time milestone payments</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment', window );">Threshold net sales amount to determine one-time milestone payment</a></td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember', window );">Mayne License Agreement [Member] | Milestone Payments 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_OneTimeMilestonePayments', window );">One-time milestone payments</a></td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment', window );">Threshold net sales amount to determine one-time milestone payment</a></td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember', window );">Mayne License Agreement [Member] | Milestone Payments 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_OneTimeMilestonePayments', window );">One-time milestone payments</a></td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment', window );">Threshold net sales amount to determine one-time milestone payment</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember', window );">Mayne License Agreement [Member] | Royalty Rate 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_RoyaltyRateAsPercentageOnNetSales', window );">Royalty rate as percentage on net sales</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate', window );">Threshold annual net sales to determine royalty rate</a></td>
<td class="nump">$ 80,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember', window );">Mayne License Agreement [Member] | Royalty Rate 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_RoyaltyRateAsPercentageOnNetSales', window );">Royalty rate as percentage on net sales</a></td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate', window );">Threshold annual net sales to determine royalty rate</a></td>
<td class="nump">$ 80,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DecreaseInRoyaltyRateOnProductByProductBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in royalty rate on product-by-product basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DecreaseInRoyaltyRateOnProductByProductBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inflation rate adjusted for minimal annual royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of license revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumAnnualRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum annual royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumAnnualRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OneTimeMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>One-time milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_OneTimeMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PeriodOfMinimumAnnualRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of minimum annual royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PeriodOfMinimumAnnualRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyRateAsPercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty rate as percentage on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyRateAsPercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_TermOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_TermOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold annual net sales to determine royalty rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold net sales amount to determine one-time milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_MayneLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=txmd_MilestonePaymentsThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=txmd_RoyaltyRateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=txmd_RoyaltyRateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=txmd_RoyaltyRateTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=txmd_RoyaltyRateTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824839315168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes continuing and discontinued operations</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss (&#8220;NOL&#8221;) carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 577.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_NetOperatingLossCarryforwardsTerm', window );">Carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_PercentageOfFutureTaxableIncome', window );">Excess taxable income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes continuing and discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes continuing and discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=txmd_ExpirationPeriod20YearsMember', window );">Expiration Period 20 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss (&#8220;NOL&#8221;) carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=txmd_ExpirationPeriodIndefiniteMember', window );">Expiration Period Indefinite [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss (&#8220;NOL&#8221;) carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 557.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetOperatingLossCarryforwardsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetOperatingLossCarryforwardsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PercentageOfFutureTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future taxable Income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PercentageOfFutureTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=txmd_ExpirationPeriod20YearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=txmd_ExpirationPeriod20YearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=txmd_ExpirationPeriodIndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=txmd_ExpirationPeriodIndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824846589152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Income (Loss) from Continuing Operations Before Income Taxes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems', window );"><strong>Income Taxes (Details) - Schedule of Income (Loss) from Continuing Operations Before Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">United States</a></td>
<td class="num">$ (7,742)<span></span>
</td>
<td class="nump">$ 1,074<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139825020462848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Effective Income Tax Rate Reconciliation - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract', window );"><strong>Schedule of Effective Income Tax Rate Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate (in Dollars)</a></td>
<td class="num">$ (1,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal tax benefit (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal tax benefit, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Adjustment in valuation allowances (in Dollars)</a></td>
<td class="num">$ (22,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Adjustment in valuation allowances, percentage</a></td>
<td class="nump">286.40%<span></span>
</td>
<td class="num">(3228.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Excess stock benefits (in Dollars)</a></td>
<td class="nump">$ 2,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Excess stock benefits, percentage</a></td>
<td class="num">(31.80%)<span></span>
</td>
<td class="nump">835.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars', window );">Interest expense accretion (in Dollars)</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars', window );">Interest expense accretion, percentage</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Permanent and other differences (in Dollars)</a></td>
<td class="nump">$ 21,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent and other differences, percentage</a></td>
<td class="num">(274.60%)<span></span>
</td>
<td class="nump">2368.50%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit) provision for income taxes (in Dollars)</a></td>
<td class="num">$ (43)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_EffectiveIncomeTaxRateDiscontinuedOperations', window );">(Benefit) provision for income taxes, percentage</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_EffectiveIncomeTaxRateDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_EffectiveIncomeTaxRateDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense accretion, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense accretion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824846459632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Components of Net Deferred Income Tax Asset - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract', window );"><strong>Deferred income tax assets (liabilities):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 158,040<span></span>
</td>
<td class="nump">$ 176,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Share-based payment compensation</a></td>
<td class="nump">3,339<span></span>
</td>
<td class="nump">8,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Interest expense limitation</a></td>
<td class="nump">19,547<span></span>
</td>
<td class="nump">19,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty', window );">Gain on sale of ANNOVERA</a></td>
<td class="num">(3,401)<span></span>
</td>
<td class="num">(3,624)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Accrual for sales returns and coupons</a></td>
<td class="nump">288<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D credit</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">256<span></span>
</td>
<td class="num">(1,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DeferredTaxAssetsLiabilitiesGross', window );">Deferred income tax asset</a></td>
<td class="nump">178,255<span></span>
</td>
<td class="num">(200,428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(178,255)<span></span>
</td>
<td class="nump">200,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred income tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset gain on sale of intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DeferredTaxAssetsLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset (liabilities) attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DeferredTaxAssetsLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset (liabilities) attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824839443056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Common Share (Details) - Schedule of Computation of Basic and Diluted Income (Loss) Per Common Share - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income (loss) from continuing operations (in Dollars)</a></td>
<td class="num">$ (7,699)<span></span>
</td>
<td class="nump">$ 1,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net income (loss) from discontinued operations (in Dollars)</a></td>
<td class="num">(2,579)<span></span>
</td>
<td class="nump">110,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) (in Dollars)</a></td>
<td class="num">$ (10,278)<span></span>
</td>
<td class="nump">$ 111,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares for basic income (loss) per common share (in Shares)</a></td>
<td class="nump">10,441<span></span>
</td>
<td class="nump">9,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares for diluted income (loss) per common share (in Shares)</a></td>
<td class="nump">10,441<span></span>
</td>
<td class="nump">9,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Income (loss) per common share, continuing operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic</a></td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted</a></td>
<td class="num">(0.74)<span></span>
</td>
<td class="nump">0.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Income (loss) per common share, discontinued operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Basic</a></td>
<td class="num">(0.25)<span></span>
</td>
<td class="nump">12.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Diluted</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="nump">$ 11.84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824851024192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Common Share (Details) - Schedule of Outstanding Securities - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Outstanding Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=txmd_StockOptionsMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Outstanding Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Outstanding Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">40<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Outstanding Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">14<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Outstanding Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=txmd_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=txmd_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824851025056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related parties (Details) - Rubric Capital Management L P [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 15, 2023</div></th>
<th class="th"><div>Jun. 28, 2023</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Price per share</a></td>
<td class="nump">$ 2.2761<span></span>
</td>
<td class="nump">$ 3.6797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Gross proceeds</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Additional shares of common stock</a></td>
<td class="nump">877,192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_SubscriptionAgreementMember', window );">Subscription Agreement [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Preferred stock at a purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Preferred stock investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=txmd_RubricCapitalManagementLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=txmd_RubricCapitalManagementLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_SubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_SubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139824847350096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Concentrations (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_TheramexMember', window );">Theramex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessConcentrationsDetailsLineItems', window );"><strong>Business Concentrations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_CustomerLicenseRevenuePercentage', window );">Customer license revenue percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_MaynePharmaMember', window );">Mayne Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_BusinessConcentrationsDetailsLineItems', window );"><strong>Business Concentrations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_RoyaltyReceivableShortTermPortion', window );">Royalty receivable short term portion</a></td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txmd_RoyaltyReceivableLongTermPortion', window );">Royalty receivable long term portion</a></td>
<td class="nump">$ 18.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_BusinessConcentrationsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_BusinessConcentrationsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CustomerLicenseRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customer license revenue percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CustomerLicenseRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyReceivableLongTermPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty receivable, long term portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyReceivableLongTermPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyReceivableShortTermPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty receivable short term portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyReceivableShortTermPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_TheramexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_TheramexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_MaynePharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_MaynePharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M^!5@7^GY;5=#PQSR1*!%5F2I[.W?/L%1:"%(RO_6(2\D [VD' H^\BT.R?D
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M 'Y?"FB$NQ=SA;F_LI[_!U!+ P04    " #]@WU8BS?R)*L"  !D!P  &
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M5P;P_P5C\OE!_4!W83W['U!+ P04    " #]@WU8ZFV?VO0%  !-)   &
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M)J4<(/Z_H90_G\CO/8Y?$*W^!5!+ P04    " #]@WU8>UY/214(  "W)P
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M,>](+9M@6O$5 ].^+=L'PT;C:0=+OQ6ER=0E+(8EVV')3AOM%LD61ED_[N'
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M)3,VA&'8EX0=4NIN"_A8\PEVSFZS$T 5T 2[NPU&4AJ0"]DOMOP-PVTX&($
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M!>TMM)&!=H"IN00M!A!"H2X\]7AV=G:&_PNO33,IB!N0O"6<_WVP&<_.J7Z
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M1QJI;.<XJ=@@8N_5M_+E@-CI$_#$^J9Z;SACR!>*38[D"CH3UWE-$56:'<4
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M3-<L^U=6EYHC!9O=AY#./[BZU!RL+AWG\-X'[*"Z]".+2\WAXM*,BTNC@/H
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M(U:)%34+UH8G3Z2N GSM,.[$S6C(- FV58HAO=3#P_ZM/7#D1"1UM=^6Z(#
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M"34ZF@/I@N[!BD:,]\58,65O%$B7 $&4PN*<B2K LJ*:./7^C=ZDP/EA&;Q
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M+W=O<FMS:&5E=',O<VAE970Y+GAM;)U8:V_;QA+]SE^Q4(U"!@B)#TF67-N
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M;C'@GZ$"&4#ZH$Q+:EE3;LR.*6:@B:&*8ML Q0>2:Q3:T)._$]>EF !XXVJ
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MZHOYKC,15F%Z+ [;4E\_PTTD5@1:-"S2$M,DZL"?YIO?NFB"1$2<2KAD7LA
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M@C?O;Z^OW6WXYA0&69Y1V%Z$?MQ]LZ"PN-TD:UZ$(<CAT:OH2'^P%6S-4VH
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M#OC0!+Q?*F7;!U+0_7IR\1]02P,$%     @ _8-]6,+\DN%@!0  T0T  !D
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MX_99Z0UDIK5*/S)*6$ %IL] ,JJ4N4NB* K/!\)RZUPK#BIWMJ=>/[_ '?9
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M!-TN3NW!JMHO*PME:?7QCP7MFJB= -TO%?7SYN ,=-OK[!M02P,$%     @
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M@HPXZU*AR[,DA#+DW1:1;G=1GJ$9O8=/:.(!KM<22VND.1"8[*,Q&OH&SGN
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M]O@$,7 1[!,83;9Z'XM';$3&CN&C )IN)<8,*7YFC?SX[UT&-DX-LSFS@/Q
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MUV*CW. 'I@:;XZG!":<&>U9Y#PB]4456U =-LR#REK.Z<QA#;EO42O-<RPM
MUR?5QD_!YR]U.#I?>/1!&C;S5$1?^B>+]#-Y-V1=4QE'+QUW?3G)%G\$:S7@
M(I12 Y!OQACL]$A?SY)C@\$I5P=?(W7DH5Z+%M&@?:)6D*1UY5[ZNH(_CGU]
M>WGUM0LIB,_A\NH7&N[L_%6J'I)W)5DW/V>?X*1/?JX.8+B_>'I^FIPE[_:(
M5<)_ ?[^T>2M1U#7M"<8'7C?-A/7H? @D@NK6\/^<4F2ZQH+&I@F_10\?@OC
MAP2P5-U&Y3F&$5'$8$J[[\B@&B"\JOXD 7-1A@F^I+61ZP;5?:SJ+#QO]$NP
M4FL3#,<>YM^ZNFCR0EP\X:;5%>L3]%0>J*$!LQ=$73J+\1OU91GR% S[;*I!
M$UEC,F4&&FI!Z:CD.:F:@ZR BLQGR9\U^0;LH^!7>FTE[2 :),H]NNQ!C'R3
M8052ILB*4@ZK#((G0@,*?K;HC>.V1J2P.8TSA)"6A_%K_Z<Y<N2$)%4Y;' U
MRKPF2/^5(_U7DP3[-N3:/SG..D;YDP.-)V90RNCX#/'W 4]'-:"F8(+/6Y$H
M XGIYH#9RJ1WM%S#7N8NBXCX8^KSD9+,^ROWV6^ E+CN*.>.QEZ!=;)$66?I
M]',V2KH"!!3K-FZ!DBP:NKT10=&/?^AJ7)OJB7X);JYF6ZQ;9/F<PL,K8J+I
M88@S14-IUYN7U0_G*4%&Y=FC4?8((^;D2>,N3L+\+J_>.,<XL[[%^;.4,C>=
M4@Q0\HSW*M0JPM0 \B&0 -MC/[(1D1G8*>32CC4DXI.1[1.KC\Z9XO*0)-3/
MPO(V5%P"E-%.2;T4J*F$)]Q'A>GBFKM%(31VM2@C#'"+4CE[1\N(BJR)Y/J]
MCMC<=<0@4RNG+R#(R"V<)Z+BLVH;Q_YE2!2MDCHO_EZF(G3:K-26/Z)<D4+M
M'%++VV&NXTB8/O7.371'DQ5+,(V4>EI#)S%UZ@1!>12W'+#V.;V&PLG+JJXI
MTM_T_(NN#E7W1H#8(S7^PV%PKHT ?:"9,W4S7 <%Q]S[I+"O5B IY.4K2^W
M+I$N9!CQTZ/^BYYWK/?\I+Q"X]*T["P4;*AEHW!CIG^"KYXR=(X@8TJ^(@1T
M]FDLDU;-T"/Z>*A52NND/Z*\]YE21-V1,B\FX7'BQ<R-.G1_!CH*ABNM*O%G
MQR3'E-B;G_O.H^>3@N\;Y_26:I%N?S@J^J;'.B+[WH(N<6P27QE>.TR]VQ/
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M6S1,B-(>9)J3ARF$N*RR=8(R'#MWW62Z$C@&U8=@N UPNJ&& .2%]Q"-P,A
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M7BK7RI+P^FE-+QUJ9T#_2Z7L_<(%&-[.^2]02P,$%     @ _8-]6&LE/!G
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M$4I&5'>V:J'XSMR3UESAK<L\IGC-!:$-<'_#N6H6.D![<9[_ U!+ P04
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MI<&N=\<*QRPHZX#OA91F?[$!AL&=_@902P,$%     @ _8-]6!#,V\W* @
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MVL\"_TD@30"NYT+H[< 0]'^YV6]02P,$%     @ _8-]6"5$>)Y)!   _@H
M !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULG591;]LV$'[7KR#4KD@
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M(EY"-F)1Z#,>\.@ 7M0G&CF\Z&<2_6N^,%9C1?R]+]46*-X/1%UR8FJ1P=D
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MRN+]SRW7>.$&30;X?:F4W3Y0@/X*/_L?4$L#!!0    ( /V#?5C!Q5""$ 0
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M*=8O9E3Y!XN?&%F[1\)*&GQRN&&!;SQ0]@#NKZ4T^XEUT+X:%_\"4$L#!!0
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M)#"&!-/2Q<U+ %GW2.=<KCBYXQT77^4&0*'G)&9RXFR4VEZYK@PWD!!YP;?
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M(63&-0[E[4"M)/"XF)2E ^9YX2#C2=Z;GA;OKN3T5*QUFN1P)8E:9QF7_UQ
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M=#0P+GAM;*U6;6_:,!C\*U963:VT-N05UH5(+6C:I$U4I=T^F^2!6'7LS':
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MW0O[V,(V!-;*P+C*P/C9=8VQR>0: FLEUZN2ZYGI&EZWMCUX?  T1@B-] ?
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M7/%.TJ/>?L*=GDN/5VIIPQ>VT??:,9:=)=WL@IW="!57_K*KPT$ 8Z\$L%T
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M:*V"S,C.XD+27"C-@])\*"V TD(439=ALYQN?>1ZN@5=4(?27"C-@])\*"V
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M3\NW:T873!0-U-^7G,O7@Z*#W>Z4L_\!4$L#!!0    ( /V#?5@'@'!\$P,
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MO*IODWIB9%$UY)4TV-ZK8887,"@;@/_74IKGB>WQ[94>_P502P,$%     @
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MM[FNE -BCR_4H7;1JPN"+_+K+#E,CN@:K+=)_G';(P:CEL%H)X,9LR6L&"^
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MNL%I _5^PIA<-?0 Y6>?T;]02P,$%     @ _8-]6(AG8_$?!0  J1P  !D
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MOJ,A8,I71K[XE*OT#$1DS2'Y/L4=I^5;&.4-2W?%BPP/*6-I7%QNB<^KV=R
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M8PHX 6$,]/L-YVH_, O4ESC1?U!+ P04    " #]@WU8GGH.MZX#  "(#P
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MY*4JJ#9=-0WK2C&:U4 J1-CM=)*PH%R285_.BYM"U\&DG$L](+TV%+C+UVQ
MHN0C"9S<J,S8@#R<O?\U+_7UN\!=3SZ<G'0>SJ]WXV<6.">A5_3R -&+3@<7
M!A 33PX3WZ>-25]M2]OAIT;($4\Q6L]#,UG63.A@Y/3 M=J_6-B4KCH'R>_1
MQH0C[Z0WIFR)85.%PWY>RG4QQL0%C#(M6/!(Q8",J.!CQ8&5TX*+I0MW(3 I
M1:D";>X"DRJ"2/W'P9'KP0W2Z!1<ELKF=AG<[W$S? =8]< @%Z(UV"4N,.Q7
M5&NFY(WIV,$V^ 0*FO;]LC(.IXHNH^XE61/LQ209ERICJDT3D55HV!<L!SN*
M3V=PU645 JAU69A&QNFTE-1Z6#&:AI&=,"'NX.GQ,]_27N0;>V9+0;9-8ZAI
M.AG7 ?U--:>]*7OY(MV@XH^E_C(WTY&V#T7&;A7+^<+V%WEK %./<'5:56+Y
M6?"I+)B;_,$)AWVZX@6S4O$_)AN4RL0$F"+!(U.:3S8COQ6M[ME"K\IID>.>
MNV_0\[]=YRF33%&Q:=K4_C&O\HL=-Z_;U_!L'RN[CKTFXZOC]]@<,8[=9'+\
M)N/T^#TV![-C-]E["R;?PG9?O=J3_3DFHZ,T&3;'M8TSX=:)L(T&</(>D!]P
MAA?KI,%XSH7FLNG->)8Q^>1@:.0U'9L_5K?TS?B,Y70N]'T+#LBZ_9UE?%ZD
M[:A;6(AFU+K]#:87)>VQW^3B,F,+EHV:KIJ.;3,P#9.U^0!A%[FQ'S^"<1SF
M1P##\F .,(YC87G^I_GTT/DX#//6\R(]E--#.8[E0T;VB^7Q<U+S\<\T3>,X
M2; 5'8V\#D;8NB4)_/C5,&_ P/) IN>M-;[;>(7LKP-L3_=5"#93O!*QF>)K
M#8A_W8"1IO[=QO(  ]L%K'8@OS\/U)2?$\>PJY@W[ [&D33%$*A%?XTF";(Z
M"7S]^X/=)7&<IGX$,+^#.,80N!MQ!', 'C DCNU[<.=]%*[>4^'Z/[C#OU!+
M P04    " #]@WU8EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P
M#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TX
MI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606
MIW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E
M_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU
M@LD/['X 4$L#!!0    ( /V#?5@QL,>J\00  (PK   /    >&PO=V]R:V)O
M;VLN>&ULQ9K;;MLX$$!_A?!3"K1K6[>V01P@M=.N@6!KQ$%?"UJB8R(2Z9*4
MD_3K.Y1BA$R=P;Y,_)2(NOAH-)HS$G5VK\W=2NL[]M#4RDX&&^>VI\.A+3>B
MX?8?O14*UJRU:;B#17,[M%LC>&4W0KBF'B:C43%LN%2#\[/]L19F&"YH)THG
MM8)!/_!#BGO[O-XOLIVT<B5KZ1XG@^[_6@Q8(Y5LY&]130:C ;,;??^O-O*W
M5H[7R]+HNIX,QOV*'\(X6?XUO/20-WQENQ''5]<<0":#8@0'7$MC7;=%=WP.
MC#L!&_=+K=-?9>V$F7$GOAG=;J6Z]8>!LQ@&I]'%8?^W#^*I^3]AU.NU+,5,
MEVTCE.OC:$3M 97=R*T=,,4;,1E,]4X8?S[P _.J/S<'4$&DS*F$%69>=7AT
M*!=M)1V;JWYG6!M@)0A60HLUA65=RPI^O6)?>,U5*5AW96T F"* Z=$ V<F"
M!Y 9 IF](>320_@=+--K]GT;96".0.9'@UPZ70:0!0)9' URRNTF@/R(0'ZD
MA?S26JF$M>\A(:WLX!9&6-CIY9W]"8'\1 LYD[:$>B]5"Y'T6=AO$L!]1N ^
MT\)!N+9<5HPK8',;8=BT-0;V81?6"A>6[!%6LT>TF%_E P2O0PH#-T8]0BR2
M*]A,6<"ZEK<;N#.>0SB'_ N3;XQY94PLEHNR-#[S+A^V'M>^N-0A)F:7,;%>
M9F(591LFD3&Y19I&NK[>^6A-N]OW5JA2BBC],(F,B2WB57&WT74EC/W)+G^U
MT'BRDYF W:5[%U)B%AD3:^1:[ 04OA '\\686!AS5>I&L!O^$%](3 ]C8C\\
M,9U<:6O?L86_+R'_M(+FBILH<I@GQL2BN/:#4$:V')Y2HN EF!@28C'L.P!_
MCT(Y=G_+-<$<D1 [8MFNK/C5>I]>[GP]"<'0IPUB*RSX(]M9GVW=[KZ7]WU*
MK6T;Y5R".2$A=L)<60GEC=T87D']91?&<"C#S<M 8JY(B%T!>M5MIP>V@'[9
M&^(]6SWV"X\LQ,1LD1#; NV4?R8A)J:+A%@7K_3*[.2& TATT3&-),0:0;OF
M.)J861)BLX1=\SZ$86>08$))B(6"ML]1#%-,,"FQ8-#V.<;$1),2BP9M6=E)
MB(EI)R76#MZTAM4R15]UD8OGN4T\=..DF'%28N/@_6(40\PXZ5&-DX:8F'%2
M8N/@F%F(B1DG)3;.JV*<"<=E'6)BQDF/\ZZKQXRK)>:>E-@].&:8FQGFGHS8
M/7B;$6%B[LF(W1.W&7U"1N4RPY23$2OG,!W[P)9P\*H-,3'E9,3*P=NAZ%JC
M\RO$\L$QPW*98?+)B.6#8^8A)B:?C%@^>',9771,/AFQ?'#,Z*)C\LFHY2-6
M[G#]P5R3$;L&[<PC)>:8:W)BU^"882KFF&OR8S[G1*F88]+)R6?S,<RP_N28
M=')BZ:"/8W%N8M+)B:6#8T:YB4[K'W-&)LY-3#HYL71PS"@W,>GDQ-)YFCDZ
M6-!S3#/YV\S7/+T<.$2'Z28GULUAND/M;H'IIB#6#8H959X"TTU!K!L<,ZP\
M!::;@E@WZ"NA.)J8;HJW>:WV"F8434PW!;%N7DQU'KS'"TPTQ1N]6GLQZ7G@
M95"!?D'6B6;8;6S/SRHP@!+5?_ 3%L9+7I<+P_R?_AN6+/<3T.NVKJ<P]EU=
M:5[M/R;=?PA[_@=02P,$%     @ _8-]6![?F5X< @  /2<  !H   !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:2VZC0!2%X:U8+"#E^ZHDK3BCGF3:
MR@:04WXHMD$4K4YVWY8SL _J04\BS@@5B,L_X1,"GGZ50SONNU/=[?NZ^#@>
M3G75[,:Q_Y%27>_*L:UW75].YR.;;CBVXWDY;%/?KM_;;4FZ7.8TW,YHGI]N
M9RY>/_OR/Q.[S6:_+C^[]>]C.8W_&)S^=,-[W94R-HO7=MB6<=6DC\-U=TV7
MC=R=)S>+E[=5,[R\29/F#E((TOF##()L_B"'()\_*" HY@_*$)3G#[J'H/OY
M@QX@Z&'^H$<(>IP_2)8HXY(@:8(U@=:"7 N!UX)@"X'8@F0+@=F": N!VH)L
M"X';@G +@=R"= N!W8)X"X'>BGHK@=Z*>BN!WCIYV";06U%O)=!;46\ET%M1
M;R706U%O)=!;46\ET%M1;R706U%O)=#;4&\CT-M0;R/0VU!O(]#;)B]+"/0V
MU-L(]#;4VPCT-M3;"/0VU-L(]#;4VPCT-M3;"/1VU-L)]';4VPGT=M3;"?1V
MU-L)]/;)RVX"O1WU=@*]'?5V KT=]78"O1WU=@*]'?5V KT#]0X"O0/U#@*]
M _4. KT#]0X"O0/U#@*]8_*QDD#O0+V#0.] O8- [T"]@T#O0+V#0.^,>F<"
MO3/JG0GTSJAW)M [H]Z90.^,>F<"O3/JG0GTSI.?3;Y3[SI^'DJ]]GRM\?K?
M2?5X/K=<+W]9?NV<W.,7G--M17W^"U!+ P04    " #]@WU8I7\.<>X!  "0
M)@  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-VLM.PS 0!=!?J;)%C>LG#]%N
M@"VPX =,,J51D]BR72A_CY,"$@@J4)&XFT:M[;D3CW16/;][]A0GVZ[MX[Q8
MI>3/&(O5BCH;2^>ISRM+%SJ;\M?PP+RMUO:!F)C-#*M<GZA/TS34*!;GE[2T
MFS9-KK;YY]BX?EX$:F,QN=AM'++FA?6^;2J;\CI[[.M/*=/7A#*?'/?$5>/C
M4=Y0L"\3AI7O U[/W3Q2"$U-DUL;TK7M\BZV;5E,SRW%<G^)+WITRV534>VJ
M39>/E-$'LG5<$:6N+7=%C_8GIWS#M/OD!^>/9?8%YIVWP?F8)Q;H]W%O(QE.
M3WTN1"$U^U_Q/3&7/OC]:)AV3?4/L_/U/KFP'N<1V?@X_(X_SOB]_B_[$"!]
M2) ^%$@?&J0/ ]+',4@?)R!]G(+TP6<HC:"(RE%(Y2BF<A14.8JJ'(55CN(J
M1X&5H\@J4&05*+(*%%D%BJP"15:!(JM D56@R"I09!4HLDH4626*K!)%5HDB
MJT215:+(*E%DE2BR2A19)8JL"D56A2*K0I%5H<BJ4&15*+(J%%D5BJP*15:%
M(JM&D56CR*I19-4HLFH4636*K!I%5HTBJT:15:/(:E!D-2BR&A19#8JL!D56
M@R*K^4]9[YU;_W'\^"P[V_1O^6S\(]KB!5!+ 0(4 Q0    ( /V#?5@'04UB
M@0   +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L!
M A0#%     @ _8-]6(V:R7?N    *P(  !$              ( !KP   &1O
M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ _8-]6)E<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" #]@WU8TN&I<<$(  "K-P  &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ _8-]6/C9>!4W @  IP4  !@
M             ("!!!$  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( /V#?5B,RWB&N04  +X6   8              " @7$3  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #]@WU8BS?R)*L"  !D
M!P  &               @(%@&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ _8-]6",?N6HZ!@  O!X  !@              ("!01P
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( /V#?5CJ;9_:
M] 4  $TD   8              " @;$B  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " #]@WU8>UY/214(  "W)P  &
M@(';*   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ _8-]
M6*"KIOOZ*@  _8<  !@              ("!)C$  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( /V#?5CX]U.78P@  !H4   8
M      " @59<  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /V#?5B(=%3;.@,  "T'   9              "
M@7ES  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ _8-]
M6%MSVP)?$@   3$  !D              ("!ZG8  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " #]@WU8+D[M+,<(  !)&0  &0
M        @(& B0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( /V#?5C"_)+A8 4  -$-   9              " @7Z2  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ _8-]6.5P2,=0!P  MA
M !D              ("!%9@  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " #]@WU8@H+XE5$$  #)"@  &0              @(&<GP
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /V#?5C';_J+
M3@4  .D+   9              " @22D  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ _8-]6/YU%O*(!   /0H  !D
M ("!J:D  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #]
M@WU86XBKD%,"  !0!0  &0              @(%HK@  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( /V#?5A)'+&P3 (  *0%   9
M          " @?*P  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#
M%     @ _8-]6&0ZHFM# @  B@8  !D              ("!=;,  'AL+W=O
M<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #]@WU8A/2=BV\Z  #8
MPP  &0              @('OM0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;%!+ 0(4 Q0    ( /V#?5BT\BB2'0,  $<'   9              " @97P
M  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ _8-]6&LE
M/!G !   1 L  !D              ("!Z?,  'AL+W=O<FMS:&5E=',O<VAE
M970R-RYX;6Q02P$"% ,4    " #]@WU8!2^?^XL"  #$!0  &0
M    @('@^   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M /V#?5@0S-O-R@(  /\%   9              " @:+[  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ _8-]6(QU6OR_ P  ;0D  !D
M             ("!H_X  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " #]@WU8OIHJH@$#  #Q!@  &0              @(&9 @$ >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( /V#?5@E1'B>200
M /X*   9              " @=$% 0!X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ _8-]6$#5['5U!0  <!$  !D              ("!
M40H! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #]@WU8
M;N"WZ!D%  #."P  &0              @(']#P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( /V#?5C!Q5""$ 0  $$*   9
M      " @4T5 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ _8-]6 3QD \M'@  *.T! !D              ("!E!D! 'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #]@WU8RN1#: \$  !^%
M&0              @('X-P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( /V#?5CZM8N!B (  %(&   9              " @3X\ 0!X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ _8-]6%99WJ=T
M!0  M18  !D              ("!_3X! 'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    " #]@WU8+D2AG, "  !C"   &0
M@(&H1 $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( /V#
M?5BN(2V[C@(  "4'   9              " @9]' 0!X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ _8-]6)_@1+A' @  E04  !D
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M=#0V+GAM;%!+ 0(4 Q0    ( /V#?5A\.%$S.@(  -T$   9
M  " @1A; 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
M_8-]6.!X(M-  P  K@H  !D              ("!B5T! 'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    " #]@WU8K(QA+H8"   <!P  &0
M            @($ 80$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( /V#?5BQ\Q 2+P@  *E2   9              " @;UC 0!X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ _8-]6 > <'P3 P
M4PL  !D              ("!(VP! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"% ,4    " #]@WU8CSGBV]X"  #>!P  &0              @(%M
M;P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( /V#?5BN
M)V/#2@,  %P)   9              " @8)R 0!X;"]W;W)K<VAE971S+W-H
M965T-3,N>&UL4$L! A0#%     @ _8-]6$DQW"*F!0  62,  !D
M     ("! W8! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
M" #]@WU8XBM&+FD$   "$@  &0              @('@>P$ >&PO=V]R:W-H
M965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( /V#?5B(9V/Q'P4  *D<   9
M              " @8"  0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L!
M A0#%     @ _8-]6)=R(*$*!@  %R,  !D              ("!UH4! 'AL
M+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " #]@WU8LZAP\9@$
M    &   &0              @($7C $ >&PO=V]R:W-H965T<R]S:&5E=#4X
M+GAM;%!+ 0(4 Q0    ( /V#?5@[MCY."P0  /L4   9              "
M@>:0 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ _8-]
M6-&-I:./ @  )0<  !D              ("!*)4! 'AL+W=O<FMS:&5E=',O
M<VAE970V,"YX;6Q02P$"% ,4    " #]@WU8T#"(.T $   >$0  &0
M        @('NEP$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0
M   ( /V#?5C:'V/OC ,  ) +   9              " @66< 0!X;"]W;W)K
M<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ _8-]6!:JK[P0!   S0\
M !D              ("!** ! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q0
M2P$"% ,4    " #]@WU8^^+4$Y8#  #0$0  &0              @(%OI $
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( /V#?5B>>@ZW
MK@,  (@/   9              " @3RH 0!X;"]W;W)K<VAE971S+W-H965T
M-C4N>&UL4$L! A0#%     @ _8-]6!@TU<"L @  T@<  !D
M ("!(:P! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " #]
M@WU8$"C/BE<#  #.%0  #0              @ $$KP$ >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( /V#?5B7BKL<P    !,"   +              "  8:R
M 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( /V#?5@QL,>J\00  (PK   /
M          "  6^S 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #]@WU8
M'M^97AP"   ])P  &@              @ &-N $ >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " #]@WU8I7\.<>X!  "0)@  $P
M        @ 'AN@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     2@!* #T4
(    O0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>141</ContextCount>
  <ElementCount>417</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Statements of Stockholders??? (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Stockholders??? (Deficit) Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Prepaid and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssets</Role>
      <ShortName>Prepaid and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/FixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Licensed Rights and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssets</Role>
      <ShortName>Licensed Rights and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Income (Loss) Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/IncomeLossPerCommonShare</Role>
      <ShortName>Income (Loss) Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/Relatedparties</Role>
      <ShortName>Related parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Business Concentrations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/BusinessConcentrations</Role>
      <ShortName>Business Concentrations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/DiscontinuedOperations</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Prepaid and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/FixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/FixedAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Licensed Rights and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables</Role>
      <ShortName>Licensed Rights and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/CommitmentsandContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Stockholders??? Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/StockholdersEquityDeficitTables</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Income (Loss) Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTables</Role>
      <ShortName>Income (Loss) Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details) - Summary of Restructuring Cost Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable</Role>
      <ShortName>Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details) - Summary of Restructuring Cost Recognition</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails</Role>
      <ShortName>Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Discontinued Operations (Details) - Schedule of Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable</Role>
      <ShortName>Discontinued Operations (Details) - Schedule of Discontinued Operations</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Discontinued Operations (Details) - Schedule of Classes of Liabilities of Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable</Role>
      <ShortName>Discontinued Operations (Details) - Schedule of Classes of Liabilities of Discontinued Operations</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Prepaid and Other Current Assets (Details) - Schedule of Prepaid and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable</Role>
      <ShortName>Prepaid and Other Current Assets (Details) - Schedule of Prepaid and Other Current Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssetsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Fixed Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/FixedAssetsDetails</Role>
      <ShortName>Fixed Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/FixedAssetsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Fixed Assets (Details) - Schedule of Fixed Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable</Role>
      <ShortName>Fixed Assets (Details) - Schedule of Fixed Assets, Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/FixedAssetsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Licensed Rights and Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails</Role>
      <ShortName>Licensed Rights and Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable</Role>
      <ShortName>Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Licensed Rights and Other Intangible Assets (Details) - Schedule of Intangible Assets Subject To Amortization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable</Role>
      <ShortName>Licensed Rights and Other Intangible Assets (Details) - Schedule of Intangible Assets Subject To Amortization</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of Other Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details) - Schedule of Other Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/Debt</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Remaining Lease Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Remaining Lease Payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Commitments and Contingencies (Details) - Schedule of Supplemental Balance Sheet Information Related to Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Supplemental Balance Sheet Information Related to Leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Commitments and Contingencies (Details) - Schedule of Other Information Related to Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofOtherInformationRelatedtoLeasesTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Other Information Related to Leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Stockholders??? Equity (Deficit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Stockholders??? Equity (Deficit) (Details) - Schedule of Outstanding and Exercisable Warrants and Related Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Details) - Schedule of Outstanding and Exercisable Warrants and Related Transactions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Stockholders??? Equity (Deficit) (Details) - Schedule of Stock Options Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Details) - Schedule of Stock Options Activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Stockholders??? Equity (Deficit) (Details) - Schedule of the Status of our Unvested and Related Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Details) - Schedule of the Status of our Unvested and Related Transactions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/RevenueDetails</Role>
      <ShortName>Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/Revenue</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/IncomeTaxesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Income Taxes (Details) - Schedule of Income (Loss) from Continuing Operations Before Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Income (Loss) from Continuing Operations Before Income Taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/IncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Income Taxes (Details) - Schedule of Effective Income Tax Rate Reconciliation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Effective Income Tax Rate Reconciliation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/IncomeTaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Income Taxes (Details) - Schedule of Components of Net Deferred Income Tax Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Components of Net Deferred Income Tax Asset</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/IncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Income (Loss) Per Common Share (Details) - Schedule of Computation of Basic and Diluted Income (Loss) Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable</Role>
      <ShortName>Income (Loss) Per Common Share (Details) - Schedule of Computation of Basic and Diluted Income (Loss) Per Common Share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/IncomeTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Income (Loss) Per Common Share (Details) - Schedule of Outstanding Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable</Role>
      <ShortName>Income (Loss) Per Common Share (Details) - Schedule of Outstanding Securities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/IncomeTaxesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Related parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/RelatedpartiesDetails</Role>
      <ShortName>Related parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/Relatedparties</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea0201465-10k_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Business Concentrations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails</Role>
      <ShortName>Business Concentrations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.therapeuticsmd.com/role/BusinessConcentrations</ParentRole>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:IncomeLossFromContinuingOperationsPerBasicShare -  ea0201465-10k_therapeu.htm 9419</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ea0201465-10k_therapeu.htm">ea0201465-10k_therapeu.htm</File>
    <File>txmd-20231231.xsd</File>
    <File>txmd-20231231_cal.xml</File>
    <File>txmd-20231231_def.xml</File>
    <File>txmd-20231231_lab.xml</File>
    <File>txmd-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="633">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>90
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0201465-10k_therapeu.htm": {
   "nsprefix": "txmd",
   "nsuri": "http://www.therapeuticsmd.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "ea0201465-10k_therapeu.htm"
     ]
    },
    "schema": {
     "local": [
      "txmd-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_def.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_lab.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_pre.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "txmd-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "txmd-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "txmd-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "txmd-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 325,
   "keyCustom": 92,
   "axisStandard": 21,
   "axisCustom": 1,
   "memberStandard": 26,
   "memberCustom": 31,
   "hidden": {
    "total": 107,
    "http://fasb.org/us-gaap/2023": 84,
    "http://www.therapeuticsmd.com/20231231": 20,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 141,
   "entityCount": 1,
   "segmentCount": 61,
   "elementCount": 811,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 633,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "http://fasb.org/srt/2023": 1
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Consolidated Statements of Stockholders\u2019 (Deficit) Equity",
     "shortName": "Consolidated Statements of Stockholders\u2019 (Deficit) Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "txmd:WriteoffOfPatentAndTrademark",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies",
     "longName": "995306 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies",
     "shortName": "Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.therapeuticsmd.com/role/DiscontinuedOperations",
     "longName": "995307 - Disclosure - Discontinued Operations",
     "shortName": "Discontinued Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssets",
     "longName": "995308 - Disclosure - Prepaid and Other Current Assets",
     "shortName": "Prepaid and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.therapeuticsmd.com/role/FixedAssets",
     "longName": "995309 - Disclosure - Fixed Assets",
     "shortName": "Fixed Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssets",
     "longName": "995310 - Disclosure - Licensed Rights and Other Intangible Assets",
     "shortName": "Licensed Rights and Other Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "longName": "995311 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.therapeuticsmd.com/role/Debt",
     "longName": "995312 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.therapeuticsmd.com/role/CommitmentsandContingencies",
     "longName": "995313 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.therapeuticsmd.com/role/StockholdersEquityDeficit",
     "longName": "995314 - Disclosure - Stockholders\u2019 Equity (Deficit)",
     "shortName": "Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.therapeuticsmd.com/role/Revenue",
     "longName": "995315 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.therapeuticsmd.com/role/IncomeTaxes",
     "longName": "995316 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.therapeuticsmd.com/role/IncomeLossPerCommonShare",
     "longName": "995317 - Disclosure - Income (Loss) Per Common Share",
     "shortName": "Income (Loss) Per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.therapeuticsmd.com/role/Relatedparties",
     "longName": "995318 - Disclosure - Related parties",
     "shortName": "Related parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.therapeuticsmd.com/role/BusinessConcentrations",
     "longName": "995319 - Disclosure - Business Concentrations",
     "shortName": "Business Concentrations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.therapeuticsmd.com/role/SubsequentEvents",
     "longName": "995320 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c24",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c24",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "txmd:GeneralInformationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "txmd:GeneralInformationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables",
     "longName": "996002 - Disclosure - Discontinued Operations (Tables)",
     "shortName": "Discontinued Operations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "txmd:ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "txmd:ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssetsTables",
     "longName": "996003 - Disclosure - Prepaid and Other Current Assets (Tables)",
     "shortName": "Prepaid and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.therapeuticsmd.com/role/FixedAssetsTables",
     "longName": "996004 - Disclosure - Fixed Assets (Tables)",
     "shortName": "Fixed Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables",
     "longName": "996005 - Disclosure - Licensed Rights and Other Intangible Assets (Tables)",
     "shortName": "Licensed Rights and Other Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "longName": "996006 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "txmd:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "txmd:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesTables",
     "longName": "996007 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitTables",
     "longName": "996008 - Disclosure - Stockholders\u2019 Equity (Deficit) (Tables)",
     "shortName": "Stockholders\u2019 Equity (Deficit) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "txmd:ScheduleOfWarrantRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "txmd:ScheduleOfWarrantRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.therapeuticsmd.com/role/IncomeTaxesTables",
     "longName": "996009 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTables",
     "longName": "996010 - Disclosure - Income (Loss) Per Common Share (Tables)",
     "shortName": "Income (Loss) Per Common Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
     "longName": "996011 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details)",
     "shortName": "Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "txmd:TermOfRoyaltyPayments",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "txmd:PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable",
     "longName": "996012 - Disclosure - Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details) - Summary of Restructuring Cost Recognition",
     "shortName": "Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details) - Summary of Restructuring Cost Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "txmd:DisposalGroupIncludingDiscontinuedOperationRestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails",
     "longName": "996013 - Disclosure - Discontinued Operations (Details)",
     "shortName": "Discontinued Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c43",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c43",
      "name": "txmd:DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable",
     "longName": "996014 - Disclosure - Discontinued Operations (Details) - Schedule of Discontinued Operations",
     "shortName": "Discontinued Operations (Details) - Schedule of Discontinued Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c43",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c43",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable",
     "longName": "996015 - Disclosure - Discontinued Operations (Details) - Schedule of Classes of Liabilities of Discontinued Operations",
     "shortName": "Discontinued Operations (Details) - Schedule of Classes of Liabilities of Discontinued Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "txmd:DisposalGroupIncludingDiscontinuedOperationRentReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "txmd:DisposalGroupIncludingDiscontinuedOperationRentReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable",
     "longName": "996016 - Disclosure - Prepaid and Other Current Assets (Details) - Schedule of Prepaid and Other Current Assets",
     "shortName": "Prepaid and Other Current Assets (Details) - Schedule of Prepaid and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.therapeuticsmd.com/role/FixedAssetsDetails",
     "longName": "996017 - Disclosure - Fixed Assets (Details)",
     "shortName": "Fixed Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable",
     "longName": "996018 - Disclosure - Fixed Assets (Details) - Schedule of Fixed Assets, Net",
     "shortName": "Fixed Assets (Details) - Schedule of Fixed Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails",
     "longName": "996019 - Disclosure - Licensed Rights and Other Intangible Assets (Details)",
     "shortName": "Licensed Rights and Other Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c78",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable",
     "longName": "996020 - Disclosure - Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net",
     "shortName": "Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable",
     "longName": "996021 - Disclosure - Licensed Rights and Other Intangible Assets (Details) - Schedule of Intangible Assets Subject To Amortization",
     "shortName": "Licensed Rights and Other Intangible Assets (Details) - Schedule of Intangible Assets Subject To Amortization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "longName": "996022 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:AdvertisingExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:AdvertisingExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable",
     "longName": "996023 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of Other Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details) - Schedule of Other Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.therapeuticsmd.com/role/DebtDetails",
     "longName": "996024 - Disclosure - Debt (Details)",
     "shortName": "Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InterestExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InterestExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails",
     "longName": "996025 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c90",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "sqm",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c90",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "sqm",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable",
     "longName": "996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Remaining Lease Payments",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Remaining Lease Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable",
     "longName": "996027 - Disclosure - Commitments and Contingencies (Details) - Schedule of Supplemental Balance Sheet Information Related to Leases",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Supplemental Balance Sheet Information Related to Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OperatingLeaseLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofOtherInformationRelatedtoLeasesTable",
     "longName": "996028 - Disclosure - Commitments and Contingencies (Details) - Schedule of Other Information Related to Leases",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Other Information Related to Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails",
     "longName": "996029 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details)",
     "shortName": "Stockholders\u2019 Equity (Deficit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable",
     "longName": "996030 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details) - Schedule of Outstanding and Exercisable Warrants and Related Transactions",
     "shortName": "Stockholders\u2019 Equity (Deficit) (Details) - Schedule of Outstanding and Exercisable Warrants and Related Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c108",
      "name": "txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrants",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c106",
      "name": "txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrants",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable",
     "longName": "996031 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details) - Schedule of Stock Options Activity",
     "shortName": "Stockholders\u2019 Equity (Deficit) (Details) - Schedule of Stock Options Activity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c111",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable",
     "longName": "996032 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details) - Schedule of the Status of our Unvested and Related Transactions",
     "shortName": "Stockholders\u2019 Equity (Deficit) (Details) - Schedule of the Status of our Unvested and Related Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c114",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c112",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.therapeuticsmd.com/role/RevenueDetails",
     "longName": "996033 - Disclosure - Revenue (Details)",
     "shortName": "Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "txmd:TermOfRoyaltyPayments",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://www.therapeuticsmd.com/role/IncomeTaxesDetails",
     "longName": "996034 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable",
     "longName": "996035 - Disclosure - Income Taxes (Details) - Schedule of Income (Loss) from Continuing Operations Before Income Taxes",
     "shortName": "Income Taxes (Details) - Schedule of Income (Loss) from Continuing Operations Before Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c125",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c125",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable",
     "longName": "996036 - Disclosure - Income Taxes (Details) - Schedule of Effective Income Tax Rate Reconciliation",
     "shortName": "Income Taxes (Details) - Schedule of Effective Income Tax Rate Reconciliation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable",
     "longName": "996037 - Disclosure - Income Taxes (Details) - Schedule of Components of Net Deferred Income Tax Asset",
     "shortName": "Income Taxes (Details) - Schedule of Components of Net Deferred Income Tax Asset",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable",
     "longName": "996038 - Disclosure - Income (Loss) Per Common Share (Details) - Schedule of Computation of Basic and Diluted Income (Loss) Per Common Share",
     "shortName": "Income (Loss) Per Common Share (Details) - Schedule of Computation of Basic and Diluted Income (Loss) Per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable",
     "longName": "996039 - Disclosure - Income (Loss) Per Common Share (Details) - Schedule of Outstanding Securities",
     "shortName": "Income (Loss) Per Common Share (Details) - Schedule of Outstanding Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.therapeuticsmd.com/role/RelatedpartiesDetails",
     "longName": "996040 - Disclosure - Related parties (Details)",
     "shortName": "Related parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c135",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c135",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails",
     "longName": "996041 - Disclosure - Business Concentrations (Details)",
     "shortName": "Business Concentrations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c139",
      "name": "txmd:CustomerLicenseRevenuePercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c139",
      "name": "txmd:CustomerLicenseRevenuePercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0201465-10k_therapeu.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Other Accrued Liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r627"
     ]
    },
    "txmd_AccruedContractTerminationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "AccruedContractTerminationCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "txmd_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued contract termination costs",
        "documentation": "Accrued contract termination costs.",
        "label": "Accrued Contract Termination Costs"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_AccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued expenses and other current liabilities",
        "documentation": "Accrued expenses and other current liabilities",
        "label": "Accrued Expenses And Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_AccruedExpensesAndOtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses And Other Current Liabilities [Member]",
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities Member"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_AccruedPrepaidRoyalty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "AccruedPrepaidRoyalty",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "txmd_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid royalty",
        "documentation": "Accrued prepaid royalty.",
        "label": "Accrued Prepaid Royalty"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "txmd_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "txmd_AccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "txmd_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r166",
      "r460"
     ]
    },
    "us-gaap_AcquisitionCostsCumulative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquisitionCostsCumulative",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized legal",
        "label": "Acquisition Costs, Cumulative",
        "documentation": "The capitalized costs incurred (excluded from amortization), as of the date of the balance sheet, to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "txmd_AdditionalFund": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "AdditionalFund",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional fund",
        "documentation": "Amount of additional fund paid.",
        "label": "Additional Fund"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional milestone payments to be received on achievement of sales milestone payments",
        "documentation": "Additional milestone payments to be received on achievement of sales milestone payments.",
        "label": "Additional Milestone Payments To Be Received On Achievement Of Sales Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r627",
      "r850"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r492",
      "r777",
      "r778",
      "r779",
      "r832",
      "r852"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "txmd_AdjustmentsToAdditionalPaidInCapitalLenderWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalLenderWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender warrants",
        "documentation": "Lender warrants.",
        "label": "Adjustments To Additional Paid In Capital Lender Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for vested restricted stock units",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rounding for fractional shares in connection with the reverse stock split",
        "label": "Adjustments to Additional Paid in Capital, Stock Split",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r129"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total adjustments",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities",
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) continuing operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising expense",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "txmd_AggregateMinimumAnnualRoyaltyPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "AggregateMinimumAnnualRoyaltyPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate minimum annual royalty Payments due",
        "documentation": "Aggregate minimum annual royalty payments due.",
        "label": "Aggregate Minimum Annual Royalty Payments Due"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r673",
      "r689",
      "r717"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r664",
      "r676",
      "r692",
      "r720"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r668",
      "r677",
      "r693",
      "r712",
      "r721",
      "r725",
      "r733"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r372"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r42",
      "r46"
     ]
    },
    "txmd_AnnoverasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "AnnoverasMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails",
      "http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails",
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annoveras [Member]",
        "documentation": "Annovera.",
        "label": "Annoveras Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Outstanding Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfLand",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rentable square feet (in Square Meters)",
        "label": "Area of Land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails",
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r170",
      "r196",
      "r231",
      "r244",
      "r248",
      "r254",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r399",
      "r402",
      "r414",
      "r453",
      "r532",
      "r627",
      "r640",
      "r794",
      "r795",
      "r838"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r174",
      "r196",
      "r254",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r399",
      "r402",
      "r414",
      "r627",
      "r794",
      "r795",
      "r838"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r70",
      "r86",
      "r122",
      "r161",
      "r162"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets of discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r70",
      "r86",
      "r120",
      "r122",
      "r161",
      "r162"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r653",
      "r656",
      "r669"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r653",
      "r656",
      "r669"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r653",
      "r656",
      "r669"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable",
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable",
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "txmd_BijuvasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "BijuvasMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bijuvas [Member]",
        "documentation": "BIJUVA.",
        "label": "Bijuvas Member"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_BusinessConcentrationsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "BusinessConcentrationsDetailsLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Concentrations [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_BusinessConcentrationsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "BusinessConcentrationsDetailsTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Concentrations (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r656",
      "r669"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r455",
      "r503",
      "r527",
      "r627",
      "r640",
      "r760"
     ]
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received in acquire businesses",
        "label": "Cash Acquired from Acquisition",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r137"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and restricted cash - continuing operations, beginning of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r110",
      "r194"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and restricted cash - discontinued operations, beginning of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r110",
      "r194"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Total cash and restricted cash, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r110",
      "r194"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r110"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash FDIC insured amount",
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r110"
     ]
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r110"
     ]
    },
    "txmd_CashReceivedForNetWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "CashReceivedForNetWorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of net working capital",
        "documentation": "Cash received for net working capital.",
        "label": "Cash Received For Net Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Financial Officer [Member]",
        "label": "Chief Financial Officer [Member]",
        "documentation": "Person with designation of chief financial officer."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r171",
      "r172",
      "r173",
      "r196",
      "r217",
      "r218",
      "r220",
      "r222",
      "r229",
      "r230",
      "r254",
      "r282",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290",
      "r295",
      "r296",
      "r299",
      "r302",
      "r308",
      "r414",
      "r483",
      "r484",
      "r485",
      "r486",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r504",
      "r519",
      "r541",
      "r564",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r751",
      "r773",
      "r781"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant per share",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 8)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r68",
      "r454",
      "r518"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r273",
      "r275",
      "r587",
      "r791"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r588"
     ]
    },
    "txmd_CommitmentsandContingenciesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "CommitmentsandContingenciesDetailsLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining shares of common stock available for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r631",
      "r632",
      "r634",
      "r635",
      "r636",
      "r637",
      "r777",
      "r778",
      "r832",
      "r849",
      "r852"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Par or Stated Value Per Share | $ / shares (in Dollars per share)",
        "verboseLabel": "Par value per share (in Dollars per share)",
        "netLabel": "Price per share",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Shares Authorized",
        "verboseLabel": "Number of authorized shares of common stock (in Shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r519"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Shares, Issued",
        "verboseLabel": "Shares of common stock (in Shares)",
        "netLabel": "Common stock shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Shares, Outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r92",
      "r519",
      "r538",
      "r852",
      "r854"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value $0.001; 32,000 and 12,000 shares authorized, 11,532 and 9,498 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r456",
      "r627"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss):",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r177",
      "r179",
      "r187",
      "r449",
      "r466"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer and office equipment [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessConcentrations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Concentrations",
        "label": "Concentration Risk Disclosure [Text Block]",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "txmd_ConsultingAndLegalExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ConsultingAndLegalExpensesMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting And Legal Expenses [Member]",
        "documentation": "Consulting and legal expenses.",
        "label": "Consulting And Legal Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ContingentCashConsiderationFromSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ContingentCashConsiderationFromSaleOfBusiness",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent cash consideration from sale of business",
        "documentation": "Contingent cash consideration from sale of business.",
        "label": "Contingent Cash Consideration From Sale Of Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ContractAssetsAndLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ContractAssetsAndLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Assets and Liabilities",
        "documentation": "Contract assets and liabilities.",
        "label": "Contract Assets And Liabilities Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r445"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r124",
      "r125"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r198",
      "r199",
      "r291",
      "r297",
      "r439",
      "r604",
      "r605"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "txmd_CurrentLiabilitiesForDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "CurrentLiabilitiesForDiscontinuedOperationsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities For Discontinued Operations [Member]",
        "documentation": "Current liabilities for discontinued operations.",
        "label": "Current Liabilities For Discontinued Operations Member"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_CustomerLicenseRevenuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "CustomerLicenseRevenuePercentage",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer license revenue percentage",
        "documentation": "Customer license revenue percentage.",
        "label": "Customer License Revenue Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing fees amortization",
        "label": "Debt Related Commitment Fees and Debt Issuance Costs",
        "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "txmd_DecreaseInRoyaltyRateOnProductByProductBasis": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DecreaseInRoyaltyRateOnProductByProductBasis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in royalty rate on product-by-product basis",
        "documentation": "Decrease in royalty rate on product-by-product basis.",
        "label": "Decrease In Royalty Rate On Product By Product Basis"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DeferredIncomeTaxAssetsLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DeferredIncomeTaxAssetsLiabilitiesAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax assets (liabilities):",
        "label": "Deferred Income Tax Assets Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DeferredTaxAssetGainOnSaleOfIntellectualProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DeferredTaxAssetGainOnSaleOfIntellectualProperty",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of ANNOVERA",
        "documentation": "Deferred tax asset gain on sale of intellectual property.",
        "label": "Deferred Tax Asset Gain On Sale Of Intellectual Property"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D credit",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r830"
     ]
    },
    "txmd_DeferredTaxAssetsLiabilitiesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DeferredTaxAssetsLiabilitiesGross",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax asset",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset (liabilities) attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Liabilities Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax assets, net",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "txmd_DeferredTaxAssetsLiabilitiesNetOfValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DeferredTaxAssetsLiabilitiesNetOfValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset (liabilities) attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Liabilities Net Of Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r830"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r830"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r830"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense limitation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r830"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComponentsofNetDeferredIncomeTaxAssetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrual for sales returns and coupons",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r830"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r682",
      "r696"
     ]
    },
    "us-gaap_DepositContractsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositContractsAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets",
        "label": "Deposit Contracts, Assets",
        "documentation": "Carrying amount of assets as of the balance sheet date pertaining to amounts paid by the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r47"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation &amp; amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r47"
     ]
    },
    "us-gaap_DirectTaxesAndLicensesCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DirectTaxesAndLicensesCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial batch release amount",
        "label": "Cost, Direct Tax and License",
        "documentation": "Amount of tax incurred and cost of license directly related to good produced or service rendered."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ]
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Benefit (provision) for income taxes",
        "label": "Discontinued Operation, Provision for Loss (Gain) on Disposal, before Income Tax",
        "documentation": "Amount before tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r76",
      "r78"
     ]
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DiscontinuedOperationsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DiscontinuedOperationsDetailsLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations (Details) - Schedule of Discontinued Operations [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DiscontinuedOperationsDetailsScheduleofDiscontinuedOperationsTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations (Details) - Schedule of Discontinued Operations [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DiscontinuedOperationsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DiscontinuedOperationsDetailsTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations",
        "label": "Discontinued Operations, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r18"
     ]
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails",
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "Disposal group, including discontinued operation, accrued expenses and other current liabilities.",
        "label": "Disposal Group Including Discontinued Operation Accrued Expenses And Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net working capital",
        "documentation": "Disposal group including discontinued operation cash received for acquisition of networking capital subject to certain adjustments.",
        "label": "Disposal Group Including Discontinued Operation Cash Received For Acquisition Of Networking Capital Subject To Certain Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid royalties",
        "documentation": "Disposal group including discontinued operation cash received for prepaid royalties.",
        "label": "Disposal Group Including Discontinued Operation Cash Received For Prepaid Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency accrual",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of goods sold",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r162"
     ]
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": "txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expense for accretion of Series A Preferred Stock",
        "documentation": "Disposal group including discontinued operation expense for accretion of series a preferred stock.",
        "label": "Disposal Group Including Discontinued Operation Expense For Accretion Of Series APreferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGainOnSale",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": "txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on ANNOVERA sale",
        "documentation": "Disposal group including discontinued operation gain on sale.",
        "label": "Disposal Group Including Discontinued Operation Gain On Sale"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": "txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of vitaCare",
        "documentation": "Disposal group including discontinued operation gain on sale of business.",
        "label": "Disposal Group Including Discontinued Operation Gain On Sale Of Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit (loss)",
        "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)",
        "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r162"
     ]
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": "txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense and other financing costs",
        "documentation": "Disposal group including discontinued operation interest expense and other financing costs.",
        "label": "Disposal Group Including Discontinued Operation Interest Expense And Other Financing Costs"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payment",
        "documentation": "Disposal group including discontinued operation license payment received.",
        "label": "Disposal Group Including Discontinued Operation License Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss before from income taxes",
        "documentation": "Disposal group, including discontinued operation, loss before from income taxes.",
        "label": "Disposal Group Including Discontinued Operation Loss Before From Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss from discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpenseIncomeAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Disposal Group Including Discontinued Operation Other Expense Income Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": "txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "documentation": "Disposal group including discontinued operation other income (expense).",
        "label": "Disposal Group Including Discontinued Operation Other Income Expense"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationRentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRentReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "documentation": "Amount classified as rent receivable attributable to disposal group held for sale or disposed of,  expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group Including Discontinued Operation Rent Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "documentation": "Disposal group, including discontinued operation,research and development.",
        "label": "Disposal Group Including Discontinued Operation Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationRestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable",
      "http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total restructuring expenses - discontinued operations",
        "verboseLabel": "Restructuring charges",
        "documentation": "Disposal group, including discontinued operation, restructuring charges.",
        "label": "Disposal Group Including Discontinued Operation Restructuring Charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue, net",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r162"
     ]
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling and marketing",
        "documentation": "Disposal group, including discontinued operation, selling and marketing.",
        "label": "Disposal Group Including Discontinued Operation Selling And Marketing"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "documentation": "Disposal group including discontinued operation total other income expense net.",
        "label": "Disposal Group Including Discontinued Operation Total Other Income Expense Net"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "documentation": "Represent the amount of accounts payable.",
        "label": "Disposal Group Including Discontinued Operations Accounts Payable Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DiscontinuedOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r119"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r624"
     ]
    },
    "txmd_DivestitureOfBusinessPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DivestitureOfBusinessPolicyPolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "vitaCare Divestiture",
        "documentation": "Divestiture of business policy.",
        "label": "Divestiture Of Business Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r682",
      "r696"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r656",
      "r669"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r656",
      "r669",
      "r713"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r656",
      "r669",
      "r713"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (loss) per common share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) per common share, basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r215",
      "r217",
      "r220",
      "r221",
      "r222",
      "r226",
      "r412",
      "r413",
      "r450",
      "r467",
      "r607"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (loss) per common share, basic:",
        "verboseLabel": "Income (loss) per common share, continuing operations",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) per common share, diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r217",
      "r220",
      "r221",
      "r222",
      "r226",
      "r412",
      "r413",
      "r450",
      "r467",
      "r607"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (loss) per common share, diluted:",
        "verboseLabel": "Income (loss) per common share, discontinued operations",
        "label": "Earnings Per Share, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per common share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeLossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income (Loss) Per Common Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r223",
      "r224",
      "r225"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes continuing and discontinued operations",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "txmd_EffectiveIncomeTaxRateDiscontinuedOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "EffectiveIncomeTaxRateDiscontinuedOperations",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Benefit) provision for income taxes, percentage",
        "documentation": "Effective income tax rate discontinued operations.",
        "label": "Effective Income Tax Rate Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "txmd_EffectiveIncomeTaxRateDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory tax rate, percentage",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r380",
      "r392"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "txmd_EffectiveIncomeTaxRateDiscontinuedOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Adjustment in valuation allowances, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r831"
     ]
    },
    "txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "txmd_EffectiveIncomeTaxRateDiscontinuedOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense accretion, percentage",
        "documentation": "Interest expense accretion, percentage.",
        "label": "Effective Income Tax Rate Reconciliation Interest Expense Accretion Percentagein Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense accretion (in Dollars)",
        "documentation": "Interest expense accretion.",
        "label": "Effective Income Tax Rate Reconciliation Interest Expense Accretionin Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "txmd_EffectiveIncomeTaxRateDiscontinuedOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent and other differences, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r831"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excess stock benefits (in Dollars)",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r828"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "txmd_EffectiveIncomeTaxRateDiscontinuedOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excess stock benefits, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r828"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "txmd_EffectiveIncomeTaxRateDiscontinuedOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State tax rate, net of federal tax benefit, percentage",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r831"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "txmd_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll and related costs",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation over a weighted average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized share based compensation",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "txmd_EmployeeTerminationBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "EmployeeTerminationBenefitsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Termination Benefits [Member]",
        "documentation": "Employee termination benefits.",
        "label": "Employee Termination Benefits Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'.  This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Deficit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r160",
      "r181",
      "r182",
      "r183",
      "r200",
      "r201",
      "r202",
      "r204",
      "r210",
      "r212",
      "r228",
      "r255",
      "r256",
      "r310",
      "r365",
      "r366",
      "r367",
      "r388",
      "r389",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r415",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r434",
      "r476",
      "r477",
      "r478",
      "r492",
      "r564"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r673",
      "r689",
      "r717"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r658",
      "r670",
      "r686",
      "r714"
     ]
    },
    "us-gaap_ExcessStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExcessStockSharesIssued",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock (in Shares)",
        "verboseLabel": "Additional shares of common stock",
        "label": "Excess Stock, Shares Issued",
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "txmd_ExecutiveTerminationBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ExecutiveTerminationBenefitsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Termination Benefits [Member]",
        "documentation": "Executive termination benefits.",
        "label": "Executive Termination Benefits Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "txmd_ExpirationPeriod20YearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ExpirationPeriod20YearsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Period 20 Years [Member]",
        "documentation": "Expiration Period 20 Years",
        "label": "Expiration Period20 Years Member"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ExpirationPeriodIndefiniteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ExpirationPeriodIndefiniteMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Period Indefinite [Member]",
        "documentation": "Expiration Period Indefinite",
        "label": "Expiration Period Indefinite Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r262"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of License Rights and Other Intangible Assets, Net",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails",
      "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r446",
      "r447"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails",
      "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r45"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofIntangibleAssetsSubjectToAmortizationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r446"
     ]
    },
    "txmd_FixedAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "FixedAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r677",
      "r693",
      "r721"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r677",
      "r693",
      "r721"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r677",
      "r693",
      "r721"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r677",
      "r693",
      "r721"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r677",
      "r693",
      "r721"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r655",
      "r680"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": "txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on disposal of assets",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r787",
      "r788"
     ]
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of business",
        "label": "Gain (Loss) on Disposition of Business",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r771"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": "txmd_DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on the extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r54",
      "r55"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "General and administrative operating support expense",
        "netLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r543"
     ]
    },
    "txmd_GeneralInformationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "GeneralInformationPolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General",
        "documentation": "General information",
        "label": "General Information Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_GoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "GoingConcernPolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Going Concern",
        "documentation": "Going concern.",
        "label": "Going Concern Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensed Rights and Other Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License rights and other intangibles assets",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r196",
      "r231",
      "r243",
      "r247",
      "r249",
      "r254",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r414",
      "r609",
      "r794"
     ]
    },
    "txmd_HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hormone therapy drug patents applied and pending approval [Member]",
        "label": "Hormone Therapy Drug Patents Applied And Pending Approval Member"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_HormoneTherapyDrugPatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "HormoneTherapyDrugPatentsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hormone Therapy Drug Patents [Member]",
        "documentation": "Hormone Therapy Drug Patents Member.",
        "label": "Hormone Therapy Drug Patents Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r653",
      "r656",
      "r669"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow",
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) from continuing operations",
        "terseLabel": "Net income (loss) from continuing operations",
        "verboseLabel": "Net income (loss) from continuing operations (in Dollars)",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r103",
      "r112",
      "r205",
      "r206",
      "r207",
      "r208",
      "r219",
      "r222"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) from continuing operations before income taxes",
        "terseLabel": "United States",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r99",
      "r141",
      "r231",
      "r243",
      "r247",
      "r249",
      "r451",
      "r462",
      "r609"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing operations (in Dollars per share)",
        "verboseLabel": "Basic",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r140",
      "r142",
      "r188",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r217",
      "r220",
      "r221",
      "r413",
      "r450",
      "r847"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing operations (in Dollars per share)",
        "verboseLabel": "Diluted",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r188",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r217",
      "r220",
      "r221",
      "r222",
      "r413",
      "r450",
      "r847"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow",
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable",
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) from discontinued operations",
        "terseLabel": "Income (loss) from discontinued operations, net of income taxes",
        "verboseLabel": "Less: Income (loss) from discontinued operations, net of tax",
        "netLabel": "Net income (loss) from discontinued operations (in Dollars)",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r88",
      "r162",
      "r394",
      "r463"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operations, net (in Dollars per share)",
        "verboseLabel": "Basic",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r188",
      "r218",
      "r220",
      "r221",
      "r846",
      "r847"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operations, net (in Dollars per share)",
        "verboseLabel": "Diluted",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r218",
      "r220",
      "r221"
     ]
    },
    "txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Computation of Basic and Diluted Income (Loss) Per Common Share [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "IncomeLossPerCommonShareDetailsScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Computation of Basic and Diluted Income (Loss) Per Common Share [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails",
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r624"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r375",
      "r381",
      "r383",
      "r386",
      "r390",
      "r393",
      "r395",
      "r396",
      "r488"
     ]
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Benefit (provision) for income taxes",
        "totalLabel": "(Benefit) provision for income taxes (in Dollars)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r154",
      "r211",
      "r212",
      "r235",
      "r379",
      "r391",
      "r468"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r377",
      "r378",
      "r383",
      "r384",
      "r385",
      "r387",
      "r482"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment in valuation allowances (in Dollars)",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory tax rate (in Dollars)",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent and other differences (in Dollars)",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofEffectiveIncomeTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State tax rate, net of federal tax benefit (in Dollars)",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) - Schedule of Income (Loss) from Continuing Operations Before Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "IncomeTaxesDetailsScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) - Schedule of Income (Loss) from Continuing Operations Before Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "txmd_IncrementalAccrualForNetWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "IncrementalAccrualForNetWorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental accrual for net working capital",
        "documentation": "Incremental accrual for net working capital.",
        "label": "Incremental Accrual For Net Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r668",
      "r677",
      "r693",
      "r712",
      "r721",
      "r725",
      "r733"
     ]
    },
    "txmd_InflationRateAdjustedForMinimalAnnualRoyaltyPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "InflationRateAdjustedForMinimalAnnualRoyaltyPayment",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inflation rate adjusted for minimal annual royalty payment",
        "documentation": "Inflation rate adjusted for minimal annual royalty payment.",
        "label": "Inflation Rate Adjusted For Minimal Annual Royalty Payment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r737"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r737"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r737"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensed rights and other intangible assets",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet",
      "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License rights and other intangible assets, net",
        "verboseLabel": "Net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r44"
     ]
    },
    "txmd_IntangibleAssetsSubjectToAmortizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "IntangibleAssetsSubjectToAmortizationMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets Subject to Amortization [Member]",
        "label": "Intangible Assets Subject To Amortization Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r144",
      "r184",
      "r234",
      "r422",
      "r549",
      "r638",
      "r851"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deb interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r292",
      "r293",
      "r613",
      "r614"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r683",
      "r684",
      "r685"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_LandAndBuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandAndBuildingMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land and Building [Member]",
        "label": "Land and Building [Member]",
        "documentation": "Real estate held for productive use and structures used in the conduct of business, including but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": []
    },
    "txmd_LeaseConsecutivePeriods": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "LeaseConsecutivePeriods",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease consecutive periods",
        "documentation": "Lease consecutive periods.",
        "label": "Lease Consecutive Periods"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Information Related to Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Information Related to Leases",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal costs",
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "txmd_LegalProceedingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "LegalProceedingAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Proceeding [Axis]",
        "documentation": "Legal Proceedings",
        "label": "Legal Proceeding Axis"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_LegalProceedingDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "LegalProceedingDomainDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LegalProceedingDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Remaining Lease Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease extend term",
        "label": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiry year",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "lease expense",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r196",
      "r254",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r400",
      "r402",
      "r403",
      "r414",
      "r517",
      "r608",
      "r640",
      "r794",
      "r838",
      "r839"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r139",
      "r458",
      "r627",
      "r774",
      "r785",
      "r833"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r164",
      "r196",
      "r254",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r400",
      "r402",
      "r403",
      "r414",
      "r627",
      "r794",
      "r838",
      "r839"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofClassesofLiabilitiesofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r70",
      "r86",
      "r122",
      "r161",
      "r162"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities of discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r70",
      "r86",
      "r120",
      "r122",
      "r161",
      "r162"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r70",
      "r86",
      "r122",
      "r161",
      "r162"
     ]
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and service revenue",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "txmd_LicenseRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "LicenseRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License revenue",
        "documentation": "Amount of license revenue.",
        "label": "License Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_LicensedRightsandOtherIntangibleAssetsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "LicensedRightsandOtherIntangibleAssetsDetailsLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensed Rights and Other Intangible Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "LicensedRightsandOtherIntangibleAssetsDetailsScheduleofLicenseRightsandOtherIntangibleAssetsNetTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensed Rights and Other Intangible Assets (Details) - Schedule of License Rights and Other Intangible Assets, Net [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_LicensedRightsandOtherIntangibleAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "LicensedRightsandOtherIntangibleAssetsDetailsTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensed Rights and Other Intangible Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensing Agreements [Member]",
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r374",
      "r827"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "txmd_MakeWholePaymentAccretion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "MakeWholePaymentAccretion",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Make-whole payment accretion",
        "documentation": "Make-whole payment accretion.",
        "label": "Make Whole Payment Accretion"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails",
      "http://www.therapeuticsmd.com/role/IncomeTaxesDetails",
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r331",
      "r444",
      "r475",
      "r508",
      "r509",
      "r571",
      "r573",
      "r575",
      "r576",
      "r578",
      "r598",
      "r599",
      "r611",
      "r615",
      "r625",
      "r629",
      "r796",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845"
     ]
    },
    "txmd_MayneLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "MayneLicenseAgreementMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mayne License Agreement [Member]",
        "documentation": "Mayne License Agreement.",
        "label": "Mayne License Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_MaynePharmaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "MaynePharmaAgreementMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mayne Pharma Agreement [Member]",
        "documentation": "Mayne Pharma Agreement.",
        "label": "Mayne Pharma Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_MaynePharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "MaynePharmaMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mayne Pharma [Member]",
        "documentation": "Mayne Pharma.",
        "label": "Mayne Pharma Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "txmd_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "MilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "documentation": "Milestone payment.",
        "label": "Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_MilestonePaymentsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "MilestonePaymentsOneMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payments One [Member]",
        "verboseLabel": "Milestone Payments 1 [Member]",
        "documentation": "Milestone payments one.",
        "label": "Milestone Payments One Member"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_MilestonePaymentsRecordedAsLicenseRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "MilestonePaymentsRecordedAsLicenseRights",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate of milestone payments",
        "documentation": "Milestone payments recorded as license rights.",
        "label": "Milestone Payments Recorded As License Rights"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_MilestonePaymentsThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "MilestonePaymentsThreeMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payments Three [Member]",
        "verboseLabel": "Milestone Payments 3 [Member]",
        "documentation": "Milestone payments three.",
        "label": "Milestone Payments Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_MilestonePaymentsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "MilestonePaymentsTwoMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payments Two [Member]",
        "verboseLabel": "Milestone Payments 2 [Member]",
        "documentation": "Milestone payments two.",
        "label": "Milestone Payments Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_MinimumAnnualRoyaltyPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "MinimumAnnualRoyaltyPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimal annual royalty payment",
        "documentation": "Minimum annual royalty payment.",
        "label": "Minimum Annual Royalty Payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails",
      "http://www.therapeuticsmd.com/role/IncomeTaxesDetails",
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r331",
      "r444",
      "r475",
      "r508",
      "r509",
      "r571",
      "r573",
      "r575",
      "r576",
      "r578",
      "r598",
      "r599",
      "r611",
      "r615",
      "r625",
      "r629",
      "r796",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845"
     ]
    },
    "txmd_MiscellaneousIncomeexpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "MiscellaneousIncomeexpense",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Miscellaneous income (expense)",
        "documentation": "Miscellaneous income (expense).",
        "label": "Miscellaneous Incomeexpense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them.  The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) discontinued operations",
        "label": "Net Cash Provided by (Used in) Discontinued Operations",
        "documentation": "Increase (decrease) in cash associated with the entity's discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operations:",
        "label": "Net Cash Provided by (Used in) Discontinued Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from continuing financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) continuing financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from continuing investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in continuing investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) continuing operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow",
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable",
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)",
        "netLabel": "Net income (loss) (in Dollars)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r112",
      "r143",
      "r162",
      "r175",
      "r178",
      "r183",
      "r196",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r211",
      "r212",
      "r219",
      "r231",
      "r243",
      "r247",
      "r249",
      "r254",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r413",
      "r414",
      "r464",
      "r540",
      "r562",
      "r563",
      "r609",
      "r638",
      "r794"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_NetOperatingLossCarryforwardsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "NetOperatingLossCarryforwardsTerm",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carried forward",
        "documentation": "Net operating loss carryforwards term.",
        "label": "Net Operating Loss Carryforwards Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New accounting standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r683",
      "r684",
      "r685"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r677",
      "r693",
      "r712",
      "r721"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of noncash financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (loss), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_NumberOfEmployeesAfterWorkforceReduction": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "NumberOfEmployeesAfterWorkforceReduction",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees after workforce reduction",
        "documentation": "Number of employees after workforce reduction.",
        "label": "Number Of Employees After Workforce Reduction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segment",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "txmd_OneTimeMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "OneTimeMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-time milestone payments",
        "documentation": "One-time milestone payments.",
        "label": "One Time Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r243",
      "r247",
      "r249",
      "r609"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r626"
     ]
    },
    "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLeaseIncomeLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOtherInformationRelatedtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities from operating lease (in thousands)",
        "label": "Operating Lease, Lease Income, Lease Payments",
        "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r433"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Remaining Lease Payments [Abstarct]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofRemainingLeasePaymentsTable",
      "http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "terseLabel": "Present value of lease payments",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "txmd_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable",
      "http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities current (included in accrued expenses and other current liabilities)",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet",
      "http://www.therapeuticsmd.com/role/ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets",
        "verboseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOtherInformationRelatedtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate - operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r626"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOtherInformationRelatedtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining term (years) - operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r626"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss (\u201cNOL\u201d) carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business, Basis of Presentation, New Accounting Standards and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business, basis of presentation, new accounting standards and summary of significant accounting policies",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r135"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "txmd_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/ScheduleofOtherAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses and current liabilities",
        "verboseLabel": "Accrued expenses and other current liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r15",
      "r176",
      "r179",
      "r186",
      "r415",
      "r416",
      "r421",
      "r448",
      "r465",
      "r765",
      "r766"
     ]
    },
    "txmd_OtherContractTerminationCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "OtherContractTerminationCostsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Contract Termination Costs [Member]",
        "documentation": "Other contract termination costs.",
        "label": "Other Contract Termination Costs Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other current assets",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Operating Activities, Cash Flow Statement",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r786"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r675",
      "r691",
      "r719"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r666",
      "r678",
      "r694",
      "r722"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r666",
      "r678",
      "r694",
      "r722"
     ]
    },
    "txmd_ParagraphFourCertificationNoticeLetterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ParagraphFourCertificationNoticeLetterMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragraph Four Certification Notice Letter [Member]",
        "label": "Paragraph Four Certification Notice Letter Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents [Member]",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_PaymentsForDerivativeInstrumentFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForDerivativeInstrumentFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of make-whole derivative",
        "label": "Payments for Derivative Instrument, Financing Activities",
        "documentation": "The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r606"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfPreferredStockAndPreferenceStock",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of Preferred Stock at liquidation preference",
        "label": "Payments for Repurchase of Preferred Stock and Preference Stock",
        "documentation": "The cash outflow to reacquire preferred stock during the period."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of debt financing fees",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to acquire businesses",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r397"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Receipts (payment) for patents",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "txmd_PaymentsToAcquireNetWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "PaymentsToAcquireNetWorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of net working capital",
        "documentation": "Payments to acquire net working capital.",
        "label": "Payments To Acquire Net Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "txmd_PercentageOfFutureTaxableIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "PercentageOfFutureTaxableIncome",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excess taxable income",
        "documentation": "Percentage of future taxable Income.",
        "label": "Percentage Of Future Taxable Income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable",
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable",
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares [Member]",
        "verboseLabel": "PSUs [Member]",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "txmd_PeriodOfMinimumAnnualRoyaltyPayment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "PeriodOfMinimumAnnualRoyaltyPayment",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of minimal annual royalty payment",
        "documentation": "Period of minimum annual royalty payment.",
        "label": "Period Of Minimum Annual Royalty Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PhantomShareUnitsPSUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PhantomShareUnitsPSUsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phantom Share Units (PSUs) [Member]",
        "label": "Phantom Share Units (PSUs) [Member]",
        "documentation": "Share-based payment arrangement awarded as phantom share or unit."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825"
     ]
    },
    "txmd_PopulationCouncilLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "PopulationCouncilLicenseAgreementMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Population Council License Agreement [Member]",
        "documentation": "Population council license agreement.",
        "label": "Population Council License Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet",
      "http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Prepaid and other current assets",
        "terseLabel": "Prepaid and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets [Member]",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofPrepaidandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r612",
      "r786"
     ]
    },
    "txmd_PrepaidRoyaltyLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "PrepaidRoyaltyLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid royalty liabilities",
        "documentation": "Prepaid royalty liabilities.",
        "label": "Prepaid Royalty Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_PresentValueOfAnnualMinimumRoyaltyDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "PresentValueOfAnnualMinimumRoyaltyDiscountRate",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of annual minimum royalty discount rate",
        "documentation": "Present value of annual minimum royalty discount rate.",
        "label": "Present Value Of Annual Minimum Royalty Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of prior year presentation",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "txmd_ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from acquire businesses net of working capital adjustments",
        "documentation": "Proceeds from acquire businesses net of working capital adjustments.",
        "label": "Proceeds From Acquire Businesses Net Of Working Capital Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromDerivativeInstrumentFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from make-whole derivative",
        "label": "Proceeds from Derivative Instrument, Financing Activities",
        "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r606"
     ]
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of business, net of transaction costs",
        "label": "Proceeds from Divestiture of Businesses",
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of common stock, net of costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Series A Preferred Stock, net of transaction costs",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ProceedsFromRoyaltiesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRoyaltiesReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received for prepaid royalties",
        "label": "Proceeds from Royalties Received",
        "documentation": "Cash received for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "txmd_ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of common stock related to employee stock purchase plan",
        "documentation": "Proceeds from sale of common stock related to employee stock purchase plan.",
        "label": "Proceeds From Sale Of Common Stock Related To Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails",
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r445",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r601",
      "r616",
      "r628",
      "r755",
      "r792",
      "r793",
      "r798",
      "r848"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r445",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r601",
      "r616",
      "r628",
      "r755",
      "r792",
      "r793",
      "r798",
      "r848"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/FixedAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r149",
      "r152",
      "r153"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r165",
      "r461"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet",
      "http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Fixed assets, net",
        "terseLabel": "Fixed assets, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r452",
      "r461",
      "r627"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r149",
      "r152",
      "r459"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/FixedAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fixed Assets, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life of assets",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "txmd_PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General",
        "documentation": "Purchase of transferred assets and grant of licenses cash payment.",
        "label": "Purchase Of Transferred Assets And Grant Of Licenses Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "txmd_QuarterlyRoyaltyInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "QuarterlyRoyaltyInterest",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quarterly royalty payment, interest per annum",
        "documentation": "Quarterly royalty interest.",
        "label": "Quarterly Royalty Interest"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_QuarterlyRoyaltyPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "QuarterlyRoyaltyPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quarterly royalty payment",
        "documentation": "Quarterly royalty payment.",
        "label": "Quarterly Royalty Payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails",
      "http://www.therapeuticsmd.com/role/IncomeTaxesDetails",
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r330",
      "r331",
      "r359",
      "r360",
      "r361",
      "r443",
      "r444",
      "r475",
      "r508",
      "r509",
      "r571",
      "r573",
      "r575",
      "r576",
      "r578",
      "r598",
      "r599",
      "r611",
      "r615",
      "r625",
      "r629",
      "r632",
      "r789",
      "r796",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails",
      "http://www.therapeuticsmd.com/role/IncomeTaxesDetails",
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r330",
      "r331",
      "r359",
      "r360",
      "r361",
      "r443",
      "r444",
      "r475",
      "r508",
      "r509",
      "r571",
      "r573",
      "r575",
      "r576",
      "r578",
      "r598",
      "r599",
      "r611",
      "r615",
      "r625",
      "r629",
      "r632",
      "r789",
      "r796",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845"
     ]
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]",
        "documentation": "Pertinent information about recorded unconditional purchase arrangements to acquire goods or services, by category of goods or services."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r658",
      "r670",
      "r686",
      "r714"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r548"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/Relatedparties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436",
      "r437",
      "r438",
      "r440",
      "r489",
      "r490",
      "r491",
      "r546",
      "r547",
      "r548",
      "r568",
      "r570"
     ]
    },
    "txmd_RelatedpartiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "RelatedpartiesDetailsTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RentalIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RentalIncomeNonoperating",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental income",
        "label": "Rental Income, Nonoperating",
        "documentation": "Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of debt",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r659",
      "r671",
      "r687",
      "r715"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r660",
      "r672",
      "r688",
      "r716"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r667",
      "r679",
      "r695",
      "r723"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r772"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs [Member]",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs) [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "verboseLabel": "Total restructuring expenses - general and administrative expenses",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r268",
      "r270",
      "r790"
     ]
    },
    "txmd_RestructuringChargesIncludingDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "RestructuringChargesIncludingDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges including discontinued operations",
        "documentation": "Restructuring charges including discontinued operations.",
        "label": "Restructuring Charges Including Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r270",
      "r271"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r270",
      "r271",
      "r272"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring costs",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r269"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r129",
      "r457",
      "r479",
      "r480",
      "r487",
      "r520",
      "r627"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r200",
      "r201",
      "r202",
      "r204",
      "r210",
      "r212",
      "r255",
      "r256",
      "r365",
      "r366",
      "r367",
      "r388",
      "r389",
      "r404",
      "r406",
      "r407",
      "r409",
      "r411",
      "r476",
      "r478",
      "r492",
      "r852"
     ]
    },
    "txmd_RevenueDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "RevenueDetailsTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License sales",
        "verboseLabel": "License sale",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r242",
      "r245",
      "r246",
      "r250",
      "r251",
      "r253",
      "r327",
      "r328",
      "r445"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r600"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r329"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue, net",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r196",
      "r232",
      "r233",
      "r242",
      "r245",
      "r246",
      "r250",
      "r251",
      "r253",
      "r254",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r414",
      "r451",
      "r794"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, net:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOtherInformationRelatedtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease obligations (non-cash in thousands)",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r626"
     ]
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Concentrations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyAgreementsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Agreements [Member]",
        "label": "Royalty Agreements [Member]",
        "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r374",
      "r827"
     ]
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyIncomeNonoperating",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty sales",
        "label": "Royalty Income, Nonoperating",
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "txmd_RoyaltyPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "RoyaltyPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payment",
        "documentation": "Royalty payment.",
        "label": "Royalty Payment"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_RoyaltyPaymentPayableUnderLongTermServiceAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "RoyaltyPaymentPayableUnderLongTermServiceAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payment payable under long term service agreement",
        "documentation": "Royalty payment payable under long term service agreement.",
        "label": "Royalty Payment Payable Under Long Term Service Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_RoyaltyRateAsPercentageOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "RoyaltyRateAsPercentageOnNetSales",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty rate as percentage on net sales",
        "documentation": "Royalty rate as percentage on net sales.",
        "label": "Royalty Rate As Percentage On Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_RoyaltyRateOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "RoyaltyRateOneMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Rate One [Member]",
        "verboseLabel": "Royalty Rate 1 [Member]",
        "documentation": "Royalty rate one.",
        "label": "Royalty Rate One Member"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_RoyaltyRateTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "RoyaltyRateTwoMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Rate Two [Member]",
        "verboseLabel": "Royalty Rate 2 [Member]",
        "documentation": "Royalty rate two.",
        "label": "Royalty Rate Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_RoyaltyReceivableCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "RoyaltyReceivableCurrentPortion",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty receivable, current portion",
        "documentation": "Royalty receivable, current portion.",
        "label": "Royalty Receivable Current Portion"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_RoyaltyReceivableLongTerm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "RoyaltyReceivableLongTerm",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty receivable, long term",
        "documentation": "Royalty receivable, long term.",
        "label": "Royalty Receivable Long Term"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_RoyaltyReceivableLongTermPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "RoyaltyReceivableLongTermPortion",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty receivable long term portion",
        "documentation": "Royalty receivable, long term portion.",
        "label": "Royalty Receivable Long Term Portion"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_RoyaltyReceivableShortTermPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "RoyaltyReceivableShortTermPortion",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty receivable short term portion",
        "documentation": "Royalty receivable short term portion.",
        "label": "Royalty Receivable Short Term Portion"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_RubricCapitalManagementLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "RubricCapitalManagementLPMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rubric Capital Management L P [Member]",
        "documentation": "Rubric capital management LP.",
        "label": "Rubric Capital Management LPMember"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast [Member]",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r757",
      "r780"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r332",
      "r752",
      "r780"
     ]
    },
    "txmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accrued Expenses and Other Current Liabilities",
        "documentation": "Schedule Of Accrued Expenses And Other Current Liabilities",
        "label": "Schedule Of Accrued Expenses And Other Current Liabilities Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Outstanding Securities [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Outstanding Securities",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "txmd_ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Discontinued Operations",
        "label": "Schedule Of Classes Of Assets And Liabilities Of Discontinued Operations Table Test Block"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfClassesOfLiabilitiesOfDiscontinuedOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Classes Of Liabilities Of Discontinued Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfComponentsOfNetDeferredIncomeTaxAssetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Net Deferred Income Tax Asset [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ScheduleOfComputationOfBasicAndDilutedIncomeLossPerCommonShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfComputationOfBasicAndDilutedIncomeLossPerCommonShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Computation Of Basic And Diluted Income Loss Per Common Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Balance Sheet Information Related to Leases",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r776"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Net Deferred Income Tax Asset",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "txmd_ScheduleOfDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfDiscontinuedOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Discontinued Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DiscontinuedOperationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Classes of Liabilities of Discontinued Operations",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r14",
      "r17",
      "r70",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r87",
      "r89",
      "r90",
      "r123"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Computation of Basic and Diluted Income (Loss) Per Common Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "txmd_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "txmd_ScheduleOfFixedAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfFixedAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fixed Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income (Loss) from Continuing Operations Before Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "txmd_ScheduleOfIncomeLossFromContinuingOperationsBeforeIncomeTaxesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfIncomeLossFromContinuingOperationsBeforeIncomeTaxesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income (Loss) from Continuing Operations Before Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfIntangibleAssetsSubjectToAmortizationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets Subject To Amortization [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ScheduleOfLicenseRightsAndOtherIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfLicenseRightsAndOtherIntangibleAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of License Rights and Other Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfOtherAccruedExpensesAndOtherCurrentLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Accrued Expenses and Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/PrepaidandOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid and Other Current Assets",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ScheduleOfOutstandingAndExercisableWarrantsAndRelatedTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfOutstandingAndExercisableWarrantsAndRelatedTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Outstanding and Exercisable Warrants and Related Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ScheduleOfOutstandingSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfOutstandingSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Outstanding Securities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ScheduleOfPrepaidAndOtherCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfPrepaidAndOtherCurrentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r270",
      "r271",
      "r272"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restructuring Cost Recognition",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r52"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Options Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r58"
     ]
    },
    "txmd_ScheduleOfStockOptionsActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfStockOptionsActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Options Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Supplemental Balance Sheet Information Related To Leases Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ScheduleOfTheStatusOfOurUnvestedAndRelatedTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfTheStatusOfOurUnvestedAndRelatedTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Status of our Unvested and Related Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Status of our Unvested and Related Transactions",
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ScheduleOfWarrantRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ScheduleOfWarrantRollForwardTableTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Outstanding and Exercisable Warrants and Related Transactions",
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of warrants that were granted, exercised, forfeited, and expired during the year.",
        "label": "Schedule Of Warrant Roll Forward Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/LicensedRightsandOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets Subject To Amortization",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDiscontinuedOperationsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/DiscontinuedOperationsDetails",
      "http://www.therapeuticsmd.com/role/ScheduleofDiscontinuedOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations [Member]",
        "label": "Discontinued Operations [Member]",
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r71",
      "r72",
      "r73"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r251",
      "r610"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Stock [Member]",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r797"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive termination obligations",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment compensation costs",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unvested, Cancelled/Forfeited (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Cancelled/Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share",
        "documentation": "Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value, Cancelled/Forfeited",
        "negatedLabel": "Weighted Average Grant Date Fair Value, Cancelled/Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested, Granted (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share",
        "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value",
        "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested, Beginning balance (in Shares)",
        "periodEndLabel": "Unvested Ending balance (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning balance",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unvested, Vested (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share",
        "documentation": "Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of risk free interest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options awards exercisable, Beginning balance",
        "periodEndLabel": "Options awards exercisable, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options awards exercisable, weighted average exercise price, Beginning balance",
        "periodEndLabel": "Options awards exercisable, weighted average exercise price, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options awards outstanding, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options awards outstanding, Cancelled/Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options awards outstanding, aggregate intrinsic value",
        "periodEndLabel": "Options awards outstanding, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options awards outstanding, Beginning balance",
        "periodEndLabel": "Options awards outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options awards outstanding, weighted average exercise price, Beginning balance",
        "periodEndLabel": "Options awards outstanding, weighted average exercise price, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable",
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options awards outstanding Weighted Average Exercise Price, Expired",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options awards outstanding Weighted Average Exercise Price, Cancelled/Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment awards",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r337",
      "r356",
      "r357",
      "r358",
      "r359",
      "r362",
      "r368",
      "r369",
      "r370",
      "r371"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options awards exercisable, Aggregate Intrinsic Value",
        "periodEndLabel": "Options awards exercisable, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options awards exercisable, Weighted Average Remaining Contractual Life (in Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options awards outstanding, Weighted Average Remaining Contractual Life (in Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofStockOptionsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options awards outstanding, Weighted Average Remaining Contractual Life (in Years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares, Issued (in Shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Issued, Price Per Share (in Dollars per share)",
        "verboseLabel": "Preferred stock at a purchase price",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/ScheduleofFixedAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software\t[Member]",
        "verboseLabel": "Software and Software Development Costs [Member]",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r171",
      "r172",
      "r173",
      "r196",
      "r217",
      "r218",
      "r220",
      "r222",
      "r229",
      "r230",
      "r254",
      "r282",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290",
      "r295",
      "r296",
      "r299",
      "r302",
      "r308",
      "r414",
      "r483",
      "r484",
      "r485",
      "r486",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r504",
      "r519",
      "r541",
      "r564",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r751",
      "r773",
      "r781"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r26",
      "r160",
      "r181",
      "r182",
      "r183",
      "r200",
      "r201",
      "r202",
      "r204",
      "r210",
      "r212",
      "r228",
      "r255",
      "r256",
      "r310",
      "r365",
      "r366",
      "r367",
      "r388",
      "r389",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r415",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r434",
      "r476",
      "r477",
      "r478",
      "r492",
      "r564"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r251",
      "r252",
      "r505",
      "r506",
      "r507",
      "r572",
      "r574",
      "r577",
      "r579",
      "r586",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r602",
      "r617",
      "r632",
      "r798",
      "r848"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r228",
      "r445",
      "r481",
      "r504",
      "r510",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r519",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r539",
      "r542",
      "r543",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r564",
      "r633"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r332",
      "r752",
      "r753",
      "r780"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r228",
      "r445",
      "r481",
      "r504",
      "r510",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r519",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r539",
      "r542",
      "r543",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r564",
      "r633"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r662",
      "r674",
      "r690",
      "r718"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for sale of common stock related to employee stock purchase plan (in Shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r91",
      "r92",
      "r129"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for sale of common stock, net of cost (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r91",
      "r92",
      "r129",
      "r483",
      "r564",
      "r581"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for sale of common stock related to private placement sale (in Shares)",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares authorized",
        "label": "Stock Issued During Period, Shares, Period Increase (Decrease)",
        "documentation": "The increase (decrease) during the period in the number of shares issued."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r852",
      "r853"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for vested restricted stock units (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r129"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for vested restricted and performance stock units (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r91",
      "r92",
      "r129"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rounding for fractional shares in connection with the reverse stock split (in Shares)",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for sale of common stock related to employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r91",
      "r92",
      "r129"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for sale of common stock, net of cost",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r91",
      "r92",
      "r129",
      "r492",
      "r564",
      "r581",
      "r639"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for sale of common stock related to private placement sale",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for vested restricted and performance stock units",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r91",
      "r92",
      "r129"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment award compensation costs",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r129"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r91",
      "r92",
      "r129"
     ]
    },
    "txmd_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options [Member]",
        "documentation": "The member represent stock options.",
        "label": "Stock Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_StockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "StockPurchaseAgreementMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Purchase Agreement [Member]",
        "documentation": "Stock purchase agreement.",
        "label": "Stock Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRedeemedOrCalledDuringPeriodShares",
     "presentation": [
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding shares",
        "label": "Stock Redeemed or Called During Period, Shares",
        "documentation": "Number of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock investor",
        "label": "Stock Redeemed or Called During Period, Value",
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedBalanceSheet",
      "http://www.therapeuticsmd.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r95",
      "r96",
      "r116",
      "r521",
      "r538",
      "r565",
      "r566",
      "r627",
      "r640",
      "r774",
      "r785",
      "r833",
      "r852"
     ]
    },
    "txmd_StockholdersEquityDeficitDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "StockholdersEquityDeficitDetailsLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Deficit) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Deficit) (Details) - Schedule of Outstanding and Exercisable Warrants and Related Transactions [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "StockholdersEquityDeficitDetailsScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Deficit) (Details) - Schedule of Outstanding and Exercisable Warrants and Related Transactions [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Deficit) (Details) - Schedule of the Status of our Unvested and Related Transactions [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "StockholdersEquityDeficitDetailsScheduleoftheStatusofourUnvestedandRelatedTransactionsTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleoftheStatusofourUnvestedandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Deficit) (Details) - Schedule of the Status of our Unvested and Related Transactions [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_StockholdersEquityDeficitDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "StockholdersEquityDeficitDetailsTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Deficit) (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Equity (Deficit)",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r195",
      "r294",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r310",
      "r410",
      "r567",
      "r569",
      "r585"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split, description",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "txmd_SubscriptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "SubscriptionAgreementMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription Agreement [Member]",
        "documentation": "Subscription agreement.",
        "label": "Subscription Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.therapeuticsmd.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442"
     ]
    },
    "txmd_SummaryOfRestructuringCostRecognitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "SummaryOfRestructuringCostRecognitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Restructuring Cost Recognition Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "txmd_TermOfRoyaltyPayments": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "TermOfRoyaltyPayments",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of royalty payments",
        "verboseLabel": "Period of minimal annual royalty payment",
        "documentation": "Term of royalty payments.",
        "label": "Term Of Royalty Payments"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_TheramexLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "TheramexLicenseAgreementsMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Theramex License Agreements [Member]",
        "documentation": "Theramex license agreement.",
        "label": "Theramex License Agreements Member"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_TheramexMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "TheramexMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Theramex [Member]",
        "documentation": "Theramex.",
        "label": "Theramex Member"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ThresholdAnnualNetSalesToDetermineRoyaltyRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ThresholdAnnualNetSalesToDetermineRoyaltyRate",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold annual net sales to determine royalty rate",
        "documentation": "Threshold annual net sales to determine royalty rate.",
        "label": "Threshold Annual Net Sales To Determine Royalty Rate"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold net sales amount to determine one-time milestone payment",
        "documentation": "Threshold net sales amount to determine one-time milestone payment.",
        "label": "Threshold Net Sales Amount To Determine One Time Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r837"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TrademarksAndTradeNamesMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofLicenseRightsandOtherIntangibleAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trademarks and Trade Names [Member]",
        "label": "Trademarks and Trade Names [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "txmd_TransactionCostsRelatedToDivestitureOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "TransactionCostsRelatedToDivestitureOfBusiness",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "documentation": "Transaction costs related to divestiture of business.",
        "label": "Transaction Costs Related To Divestiture Of Business"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "txmd_TwoThousandNineteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "TwoThousandNineteenStockIncentivePlanMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/StockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Thousand Nineteen Stock Incentive Plan [Member]",
        "documentation": "Two Thousand Nineteen Stock Incentive Plan.",
        "label": "Two Thousand Nineteen Stock Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails",
      "http://www.therapeuticsmd.com/role/RelatedpartiesDetails",
      "http://www.therapeuticsmd.com/role/RevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/SummaryofRestructuringCostRecognitionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r270",
      "r271"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofIncomeLossfromContinuingOperationsBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States [Member]",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the unconditional purchase arrangement."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274",
      "r276",
      "r277"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r382"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.therapeuticsmd.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimates and assumptions",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r147",
      "r148",
      "r150",
      "r151"
     ]
    },
    "txmd_VitaCareDivestitureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "VitaCareDivestitureMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vita Care Divestiture [Member]",
        "documentation": "vitaCare divestiture.",
        "label": "Vita Care Divestiture Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingSecuritiesTable",
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant [Member]",
        "verboseLabel": "Warrants [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r631",
      "r634",
      "r635",
      "r636",
      "r637"
     ]
    },
    "txmd_WarrantsIssuedInRelationToDebtFinancingAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WarrantsIssuedInRelationToDebtFinancingAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued in relation to debt financing agreement",
        "documentation": "Warrants issued in relation to debt financing agreement.",
        "label": "Warrants Issued In Relation To Debt Financing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Weighted Average Remaining Contractual Life",
        "documentation": "Warrants outstanding and exercisable other than options warrants weighted average remaining contractual life.",
        "label": "Warrants Outstanding And Exercisable Other Than Option Warrants Weighted Average Remaining Contractual Life"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WarrantsOutstandingAndExercisableOtherThanOptionsWarrants",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, Warrants",
        "periodEndLabel": "Ending balance, Warrants",
        "documentation": "Warrants outstanding and exercisable other than options warrants.",
        "label": "Warrants Outstanding And Exercisable Other Than Options Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants, Aggregate Intrinsic Value",
        "periodEndLabel": "Warrants, Aggregate Intrinsic Value",
        "documentation": "Warrants outstanding and exercisable other than options warrants aggregate intrinsic value.",
        "label": "Warrants Outstanding And Exercisable Other Than Options Warrants Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised, Weighted Average Exercise Price",
        "documentation": "Warrants outstanding and exercisable other than options warrants aggregate intrinsic value exercised.",
        "label": "Warrants Outstanding And Exercisable Other Than Options Warrants Aggregate Intrinsic Value Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised, Warrants",
        "documentation": "Warrants outstanding and exercisable other than options warrants exercised.",
        "label": "Warrants Outstanding And Exercisable Other Than Options Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired, Warrants",
        "documentation": "Warrants outstanding and exercisable other than options warrants expired.",
        "label": "Warrants Outstanding And Exercisable Other Than Options Warrants Expired"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, Warrants",
        "documentation": "Warrants outstanding and exercisable other than options warrants granted.",
        "label": "Warrants Outstanding And Exercisable Other Than Options Warrants Granted"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance, Weighted Average Exercise Price",
        "documentation": "Warrants outstanding and exercisable other than options warrants weighted average exercise price.",
        "label": "Warrants Outstanding And Exercisable Other Than Options Warrants Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised, Weighted Average Exercise Price",
        "documentation": "Warrants outstanding and exercisable other than options warrants weighted average exercise price exercised.",
        "label": "Warrants Outstanding And Exercisable Other Than Options Warrants Weighted Average Exercise Price Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired, Weighted Average Exercise Price",
        "documentation": "Warrants outstanding and exercisable other than options warrants weighted average exercise price expired.",
        "label": "Warrants Outstanding And Exercisable Other Than Options Warrants Weighted Average Exercise Price Expired"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, Weighted Average Exercise Price",
        "documentation": "Warrants outstanding and exercisable other than options warrants weighted average exercise price granted.",
        "label": "Warrants Outstanding And Exercisable Other Than Options Warrants Weighted Average Exercise Price Granted"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofOutstandingandExercisableWarrantsandRelatedTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Weighted Average Remaining Contractual Life",
        "documentation": "Warrants outstanding and exercisable other than options warrants weighted average remaining contractual life.",
        "label": "Warrants Outstanding And Exercisable Other Than Options Warrants Weighted Average Remaining Contractual Life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares, diluted (in Shares)",
        "verboseLabel": "Weighted average common shares for diluted income (loss) per common share (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r222"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedIncomeStatement",
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares, basic (in Shares)",
        "verboseLabel": "Weighted average common shares for basic income (loss) per common share (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r222"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.therapeuticsmd.com/role/ScheduleofComputationofBasicandDilutedIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_WorkingCapitalAmounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WorkingCapitalAmounts",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital amounts",
        "documentation": "Working capital amounts.",
        "label": "Working Capital Amounts"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_WriteOffOfAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WriteOffOfAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/BusinessBasisofPresentationNewAccountingStandardsandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on intangible assets write off",
        "documentation": "Write off of asset.",
        "label": "Write Off Of Asset"
       }
      }
     },
     "auth_ref": []
    },
    "txmd_WriteoffOfPatentAndTrademark": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "WriteoffOfPatentAndTrademark",
     "crdr": "debit",
     "calculation": {
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.therapeuticsmd.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "documentation": "Represent the amount of write-off of patent and trademark.",
        "label": "Writeoff Of Patent And Trademark"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-11"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1D",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10.(c)(7)(ii))",
   "SubTopic": "10",
   "Topic": "932",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a),(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1A"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1C"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.13)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//250/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 5.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479836/810-10-S99-5"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "(m)",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483081/340-30-45-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483054/340-30-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-6"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(10)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-23"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation",
   "URI": "www.leiroc.org",
   "URIDate": "2013-08-21"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001213900-24-028003-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-028003-xbrl.zip
M4$L#!!0    (  *$?5C"_A=KV4P" #7R$0 :    96$P,C Q-#8U+3$P:U]T
M:&5R87!E=2YH=&WL?>EWVU:6YW?\%1AWJML^ \HB)>\ISU%D.U&5M[:45%5_
MZ?-(/)*(08#!(IGUU\_=WH*%DBA+EB*KYTS%(K:WW'?W^[L__K\OBS0\UD69
MY-E?_VNXM?U?H<XF>9QDL[_^U][A_L'!?_V_E\&/_V<P"'_6F2Y4I>-PO KW
M\\7R<)*$1X7*RFE>+,+[U>)!. CG5;5\_O#AR<G)U@3N*2=)H<N\+B:ZQ!_"
MP4!>MU]H?-GS\$V1A.]4$8Z>A:/MY]N/GP^?AK\>[<,?HUV^?5[!(&&@6?E\
MDM=95:S^>D^^\V5<I%NEGFS-\N.'<O$A/+ES3QZ(J\+>C(.B!_)B]A N/*Q6
M2XUWCP;;.X.=H7DF^5+U/Y-D:9+I?_[TZ>W#RDQ<5;!T^)+MP?9H,!QY+QG
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MW&M@YP$*9Z*P'&0[$8E'.X;2/6HDEF?=?\CS)SGY-H&UIZLR88Z=84 ;6/@
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M\%[X?T^Y(8JW T3T/=S(TQ!\R=K#A#;0&GJ-1D_N;ZQ5!);UP)&=)ZD^1>T
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M:,J,#]H:Z!8Q3+,.93V9:(VV/OP:F('#@QM\OPM#BE^0=UD?.,]6W?+#"@I
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M$!]R,^GJC *G9QB"\5JM66X\YH'U&UO>S]@8QWH08W> / 7A.#C12,BH<&/
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M)[**,?;G['G^2HW=D((WITY*V(!"-@(LKB9,BRDP5E8.,1X'[U\131J6*&
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M^HF8<O#%?J^H)J_ST_1B/0&UA/M9:^#9?MO %H=L'W/*=.04QPA[*&FKSL"
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M%DF*5@E&;+E&<[0]&K'?Z="0*_9OPDQE*NHR)1S^RFT^CMZ61>ZD(*0- 73
MZF1U02V@T,V$6T?2S6W5(HD'*4(V;&@@>:\+[POG-\AQC?,YRSDDCC8CQZX2
M7B7?N5.2-QFN;#0*S-]XL*8R]O'V]JZQC8 QN))0/B[-IE ^9:MQ7F\FOBB_
MGZ!RM0W4M;$5#3ZV]G 3L;K8)F+GO7K(G1RZ$0YM%^=NM1?KZU[&)=V+9&,+
M%U^&9X#]CE8+YA[)P#@(PI>:T\2,[\'^4YA[LC3,>-RZ5XH;-AE&1D6*!$S$
M%6,T&0XUN0!SH1)B*RP2C0Q%*)@T)^A5@OII3&A39W;_2W$<%'$J%7:6G\ ]
MG(9$O;OHL\VN50[L*&_T]=J,ZR+::*(MJ QA0Y<O;F(#B)N1R3V\R^3N9'(_
MN\ODOA- F[4W,4(G=!@4I/11^QI3&SL&KF;M)0Z(8LQ\4[<$BI*!R;4@1M>)
MVAJ91)E(!#M)<)!=1V"R&*/>B0KWAMIM$TF8W-H-KXVKG4L(X[N@3V,&$WP_
MG<)SJQ>^L":%3$3)9N*X*48FE'B:&)P[!PI'WHKFO08(WZ:16A V/V]PD\',
MZ@2]N9F7PN8EO7F=4/%&TQ)U4:<S53E/7T]8=E.9;)L*6)0[I\+;'+5QLU]H
MGV+K62"V]_:&5GNS2>K:/6?UO(5(;8WG'IMV8POU7/;ONG7(/4 ]@;A.<)3E
M9HVH>K53VZ.; D:)0Y#"AN@%*76(E#]#QMYP?/2U_-@TNBEM%Y:F30GK8'G1
M_":[^AC(U-/=5B_:.K=ML;MQ,H)IA\N-;<69:'OC-B@ XRA]&=,$W$@/,?N+
M$TR%VRQF@S$RYMI$(HAC[Z"9$#FI-,B$5!Y(^&(6RXHM9_0KU ::>,*AE@OR
M$T9-_WYZ6'WL8^8K]@X9!&+BYMB*.0I,BQ85'^>$KC8K\GHICA/7_[@)T>E#
M))OJ:>]^ZY7Q^E7[?1=,:Q0FU'J)_"D0N,[D&"=,-,'00 )M:;#QQY+K9!*8
MF\#U< XQC,_!'$]6T*#;N=AXVFY2NO\E?^\GC8E.UI)$E1H4,/FS]+*OT6S.
M5%&@9]&%V5W%-J/_V/(7#&# !A5C].I8#RZ0"+ETESGL/:6G$UA0OG #L"$?
MU^%&+IF@%5<4@<V[P)SR.'?/3 QZB9>X;JORQ7OLP[8@G 4F4](>AZ^9!WCM
M4AASVDM.E^12=N4%HN[XP,=KT''/2F>W ^=^VU2$SYGR:,(O)0^X<<+<^@1-
MS#UX#%T!)?J&*5\$;?5*J@08%=LZ1HZ3W!7QN-P.L^]YX0%MK>D![O2<P&K
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M]B=,@@CW/!9("F4&+!=A90V857<$)I+AA@L"!,6+;2Q2)T"3/Z%KZ">N/_?
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M?F EL^Z$K9K[9OM!-/W?"*Z=48Z9Z^81<(BL3CE$X@)C+ICIRGDEMD<*;VI
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M+74%A(#C6@@>M7P[--\.N&T=<M<<^Q*1.L?'&6&RA#537SR$^F>HKSTZY:^
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MH> HU[SK.36G]F0*-4:EQM8-ZC@7/02N(*CC),8M-5YB&VM%-I@8I89XFA\
M1"BX*.Q >+,4L2-K59:B>W*"K4@=0 '&RDE[=QRC!\8 E"8@46*HC?3_5A]3
M<59*PK_SD(GKY.<\CT$+]*I.@H_H!,8<6=/!=_+SNX^EZ>%+:T&2A]KMP.2H
M,A)%ASF.;0FTCS6/^#%QB!_F:2T\\NW;?7NX&^#25&SCG/<<*:&M$2W%=8\'
M1<#V!/<C =P &_M3-8:KN@.VGF\:[G_+,/=^BH"&3P*4-/@5.!0H&KJ3F'H!
M!:=$F5>B?HN#.'68PO[(A_U6D8\P1%8S$.D8!28B3WFEXN@S33$)_JKAMH^X
MZI.Y(QP%3(-XI^-WKW@A\XGZN<"ULVPJ=&>65M:MD9D)<>&@=Z,, S[75URG
MLT[9JB:LU5B.B*]RE*'-^,),<-<R&'$.;3HN,>I:ZF2]@RD)731:[.9F*,Z=
MTP;S*'J!/$M0!S1LT7<NLC_U\QK6F((E-D ;JP(,VZ(T/N &7SYG.3;JO&E'
ML#=R);S7BH%@8UE!3RR+6\W/5);\6QBKX6_[[SYX[.V(B ]_HZ_X:9-M >,Q
M\0Y[1C(]FT5S9 $^)ID0[@-E'^O#$"WJ*$E>E^F*V1]8<\N&D01LOI']&+P!
MRSO<?;H3YF-D)\KS%DAB%@G2_\_>NS6Y;5W;PN_X%:S4V:?L*JB/?$GB;->7
M*D6R$V7;D<I2MI]!$NR&!0(=7+K-_/IOS3$O:RX ;(FZ1++$\W!VK";!A769
M:U[&'&.@,'$W7);U9-;H@AYX@"'@'''2%APRB:D6K8.\2Q;?Y:XWM^KL:[WO
MZN7OF\G[AE\41V+IY1;?)/$)$EL6['$G4&='ZEILMQU%)?) W2/,_9Q56R:#
M5NFZ,BH*\WOT>)%XV5EO2GQ_WJJ(=8LA_HLW@/@^2TL2U";=RAD7J-4C\%+V
MG[:I$X!P>C.P28HWD,2[27C@3X7IK<L> <Z8M0;F;A[B8>[;.&(P])3)IL\H
M8G9FAI+^X0V2KD]N;A\.N?_7?ESOPQ[$+T\8:Y(@:2T1DF AJC[\&)7'7&*/
M Y]@9Z9?=#*;FJR4 U>5QAP[L9U'#$LJ\+= &UOR^$,D'N:D1DB DYA:LOCS
M"6^LH^Q*"O"<WN%.VMTRYGZ"6D_V2K:HC;).",$%JR@%WVI#A<BPH488 #%U
MDZ9==?[(EK4L>@ \C8)HL &*2RHV<^B<3>\F./0<0$OBZ>CU]+TPZ*P/7K5U
MZ4C$UQ0BU/HP#50R^F%O8&)5-[DJ[Z!4Z\-;R(0 U$EZL^(8COPXOS=\!+2C
MI W]PR^C/"+/-M5-58>Y;QB2F0</MN6A!1,PA%T4_HD3!#EQJ! &1(=-K[;M
MBMN".4/Y6(3_R%/J6.O%SCE2M0U5";7+(<_"K1'B5]J2\9EY L*0IK&P 3NE
M-]IT%>7J:B,:U\Z*0Y3T7>Y.T-;(27="=FH#A^O<>#([D-IAXG*4,:28!HCN
MP&:3K=6D (,I-$2(<G8<"&R3W[OC5](-3(D&%NX]-@Q?\!?[YP]DR[!?QA;4
M(@.,DRJ[8LEYI)[I5UJP;'G!8GC+WXKUI(G1TPP7GU+X!I=0(!#068@L<3^H
MN^YBNH3K.T-F='K2A>,P3)"=Y6T9=KT6J2:6VT&:-=YD0!A /013#V]!5^2*
MLR(.,84%SXPJ(U' ^)3=%,U-<:K#516++,$5&JBQV!-(%%+,Q:TY*'V2QQ#S
M"NS9+G55IA+>'D.(W359=2)8HX]C7U5R8:2_3#_\]+'?PMK':FE[F&?-*KK;
MQ7;&:F%G8,/QE[)M>=-21X,#(Z)N0>642VD80PAJ"0/-Y:;'B5P-?G#%TY#^
M.9FJU3[<Z='%(Q>0:,S"=Q.Y"$DM!O/18WW$,UHP-0[7[R;+X1MGE\SD1"=B
M6FQTR+CQ!HK.ZO)=(?UX=]X*\1;1PO0G=#Q/!4#]_@R F@.@OCH#H#[06@]W
M1KB<*-TX8E[ORAI/C!#1-]*_D,E'PB68J>6RBUPT>G/HC4-?-&_#G!%ZE )H
M[!^CE>SY40X9Y>\6&@-EA&*GXC0)1EU_W!FYN6K;G@L[&V8-Q:L!VHO[INPS
MLM]O^<99LOS^=99,?W;$]"?^)H.SD\C)4K.NTN;*"3$/RPFGFF3P^I@KW7&/
MF-5(<4%D'#1(A;43KY&O;-?0,/O>?PSY\R$X<]:JM:"UFAU-AQ\377T'0JJ9
M":F>P7R_^_/3.#<:(Q(5)0A2LZ43Q_DF/06C-# SID=R!LQY )6NL =DG5F#
MM+P(CN/"NJ6_%',>E*D\1=SI)<2W:M65^#9A],B-SB-W@KLY]F86.W2*53,"
MCAB&+9T<2)NY*)A,HC1W<'_VM)EC]0[(7C\]CIG7%EI *:,.)F6#@&-K\0V9
M?5["EZN*O98^T^F;%)M) ZEWP>!UWC>OO&^<S5KB CI(:J L-E?&"HUV&DI_
MGBRT&HF'!LJ"4#[@O/[OWVXHF8:N"?-)2M*=LK8N2VL?.I%+TE&7C,&':L,U
MJ[S.1VZ_\\YX[SN#-\%-R0V C62VZ" 7S!'B1;S;9I9E/&V#<-[0-J$$EOUA
M?QWFP=]D*"PP-<< B-9YJ[SWK3+K>?4<GR8.&;82:BPJU$X@\_/BO??%LWN9
MR69VRWD'I^"7HJM/.N<BK'M>]?>_ZB1\#L2#F57S\:H^ECIV3+E4CSUL_&F:
M?%0W'.NB$W:EJ[9'QW[O.GPDXY8  :>D#@5+!QJ,D9KA3W,_>RZJ*O9& 8=
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MV!75)$,DVM<(25D'!61.3N^9Z9BI$L0H-P8'!..I8LB+^QFO$8MG45H^4Y;
M6Y'GXEMV=*?'9M$M54I!NI\J>1\;QB>N+GD:;N^/9]S>'+?W^S-N[[=]!' Y
M_X#T BSB#@:W)@]V9!![N#:& ]S;FJOJE.7_E=)_% A&LPH !SJ< %%BJ9=<
M,/CBD+(=^J5L0VRRI=(.^)6I':Z7RC&'+Y[D_'R5(VN=1B7:&U UF8NZ "'G
M.A9: 9 T2JI'.]1!.D[&3&Y&CLI2-92+U2-=.U1<.KHA%2(X\E>"*YU9D]J&
M IZR4Q5 ;C+D1';<5BO;5DX3A$F/J.S/W]4(SU=?%O>(N]'?#BGB6]XFO\F&
M[?D<W-'"??3#]Y>[NH]][W=$1'%2IWZ_"1N)?3T8D4L$@PI#00BN^\35&=-&
MTWL:UK+)>A=<#^<=]=YV%&'"3]E1T[;))3,$79,7Y6I?U2$R:1O2!D #[R%W
M#-T*K-:]V/8GTCE.B_NET[ P )S^S'G;GK?MR[>MRB:5D4X;[?I4FBW00R^2
M5/C&>4^=]]3+]U39,&$=:5:'"4\@+8M>WWE;?53;2B'?)]UMTE*T1)!G<+^A
MW%PU;=U>'K32RUH4MM.X6V%AAYVVS;E]ZVE[+>"RU4-2(JQ$O!)UAL%'*LD@
M9U'6>7=_5+O[U(BDO6W*CL2[.9="@@>6HB5-]7M7[2WB:+I[E\(4JVJ@89RP
MW/3W7ZBU[Z2!H&E,RB1C7TY3.S$&7Q^FHM^DIQ&Q&12/TSN=2?#>*Q.:I<HL
M&F!9XRE^.N<ND*+I=Z0WT5'-,@SEI+W#@"X\\,R!]]Y7/O('<Z]Q!'!\PG1W
MSY%NC.J;AGG0LKWS4O.7^K&L;+AH'N$$"/1"G\')5Z?JY,2D8E-Z9F \P!*T
ML:[K"O&2^^5JHC#DR3-I]6^H\*2.BGL '?6Q9T"(AWXX4$:V"$8_5P$CQ+)9
M_7VLN7T,W&THFG'EN<V.>(8_B-?WP*YM2IQS8P8:L4#8 D(%R4P>[6H1JAM[
MD#'5C?,O49-T'U5" -@RY5_%/*4R:CZ+A*05X5U(K5US5RXOJKFDW'JN(XXJ
MPI LIX]CYL!^"]Z,*!6'/^R;:L>"GOI;=+B$B;"_5F%PD@CV4$*@OB;2:+/?
MQ"IY.51?0<+T/@2Q\,$:W]1KCT-^I46FELR^K5$F2;1,B?LZO)#40>1OS^D2
MYL[E]W3&?AG[(4S[!W',=LF,Y<G29R^-JE(SS"Y-.5N''/AH3M"6Y;!0.\)C
MYD\GZ$AFX#4957YL8SC(6_3#Z!7D9BX7*@\0J$N4 (A7DW7.R7*[6SW/YH_N
MRGMB7@95#:'7=Q&R(?CR2+!9@Y[K6CT'2AHO7W)150KD)S2EF6[MB.X-?]VR
M54&;//&?;B>O>@L^;Y$PP&3S6#5N=HKW<?!T1H-=VY>%\EG$2<_22;?9JZ7'
M4SG4E(3EI<8C?-"V6;$CZQENR/ 38T?=)[8'")E DEYX;!9?<$V$;%,M8[Z!
MCSZ$MUZQL.^F^"7X*2TK1,1[A*\0H_PC5E543*48/Y134"\M]/S-E254>Y/=
M6LB5\K% %5_?%5CJ[N+CX*PYW 0M-<9EG5X*GU6?\]%EG'RNFY-PKI=$6=LE
MC#<Y6Q3W+]A*A.7*P6^44QRO+ +>E:!!_J">Z5/MK:@6B%CX.B9VI)8R:;VE
M)DA$M2+DJGSFLXH'_Y+Q90PGP%?P5_[O<GMD3.TX@*Y[/K!%\=17?H=L\@Y\
M("THN"/?TDNOFUJUV=4=6\Q>IA2>W:T4/D'I?8)"X4>@+3RYQ/.4N-ZUH9(
M+6(=7K=N.)__T^"&O!Z[?BQ\)MF=4/E,X5US=V87J27QF]R01HW/#XNFV/)=
M^+COBI([9# "0J,7^_+7N\=@GWJU4?A6.!E1IF=';CH*+G)Z5H@><7IF8_S$
M=]8SI<]..LY$(=JX[AP"#;::J5\B'_<T0H&SQLS<=S'I5#O?-QDMYBI=11Y'
M6#R0GJ"+>+[*SFSY(*?7_7/\B'!SOMEDYO:K#<"-AS]NLDA1=>IL)%.+1R<6
MGI[_DEE*.["UO7%;A95DJ!N.56E,'?-F><H!A4U$19HEBNL<3=L2QR9DAH3K
M[LK8,$Q/T.@;I'GA:>W'DAUYH^Z-G\M5FLLJ^JLLN.GQ-JN:$&D.HR;30-P6
M/KPNZJ*1CF)0U)3$#</<>?5!:."VS,!P!GO&CNU]\4O;.784M#)5?795\NDM
M-@!:HG,;IVQ=-"\89AG7P6)F;3X#Z\YN=14.^.I?(?X+/W 1KHWP:'WNMH1;
M0H1I]A/D_\C*T:'^/U_^_GY^__[]['NA0'S$WPF&1&6<'K9=L#CLP2D7X_>/
M'C]4,D:G^"0K3V(,L*R+[P&*J7 @R3K$#L=GP48$=SW[W["5P@G^2_BFD0>L
MZ.?"5]H7%B"")8K:5;^\_^57\.#9,M6@!2&C02&:]"&RB<5?]CP+.D,T$QR?
M2=N?O$GF6$2,!%'IRCA1ID3A<4$;>[RU:]-K5L+MD#3I14.:MF=SFM@8O;/E
M,RGM:NJ6L,OE,]';\(P-/6^' DI8F& (MQ7G!J@)N!+Z&5H$YI,G%]L\8D2M
MNN'"ELD<CT;:&[K<,+B<HUYJ^XHL:OIEF07A@G&LL-=A',DL%K7P:7-W)!*B
M:>[SS%,M_2[?G/M=YOTN?SCWNWRXVQNNRI,E>@F';>A*A?*0BP?\4:^<U=1^
M7R>489%QZNTZ)Q_@!!YK(4V%P@P%E:53%X*&%I+CVS;\[E!MEF?1=U_&?Y6K
MBQCY..?^$ ?94R>'W_Z_Q?[ZV\B5^TQ(=C/U,(38D-F>M2I\4_5**V 1R2.B
M1C!21N8QPTO\;0Q39P_V8Z5TTQ-B.($#%3P="H#"X/XJ;;,ZAB>/_VICR([\
MX-^I*.-8JA\]^7L<-WTG?ASC?E3N.&L<1OB_Q%E-6?('NW /=P+VB$"ZF;(;
ML6UG++,E]SL*W?9?F'GR<[;Q1W.A=Z8?K-M-0N3;FY97U6D@*%RI8(MW[?9<
M>2.615GIL%8+:BP0&-F784JT6PQ,FASSLCB8VT-0/-M<A:_V(!4/+UY0#CS7
M#11_C(L4#!H$Z97HIW")1=5+DFII'N9K\X*X-\/_5*4PZV$;NFH]JG>XI"LC
M-H1?1MZ@@F\U_6SRT4P$<VDX<4KK0YQ ),?2%YMEE;G<>MV5]S9AU*#[PH_H
M?PPE\-Z3E+-.0ZKODH7=$6[KU8NRO,9WC#W93PLQ'80;);?8//?R<[G7GJ/4
M1I[,82ZIXEQ%3BB-/&,LBQ15/)O4W4U6)E47D$..*$(X^68'@1/IE 19=VVQ
MS1U/(F9W[8V;NQ<<Y^#Z8-L\.1!*<-9V2"&H>VW,J)YHE E,A7K"%_)IGXP]
M[>IG%%?H#SDCR5PZ&<4)-9_C?4N$M"617'/ZNJ "1L?$(O@G1B#X2^RCB*Q?
M<P0_ET<\ MH!F>]%C!P "?FUK05#+U#EC$+(1Q42AJBE8"W]B#\;+'\"QLD>
MQ*J</LZXT?UHZN*V]TH;PMG !/(8C#+=GKLB)XZ.(O%> <)W!$_Q2L!DP1HO
M(?WX3\LIOU<$)C\_$9BLF^E!,U3W_J?:O%A3_/5,]$9,,N-_S(G"$+(SD/V\
MB>+_>Q@<ZGKU8]NP0_/4M"E^*&Y7T1%_^L.[W$2O%<S(OQ 4C7[G_L77YXWU
M 6TLB<)B#ODIL11()@^$H)R.UG]ZP#Q!7_SI3W^P??>WQT\?/#AOO$][XV$3
MY*<UHP4_:@_%</7C;#=&U.OS"+4C%_X[96&BO?E08RSYGFS.+^_?_]-) XD;
M^?EW#_]VWLF?]DY^QCBTDW;0[S\K/M=<E];GGG=$L?VPW>\K@*5H>Y[WU*>Y
MITZ]EI^JPKU**/:K9V/37Y%JWGD;?;+;Z$%P^]O+=NQ/(^M!"F,I;_$;"#7_
MDPKTS<&C]@7J%::-^P)8Y[DDL,8.>F< PQNG4?1B7))4,\R5L )#"VWLTG1^
MS*0R4N2Z;!AF[C@U)4E&:G,IBY(4_Y6X4Y+45?\"25UM2%C=5&WM0!(1>1;?
MTHUH^A-I"4KT8BXRS)C;75PUX.9I1O$+[5-"M@V*3>0#@592!-@UH>>N91HU
M:4*/I3&.0H 'AA368 S_ ?R'H.LO0G3<E2UDM&@*FG&_+COM12#J/('U0'9W
MGN'#"R32BCJE,^F_1%[1R+6S DQP@#N+TJDR=$SGV//!;- AI?#O*")**+EV
MQ<\$B@C?6Y>ZD@R;WH.#V_&8.E52%D<]+DK"8$IN;J </2NN$/AZHP)))E^N
MK0M"3\U94H:5, *2]P:WSA$:1G>@&PKK6UI?T#25RZCO:75)%RKYY&79;)CE
M;E.*D%\XG_T5D4$;;VW59),7MJG61E1?!U 56&IQZIFG3\6J?$'2*^5.5!VH
MRD3%%!-$96,KQ^ZJNNZ9_!]JLD1:I0L"W/PSTGXVJS.9*R%9CRI^"7D]<D/8
MZ%VUAWQ=7PY#7;Y%7,UOUJA_)[TW.(T$>C2^\LSSL*?<Q)&9T2.UI"^EZK9*
ME3CYFJ,"@,F1-DO7[K-01LA\&<&@9HR(N%@]"!\',WKL7HNF+ZJID;[L55E?
MK_;,3E\FMT"RF?+D>DK/8%:HVK@J?)"-HM"%SG^\0M+;,;<?ZY58&8SN0]71
M!5G6%3?G;;V)CF(E;#]ZE2ETEGTZ>W.CO>N*<2LBQYL#=>ML1J[G%J97#5 =
M33:WCK<W<7:C9M*$SK[P0DPP-UJR)(PW+ZO2++E[4KINP5U#33*0&. '-JD%
MT\(S!A6\"<@X,H"/JK4;412FG=I0MWV&DJ/45VU[1FM-WZ/WX'V'@BQ3B/2B
M,!<6BV *BUO>M?5*:8PO87H"7Q)#6>QI%#05\%TZN@K&1N^D8)%L=V@?7+)'
M5B(?.16>Q 4ZT=0&X2D0]>BRSW5>U@F":&8!<S-_>F%[&965R3GGJVVQ#R_"
MY/9*E2N](;35R7NY6[T0$$PY+&%+% 3XI+LO.2730T(]2@2\ORT3$2'R)DF:
M3!]3#<JNOB&=4;E2*VIQ3-X9/, &JLRS8%?+CFN:+&]&@[>^ZV(8F! G,MO8
M7IAN*\%=8)*X,:&\'GF'3WQ']TKBQ64F[HZM@7N+9X11S#8;Q_T"]-3++0AB
MT-5PN!8E7ND2$.0-!-+@@Y"#'.<F2P5/3"*[*2]E+XSK8%/,3DR;0;7+MQ_:
MS8NKMF;NVXJ=]IGR(% ,R_*#V4R&XQBN]IB>PJ=\=2=;C;=M>"Q!X/!_)\K4
MM^6,-T^LQH8\JV60@9JFI)1O&L=ZWU"+$ .SQ/&$%D]F^V 2'47IP F?E)/9
M)&U-D08L7!\X>_,=\2-HYXPD%15G3:\X;,17;,K;S"E\YBL/^/ON5US>85\^
M(?POJ[QL)!5)S+VCNO\B](EWC+RGK'.*JR_<KQ+$AC,O[BO(L _BWU)4:AV9
M--PY>D/=#?FQ.OSO?E-<E\:J=$Q=\+U0IGSH(/$_G4'B<Y#X'\\@\0]T>R^V
MB8(W*6(H)?J):NB9WO8L<SQ&MTIMHP$-E7>$;!8%[]NBV\+@D=L "P^G&LD,
MU4.</02*,*+;O/:_2OWV[M)@C.8]P6BJ3Q(I\45 9]MN1A-E5C,NQ!\5-\A.
MAY!(-[<>A6O@3S\0I_H0Y4'9^+M/A=_KB5RA=AS9-$]^W)[):K8BK^C<?"S>
MRALU;/ZD&:D0;2","D&3Y,F.2W%SQ#/ITIU*AKX\*EG---592_W<W1F%'[&5
MD<174I;U(7/3VE*O04795X#P9<G:CH,PU5DGQAS6I1XB/%PU?%OK:4,\.%."
MCMW1&G^[G4&'BG#X*A<BK"<^W)CN$T1HS(*_$B*,<)YG&_%(QAL3$L([=!M6
M])%@ 3,5WE9W3@6YEY2M1;#D(VG7?GTV#7;;]0)1$6YTAEK_9<=\L+/ PN<%
MG9E89&'A%I(2:HJ U)?&H3+5FW:/A99CVVB6K>U8>%J_21FQ]!O<!/%4LN)/
MNW80>AZ PNCP;/&N#^GI!+PQ).M#PX*I3$T(TCK<.Q(!9?)B80<Z4T@1PH[(
M.F[;[L7+@^NYQN6BA/$[CJY_(];O>UX 5LQ;@,MG_=4X0$Q3>[[;#66<N&LB
M2@DR]UB^!+A7HY>P>Z:=7'-:..LJHV72CK,\DW2?*&!?K)Y5^["Q.Z)5"R_
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M8+$P:^B[L$0D);8A81]TV4__M]A??_N(<F2[G2C$D?P0)6C"\H#\*TW5IGU
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M-O0$0L#0;7'B.$1G78'JNA RDNMPX B><UZ[][IVY:]7Q=C[$J@IWA*UHR@
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MR,"L;5D7!Z8RZ:)%3_Q9EFSWL!8/%6#VJ:UO6G +KMVFT TS'?%DL:8X*6$
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MD49&=K 5SY)KVR 0,0GWP)K?)R'(A++ ^6Y$BWB<^>\5"F,?)O7,^[\_8_W
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M3>(:YVG!N2MOFMT51J"0;@WJ[.!/\GX56\!AC+$@AI06^!\:*QWGM_%$$>G
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MI%7$6(!/L^M?][;UILP>+,UUCS+IDP5321&7IRT&3C%A*W<QG6!\ME"S) 7
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MSJ+"03('BWBV7$*E$',M7/TL\"?N'K!$,.6.Z?<)-5"#,>/^TQ]_Q;P:=>[
M(L"^_PTS,?!.C,"FP9A*FU1M^QE!N+_6;_G($.[[NOJ7"YXTWJH@@ZG*0' X
M*\A56/V.<TIII+?EHVC$'/4L)S:]2Q40^50 A- II*3+F,"-?O<CA;39X7C<
MS'?9D,=SGN[4AYI"M6F!'-2&"K\4[!/)'%E_*=3$B@&)(; :B"_VN!P4+7P<
M0YH+C]ODI+4Z)9D2@^!T073A7R@X&VM/"GAR"XR>^WJ?0C=61Z"GA-IS)'#J
M@"H0)J<UX-1#>AE.V;Y47*^M2^)R'I)'A-<Y/F6D-QA4JB%%]%J:"MJ CI4;
MK^ ZC(8'0QQ6IJ"2C:NFIX$9UX$J=,4E]KJJ;;P":@XOQ/*RNO@$+?SW_P7G
MY2I,<6U4 MNHL7Q^!W:<7KK_&P87V.-+<2>'6LJH+P_6^BG!80136.H;[:;@
M%G%BEX#&B80HK/N8U^V^A[> 1G+/FNXK8&=4'6J6@LP.I(Z<8!"F&HH0X[44
M0R*H/@.B"A]>?C7JK)6G88VQHR>5%MHDB:G.@1#$ O3<X+>.6CA\<87W^QHR
M7>$4XAOD63IMQKM]\IW&*]6D'>UJTJHU:8>[FK3M9>_^R[J([]/N__DH>,W\
M7D_70!3Z1$C\F1.A1D)U4I_LEH=ST6(E5''UX6(3"46L!:T:[4?[4R15">QG
M* T<&8V6MC.+W(YOIYW4$YQ7E8#]/N4>-'P[9BH%(#"5!':[><2'H.OX(AZ+
M8/?(, XF?N&XV2Y]7&+E"-!R$1'ZIN]>4&]!I/>I(Y_\SD[SL/ 0=/F*PS *
M"Y4$$&')>%ZS4_@NQ8E!&0(K@*V B#$8Y4?KU;$BF()PBR>G*PJ,R:$J7V3*
M[6]Q//S\31'3[L=07ZTK=>%@C)\:E%KZ-X,BPZE0!EU6,B=J:V6:Z!O\1)J@
MH=-)5#^GGVP^QTD.2IHA=\;7L$>54+:?X]!S>$0+@?"0#6&BQ8(S@>V4*I/.
M*>12)N2XV2K2 B?N^DET@",8"SFLAIV&I\J],ML[)I \M?!J5*<;.TC+Y-0+
M U^J%&O@7%9TLG"'@H5A('_#U,$-X/H-SBZCO-)-HE\*%M'<X@(%R4S9(/:Y
MA(L5;FWQ\P3'*G"R5*E(L8E'GB=:(I9>)9!I:S?7.@FPQ2R(5-<Z,W1"Z-O8
MW82EFQ&-5I/BB6$PB4)52&FG#RFSF,5-ZD?GJ:'L[4KNM":':0D*!=0&5T%K
M O*\,U.6Y)1K&_UBDJS28U@:R[:P%-*J"4 >!FXN998QW6@*1R7G3FEM],E+
MN4^PZI?.I/+C5TJE.O>82G6W,)5:#M2N'6A12C0.V# ALT0[WXYMH1!?ED#"
MYV43"]W#+*:NA;%#F;FN.H>Y2+INL)'J G9DYK7N=+8Y:)OH=0]H:W&2C4"Y
MQ\J)UYW1ZCR>MFF]2B/ZLD.S:AO1W34VHCMS&M&SRV!Q,SJ?L@%DM[)R*Z7C
M&@[G,AJ5QFIW?8W5*DQX$>D!9.4%.K/KFK^CVTQX#+9D'Z+I1_SS(YWW&#@9
M6%Y-1$*;W!^&,=#(9WT%=DR09"DX"(<'__D?O>[13Q<.3WQ2/_[\ M_RA 4"
MP1:5;J*P+IJ]JJ M0_P,JKL$N3F)R3(.X-$'E!(!6_T&S@FKPD+?W5/'.Z6"
MY5+931I\PU)!M*Z ]6\0=A$A6J=93+,0K_+QE<^S?=1C_"R)IY<WJM+.P&HX
MI0HG>W26/>U%HR)P ,',(D-[BCJ)4-* 9:"_TT?STA=#"!3Y\(9F4,+?<HRX
M<CES^I5:^Z(A",D,BWO!BT0P(BKIQ.>IE6+%,6&&""Y)#G(JYQ1"GM(XU?CZ
M ,>+Z2TCJ\87Z/3"$WA<%GJ.2)D+;"^$/SWAF[VZY'86%E+<NIV]+%"I7)1K
MBZZ*B1-9!-E?Q5HCMSA^FIK;";R8\WO@M:IEUN3C\865DH!952F-^?4HC3L7
MI-16H9272-F5<KF"W;11J%/XVW^[?_Q=H:B8J7_R9QV?FUM<HQ^V&E>@>+O,
M)SC;!;M89A1#J,QWS<;K!RJ!4Q;%ZB4.-W#BO"2J=J396RIR4C@H?+ 0I8Z5
MGO"-_\+2F^KUZ'+YZ5>)\=(4G)AQIGE^2T5(VJX,W3',HV5J9'*=-">OOJ;-
MI>ZS=&>LLGDI665\7\?"]T7AG!!.*J''Z0GKN#$J6U8]G]0B*U/.=!V!K8\(
MC8[5#D8&K?A%I3=3XA=.(7Y1N7%/F'66-0.E"LFR F4@#RK4( $7>A^=BS0?
M8\S*<R<7+[Q6"_[G>S<!30L[=G3$T=@>(HF&21CSY#[\WF6<3#".E5%3#[F(
M?:O*:/;A4\ 8Y[Q=C&EF*+MZ2(VE;= K/XTG<8;S1MF>)) J1$F&)7^-L$H"
MP_ Q"/.QGUZB9YK /W/\YW[%NJ1A8%6K[0G?I'6:7:;F[[ZM+FH.G&4.N?=3
MG3NO(M<QY4,EFVUI@VAU2V?F4B5@<6=#Y^ER_;+ZPW2.IX&16B QD:FUU7IN
MIE[3!%S0Y-'-V))[ZH.O7VO#5MDSZ0T\=;*_<7WS<U\?^B9#G_/%C<;Z*P3
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M&W-:[P\3_JX\IG3Q:CEJI'I%-8/8<8QRKJ\F0UEV;.MB> A<W>-#O*,T.G=
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MZP7-0$8LB#C4#W$4'*#KV4"I!K8H_*RD'WOD_N!2*8;G7=NJ!]%X<8%C3[.
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MCS&G+UK.>J#5A4+5I#E*(-1AQ#08[6"-?0TTS8)(6GL<V2I\H+!2JU5'=_^
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M$69Z8K*IM'/[_EB5P930;ML],]I+;C PFV#5.A96[6SPSG3VC#$S$KTZE5D
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M$3! Z(^S&_<=CFJ.+M2GOGS\A'[:%W^,&$B6^?+QM/#+];/ V@B\S>U-FL!
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M=WB0W"%CK[&C_>:X79E6S4;XO8A^0<Y;F/%0*#:+ASWTNCCL82,3?>?NC1F
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MIUCXW)[*X GVFT=/C*UW^BUWXS%<ZH@3Y.C4<=NUF$S]<"8P@^S&!E3!8&;
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M9*.1!C,YS0/O,'-$#B,222@_ )0<ZJ(%9%/4K)@I=/1D(_?)!;IAW;Z;)H_
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M\=]]17MG8Z':PG+!*D*UMEN0WVPUA*J=R5@LIF]=M*X6=KZ,S=&\7K''39"
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M\8QHO%M.XM/\(&RP2P<QUTQK':POC*NW3FX$KX ,#A[2, ^8@CM:]$=B[B-
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M-6LH?%I2&:YUP>;:E0],9YO(>BJ!8O,N\ID3G0<+ *VLALL(OZ/A$D9TH;@
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M8+SX7M7Y6HR%]-<:]F'#CT]\T#K\#(L5O\ Z1,.T**8(Z[2LAA8Q_B$<B\3
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M1SH/Z_-%]@V=&O;"9FLTGYH;YE2SX7=A@$D6G%"LQ5RH,T8.QWMCID@WBFW
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M,!A>2A)=ZK;ELXD<%1TM-P2:=;5=7&V$/R1"84TR!^ >!_M'>W7BGP$I(MZ
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M!GE!]NH;'>M74REFC(Z-,=I27<3$%*RHRCDK-3K6:8/3VQI5%Y0Y:0%M+Z:
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MPU-S$7*3K/5G!FN#_W+E@#N!9R_AJ1:!$XGO@S,!UCR"(SG;X']O /5FC[!
M::4INO0&/22Y_=/'V^MK^F?GIQ]A03:<?2#;?^Z4F%R&[%33C!EN/UK??N1R
M[ K (*@;@^S'DJ=66"=*2U73<-7(4/1IB(Z[]Q1HK#[O'VQ+(]A2)P+G;'-/
M<HMT2Y4TU=ED&NU2-D%TI4<EC@7='"SX*&0=UO2DSE@T(]Q[F%2/=8?2[O_[
M!9S.KX;]!X,%S8P'7?U;H&*)>SP9!\=GD_8NH00*K773?8%?=30"JB-\0_DU
MQUKL): P+%=C1"@,5!"$V>6I"#S]3:$DE\HKJ$(7#8W0TQ9K+%:60&^ ,K=0
M]2V\$F9ZEXJ_G6EK5(*H9<'ZP.4H&JA!=7X.WY@I*Q4(+1%H&B.$M>5*T5]1
MSP#_*3)$F[KG\#>P7,9LJR5]-21;>6D(]4Q*W&2@GY!H\S4CN#8/VP[>9X.6
M)OKJS)8TP[*8U:KJA8Y0=P$Q"#-[2X &?UG#@Y3H\/3:T8>GX1P>$#>T=&;B
M$-SS*UB0T!'UJ'LX2%\#?$@0GF?A4KJ8?2O*52&%!8&_@D5OJK/0_>>C*(8B
MW\W7)D(*[HV:/*EV:9CB5_BY3I"4'22EVP0F-C+AR(=T+"*0"#%:VA!!TR*/
M#']P<4\./_,_SL^E2Y5I\W?2-7#R)_CB7VL&ZN2=-.Q+Y^?BX^09\V_XHLG\
MZ>>VL8+5R.@QB=\X7M0 ?Q</:I9E9U'P:?[UM".6TT:'__+<OVEGNS])=Z\K
MV/345.[5V4_25Y!'3A)0IT &N>?_UEOG:T0AD@F'-MMH=0\Z^-OY/8,3  ]>
M$:W]ZQU$K!=IZJ>.CYL!*8E^N7^]N!&/F^6+ZFXMP$"EK>"UX/BSS:./R*%P
M+UV:QO("OH::['?5?KR R]6 I[F8FKY#"\J]GTV($@F,!(YPI]V2Q,HDS]^M
MX@5YO3;!7 'U#6H>[88ORJO.I,^@1='-G3Z8C+S+)OWQ@IL4'',5]#E]N'$-
MZG:I--$#I@^!28!&!P8-F](;]4<P8!"\55M;ZA/\QEK?:_1X-)*:>!>LF+U6
MM*:DFN"F@8F/QI,F5@#+ AL(E.GLL0G7[1/3C%43?O6@@BHWF[ =?8WI*+"4
MFHU'N&#\OYGCW\UO#)9O@9'6E-86 MGK=$V!=,Q4LG-HV6++8-:9QGP]LRW'
MDD*L5OCUK0W[$<88_'%%=H^%)B']#A9CJK9AJLQJX,]OU/P;]^]-BMB;NEP9
MX&OCZ^BO_&>\LGW[:;C[,=:VI<Y9Q*;0!O53A-_>6?=?66,PL:SS/W"YEI[!
M)H(G?6,@X.S<AA<TT4X"4P)^=JP?RWFF<T3 MB'48_@O'H'=EJ3<SV!*VB_+
M^;LKG>&6OSCK$9&?9#Y43SZ;]%OAN([K0ZD+27$ 1,G:M^"99"YC_&;W00%3
M#;4 N [P'7VNF TTB="U *JD(4?2R ?1X^X1M,6CH<V_,OL6%SM=(M#TG?&!
M\=@2VT*Q9 3K4B!L!\F:_.#'[&]P&';WJ*QK7_R6/'XWTM"C2OP&.T'>R6])
MZ/IXGF>)?!7 <PS=[N^,2\G/>"8<V7WP?'@VZ4;RW/&.6]+EVL3<4]1% ??!
MYE5@&J^*9JM(5#TMA16XWL4#X$'((F/1V$W80&=;-SE9;_A;;N E4U^.X$IW
MR)PP6] ;G4U&$>3[P3$0%ZIIV7'BD:EK."@>4QT<;LU9O4\\?#M-)A)CV-&N
M(X1J -_EXR[JA=T['!^83WVPB(:M<.TX\2F\GWL#+,P8IF7JVBB):?T.,FWG
M50T&^9]L1N;@C)FV@GRDL"SIUR8NOJ$D#%9UXZ-5?*.PFZN%V(RGROT+E_'2
MB0XH^<=V;+A:+0ECG0%500H)J WZF#L4N\.9[8P"^4&\X9/NX]&5+A3;^U?G
M'XJE)I9-,+3D;3I$<73F^?WKN?@G)F%52UJOA(X!8FDJ,QNP:6,V6YN.'4Y_
M>UFII@A0XF6%GI<M4@;X=TT!];2"/5#R]XF).\YYD^?=20],)TG X27B =[G
M-&6MSQ[QNZK>"&GV5K*[ R1?7:Z7SGGT726QT>EV5H/C"W\G/XE!24UV\L#.
M[.XR.>!$<4,!_<XB#A4/TUXM=J[<OT*PZSQ,N. 1:WJ#:G!YJK[02#H:>!6[
MBE%<Q6E.5+)*+]K/)^>EI.3%<BX-D_:G:#LY$W.PP!X,Q_U_B-2%"V[E!'4B
MST+1B0#[CUDS4[W'I!(#M=22?G7/'YZQ5^=$Y8OR)]6;PRB]><XM4OZ]!MXE
M/)0EPBR6&\N"C0=.),_>[0@3\#-[SV;&DL&Q7ZPU[95GX]8K/BQ)Z.(%?,$-
MZ^"=$AENJFS4Y)/N99?=0HSWGW[Y];>INRO7HDU1T9 R8Q83Z/WDR.64XE)L
M?J>\)--6HYA$\E*AF)EIK!\>B75PSYJPM)<(D8@O@,BLE<7+!!F2;0V1(&(4
M,9YT,B<,RE1KCEBN'+?D&8@<.!E-7[6/*P_P;T<63+["5F/J)JFU5U=Z1 ZQ
M1#GAIP[D <3BJZ$;L$D%BY02D6Q F=&P4>RW]0W2BBJ]8(.$SI%WS\/TZ]>K
MWS[>3+U,H$\W52.[$AQ;Q^D&A^>#:LW O(0+Q,VAN'/).KMS,KN>$<C#H*]=
M6A[F'SAKR?_L<PM$C[^ JA4[G9;$E]JPE1=F\40-?FLBB81-];1Q*F9Z<^CX
M/M]3.M%C#_S'LM795$?C@JD/^I8Y=#'\SOF:X $$M^UJ[1ZO-UA?\B-<H<;2
MV1L>-7&H,?G 4Z3.YXF1DFHU%,=7LH)S!,5D0/\I++  -C1X,F8\8%ZVU&P\
M8/XAX.X(M8&[J:C,?GP-P1]H%G[4R9+UU_ZD7UOB1K12Z"#GI$.2$=X1>S[X
MHN42&95K&-UP\$.XOG]KEZ O(K"Y(=_\G;2=*+ZO%C%"V3=T*<LTY1A8A8WD
M9[+ 4]#4^ R7A.,8\!OBRKT@-I0KLSZ^@/, VU!UQ7S]9+,E-H[@DDQ0AO#5
M3RB%H(!=>[&[!3PA>&_)9Y-A<]B+QTS8S==$Z"Y'(QHQDC&HOF1L%PC,%3?;
MPU2S!1,*1-IFH0+,FZ@*NH#'D;,FCVO);88]B<L[7$5DB9Z8(DVA'J:C/QI1
M'(]>&R.O5<>&$.-)M9Q"?]7G!:"'-P>_Q2UX]FS-IC1;FR;Z^?"=.5LP^&'>
MDL*O#X\6W0B?*$XW3&P,,4-0WJV*72P8//')$W$,)T:=A(3!PT$OVCG^ 6GF
M6><-CV)1Q G11O;S)D8C=/+TQ!1/D#X0)((<L<F_CBQ7:R.#;9R-.BB2>U!\
M+AGN>=NY:8#67/$58R@HZA05U6:#08]LVJA<OSVN9V?!X/(4&5<W9$7=%6X/
MV=>KSTX+66.FF.;K@@^/3Q!X[>4(J%TYJ\&[],+_WF01M>'9I#\<[DS$\H"B
M:DG*DZ)JY-%B/'*QL( :HCD&9([^P$6P)4U7()HOL& ;9"IF^QTY3Z]&7@)@
MK]FX%38,_:U*5!<A1 #X;$DS16_<@V,/KU-Y*HK:*^(R9L-DV92OS-Z^*TRU
M!'<PWI&1QG,O,B$/&&@Q>.Z'\0;.;E_DI=E21$GC.'5 41TB3F-_V J/]'%9
M!6R1(MBBPL6V4-&;TUXQJ$AY HR#TP4O))A++D\_ 8]AFQAAIR(R4Z4\/H6Y
MB/V467;Z8!W1YP0G.NL\KTQ3RQWR2YJZ5$4J*WD39HJTI*_89'%)>[KC*^/7
M4,*[9MB)K*;Y 2N;>.IPQD#K;9[W.U]6''N3@/[ZC 8#2L:SCKW\ZDITT$DK
M7Z'OIYL+4,FSEH33FJ0I=BC#;;36["8E/,1A\T1%4JQ&9#_8!I4KFZ_+&"&.
MMBFP[TF?J9I*-WG>\'#Z=P0E!WSL*1G1WL>!(_8S8[JP2;#];$VM9G9 IUJV
M8J]MP^25,52ACW\.-$8R9W7X+)[A5ZG!4P22RXL<!R0@)F2<BT^G>/$I3EJ1
M..F@%Q$G!5\^=&"=P[@U;)(TWI4NG)4ZD-G.':S"LQPXQ^ZO!;;!>QXTF-J"
M2K<.D0*Z(%W@<DAQJH$<QD+8$:=*$Z/,SI[H@[2;1_L-I@39E90O,?81SI:,
M*MM(Q8\?ZL"/82WXT2^0'WG0CL,/I<21JR";/'BP<(T>_(.(,SIK+6GD>&+,
MT'X,9FC<&LI:_P&U!C%QJL\_&R %OFQ$4O&DT%V\=.Y0$8<@:LE'/R]1L0FH
M%3_FK8!SGL6$"K]VZM;H8E3@2=&$\Z"@YX)P+U;)S-Z[;71!KOXG_8.((,,'
ML/33MGYS-C]U]I[2(!J!OI>;G6$\"N .,^@(%546BN,Q"Y,\?-XPPC@:M.*3
MI?M78[LENV0]EI7FVTD]:H-J:\KR* +]+(%\EV+'?.0A/PZPY^ $5N8DI=17
MB:ZG+0AV2 ;X@N/G45]KHFJ#40<'TO<&6>R O5A8*>Z'0Y%;A+?3ZJZ1# >J
M$Y$T2'Z:CM,$RTST';3NGDU&W7Y$,JVREIE3-.1"QRJSF<EPS753<)0#2L)Y
M9\LB:C5U-JSJ'S!^;%K)5!JV$<:/MCH6?9:;NEYV+DSGI*JL'UT&<H2:K'1R
M[Z!R7H^]2.-KZ] ;V-]2T9VF-M[S-%>!8";SNY,9TAO!Y-*.,39)Q27=D\JV
M_[;XJX16[[GI"74@]K1VFO*@DQJ17DS;24K#VO'OH ;E5F8F5;088QCV$KA@
MB=GZ8RCB7SN6'M):W<G1'8S$P$6S.Q@EN#43L_(@ENJ65H(WPD[_<4<E:(+A
M&/D&IR3(W!;?F%+('1!,W*8+1.*T\5[&420)$K1[X%+&Z6![B'ON,/\^^(J8
M4Q=2CSO)+.B$3(O5Z?5E6K$V>SZFR<D,\G1,VVS,*;2_/XPI'HTMT/"#/1\*
M&'QP @;W@,'[)V#PW:(=6?^8$):BB*7\SD"G2;IABQ$(-#](>96P\!@O;74!
M)ABXQ4Z5A6%2L5H0@J"A>(7&?NPQ/B[#:P03")J\%810Q<(-($P4*#O5YA:O
M$U^9JF'ZY@S4H'MF6\,?=?8E+R+-6.$<RJ%A?8 *QU13$5(M;W%SJL<'[Y_N
MV<3Y=K#%2@@0\=MF".^M@!SXPC!>^3/.?*%\$5:O*[0 BMQHWA+\ #PT=D;5
M%1T1O^$/B!SNM'%AW1!<DBL#)[M0X3V651LZX5R+9A444Z=YB[[@O#+0Y]1P
MJ^?QN5B.*BDF*Z>F>H=PI:NPSBHGI^+JK'7*)P".4V%Y^JJ!")7I:*$W/JV'
MB#^EIB;B/[C'O%26Q1P.%^5L\C5D[AR^SC_%U*]T8:'0S9*@87%7>F",B/[]
M4;/=RUF=O+.RNRJ4[U6)\H@@.QPT!]WXS$QBRA=<'!XSR_:0"=M"#Q%ZA>)W
M(MP:&)&KST7T-2%G$2&WV>UF*?X]?*UZH6>D8,(.SR:C9G^<MT3MX 4\U !\
M[$>(\F')^$KX!LU^;W@Z,;GH."8Z#MMYZ5CL-?(S0H'C]&O8@!_1]J#U55F$
M7\PJ"'(,=W>EXZP)!..TP5-G,YS)=FVB46J_ILK8]=M46]UKQ]L$^^\<V$W0
M+*=@'P3M($$'<I:^@!\/<UU@@1A.",  &X>!-IF]-L68O)F!(RH.6MM>\L5Q
MPRQF/C$,F@E26(EU8+^-LT]&64JI]W.1)&US'.1J<RQ6@=_\'V6Y^NF#- ,>
ME=\(NC?)^X0#9K"6_$:,!P6!^\#G@P;F8>P4-^Q]'V7I@SDRNZ408O:*(.:A
MBYY$U/**SW?3F;VY_..JJBLVFI5<SV-/?;_ ZL?OHJBUV #8)K,26&,#@K0=
MQ'??)*]:W6MBH&Z77Z2%;?ERD3^;AI4H^M)O#S%@27JQJM?=GCR4G?1+< A&
M-!.VV9,S=?Q5ZI;[+8P3<.0JM)13B&B:BYRP _WV./D!3:M>:\S._>N$!-S<
MRL1..[ERR&3;E-OZ1=7$V]/JB>SAJA;[)_;=AS&^>P:,_B.FUJAX:NUIHD'>
MZ07ALM%[IJD,X4,?%5M2;40/7>)L*DW]AAC5\&N=ZDKI[\]B/B_^PD'[;5CK
MQ4*=J9BJC82]IAES#"CW-_.C>V&,45,$]"^BVD96YNDTIL]:SQZ;DA*%$20]
M*EA0R/0&LY#VJO6(2*H/BJI;-@TKQ\J_[55_P./'".!<I_2O+E6JF1]WJR(1
MD?Y\Q#G-/ "Z^*:5$61SIT.P[Q[&<Z#FM\%K?IN\[Q8>]FOKMN56&^,O+0_V
M3826.;PV/D,@<"M+5:=75A:F> L@OBLM+C)^8([?3ETTWACZM^O#'<S5Z(:8
M]^>,_:/*5\-2.;/H4"%'\%2M.,:P2W)QB$T.(JP"=_CQNV=@'H@1NIR'8A^Z
M 7_P5>#ZSV]K2U-'!0=$?E1,!!_'R?-489*Z8GKK _RC(?O]7*,A_3/Y.K(S
MYM&9)HCSI^'G)68U<06^>7T5.R915V56?.\-LN,X=APQ^$'5$# [-[1WFL<'
M;>;.V01KS'VC[>G&HXL%#'JX4VQ1@K[F91=TU^#SQ= 1>D-#W<ECZ0U39H_>
M;&\XJ<ILAO7RE*G#-^!H7=-BTBW!4-VN-.QZ=?ZXHA'CEK0RF<5H8'1@K&23
M8.M7=@/?RU_(J_'+'#B9"C8\(_N/HZ@].8GSE;_G:SM+-K72RCRV,@W92ZFO
M+Y<-\M[8D+AF/RO%CY)DR3H&]B>D:;=^-B$-KMB&N;NE(*;-(K)2/TF(/?=S
M]U?HGZ=MBWZ#$W7P$>?CE2]0A1]X)XU7HG$@Z9#H'179F81M1PE\]HWO+I;/
M]MP] 5WLFK*9+@K>H3&J@W%\]75!--\U6_6[D(WD( VEBL9VB<@R1S4/I8L*
MM^=1@;MR UDUXY;AC'LQ.!)G@(IB7/GOW+-JC08XH5S5G?*24LGV$+2J/XQ7
MLCDMM$0*]R1P5=37R>5MNYAACURGW1S+Z4&L"A"T_1F^16KZ7@X]7]S)RIV6
M+-34*>EMI6MP8)!WJ%*J:"RU:S?E8?HZ@EZ%-/3W)$>E*>:M8K1=>K#8K]-I
MCL?QO62%B\^![.=8=?F!Z09E1>/"-_DK&4^($$7>E[&<_9WA3K%4 5:) &7^
MQ _ED$2Z:'>***O:VZGABK<ORU-2>>XZAP=3SH*O:\Q,7"THUV1=K6W+5BAK
M07FG2"7&N1748R.Z!7N]^(;*P]'Y:-B?YXXJA_WCL\FXV4Y02UG#^ZJX> ]'
M1,6D.*7"<8"UQ69KDZI93]YVO@.3L ZR@YW*J0HA"_9P3QRNA4H4Y18AO>@A
MSR=5CC)B#70SEYD?6V0E1QPE@?DH:HQ*,B KYC=G! "OE5VZ[1PF/GV=Q)9I
MJ0[V2=@JK_(+$#89[>#N('V_=&6".<DT<67C(95:S#ZNW'M#FY=:OK.[(KNY
MNXZG0LRHU&*J%&XE3[]R,9503F!?J2.YX-J9:V82A>E2<2^2]I;<$GPZZE[I
MXMR3!)4U!\DFU40&DAL3>Q.!!)SO(><[\4 >Q^8F)DP5<8/MR"7WL-K+;Q1G
MU5_]D_ZJM_[:)@0)>$]#=#O[2PSEMZT.;E/'5(!6R)"MU&+J=7>=[.[";J[=
M-9"%6.!#U&)R/.+/Z08[] V641@2R  6.<@M.;X:NSI7V<G4KJ?"*L+H'I]4
MUK&HK.SF=[>-%::M4;F^5UI4J*K!=SB00,],3%C$)#.A_:")OJ-AE9+.?"@H
M(@"M#!NTJ*IHVFLCHL:'9BK.&5NZ"#0*?/K<^623D"Y,U+S::Q/1+.#CSXJ%
MB#1L5^T0S7XT:=(L7X<+NM%P$N*TCQ#6AH-<% +I $KLS+7CEQ%MPP*I=FG0
M*ASM:<NPY"K,2AZ>9B5[LY('IUG)Z5"<P@@P2>":"I'R;*A$4_BUHWEN7<7S
M\66FK>=LSB-'+NY/&,4F:C<) 8N*>G/P6DR&961X-0 !->Y,UVV$T8:>']79
M(\<;0\1 N%9HG9+*1__"U3U;:XJ#CN2H6R96'5;1OL'3WFS> *1118"+2I"0
MX\ T.@WJ/0WJ/?R@WN(GPG+X-6.U&[DE*>9&TEAQCKFD'3E/S5A._38EE+FD
ME61=A%>)S_H>9E9L"8P9U88QB')2)&>RQ/@F-[>_'G0T64<>UX9AO;-)@JG+
M!TIS)6];D?<TJ2S-/3&Y/K0<=NHCAPBRD64\8L7DL+LG.0Q;(UO,H=\5TU1T
M.V2!'-<$C0YXK'61],'9) $NW/<V,BR&O7)MV(N8%0DFYY8\-B6+/U.6%U@#
M <O3FK5?\<*Q70FREB?U45 OU'ZY.P;N#C/#C.7,/&X=W- H+.H?E7NAZ0;.
M0N\C\DR[0_*[PN0W?)S,M6+:KW=@!EF<GA9FE#7#6F^9VC!"P(Z"IC9T6Y)8
MA;2"91"402EC&@IXV)4N3=</:\N6,&/K3B]15BM#I>C]%[,E_0)_5W5XWCU<
M/13L5Z2Y:K*9C2,&C,8"IP%A=OA9>\5AS;3U)V6FZ+-7"</Z:U-Z;RCFG.:F
MB"]:+7JV\U#,ZC*<N,XSP19.XMYXDV+3DV;&\E[5F0C\BPQ 5YKJ(,):XPMC
M./A$>F3:'-_]RUIGDCS@(UHV7HG+YB^" ZMJ]'0=I$,\2W*>!:NFT-ZCH8&:
MLB18"__"HTI3B7#\,/P.?IBO@0)B&PU<LDM'^ $_S1134QF..5+L1_PEZ ,X
M&'3V6M(TL%^<OP,K0F6CZ*_-P-KQ4; $6^/D@F\PS(#CJ D&,L_3$91@:5!&
M&B1!A]=BG@8>:6 F78(3=LZ6*\UX9<Q]*TC*',Z7J=Y[*1IP?^B![AO1WY';
M/SFLI"4ZKZ6_=7["[^*KIDNFSQ$=H/'5:$D=7.PEJ&*0U?-_NB,J%BHJ2SYU
M"#X.;]B<K@-B"5*&V2159*)N?=DGD %0SX^*_L!P+4O5LBB=I$M?E%=)S.=I
M2O=KN_'(9T4YHD9#K3SZ 9V#-%P(OJ&8J#,AD9&$0_&T\:,VG+>@H,%"3:
MB 9)&YZ@AB*ABD*> )MOUO>@YUK2%<HK?$P>.YN^92M;$*+M_.X*7H>_D4?.
M;Y  @9W"$29%2SS$X[2^1YZN^-2L!Q,K+L!#;! U?6_WR.Z^#?C(BS!HSI9+
M?GCXTDGZ21=HDB[ *+49'XWDRG235Y"($@\%#ER,U1\8<_GIZV6JFYM.Z8UX
MVY5Y >]C\P^4+[RFO.2MN("3W<T]G(DX;K;;X6B9/Q':$"4@J";@+?"OJ71M
M.K/&>%)@9;(GU5A;P%P0SK48X[( F5:!:)8G!"A&BK1:FR#.%H/OH=3!7_\S
MAFZ!@9+M=%2CY7^B95WC^QQ+)EUA50^!!9K=;MB6D=S1,BT0 <N :U&=2V+2
M5".:"JN5:;S :FV</Q>W^>!LU'ZQ,H,#-3U2#': %_;DLTFW%2$L2[AIZ.2A
M]E@JW]CY,]PEP%WE%<\ALMM:*SJI(E*XT<?5+T7^X]VX9_8S8[JTYKHPH$[P
M^AO[]((0/YK&AFT=,:3MYS"D+RAM3P3VRUCBX]<%<G;D9C_"^9&\,\??(LX9
M$#!PCNCX>).-V%]XK\.'XB0JL.U>UEV#BK\R;W'F'9>BC >KAV(U&$9 8C8V
M)>?6+SE31W*(V^*.FTL/)I6^F<:,L;F51+D, D*0CAS7XCWH-_F-\P_LWDYV
MJC!.W.I$R( X5G"Q4YV4Q%[PXL;J/Y#\K\83O\HZ?3&?3PC&W&3/C;GQ#"<+
M_A]X5?@P)?9BRN-1@G$")F+V@S XFXR&PV9G'$ZS;3L(^<1_6"7Q'\(MW)*'
M@W"$K27]SO+(]2C'O9%?KC&NL^NVP"+;!LTM-95G%-BPH&\O"2VL9J^$D:5%
M^?H7AH[Q!%YY?*-:W^*<?+FXT8R]EO1^;8$?"B(W\Z^C+&<_Y^.HNL\$4JYM
M=69]^4 .M\^>4*1G ZX*RF0-?[+ ?U8T^W&FF-RI1,>(;'^EX7I7"^[KHX>,
M]PL6Z3%SIBJ:^C?^3M5UXTFAPFPXD_/U# P8<D566$].MY6F+AB-/85GT>MY
M83DL"]P'#![@ M'K-- 1-8WUPZ,$GS)6RMIBK<8GG\/BABZX&RBJN!T.46TY
MM9B"4@05LU1F1 C0AJ;Q"CM]=7;9]'EK7+/@7OB'T+2'E;B[T4"[PC&<XY35
MC:<:YH.BJW^+FGB:N+JBX;B6CTX2B+8[O-UQMDUP39_H1@?_007'DLK9IQ;%
MDAR'R\;(%E=6G#:*5UA)*@.\03#\/O,%>H9 $YU9?";MG%EKS29%Z5O31BD_
MNFQ>3:=* 1_N\\%!HUE^Z/0]*D^,YB_#0Q<B_ 'RM:5MUXD-X/A9#.]2O&BA
M(LMQ!30DF Q>W+<[ 5KS!MWC\&9CIM+W7(_4MP>7[R"^C9D&GP;OE-$0:27Z
M@51YFGRQ]XI&[K#UR!@MTS,CYJX.PC&\#PIU+P0>WO ]',\7R-.3*BIBOQI
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MO+^R,M[?BXH\JH1$;\';.6[7 QPB%0.*,:]/S9O^_M[>#K]]$'Z[95\M?C;
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M,:A,A8M%1RI[(>7J)PUJ#2RDN5JX#1/<#-'G_!>8 Z'?E'*R>N$8MB '6#]
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M8%"]AAT>+@%A'D8J'D43G=^K!/88YCHBR71C@3B<5F7P&ET(^E/IN!R;0D
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M#]\OJWXUDESDFZ>"'((@!>EU^A)0(X _'Z4+,DJ%)!I@KQ-4(%Q0/HPDI0#
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MFKV<%9V!U\'UIW.Z]?__NSWP^NGM@66U.EM\FWYZT/X6(?UDX;\ 4$L#!!0
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MIQF[70 ,318EQ6Y,(6 R)04<F?F%J)[F>I0QU9DA>B=A/TLAH=KU*@1$NG!
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MI[>QOUH'G//L9P^4+'YZFSRO/$;MP[?O/^2T_@__R:_TU[,HC*/ ]SA(IT[
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MMG[._2#=)KT(SM)]IFM&$,/OVYG^.7'92;N_>R<><1P7!><D<7S='"]\=L#
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MHA\,NT;%6$!4*%A,XS%#HBH=G!X0-U$8U:F5?4EPW+%N>@=RN2/URQ2D!MW
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MW?WQK=Y]R.R#H.N(<JTN8&]-%"CDM&R&W511Z9 64CBMV1,2!1P!D5$L%I&
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M/GR27%B#&G,5E_Z:WW_2+PZE3MA\>5A0>VXP[ $G\!A+2N$Q>[23=-9Y>AV
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M_*+;D F+KK'^2I#CKB9TQ!!'<S:<+&_HGC)VV XS#.KM5%\0S *Q8A56[3/
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M=B->/+M!RCC-]\RM+9XNFFCL&5T@905CR_R)M6V&6D]>6O)]^C\*!<O<D%E
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M/"<;=2=3%Z@.B@/TTF@Q69VJ*D2J2X"@9LR  S6?#@%$*Z80"T<L\WC+(Q9
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M_/S=W>RA548V^QDT?D(Z5BM<C# 3BTRES07.HLN>31MZS>5$[5[>H:RZ0IK
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ML&=A6F;>8B[+]2U\A/%DSQH,<3/L7_+"ZY*B" QV\97[\I>*^CMX:&VPY_J
MNHS]9 OOO>?)7W3IXV2UA'2/( (8L18 -YE5I6@)W36!--3O<>_T,>I729I>
M8"'9.R\Y7FZ*,N?8))[ =8)@)87V8WUC.#EXL6^$N%(/[5)HOB+T7P."#U"S
M #4/P)@ "2B[?'YW-(:XC_&.4X"Z<4U1]C=R.$E=B \PV2!O]Q#Z7B1;A @3
M:)A4_%-M3OMI6S&DO2((,-O\S/$+Y5+:(3@:[J?F,X\U-L_7:TC*R]3@N\7\
M;B$1/XS",:^.*Y%V8!=5Y),PA!6YAHD#A")HDYR=T=.! ,?**0_G:.R2+5,2
MT\W/^AIF9W -$2(;GH(_?9M:$[QJM.V46QLCH@2 :WKD)TP1E"2;B*94YY;:
MHX4$#H;5AU3WQ1,/D5A=>@,1W=]/]?:)B(W55U $0O3O=5Y%U*'<D4=UD^T6
MV\V4-)[1[F=(AZUW4?K&8$1"6)%K=N.A;#^<Y3@:3X/LK.ZCAZ01QF18KN(.
MMQ.^=>H 3[*Z;.)*:@@T;=1MF/Z2+N+@$Y8<95X8B]^W'P^L7EXVK56O)**Z
M^7D:QC!-R<[7QZM'N>6=#;)D--F"U> @C$EBS5<I_#7'XW3^2);:B2 E9&,3
M32(A1.Y8]3E@W\_E%? AG;7.-/KZ/ (WU/F:"BT'Q$UC9/ 5RC9_T?$O_>@'
ME_D@?"4TU<_IR6BEG^;8#8^G>E&2S\/PV9(D @ZD$!709E\!;RZ $"BHBPM>
M__0/CTZ]],$P&"A)Z].?<!7I&O^)WK'QR3^P80T?O0@>/#7KHDYZ8^Q;)='+
MKHS:UF!XA#[V; FU C/&]S(\'K9G/5<*X<:E_)9BP>6L[U50>X,BZI]F^.\V
MV7M1MK^%/L03817!@N9-@HC3+17F&Z)A"P0RPHBPP%H!5#4[ GZQ*NQ82X>1
M.4DE51$XF3'0OLG %I[E^BQ,=TGJ11]0DN\N8S_*2382.8MF)W(PJ [DIK$X
M(P29XG%Z.8=$1UPIKX4$F8,&D?)A>[QQ=KRRC0=,U^_1'D9MV%_&&1[\$$\F
M)L$US,Z?"ZX?DB1X"J/(,,"E6-I>866$$@#V*O1AG$* 2"(X>]PXH4^YAQ7-
M LQ'((:9VR"/BK[;63F2XV/^D.L1HE5B1GN\3-3KIDJ^0(UHE7SCK[=72;RY
MAVBKYSY5K<U#1-%W*B51\)HBW 1@-EL7_K2<-L1^4JN_FG%^FCE<( U+.HGK
MP^=A>RG@2B$J/D0-?9S$;_R6V^+ZU+%76TTK(NZL?KRE\%#BS17T4D@?.UNN
M/Z7,3IF&3"\OZQ&:7G%$YH:^:8?]W#R%7?BX (^,_EH@&NSU!#L3";=@4"Y^
MG:>B$8A(*^;6O4G6;WCJ^2*THUW$^RKT5F$4TF._.*"/T3TD48 G";MX,E$D
M7IJM14=#53;A7J)J3C<2:8/ ;W_SW?MWW_Z>!G>S_0]N;82JZIN 5!HCW8NS
M#2;3G@OU,++MN8A%&8BU1'5#I\=$PTH3X,CL@='"]Y,\SM(;;]\(,YJ.\_&9
M&,^-&H[@<041'2X7'X,=^]JM%>I75"N^)NZDYN)W0!%;,N9+^S[*8=#%YK3P
M&6;O)#BL**08=.1[ )_)Y5?8C+'Y70OF.BZLB8L>M,J-FW8,N$%O!N<?8Z5Q
M@?.1,LNOSO,]#C$$(L'Z;O]@1)?Y9,$Q P(Y]$<U11;6_&[OT1LSY*@9C9N)
M+SL20";FA+G@'EF(&E),&PSF,W(2$>:*(AT6%O@GSF+#O1KL!(C%?1^1E9=L
MMV%&JY)@_X;==][ V,<\#".ICY/][5:/-"(_H&[!4OR:;<"KZR2#X#OG]5(E
M]-E* !P8!MUW!6T%(?O#CE81I1QEO!-&%<&K *Y#/\Q>.XXOJD44)6*(^D8J
MB2GY*:KC=<C;ALZA #T6B-RM)-\=D2MQ[!%5\'^.OSX^?O=[\,W[H^/C8VJ<
MWK%_TFN8V%SEV4."PK^3BN/OWAW][IOW]*/OC_[M^^_*;\(TS8L' AIOMP*/
M;G;.H ])G6+PS;LC0,:/?G?XV_=' %/:L9OET=ZEVR="S*'MZXRZ$9#>>&B)
M:#&(@%(N;Y).AULA1P>'+Q)B]0/\C@$<-P8) JPY*TL', %6F1S\/_!_P-L2
MO*1@^5D211Y*Z2UD^NO7KI/NY0$A@&7O\)D^59<XR944C7>>>U-9JTH_$EK[
M\M1V;-#7_9XI+H:]]5 E!7O'4QIY!ZY6S1<]G][I!ZD:'-BK"8MJO9W.XG<X
MN=E#":21,O"L$:A;N75V)=0HP!6W]X:=2#7SS).(FW9+GY\@+E[M(Y:+*OZE
MW_ XY_0JB%E5Z=<%[Q"^I%[TU+.^X.+BC$4@B\)\/P*LR4RV!SR]]6*GT6'C
M)E=GDM?R\";XW<N;RUJZ.#:YTU%VK ZEX3E3S=U[>],]LV5/:_S?F=DY,[++
M.@ QM2EMLIJ%/6T(I&14&^UF95DYNNR%U&'_]:^2!D%(SMR\Z,8+@\OXU-N%
MF6?Z&IV(BY,\'[XLHG2>ZFNPPY^_P2N"SQJX3MWI5UPK0Z>GQ]K N86DBA(,
MRCIP"]_/MSFMW77&PO*&,23!T/H5BF&9Q%EBY8>@.,5P7:I-5IWM6@A2_1]5
M-X.6YI^N_-\!>?O5,MH"]+^Z0"_E_N#8\HA4T@8&IUOZOD]);B+M.UF'2N8"
MC=\GV$0#U-"[V^HH;07P=#UN/3E-TFRY)I>!Z44+B!Y#'Z9W260^3B!D9/]$
M4R2*T*E-Z>V[ A9N7=@A?;4=V-Z>&KB_>5[D6T^T4(CY.#@[% HSF()89J6[
M7D,&U<:]%,CMKFY4\@.,,=D(PW$1;,,X3&F1TT=8,#&,GR%NMDW/@#RB9!P8
M86*;([!AS6F"@]<BX-(F2:JTB2V9<7!2)D1",%XD\X-0,67Z/;8":;XC%;5*
M:_#EJ>RPCHB-0*>$6+R IUAA7YY:WHW9"9[!'8)^\>H&9K(EE=3^[G5+Y(VV
MU7V<[)\?]T@CL-+-%N"WWG;W>^ U6KD--$BHL?54WT#O=2O!DR*.N9_E"-O#
MTP</;2;87')8.' 6>7+TE>,L/W4=CQ(KJ%.-D]<[!XE?(EEXZW2YO6^TJ*^,
MONGQKZJOG$>!QBGH6#]4<)W$E2_#WE8IUIB)]G[#_%S$CP:EZKWO$Q9OTA1H
M>NVTE(*T0IO DNN_-L@.W[<Y\=+0M_2H49N7]5.-7G&TWC@Z BM"HQ%U<( R
M*8WV/7'4'0<WI:(&Y>(M.$,*\NLG3OGWM+\,E6G7CQI^\A3SI.RFN,2@RMW^
M-D510F& FX/"H11X)X50M=#0?3M:;<#L9\MJ2,FS/O0+U];$C=+T\V;;S+A7
MY4DEW>7ZWGNV9WQ4Y'!MAA1D%<52^ 5,Z('L\-4<YR#7 (T8[JJCZ=I:*<K[
M0NR62Y7JV[)#Q^PLC/(,!I8V5(?<;)^V#<BCN:<*&!6G6W=)O?;YZ+S!<'+D
M)B&8SLYJGC6PIE&<5@%_)>>J8.ILD]7B;STTHRRBR7W6#!8_!5 HN^V=87,3
MW=&2E6>7BF\<VQEW^C,4ZAETD:Q9)#5)'-LF)6$GV7S- .Y:V!GAK<_2A"E+
M_5*,F6OM:ANXSY \K( ]-ZQ+;P/9]?;ENG.UC&[^#)LT-=X.\B64!!08KI(&
M\!B1UHX@+4[#1->+'>!:"Q!-)*L/FH/\#&4A>8:H7[5@G:!"NV'OMI"K_'\(
MS8](_!#P:MK%"6]%JW*W'_Q6E%#3>!5A)X'YF@^&AV A@>+>D;,?WM:04M.$
ME3K6,&+S6L(F!H%Z0)R^>O@IIC^)XM^"5RJ[K>R9&+X  @OBR)OI']KJR4E^
M+T;$+6E&W6FRW2'X .,T?(2U8U^Z[X;7(BF63DJ/#PC5FY3H-]L6ML?M^W4*
MFNT4(I<9"?V+C[08"*LL<T9S:_$&,4Q8Q;YK^$3_8CJE78ZG?;]'2B[1E;9F
MC2&Z]J5>! ]+0;&0$_UEZKA2@Y+B.X6GI49I3#WS+@,VPI8Q><C418:VG&CF
M<#F7/:4:#B0@RALQY4TD7?L7P<]YRBKYWR>"NCA7, X@^NPAY.'/I#PS#;*V
M'Q97%U'T["?]"#P57SE9GT?JLG(%-0=%]Q4^"6ZLQM<N,EX^29&Y;=]133S1
M_;4D9_7XB;E<$]>>5>XJZPC&),L]AO37X"G,'@#VTV@Q#2Q=67.0T'=>VTL'
M*.V27\K#:=P595;[EHUNS<RJ \#A/AOW5"3AU.#F1VWFYB>(<2/M, B&UJQW
M2]UG>LDQ]$F4B'RUP(MC\ 'AS9[%#9A8AAGYOOV22KO"CY@"_B>J"-&+LCN(
M\!^W'@9>@?<\#AL>RGP@+@<:V<U;_WAJG[8,S*TN3QK9N$C0&H99CNSN]*3D
M<7":/%KH:>;$G"+WQG"FL#!(CKMNMGO?;#W?[J)D#]FR=(,!]^"E\ 8KU^):
M(99A;FN%4-)181,\2UCMU2P!L.!0_&57\  [3'>N2\<@AF27CO[AG6;I$/*T
MNF#T2#&W94(LJI5)\&+6BF%@2:\0 T,^Q;HP'X]*7ASK.<9C)>Z;,&]66,?8
M8_+V)&X"/-*>'DG".&6UM$B0/9WOZ8]A7TEM4$><GTL%JXIJ#C X;6B$RK3<
MT4396_(J;!IFL*@NRSIQ"_UD$X<35(FS);6;-Q*L]&W$WH:WOY]SM-8<?)7#
MO(;T9"^.8#%R-B3$7!:X 3G-3*3Y9'2.@\RH.,!!X,R\G\>?CQ8].X$ \]GU
M]$@IX;\U/3;'YWCZ,)!USWI&:8H]"LUKLPA5QF]N,2DJE;&M]PZ%C_C?9*OM
M0[KS("U<.S72*)!%:CUHTS@2%J'99#@O!\$&,E^(EZ *TL,!'+'ZX_WQJ9<^
MW*#D,0Q@<++_A.WS95P]8['PL_ 1.]:3/5:B(8"#U5]=2E$Q"TP%K*/D*04$
M((V'#KR*A-O2H_J(:%6\U1LP74>@M;DDN\'8#R.(A:ASV>\3MT"?1$3K)GV*
M7@B?LZQ8$0N/2F8TC;A]V0O_F?S2)Y-K5S &JSUXE:?T8MAK3LE8T91S'I8Q
M#%]A#,:D]C16()K4^AF%&4S6Z^7Z!J_><;:(@WOD!7#KH5^DLIE["=ATQ@>E
MD7D @Y;0YS]_83UE648U57+R8,>U=WA6(A ]40:[#K-N(*$\".H] G+C^,K'
M#GKC ]J7'3FFBUBX"^R#W648K&3<#.-)GJ^3:X\RDO7=?729::*LTLY51^G>
MZR>9X]4400SD,\C^VU@_BX..B7Q,!<9.RAU+"B?:.SW@GUCZ>,.'2U.('42R
M<D:AMPJC W_.3>4E1?4?%%I2&2;]NG$'7!:^G^38,;SQ]MXJFJ ZW  _%Y'3
M0:G$3Z+3K\BZ2SYS7^I+3IG]../U73L RB6/<AA<U;,4>XEMD]SXFPW\J8CC
MHD3A*(G%T"5$Z@>\B.5,6$F#'"'B1#;LJ&OOT12*!H&O.K#C2@<?&GC"ZAJ/
M!E. S5G0PWH&B!=+UUN;(T[B-_U@G@64A]4^X!?TCX[Y4X'+F.1D.#P5Z!-@
M/J<"/5)*G@HTHI5A26P^T4I]=$B<$ P-GFX@2<#N(HR]V'<(Z3X!Y@/I'BG5
M(;TNB<T>TA+HD(#TT.#I0AKS\2$,:$%><DA,+LXMUZ?TA)R>'!M&\# _%WNX
M0:D$ "W;,7@.%JQQ>C576M---,H-C%YMFB;M.SQT+;JW+"WC/I&\/B@XVAG+
MP_KISTB!M7&J?$/0P6F2(<!4!TXFQMJLW;W!6(;8$2_R<^. _0+B/]HSQH-"
M6-_4Z<DI-1?N(,)+*5B BAJX:]EMO,3&*2L^,H?[4.-P,VS:I09UQ*ZPR?4,
MTH0[6BV2/)I.3DTX?LZ$H)>5P/81FX:,4FC?>K_ -T\/6 805&3GXI0HPD&$
M997QTC^>$[CI_#<M[.X&!V1PX5]K2:KV2,XL$Q[EX""Q_9,8*>U3%LE<+;X(
MAB$]3A;;9GJ4M )X7Y<YB$7:(3?5T*T/8@0P3="/'T=]0RX9/W2&?GE9YH!^
M:6F'T-_,P.6%KYU:>R.8&9H :D-I=@)P_"5G$T!>ECE, &EI528 +]@]NPF@
MC)FA": VE"/*N>:[7413]KRHS.*[C&D5.4)^(N==EJO]"W=R@HD2BANMZ4O0
M49+FB(4;R],<;- K<H[/;!1UWTHU5ABG49D>6&-X(2 U+K!Q,)[,T:;NX+3P
M0 3AV_#L*[##G[E.PN!JI)UGT>V3]J$SE@C#JW8'XJ"RC)<9W$X679#F:WO=
ME99,W4;%C/30\;*+"(,J#%I1!:414U]*V?V=XLD =M?X,J8G*-@2WB=G<-4(
MP6T0Y%R8$-W-4B5J_[Z6HH2B5P@+,N6%=;SS1P4E<B878%I-5);47"57CM)X
M?>5+9^RT7J#[B*<YC/"(PR1/V4W%(GM5"H8]S4U9O^\9V&*X(>>.0KB))1$
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M= *,783/V#!YSET>'1VWES;%H1CS'IR(EW44SA%[*DXX0Q]S38_ =:LZR)Q
MJ >]Z0'W 9F_-3C S$$^2+]$*H9M5J!J*4\*4'5_M9\VJ NMG\$=@GY(HU_X
MWQ$LRQYO$Y05A9.%DAAW\ V)93\H84IT48X@3-,?2#7OJCY^T.#"RA8TR#N.
MGIF&5WLO8G"@M9_7;K_R.;T#*L/1@4F6$*O_5:< H'#SD#5/YL**YBR2+11T
MW7Z36&YD="WX11B'&;S"6_#@D%43_L4&;-)@\2A1'(!VC+P2SFSY7MEM#6P6
M6*Z9"5Q=%_ V@:,F[D</KE;.YB&KNWSU,_2S^Z3)4ZFT@!I%VW5AE*03AJP/
M["Q(&160)2UGPFG] "W-5CD/ZN-DR".@+OKY<W'43,KC/851-+%3(&#JXOJJ
MG&BB>]3D8W#J(;0GA>JPKO+8M9U44W"?)] S%-I76/NL;NTO-T%OT0<0"#"S
ME9\OI<1#98OY[+OT82"[A/>,DI&%^SK)S*_=@T2MWR94E5!Z"8^3;'@9=[V&
MRRI9N(Q+#=?8^X')NF<B7.09WLK9WFD9%<WVN:=)X26V89W=%B@@ ^Z3.=GL
M*>#&2P,R-NSZ![AJ>\-KS/7^"4:/\&,29P^FSS=&"F,_PCQ.8,&,P</R;R[/
M>\U 0C\ P1TFS3V@&N>_0 _=/R5.45W*X&*'J"6I&,6_<WJX-TKU^NAMCLHD
M>T<!2PQ6T[E]NE+,;!?9(ZH8N_\^XVVC! )&XK<:&SM'(83G!0:%<_Q2(:SG
MZ^C)*<;NMVY/Y\;I?AQRJX$9D=*CP=5\7K6F$"\!N^*$;#P*W[TX[ KRLT<,
MC#7L+M98O[, <%N2F:.X):SH'N<#1- C'[XH1X*+"'U8=T=J3'&5=L6 XD)T
MXU9I>2>Z\:LZQ:/(=Y\J#&A8.!>[/[-=,'S]WU7.W 2(.\B<,SWF>M4SZIN)
MTH4&^L+J@P_2ZG*QG=4Q6F*)L#A+12IGQGES9K2OOUYQ9H;M@R-C0.&\0SMF
MB#4#A.?;793L(;R%] 2UP6.:2V_#_%R8_D&I1!4#O#UFP)YH0ZPM\,EM1+=>
MO+12FZ98;@STK&L![-,DIF>A]Q!MP]BK[FY*V<XA&E8K9 T(,[#X^T4SD-7M
M#G%CVZY)JJBR6C(C, HL_!?02MNH ID!2I:+6$H)I?A&7N5..L>/G-8.420Q
M&.,V3H3)#4K6,$UI>=8+.-4"-\#,P=E OT3B]]&KK\$:.D*6F@8/-A9#G=:-
M[5?OTEU!#X]\L4[N)RH2T,_, 9SZ)1+5"R@;@8BT<E[B3DV7K5("P]TW';Y[
MA&B5C%7*L9I6JFC$JY 6)\->2QB3RWX*T8O7K@MF3:#<XW%.35&#XC;9>U&V
M5W%B#EJZ\';;(@P444/L*X?UM'N'_- #X?1-.WN!;MJ[H:P)J\B(F;E8('HE
MZGT[AVM?^N*BKBK/#&JW4WVF?T!<+!F#4O&6C!<5OYY"51H+0$G\*HDW9)],
MGH>;ZAR&S\-V7C57"L',/VN]_^<&*+V::=5P%79,/P7Y--ENPXQL>$G$]Y36
M?]W V&\==4R%%T7FMH&D)IZHSEU-A"TH33*NH:>G_28F-<9H1'ELO)N&4. G
M?_2R'.'_3GKA1$<"Z_9/74:)<[);N/7"F&S7*$%PX^VIUIWNH$< HF58-4=L
M(B270WN63WWG0UN,66&Z1U"96QZNEOV1$) &\-#P3(_B::YVJ'*W?T-)44*9
MRQPS!FK/+0Z=@=#,*5!B-<&]#77^UA,NE464NZDQ=VB*KFCH#<>((T$5AA/<
MS%!F[R(I1E5(J0L9,T>HZ":&UECH!XI4N)E/75=F/WMTREZYF#LZ!4GI6F,Q
M.3JGO%VA)\.<<:I]J6+&F!V\3:$_.-.@]U,<D!>X\C@C6;@^_I05^K*)7J$,
MLT.O2-+>>L'A=I=G-)L ,X>I^]#_&#Q(8[EWJ)2QG**LD35^FL0!K5O;?(Q<
M/02+B3:PBW^J<:O.S]Y&7UDVB4#K7;[;1?1]=R\"!25 28'+>)V@+<O8+3*E
M25$KJFU7QYW:<"#PU1L_S?>6/\7T)QB45;'>2:7 <)I9+X_6E4$ )%<&;6"
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M;$[Q)ZGATS"3E$TY>(T!)@^/UL-+XT'WV%(O=W0PRP:B'6E9]R7WHJMP#:5
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MX23FHX>1[21LL2@">%0-:,+ANF@R#T,QK,"F?1CHNGZ.!KO4 A$)N=$:C).
M2,3%Q4T2@2S"G1;[FJ6LKM>A#P$L6W:1Y"23OU>#[>1]<=?UCSZ3=?;D4626
M_VR4]!3NL<;[-=)\;=LI:<F&,)<6K?_7+"R6LJ);#H[2F)CW-O"RNTH,JNV8
MH[>R%;45U0\-&L*-]1>MS>,QY[!7T$OA0Q(%EUN2OTF/C::Q)WV<[%^K[Y%&
M8#6J%B!L-'&\!U=08Q-?0[W7B=W\1X*V20SO'[ #OMN?H7QSXV4B- EV14,T
MK-9I'1!& ).B%2B: =(.% WGL8N25%2UJY(9!V7OII_R8K>+0AA@\W<#60F:
M'<&I%YG TA#Q>8!L0,H!]&4%^@*"OEV!/H^1I,OGCA$EOZ-4N="<#3(E\3 ,
M69E1U</R99QA182K"+(SWKM\]3/TL_MDL4U0%OZ=AIH4X*M"SWHX6T$X\97%
M@@)[,C0%!0V0):!)91XV4T.[%1A5!TLW]'V/O !N/?0+>:&$_G#M;2>*6O7S
MLE[>I5<< 0+K-M0@TA\!;>;:%BHIM.G6#0_#B)W"9X\DEDT3OVK3=E(3LRF!
M #'%-W.!!U<AK2)_G3X9WV=);/L[4O"V]L5'<]E.J0_M\8@8\2U,,Q3Z67%7
M]E,<9NGMW:=)9EH_+^N&NU<<8:&AL@V[D0UH*_ *MTM?SR/X(Z71=L&AH7$8
M8;EO(%ICAYCD&;+$Z4F0)>+BPIH+9!$ JO%UD5GNW.F45%T30GU]=F'W>^3A
MK0 W>/;.964U,^HZ2X)/JMRA_=_PB(AG9PK]KS?)X]OB8S8YBQ_J>=D@9<VL
MUSR%5SM"9K?Q=MRYNKN#331[T >=4"BUX<55"H4M/Z>9]9U]5P91@2RZ]":[
M&>0&#8QYM1$7]$UWOWVP9MMPUQP=N'*E$'EG,[+CO1KJ<;\,97Z01+,-/:^+
MTS HLLU.]O>X\>(Y3 U#99C?!,8DZD'-H$#BY/NB'6@U!*L]($W!3Z2Q6P=?
M6KD'M1TE!D0[48106:X;U_\F !F?AV%[U <JK@!"($6X=4)&^1&"1AL:\&O^
MS'+ULP>/Y.8W&QU"S4T<L$^QK?B?<'#4S5B*LK_=$CJR*,(-&@C"/]7H:=.R
M@)860Z$#@U6<9J'O1> C]$B%599SUE&Y39USAYWHN-LE5;^%4*".-^GFG0]C
M#X6)(>WRZ5I:<(0""%\Z8)^X7$@&E5'J7-PQS<SFBN!IY*7I<DT]G@F6"C$?
M\]EG?2N&4 [1JD$^HQ4@Z0[G ",N,LF&%-;*'.OMK>Y6Y\2+6(0#PNR*?$GN
M+IN'C)"-Z0!&'UY$0HC*'[+/ ?T>E VZJX@#X QIK8F;WEZ/>G'!3U  @T\Q
M%C@("5DONL'Z>O!2N%Q%X:;P@4\Q;C<)VB_7EQC Y1?!!"@S(I+EO90)F87'
M*8PT:-$&95-04R<;L)(^,9"$0_5=,(=MF4FTM>,#AH9?+[>(7MB^08D/(<U9
MZLP)04"1U\YN"0>.!,+T6G+'OO[4[=9K:-BKF**H@WH;KOLP(X]/76*,/89!
M[D6&W',^78ON.5< 46(.^9;:E^IKI\OIH&)*5UW<24U7_0:/"\G@F6 1;)$V
M?CS8MY0U.8L.9/%/-!5K%FX43PNM(\###FEJ^]Y[9L6VIHC;M6A;=EY:S$63
MWGL&["/' 9A>;;2";9U>*2_NQ&B<DN-&B,BK67N5N3Y@\;EDK<QS$7=AD+;^
M5##GK5O[/IV4QE[81?T3HX5/SYZQ&W&31*%/7E&8YJGR'D860_EB*435"*H&
MH&R!P5*T<1JB&=9<ZRG$_HYKUN]:QO ^W,*/8033+(EA4?!1;J<@;&QWNR 2
M0U1B*89O,OP]V)8-P*YHX;*HTH BZDI*?;W51,$]5G-*;O9=P^S.PX39PYGW
MR1G,:,$=*. J!1-]ZI;KOFD+*G)/2GH@AAE("47@49+DODI0$@6)$)%.KZ^,
M1D6%V7$#JUMA[C;9>U&V)R4V%^1)V*+(Z#(NI9!"[S 5Z^E6@R*)@G:L'4"X
M(?#21N%5#,$:HRZC)](ZJ[ E-QA:)9HJV"[B&&_,2X(-V#:8JYE"*8JVRSLI
M23=H\SQ*I&'Z6C8/-;#H$G!:.NX:-ND1T\D,)47OENN"DI*'QF]I]:XR5P1Q
M3CW9RR?K"AX<S\P^1/J&OX:"L)\V\^C[1>&FT%=CCN$:;O&,+2;N@0J</0(Z
M<OAU$NK9DX;01Z3BQ67<F,-+\E9;D/O9R;[\AY=*'JPH$;2[A5(1350 LB!!
MZKPWC3MQ+7:L^9O5_DWQ3[ BI%P^BZFAW?JU2]7ATH3@1S(C\RU;7-K8ED)<
M7WO+>ZL>402 ^BAGCAQ@1T(M%52&^JV[N6%F>[D>"Q$9.K;]4 F9!AT(R<7,
M.G84]%9A2'8\='S+RW@=T30$NH&BKW7 X")!Q>S3QI4.7:M^J8: PJHD!:5B
M8UW0HN_9SM2G&J'U1H42O0'4RV:I\F;6]\B+4_8V"BN-LHB##^1>_7)]%?KT
M>8)3+WU0,H*ZQ*TB5E=* 6P_P!@B+W(:8ARKU=I$CAD;3406FXS[9.'_FH<(
MXMW_YP3]$L:;4V\79EXDA[UA,G;W L,""4_:\.<IS7,C*S )_#RQ=L!G#=UB
M35I?-:KDAD+_\+;( 4LOL)C,5(8PO84^#!^AZ2<(^WE9+^+1*X[HV!]/7("*
M;^CZND-PYX5!L;"&SA^-EU)H*P]H<!BT=PAL:(H5^"KT5F$4$NIR9DG8VOIN
M0"2): _0@L0>1'4+EYO&07745J>WPSI._I]S#^%!CO8:CKRHK?53+X$@ A14
M7_<%#JR#8$ 1%03Z^JIUE'5(\)*D(<%4#P)58[N.B4@,500<@;!H24Y Z=9L
MZVPG-J08(21:O=>,+[;1A?_CK2+X*0X@NDKB#0FIWT'TB+WFQ09!*&TR-,C:
M7E3411PX4R^P1?Y+2(&<T (1)@;(22!(&3G@E?1F<,JNH??#8W?5 =19O306
M+<Y:Y0I;<KAQ9G\&%B)AQ%I9BXN@O )U@>>&E!8/FMC58INY\'GCZNK;&G_E
M3(O\P:V?N.KV973"<5K,^44<T$(8^-<HAX%PGV$J_UB"K^U*1]*2]:<HIZ @
M0"N-L.HB!0UPQ=O$N,M9EE<^)X59<IS,1%7.\#XZS>@K7<OU29Z&,4Q3X]B4
MX>C@.4<)L82;:-82$/73_"T2TEL5S8YH< __(B/!5L^G(3^?/##C,I]>0>VB
M"$S?(.FE$-8#1!_@N861E\'@/N%RDEH5%4G:3?92DDU<8UT *A>^LIX&Z[PD
M]1'1KN7UP0OCJR1-ES')0A3!:K2Q$[*Q'D,622(Z\<*?DW2D0W/F]J;HD-::
MMJJWP[J!XD:%.2]]:%69(S:Q#TL"$Z5&T?;>7TFZX7*#/CF4\%LU![F+IL-D
M-RT-5R9,?;PT[S(3\L5!6T H-PX4#9NP/D[VGY7KD4;J( Q;-8\UK\#F>)L@
MH<E6C<N! =")&C7=NH)V[=!=PVRY;I_DL@P6^=3Z,?0M'^CK2RJU.^ABK]P>
M'!S_%ZE1KJ]:&D!&XZQNW-CJ;W)9X?C+-,V-9PJT2-LWATWVHF*,]),CP#X"
MK[ %9+]Z[=:7XRFE56COL&NZY1@;=&Y0Z,,;B.CO)D1"FX^#:(90F%Z0%!@Y
M K0)*1?"H$)!<T;J]B)Z$Q*DY+<SP@]7KR(P=<?#]!HC\U9SGT#<NT<8I313
M#Z2T;*:7 0_LRAIR.T+B2]''L?ZVOI4BQ,('-Z2 R!E<F:[QT<O*R9L\/0*)
M=OD(;Y#)E2/:T*D;+*,Y83(8K[?:&#I_]K%+0NNZ3N@XB+BX0(Y EOZU ONL
M?K+=DA@1-4A<Q\(!D ;4U\107[]=O.C4(P]O26B<J*9<G3A.\#2CB3$/_Y'-
M\L79Y>EE3*K/!ZR4Q@3QD2X/V^>J7"GZ(B+D8Q"RKXM**ZXKPO5JZS &PN_L
MJ(-0[-EF>U)L,%O$P3G>H.[(YO-3"M=Y=!6N36\89#BZ.0@=$DOT]AC] $3X
M"V*)/'JEQ/$IIZQ.#UP+J1'0.N7\C,(,+M?KY9I>N9&*GQVVL7T*<,!_X,@H
MK%\>9Q  3Z0]AL3:W5U2P;!7P2E>%S4##LU7QTFQVO;CY*8S??J9.; ?_1*)
MTGJ:#])CV]'!D-N]K9Q*6_D[PZ/@(.HP+!77SVPJ!S[OR,7 +T\?(Z(.USEY
MSFZYOH4[S(7D:]W!#>=X9/1L[V%DV^$4BR*8XJP!+5A4-0$I:^-XHS*LOR:4
M!GJN[X*6A)<[>F0<;R9&49>/@^5"*,P@C)*R11=%#C$D5!X/0OQ.ZSXBU+F"
M6Q^OT4"?Z?W+$#O[QV%#(HG.:(MFI.S>S+(#9'7:VK_(C().GD =<.J4U+U/
M3F!Y%7<9+_R'$#[2JRS+-2WSIU<UV2A#J]F=)B4?OE#1+<],H+R"==Y+0O)>
M*D[$?+)"D[V%G>UOTZ9 &.=JAR&=Z!7#6&PV"&Z\#/;4*$K/<KDJJ=+$;,<,
M9 43@;MLSLH"Y=O#LD"5S0YRZ"ZLH*K+&HLJPZ.7TP533.-'+\K)D[64?,&K
MX'(6IO2.B71%7D62=@O^*,DF+H= B(!'0H6&,!GF2@B6V L*4NV*O ZJ)&AH
MN%DZ077$M#?(M]B:QCDD9[4D0Y:\Q/ YS!Y.<VQ3MQ!=QGZ4T]>]B(^2PN#>
M>S;LK.I(8'M+K2&CZ*TW5KW):8UR [IOOQ"H-SCFUSV).)NFL+S@6U.5+L]2
MW*KQ^" O0N%I1S9^!5^I=>Z@B>4''5O,!^8W8E\Y6X+X@UN_W=CMBWYTK*KE
MX6.@7"=Q%?XQO5((^3B(C@F%&2B5<&CX71B,(7VUS$)O/W4#8F=PEZ1A5AJ:
M=)(3. $3^\$OOB ]E[+(5YWC-0=(Z5=3$R8]7=3-#B<I1^15"CRZY)P_VQ-K
MA4>:Y2+MHM!TOI ,1Q<9X\-B"=^WIM\5:8 I^?((!##U4;@CX1:GV%+0;RL_
M67(TM"U3F&(D>]$'E.2[RNFA&RYR@3"'07$T0*Y"-RX1FK9=NF+8WAKI"BKR
MGTC:LU_>U?3WP"-U-=P5734%BY:M'#-DFH6+RG.M\^TN2O80IHLU5BVYUK5.
M,"1N(7GJH0-C@1LN3<QV:%-6, 'XJF; (^WHS3_:$+OS14MW 4U5#5:^OM*@
M:)4V@VF&,(T<D2N"#Q[:P+0?UI*/UFG0M1K:U!!0N%(W* &?D0)A28O%-0MB
MY?$ZIN;P_ND(I==UV33';T2TL\$0_P#1H^G<82X+%_M3CAQRX#LL5N,DI"76
M4SMF)>BD5@*PPKI<Q$^*XR!^K7.!51O/Q?:J.EKBOML.,W@)R9C>ZZ>UC(R8
MSEJLXEOBX2_Y722H4:YBN;Z&V5/KRO]=OOH9^ME]<@I1YH6Q:J$)%W+->)Z8
MZJ,H%:_GU8H9SR[3B-29CT8U8W<&MTKNRSZ18)"=Y=<>C0DN]01#Z"IJ/Q$H
M#,P-[CCJ'R.=P1V"?CA)-*U)VDG\OV(O?'BT_J1[D\--Z+^CC8. ?[M/NG>R
M@D=L.[&)C3?GK-N&=<]AX.(F?U<,8?)H]>$L@"!64.L6#[][VCOU\F&(:3!Q
M2-W!_OQ !.&KC,4;'X=(<  $@4J:*.!U2O<@YH#6!'5B>!RL5W_E""%<(E;U
MFR_=RWXS@(2H(HRHCQJ90_7RL\J*XC*GR78;4J?[@@2WXX#\C52I\+#\M%RQ
M<6]"A;<#VZ(DH !M%V&,/R&+T)H>B#1N:3KV2S04WW9<5 ='UX(M$/26ZROO
M\*&0\2Y-3=C%-?**NS">'!=W2'_-28TZ#*",%2%B/W^$A,=KQ[:KJYV6/]/N
MI"X$KDBJ)*PN$UY!+X7D6:'ENLR4,0P-"8;6E[AAF43) .1+LM2%: _VT$,N
MW1]Y539Q)-GW$2LAC\.2IO?<)^?/&31N?208S@)B;9D&($8^H6^<S0UB?%4.
M08S3=^TT;4*/Y*% /\_"1U(/,DP"N>"BJ*WU9S<%@O2"PJ\_)Z55R?=.;V .
M**+.[>[IJ^XZUD97^<C1_B[#;A2[C%GXBUYTD[!P.85>2BIY7(6'3W2.MD'C
MY7'@.(T66@#7BBZ@A(^J=[;V1Z B3B[-5>1!21_\5', YW&^+2*]?W7LG!G#
M6]-0FAE_,U.(["XFG1.4@8M 9U>,0=A&I9_G.L0EUI$81U4/1V0EX?U2-/WU
M&1$;Z]Z:2)*^_61$LN'P]TZ##T.::N<F]712^Y6C]@G<-<S:+S-(>66#1.R=
MD$G)(WQPLCJ:)XM;W)/SX."Q(DE%U>\3R0R"+FPP"A%=XKQHP?+IM<$C2<JZ
MAR\GE_"8I6I<7C@ ZP3-#%-J6JR0I3 R>G53VV_#T)*_<MM#?DNK*=Q<$00H
M^7SX$!#[VEEF5>_ U_53A3W4*Y)S6'!'2M.=1E:5?,A=H-^/AQ67G&[W1>-<
M*9;;*VTG]"Q$))/->Z8'(456:CK)\5D/)P>Y.6)IA!=TMWB;3+?1*R_SR1-V
M; /3J=7NY)[:H!K;5]'Z>Z^3P-BIR(7=F@0%,%BD9=F!</,@N41($[.=["LK
MV& 5+>RZ]I9Z<VUWAM0GM$>](Z*9+7:%QRPBA[7&SS1*N@Z.+@K6PF T_KO;
M)Z2%H]\^AFCV8\2!UAVYSUV=P+\SK.E#ZBXN]+=%$%U&?2X/'\BQ5!@7%=A7
M4;AQ>?EO0$NMJ_J<?NI&3^GM?O;TS!F][<5.-=B3-.S?=)_CD?0B]E_3P-&0
MP/9E? T9>YR<Z@&IX@TC+\\>$A3^'08N8[0CD-"I(Z$Q5".>/(J\-%VN/WL(
M3XILB>AJB&<Y=B532)_:J_Z8%G\U;OWT9'!QC* EJ6CCSKZK'\ATO9".@D+K
MO27M4=+>*-(9LL+3@:3/D1,;NAHM"(\-#3.=[.M/"E=P\>2AX,(+$:UIN<"S
M;DL3%%*2$>IG," I,<97^ND$=?5N["2]$?H?[)MV5HR[!TPGA5SG!=3I1EK;
M R(\3X;%.E$1Z\<DPF3(*7BWUK"9"3BQQ-:W:Q8Z);J/B*TZB>)O:,S@L6HR
M@[EI!Y:=26I!#6/VL5.(>!8^A@&,@Y<R75ORVH_N3MZGH<4S*+YM%R3_@J8J
M#Y"33]2.!G1K3)H4[C9,?[E $):WG>8^1;GROO IRNN3U'**<$.PQBVK*W9?
MTF3M@^9DDU6H"]N3E27#IS]B&6! 7HTM??*$_&J99VGFQ:3H :N4-Y<YJRKV
MRW&%%7LV^-Y<^<9ZW=!M95O+0#4R@W5T,L(Y9O%E&H0M:^E0)19%W$@*W$6>
MY0B6US%-!T*5^5N?7LHB"M-GMUX8T]<8BWFR!GXSO.\]>F%$+VR2G+<UI0G"
M@JC+4+\V2%HA4JUA'+OOTXD?T?\CLXT4,Z2AVMI'F4MLM%?&EQ06[>N(8"(5
M7Y-CA.+#&81>I@*:D8CHX"!K7ZV/Z-]AP%_O)JHD),?4274A*=$$N*9MWE#E
ME0E(P*N5>S23E\655-ZZRR\_.-JG8F5Q[3N\IH0^Y'.Z3N)'YE^1>9'>)W@Q
M:OZ=Y$E<)]E?(*D#FFQB<M1.%Z[".3.,9SLRV\Z!L-(KP4RB=$ >HZH1\[D
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M/IP//_*%G88:BP FM!&.<!J$45YZT35UDJ>7]]_]HOB9BF9H:=4\&3_JX0C
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M/FG D]]A L)GB.Z)GTHB[XX937;$?2*+BI80FB62JYB*=T>W%"Y,9PJE'$2
MH*0>1M2XJ#:(7HQL/ L@ 2)#[/*YIHM\?&T^D:K*!8B,5TE:\- >]KB=CD(Q
MNTO+/ZX*"@WY*%MHU;2[[U>!]*EU/0C,M%95"1:P(K $$5Y%M$6L""R#P#J(
M6@B!E<2-LCHWG9V"YOF9B^%8E94,RRH_TD(F?-S1%\JN."8]0X1[\NC4&]2X
MNE"0'$F:H5'+&/CP,DPF881 O$;8TU. .?62BC^O,VZT:8RJ 5'H"@9YIZ"\
M!Q>W,(<UD*S.SP@G>@C*ML,YG&2(_'3XBYAVDV3;.7UO-<0WY'OKH<( WYN7
MEDNQ _3X'WH5_OBNB'ZD!JKO;4<$%E\ZS5=N3N"-7^^%"4FSF+,G/-TZW0ZJ
M(8Z$0@08: HA36H:I!7AL.*>O$%HVQ@Y@F[8F2&M4% C!%0%AVH_:A0X&1_J
M59^[H;8K>X1M$X"K_5C3H^L87(="O8!PW&GTL[HPSL A7!/?;4&?D]35!D+<
M:I[B10*"LKZ5VDY1.T*%8W2#FR(IXZ$8VS7S8?1"TWN\%8YME[Y11UB5=38B
ML2,419^WP#.:]U?T^@B(4/U*LQTME*/:Q2(]OG=CQO=>U_&]1,"KXP#B]D(9
MC+_!T;$D1 VS3PNZK7CF*/3 $)IVR2/_W?T_R@KLSS"0A^3 =2E'1@W)<:-B
MMRI[,$>[^ +J/EGKC(FB5^KP?-.+7AF7WY^@]M4YJE?V6WN$"1#.:X]V6%M?
MX3MP_RK7C40F_:?0&OE'*VL8;EQQHH.GW8IC(06*)B$V!YNZ.&TKGF_[B2DW
MC]3G!G(>&AT4D;#\_K:88L0([,WC-9:"N$?N2Y)F)83M,.TU^_P3CLDI+9_@
M)ECO+^F#\Q#"0/(.1KXG3!1L#P4+  R.^3AY,;,=NT!R+#:D@C^FZ_V7/-^5
M]_G!Z?H<'D,ADBT97SEL L#?3M!$ERP3HR3L5,9*5=<=O??)@:[WG_+C,1=5
MF>[H <(C-WEO903;/5U[PWG1%P!,UGLB0,LT0 D<=(JPLA,1[NZ)U#'N\5FH
MC5^!Y(EM2UJ4G_]Q2JM7GR]%?+4B%U55I ^GBH>+5SF3KX1Q;B%N$S=B5B>U
MAPR8JOW]]HGN3GSS'!+^N.QE[%ZVZZ8G6@2##3!DPP2*7J.LFH0?6S$-_%4:
MTBZREG$6?N.0O B?CL!\PB(;M93IG)0S#O<9^((98V/L\)N\H@.BX,0@N_%]
M$>?;@4_8<>\E!G)(^I 0S(*)GU#/*JU $)TQ"A8 $P%92NZ1"S&,)LI$^<U*
M8AR9GOM^BM?__7[O8NSWF^O-YTMRO[G8?+Z/<1R;)>ID[BX<TV1JAK1TG&@#
M0W^Z[LO8UB /=F%1/E:2(-;X&7#^I"?L*N<EBGC)F/7^GA;@_+PM9-(FO]#G
M*FHI9R1L2E+/"3*0F)4TTPJ%)J;(<Q9"&J+/&=FUR.)A\U0-BWM3!",;$G?@
MH12R@/0Y*3*V_TJ5LG:9'DZ5.W1??=YDZ8%_C ^)*<$ZL+"QHQ=AY+J5]@*;
M(J;IAO[@OW(>H+X:I0($Q.O]$%]$3VP-P]6I8 12"3GUF)]C$4SH+[\AKC85
M2&D6W(B1;6Q#P,:#'DPQS3G?TBP]GHX7679*#K*7DTQS< DL<@@18XCJ6"5'
M16YVZ,3&D!J\F&,9P;\Q084>&(EI?BI%,6[:Y"C:.:"-(*TA\9K<.K&P4+X?
M8=PKYXY629K1G7K%/,W"Y->D?K8M87TQ+AX[&K:;IP]AW"*=G9(V["_J9U).
MYY?DH,H^\/?Z%Q+*2@C!L7U\@>A:#4*#2(476W&=[46'2\AT$Q%K=,>4*WZW
M0NYU^*M2@^*)B$0!XVJN!.=]<;#OO!'H&Y?A:!*V;LF\C2VO+),7-I8U?@(M
MQ/^>,@'$FJ7SQ)1B,?+#KW_Y]3]^8?_[MY_E[E\&P4(+A@M<$!#0XW72JT\U
M (B"L P_4A '+1XB/W$0C6U: ]&+LLG/7&<WM (OM3L:2UX#XKXHM4Q5LLX@
MKXI[_N,& GN1,X.MPLB!ZH:_HZJ?>7\@5?.=$34532IJK]PN#]FP0S8:.3(@
MKS/>TV#&;-(:XAO*)NVA@HVA8VF))S==/#X6])$=\1XEM+P\.17 >CSI5\9+
MPH!$#.0.Q=.X!8<1"%-KJ<.C:/&2;JF]?L1-SO<:W?%2$>4FA_XPVN\AZNXF
MK_Y&JSNZS1\S"/,>70BQGDP5_0#H[*<5>65703/!"HJ*G>*:Q\Y&/:M=^KRL
MPK(/_?<I*2I:'%[#%*GZ<Z>>A'T+.! P#GTOHJ@"CS!*04 %Q$I^$FY$]G(T
M\5),,N-YT;W%&&6[01E:SDLS-;!:!;G ]\/A=>HT1A*;!N+O\.H/)R'F1<ZF
MYXVZ,GDS>')%M<]518"8W0H\6-@XTHLPHL+7)#-^2YD^4^4952_Z)O](59VO
M=7:Q?4KI"Q49"USW,0:XTT;K/-%Z3",4;7+RD=:UT4!;U*;BH10PF65DM"MT
M3IJ9PM;L#,&UX'?]S_Q6T45[:^ZWQ>TN;F"+,K0 _WL+J1 OO(4*:!ZMY)7M
M"+:(8U)WG.^_7?D((H:0>HR9AH_NU7)B8GJU/$CCG@E0@.$_B!]^82>5'4V>
MQI="=6'XQ46V:_] ^U*$ W3C\NKD5/:7)U _P$;U>;^G;EL$P%T):X0&?D6:
MF8GX!"*5.C]LCQ!+(I8H2#UK5JU,V 3%VN):-'#Y8+L78NP$%&$=6C%]2WZ"
M>:#?9RL_BMY=JK58G54.3%"+$[8K>?&P\IK-D!WX(ST<>K+8NV7-1(3^N^9H
M*ACO([MAPS"U:S3A-%I0U)O]"$\)@7/?Q9%Y.X(.-D:/)B>RSP"R-U-1(H;=
MX4+%?J39-F6KS _I]M6;-:5!X$]P"P9C-(="?I=_+JA2>#CJUB=Q(.$PS1)W
M4)1OO?]>BEMF_2""=:XS]=9>Y86C/Y?3+0<@/^3[#PRHN*") @LI)+70M,\+
MK<((A]UT-(L=WC2>+%:?WU0J8ZE2C=->1K<[2J]I0>\RE5/;P=9&,5JP@\H.
MJ&O871@U[/1\6Y54^]-,JHT7"S&2/#U1$I,(CGEE:%G\MTFQ+NXKR.3GQ<GU
MMCF_.AX 51-A!4GRA-T!8KPL&V_V#HIWXWN0=%WU0;3!<_ZJF@KK_:9(LE)$
M\=6YVE^@EMMZ7Y<4 T=VO\.G+EC!3K(&4<^6YT#A]PJLC! P0[;1:UR,)(9Q
M;J=1%='\/:&7'__DK*T3Y0P1;_3IY#&VQEP41[;@-3>749*Y3YYOKG.EKVD#
MHQ8D[L/(<W<[*(##$6Z>$7$H'D.3#,:);FC2%VL8FDQ,$ U-7RF[DJE#M-8"
M>Z!\[57ZXK13"#BKKK[2:L%<Y>2!RLJ*O(,> (SITQF*O.U0C",@XONFZLBK
MZ)OR8E_1XK>\^(/IEUMZQZ3K+=RRKE=,%MYGPDH-@7 0I(9!:B 1'ZI0/(WG
M:!B!<#-RG@NZ31,UNSWKIODFMA5(7XOMK)CXH&4BJ.P<$09CZ]KMB^.MLYAD
M%%&3Y=12QLV,!/0B#\&H&D=A*)6PK"ZFCG^5%_;"6?U^;9OY!#*:7/7*.@YO
M_"Y; _$V.#J2<I@IST8RG;;8&\JT1+ .B#9PAT/^ ^*EG+5;S!3$%JLA%I\]
M9#5 4D.,?UP'H.\\MX-)&+.[1UTFA*_X4Y-Q;R\AVFKKH9=2D1[.3YUB _&;
M>5@1M+V+P73![?=C;W+0KW)U&D)\2)N&$+;$["BE;OKPLK$G@!!8#^&&[8OD
M2'_VOW+J*R->"_MN:R_7N+9LV&"^/.U>E"YJ=CIPQJ-F>[D&-6W8X'O GT],
M>8*(I>=VP)W#/,8_)_7WBXCA=F#A,(FY$49^7*6M >0[6J0OO+GZ=0:M N#G
MEMZ-SA9:*BX;'- -+-( 6UF;8,9]>@>C;WV)1Q(1,54QRW)H$.A1=.K/%M Z
MJ[-DX^*RHH1I9ZFM=[5OV6,+:*R<M8O>FK(;Y20XL;%M> _J>/MZ0-'(LE-O
MT*,Z#"SH61HU7*.J%C,1QU099Z(W<K\2^E#)S@A-T-@5Y=$@\#N($@3MMK?G
M&7Q8-YQHP!" PQ5+_H$")=J31"YG/01MN^5U,-V6TLOYXI@75?I/O5SL#?U9
M;7[0PPO]QC;KDY/1O;V>5_SNYND-^A32-;7.HB=]3J.);1?,067,=]F>(:XE
MVW]\;3Z1HAM/&Y=Q W\5B>393G%ZD\./-+>U\/V$I/KK*]#S_:&:A[4D@,C]
MERM9$;$6?KW4^Z[*^8]7[5[68DVQ0[>12&_;IKALCYC5,:"?AI'2H?6Z7DZ+
MZP $;0P/I@MNLZ.)VU#;;PS!(LW*=,L#'9TAP#->-ZT;I9Y>Q)"^\:O%2==S
MW"4>)F*WY'%EP30)@_PSC@'/AYJ25Z0E@(K/Y2;C@&-+1^/(8=TB$PB+R/_;
M(F<*6?4*K=\J>-R4R5'V<'4TWN-C5KQY7B6D#S4.:J='SL;MP\GN*//1 %<=
M=50VLY@);0571E:,LYE>5_9"-E&%@6G$L;%_#G*_"?U%=!EK[,YE-R):B+C7
MF;BJ?J.0/L5$7K"B/E(>7'_)=/VK)"WJQ^I,"HYL]*:M5?KE*RVDO59_TJQ^
M9=2BB5RU3(J =1-8N"FKO"EA96X6SBK<G&=_H0?SJ7 7:*V\SD0+5>AN?C@P
MM>^4'-1S$1XN1'COZ756-ZG5P1$%;SG!0C[,O9%"8:1#[ XOR^WR&D=@;+Y_
MRHMJ0XOC+1BHW&'*=?7A>B3A0PF,)7)PQ/!D+V(&JP))@:\3/_AOG >'.J4E
M^;35J5\PE&)M]EZE.-I#<Q;*.E^.,_(Q0G5(=J,%5EEH K@#2RI$J_AHXF0W
MG_7ACZBBMK-@.E(#=RV>L@IJ$\DZZG[WNDPB,F1%!8P7EEJI4O.QS_!0_'L=
M\H-H&*<_P#JC3<B&+9V]U1* ?1T[GMZV=N>[:R*(6G=$A/&I8JT0DO%;6CU]
M.I45.^Q%[;$'*8[]#P0ZIV@D0#4%;P$8^<&@$05.;_*L(,(%&3,,;P0%; =J
M-"';L9-C.KHXHBG&M73Q $.\ 4+7%-#6Q1F"T\VBBE?()(R)EGHE <1!-1_S
M' .F\Y\*E?]A#?Z4B1;UAY&]1=UUV\W"-MR08Y^') )OV)F?-Y6:0XPKL@XF
M@(V5(ZF(ZL0/**0N6^[.6(U>0EQ$[9_!)'!K+8/IB,OI5E'!ZZS>ES(%R!<G
M;"G)"";PYF37N5'6Z.$XK W$V<'3011#=\:4PL_;ZP]A!TY\%=5[IB_7:<%I
MH8.KG;1[EEYLMZ?CB<>77M)]NDU[>I)U&[:^TP83.3IVY5(_?G95(XPJB'?8
M@#!O=@67Z4[^PQD[W0JF7WFCZ;ECN@$;VT(SEAPV;D\C+;)TRJ-7[N@.ZN#O
MUL6GY'!HA[OT^XEY^(\:#C4)!8!NY- BPLN",'4& @72"#G.A*&=E$]-Q[QL
M5P<]7%?TZ&]"* !HW08A%*B)).% %I3#%(RP-4QD&+6P3^)8UTOM;;]@C_Y1
M^6%DA#,MCK^<,<JC"<@@VNQ:"@4L(/:F.1]E9W6A!?(1UZ_;'P/Y0HN2BL)_
MSTP1GQA5RJ')D%(!;PE/1CCVSK=C* '?1"R:]/A>Y<6>IM4)E X9%H21-J--
MVP2/Q?1*G(&.LX9V^=B%W GC;!%J+02[@?EQ8QVUI1EA)JKIJ[6.]UO:SN,9
MA!O)Z-DGN%FNIR+C2^$2Z4^^J/X**?4(*:^+,;922C$25)WHV%CL0QY;#,_W
M%=M L!KUUTOV3!]RGD_ \Z#[*VRH49PS]3\T&")Q?#%EKX(1MI[/8=3"=KV%
M5_'4JP':U-T8?K/^PIQ>))>2@U:W]^;-'63Y?\C4F:0N**A27ZB;*W# 407!
M<;08K#SXR(KZ@D&X.+CL5,CXQU.99M2=9LC#Z:6'DXE:PF3*B^F1?$_4Z+C/
MF LG&Z?Z\4<\B:IH]1U]SHN*1X?3Q[KCK]4$*.IX,[(W8X@:%/,@N5&Q&O<\
MB&/6#Y0=B63XB8P;=%;DDDV=5("-_#Q>+HEU]48\4P^.B"%GO)FO+' XJ(6Q
M*M[8T\,X4A=C.S8&_;V88\9W@VY5>_2U;,ND?+HZY#]X,R?5Q,<:V,VUY2;\
MH97 "OX)@$)J,)'-@L'HVNZI@;2*4*BSH$]L4_'ZAA")P^M$R^!75['.>@AI
M!2_Q3')X67A*Q47%U.R'DWA@JARZF.F\C%30TX&MC75>XJ E.H[NE'3QR*Z*
M1[;#VC:/\[>LJB?N&KYLS:S>3"\K'SF-6_O,C$.^+>[8^4T.\B3D6:YN-7>,
M#WPO[PAV.6A#HFK:+CSLL3Q].&/5^_Z6'FA9Y1E5H:_>E)MZA#)>E[;$FP@R
MCQ,34^3Q((U=5[F"-?3;:>5'BS'VM19MV]X6K!#%^>\9_Q?=*4O6KR["UE_6
M*2&_1A7=S94;V]>%'%X2O;$"9VB(2=Y?ED7>7_SDC1$O(1IT"-58,\QZ*A'+
MAB72$*"-LW0OB:CR./%RZCD>2N"&L@ASD+ /@2V5)T4'IH;+P:0>O=P,\2 \
MK=;F< *A*3K&H?Y+^(WUEV7=6'_QWUA_P7X0C%(B\G@.KZFB&J@ML*!*&R>#
M"T$TB-926*;'U$4':?%"=U=Y<74"1[DJS]UCF]'Z#*ND(@&,*&B\G8> 5Q<W
M7TK_X3#T'<::,33$3<&PY $'/DB.!.G 9RE2BH4?71LG!] ),W#RMLBWE.YX
MEJ(LH7^;%-4KE,UW)U&+,2*K4[4:X,-X<X&8QM ^?*R:HA=_Y$O34@&R"?6O
M[>SVW>2\0-WE-IN4"=U;X3B7D<_>)-I8;]?IQ(Z17C$A</;SS^=4KA\SSEF;
M]L\1YVRAHU49.1>[D..<ZZH?7!^6HJ6H9K\!8=.O>:JJ*/E>.EB4J"WK_?_.
MX2SHH0_'V<KX@11#4T6GEL;37#Z=ZEUW])BDD!BLZA"=D@,D_)2_]A8_?.B_
M8#[*"^;!O%]J]YSNS3-JJ=7+(MJZB%A81/TN!A\,I3'>9L"]OV2 2;^30\72
M+,7)T5JT[8ZQ8(7HY%#>JTU^L?W'*2T@B."WO/BC*8;A+-NO/'>;G,BQ/,)"
MCE8*?K3B6'[,C(,42@QD:5%7;J9V36WI?*/:IL;JP3"4!#XU<7CK5,RNYG\_
ME97<BW<4")0>8#<V]8@VN4WML<1RN;:"-@<$0-6S\$/<+OO$?MVC>]HBY6+?
MNG,2T+:1YF<09DBP$;L &!1LE1>EZL\-8D#IC%HUPS<4!*8(U.&L LB2PCD<
M>/J#.WH)M/Q(.]X,X8P!=1)^S/[-4VEC[(%YB(W\<'S>[^FVJB-"-\E/J!"L
M+JB4*P9V:\;GGUO*+JWDYT>:T7U:>:I?UQ.1IE"YJ*#<GFS%?R&;=9)W$OC[
ME=W>U*@LEG+9$9Z1V<EI>TO.Q#/DG=>IABD*Z_&W$/ZJ[M'@8NK\CSHX4_Q+
M 8D=<1^$J34,90"-8ID&N[U7H/FR%C(SW$YH]J\1_:M;2:X]9L.H1L-!U.BW
M((X@+&)C^^[BM)75G03#NA.5+<YVVS#&[D5D(&:\^X&DB!@H&1YU%)'PQJK]
M$4?=H(<!U>Q/QV-2O$+"):CRVXHG*$/&/SRCCQE/YAU6TGX01,RZ]D,6YBIN
M+V! ;?L6%%X,@FAP+!L)W<(^AK6-:7PPM1!C;K2H(!$.='&JGO(B_:=;4VO'
M4,G8J698;,^^&R%/5)0=_^4KU@'^DJ_IWEE=?;+B'>@G@S6\P8RV0.K.I[H/
M8F<L"?T[#VVANT[7Y^_L,BOO\L/A*B_ N3=<4E> S9[:'#8!X$1"7[*G?Q2!
M^H7W"31'E V&[ONHM]C$2^P-F!BQK['1M]C;"7NK4>_@J%*/;]GA=.[3LW7I
M-#:P6@[AZXE],>)0_3R!<P,8COP>]Y7#X@=S2D$Q#F"QA</XZJS\#B0*5F:Z
MNO%L!C=+S+Y=XY*M"*5QZZ)CNC12&Z(^40,0-IZ;P<1"S9B\H56@/]W6I<E9
M;XQ60T,;5O8&6%$-UM.(8SO)<Y ;77T7-\]UQC- V#HV.>1_-$$]JC*55Y"5
ME_-U1A0HB'(#8'IPE (7+<1M*-Y."7,8X5#/_:!>>S_R>?L5_L@CRVX#L;?&
MEXXAX(*:"'M-& &=@\GOR[%3A*)KX^4P4N$WYWC*#SM:E*+>N:OXC_BMMP1;
M)&7)0,,IYUJ0Q55!V/V<5NPLO\#573$2IXR24GH[0L+X/V64" ^^";,'"I@?
M.%#20*VE7PUN'=738PJ,4?!] E5LO)Y.9=SWLA':>7?GT.YOT(^J*8<R3U>]
M5O&89H+8P<'3261]9V<B_ (C!D7YG";D>7I0H"PRU( TX_T6&N[7I<78B#X[
M3=%4)DGMY)&N]Z+T!%LEW%UBR<ZDGWH8! _(.AURI&1ZS"!@#U:&_A-$A24T
M(Q+VT(N,/4&P8+:U>'%]898)2?VVA-@NL%K4<-S#K<X!),3,P1CP0O"K0LH7
M8F/Z(L':3[7WI9;7L9+GY.5M"2+##]^;@TIFB-]\M$<O<MO4-MFPDURRA8#!
M#=9^R$NXP/SJLE[H10="&BC+4IB#<;;KS -)AMTQX)9=5\<DI$^ ^-+2'"!*
M;P!]W<81<V"&V0:H#MZPOP=<AY=^1FG-?@V,F?&EK@BH*^4T>/4$R\2-EAE+
MG?Z F6DTQWR(NTK]_>GA[TQZW^2Z=M]?<\"TDT@@/#=>-YG$/[H#T#4.]6!2
MH5H^;@NH?UZ]@EA70:#,/TXI[_P66,5.C5_QMET53U*I82RWQ&HHVK;S.HQD
MJ-QL!VRSV^21.I-0.D'LXN/(1?S-U=N%$Q>6BW2RS>-=B]O(,!#5*:ZT6.X7
M,_*&]^6PO\6]THUR@:]40V"OS)/L*Z9"-HULXR;P#:;&@&@F+TUQ&5^+7)^3
M J(\2[9*M;ITRR[UR_1PJNB(>' %L&D#O2(<*'\:)=@E!X(/HDB_/#N"N/HV
M&)#*5D_YZ9"PZZ9<[[N>!4L5RV&Y;=.FP,M\G+905_*;VN'K/9%@X:]Z3!_[
MIZ-TZB*,8O-LD29';CJ5D:U@1HHN^XOZF;35M>*-LYTLD.#T7%G2F$7EBOH7
M$NZJ'3D.%Z&"'?7%&T\2V[TWE<"8^;!ZQ^' KIN=+LWNMIOH)[L'&?/<>C%'
M%43J%M"T>$FW#@'I)I>)5#S*O]SD57+0?P^9N3=Y]3>J\G/_*3.MI-%HM$FN
MGKB=R;$2*<]L2O)*Z]3G?X+@>W',3Y'=T1@4M?JO\5B):>EKRC +0?XZV[$[
M"Z)[^J^+9IS,TR#-R"5TZO7A9=P<88086(BAT9IDS]CU7@80)X=;V4_=+J8"
M 4I& 8[]/BD?. DDO'\'^?7?Z:$JU4^X1,NEV4%38KH> M;CDD[54%# ZL%$
MC2:_J_&Q7?4#N-S6J0-)LXAL+J[JCT[FDJ:3=BY7+'9Y\!MJ_V@G<R%RZH)I
M(CM0NM,7]CYMV;I 2_G\$YSX="<BHX_/ITIX[PV]7;SJSIJH&G#20"<*O(HQ
MKR=PF4DZPD,<IL]"*MO&F)$'F.56+/E,EH*_L_5DL951?DL]68)I8]LB,Q ;
MV:APE:0%O]J^T02B0AHW6*#_$ #(-N(:B##'88PX^5!\;>P=2"QD5G+'#.@?
M839OZ:OBFN#BK-D.7.SNJ1ZTEQ#%&I#X+[)IFHKL9;=4SU^YSHG0]4BL1"N,
M7\HPR4JKQ,2$/&%5,-LA+2> =GZR6Z5%5)8CR@TW],?%=@LB"XC 19ZQOVXY
M1N6@]X'!(0T@TH84]$Q$R2P?AKQM9XPC(.Z%Y8R$&1!9VQM %!!<NZ3@H<#@
MVN%DPRK]<5O0YR3=R8:ZFD/+F=HB!A#53U@;$M6ZYT3$,.MY4,9K3E8[%&5]
M@;N^"FE6!XWFHY4PVM7GNE+:,MRQ/G1[7*]AE,(Z/-U SYN\LL9Z^O)0S,!8
M\+2X@F-MOO7H\;$^U V>CJ,=7E#%%YHQ/?MPG>WSXBB< &&5D.1 HHWLK7Z$
MS3DO8@:K DF!'<5<MZA2W<#7>ZU4;EAK+S44#)1ZT>"HZHD7-X>($4(0[%:$
MXY*]/YTUQ?Z3F5__AM+K/\V?6__)3*P_]PXIBTJ/J,JS'43+[#XF!]BX]T^4
M!EJEZJ%$CB5\\'(L5(,QU3D[DDS8G1>[#2$_GLHT@RCPIA6$]2Y6;=&JIC=F
M,W1E=,6(<QM[D+->QD$$P:P>U:D+>G."  89E2OK3FKE<^MZ"R[.&:5<!4!X
M1F5@O 9NI8*@5UHIBZ@O[$AJV%@]B;!XXNQM_GPZR("C$Y37D WZ D,!F^%$
MCJ_;%[K# F-8 <+0-&T"0\B#?+OB]ZW^]8S^@MHCT+H@!C0R7T#M#5QF.+T(
M,?8$WHUUL=T6ISJ.&@KM<H>'E%4#+)42@ I)%S6)A6]* EF,\3(85^/B&DBE
M);@WIP0G;R&.1"(;M>YW>':<)P-NF540+R!-$4J=7K$!HXH@KCB;>',4';[*
M@.2%8P%X9"U\ EFL 1]3J8SHL%5*2AUB*CI^^;6U)N16]D*+F]/CPJ-/,;/C
MC!G[3.&Y9;CQZ7]QWHGJLPZ=8UQY[15;[SH;4KAIOF>+KJCS.-BY+M*L3+<\
ML.N,352,R!HSL$9+V $KJ%R8B*Z+'4J-S0G<8)O>[8 K91E9B$WEA;PL/R5%
M\;H7OM)A>9U:E0H&A[0 Q57"!F!LVQ6#"8;+3]GKFBU%%3#O]HWX2-GZFJJI
M$%/.5+6\8.I<4KQ>5_0(^Q/L_&PR-L4CVZ24+=/9T4&6,GP'D[YO*L0;W3O(
M Y]9JUNK2A8W<Q$U652AX(Q$M&VIL_,,VZ+O"EB:&-W5ZY594F#7N' N_""N
M?O?O;2&O.NX!9BL5/Z#@.QKG)*\ARI:7P-X&Z&*=YSY"A'O4PTB*R/FF>':K
M<#;/((3N5/D60C?J:V=Z47(.F3.>P^X\!O'SP0<2Q'V=#Z0IIC5'-_+)TA.^
MB[EM^91Q9M80VP@\Z\''QA\O^F^N)7:K4>,7^,+=W7S^=MCM1IQ$SA\S6O2<
M=#6,Z.=G(G+^)OP'0LE+<@#EM6G'#+]@J+5_H'W9E[^Y$BT M:]7>@ML\0D\
M"YT?ZB,6D+\YFC:VBV@&8B-+]K6NJUQ&SO>B5O_5EU$?B.ZRK<^"'3>TQX")
M!"+',SEPOUP"0>HWM/HM+_X 2W/RG+)?]2CA:C21PR&0GT#S30F!2!!Q*R.'
M(&G<L4-H,[DDH)Y6WRE!V&CJMTR$$.&Q/-M^9&G *5-AUO^:9<4AM0*UJ@_L
MGZ(0YH56"%.J"]RF"*4@5-@US+.TNH$S["-;_<"I',#*;Y$I4M(P[BPK+3/!
MY&?QRL*UEVLPP(8-9ETM&:JAXFH@J";-ZAI@WC"6NF6G-K#K?8T5N.+"R16N
MTD\#7',[E])$E"ZOR<+_+BHM]58S46.$C4P;%=>BV8..2X#MQ1[3JO$E23.X
M^M:92%Y(Q14I-'P7,V"0\ERP$Z&-%/9*8:J5UFBM48&HP\/]&^F!ZRU?DK+Y
M'GZP27E0L_I93/FWES0VQ@;0$E,IA=/-YLZW*709@FZ\GW^FU;I062I-K9MU
MT:KV[VG>Q@&3!K)H: RP"1.=ZT2ANL4,^V&[#4)_HXHX1W@JL:P'?1X.(%:U
M/CV4VR(5[>@""]9J0WKCTM%%2C<NIISHPQO7JV1W='TOZ?YT^)KNG<&!GC8Q
M @ !" OU #8H#G(!=BF#=V &)/S)[ 8I"M_1+86(1=>Q&MHF466&J'@F!3]J
MB/5DZA@'=29ZHUFGF-!=G@Z5,&Y_I8_)09G)^F_59AS7X_G()JB^<[EBL]6'
ME,&U,"H@WK$R!&E(ONY\>=%B\K@W\ @"V&[DT71$M0'L=EP03PY7I\QYX39?
M$?@LGD6EO5Q3F[=@@YT<5UO56C(K=[OPAJ9<[@WH]JKK!,*))?J_"@5C:7%+
M ]&VG9=1E,.T!O2V$?N>[>!$G\#%RC1Y]FE_R>*0UFLZ3"* +B"<9109; R?
M0$]$1X5JJJ"9!E73%$_[ 3FP91]50Z.W+/&B95RN@83 TR^XL"2#XN"B^)DZ
M;=9"1FR^)?!Q1#.U9>D&O9WH(;]HUA9JSJ@]5^^YJ#&85A1L5U(/KM@=XX5S
MJ#:XE/VMC)7/J_F>_"Y&1 VC<V!A(WTOPK@>F#KTM F[9/)')_32FLDC7BHV
M0-Z,_3) >(@K_$*JA>2=A/T^H+NGV<\@RO&;F9[6DWL6GOU)<@7;E9C-#+%E
ME>(V,@?5/FX>E>6EVI^;35:-*>*&:=W(8QM-\02%I_RPHT4IUG3^3E,]<R)W
M?@Y84DBW*7WTOR;/>?F?ZN!9FD[%;3GEY[>CYY2'0O&S6_@!:JIIS9#5(FY*
M#:3YFB\GEZ6+OHV=@RB'6?F@MCN)%782(R_9'V7%0^*NV,_3QVQX1V[):R-9
M=444=&[BD_#[C'M137NCZ--OZIM <DP;D%6X=#=!LIJ#G"??UUH*W30T %O3
M2C285)CN#JEDPI(V/_)&P_RU1Z7F/&)?Q_8LVM9ND-^-()I;]V/Z]]-+XC&.
MRH^64**QM5Z#H!9LD,5$=S/'&_J#_\;=7MG?Y1*ZVP@@L1N3!N!IEQ*#"83I
M+()0^51(-.P9$P48'BD3>]S<TH9P<: U**K4UX.,C25>W)=;9^X\)>9LQ>46
M7UMNOK)RZ!7E^,V]*9*L9!JBBN677N1-?IE"I:2T.A5, %6%L%T/E09%NMZ5
M(WZ3$PT2SRV2L**)",-0-MZZ,11#E,+/DA6M_A$ON;U>041_Y'E):VPT#$YB
MJA7?DC_H;T_L$V5DW6X+J@*Z;)L*!A ^HK&9JS'1;@\G%@;_//AB/N_W3-JC
MY46["DZ_KU0,(1=&[: E>$Q[\+%*OS[T47DQUA]1MR5F(L3I*(Z\$J78VY/N
M:+8#E?:,OBJM"[2V"$VB4^O@]H WZ7\*I?*LKJ9AK,7<K:KT[E5>W-%G!OF)
MK7U"B3)5C7C/4[H4P.$URJ+6+!Y(#-M6F4175-N*47<3;,_R9U)UN:,E+5YX
M'7M9)4+X2@<5+H6_U[^0@'FI&@Z:;P<%7/I]8MXO$ZABVPZ3B8SH"NJ-2%7[
M^A+L2C^KS0]Z>*'?\JQZ<EIT0H)\JYP\@!28[J2=8)U%-A.,I8*-^],HBBG#
M6W5<9Y]K>UJ:U1J@FFTNJ>=F.+*&[#^43JA)W75SR=[0)KVQ9FT(%R;DV/7
M.ABXK*LFELCAJ:'GFIO^V,RSWI  <+$9$!;DIUR,;0+BQL'>/B59E1^Y8/\]
M2ZOR]OZ[)PY9#I'5D_@@\@Z&O3>UZSB"KALGJS#K(P&:6W5 &N'D3E5#$ZQ'
M=K9:<,KU^ 98Y^,3\A5O;22YWAL])$7!,$]'^8'].465-DO\XF*:<_H(8;M,
M)E 4N4]:'9_5VLUE_W8N1<A/';:I-P4&U:Y.SH71A[QD$J0_$;9]%97^'')/
M;FSD[%@T>O:'W2&S%3=B1F*9[WN\U%<G4& LONKAP9V](0%LPXJI6A$!=2Y/
MWU:-N$_G(%W?!IR/-<AOXI<\W_U(#P>V[[O+[OZ[OTR8 L2-?Y9-8_F1M!_T
MU@>+40AN*$EL&V,D73&CQ"<VN-6<VX$-;MT]^&9L>JPMZ_^CIL<CF.%TBL78
M$ZCO:7^UR^44[+%QJ%-=$O.IN*,OE,E1I4\S4M\M)%NKNVP;5>VHH0;<I =:
M5GE&6\63+7$VZCNC&#1Z<$UGQ69,C14EQ/"Z 88+U0I.M0V6A@NSA>T<QB4U
M62TT-\8E9]??)9N6@H@WQ:PT@#NHT4&GAY+^X\2V]N<7,&[[E:QZ !$C%M,=
MRHF*54KHQQOU+9<=8'P=8CJ_]U0\AN+C/%_!UXW'\=5"%9LIM++Z[2;3'G>K
ML%MBO0?%# S3][1X2;>TO,\/N[[2UV 0X6,XK]4H L,BEZ%WHF/WL?8CCRGK
M;'[DFZ?\5#*"WJ09K2@5SE_V"+ -DKY0*/G;GVT'V8L*!E% 9#!:#8;715Y"
M0MX A(UG<C"Q4,_4#:W@>-\6.00^[CZ^?B_!_F4WN_H4!VC#Q"]3!0YT_G<
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M%SE/4&1SDE?*/75RUI5TH9!]7A!MYK@N%5PB]PETF&Q&+HWVG)=II?*@R_Z
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MWF42EZ]LJ)1]V4_8/R"$';[X?U!+ P04    "  "A'U86Z68_[!3  !RK@4
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MFQX3#^B%W?=<PK@4.*/9[AI\5$]-4OJ5S7>=PLACHA3-R6#2H8;)M.5$D>J
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M$(&X)2LFJ#=D$\5#7=WE8$[)>Y>DHDE#9X";6D\RH5VF*P*?CL%7I:I!AV:
M.QR;/S9?LLG(EJ_H'8"FP]LN:AFT*0;@(T_N.G$2>K6(UJS4-\\I+IM,7?)7
M>/^1#[6V8\IU,)@.Y[7H:]#M%Z3I:Y$):_=@"\%,R%,3DPJN;Z^FD6XF<-IE
M9A^TZ1S87KK!]7C5JE\FU.\G5VSFAV7#VP5I2CYU)\5*9@*$S(!+;&U[5=*
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M]_\KBM=12.ZX3[0]B[/5@CKX@NB1P*[TK8$9 -'D1"]9L*XP0L1FFTW@$Y8
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MH96K<#L,3/6OR1,!L0"[Y^A%\:-E^H4Y]E3+%'^L-% [C9+43CQ*'NX$>:U
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M:&5R87!E=2YH=&U02P$"% ,4    "  "A'U8J9SVS0T"  "^!P  '@
M        @ $130( 96$P,C Q-#8U,#%E>#(Q+3%?=&AE<F%P974N:'1M4$L!
M A0#%     @  H1]6"SC-8OR @  P@@  !X              ( !6D\" &5A
M,#(P,30V-3 Q97@R,RTQ7W1H97)A<&5U+FAT;5!+ 0(4 Q0    (  *$?5C$
MH?EP'0(  /4&   >              "  8A2 @!E83 R,#$T-C4P,65X,C,M
M,E]T:&5R87!E=2YH=&U02P$"% ,4    "  "A'U8ZQEI6!$'   +(P  '@
M            @ 'A5 ( 96$P,C Q-#8U,#%E>#,Q+3%?=&AE<F%P974N:'1M
M4$L! A0#%     @  H1]6#132C+(!@  ""(  !X              ( !+EP"
M &5A,#(P,30V-3 Q97@S,2TR7W1H97)A<&5U+FAT;5!+ 0(4 Q0    (  *$
M?5C(2&,J.@0  )T0   >              "  3)C @!E83 R,#$T-C4P,65X
M,S(M,5]T:&5R87!E=2YH=&U02P$"% ,4    "  "A'U8E?2NB?8#  "8#0
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MM8<" '1X;60M,C R,S$R,S$N>'-D4$L! A0#%     @  H1]6,]01UV*$P
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I;60M,C R,S$R,S%?<')E+GAM;%!+!08     #P / "X$  #),00    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>ea0201465-10k_therapeu_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:txmd="http://www.therapeuticsmd.com/20231231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="txmd-20231231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2024-03-27</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:MilestonePaymentsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:MilestonePaymentsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:MilestonePaymentsThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:RoyaltyRateOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:RoyaltyRateTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MayneLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">txmd:VitaCareDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-14</startDate>
            <endDate>2022-04-14</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">txmd:VitaCareDivestitureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-14</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">txmd:VitaCareDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-14</startDate>
            <endDate>2022-04-14</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-09</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-09</startDate>
            <endDate>2023-06-09</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-15</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-15</startDate>
            <endDate>2023-11-15</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">txmd:AnnoverasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">txmd:AnnoverasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:RoyaltyRateOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:RoyaltyRateTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">txmd:MilestonePaymentsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2034-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:TheramexLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2022-05-06</startDate>
            <endDate>2022-05-06</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-06</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-06</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">txmd:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">txmd:CurrentLiabilitiesForDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">txmd:ExecutiveTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">txmd:ConsultingAndLegalExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">txmd:OtherContractTerminationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">txmd:EmployeeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">txmd:AnnoverasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">txmd:AnnoverasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:IntangibleAssetsSubjectToAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:IntangibleAssetsSubjectToAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MaynePharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MaynePharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MaynePharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MaynePharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:PopulationCouncilLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">txmd:AnnoverasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:PopulationCouncilLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:LegalProceedingAxis">txmd:ParagraphFourCertificationNoticeLetterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-26</startDate>
            <endDate>2023-01-26</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-26</startDate>
            <endDate>2023-01-26</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriod20YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriodIndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-30</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-28</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-28</startDate>
            <endDate>2023-06-28</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-15</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txmd:RubricCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-15</startDate>
            <endDate>2023-11-15</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:TheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:MaynePharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqm">
        <measure>utr:sqm</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-10859">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-10860">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-10861">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-10862">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-10863">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-10864">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-61">001-00100</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-74">THERAPEUTICSMD, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-85">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-90">87-0233535</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-10865">951 Yamato Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-10866">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-10867">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-10868">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-117">33431</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-10869">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-10870">961-1900</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-153">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-158">TXMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-163">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-10871">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-10872">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-10873">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-10874">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-216">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-223">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-230">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-243">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-249">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0" id="ixv-261">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="0" id="ixv-10875" unitRef="usd">34439072</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-10876"
      unitRef="shares">11532443</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c0" id="ixv-279">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;Part III (Items 10, 11, 12, 13 and 14) of this annual report on Form
10-K is incorporated by reference from the definitive Proxy Statement for the 2024 Annual Meeting of Stockholders or an amendment to this
annual report on Form 10-K to be filed with the Securities and Exchange Commission no later than 120 days after the end of the registrant&#x2019;s
fiscal year covered by this report.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c24" id="ixv-10877">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c24" id="ixv-10878">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c24" id="ixv-10879">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c24" id="ixv-10880">false</ecd:Rule10b51ArrAdoptedFlag>
    <dei:AuditorFirmId contextRef="c0" id="ixv-10881">248</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c0" id="ixv-10882">GRANT THORNTON LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-10883">Miami, Florida</dei:AuditorLocation>
    <us-gaap:Cash contextRef="c3" decimals="-3" id="ixv-10884" unitRef="usd">4327000</us-gaap:Cash>
    <us-gaap:Cash contextRef="c4" decimals="-3" id="ixv-10885" unitRef="usd">38067000</us-gaap:Cash>
    <us-gaap:RestrictedCashCurrent contextRef="c4" decimals="-3" id="ixv-10886" unitRef="usd">11250000</us-gaap:RestrictedCashCurrent>
    <txmd:RoyaltyReceivableCurrentPortion contextRef="c3" decimals="-3" id="ixv-10887" unitRef="usd">3090000</txmd:RoyaltyReceivableCurrentPortion>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-10888" unitRef="usd">4035000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-10889" unitRef="usd">6034000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c3" decimals="-3" id="ixv-10890" unitRef="usd">344000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" id="ixv-10891" unitRef="usd">11796000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="-3" id="ixv-10892" unitRef="usd">55351000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-10893" unitRef="usd">78000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="-3" id="ixv-10894" unitRef="usd">6098000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c4" decimals="-3" id="ixv-10895" unitRef="usd">6943000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <txmd:RoyaltyReceivableLongTerm contextRef="c3" decimals="-3" id="ixv-10896" unitRef="usd">18484000</txmd:RoyaltyReceivableLongTerm>
    <txmd:RoyaltyReceivableLongTerm contextRef="c4" decimals="-3" id="ixv-10897" unitRef="usd">20253000</txmd:RoyaltyReceivableLongTerm>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="-3" id="ixv-10898" unitRef="usd">58000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c4" decimals="-3" id="ixv-10899" unitRef="usd">253000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-10900" unitRef="usd">6873000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" id="ixv-10901" unitRef="usd">7580000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c3" decimals="-3" id="ixv-10902" unitRef="usd">43309000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="-3" id="ixv-10903" unitRef="usd">90458000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="-3" id="ixv-10904" unitRef="usd">27000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c4" decimals="-3" id="ixv-10905" unitRef="usd">2162000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-10906" unitRef="usd">3133000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-10907" unitRef="usd">18846000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c3" decimals="-3" id="ixv-10908" unitRef="usd">3694000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="c4" decimals="-3" id="ixv-10909" unitRef="usd">25831000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-10910" unitRef="usd">6854000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-10911" unitRef="usd">46839000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent contextRef="c3" decimals="-3" id="ixv-10912" unitRef="usd">6532000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent contextRef="c4" decimals="-3" id="ixv-10913" unitRef="usd">7369000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c3" decimals="-3" id="ixv-10914" unitRef="usd">636000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c4" decimals="-3" id="ixv-10915" unitRef="usd">1107000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" id="ixv-10916" unitRef="usd">14022000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="-3" id="ixv-10917" unitRef="usd">55315000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-10918"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="3"
      id="ixv-10919"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="INF"
      id="ixv-10920"
      unitRef="shares">32000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="INF"
      id="ixv-10921"
      unitRef="shares">12000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="INF"
      id="ixv-10922"
      unitRef="shares">11532000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-10923"
      unitRef="shares">11532000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="INF"
      id="ixv-10924"
      unitRef="shares">9498000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-10925"
      unitRef="shares">9498000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" id="ixv-10926" unitRef="usd">11000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="-3" id="ixv-10927" unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" id="ixv-10928" unitRef="usd">978917000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="-3" id="ixv-10929" unitRef="usd">974497000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" id="ixv-10930" unitRef="usd">-949641000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="-3" id="ixv-10931" unitRef="usd">-939363000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-10932" unitRef="usd">29287000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-10933" unitRef="usd">35143000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" id="ixv-10934" unitRef="usd">43309000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="-3" id="ixv-10935" unitRef="usd">90458000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c5" decimals="-3" id="ixv-10936" unitRef="usd">1302000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c6" decimals="-3" id="ixv-10937" unitRef="usd">69963000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="-3" id="ixv-10938" unitRef="usd">1302000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="-3" id="ixv-10939" unitRef="usd">69963000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c7" decimals="-3" id="ixv-10940" unitRef="usd">1397000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c0" decimals="-3" id="ixv-10941" unitRef="usd">1302000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c7" decimals="-3" id="ixv-10942" unitRef="usd">68566000</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-10943" unitRef="usd">8903000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-10944" unitRef="usd">56710000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" id="ixv-10945" unitRef="usd">922000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c7" decimals="-3" id="ixv-10946" unitRef="usd">1193000</us-gaap:DepreciationAndAmortization>
    <us-gaap:RestructuringCharges contextRef="c7" decimals="-3" id="ixv-10947" unitRef="usd">9472000</us-gaap:RestructuringCharges>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-10948" unitRef="usd">9825000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c7" decimals="-3" id="ixv-10949" unitRef="usd">67375000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-10950" unitRef="usd">-8523000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="-3" id="ixv-10951" unitRef="usd">1191000</us-gaap:OperatingIncomeLoss>
    <txmd:MiscellaneousIncomeexpense contextRef="c0" decimals="-3" id="ixv-10952" unitRef="usd">-781000</txmd:MiscellaneousIncomeexpense>
    <txmd:MiscellaneousIncomeexpense contextRef="c7" decimals="-3" id="ixv-10953" unitRef="usd">117000</txmd:MiscellaneousIncomeexpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-10954" unitRef="usd">781000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c7" decimals="-3" id="ixv-10955" unitRef="usd">-117000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" id="ixv-10956" unitRef="usd">-7742000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="-3" id="ixv-10957" unitRef="usd">1074000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-10958" unitRef="usd">-43000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c0" decimals="-3" id="ixv-10959" unitRef="usd">-7699000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c7" decimals="-3" id="ixv-10960" unitRef="usd">1074000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c0" decimals="-3" id="ixv-10961" unitRef="usd">-2579000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c7" decimals="-3" id="ixv-10962" unitRef="usd">110923000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-10963" unitRef="usd">-10278000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-10964" unitRef="usd">111997000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c0"
      decimals="2"
      id="ixv-10965"
      unitRef="usdPershares">-0.74</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c0"
      decimals="2"
      id="ixv-10966"
      unitRef="usdPershares">-0.25</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c7"
      decimals="2"
      id="ixv-10967"
      unitRef="usdPershares">12.29</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-10968"
      unitRef="usdPershares">-0.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-10969"
      unitRef="usdPershares">12.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c0"
      decimals="2"
      id="ixv-10970"
      unitRef="usdPershares">-0.74</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c7"
      decimals="2"
      id="ixv-10971"
      unitRef="usdPershares">0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c0"
      decimals="2"
      id="ixv-10972"
      unitRef="usdPershares">-0.25</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c7"
      decimals="2"
      id="ixv-10973"
      unitRef="usdPershares">11.84</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-10974"
      unitRef="usdPershares">-0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="ixv-10975"
      unitRef="usdPershares">11.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="-3"
      id="ixv-10976"
      unitRef="shares">10441000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="-3"
      id="ixv-10977"
      unitRef="shares">9028000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="-3"
      id="ixv-10978"
      unitRef="shares">10441000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="-3"
      id="ixv-10979"
      unitRef="shares">9366000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-10980" unitRef="usd">-10278000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-10981" unitRef="usd">111997000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="-3" id="ixv-10982" unitRef="usd">-10278000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c7" decimals="-3" id="ixv-10983" unitRef="usd">111997000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ixv-10984"
      unitRef="shares">8597000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="-3" id="ixv-10985" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" id="ixv-10986" unitRef="usd">957730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" id="ixv-10987" unitRef="usd">-1051360000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="-3" id="ixv-10988" unitRef="usd">-93621000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c12"
      decimals="INF"
      id="ixv-10989"
      unitRef="shares">565000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c13" decimals="-3" id="ixv-10990" unitRef="usd">2454000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c7" decimals="-3" id="ixv-10991" unitRef="usd">2454000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <txmd:AdjustmentsToAdditionalPaidInCapitalLenderWarrants contextRef="c13" decimals="-3" id="ixv-10992" unitRef="usd">2727000</txmd:AdjustmentsToAdditionalPaidInCapitalLenderWarrants>
    <txmd:AdjustmentsToAdditionalPaidInCapitalLenderWarrants contextRef="c7" decimals="-3" id="ixv-10993" unitRef="usd">2727000</txmd:AdjustmentsToAdditionalPaidInCapitalLenderWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c12"
      decimals="INF"
      id="ixv-10994"
      unitRef="shares">142000</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c12"
      decimals="INF"
      id="ixv-10995"
      unitRef="shares">189000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c12"
      decimals="INF"
      id="ixv-10996"
      unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c13" decimals="-3" id="ixv-10997" unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c7" decimals="-3" id="ixv-10998" unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c13" decimals="-3" id="ixv-10999" unitRef="usd">11572000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c7" decimals="-3" id="ixv-11000" unitRef="usd">11572000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="-3" id="ixv-11001" unitRef="usd">111997000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-11002" unitRef="usd">111997000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c15"
      decimals="INF"
      id="ixv-11003"
      unitRef="shares">9498000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" id="ixv-11004" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-11005" unitRef="usd">974497000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" id="ixv-11006" unitRef="usd">-939363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-11007" unitRef="usd">35143000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c18"
      decimals="INF"
      id="ixv-11008"
      unitRef="shares">844000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c18" decimals="-3" id="ixv-11009" unitRef="usd">1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c0" decimals="-3" id="ixv-11010" unitRef="usd">1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c19" decimals="-3" id="ixv-11011" unitRef="usd">1271000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-11012" unitRef="usd">1271000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c18"
      decimals="INF"
      id="ixv-11013"
      unitRef="shares">1190000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c18" decimals="-3" id="ixv-11014" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c19" decimals="-3" id="ixv-11015" unitRef="usd">3149000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c0" decimals="-3" id="ixv-11016" unitRef="usd">3150000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss contextRef="c20" decimals="-3" id="ixv-11017" unitRef="usd">-10278000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-11018" unitRef="usd">-10278000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c21"
      decimals="INF"
      id="ixv-11019"
      unitRef="shares">11532000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" id="ixv-11020" unitRef="usd">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" id="ixv-11021" unitRef="usd">978917000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="-3" id="ixv-11022" unitRef="usd">-949641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-11023" unitRef="usd">29287000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-11024" unitRef="usd">-10278000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-11025" unitRef="usd">111997000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c0" decimals="-3" id="ixv-11026" unitRef="usd">-2579000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c7" decimals="-3" id="ixv-11027" unitRef="usd">110923000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c0" decimals="-3" id="ixv-11028" unitRef="usd">-7699000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c7" decimals="-3" id="ixv-11029" unitRef="usd">1074000</us-gaap:IncomeLossFromContinuingOperations>
    <txmd:WriteoffOfPatentAndTrademark contextRef="c0" decimals="-3" id="ixv-11030" unitRef="usd">922000</txmd:WriteoffOfPatentAndTrademark>
    <txmd:WriteoffOfPatentAndTrademark contextRef="c7" decimals="-3" id="ixv-11031" unitRef="usd">1193000</txmd:WriteoffOfPatentAndTrademark>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-11032" unitRef="usd">1271000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="-3" id="ixv-11033" unitRef="usd">11572000</us-gaap:ShareBasedCompensation>
    <txmd:MakeWholePaymentAccretion contextRef="c7" decimals="-3" id="ixv-11034" unitRef="usd">354000</txmd:MakeWholePaymentAccretion>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c0" decimals="-3" id="ixv-11035" unitRef="usd">-129000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c7" decimals="-3" id="ixv-11036" unitRef="usd">-40000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" id="ixv-11037" unitRef="usd">-1999000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c7" decimals="-3" id="ixv-11038" unitRef="usd">-620000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c0" decimals="-3" id="ixv-11039" unitRef="usd">1126000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c7" decimals="-3" id="ixv-11040" unitRef="usd">7636000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="-3" id="ixv-11041" unitRef="usd">-2135000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c7" decimals="-3" id="ixv-11042" unitRef="usd">-1211000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c0" decimals="-3" id="ixv-11043" unitRef="usd">-15713000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c7" decimals="-3" id="ixv-11044" unitRef="usd">4262000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c0" decimals="-3" id="ixv-11045" unitRef="usd">-471000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c7" decimals="-3" id="ixv-11046" unitRef="usd">-121000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-11047" unitRef="usd">-15382000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="-3" id="ixv-11048" unitRef="usd">8285000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c0" decimals="-3" id="ixv-11049" unitRef="usd">-23081000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c7" decimals="-3" id="ixv-11050" unitRef="usd">9359000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c7" decimals="-3" id="ixv-11051" unitRef="usd">355000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="c7" decimals="-3" id="ixv-11052" unitRef="usd">-355000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="-3" id="ixv-11053" unitRef="usd">3151000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c7" decimals="-3" id="ixv-11054" unitRef="usd">2454000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <txmd:ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan contextRef="c7" decimals="-3" id="ixv-11055" unitRef="usd">14000</txmd:ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan>
    <us-gaap:RepaymentsOfDebt contextRef="c7" decimals="-3" id="ixv-11056" unitRef="usd">219432000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="c7" decimals="-3" id="ixv-11057" unitRef="usd">21684000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock contextRef="c7" decimals="-3" id="ixv-11058" unitRef="usd">38657000</us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities contextRef="c7" decimals="-3" id="ixv-11059" unitRef="usd">3322000</us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities>
    <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities contextRef="c7" decimals="-3" id="ixv-11060" unitRef="usd">2969000</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c7" decimals="-3" id="ixv-11061" unitRef="usd">1622000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="c0" decimals="-3" id="ixv-11062" unitRef="usd">3151000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="c7" decimals="-3" id="ixv-11063" unitRef="usd">-235206000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c0" decimals="-3" id="ixv-11064" unitRef="usd">-25060000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c7" decimals="-3" id="ixv-11065" unitRef="usd">-13437000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c0" decimals="-3" id="ixv-11066" unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c7" decimals="-3" id="ixv-11067" unitRef="usd">223834000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="c0" decimals="-3" id="ixv-11068" unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="c7" decimals="-3" id="ixv-11069" unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations contextRef="c0" decimals="-3" id="ixv-11070" unitRef="usd">-25060000</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInDiscontinuedOperations contextRef="c7" decimals="-3" id="ixv-11071" unitRef="usd">210397000</us-gaap:NetCashProvidedByUsedInDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-11072" unitRef="usd">-44990000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c7" decimals="-3" id="ixv-11073" unitRef="usd">-15805000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" id="ixv-11074" unitRef="usd">49317000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c11" decimals="-3" id="ixv-11075" unitRef="usd">64907000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations contextRef="c11" decimals="-3" id="ixv-11076" unitRef="usd">215000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c3" decimals="-3" id="ixv-11077" unitRef="usd">4327000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c4" decimals="-3" id="ixv-11078" unitRef="usd">49317000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet contextRef="c7" decimals="-3" id="ixv-11079" unitRef="usd">13545000</us-gaap:InterestPaidNet>
    <txmd:WarrantsIssuedInRelationToDebtFinancingAgreement contextRef="c7" decimals="-3" id="ixv-11080" unitRef="usd">2727000</txmd:WarrantsIssuedInRelationToDebtFinancingAgreement>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c0" id="ixv-7342">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;1. Business, basis of presentation, new accounting standards and summary of significant accounting policies&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;General&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;TherapeuticsMD, Inc. (the &#x201c;Company&#x201d;), a Nevada
corporation, and its consolidated subsidiaries are referred to collectively in this Annual Report on Form 10-K (&#x201c;2023 10-K
Report&#x201d;) as &#x201c;TherapeuticsMD,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; and &#x201c;us.&#x201d; This 2023 10-K Report
includes trademarks, trade names and service marks, such as TherapeuticsMD&lt;sup&gt;&#xae;&lt;/sup&gt;, vitaMedMD&lt;sup&gt;&#xae;&lt;/sup&gt;,
BocaGreenMD&lt;sup&gt;&#xae;&lt;/sup&gt;, vitaCareTM, IMVEXXY&lt;sup&gt;&#xae;&lt;/sup&gt;, and BIJUVA&lt;sup&gt;&#xae;&lt;/sup&gt;, which are protected under applicable
intellectual property laws and are the property of, or licensed by or to, us. Solely for convenience, trademarks, trade names and
service marks referred to in this 2023 10-K Report may appear without the &lt;sup&gt;&#xae;&lt;/sup&gt;, TM or SM symbols, but such references
are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the
right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other
parties&#x2019; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a
relationship with, or endorsement or sponsorship of us by, these other parties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;TherapeuticsMD was previously a women&#x2019;s healthcare company with
a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause.
In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed
to pharmaceutical organizations that possess commercial capabilities in the relevant territories. On December 30, 2022 (the &#x201c;Closing
Date&#x201d;), we completed a transaction (the &#x201c;Mayne Transaction&#x201d;) with Mayne Pharma LLC, a Delaware limited liability company
(&#x201c;Mayne Pharma&#x201d;) and subsidiary of Mayne Pharma Group Limited, an Australian public company, in which we and our subsidiaries
(i) granted Mayne Pharma an exclusive license to commercialize our IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under
the BocaGreenMD and vitaMedMD brands (collectively, the &#x201c;Licensed Products&#x201d;) in the United States and its possessions and
territories, (ii) assigned to Mayne Pharma our exclusive license to commercialize ANNOVERA&lt;sup&gt;&#xae;&lt;/sup&gt; (together with the Licensed
Products, collectively, the &#x201c;Products&#x201d;) in the United States and its possessions and territories, and (iii) sold certain
other assets to Mayne Pharma in connection therewith.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In a License Agreement, dated December 4, 2022, between TherapeuticsMD
and Mayne Pharma (the &#x201c;Mayne License Agreement&#x201d;), we granted Mayne Pharma, on the Closing Date, (i) an exclusive, sublicensable,
perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell, use, and commercialize the
Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable
license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States for commercialization
in the United States and its possessions and territories.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Under the Mayne License Agreement, Mayne Pharma will pay us
one-time milestone payments of each of (i) $5.0 million if aggregate net sales of all Products in the United States during a
calendar year reach $100.0 million, (ii) $10.0 million if aggregate net sales of all Products in the United States during a calendar
year reach $200.0 million and (iii) $15.0 million if aggregate net sales of all Products in the United States during a calendar year
reach $300.0 million. Further, Mayne Pharma will pay us royalties on net sales of all Products in the United States at a royalty
rate of 8.0% on the first $80.0 million in annual net sales and 7.5% on annual net sales above $80.0 million, subject to certain
adjustments, for a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product
basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version
of a Product launching in the United States. Mayne Pharma will pay us minimum annual royalties of $3.0 million per year for 12
years, adjusted for inflation at an annual rate of 3%, subject to certain further adjustments, including as described below. Upon
the expiry of the 20-year royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully
paid-up and royalty free license for the Licensed Products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Under the Transaction Agreement, dated December 4, 2022, between TherapeuticsMD
and Mayne Pharma (the &#x201c;Transaction Agreement&#x201d;), we sold to Mayne Pharma, at closing, certain assets for Mayne Pharma to commercialize
the Products in the United States, including, with the Population Council&#x2019;s consent, our exclusive license from the Population Council
to commercialize ANNOVERA (the &#x201c;Transferred Assets&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The total consideration from Mayne Pharma to TherapeuticsMD for
the purchase of the Transferred Assets under the Transaction Agreement and the grant of the licenses under the Mayne License
Agreement was (i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million at closing for the
acquisition of net working capital as determined in accordance with the Transaction Agreement and subject to certain adjustments,
(iii) a cash payment of approximately $1.0 million at closing for prepaid royalties in connection with the Mayne License Agreement
Amendment (as defined below) and (iv) the right to receive the contingent consideration set forth in the Mayne License Agreement, as
amended. The acquisition of net working capital was determined in accordance with the Transaction Agreement and included significant
estimates which could change materially for a period of up to two years following the Closing Date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On the Closing Date, TherapeuticsMD and Mayne Pharma entered into Amendment
No. 1 to the Mayne License Agreement (the &#x201c;Mayne License Agreement Amendment&#x201d;). Pursuant to the Mayne License Agreement Amendment,
Mayne Pharma agreed to pay us approximately $1.0 million in prepaid royalties on the Closing Date. The prepaid royalties reduced the first
four quarterly payments that would have otherwise been payable pursuant to the Mayne License Agreement by an amount equal to $257 thousand
per quarterly royalty payment plus interest calculated at 19% per annum accruing from the Closing Date until the date such quarterly royalty
payment was paid to us. We and Mayne Pharma settled the $1.5 million of consideration due to Mayne for the assumed obligations under a
long-term services agreement (see the section entitled &#x201c;vitaCare Divestiture&#x201d; below for a discussion of the long-term services
agreement), including our minimum payment obligations thereunder. As the parties agreed, during the second quarter of 2023, Mayne Parma
held back our royalty payment of $0.6 million and we funded an additional $0.9 million in August 2023 to settle the original $1.5 million
payable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As part of the transformation that included the Mayne License Agreement,
historical results of commercial operations for all periods prior to the Closing Date have been reflected as discontinued operations in
our consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities
of discontinued operations in our consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in
Note 2.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We also have license agreements with strategic partners to commercialize
IMVEXXY and BIJUVA outside of the U.S.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: left"&gt;In July 2018, we entered into a license and supply agreement
(the &#x201c;Knight License Agreement&#x201d;) with Knight Therapeutics Inc. (&#x201c;Knight&#x201d;) pursuant to which we granted Knight
an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: left; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            September 2019, we entered into an exclusive license and supply agreement (the &#x201c;Theramex
                                            License Agreement&#x201d;) with Theramex HQ UK Limited (&#x201c;Theramex&#x201d;) to commercialize
                                            IMVEXXY and BIJUVA outside of the U.S., excluding Canada and Israel. In 2021, Theramex secured
                                            regulatory approval for BIJUVA in certain European countries and began commercialization
                                            efforts in those countries.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In connection with our transformation into a pharmaceutical royalty
company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief
Executive Officer) and all other employees was completed by December 31, 2022. Severance obligations for all employees other than executive
officers were paid in full in January 2023 and severance obligations for terminated executive officers were paid in accordance with their
employment agreements and separation agreements as previously disclosed. As of December 31, 2022 and 2023, we employed one full-time employee
primarily engaged in an executive position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We have engaged external consultants who support our relationship with
current partners and assist with certain financial, legal, and regulatory matters and the continued wind-down of our historical business
operations. On August 15, 2023, we entered into a master services agreement with JZ Advisory Group, pursuant to which Joseph Ziegler would
serve as our Principal Financial and Accounting Officer. On August 17, 2023 Michael C. Donegan notified us of his decision to resign from
the positions of Principal Financial and Accounting Officer of our Company effective as of August 17, 2023. Mr. Ziegler succeeded Mr.
Donegan as Principal Financial and Accounting Officer as of the date of Mr. Donegan&#x2019;s resignation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;vitaCare Divestiture&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On April 14, 2022, we completed the divestiture of our former subsidiary
vitaCare Prescription Services, Inc. (&#x201c;vitaCare&#x201d;) with the sale of all of vitaCare&#x2019;s issued and outstanding capital
stock (the &#x201c;vitaCare Divestiture&#x201d;). We received net proceeds of $142.6 million, after deducting transaction costs of $7.2
million, and we recognized a gain on sale of business of $143.4 million. Included in the net proceeds amount was $11.3 million of customary
holdbacks as provided in the stock purchase agreement (the &#x201c;Purchase Agreement&#x201d;) which we received in 2023. Additionally,
the Purchase Agreement provides that we may receive up to an additional $7.0 million in earn-out consideration, contingent upon vitaCare&#x2019;s
financial performance through 2023 as determined in accordance with the terms of the Purchase Agreement; however, we do not believe this
earnout will be realized. We will record the contingent consideration at the settlement amount if and when the consideration is realized
or realizable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Purchase Agreement contains customary representations and warranties,
covenants, and indemnities of the parties thereto. The commitments under a long-term services agreement related to vitaCare were transferred
to Mayne Pharma as part of the Mayne Transaction. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The divestiture of vitaCare was determined to be a component of discontinued
operations in December 2022, when we changed our business by becoming a royalty company and as a result vitaCare activities were reclassified
to discontinued operations for 2023 and 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Going concern&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On December 4, 2022, we entered into agreements with Mayne Pharma pursuant
to which we granted Mayne Pharma an exclusive license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products (in
the United States and its possessions and territories), (ii) assign to Mayne Pharma our exclusive license to commercialize ANNOVERA in
the United States and its possessions and territories, and (iii) sell certain other assets to Mayne Pharma.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The total consideration from Mayne Pharma to the TherapeuticsMD for
the purchase of the Transferred Assets under the Transaction Agreement and the grant of the licenses under the Mayne License Agreement
consisted of (i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million at closing for the acquisition
of net working capital subject to certain adjustments, (iii) a cash payment of approximately $1.0 million at closing for prepaid royalties
in connection with the Mayne License Agreement Amendment and (iv) the right to receive the contingent consideration set forth in the Mayne
License Agreement, as amended.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On the Closing Date, we repaid all obligations under the Financing
Agreement, dated as of April 24, 2019, as amended, with Sixth Street Specialty Lending, Inc., as administrative agent, the various lenders
from time-to-time party thereto, and certain of our subsidiaries party thereto from time to time as guarantors (the &#x201c;Financing Agreement&#x201d;)
and the Financing Agreement was terminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Following the transaction with Mayne Pharma, our primary source of
revenue is from royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories.
We may need to raise additional capital to provide additional liquidity to fund our operations until we become cash flow positive. To
address our capital needs, we may pursue various equity and debt financing and other alternatives. The equity financing alternatives may
include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders,
or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity
securities may be limited by market conditions, including the market price of our common stock, and our available authorized shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;To the extent that we raise additional capital through the sale of
such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include
liquidation or other preferences that adversely affect the rights of our existing stockholders. If we are not successful in obtaining
additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, or merge,
consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On May 1, 2023, we entered into a Subscription Agreement (the &#x201c;Subscription
Agreement&#x201d;) with Rubric Capital Management LP (&#x201c;Rubric&#x201d;), pursuant to which we agreed to sell to Rubric, or one or more
of its affiliates, up to an aggregate of 5,000,000 shares of our common stock, par value $0.001 per share (our &#x201c;Common Stock&#x201d;),
from time to time during the term of the Subscription Agreement in separate draw-downs at our election. On June 29, 2023, we issued and
sold 312,525 shares of Common Stock at a price per share equal to $3.6797 pursuant to the Subscription Agreement. We received gross proceeds
of $1.15 million from the draw down, before expenses. On November 15,
2023 Rubric drew down an additional 1,000,000 shares of Common Stock at a price per share equal to $2.28. We received gross proceeds of
$2.0 million from the drawdown, before expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In February 2024, the Company received Mayne Pharma&#x2019;s
                                                                         calculation of allowance for payer rebates and wholesale distributor fees which differed significantly from the Company&#x2019;s
                                                                         estimate of the allowances. The Company believes its estimated allowances for payer rebates and wholesale distributor fees are
                                                                         reasonable and intends to resolve this matter through the process outlined in the Transaction Agreement. Given the recent receipt of
                                                                         Mayne Pharma&#x2019;s allowance calculation and the nature of the estimates involved, the outcome of this matter is uncertain at this
                                                                         point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any
                                                                         additional liability associated with Mayne Pharma&#x2019;s allowance calculation for payer rebates and wholesale distributor
                                                                         fees.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2023, the Company believes no additional accrual
is required for amounts that may be owed for the allowance for returns under the Transaction Agreement. The Company has not recorded any
contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital
items as changes to estimated amounts owed or amounts due from Mayne Pharma that may be material.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;If Mayne Pharma&#x2019;s sales of IMVEXXY, BIJUVA, or ANNOVERA
grow more slowly than expected or decline, if the net working capital settlement with Mayne Pharma under the Transaction Agreement
is greater than our current estimates, if we are unsuccessful with future financings or if the supply chains related to the
third-party contract manufacturers are worse than we anticipate, our existing cash reserves may be insufficient to satisfy our
liquidity requirements. The potential impact of these factors in conjunction with the uncertainty of the capital markets raises
substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial
statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The accompanying consolidated financial statements do not include any
adjustments that might be necessary if we are unable to continue as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;A.&#160;Basis of presentation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The consolidated financial statements and related notes include our
parent company and all wholly owned subsidiaries. The consolidated financial statements are prepared in accordance with accounting principles
generally accepted in the Unites States of America (&#x201c;U.S. GAAP&#x201d;). Our fiscal year-end is as of and for the year ended December
31st for each year presented. All intercompany transactions among our businesses have been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As part of the transformation and as a result of the vitaCare divestiture
and the Mayne Transaction, historical results of commercial operations for all periods prior to the Closing Date have been reflected as
discontinued operations in the consolidated financial statements. Assets and liabilities associated with the commercial business are classified
as assets and liabilities of discontinued operations in the consolidated balance sheet. Additional disclosures regarding discontinued
operations are provided in Note 2 of these consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Certain amounts in the notes to the consolidated financial statements
may not add due to rounding. Certain prior period amounts have been reclassified to conform to current-period presentation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;B.&#160;New accounting standards&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Adoption of new accounting standards&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
issued ASU 2023-09, &#x201c;Income Taxes (Topic 740) - Improvements to Income Tax Disclosures.&#x201d; ASU 2023-09 enhances the transparency
and decision usefulness of income tax disclosures by requiring consistent categories and greater disaggregation of information in the
rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 will be effective for the Company in its income tax
disclosure included in its 2025 Annual Report on Form 10-K and will be applied on a prospective basis. However, retrospective application
is permitted. Early adoption is also permitted. The Company is evaluating the impact of ASU 2023-09 on the Company's income tax disclosures
and on its consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;C. Discontinued Operations&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Discontinued operations comprise activities that were disposed of at
the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting
purposes and represent a business shift having a major effect on the Company&#x2019;s operations and financial results according to Accounting
Standard Codification (&#x201c;ASC&#x201d;) Topic 205, Presentation of Financial Statements. An adjustment has been made to the consolidated
statements of operations for the twelve months ended December 31, 2023 and 2022 to reclassify commercial activities and vitaCare activities
to discontinued operations as both components, in the aggregate, represented a business shift that will have a major effect on the Company&#x2019;s
operations and financial results. No amounts for shared general and administrative operating support expense were allocated to discontinued
operations. As required by the terms of the Financing Agreement, the proceeds from both transactions were used to fully repay our outstanding
debt borrowings. As a result, interest expense and amortization of deferred financing costs as well as expense for accretion of Series
A Preferred Stock and loss on extinguishment of debt are included within income (loss) from discontinued operations, net of tax. Additionally,
the related assets and liabilities have been reported as assets and liabilities of discontinued operations in the Company&#x2019;s consolidated
balance sheet as of December 31, 2023 and 2022. For additional information, see Note 2 - Discontinued Operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;D. Estimates and assumptions&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The preparation of consolidated financial statements in conformity
to U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the
reporting period. We evaluate our estimated assumptions based on historical experience and on various other assumptions that are believed
to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different
assumptions or conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;E. Cash and Restricted Cash&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;For the purpose of the statements of cash flows, all highly liquid
investments with an original maturity of three months or less are considered to be&#160;cash&#160;equivalents. The carrying value of these
investments approximates fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We maintain cash at financial institutions that at times may exceed
the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limits of $0.25 million per bank. We have never experienced any
losses related to these funds.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Restricted cash was comprised of escrowed funds deposited with a bank
relating to the vitaCare Divestiture. All restrictions were lifted in March 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;F.&lt;/b&gt;&#160;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Fair value is the price to sell an asset or transfer a liability and
therefore represents an exit price in the principal market (or in the absence of a principal market, the most advantageous market). It
represents a market-based measurement that contemplates a hypothetical transaction between market participants at the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The unique characteristics of an asset or liability and the availability
of observable prices affect the number of valuation approaches and/or techniques used in a fair value analysis. We measure fair value
using observable and unobservable inputs. We give the highest priority to quoted prices (unadjusted) in active markets for identical assets
or liabilities (Level 1 inputs) and the lowest priority to unobservable inputs (Level 3 inputs).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We apply the following fair value hierarchy:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: left"&gt;Level 1 - Quoted prices (unadjusted) in active markets for
identical assets and liabilities.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: left"&gt;Level 2 - Quoted prices in non-active markets or in active
markets for similar assets or liabilities, observable inputs other than quoted prices; and inputs that are not directly observable but
are corroborated by observable market data.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: left"&gt;Level 3 - Inputs that are unobservable.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The carrying amount of our cash, restricted cash, accounts receivable,
accounts payable and accrued expenses approximate their fair value because of the short-term maturity of such instruments, which are considered
Level 1 under the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;G.&#160;Fixed assets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Fixed assets are carried at cost less accumulated depreciation and
amortization. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs
to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related
assets, which range from three to seven years. Leasehold improvements are depreciated over the shorter of their useful life or the term
of the lease. Long-lived assets held and used by us, including fixed assets, are assessed for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We capitalize software and software development costs incurred to create
and acquire computer software for internal use, principally related to software coding and application development. We begin to capitalize
software development costs when both the preliminary project stage is completed, and it is probable that the software will be used as
intended. Capitalized software costs include only external direct costs and services utilized in developing or obtaining computer software.
Capitalized software costs are amortized on a straight-line basis when placed into service over the estimated useful life, generally five
to seven years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;H.&#160;License rights and other
intangibles assets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We record license rights and other intangible assets at cost, which
includes external costs, consisting primary of legal costs, incurred in securing our patents and trademarks.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;License rights costs related to ANNOVERA were amortized until December
30, 2022 over the useful life over which the license rights would contribute directly or indirectly to our cash flows. The cost was amortized
using the straight-line method as the pattern of economic benefit could not be reliably determined. On December 30, 2022, we assigned
our ANNOVERA license to Mayne Pharma and included the remaining ANNOVERA license cost of $30.2 million in our calculation of the gain
on sale of assets. In addition, amortization of license rights of $3.0 million for 2022 was reclassified to discontinued operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Intangible assets subject to amortization, such as patents, are amortized
over the useful life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs
at that time. Intangible assets not subject to amortization, such as trademarks, are perpetual and have indefinite lives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We review license rights and other intangible assets subject to amortization
on a periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision to their remaining useful
lives. We assess other intangible assets not subject to amortization for potential impairment at least annually during the fourth quarter
of each year, or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the
intangible assets below their carrying value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;I.&lt;/b&gt;&#160;&lt;b&gt;Segment reporting&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We manage and operate as one business, which prior to December 2022
was focused on creating and commercializing products targeted exclusively for women and after we signed Mayne License Agreement, is focused
on collecting royalties from licensing our products. Our business is led by our chief executive officer. We do not operate separate lines
of business with respect to any of our products, and we do not prepare discrete financial information with respect to separate products.
Accordingly, we view our business as one reportable operating segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;J.&#160;Revenue recognition&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We determine the amount of revenue to be recognized through application
of the following steps:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18.6pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;Identification of the contract with a customer;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18.6pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;Identification of the performance obligations in the contract;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18.6pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;Determination of the transaction price;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18.6pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;Allocation of the transaction price to the performance obligations in the contract; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18.6pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;Recognition of revenue when or as we satisfy the performance obligations.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;A performance obligation is a promise in a contract to transfer a product
or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains
control, and we treat shipping as a fulfillment activity rather than as a separate obligation. We generally recognize revenue at a point
in time when all of our performance obligations under the terms of a contract are satisfied. Revenue is recognized upon transfer of control
of promised products or services in an amount that reflects the consideration we expect to receive in exchange for those products or services.
The collectability of consideration on the contract is reasonably assured before revenue is recognized. To the extent that customer payment
has been received before all recognition criteria are met, these revenues are initially deferred in other accruals on the balance sheet
and the revenue is recognized in the period that all recognition criteria have been met.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;License revenue&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;License arrangements may consist of non-refundable upfront license
fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones and future product
royalty payments. Some of these arrangements may include multiple performance obligations. Non-refundable up-front fees that are not contingent
on any future performance by us, and do not require continuing involvement on our part, are recognized as revenue when the right to use
functional intellectual property is transferred to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On December 30, 2022, we granted an exclusive license to commercialize
our prescription products and assigning the Company&#x2019;s exclusive license to commercialize ANNOVERA to Mayne Pharma, which resulted
in a business shift that had a major effect on our operations and financial results. As part of the transformation that included the Mayne
License Agreement, historical results of commercial operations have been reflected as discontinued operations in the Company&#x2019;s consolidated
financial statements for all periods prior to the Closing Date. As of December 31, 2022, we are no longer directly engaged in the sale
of prescription products.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Under the terms of the Mayne License Agreement, we received $140 million
at closing and we are eligible to receive additional payments in the aggregate of up to an additional $30 million, based on the achievement
of sales milestones (collectively, the &#x201c;Milestone Amounts&#x201d;). The proceeds at closing were allocated between consideration
for the sale of ANNOVERA and the initial license fee for the Licensed Products, as the sale of ANNOVERA was accounted for under ASC 610-20,
Gains and Losses from Derecognition of Nonfinancial Assets in arriving at the gain on disposal (see Note 2), while the license grant of
the other products were recognized under the provisions of ASC 606, Revenue from Contracts with Customers, as a license of functional
intellectual property. The proceeds were allocated among the Licensed Products on the relative net present value of forecasted future
product sales from those products. The Milestone Amounts will be recognized, as applicable, in subsequent periods based on actual product
sales that exceed the respective net sales milestones as such variable consideration is constrained by the occurrence of the subsequent
sales.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Our royalty revenue in 2023 primarily related to royalties provided
for under the Mayne License Agreement based on Mayne Pharma&#x2019;s sales of the licensed products subject to that agreement. Under the
Mayne License Agreement, the Company is entitled to earn royalties on net sales of all of the Licensed Products at a royalty rate of (i)
8% on the first $80 million of net sales of the Licensed Products and (ii) 7.5% on net sales of all of the Licensed Products after the
first $80 million of net sales. The royalty rate is subject to a 2% reduction upon the earlier to occur of (i) the expiration or revocation
of the last valid claim covering a Licensed Product, and (ii) a generic product launch (a &#x201c;LOE&#x201d;). We are entitled to minimum
annual royalties beginning with the year ending December 31, 2023 ($3 million annual minimum) and continuing with 3% annual increases
through the year ending December 31, 2034 (the &#x201c;Minimum Annual Royalty&#x201d;). The total Minimum Annual Royalty we are entitled
to is $42.6 million, and this total amount was allocated among the Licensed Products on the relative net present value of forecasted future
product sales from those products. The portion allocated to consideration for the sale of ANNOVERA was attributed towards the gain on
disposal of that asset. For the remaining portion allocated to the license grants for the other products, we determined that the minimum
guarantee underlying the Minimum Annual Royalty should be treated as fixed consideration and recognized under ASC 606 at the point in
time when the license was transferred. Since the Minimum Annual Royalty will be received in annual installments through 2034, we determined
the transaction price allocated under ASC 606 contained a significant financing component, and we therefore determined the initial royalty
revenue and corresponding receivable based on the present value of the allocated Minimum Annual Royalty. The present value was calculated
using a discount rate of 10.45%, based on the credit characteristics of Mayne Pharma and the timing of future payments, and the value
will be accreted to full value through the earlier of January 1, 2034 or a LOE. This royalty receivable is a contract asset as of December
31, 2022 and 2023, and is further subject to offset by Mayne Pharma (see L. Contract Assets and Liabilities below).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Royalty revenue earned in excess of the Minimum Annual Royalty will
be recognized under ASC 606, which provides revenue recognition constraints by requiring the recognition of revenue at the later of the
following: 1) when the subsequent sale occurs or 2) when the performance obligation to which some or all of the sales-based royalty has
been allocated has been satisfied (or partially satisfied). We applied the royalty recognition constraint required under the guidance
for sales-based royalties, which requires a sales-based royalty to be recorded no sooner than the underlying sale. Therefore, royalties
on sales of products commercialized by Mayne Pharma will be recognized in the subsequent periods that the Licensed Products are sold.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In 2023, we recorded BIJUVA license sales of $0.3 million made through
the Theramex License Agreement and $1.0 million pertaining to our licensed products with Mayne Pharma, which was recognized as license
revenue. Additionally, we recognized $0.5 million in other income pertaining to royalty sales of ANNOVERA.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;K.&lt;/b&gt;&#160;&lt;b&gt;Cost of revenue&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Cost of revenue includes the cost of inventory, manufacturing, manufacturing
overhead and supply chain costs and product shipping and handling costs. Costs related to the Population Council License Agreement, which
were based on our net sales of ANNOVERA, and amortization of license rights were reclassified to discontinued operations for 2022 as a
result of the transaction with Mayne Pharma.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;L.&#160;Contract Assets and
Liabilities&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Contract assets totaling $21.6 million as of December 31, 2023, include
royalties recognized from the Minimum Annual Royalty (see J. Revenue Recognition above).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;M.&#160;Share-based payment
awards&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We account for share-based payment awards on a fair value basis of
the equity instrument issued. Under fair value accounting, the grant-date fair value of the share-based payment award is amortized as
compensation expense, on a straight-line basis, over the service period (generally, the vesting period) for both graded and cliff vesting
awards. We have elected to account for forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Common stock reverse stock split&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On May 6, 2022, we completed a reverse stock split of our Common Stock.
As a result, shares of our outstanding Common Stock were split at a ratio of 50-for-1 (the &#x201c;Reverse Stock Split&#x201d;) with any
fractional shares resulting from the Reserve Stock Split rounded up to the next whole share of Common Stock. The number of authorized
shares of Common Stock was also correspondingly reduced from 600.0 million shares to 12.0 million shares to give effect to the Reverse
Stock Split. Additionally, all rights to receive shares of Common Stock under outstanding warrants, options, restricted stock units (&#x201c;RSUs&#x201d;)
and performance stock units (&#x201c;PSUs&#x201d;) were adjusted to give effect of the Reverse Stock Split. Furthermore, remaining shares
of Common Stock available for future issuance under share-based payment award plans and our employee stock purchase plan were adjusted
to give effect of the Reverse Stock Split. Pursuant to Section 78.209 of the Nevada Revised Statutes, the approval of our stockholders
was not required for our Board of Directors (the &#x201c;Board&#x201d;) to effectuate the Reverse Stock Split.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;All historical numbers of shares of Common Stock and per share data
have been adjusted to give effect to the Reverse Stock Split. Additionally, since the Common Stock par value was unchanged, historical
amounts for Common Stock and additional paid-in capital have been adjusted to give effect to the Reverse Stock Split.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Increase of authorized shares&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On June 26, 2023, at our combined 2022 and 2023 Annual Meeting, our
stockholders approved an amendment to our Amended and Restated Articles of Incorporation to increase the number of authorized shares of
Common Stock from 12 million shares to 32 million shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;N.&#160;Income taxes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Income taxes are accounted for under the asset and liability method.
Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and income
tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in income tax rates is recorded as a component of the income tax provision in the period that includes the enactment
date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Regular assessments are made on the likelihood that our deferred tax
assets will be recovered from our future taxable income. Our evaluation is based on estimates, assumptions, and includes an analysis of
available positive and negative evidence, giving weight based on the evidence&#x2019;s relative objectivity. Sources of positive evidence
include estimates of future taxable income, future reversal of existing taxable temporary differences, taxable income in carryback years,
and available tax planning strategies. Sources of negative evidence include current and cumulative losses in recent years, losses expected
in early future years, any history of operating losses or tax credit carryforwards expiring unused, and unsettled circumstances that,
if unfavorably resolved, would adversely affect future profit levels.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The remaining carrying value of our deferred tax assets, after recording
the valuation allowance on our deferred tax assets, is based on our present belief that it is more likely than not that we will be able
to generate sufficient future taxable income to utilize such deferred tax assets. The amount of the remaining deferred tax assets considered
recoverable could be adjusted if our estimates of future taxable income during the carryforward period change favorably or unfavorably.
To the extent we believe that it is more likely than not that some or all the remaining deferred tax assets will not be realized, we must
establish a valuation allowance against those deferred tax assets, resulting in additional income tax expense in the period such determination
is made. To the extent a valuation allowance currently exists, we will continue to monitor all positive and negative evidence until we
believe it is more likely than not that it is no longer necessary, resulting in an income tax benefit in the period such determination
is made.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Our policy is to recognize both interest and penalties related to uncertain
tax positions as part of the income tax provision. Significant judgment is required in evaluating our tax positions, and in determining
our provisions for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred
tax assets. We establish reserves when, despite our belief that the income tax return positions are fully supportable, certain positions
are likely to be challenged and we may ultimately not prevail in defending those positions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;O.&#160;Earnings per common
share&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basic earnings or loss per common share is computed by dividing net
income or loss available to common stockholders by the sum of the weighted average number of shares of common stock. Diluted earnings
per common share is computed by dividing net income available to common stockholders by the sum of the weighted average number of shares
of common stock and the number of additional shares of common stock that would have been outstanding if our outstanding potentially dilutive
securities had been issued. Potentially dilutive securities include awards of non-vested or vested and not settled restricted stock units,
performance stock units where the performance requirements have been met and not settled, warrants and options. The dilutive effect of
potentially dilutive securities is reflected in diluted earnings per common share by application of the treasury stock method, except
if its impact is anti-dilutive. Under the treasury stock method, an increase in the fair market value of our common stock can result in
a greater dilutive effect from potentially dilutive securities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;P.&#160;Leases&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We determine if an arrangement is a lease at inception. Determining
whether a contract contains a lease includes judgment regarding whether the contract conveys the right to control the use of identified
property or equipment for a period of time in exchange for consideration.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We account for our lease-related assets and liabilities based on their
classification as operating leases or finance leases, following the relevant accounting guidance. For all the lessee arrangements, we
have elected an accounting policy to combine non-lease components with the related-lease components and treat the combined items as a
lease for accounting purposes. We measure lease related assets and liabilities based on the present value of lease payments, including
in-substance fixed payments, variable payments that depend on an index or rate measured at the commencement date, and the amount we believe
is probable we will pay the lessor under residual value guarantees when applicable. We discount lease payments based on our estimated
incremental borrowing rate at lease commencement (or modification), which is primarily based on our estimated credit rating, the lease
term at commencement, and the contract currency of the lease arrangement. We have elected to exclude short-term leases (leases with an
original lease term less than one year) from the measurement of lease-related assets and liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We test right-of-use assets in an operating or finance lease at the asset group level (because these assets are long-lived nonfinancial
assets and should be accounted for the same way as other long-lived nonfinancial assets) whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We sublease our unoccupied facilities to third parties. Any impairment
to the associated right-of-use asset, leasehold improvements, or other assets as a result of the sublease is recognized in the period
when a decision to sublease is made and recorded in our consolidated statement of operations. We recognize sublease income on a straight-line
basis over the sublease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Q.&#160;Loss Contingencies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In determining whether an accrual for a loss contingency is required,
we first assess the likelihood of occurrence of the future event or events that will confirm the loss. When a loss is probable (the future
event or events are likely to occur) and the amount of the loss can be reasonably estimated, the estimated loss is accrued. If the reasonable
estimate of the loss is a range and an amount within the range appears to be a better estimate than any other amount within the range,
that amount should be accrued. However, if no amount within the range is a better estimate, the minimum amount in the range should be
accrued. When a loss is reasonably possible (the chance of the future event or events occurring is more than remote but less than likely),
no accrual is recognized. See Note 8 for more information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;R.&#160;Restructuring charges&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the year ended December 31, 2022, the Company initiated and
completed a restructuring plan that resulted in a reduction of its workforce to one employee. One-time termination benefits include severance,
continuation of health insurance coverage, and other benefits for a specified period of time, as well as contract terminations and fixed
assets write-downs, which resulted in $15.7 million of restructuring costs for the year ended December 31, 2022. There were no restructuring
costs incurred during the year ended December 31, 2023. Restructuring costs have been recognized in the accompanying consolidated statement
of operations as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Executive termination benefits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,897&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Consulting and legal expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other contract termination costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,515&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total restructuring expenses - general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,472&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Employee termination benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other contract termination costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,367&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total restructuring expenses - discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At December 31, 2023 and 2022 respectively, $2.5 million and $6.2 million
of restructuring costs were included in current liabilities of discontinued operations in the accompanying consolidated balance sheets.
At December 31, 2022, $9.3 million related to restructuring costs was included in accrued expenses and other current liabilities.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;S. Reclassification of prior year presentation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Certain prior year amounts have been reclassified for consistency with
the current year presentation.&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <txmd:GeneralInformationPolicyTextBlock contextRef="c0" id="ixv-7346">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;General&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;TherapeuticsMD, Inc. (the &#x201c;Company&#x201d;), a Nevada
corporation, and its consolidated subsidiaries are referred to collectively in this Annual Report on Form 10-K (&#x201c;2023 10-K
Report&#x201d;) as &#x201c;TherapeuticsMD,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; and &#x201c;us.&#x201d; This 2023 10-K Report
includes trademarks, trade names and service marks, such as TherapeuticsMD&lt;sup&gt;&#xae;&lt;/sup&gt;, vitaMedMD&lt;sup&gt;&#xae;&lt;/sup&gt;,
BocaGreenMD&lt;sup&gt;&#xae;&lt;/sup&gt;, vitaCareTM, IMVEXXY&lt;sup&gt;&#xae;&lt;/sup&gt;, and BIJUVA&lt;sup&gt;&#xae;&lt;/sup&gt;, which are protected under applicable
intellectual property laws and are the property of, or licensed by or to, us. Solely for convenience, trademarks, trade names and
service marks referred to in this 2023 10-K Report may appear without the &lt;sup&gt;&#xae;&lt;/sup&gt;, TM or SM symbols, but such references
are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the
right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other
parties&#x2019; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a
relationship with, or endorsement or sponsorship of us by, these other parties.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;TherapeuticsMD was previously a women&#x2019;s healthcare company with
a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause.
In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed
to pharmaceutical organizations that possess commercial capabilities in the relevant territories. On December 30, 2022 (the &#x201c;Closing
Date&#x201d;), we completed a transaction (the &#x201c;Mayne Transaction&#x201d;) with Mayne Pharma LLC, a Delaware limited liability company
(&#x201c;Mayne Pharma&#x201d;) and subsidiary of Mayne Pharma Group Limited, an Australian public company, in which we and our subsidiaries
(i) granted Mayne Pharma an exclusive license to commercialize our IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under
the BocaGreenMD and vitaMedMD brands (collectively, the &#x201c;Licensed Products&#x201d;) in the United States and its possessions and
territories, (ii) assigned to Mayne Pharma our exclusive license to commercialize ANNOVERA&lt;sup&gt;&#xae;&lt;/sup&gt; (together with the Licensed
Products, collectively, the &#x201c;Products&#x201d;) in the United States and its possessions and territories, and (iii) sold certain
other assets to Mayne Pharma in connection therewith.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In a License Agreement, dated December 4, 2022, between TherapeuticsMD
and Mayne Pharma (the &#x201c;Mayne License Agreement&#x201d;), we granted Mayne Pharma, on the Closing Date, (i) an exclusive, sublicensable,
perpetual, irrevocable license to research, develop, register, manufacture, have manufactured, market, sell, use, and commercialize the
Licensed Products in the United States and its possessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable
license to manufacture, have manufactured, import and have imported the Licensed Products outside the United States for commercialization
in the United States and its possessions and territories.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Under the Mayne License Agreement, Mayne Pharma will pay us
one-time milestone payments of each of (i) $5.0 million if aggregate net sales of all Products in the United States during a
calendar year reach $100.0 million, (ii) $10.0 million if aggregate net sales of all Products in the United States during a calendar
year reach $200.0 million and (iii) $15.0 million if aggregate net sales of all Products in the United States during a calendar year
reach $300.0 million. Further, Mayne Pharma will pay us royalties on net sales of all Products in the United States at a royalty
rate of 8.0% on the first $80.0 million in annual net sales and 7.5% on annual net sales above $80.0 million, subject to certain
adjustments, for a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product
basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version
of a Product launching in the United States. Mayne Pharma will pay us minimum annual royalties of $3.0 million per year for 12
years, adjusted for inflation at an annual rate of 3%, subject to certain further adjustments, including as described below. Upon
the expiry of the 20-year royalty term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully
paid-up and royalty free license for the Licensed Products.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Under the Transaction Agreement, dated December 4, 2022, between TherapeuticsMD
and Mayne Pharma (the &#x201c;Transaction Agreement&#x201d;), we sold to Mayne Pharma, at closing, certain assets for Mayne Pharma to commercialize
the Products in the United States, including, with the Population Council&#x2019;s consent, our exclusive license from the Population Council
to commercialize ANNOVERA (the &#x201c;Transferred Assets&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The total consideration from Mayne Pharma to TherapeuticsMD for
the purchase of the Transferred Assets under the Transaction Agreement and the grant of the licenses under the Mayne License
Agreement was (i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million at closing for the
acquisition of net working capital as determined in accordance with the Transaction Agreement and subject to certain adjustments,
(iii) a cash payment of approximately $1.0 million at closing for prepaid royalties in connection with the Mayne License Agreement
Amendment (as defined below) and (iv) the right to receive the contingent consideration set forth in the Mayne License Agreement, as
amended. The acquisition of net working capital was determined in accordance with the Transaction Agreement and included significant
estimates which could change materially for a period of up to two years following the Closing Date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On the Closing Date, TherapeuticsMD and Mayne Pharma entered into Amendment
No. 1 to the Mayne License Agreement (the &#x201c;Mayne License Agreement Amendment&#x201d;). Pursuant to the Mayne License Agreement Amendment,
Mayne Pharma agreed to pay us approximately $1.0 million in prepaid royalties on the Closing Date. The prepaid royalties reduced the first
four quarterly payments that would have otherwise been payable pursuant to the Mayne License Agreement by an amount equal to $257 thousand
per quarterly royalty payment plus interest calculated at 19% per annum accruing from the Closing Date until the date such quarterly royalty
payment was paid to us. We and Mayne Pharma settled the $1.5 million of consideration due to Mayne for the assumed obligations under a
long-term services agreement (see the section entitled &#x201c;vitaCare Divestiture&#x201d; below for a discussion of the long-term services
agreement), including our minimum payment obligations thereunder. As the parties agreed, during the second quarter of 2023, Mayne Parma
held back our royalty payment of $0.6 million and we funded an additional $0.9 million in August 2023 to settle the original $1.5 million
payable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As part of the transformation that included the Mayne License Agreement,
historical results of commercial operations for all periods prior to the Closing Date have been reflected as discontinued operations in
our consolidated financial statements. Assets and liabilities associated with the commercial business are classified as assets and liabilities
of discontinued operations in our consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in
Note 2.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We also have license agreements with strategic partners to commercialize
IMVEXXY and BIJUVA outside of the U.S.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: left"&gt;In July 2018, we entered into a license and supply agreement
(the &#x201c;Knight License Agreement&#x201d;) with Knight Therapeutics Inc. (&#x201c;Knight&#x201d;) pursuant to which we granted Knight
an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="text-align: left; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            September 2019, we entered into an exclusive license and supply agreement (the &#x201c;Theramex
                                            License Agreement&#x201d;) with Theramex HQ UK Limited (&#x201c;Theramex&#x201d;) to commercialize
                                            IMVEXXY and BIJUVA outside of the U.S., excluding Canada and Israel. In 2021, Theramex secured
                                            regulatory approval for BIJUVA in certain European countries and began commercialization
                                            efforts in those countries.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In connection with our transformation into a pharmaceutical royalty
company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief
Executive Officer) and all other employees was completed by December 31, 2022. Severance obligations for all employees other than executive
officers were paid in full in January 2023 and severance obligations for terminated executive officers were paid in accordance with their
employment agreements and separation agreements as previously disclosed. As of December 31, 2022 and 2023, we employed one full-time employee
primarily engaged in an executive position.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We have engaged external consultants who support our relationship with
current partners and assist with certain financial, legal, and regulatory matters and the continued wind-down of our historical business
operations. On August 15, 2023, we entered into a master services agreement with JZ Advisory Group, pursuant to which Joseph Ziegler would
serve as our Principal Financial and Accounting Officer. On August 17, 2023 Michael C. Donegan notified us of his decision to resign from
the positions of Principal Financial and Accounting Officer of our Company effective as of August 17, 2023. Mr. Ziegler succeeded Mr.
Donegan as Principal Financial and Accounting Officer as of the date of Mr. Donegan&#x2019;s resignation.&lt;/p&gt;</txmd:GeneralInformationPolicyTextBlock>
    <txmd:OneTimeMilestonePayments contextRef="c25" decimals="-5" id="ixv-11081" unitRef="usd">5000000</txmd:OneTimeMilestonePayments>
    <txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment
      contextRef="c25"
      decimals="INF"
      id="ixv-11082"
      unitRef="usd">100000000</txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment>
    <txmd:OneTimeMilestonePayments contextRef="c26" decimals="-5" id="ixv-11083" unitRef="usd">10000000</txmd:OneTimeMilestonePayments>
    <txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment
      contextRef="c26"
      decimals="INF"
      id="ixv-11084"
      unitRef="usd">200000000</txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment>
    <txmd:OneTimeMilestonePayments contextRef="c27" decimals="-5" id="ixv-11085" unitRef="usd">15000000</txmd:OneTimeMilestonePayments>
    <txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment
      contextRef="c27"
      decimals="INF"
      id="ixv-11086"
      unitRef="usd">300000000</txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment>
    <txmd:RoyaltyRateAsPercentageOnNetSales contextRef="c28" decimals="3" id="ixv-11087" unitRef="pure">0.08</txmd:RoyaltyRateAsPercentageOnNetSales>
    <txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate
      contextRef="c29"
      decimals="INF"
      id="ixv-11088"
      unitRef="usd">80000000</txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate>
    <txmd:RoyaltyRateAsPercentageOnNetSales contextRef="c29" decimals="3" id="ixv-11089" unitRef="pure">0.075</txmd:RoyaltyRateAsPercentageOnNetSales>
    <txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate
      contextRef="c28"
      decimals="INF"
      id="ixv-11090"
      unitRef="usd">80000000</txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate>
    <txmd:TermOfRoyaltyPayments contextRef="c0" id="ixv-11091">P20Y</txmd:TermOfRoyaltyPayments>
    <txmd:DecreaseInRoyaltyRateOnProductByProductBasis contextRef="c30" decimals="3" id="ixv-11092" unitRef="pure">0.02</txmd:DecreaseInRoyaltyRateOnProductByProductBasis>
    <txmd:MinimumAnnualRoyaltyPayment contextRef="c30" decimals="-5" id="ixv-11093" unitRef="usd">3000000</txmd:MinimumAnnualRoyaltyPayment>
    <txmd:PeriodOfMinimumAnnualRoyaltyPayment contextRef="c30" id="ixv-11094">P12Y</txmd:PeriodOfMinimumAnnualRoyaltyPayment>
    <txmd:InflationRateAdjustedForMinimalAnnualRoyaltyPayment contextRef="c30" decimals="2" id="ixv-11095" unitRef="pure">0.03</txmd:InflationRateAdjustedForMinimalAnnualRoyaltyPayment>
    <txmd:TermOfRoyaltyPayments contextRef="c30" id="ixv-11096">P20Y</txmd:TermOfRoyaltyPayments>
    <txmd:PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment contextRef="c0" decimals="-5" id="ixv-11097" unitRef="usd">140000000</txmd:PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment>
    <txmd:PaymentsToAcquireNetWorkingCapital contextRef="c0" decimals="-5" id="ixv-11098" unitRef="usd">12100000</txmd:PaymentsToAcquireNetWorkingCapital>
    <us-gaap:ProceedsFromRoyaltiesReceived contextRef="c0" decimals="-5" id="ixv-11099" unitRef="usd">1000000</us-gaap:ProceedsFromRoyaltiesReceived>
    <txmd:PrepaidRoyaltyLiabilities contextRef="c31" decimals="-5" id="ixv-11100" unitRef="usd">1000000</txmd:PrepaidRoyaltyLiabilities>
    <txmd:QuarterlyRoyaltyPayment contextRef="c0" decimals="0" id="ixv-11101" unitRef="usd">257</txmd:QuarterlyRoyaltyPayment>
    <txmd:QuarterlyRoyaltyInterest contextRef="c0" decimals="2" id="ixv-11102" unitRef="pure">0.19</txmd:QuarterlyRoyaltyInterest>
    <txmd:RoyaltyPaymentPayableUnderLongTermServiceAgreement contextRef="c30" decimals="-5" id="ixv-11103" unitRef="usd">1500000</txmd:RoyaltyPaymentPayableUnderLongTermServiceAgreement>
    <txmd:RoyaltyPayment contextRef="c32" decimals="-5" id="ixv-11104" unitRef="usd">600000</txmd:RoyaltyPayment>
    <txmd:AdditionalFund contextRef="c33" decimals="-5" id="ixv-11105" unitRef="usd">900000</txmd:AdditionalFund>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="c34" decimals="-5" id="ixv-11106" unitRef="usd">1500000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <txmd:DivestitureOfBusinessPolicyPolicyTextBlock contextRef="c0" id="ixv-7421">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;vitaCare Divestiture&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On April 14, 2022, we completed the divestiture of our former subsidiary
vitaCare Prescription Services, Inc. (&#x201c;vitaCare&#x201d;) with the sale of all of vitaCare&#x2019;s issued and outstanding capital
stock (the &#x201c;vitaCare Divestiture&#x201d;). We received net proceeds of $142.6 million, after deducting transaction costs of $7.2
million, and we recognized a gain on sale of business of $143.4 million. Included in the net proceeds amount was $11.3 million of customary
holdbacks as provided in the stock purchase agreement (the &#x201c;Purchase Agreement&#x201d;) which we received in 2023. Additionally,
the Purchase Agreement provides that we may receive up to an additional $7.0 million in earn-out consideration, contingent upon vitaCare&#x2019;s
financial performance through 2023 as determined in accordance with the terms of the Purchase Agreement; however, we do not believe this
earnout will be realized. We will record the contingent consideration at the settlement amount if and when the consideration is realized
or realizable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Purchase Agreement contains customary representations and warranties,
covenants, and indemnities of the parties thereto. The commitments under a long-term services agreement related to vitaCare were transferred
to Mayne Pharma as part of the Mayne Transaction. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The divestiture of vitaCare was determined to be a component of discontinued
operations in December 2022, when we changed our business by becoming a royalty company and as a result vitaCare activities were reclassified
to discontinued operations for 2023 and 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</txmd:DivestitureOfBusinessPolicyPolicyTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c35" decimals="-5" id="ixv-11107" unitRef="usd">142600000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <txmd:TransactionCostsRelatedToDivestitureOfBusiness contextRef="c35" decimals="-5" id="ixv-11108" unitRef="usd">7200000</txmd:TransactionCostsRelatedToDivestitureOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c35" decimals="-5" id="ixv-11109" unitRef="usd">143400000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:RestrictedCashCurrent contextRef="c36" decimals="-5" id="ixv-11110" unitRef="usd">11300000</us-gaap:RestrictedCashCurrent>
    <txmd:ContingentCashConsiderationFromSaleOfBusiness contextRef="c37" decimals="-5" id="ixv-11111" unitRef="usd">7000000</txmd:ContingentCashConsiderationFromSaleOfBusiness>
    <txmd:GoingConcernPolicyTextBlock contextRef="c0" id="ixv-7449">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Going concern&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On December 4, 2022, we entered into agreements with Mayne Pharma pursuant
to which we granted Mayne Pharma an exclusive license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products (in
the United States and its possessions and territories), (ii) assign to Mayne Pharma our exclusive license to commercialize ANNOVERA in
the United States and its possessions and territories, and (iii) sell certain other assets to Mayne Pharma.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The total consideration from Mayne Pharma to the TherapeuticsMD for
the purchase of the Transferred Assets under the Transaction Agreement and the grant of the licenses under the Mayne License Agreement
consisted of (i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million at closing for the acquisition
of net working capital subject to certain adjustments, (iii) a cash payment of approximately $1.0 million at closing for prepaid royalties
in connection with the Mayne License Agreement Amendment and (iv) the right to receive the contingent consideration set forth in the Mayne
License Agreement, as amended.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On the Closing Date, we repaid all obligations under the Financing
Agreement, dated as of April 24, 2019, as amended, with Sixth Street Specialty Lending, Inc., as administrative agent, the various lenders
from time-to-time party thereto, and certain of our subsidiaries party thereto from time to time as guarantors (the &#x201c;Financing Agreement&#x201d;)
and the Financing Agreement was terminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Following the transaction with Mayne Pharma, our primary source of
revenue is from royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories.
We may need to raise additional capital to provide additional liquidity to fund our operations until we become cash flow positive. To
address our capital needs, we may pursue various equity and debt financing and other alternatives. The equity financing alternatives may
include the private placement of equity, equity-linked, or other similar instruments or obligations with one or more investors, lenders,
or other institutional counterparties or an underwritten public equity or equity-linked securities offering. Our ability to sell equity
securities may be limited by market conditions, including the market price of our common stock, and our available authorized shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;To the extent that we raise additional capital through the sale of
such securities, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include
liquidation or other preferences that adversely affect the rights of our existing stockholders. If we are not successful in obtaining
additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, or merge,
consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On May 1, 2023, we entered into a Subscription Agreement (the &#x201c;Subscription
Agreement&#x201d;) with Rubric Capital Management LP (&#x201c;Rubric&#x201d;), pursuant to which we agreed to sell to Rubric, or one or more
of its affiliates, up to an aggregate of 5,000,000 shares of our common stock, par value $0.001 per share (our &#x201c;Common Stock&#x201d;),
from time to time during the term of the Subscription Agreement in separate draw-downs at our election. On June 29, 2023, we issued and
sold 312,525 shares of Common Stock at a price per share equal to $3.6797 pursuant to the Subscription Agreement. We received gross proceeds
of $1.15 million from the draw down, before expenses. On November 15,
2023 Rubric drew down an additional 1,000,000 shares of Common Stock at a price per share equal to $2.28. We received gross proceeds of
$2.0 million from the drawdown, before expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In February 2024, the Company received Mayne Pharma&#x2019;s
                                                                         calculation of allowance for payer rebates and wholesale distributor fees which differed significantly from the Company&#x2019;s
                                                                         estimate of the allowances. The Company believes its estimated allowances for payer rebates and wholesale distributor fees are
                                                                         reasonable and intends to resolve this matter through the process outlined in the Transaction Agreement. Given the recent receipt of
                                                                         Mayne Pharma&#x2019;s allowance calculation and the nature of the estimates involved, the outcome of this matter is uncertain at this
                                                                         point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any
                                                                         additional liability associated with Mayne Pharma&#x2019;s allowance calculation for payer rebates and wholesale distributor
                                                                         fees.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2023, the Company believes no additional accrual
is required for amounts that may be owed for the allowance for returns under the Transaction Agreement. The Company has not recorded any
contingent gains or receivables for any such allowances. Management continues to monitor the unresolved and pending net working capital
items as changes to estimated amounts owed or amounts due from Mayne Pharma that may be material.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;If Mayne Pharma&#x2019;s sales of IMVEXXY, BIJUVA, or ANNOVERA
grow more slowly than expected or decline, if the net working capital settlement with Mayne Pharma under the Transaction Agreement
is greater than our current estimates, if we are unsuccessful with future financings or if the supply chains related to the
third-party contract manufacturers are worse than we anticipate, our existing cash reserves may be insufficient to satisfy our
liquidity requirements. The potential impact of these factors in conjunction with the uncertainty of the capital markets raises
substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial
statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The accompanying consolidated financial statements do not include any
adjustments that might be necessary if we are unable to continue as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</txmd:GoingConcernPolicyTextBlock>
    <us-gaap:CashAcquiredFromAcquisition contextRef="c30" decimals="-5" id="ixv-11112" unitRef="usd">140000000</us-gaap:CashAcquiredFromAcquisition>
    <txmd:ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments contextRef="c30" decimals="-5" id="ixv-11113" unitRef="usd">12100000</txmd:ProceedsFromAcquireBusinessesNetOfWorkingCapitalAdjustments>
    <txmd:PrepaidRoyaltyLiabilities contextRef="c3" decimals="-5" id="ixv-11114" unitRef="usd">1000000</txmd:PrepaidRoyaltyLiabilities>
    <us-gaap:CommonStockSharesIssued
      contextRef="c38"
      decimals="0"
      id="ixv-11115"
      unitRef="shares">5000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c38"
      decimals="3"
      id="ixv-11116"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssued
      contextRef="c39"
      decimals="0"
      id="ixv-11117"
      unitRef="shares">312525</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c39"
      decimals="4"
      id="ixv-11118"
      unitRef="usdPershares">3.6797</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c40" decimals="-4" id="ixv-11119" unitRef="usd">1150000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c41"
      decimals="0"
      id="ixv-11120"
      unitRef="shares">1000000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c41"
      decimals="2"
      id="ixv-11121"
      unitRef="usdPershares">2.28</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c42" decimals="-5" id="ixv-11122" unitRef="usd">2000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-7499">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;A.&#160;Basis of presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The consolidated financial statements and related notes include our
parent company and all wholly owned subsidiaries. The consolidated financial statements are prepared in accordance with accounting principles
generally accepted in the Unites States of America (&#x201c;U.S. GAAP&#x201d;). Our fiscal year-end is as of and for the year ended December
31st for each year presented. All intercompany transactions among our businesses have been eliminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As part of the transformation and as a result of the vitaCare divestiture
and the Mayne Transaction, historical results of commercial operations for all periods prior to the Closing Date have been reflected as
discontinued operations in the consolidated financial statements. Assets and liabilities associated with the commercial business are classified
as assets and liabilities of discontinued operations in the consolidated balance sheet. Additional disclosures regarding discontinued
operations are provided in Note 2 of these consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Certain amounts in the notes to the consolidated financial statements
may not add due to rounding. Certain prior period amounts have been reclassified to conform to current-period presentation.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-7512">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;B.&#160;New accounting standards&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Adoption of new accounting standards&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
issued ASU 2023-09, &#x201c;Income Taxes (Topic 740) - Improvements to Income Tax Disclosures.&#x201d; ASU 2023-09 enhances the transparency
and decision usefulness of income tax disclosures by requiring consistent categories and greater disaggregation of information in the
rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 will be effective for the Company in its income tax
disclosure included in its 2025 Annual Report on Form 10-K and will be applied on a prospective basis. However, retrospective application
is permitted. Early adoption is also permitted. The Company is evaluating the impact of ASU 2023-09 on the Company's income tax disclosures
and on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock contextRef="c0" id="ixv-7523">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;C. Discontinued Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Discontinued operations comprise activities that were disposed of at
the end of the period, represent a separate major line of business that can be clearly distinguished for operational and financial reporting
purposes and represent a business shift having a major effect on the Company&#x2019;s operations and financial results according to Accounting
Standard Codification (&#x201c;ASC&#x201d;) Topic 205, Presentation of Financial Statements. An adjustment has been made to the consolidated
statements of operations for the twelve months ended December 31, 2023 and 2022 to reclassify commercial activities and vitaCare activities
to discontinued operations as both components, in the aggregate, represented a business shift that will have a major effect on the Company&#x2019;s
operations and financial results. No amounts for shared general and administrative operating support expense were allocated to discontinued
operations. As required by the terms of the Financing Agreement, the proceeds from both transactions were used to fully repay our outstanding
debt borrowings. As a result, interest expense and amortization of deferred financing costs as well as expense for accretion of Series
A Preferred Stock and loss on extinguishment of debt are included within income (loss) from discontinued operations, net of tax. Additionally,
the related assets and liabilities have been reported as assets and liabilities of discontinued operations in the Company&#x2019;s consolidated
balance sheet as of December 31, 2023 and 2022. For additional information, see Note 2 - Discontinued Operations.&lt;/p&gt;</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c43"
      decimals="INF"
      id="ixv-11123"
      unitRef="usd">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-7530">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;D. Estimates and assumptions&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The preparation of consolidated financial statements in conformity
to U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the
reporting period. We evaluate our estimated assumptions based on historical experience and on various other assumptions that are believed
to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different
assumptions or conditions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0" id="ixv-7537">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;E. Cash and Restricted Cash&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;For the purpose of the statements of cash flows, all highly liquid
investments with an original maturity of three months or less are considered to be&#160;cash&#160;equivalents. The carrying value of these
investments approximates fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We maintain cash at financial institutions that at times may exceed
the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limits of $0.25 million per bank. We have never experienced any
losses related to these funds.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Restricted cash was comprised of escrowed funds deposited with a bank
relating to the vitaCare Divestiture. All restrictions were lifted in March 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashFDICInsuredAmount contextRef="c3" decimals="-4" id="ixv-11124" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-7565">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;F.&lt;/b&gt;&#160;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Fair value is the price to sell an asset or transfer a liability and
therefore represents an exit price in the principal market (or in the absence of a principal market, the most advantageous market). It
represents a market-based measurement that contemplates a hypothetical transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The unique characteristics of an asset or liability and the availability
of observable prices affect the number of valuation approaches and/or techniques used in a fair value analysis. We measure fair value
using observable and unobservable inputs. We give the highest priority to quoted prices (unadjusted) in active markets for identical assets
or liabilities (Level 1 inputs) and the lowest priority to unobservable inputs (Level 3 inputs).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We apply the following fair value hierarchy:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: left"&gt;Level 1 - Quoted prices (unadjusted) in active markets for
identical assets and liabilities.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: left"&gt;Level 2 - Quoted prices in non-active markets or in active
markets for similar assets or liabilities, observable inputs other than quoted prices; and inputs that are not directly observable but
are corroborated by observable market data.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: left"&gt;Level 3 - Inputs that are unobservable.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The carrying amount of our cash, restricted cash, accounts receivable,
accounts payable and accrued expenses approximate their fair value because of the short-term maturity of such instruments, which are considered
Level 1 under the fair value hierarchy.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-7603">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;G.&#160;Fixed assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Fixed assets are carried at cost less accumulated depreciation and
amortization. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs
to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related
assets, which range from three to seven years. Leasehold improvements are depreciated over the shorter of their useful life or the term
of the lease. Long-lived assets held and used by us, including fixed assets, are assessed for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We capitalize software and software development costs incurred to create
and acquire computer software for internal use, principally related to software coding and application development. We begin to capitalize
software development costs when both the preliminary project stage is completed, and it is probable that the software will be used as
intended. Capitalized software costs include only external direct costs and services utilized in developing or obtaining computer software.
Capitalized software costs are amortized on a straight-line basis when placed into service over the estimated useful life, generally five
to seven years.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c44" id="ixv-11125">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c45" id="ixv-11126">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c46" id="ixv-11129">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c47" id="ixv-11130">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="c0" id="ixv-7613">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;H.&#160;License rights and other
intangibles assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We record license rights and other intangible assets at cost, which
includes external costs, consisting primary of legal costs, incurred in securing our patents and trademarks.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;License rights costs related to ANNOVERA were amortized until December
30, 2022 over the useful life over which the license rights would contribute directly or indirectly to our cash flows. The cost was amortized
using the straight-line method as the pattern of economic benefit could not be reliably determined. On December 30, 2022, we assigned
our ANNOVERA license to Mayne Pharma and included the remaining ANNOVERA license cost of $30.2 million in our calculation of the gain
on sale of assets. In addition, amortization of license rights of $3.0 million for 2022 was reclassified to discontinued operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Intangible assets subject to amortization, such as patents, are amortized
over the useful life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs
at that time. Intangible assets not subject to amortization, such as trademarks, are perpetual and have indefinite lives.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We review license rights and other intangible assets subject to amortization
on a periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision to their remaining useful
lives. We assess other intangible assets not subject to amortization for potential impairment at least annually during the fourth quarter
of each year, or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the
intangible assets below their carrying value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <txmd:WriteOffOfAsset contextRef="c48" decimals="-5" id="ixv-11133" unitRef="usd">30200000</txmd:WriteOffOfAsset>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c49" decimals="-5" id="ixv-11134" unitRef="usd">3000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-7644">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;I.&lt;/b&gt;&#160;&lt;b&gt;Segment reporting&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We manage and operate as one business, which prior to December 2022
was focused on creating and commercializing products targeted exclusively for women and after we signed Mayne License Agreement, is focused
on collecting royalties from licensing our products. Our business is led by our chief executive officer. We do not operate separate lines
of business with respect to any of our products, and we do not prepare discrete financial information with respect to separate products.
Accordingly, we view our business as one reportable operating segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c0" decimals="0" id="ixv-11135" unitRef="pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments contextRef="c0" decimals="0" id="ixv-11136" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c0" id="ixv-7652">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;J.&#160;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We determine the amount of revenue to be recognized through application
of the following steps:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18.6pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;Identification of the contract with a customer;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18.6pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;Identification of the performance obligations in the contract;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18.6pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;Determination of the transaction price;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18.6pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;Allocation of the transaction price to the performance obligations in the contract; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 18.6pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;Recognition of revenue when or as we satisfy the performance obligations.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;A performance obligation is a promise in a contract to transfer a product
or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains
control, and we treat shipping as a fulfillment activity rather than as a separate obligation. We generally recognize revenue at a point
in time when all of our performance obligations under the terms of a contract are satisfied. Revenue is recognized upon transfer of control
of promised products or services in an amount that reflects the consideration we expect to receive in exchange for those products or services.
The collectability of consideration on the contract is reasonably assured before revenue is recognized. To the extent that customer payment
has been received before all recognition criteria are met, these revenues are initially deferred in other accruals on the balance sheet
and the revenue is recognized in the period that all recognition criteria have been met.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;License revenue&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;License arrangements may consist of non-refundable upfront license
fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones and future product
royalty payments. Some of these arrangements may include multiple performance obligations. Non-refundable up-front fees that are not contingent
on any future performance by us, and do not require continuing involvement on our part, are recognized as revenue when the right to use
functional intellectual property is transferred to the customer.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On December 30, 2022, we granted an exclusive license to commercialize
our prescription products and assigning the Company&#x2019;s exclusive license to commercialize ANNOVERA to Mayne Pharma, which resulted
in a business shift that had a major effect on our operations and financial results. As part of the transformation that included the Mayne
License Agreement, historical results of commercial operations have been reflected as discontinued operations in the Company&#x2019;s consolidated
financial statements for all periods prior to the Closing Date. As of December 31, 2022, we are no longer directly engaged in the sale
of prescription products.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Under the terms of the Mayne License Agreement, we received $140 million
at closing and we are eligible to receive additional payments in the aggregate of up to an additional $30 million, based on the achievement
of sales milestones (collectively, the &#x201c;Milestone Amounts&#x201d;). The proceeds at closing were allocated between consideration
for the sale of ANNOVERA and the initial license fee for the Licensed Products, as the sale of ANNOVERA was accounted for under ASC 610-20,
Gains and Losses from Derecognition of Nonfinancial Assets in arriving at the gain on disposal (see Note 2), while the license grant of
the other products were recognized under the provisions of ASC 606, Revenue from Contracts with Customers, as a license of functional
intellectual property. The proceeds were allocated among the Licensed Products on the relative net present value of forecasted future
product sales from those products. The Milestone Amounts will be recognized, as applicable, in subsequent periods based on actual product
sales that exceed the respective net sales milestones as such variable consideration is constrained by the occurrence of the subsequent
sales.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Our royalty revenue in 2023 primarily related to royalties provided
for under the Mayne License Agreement based on Mayne Pharma&#x2019;s sales of the licensed products subject to that agreement. Under the
Mayne License Agreement, the Company is entitled to earn royalties on net sales of all of the Licensed Products at a royalty rate of (i)
8% on the first $80 million of net sales of the Licensed Products and (ii) 7.5% on net sales of all of the Licensed Products after the
first $80 million of net sales. The royalty rate is subject to a 2% reduction upon the earlier to occur of (i) the expiration or revocation
of the last valid claim covering a Licensed Product, and (ii) a generic product launch (a &#x201c;LOE&#x201d;). We are entitled to minimum
annual royalties beginning with the year ending December 31, 2023 ($3 million annual minimum) and continuing with 3% annual increases
through the year ending December 31, 2034 (the &#x201c;Minimum Annual Royalty&#x201d;). The total Minimum Annual Royalty we are entitled
to is $42.6 million, and this total amount was allocated among the Licensed Products on the relative net present value of forecasted future
product sales from those products. The portion allocated to consideration for the sale of ANNOVERA was attributed towards the gain on
disposal of that asset. For the remaining portion allocated to the license grants for the other products, we determined that the minimum
guarantee underlying the Minimum Annual Royalty should be treated as fixed consideration and recognized under ASC 606 at the point in
time when the license was transferred. Since the Minimum Annual Royalty will be received in annual installments through 2034, we determined
the transaction price allocated under ASC 606 contained a significant financing component, and we therefore determined the initial royalty
revenue and corresponding receivable based on the present value of the allocated Minimum Annual Royalty. The present value was calculated
using a discount rate of 10.45%, based on the credit characteristics of Mayne Pharma and the timing of future payments, and the value
will be accreted to full value through the earlier of January 1, 2034 or a LOE. This royalty receivable is a contract asset as of December
31, 2022 and 2023, and is further subject to offset by Mayne Pharma (see L. Contract Assets and Liabilities below).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Royalty revenue earned in excess of the Minimum Annual Royalty will
be recognized under ASC 606, which provides revenue recognition constraints by requiring the recognition of revenue at the later of the
following: 1) when the subsequent sale occurs or 2) when the performance obligation to which some or all of the sales-based royalty has
been allocated has been satisfied (or partially satisfied). We applied the royalty recognition constraint required under the guidance
for sales-based royalties, which requires a sales-based royalty to be recorded no sooner than the underlying sale. Therefore, royalties
on sales of products commercialized by Mayne Pharma will be recognized in the subsequent periods that the Licensed Products are sold.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In 2023, we recorded BIJUVA license sales of $0.3 million made through
the Theramex License Agreement and $1.0 million pertaining to our licensed products with Mayne Pharma, which was recognized as license
revenue. Additionally, we recognized $0.5 million in other income pertaining to royalty sales of ANNOVERA.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c0" decimals="-6" id="ixv-11137" unitRef="usd">140000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <txmd:AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments contextRef="c50" decimals="-6" id="ixv-11138" unitRef="usd">30000000</txmd:AdditionalMilestonePaymentsToBeReceivedOnAchievementOfSalesMilestonePayments>
    <txmd:RoyaltyRateAsPercentageOnNetSales contextRef="c51" decimals="2" id="ixv-11139" unitRef="pure">0.08</txmd:RoyaltyRateAsPercentageOnNetSales>
    <txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate contextRef="c51" decimals="-6" id="ixv-11140" unitRef="usd">80000000</txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate>
    <txmd:RoyaltyRateAsPercentageOnNetSales contextRef="c52" decimals="3" id="ixv-11141" unitRef="pure">0.075</txmd:RoyaltyRateAsPercentageOnNetSales>
    <txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate contextRef="c53" decimals="-6" id="ixv-11142" unitRef="usd">80000000</txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate>
    <txmd:DecreaseInRoyaltyRateOnProductByProductBasis contextRef="c54" decimals="2" id="ixv-11143" unitRef="pure">0.02</txmd:DecreaseInRoyaltyRateOnProductByProductBasis>
    <txmd:MinimumAnnualRoyaltyPayment contextRef="c54" decimals="-6" id="ixv-11144" unitRef="usd">3000000</txmd:MinimumAnnualRoyaltyPayment>
    <txmd:InflationRateAdjustedForMinimalAnnualRoyaltyPayment contextRef="c54" decimals="2" id="ixv-11145" unitRef="pure">0.03</txmd:InflationRateAdjustedForMinimalAnnualRoyaltyPayment>
    <txmd:AggregateMinimumAnnualRoyaltyPaymentsDue contextRef="c55" decimals="-5" id="ixv-11146" unitRef="usd">42600000</txmd:AggregateMinimumAnnualRoyaltyPaymentsDue>
    <txmd:PresentValueOfAnnualMinimumRoyaltyDiscountRate contextRef="c0" decimals="4" id="ixv-11147" unitRef="pure">0.1045</txmd:PresentValueOfAnnualMinimumRoyaltyDiscountRate>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c56" decimals="-5" id="ixv-11148" unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <txmd:LicenseRevenue contextRef="c0" decimals="-5" id="ixv-11149" unitRef="usd">1000000</txmd:LicenseRevenue>
    <us-gaap:RoyaltyIncomeNonoperating contextRef="c0" decimals="-5" id="ixv-11150" unitRef="usd">500000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c0" id="ixv-7737">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;K.&lt;/b&gt;&#160;&lt;b&gt;Cost of revenue&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Cost of revenue includes the cost of inventory, manufacturing, manufacturing
overhead and supply chain costs and product shipping and handling costs. Costs related to the Population Council License Agreement, which
were based on our net sales of ANNOVERA, and amortization of license rights were reclassified to discontinued operations for 2022 as a
result of the transaction with Mayne Pharma.&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <txmd:ContractAssetsAndLiabilitiesPolicyTextBlock contextRef="c0" id="ixv-7745">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;L.&#160;Contract Assets and
Liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Contract assets totaling $21.6 million as of December 31, 2023, include
royalties recognized from the Minimum Annual Royalty (see J. Revenue Recognition above).&lt;/p&gt;</txmd:ContractAssetsAndLiabilitiesPolicyTextBlock>
    <us-gaap:DepositContractsAssets contextRef="c3" decimals="-5" id="ixv-11151" unitRef="usd">21600000</us-gaap:DepositContractsAssets>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-7753">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;M.&#160;Share-based payment
awards&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We account for share-based payment awards on a fair value basis of
the equity instrument issued. Under fair value accounting, the grant-date fair value of the share-based payment award is amortized as
compensation expense, on a straight-line basis, over the service period (generally, the vesting period) for both graded and cliff vesting
awards. We have elected to account for forfeitures as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Common stock reverse stock split&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On May 6, 2022, we completed a reverse stock split of our Common Stock.
As a result, shares of our outstanding Common Stock were split at a ratio of 50-for-1 (the &#x201c;Reverse Stock Split&#x201d;) with any
fractional shares resulting from the Reserve Stock Split rounded up to the next whole share of Common Stock. The number of authorized
shares of Common Stock was also correspondingly reduced from 600.0 million shares to 12.0 million shares to give effect to the Reverse
Stock Split. Additionally, all rights to receive shares of Common Stock under outstanding warrants, options, restricted stock units (&#x201c;RSUs&#x201d;)
and performance stock units (&#x201c;PSUs&#x201d;) were adjusted to give effect of the Reverse Stock Split. Furthermore, remaining shares
of Common Stock available for future issuance under share-based payment award plans and our employee stock purchase plan were adjusted
to give effect of the Reverse Stock Split. Pursuant to Section 78.209 of the Nevada Revised Statutes, the approval of our stockholders
was not required for our Board of Directors (the &#x201c;Board&#x201d;) to effectuate the Reverse Stock Split.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;All historical numbers of shares of Common Stock and per share data
have been adjusted to give effect to the Reverse Stock Split. Additionally, since the Common Stock par value was unchanged, historical
amounts for Common Stock and additional paid-in capital have been adjusted to give effect to the Reverse Stock Split.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Increase of authorized shares&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On June 26, 2023, at our combined 2022 and 2023 Annual Meeting, our
stockholders approved an amendment to our Amended and Restated Articles of Incorporation to increase the number of authorized shares of
Common Stock from 12 million shares to 32 million shares.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c57" id="ixv-11152">shares of our outstanding Common Stock were split at a ratio of 50-for-1</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c58"
      decimals="INF"
      id="ixv-11153"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c59"
      decimals="INF"
      id="ixv-11154"
      unitRef="shares">12000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c60"
      decimals="-6"
      id="ixv-11155"
      unitRef="shares">12000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c61"
      decimals="-6"
      id="ixv-11156"
      unitRef="shares">32000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-7793">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;N.&#160;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Income taxes are accounted for under the asset and liability method.
Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and income
tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in income tax rates is recorded as a component of the income tax provision in the period that includes the enactment
date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Regular assessments are made on the likelihood that our deferred tax
assets will be recovered from our future taxable income. Our evaluation is based on estimates, assumptions, and includes an analysis of
available positive and negative evidence, giving weight based on the evidence&#x2019;s relative objectivity. Sources of positive evidence
include estimates of future taxable income, future reversal of existing taxable temporary differences, taxable income in carryback years,
and available tax planning strategies. Sources of negative evidence include current and cumulative losses in recent years, losses expected
in early future years, any history of operating losses or tax credit carryforwards expiring unused, and unsettled circumstances that,
if unfavorably resolved, would adversely affect future profit levels.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The remaining carrying value of our deferred tax assets, after recording
the valuation allowance on our deferred tax assets, is based on our present belief that it is more likely than not that we will be able
to generate sufficient future taxable income to utilize such deferred tax assets. The amount of the remaining deferred tax assets considered
recoverable could be adjusted if our estimates of future taxable income during the carryforward period change favorably or unfavorably.
To the extent we believe that it is more likely than not that some or all the remaining deferred tax assets will not be realized, we must
establish a valuation allowance against those deferred tax assets, resulting in additional income tax expense in the period such determination
is made. To the extent a valuation allowance currently exists, we will continue to monitor all positive and negative evidence until we
believe it is more likely than not that it is no longer necessary, resulting in an income tax benefit in the period such determination
is made.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Our policy is to recognize both interest and penalties related to uncertain
tax positions as part of the income tax provision. Significant judgment is required in evaluating our tax positions, and in determining
our provisions for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred
tax assets. We establish reserves when, despite our belief that the income tax return positions are fully supportable, certain positions
are likely to be challenged and we may ultimately not prevail in defending those positions.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-7809">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;O.&#160;Earnings per common
share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basic earnings or loss per common share is computed by dividing net
income or loss available to common stockholders by the sum of the weighted average number of shares of common stock. Diluted earnings
per common share is computed by dividing net income available to common stockholders by the sum of the weighted average number of shares
of common stock and the number of additional shares of common stock that would have been outstanding if our outstanding potentially dilutive
securities had been issued. Potentially dilutive securities include awards of non-vested or vested and not settled restricted stock units,
performance stock units where the performance requirements have been met and not settled, warrants and options. The dilutive effect of
potentially dilutive securities is reflected in diluted earnings per common share by application of the treasury stock method, except
if its impact is anti-dilutive. Under the treasury stock method, an increase in the fair market value of our common stock can result in
a greater dilutive effect from potentially dilutive securities.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-7816">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;P.&#160;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We determine if an arrangement is a lease at inception. Determining
whether a contract contains a lease includes judgment regarding whether the contract conveys the right to control the use of identified
property or equipment for a period of time in exchange for consideration.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We account for our lease-related assets and liabilities based on their
classification as operating leases or finance leases, following the relevant accounting guidance. For all the lessee arrangements, we
have elected an accounting policy to combine non-lease components with the related-lease components and treat the combined items as a
lease for accounting purposes. We measure lease related assets and liabilities based on the present value of lease payments, including
in-substance fixed payments, variable payments that depend on an index or rate measured at the commencement date, and the amount we believe
is probable we will pay the lessor under residual value guarantees when applicable. We discount lease payments based on our estimated
incremental borrowing rate at lease commencement (or modification), which is primarily based on our estimated credit rating, the lease
term at commencement, and the contract currency of the lease arrangement. We have elected to exclude short-term leases (leases with an
original lease term less than one year) from the measurement of lease-related assets and liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We test right-of-use assets in an operating or finance lease at the asset group level (because these assets are long-lived nonfinancial
assets and should be accounted for the same way as other long-lived nonfinancial assets) whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We sublease our unoccupied facilities to third parties. Any impairment
to the associated right-of-use asset, leasehold improvements, or other assets as a result of the sublease is recognized in the period
when a decision to sublease is made and recorded in our consolidated statement of operations. We recognize sublease income on a straight-line
basis over the sublease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0" id="ixv-7848">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Q.&#160;Loss Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In determining whether an accrual for a loss contingency is required,
we first assess the likelihood of occurrence of the future event or events that will confirm the loss. When a loss is probable (the future
event or events are likely to occur) and the amount of the loss can be reasonably estimated, the estimated loss is accrued. If the reasonable
estimate of the loss is a range and an amount within the range appears to be a better estimate than any other amount within the range,
that amount should be accrued. However, if no amount within the range is a better estimate, the minimum amount in the range should be
accrued. When a loss is reasonably possible (the chance of the future event or events occurring is more than remote but less than likely),
no accrual is recognized. See Note 8 for more information.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c3" decimals="INF" id="ixv-11157" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy contextRef="c0" id="ixv-7855">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;R.&#160;Restructuring charges&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the year ended December 31, 2022, the Company initiated and
completed a restructuring plan that resulted in a reduction of its workforce to one employee. One-time termination benefits include severance,
continuation of health insurance coverage, and other benefits for a specified period of time, as well as contract terminations and fixed
assets write-downs, which resulted in $15.7 million of restructuring costs for the year ended December 31, 2022. There were no restructuring
costs incurred during the year ended December 31, 2023. Restructuring costs have been recognized in the accompanying consolidated statement
of operations as follows (in thousands):&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Executive termination benefits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,897&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Consulting and legal expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other contract termination costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,515&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total restructuring expenses - general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,472&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Employee termination benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other contract termination costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,367&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total restructuring expenses - discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At December 31, 2023 and 2022 respectively, $2.5 million and $6.2 million
of restructuring costs were included in current liabilities of discontinued operations in the accompanying consolidated balance sheets.
At December 31, 2022, $9.3 million related to restructuring costs was included in accrued expenses and other current liabilities.&lt;/p&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy>
    <txmd:NumberOfEmployeesAfterWorkforceReduction contextRef="c7" decimals="0" id="ixv-11158" unitRef="pure">1</txmd:NumberOfEmployeesAfterWorkforceReduction>
    <txmd:RestructuringChargesIncludingDiscontinuedOperations contextRef="c7" decimals="-5" id="ixv-11159" unitRef="usd">15700000</txmd:RestructuringChargesIncludingDiscontinuedOperations>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c0" id="ixv-11160">Restructuring costs have been recognized in the accompanying consolidated statement
of operations as follows (in thousands):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Executive termination benefits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,897&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Consulting and legal expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other contract termination costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,515&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total restructuring expenses - general and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,472&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Employee termination benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other contract termination costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,367&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total restructuring expenses - discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges contextRef="c64" decimals="-3" id="ixv-11161" unitRef="usd">3897000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c65" decimals="-3" id="ixv-11162" unitRef="usd">3060000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c66" decimals="-3" id="ixv-11163" unitRef="usd">2515000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c7" decimals="-3" id="ixv-11164" unitRef="usd">9472000</us-gaap:RestructuringCharges>
    <txmd:DisposalGroupIncludingDiscontinuedOperationRestructuringCharges contextRef="c67" decimals="-3" id="ixv-11165" unitRef="usd">4813000</txmd:DisposalGroupIncludingDiscontinuedOperationRestructuringCharges>
    <txmd:DisposalGroupIncludingDiscontinuedOperationRestructuringCharges contextRef="c66" decimals="-3" id="ixv-11166" unitRef="usd">1367000</txmd:DisposalGroupIncludingDiscontinuedOperationRestructuringCharges>
    <txmd:DisposalGroupIncludingDiscontinuedOperationRestructuringCharges contextRef="c7" decimals="-3" id="ixv-11167" unitRef="usd">6180000</txmd:DisposalGroupIncludingDiscontinuedOperationRestructuringCharges>
    <us-gaap:RestructuringReserve contextRef="c62" decimals="-5" id="ixv-11168" unitRef="usd">2500000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c63" decimals="-5" id="ixv-11169" unitRef="usd">6200000</us-gaap:RestructuringReserve>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c63" decimals="-5" id="ixv-11170" unitRef="usd">9300000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c0" id="ixv-7928">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;S. Reclassification of prior year presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Certain prior year amounts have been reclassified for consistency with
the current year presentation.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c0" id="ixv-7937">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;2. Discontinued Operations&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt"&gt;As discussed in Note 1, we changed our business in 2022 by
licensing our products to receive royalties and future sales related milestone payments, after granting an exclusive license to commercialize
our IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands in the United States and
assigning our exclusive license to commercialize ANNOVERA to Mayne Pharma.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt"&gt;This plan represented a strategic shift having a major effect
on our operations and financial results. Upon our conversion from a commercial pharmaceutical company to a licensing only company with
the consummation of the Mayne Transaction, we classified all direct revenues, costs and expenses related to commercial operations, within
income (loss) from discontinued operations, net of tax, in the consolidated statements of operations for all periods presented. We have
not allocated any amounts for shared general and administrative operating support expense to discontinued operations. As required by the
terms of the Financing Agreement, proceeds from the Mayne Transaction and the vitaCare Divestiture were used to fully repay our outstanding
debt borrowings, and as a result interest expense and amortization of deferred financing costs as well as expense for accretion of Series
A Preferred Stock and loss on extinguishment of debt are included within income (loss) from discontinued operations, net of tax (as disclosed
below).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt"&gt;Additionally, the related assets and liabilities have been
reported as assets and liabilities of discontinued operations in our consolidated balance sheet as of December 31, 2023 and 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt"&gt;The total consideration from Mayne Pharma consisted of (i)
a cash payment of $140.0 million at closing, (ii) a cash payment of $12.1 million for the acquisition of net working capital subject to
certain adjustments, (iii) a cash payment of approximately $1.0 million for prepaid royalties in connection with the Mayne License Agreement
Amendment and (iv) the right to receive the contingent consideration set forth in the Mayne License Agreement, as amended.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt"&gt;Our estimate of net working capital at closing was determined in accordance
with the Transaction Agreement which establishes the process for the determination of final net working capital. The determination of
final net working capital includes significant estimates which could change materially for a period of up to two years following the Closing
Date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt"&gt;The following table presents results of discontinued operations
(in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Product revenue, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(833&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;80,749&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cost of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gross profit (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(833&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;65,109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;481&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,942&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restructuring charges&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,180&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;481&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;97,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loss from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,314&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(32,522&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other income (expense):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Gain on sale of vitaCare&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;143,384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gain on ANNOVERA sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss on the extinguishment of debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,380&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense and other financing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(36,065&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expense for accretion of Series A Preferred Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,973&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss on disposal of assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,150&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expense, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(115&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total other income (expense), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,265&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;143,997&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss before from income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,579&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111,475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Benefit (provision) for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(552&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net income (loss) from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,579&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;110,923&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table presents the carrying amounts of the classes of
assets and liabilities of discontinued operations (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;344&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;344&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,694&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,588&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,694&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,831&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c43"
      decimals="INF"
      id="ixv-11171"
      unitRef="usd">0</us-gaap:GeneralAndAdministrativeExpense>
    <txmd:DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived contextRef="c43" decimals="-5" id="ixv-11172" unitRef="usd">140000000</txmd:DisposalGroupIncludingDiscontinuedOperationLicensePaymentReceived>
    <txmd:DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments contextRef="c68" decimals="-5" id="ixv-11173" unitRef="usd">12100000</txmd:DisposalGroupIncludingDiscontinuedOperationCashReceivedForAcquisitionOfNetworkingCapitalSubjectToCertainAdjustments>
    <txmd:DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties contextRef="c43" decimals="-5" id="ixv-11174" unitRef="usd">1000000</txmd:DisposalGroupIncludingDiscontinuedOperationCashReceivedForPrepaidRoyalties>
    <txmd:ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock contextRef="c0" id="ixv-11175">The following table presents results of discontinued operations
(in thousands):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Product revenue, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(833&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;80,749&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cost of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gross profit (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(833&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;65,109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;481&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,942&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restructuring charges&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,180&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;481&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;97,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loss from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,314&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(32,522&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other income (expense):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Gain on sale of vitaCare&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;143,384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gain on ANNOVERA sale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss on the extinguishment of debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,380&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense and other financing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(36,065&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expense for accretion of Series A Preferred Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,973&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss on disposal of assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,150&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expense, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(115&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total other income (expense), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,265&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;143,997&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss before from income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,579&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111,475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Benefit (provision) for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(552&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net income (loss) from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,579&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;110,923&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</txmd:ScheduleOfClassesOfAssetsAndLiabilitiesOfDiscontinuedOperationsTableTestBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c43" decimals="-3" id="ixv-11176" unitRef="usd">-833000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c69" decimals="-3" id="ixv-11177" unitRef="usd">80749000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="c69" decimals="-3" id="ixv-11178" unitRef="usd">15640000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef="c43" decimals="-3" id="ixv-11179" unitRef="usd">-833000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss contextRef="c69" decimals="-3" id="ixv-11180" unitRef="usd">65109000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <txmd:DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing contextRef="c69" decimals="-3" id="ixv-11181" unitRef="usd">75208000</txmd:DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="c43" decimals="-3" id="ixv-11182" unitRef="usd">481000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="c69" decimals="-3" id="ixv-11183" unitRef="usd">11301000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <txmd:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment contextRef="c69" decimals="-3" id="ixv-11184" unitRef="usd">4942000</txmd:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment>
    <txmd:DisposalGroupIncludingDiscontinuedOperationRestructuringCharges contextRef="c69" decimals="-3" id="ixv-11185" unitRef="usd">6180000</txmd:DisposalGroupIncludingDiscontinuedOperationRestructuringCharges>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense contextRef="c43" decimals="-3" id="ixv-11186" unitRef="usd">481000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense contextRef="c69" decimals="-3" id="ixv-11187" unitRef="usd">97631000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="c43" decimals="-3" id="ixv-11188" unitRef="usd">-1314000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="c69" decimals="-3" id="ixv-11189" unitRef="usd">-32522000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <txmd:DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness contextRef="c69" decimals="-3" id="ixv-11190" unitRef="usd">143384000</txmd:DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness>
    <txmd:DisposalGroupIncludingDiscontinuedOperationGainOnSale contextRef="c69" decimals="-3" id="ixv-11191" unitRef="usd">62031000</txmd:DisposalGroupIncludingDiscontinuedOperationGainOnSale>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c69" decimals="-3" id="ixv-11192" unitRef="usd">-8380000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <txmd:DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts contextRef="c69" decimals="-3" id="ixv-11193" unitRef="usd">36065000</txmd:DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts>
    <txmd:DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock contextRef="c69" decimals="-3" id="ixv-11194" unitRef="usd">16973000</txmd:DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c43" decimals="-3" id="ixv-11195" unitRef="usd">-1150000</us-gaap:GainLossOnDispositionOfAssets>
    <txmd:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense contextRef="c43" decimals="-3" id="ixv-11196" unitRef="usd">-115000</txmd:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense>
    <txmd:DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet contextRef="c43" decimals="-3" id="ixv-11197" unitRef="usd">-1265000</txmd:DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet>
    <txmd:DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet contextRef="c69" decimals="-3" id="ixv-11198" unitRef="usd">143997000</txmd:DisposalGroupIncludingDiscontinuedOperationTotalOtherIncomeExpenseNet>
    <txmd:DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes contextRef="c43" decimals="-3" id="ixv-11199" unitRef="usd">-2579000</txmd:DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes>
    <txmd:DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes contextRef="c69" decimals="-3" id="ixv-11200" unitRef="usd">111475000</txmd:DisposalGroupIncludingDiscontinuedOperationLossBeforeFromIncomeTaxes>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax contextRef="c69" decimals="-3" id="ixv-11201" unitRef="usd">552000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c43" decimals="-3" id="ixv-11202" unitRef="usd">-2579000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c69" decimals="-3" id="ixv-11203" unitRef="usd">110923000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="c0" id="ixv-11204">The following table presents the carrying amounts of the classes of
assets and liabilities of discontinued operations (in thousands):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;344&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;344&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,694&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,588&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,694&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,831&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <txmd:DisposalGroupIncludingDiscontinuedOperationRentReceivable contextRef="c3" decimals="-3" id="ixv-11205" unitRef="usd">344000</txmd:DisposalGroupIncludingDiscontinuedOperationRentReceivable>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c3" decimals="-3" id="ixv-11206" unitRef="usd">344000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <txmd:DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent contextRef="c4" decimals="-3" id="ixv-11207" unitRef="usd">12243000</txmd:DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent>
    <txmd:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities contextRef="c3" decimals="-3" id="ixv-11208" unitRef="usd">3694000</txmd:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities>
    <txmd:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities contextRef="c4" decimals="-3" id="ixv-11209" unitRef="usd">13588000</txmd:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="c3" decimals="-3" id="ixv-11210" unitRef="usd">3694000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="c4" decimals="-3" id="ixv-11211" unitRef="usd">25831000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0" id="ixv-8336">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;3.&#160;Prepaid and other current
assets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;Our prepaid and other current assets consisted of the following
(in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Insurance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;253&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Capitalized legal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,448&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,533&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Prepaid and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,035&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,034&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0" id="ixv-11212">Our prepaid and other current assets consisted of the following
(in thousands):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Insurance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;253&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Capitalized legal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,448&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,533&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Prepaid and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,035&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,034&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance contextRef="c3" decimals="-3" id="ixv-11213" unitRef="usd">253000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c4" decimals="-3" id="ixv-11214" unitRef="usd">1167000</us-gaap:PrepaidInsurance>
    <us-gaap:AcquisitionCostsCumulative contextRef="c3" decimals="-3" id="ixv-11215" unitRef="usd">2334000</us-gaap:AcquisitionCostsCumulative>
    <us-gaap:AcquisitionCostsCumulative contextRef="c4" decimals="-3" id="ixv-11216" unitRef="usd">2334000</us-gaap:AcquisitionCostsCumulative>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c3" decimals="-3" id="ixv-11217" unitRef="usd">1448000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c4" decimals="-3" id="ixv-11218" unitRef="usd">2533000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-11219" unitRef="usd">4035000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-11220" unitRef="usd">6034000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-8401">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;4. Fixed assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Our fixed assets, net consisted of the following (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;931&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;931&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Computer and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;49&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;49&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,522&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,522&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,445&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Fixed assets, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We recorded in continuing operations, depreciation expense of $0.1
million for 2023 and $0.6 million for 2022.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-11221">Our fixed assets, net consisted of the following (in thousands):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;931&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;931&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Computer and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;49&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;49&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,522&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,522&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,445&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Fixed assets, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c70" decimals="-3" id="ixv-11222" unitRef="usd">931000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c71" decimals="-3" id="ixv-11223" unitRef="usd">931000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c72" decimals="-3" id="ixv-11224" unitRef="usd">1167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c73" decimals="-3" id="ixv-11225" unitRef="usd">1168000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c74" decimals="-3" id="ixv-11226" unitRef="usd">375000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c75" decimals="-3" id="ixv-11227" unitRef="usd">375000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c76" decimals="-3" id="ixv-11228" unitRef="usd">49000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c77" decimals="-3" id="ixv-11229" unitRef="usd">49000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="-3" id="ixv-11230" unitRef="usd">2522000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="-3" id="ixv-11231" unitRef="usd">2523000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-11232" unitRef="usd">2522000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="-3" id="ixv-11233" unitRef="usd">2445000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-11234" unitRef="usd">78000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c0" decimals="-5" id="ixv-11235" unitRef="usd">100000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c7" decimals="-5" id="ixv-11236" unitRef="usd">600000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0" id="ixv-8500">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;5. Licensed rights and other intangible assets&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following provides information about our license rights and other
intangible assets, net (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Carrying&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Accumulated&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Carrying&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Accumulated&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Intangible assets subject to amortization:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Hormone therapy drug patents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,818&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,871&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,947&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,598&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,627&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Hormone therapy drug patents applied and pending approval&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;842&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;842&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,995&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,995&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Intangible assets subject to amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,871&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,789&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,598&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Intangible assets not subject to amortization:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Trademarks/trade name rights&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;309&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;309&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;321&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;321&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,969&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,871&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,098&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,541&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,598&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,943&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We recorded, in continuing operations, amortization expense related
to patents of $0.8 million for 2023, of which $0.5 million is accelerated amortization as a result of a review of our intangible assets,
and $0.6 million for 2022. We recorded amortization expense related to the exclusive license rights agreement with Population Council
of $3.0 million for 2022, which was reclassified to discontinued operations after we completed transaction with Mayne Pharma in December
2022, and excluded from the table above.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Our intangible assets subject to amortization are expected to be amortized
as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;533&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,347&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,660&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We use a combination of qualitative and quantitative factors to assess
licensed rights and intangible assets for impairment. In the year ending December 31, 2023, we have not impaired any of our hormone therapy
drug patent assets.&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c0" id="ixv-11237">The following provides information about our license rights and other
intangible assets, net (in thousands):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Carrying&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Accumulated&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Carrying&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Accumulated&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Intangible assets subject to amortization:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Hormone therapy drug patents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,818&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,871&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,947&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,598&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,627&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Hormone therapy drug patents applied and pending approval&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;842&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;842&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,995&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,995&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Intangible assets subject to amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,871&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,789&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,598&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Intangible assets not subject to amortization:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Trademarks/trade name rights&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;309&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;309&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;321&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;321&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,969&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,871&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,098&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,541&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,598&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,943&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c80" decimals="-3" id="ixv-11238" unitRef="usd">6818000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c80" decimals="-3" id="ixv-11239" unitRef="usd">1871000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c80" decimals="-3" id="ixv-11240" unitRef="usd">4947000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c81" decimals="-3" id="ixv-11241" unitRef="usd">6225000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c81" decimals="-3" id="ixv-11242" unitRef="usd">1598000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c81" decimals="-3" id="ixv-11243" unitRef="usd">4627000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c82" decimals="-3" id="ixv-11244" unitRef="usd">842000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c82" decimals="-3" id="ixv-11245" unitRef="usd">842000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c83" decimals="-3" id="ixv-11246" unitRef="usd">1995000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c83" decimals="-3" id="ixv-11247" unitRef="usd">1995000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c84" decimals="-3" id="ixv-11248" unitRef="usd">7660000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c84" decimals="-3" id="ixv-11249" unitRef="usd">1871000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c84" decimals="-3" id="ixv-11250" unitRef="usd">5789000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c85" decimals="-3" id="ixv-11251" unitRef="usd">8220000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c85" decimals="-3" id="ixv-11252" unitRef="usd">1598000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c85" decimals="-3" id="ixv-11253" unitRef="usd">6622000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c86" decimals="-3" id="ixv-11254" unitRef="usd">309000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c86" decimals="-3" id="ixv-11255" unitRef="usd">309000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c87" decimals="-3" id="ixv-11256" unitRef="usd">321000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c87" decimals="-3" id="ixv-11257" unitRef="usd">321000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c3" decimals="-3" id="ixv-11258" unitRef="usd">7969000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c3" decimals="-3" id="ixv-11259" unitRef="usd">1871000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="-3" id="ixv-11260" unitRef="usd">6098000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c4" decimals="-3" id="ixv-11261" unitRef="usd">8541000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c4" decimals="-3" id="ixv-11262" unitRef="usd">1598000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c4" decimals="-3" id="ixv-11263" unitRef="usd">6943000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c78" decimals="-5" id="ixv-11264" unitRef="usd">800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="-5" id="ixv-11265" unitRef="usd">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c79" decimals="-5" id="ixv-11266" unitRef="usd">600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c49" decimals="-5" id="ixv-11267" unitRef="usd">3000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c0" id="ixv-11268">Our intangible assets subject to amortization are expected to be amortized
as follows (in thousands):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;533&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,347&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,660&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c4" decimals="-3" id="ixv-11269" unitRef="usd">533000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c4" decimals="-3" id="ixv-11270" unitRef="usd">445000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c4" decimals="-3" id="ixv-11271" unitRef="usd">445000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c4" decimals="-3" id="ixv-11272" unitRef="usd">445000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c4" decimals="-3" id="ixv-11273" unitRef="usd">445000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c4" decimals="-3" id="ixv-11274" unitRef="usd">5347000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c4" decimals="-3" id="ixv-11275" unitRef="usd">7660000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c0" id="ixv-8831">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;6. Accrued expenses and other current liabilities&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Other accrued expenses and other current liabilities consisted of the
following (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Payroll and related costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;762&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,748&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued contract termination costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;978&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;489&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid royalty&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,011&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other accrued expenses and current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;409&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,604&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,133&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,846&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We expense advertising costs when incurred, which amounted to
$13.2 million for 2022, which was reclassified to discontinued operations as a result of our business shift following the Mayne
Transaction. We incurred no advertising costs in 2023.&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <txmd:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock contextRef="c0" id="ixv-11276">Other accrued expenses and other current liabilities consisted of the
following (in thousands):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Payroll and related costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;762&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,748&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued contract termination costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;978&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;489&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid royalty&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,011&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other accrued expenses and current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;409&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,604&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,133&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,846&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</txmd:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-11277" unitRef="usd">762000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-11278" unitRef="usd">8748000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <txmd:AccruedContractTerminationCosts contextRef="c4" decimals="-3" id="ixv-11279" unitRef="usd">4700000</txmd:AccruedContractTerminationCosts>
    <txmd:AccruedResearchAndDevelopmentExpenses contextRef="c4" decimals="-3" id="ixv-11280" unitRef="usd">978000</txmd:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c3" decimals="-3" id="ixv-11281" unitRef="usd">489000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c4" decimals="-3" id="ixv-11282" unitRef="usd">415000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-11283" unitRef="usd">1473000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="-3" id="ixv-11284" unitRef="usd">1390000</us-gaap:OperatingLeaseLiabilityCurrent>
    <txmd:AccruedPrepaidRoyalty contextRef="c4" decimals="-3" id="ixv-11285" unitRef="usd">1011000</txmd:AccruedPrepaidRoyalty>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-11286" unitRef="usd">409000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-11287" unitRef="usd">1604000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <txmd:AccruedExpensesAndOtherCurrentLiabilities contextRef="c3" decimals="-3" id="ixv-11288" unitRef="usd">3133000</txmd:AccruedExpensesAndOtherCurrentLiabilities>
    <txmd:AccruedExpensesAndOtherCurrentLiabilities contextRef="c4" decimals="-3" id="ixv-11289" unitRef="usd">18846000</txmd:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:AdvertisingExpense contextRef="c7" decimals="-5" id="ixv-11290" unitRef="usd">13200000</us-gaap:AdvertisingExpense>
    <us-gaap:LongTermDebtTextBlock contextRef="c0" id="ixv-8940">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;7. Debt&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Financing agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We were party to the Financing Agreement with Sixth Street
Specialty Lending, Inc., as administrative agent, various lenders from time-to-time party thereto, and certain of our subsidiaries
party thereto from time to time as guarantors. On December 30, 2022, we repaid all obligations under the Financing Agreement and the
Financing Agreement was terminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Interest and financing costs&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Included in miscellaneous income in 2023 is $0.3 million of interest
income and $0.2 million of interest expense. In 2022 and recorded in discontinued operations, we recognized $13.5 million of debt-related
interest expense and $22.5 million of financing fees amortization.&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:InterestExpense contextRef="c0" decimals="-5" id="ixv-11291" unitRef="usd">300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c7" decimals="-5" id="ixv-11292" unitRef="usd">200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt contextRef="c7" decimals="-5" id="ixv-11293" unitRef="usd">13500000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="c0" decimals="-5" id="ixv-11294" unitRef="usd">22500000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-8957">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;8.&#160;Commitments and contingencies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In October 2018, we entered into a lease for executive, administrative,
operations and sales offices in Boca Raton, Florida. The lease includes 62,748 rentable square feet, or the full premises, of which the
lease on 7,561 square feet commenced in 2018 and the lease on 48,651 square feet commenced in August 2019, or the full premises
commencement date. In June 2019, we entered into an agreement with the same lessors to
lease additional 6,536 square feet of administrative office space in the same location, pursuant to an addendum to such lease, which commenced
in May 2020. The lease will expire 11 years after the full premises commencement date, unless terminated earlier in accordance with
the terms of the lease. We have the option to extend the term of the lease for two additional consecutive periods of five years. The extension
option is not included in the determination of the lease term as it is not reasonably certain to be exercised. The term of the lease includes
escalating rent and free rent periods. We are also responsible for certain other operating costs under the lease, including electricity
and utility expenses. As a result of shifting our business
to become a license company and terminating our employees, we have sublet the majority of our headquarters and are in the process of subleasing
the remainder. We anticipate that sublease income will approximate the amounts due under our existing leases, therefore no impairment
of the right of use asset was recorded in 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;For 2023 and 2022, operating &lt;span style="-sec-ix-hidden: hidden-fact-75"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-76"&gt;lease expense&lt;/span&gt;&lt;/span&gt; (including all variable
costs) related to our real estate leases was $2.3 and $2.1 million, respectively. In 2023 and 2022, our rental income on sublease of our
three suites which were subleased following the vitaCare transaction was $1.3 million and $0.0 million, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2023, our remaining lease payments were as follows
(in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,477&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,513&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,551&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,590&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,664&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,425&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,420&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of lease payments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,005&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table sets forth supplemental balance sheet information
related to leases (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;6,873&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;7,580&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities current (included in accrued expenses and other current liabilities)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liabilities, non-current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,369&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,005&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,759&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table presents other information related to leases:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Weighted average remaining term (years) - operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Weighted average discount rate - operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Cash paid for amounts included in the measurement of lease liabilities from operating lease (in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,413&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Right-of-use assets obtained in exchange for new operating lease obligations (non-cash in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Mayne Pharma Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Mayne Pharma paid us approximately $12.1 million at closing on December
30, 2022, for the acquisition of net working capital, subject to certain adjustments as determined in accordance with the Transaction
Agreement. While the Transaction Agreement calls for much of the net working capital to be trued-up shortly after the Closing Date in
2023, for a period of one year following the Closing Date in the case of payer rebates and wholesale distributor fees and two years
following the Closing Date in the case for allowance for returns, net working capital amounts will be adjusted to arrive at final net
working capital under the Transaction Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In September 2023, we revised certain accrual estimates including increasing our working capital adjustment accrual from $3.5 million to $5.5 million for amounts anticipated to be owed under the Transaction Agreement. In December 2023, we made a $5.5 million payment to Mayne Pharma to settle certain working capital amounts that were required to be trued-up shortly after the Closing Date, excluding the allowance for returns, allowance for payer rebates, and allowance for wholesale distributor fees.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In February 2024, the Company received Mayne Pharma&#x2019;s
                                                                                                             calculation of allowance for payer rebates and wholesale distributor fees which differed significantly from the Company&#x2019;s
                                                                                                             estimate of the allowances. The Company believes its estimated allowances for payer rebates and wholesale distributor fees are
                                                                                                             reasonable and intends to resolve this matter through the process outlined in the Transaction Agreement. Given the recent receipt of
                                                                                                             Mayne Pharma&#x2019;s allowance calculation and the nature of the estimates involved, the outcome of this matter is uncertain at this
                                                                                                             point. As a result, the Company cannot reasonably estimate a range of loss, and accordingly, the Company has not accrued any
                                                                                                             additional liability associated with Mayne Pharma&#x2019;s allowance calculation for payer rebates and wholesale distributor
                                                                                                             fees.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 7pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Additionally and as of December 31, 2023, the Company believes no additional
accrual is required for amounts that may be owed for the allowance for returns. The Company has not recorded any contingent gains or receivables
for any such allowances. Management continues to monitor the unresolved and pending net working capital items as changes to estimated
amounts owed or amounts due from Mayne Pharma that may be material.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Population Council License Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Under the terms of our license agreement with the Population Council,
Inc. (the &#x201c;Population Council License Agreement&#x201d;), we paid the Population Council a milestone payment of $20.0 million in
2018, which was within 30 days following the approval by the FDA of the New Drug Application (&#x201c;NDA&#x201d;) for ANNOVERA, and $20.0
million in 2019 following the first commercial batch release of ANNOVERA. The aggregate $40.0 million of milestone payments were recorded
as license rights. The Population Council was also eligible to receive future payments upon the achievement of certain commercial sales
milestones of ANNOVERA. On December 30, 2022, we assigned the ANNOVERA license to Mayne Pharma. Our rights and obligations under the Population
Council License Agreement have been transferred to Mayne Pharma and may revert back to us upon the occurrence of certain events.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Legal proceedings&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In February 2020, we received a Paragraph IV certification notice letter
(the &#x201c;IMVEXXY Notice Letter&#x201d;) regarding an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) submitted to the FDA by Teva
Pharmaceuticals USA, Inc. (&#x201c;Teva&#x201d;). The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic
version of the 4 mcg and 10 mcg doses of IMVEXXY. In the IMVEXXY Notice Letter, Teva alleges that TherapeuticsMD patents listed in the
FDA&#x2019;s Orange Book that claim compositions and methods of IMVEXXY (the &#x201c;IMVEXXY Patents&#x201d;) are invalid, unenforceable,
and/or will not be infringed by Teva&#x2019;s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents
identified in the IMVEXXY Notice Letter expire in 2032 or 2033. In April 2020, we filed a complaint for patent infringement against Teva
in the United States District Court for the District of New Jersey arising from Teva&#x2019;s ANDA filing with the FDA. We are seeking,
among other relief, an order that the effective date of any FDA approval of Teva&#x2019;s ANDA would be a date no earlier than the expiration
of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim
to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. In July 2021, following a proposal by Teva, the District
Court entered an order temporarily staying all proceedings in the IMVEXXY litigation, which order was filed under seal. In September 2021,
the District Court made available a public version of the order following the parties&#x2019; agreement to a consent motion to redact information
Teva contended was confidential. The order provides that the statutory stay that prevents the FDA from granting final approval of the
ANDA for 30 months from the date of the IMVEXXY Notice Letter will be extended for the number of days that the stay of the IMVEXXY litigation
is in place. The length of the stay of the IMVEXXY litigation is dependent on further action by Teva. We have incurred and recorded legal
costs amounting to $2.3 million in prepaid expenses and other current assets as of December 31, 2023, for the IMVEXXY Paragraph IV legal
proceeding since we believe that we will successfully prevail in this legal proceeding. Upon the successful conclusion of the legal proceeding,
the related capitalized legal costs will be reclassified to patents, in license rights and other intangible assets, net, in the accompanying
consolidated balance sheets, and such costs will be amortized over the remaining useful life of the patents. If we are unsuccessful in
this legal proceeding, then the related capitalized legal costs for this legal preceding and any unamortized IMVEXXY patent costs that
were previously capitalized will be immediately expensed in the period in which we become aware of an unsuccessful legal proceeding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Beginning on December 30, 2022 and per the Mayne License Agreement,
Mayne Pharma is responsible for all enforcement of our patents, including the litigation discussed above with respect to Teva.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In September 2023, one of our former contractors retained to market
ANNOVERA under Title X, filed a lawsuit that accused us of breach of contract. We answered their complaint and filed breach of contract
counterclaims.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;From time to time, we are involved in other litigations and proceedings
in the ordinary course of business. We are not currently involved in any other litigations and proceedings that we believe would have
a material effect on our consolidated financial condition, results of operations, or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Off-balance sheet arrangements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2023 and 2022 we had no off-balance sheet arrangements
that have had or are reasonably likely to have current or future effects on our financial condition, changes in financial condition, revenues
or expenses, results of operations, liquidity, capital expenditures or capital resources that we consider material.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Employment agreements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In connection with our transformation into a pharmaceutical royalty
company, the termination of our executive management team (except for Mr. Marlan Walker, our former General Counsel and current Chief
Executive Officer) and all other employees was completed by December 30, 2022. Severance obligations for all employees other than executive
officers were paid in full in the first quarter of 2023. As of December 31, 2023, we employ one full-time employee primarily engaged in
an executive position. We have engaged external consultants who support our relationship with current partners and assist with certain
financial, legal, and regulatory matters and the continued wind-down of our historical business operations. The separation of our former
Interim Co-Chief Executive Officers, former Interim Chief Financial Officer and other executives from TherapeuticsMD was each a termination
without &#x201c;Good Cause,&#x201d; as defined in their respective employment agreements. In the aggregate, as of December 31, 2023, we
have accrued severance liabilities for executive termination obligations of $0.4 million.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfLand contextRef="c88" decimals="0" id="ixv-11295" unitRef="sqm">62748</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand contextRef="c89" decimals="0" id="ixv-11296" unitRef="sqm">7561</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand contextRef="c90" decimals="0" id="ixv-11297" unitRef="sqm">48651</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand contextRef="c91" decimals="0" id="ixv-11298" unitRef="sqm">6536</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c90" id="ixv-11299">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="c0" id="ixv-11300">two</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <txmd:LeaseConsecutivePeriods contextRef="c0" id="ixv-11301">P5Y</txmd:LeaseConsecutivePeriods>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="-5" id="ixv-11302" unitRef="usd">2300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c7" decimals="-5" id="ixv-11303" unitRef="usd">2100000</us-gaap:OperatingLeaseCost>
    <us-gaap:RentalIncomeNonoperating contextRef="c0" decimals="-5" id="ixv-11304" unitRef="usd">1300000</us-gaap:RentalIncomeNonoperating>
    <us-gaap:RentalIncomeNonoperating contextRef="c7" decimals="-5" id="ixv-11305" unitRef="usd">0</us-gaap:RentalIncomeNonoperating>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-11306">As of December 31, 2023, our remaining lease payments were as follows
(in thousands):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,477&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,513&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,551&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,590&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,664&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,425&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,420&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of lease payments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,005&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c3" decimals="-3" id="ixv-11307" unitRef="usd">1477000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="-3" id="ixv-11308" unitRef="usd">1513000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c3" decimals="-3" id="ixv-11309" unitRef="usd">1551000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c3" decimals="-3" id="ixv-11310" unitRef="usd">1590000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c3" decimals="-3" id="ixv-11311" unitRef="usd">1630000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c3" decimals="-3" id="ixv-11312" unitRef="usd">2664000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c3" decimals="-3" id="ixv-11313" unitRef="usd">10425000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c3" decimals="-3" id="ixv-11314" unitRef="usd">2420000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="-3" id="ixv-11315" unitRef="usd">8005000</us-gaap:OperatingLeaseLiability>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c0" id="ixv-11316">The following table sets forth supplemental balance sheet information
related to leases (in thousands):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;6,873&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;7,580&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities current (included in accrued expenses and other current liabilities)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liabilities, non-current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,532&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,369&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,005&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,759&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-11317" unitRef="usd">6873000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" id="ixv-11318" unitRef="usd">7580000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-11319" unitRef="usd">1473000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="-3" id="ixv-11320" unitRef="usd">1390000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-11321" unitRef="usd">6532000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="-3" id="ixv-11322" unitRef="usd">7369000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="-3" id="ixv-11323" unitRef="usd">8005000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c4" decimals="-3" id="ixv-11324" unitRef="usd">8759000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-11325">The following table presents other information related to leases:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Weighted average remaining term (years) - operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Weighted average discount rate - operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Cash paid for amounts included in the measurement of lease liabilities from operating lease (in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,413&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Right-of-use assets obtained in exchange for new operating lease obligations (non-cash in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3" id="ixv-11326">P6Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4" id="ixv-11327">P7Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="3" id="ixv-11328" unitRef="pure">0.083</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c4" decimals="3" id="ixv-11329" unitRef="pure">0.083</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c0" decimals="-3" id="ixv-11330" unitRef="usd">1443000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c7" decimals="-3" id="ixv-11331" unitRef="usd">1413000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <txmd:CashReceivedForNetWorkingCapital contextRef="c92" decimals="-5" id="ixv-11332" unitRef="usd">12100000</txmd:CashReceivedForNetWorkingCapital>
    <txmd:IncrementalAccrualForNetWorkingCapital contextRef="c93" decimals="-5" id="ixv-11333" unitRef="usd">3500000</txmd:IncrementalAccrualForNetWorkingCapital>
    <txmd:IncrementalAccrualForNetWorkingCapital contextRef="c94" decimals="-5" id="ixv-11334" unitRef="usd">5500000</txmd:IncrementalAccrualForNetWorkingCapital>
    <txmd:WorkingCapitalAmounts contextRef="c95" decimals="-5" id="ixv-11335" unitRef="usd">5500000</txmd:WorkingCapitalAmounts>
    <txmd:MilestonePayment contextRef="c96" decimals="-5" id="ixv-11336" unitRef="usd">20000000</txmd:MilestonePayment>
    <us-gaap:DirectTaxesAndLicensesCosts contextRef="c97" decimals="-5" id="ixv-11337" unitRef="usd">20000000</us-gaap:DirectTaxesAndLicensesCosts>
    <txmd:MilestonePaymentsRecordedAsLicenseRights contextRef="c98" decimals="-5" id="ixv-11338" unitRef="usd">40000000</txmd:MilestonePaymentsRecordedAsLicenseRights>
    <us-gaap:LegalFees contextRef="c99" decimals="-5" id="ixv-11339" unitRef="usd">2300000</us-gaap:LegalFees>
    <us-gaap:SeveranceCosts1
      contextRef="c100"
      decimals="-5"
      id="ixv-11340"
      unitRef="usd">400000</us-gaap:SeveranceCosts1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-9270">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;9. Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt"&gt;&lt;b&gt;Increase of authorized shares&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;On June 26, 2023, at our combined 2022
and 2023 Annual Meeting, our stockholders approved an amendment to our Amended and Restated Articles of Incorporation to increase the
number of authorized shares of Common Stock from 12 million shares to 32 million shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2023, the following table summarizes the status
of our outstanding and exercisable warrants and related transactions since December 31, 2021 (in thousands, except weighted average exercise
price and weighted average remaining contractual life data):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Warrants outstanding and exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; (in&#160;Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Balance, December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;103&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;76.19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;341.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Balance, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(435&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,270&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.89&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;99&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;66.61&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,793&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We used the Black Scholes option pricing model to estimate the fair
value of the warrants issued. The weighted average fair value of the warrants issued in 2022 was $0.13 per warrant and the assumptions
used to determine such fair value were as follows: expected term of 10 years, volatility of 69.4%, dividend yields of 0% and risk-free
interest rates of 2.9%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Share-based compensation payment plans&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2023, 126,573 shares of common stock were subject
to outstanding awards under our share-based payment award plans and inducement grants (calculated using the base number of PSUs that may
vest). As of December 31, 2023, 394,669 shares of common stock were available for future grants of share-based payment awards under the
TherapeuticsMD, Inc. 2019 Stock Incentive Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table summarizes the status of our outstanding and exercisable
options and related transactions (each adjusted to account for the Reverse Stock Split) since December 31, 2022 (in thousands, except
weighed average exercise price and weighted average remaining contractual life data):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Options&lt;br/&gt; Awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average Remaining Contractual Life&lt;br/&gt; (in&#160;Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Options&lt;br/&gt; Awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average Remaining Contractual Life (in&#160;Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 10%; text-indent: -9pt; padding-left: 9pt"&gt;As of January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;353&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;225.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;336&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;230.93&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;226.56&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;As of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;172&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;228.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;206.15&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;258.55&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;258.46&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table summarizes the status of our RSUs and related transactions
(each adjusted to account for the Reverse Stock Split) (in thousands, except weighed average grant date fair value):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;RSUs awards outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;RSUs&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt;
 Grant Date&lt;br/&gt;
 Fair Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt;
 Intrinsic&lt;br/&gt;
 Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Balance, January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;272&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;58.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,890.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(327&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance, as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;318.63&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(180&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance, as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;40&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.67&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;89.6&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table summarizes the status of our PSUs and related transactions
for each for the following years (each adjusted to account for the Reverse Stock Split) (in thousands, except weighed average grant date
fair value):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;PSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant Date&lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font: 10pt Times New Roman, Times, Serif"&gt;Balance, December 31, 2021&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;164&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;51.50&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,953&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;34.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Vested and settled&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(133&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;47.12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,382.98&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(44.85&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Unvested, as of January 1, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;19&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;52.15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;107.55&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Vested&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(5&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;56.05&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(10.72&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;Unvested, as of December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;50.87&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Share-based payment compensation cost&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Share-based payment compensation expense for PSUs is based on 100%
vesting which was a part of the termination benefits for all employees who were terminated in 2022. We recorded share-based payment award
compensation costs related to previously issued options, RSU and PSUs, as well as shares of common stock issued under our employee stock
purchase plan (&#x201c;ESPP&#x201d;) totaling $1.3 million for 2023 and $11.6 million for 2022.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2023, we had $0.3 million of unrecognized share-based
payment award compensation cost related to unvested options, RSUs and PSUs as well as shares issuable under our ESPP, which may be adjusted
for future changes in forfeitures and is included as additional paid-in capital in the accompanying consolidated balance sheets. No tax
benefit was realized due to a continued pattern of net losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The unrecognized compensation cost as of December 31, 2023 of $0.3
million is expected to be recognized as share-based payment award compensation over a weighted average period of 0.8 years.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="c101"
      decimals="-6"
      id="ixv-11341"
      unitRef="shares">12000000</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="c102"
      decimals="-6"
      id="ixv-11342"
      unitRef="shares">32000000</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <txmd:ScheduleOfWarrantRollForwardTableTextBlock contextRef="c0" id="ixv-11343">As of December 31, 2023, the following table summarizes the status
of our outstanding and exercisable warrants and related transactions since December 31, 2021 (in thousands, except weighted average exercise
price and weighted average remaining contractual life data):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Warrants outstanding and exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; (in&#160;Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Balance, December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;103&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;76.19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;341.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Balance, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(435&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,270&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.89&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;99&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;66.61&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,793&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</txmd:ScheduleOfWarrantRollForwardTableTextBlock>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrants
      contextRef="c106"
      decimals="-3"
      id="ixv-11344"
      unitRef="shares">103000</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrants>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice
      contextRef="c106"
      decimals="2"
      id="ixv-11345"
      unitRef="usdPershares">76.19</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife contextRef="c107" id="ixv-11346">P8Y3M18D</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageRemainingContractualLife>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted
      contextRef="c107"
      decimals="-3"
      id="ixv-11347"
      unitRef="shares">436000</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsGranted>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted
      contextRef="c107"
      decimals="2"
      id="ixv-11348"
      unitRef="usdPershares">0.14</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceGranted>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired
      contextRef="c107"
      decimals="-3"
      id="ixv-11349"
      unitRef="shares">-3000</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired
      contextRef="c107"
      decimals="1"
      id="ixv-11350"
      unitRef="usdPershares">341.5</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrants
      contextRef="c108"
      decimals="-3"
      id="ixv-11351"
      unitRef="shares">536000</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrants>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice
      contextRef="c108"
      decimals="2"
      id="ixv-11352"
      unitRef="usdPershares">13.1</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue
      contextRef="c108"
      decimals="-3"
      id="ixv-11353"
      unitRef="usd">2427000</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife contextRef="c107" id="ixv-11354">P9Y3M18D</txmd:WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised
      contextRef="c109"
      decimals="-3"
      id="ixv-11355"
      unitRef="shares">-435000</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExercised>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised
      contextRef="c109"
      decimals="2"
      id="ixv-11356"
      unitRef="usdPershares">0.01</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExercised>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised
      contextRef="c109"
      decimals="-3"
      id="ixv-11357"
      unitRef="usd">-2270000</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValueExercised>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired
      contextRef="c109"
      decimals="-3"
      id="ixv-11358"
      unitRef="shares">-2000</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsExpired>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired
      contextRef="c109"
      decimals="2"
      id="ixv-11359"
      unitRef="usdPershares">0.89</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePriceExpired>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrants
      contextRef="c110"
      decimals="-3"
      id="ixv-11360"
      unitRef="shares">99000</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrants>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice
      contextRef="c110"
      decimals="2"
      id="ixv-11361"
      unitRef="usdPershares">66.61</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsWeightedAverageExercisePrice>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue
      contextRef="c110"
      decimals="-3"
      id="ixv-11362"
      unitRef="usd">1793000</txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife contextRef="c109" id="ixv-11363">P6Y6M</txmd:WarrantsOutstandingAndExercisableOtherThanOptionWarrantsWeightedAverageRemainingContractualLife>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c3"
      decimals="2"
      id="ixv-11364"
      unitRef="usdPershares">0.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="ixv-11365">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c0" decimals="3" id="ixv-11366" unitRef="pure">0.694</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="2" id="ixv-11367" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c0" decimals="3" id="ixv-11368" unitRef="pure">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c103"
      decimals="INF"
      id="ixv-11369"
      unitRef="shares">126573000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c104"
      decimals="-3"
      id="ixv-11370"
      unitRef="shares">394669000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-11371">The following table summarizes the status of our outstanding and exercisable
options and related transactions (each adjusted to account for the Reverse Stock Split) since December 31, 2022 (in thousands, except
weighed average exercise price and weighted average remaining contractual life data):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Options&lt;br/&gt; Awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average Remaining Contractual Life&lt;br/&gt; (in&#160;Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Options&lt;br/&gt; Awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average Remaining Contractual Life (in&#160;Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 10%; text-indent: -9pt; padding-left: 9pt"&gt;As of January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;353&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;225.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;336&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;230.93&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;226.56&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;As of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;172&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;228.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;206.15&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;258.55&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;258.46&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c11"
      decimals="INF"
      id="ixv-11372"
      unitRef="shares">353000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c11"
      decimals="2"
      id="ixv-11373"
      unitRef="usdPershares">225.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c111" id="ixv-11374">P3Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c11"
      decimals="INF"
      id="ixv-11375"
      unitRef="shares">336000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c11"
      decimals="2"
      id="ixv-11376"
      unitRef="usdPershares">230.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c111" id="ixv-11377">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c7"
      decimals="INF"
      id="ixv-11378"
      unitRef="shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      decimals="2"
      id="ixv-11379"
      unitRef="usdPershares">94.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c7"
      decimals="INF"
      id="ixv-11380"
      unitRef="shares">177000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      decimals="2"
      id="ixv-11381"
      unitRef="usdPershares">226.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c4"
      decimals="INF"
      id="ixv-11382"
      unitRef="shares">172000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c4"
      decimals="2"
      id="ixv-11383"
      unitRef="usdPershares">228.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <txmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2 contextRef="c7" id="ixv-11384">P3Y7M6D</txmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c4"
      decimals="INF"
      id="ixv-11385"
      unitRef="shares">170000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c4"
      decimals="2"
      id="ixv-11386"
      unitRef="usdPershares">229.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c7" id="ixv-11387">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-11388"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-11389"
      unitRef="usdPershares">206.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c3"
      decimals="INF"
      id="ixv-11390"
      unitRef="shares">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-11391"
      unitRef="usdPershares">258.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <txmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2 contextRef="c0" id="ixv-11392">P3Y</txmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c3"
      decimals="INF"
      id="ixv-11393"
      unitRef="shares">73000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-11394"
      unitRef="usdPershares">258.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-11395">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="c0" id="ixv-11396">The following table summarizes the status of our RSUs and related transactions
(each adjusted to account for the Reverse Stock Split) (in thousands, except weighed average grant date fair value):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;RSUs awards outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;RSUs&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt;
 Grant Date&lt;br/&gt;
 Fair Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt;
 Intrinsic&lt;br/&gt;
 Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Balance, January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;272&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;58.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,890.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(327&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance, as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;318.63&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(180&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance, as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;40&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.67&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;89.6&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;The following table summarizes the status of our PSUs and related transactions
for each for the following years (each adjusted to account for the Reverse Stock Split) (in thousands, except weighed average grant date
fair value):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;PSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant Date&lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; font: 10pt Times New Roman, Times, Serif"&gt;Balance, December 31, 2021&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;164&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;51.50&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,953&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;34.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Vested and settled&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(133&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;47.12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,382.98&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(44.85&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Unvested, as of January 1, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;19&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;52.15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;107.55&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Vested&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(5&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;56.05&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(10.72&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;Cancelled/Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;Unvested, as of December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;50.87&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c112"
      decimals="INF"
      id="ixv-11397"
      unitRef="shares">272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c112"
      decimals="2"
      id="ixv-11398"
      unitRef="usdPershares">58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="c112"
      decimals="2"
      id="ixv-11399"
      unitRef="usdPershares">4890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c113"
      decimals="INF"
      id="ixv-11400"
      unitRef="shares">170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c113"
      decimals="2"
      id="ixv-11401"
      unitRef="usdPershares">16.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c113"
      decimals="INF"
      id="ixv-11402"
      unitRef="shares">327</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c113"
      decimals="2"
      id="ixv-11403"
      unitRef="usdPershares">48.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c113"
      decimals="INF"
      id="ixv-11404"
      unitRef="shares">58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c113"
      decimals="0"
      id="ixv-11405"
      unitRef="usdPershares">37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c114"
      decimals="INF"
      id="ixv-11406"
      unitRef="shares">57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c114"
      decimals="2"
      id="ixv-11407"
      unitRef="usdPershares">14.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="c114"
      decimals="2"
      id="ixv-11408"
      unitRef="usdPershares">318.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c115"
      decimals="INF"
      id="ixv-11409"
      unitRef="shares">163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c115"
      decimals="2"
      id="ixv-11410"
      unitRef="usdPershares">4.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c115"
      decimals="INF"
      id="ixv-11411"
      unitRef="shares">180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c115"
      decimals="2"
      id="ixv-11412"
      unitRef="usdPershares">6.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c116"
      decimals="INF"
      id="ixv-11413"
      unitRef="shares">40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c116"
      decimals="2"
      id="ixv-11414"
      unitRef="usdPershares">9.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="c116"
      decimals="1"
      id="ixv-11415"
      unitRef="usdPershares">89.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c117"
      decimals="INF"
      id="ixv-11417"
      unitRef="shares">164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c117"
      decimals="2"
      id="ixv-11418"
      unitRef="usdPershares">51.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="c117"
      decimals="0"
      id="ixv-11419"
      unitRef="usdPershares">2953</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c105"
      decimals="INF"
      id="ixv-11420"
      unitRef="shares">63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c105"
      decimals="2"
      id="ixv-11421"
      unitRef="usdPershares">34.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c105"
      decimals="INF"
      id="ixv-11422"
      unitRef="shares">133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c105"
      decimals="2"
      id="ixv-11423"
      unitRef="usdPershares">47.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="c105"
      decimals="2"
      id="ixv-11424"
      unitRef="usdPershares">-2382.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c105"
      decimals="INF"
      id="ixv-11425"
      unitRef="shares">75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c105"
      decimals="2"
      id="ixv-11426"
      unitRef="usdPershares">44.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c118"
      decimals="INF"
      id="ixv-11427"
      unitRef="shares">19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c118"
      decimals="2"
      id="ixv-11428"
      unitRef="usdPershares">52.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="c118"
      decimals="2"
      id="ixv-11429"
      unitRef="usdPershares">107.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c119"
      decimals="INF"
      id="ixv-11430"
      unitRef="shares">5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c119"
      decimals="2"
      id="ixv-11431"
      unitRef="usdPershares">56.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="c119"
      decimals="2"
      id="ixv-11432"
      unitRef="usdPershares">-10.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c120"
      decimals="INF"
      id="ixv-11433"
      unitRef="shares">14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c120"
      decimals="2"
      id="ixv-11434"
      unitRef="usdPershares">50.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="c120"
      decimals="0"
      id="ixv-11435"
      unitRef="usdPershares">33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c105"
      decimals="INF"
      id="ixv-11436"
      unitRef="pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="INF" id="ixv-11437" unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c7" decimals="-5" id="ixv-11438" unitRef="usd">11600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c3" decimals="-5" id="ixv-11439" unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c3" decimals="-5" id="ixv-11440" unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c0" id="ixv-11441">P0Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c0" id="ixv-10235">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;b&gt;10. Revenue &lt;/b&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Pursuant to the Mayne License Agreement, the Company granted Mayne
Pharma, on the Closing Date, (i) an exclusive, sublicensable, perpetual, irrevocable license to research, develop, register, manufacture,
have manufactured, market, sell, use, and commercialize the Licensed Products in the United States and its possessions and territories
and (ii) an exclusive, sublicensable, perpetual, irrevocable license to manufacture, have manufactured, import and have imported the Licensed
Products outside the United States for commercialization in the United States and its possessions and territories.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Pursuant to the Mayne License Agreement, Mayne Pharma will make one-time,
milestone payments to the Company of each of (i) $5.0 million if aggregate net sales of all Products in the United States during a calendar
year reach $100.0 million, (ii) $10.0 million if aggregate net sales of all Products in the United States during a calendar year reach
$200.0 million and (iii) $15.0 million if aggregate net sales of all Products in the United States during a calendar year reach $300.0
million. Further, Mayne Pharma will pay to the Company royalties on net sales of all Products in the United States at a royalty rate of
8.0% on the first $80 million in annual net sales and 7.5% on annual net sales above $80.0 million, subject to certain adjustments, for
a period of 20 years following the Closing Date. The royalty rate will decrease to 2.0% on a Product-by-Product basis upon the earlier
to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) a generic version of a Product launching in
the United States. Mayne Pharma will pay to the Company minimum annual royalties of $3.0 million per year for 12 years, adjusted for inflation
at an annual rate of 3%, subject to certain further adjustments, including as described below. Upon the expiry of the 20-year royalty
term, the licenses granted to Mayne Pharma under the Mayne License Agreement will become a fully paid-up and royalty free license for
the Licensed Products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In 2023, we recorded BIJUVA license sales of $0.3 million made through
the Theramex License Agreement and $1.0 million pertaining to our licensed products with Mayne Pharma, which was recorded as license revenue.
Additionally, we recognized $0.5 million in other income pertaining to royalty sales of ANNOVERA.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <txmd:OneTimeMilestonePayments contextRef="c25" decimals="-5" id="ixv-11442" unitRef="usd">5000000</txmd:OneTimeMilestonePayments>
    <txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment
      contextRef="c25"
      decimals="INF"
      id="ixv-11443"
      unitRef="usd">100000000</txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment>
    <txmd:OneTimeMilestonePayments contextRef="c26" decimals="-5" id="ixv-11444" unitRef="usd">10000000</txmd:OneTimeMilestonePayments>
    <txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment
      contextRef="c26"
      decimals="INF"
      id="ixv-11445"
      unitRef="usd">200000000</txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment>
    <txmd:OneTimeMilestonePayments contextRef="c27" decimals="-5" id="ixv-11446" unitRef="usd">15000000</txmd:OneTimeMilestonePayments>
    <txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment
      contextRef="c27"
      decimals="INF"
      id="ixv-11447"
      unitRef="usd">300000000</txmd:ThresholdNetSalesAmountToDetermineOneTimeMilestonePayment>
    <txmd:RoyaltyRateAsPercentageOnNetSales contextRef="c28" decimals="3" id="ixv-11448" unitRef="pure">0.08</txmd:RoyaltyRateAsPercentageOnNetSales>
    <txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate
      contextRef="c28"
      decimals="INF"
      id="ixv-11449"
      unitRef="usd">80000000</txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate>
    <txmd:RoyaltyRateAsPercentageOnNetSales contextRef="c29" decimals="3" id="ixv-11450" unitRef="pure">0.075</txmd:RoyaltyRateAsPercentageOnNetSales>
    <txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate
      contextRef="c29"
      decimals="INF"
      id="ixv-11451"
      unitRef="usd">80000000</txmd:ThresholdAnnualNetSalesToDetermineRoyaltyRate>
    <txmd:TermOfRoyaltyPayments contextRef="c30" id="ixv-11452">P20Y</txmd:TermOfRoyaltyPayments>
    <txmd:DecreaseInRoyaltyRateOnProductByProductBasis contextRef="c30" decimals="3" id="ixv-11453" unitRef="pure">0.02</txmd:DecreaseInRoyaltyRateOnProductByProductBasis>
    <txmd:MinimumAnnualRoyaltyPayment contextRef="c30" decimals="-5" id="ixv-11454" unitRef="usd">3000000</txmd:MinimumAnnualRoyaltyPayment>
    <txmd:PeriodOfMinimumAnnualRoyaltyPayment contextRef="c30" id="ixv-11455">P12Y</txmd:PeriodOfMinimumAnnualRoyaltyPayment>
    <txmd:InflationRateAdjustedForMinimalAnnualRoyaltyPayment contextRef="c30" decimals="2" id="ixv-11456" unitRef="pure">0.03</txmd:InflationRateAdjustedForMinimalAnnualRoyaltyPayment>
    <txmd:TermOfRoyaltyPayments contextRef="c0" id="ixv-11457">P20Y</txmd:TermOfRoyaltyPayments>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c0" decimals="-5" id="ixv-11458" unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <txmd:LicenseRevenue contextRef="c0" decimals="-5" id="ixv-11459" unitRef="usd">1000000</txmd:LicenseRevenue>
    <us-gaap:RoyaltyIncomeNonoperating contextRef="c0" decimals="-5" id="ixv-11460" unitRef="usd">500000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-10247">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;11. Income
taxes&lt;/b&gt;&lt;/span&gt; &lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Our income (loss) from continuing operations before income taxes is
as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;United States&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(7,742&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;1,074&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;For the year ended December 31, 2023, there was no provision for income
taxes in discontinued operations, current or deferred. For the year ended, December 31, 2023, we recorded a benefit of 0.5% in continuing
operations. For the year ended December 31, 2022, there was 0% and 0.5% provision for income taxes in continuing and discontinued operations,
respectively, current or deferred.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2023, we had federal net operating loss (&#x201c;NOL&#x201d;)
carryforwards of $577.0 million, which is available to offset future taxable income. Approximately $19.2 million of the federal NOLs can
be carried forward for 20 years and will begin to expire in 2035. The remaining $557.8 million can be carried forward indefinitely. In
the event of future income, the NOL deduction arising from NOLs generated in taxable years beginning in 2021 will be limited to 80% of
the excess taxable income. The Company experienced an ownership change pursuant to IRC Sec. 382. As a result, our NOLs carryforward as
of December 31, 2023 will be limited.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;A reconciliation between taxes computed at the federal statutory rate
and the consolidated effective tax rate is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal statutory tax rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,626&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;State tax rate, net of federal tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.9&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Adjustment in valuation allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22,173&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;286.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,228.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Excess stock benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,460&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(31.8&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;835.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense accretion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.5&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Permanent and other differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(274.6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,368.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;(Benefit) provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We do not expect to pay any significant federal or state income taxes
as a result of (i) the losses recorded during 2023, (ii) net operating losses carry forwards from prior years.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: left; margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;Deferred income taxes result from temporary differences between the amount
of assets and liabilities recognized for financial reporting and tax purposes. The components of the net deferred tax assets as of December
31, 2023 and 2022 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred income tax assets (liabilities):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;158,040&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;176,631&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based payment compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,590&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense limitation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,547&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,707&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Gain on sale of ANNOVERA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,401&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,624&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrual for sales returns and coupons&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;288&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;186&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;186&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;256&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,062&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred income tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178,255&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(200,428&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(178,255&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;200,428&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred income tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We believe that it is more likely than not that we will not generate
sufficient future taxable income to realize tax benefits related to our deferred tax assets and as such, a valuation allowance has been
established against all the deferred tax assets as of both December 31, 2023 and 2022.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Since our first year of operations in 2011, we generated net operating
losses, and our U.S. federal and state tax returns remain open to examination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2023 and 2022, we had &lt;span style="-sec-ix-hidden: hidden-fact-99"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-100"&gt;no&lt;/span&gt;&lt;/span&gt; tax positions relating
to open tax returns that were considered to be uncertain, and we had no unrecognized tax benefits.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c0" id="ixv-11461">Our income (loss) from continuing operations before income taxes is
as follows (in thousands):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;United States&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;(7,742&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;1,074&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c125"
      decimals="-3"
      id="ixv-11462"
      unitRef="usd">-7742000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c126"
      decimals="-3"
      id="ixv-11463"
      unitRef="usd">1074000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="3" id="ixv-11464" unitRef="pure">0.005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c121"
      decimals="INF"
      id="ixv-11465"
      unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c122"
      decimals="INF"
      id="ixv-11466"
      unitRef="pure">0.005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards contextRef="c4" decimals="-5" id="ixv-11467" unitRef="usd">577000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c123"
      decimals="-5"
      id="ixv-11468"
      unitRef="usd">19200000</us-gaap:OperatingLossCarryforwards>
    <txmd:NetOperatingLossCarryforwardsTerm contextRef="c7" id="ixv-11469">P20Y</txmd:NetOperatingLossCarryforwardsTerm>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c124"
      decimals="-5"
      id="ixv-11470"
      unitRef="usd">557800000</us-gaap:OperatingLossCarryforwards>
    <txmd:PercentageOfFutureTaxableIncome contextRef="c7" decimals="2" id="ixv-11471" unitRef="pure">0.80</txmd:PercentageOfFutureTaxableIncome>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-11472">A reconciliation between taxes computed at the federal statutory rate
and the consolidated effective tax rate is as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal statutory tax rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,626&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;State tax rate, net of federal tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.9&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Adjustment in valuation allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22,173&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;286.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,228.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Excess stock benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,460&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(31.8&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;835.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense accretion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.5&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Permanent and other differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(274.6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,368.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;(Benefit) provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="-3" id="ixv-11473" unitRef="usd">-1626000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="3" id="ixv-11474" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="3" id="ixv-11475" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="3" id="ixv-11476" unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c7" decimals="3" id="ixv-11477" unitRef="pure">0.039</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="-3" id="ixv-11478" unitRef="usd">-22173000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="3" id="ixv-11479" unitRef="pure">-2.864</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c7" decimals="3" id="ixv-11480" unitRef="pure">32.286</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c0" decimals="-3" id="ixv-11481" unitRef="usd">2460000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c0" decimals="3" id="ixv-11482" unitRef="pure">-0.318</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c7" decimals="3" id="ixv-11483" unitRef="pure">8.352</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <txmd:EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars contextRef="c0" decimals="-3" id="ixv-11484" unitRef="usd">35000</txmd:EffectiveIncomeTaxRateReconciliationInterestExpenseAccretioninDollars>
    <txmd:EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars contextRef="c0" decimals="3" id="ixv-11485" unitRef="pure">-0.005</txmd:EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars>
    <txmd:EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars contextRef="c7" decimals="3" id="ixv-11486" unitRef="pure">0</txmd:EffectiveIncomeTaxRateReconciliationInterestExpenseAccretionPercentageinDollars>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c0" decimals="-3" id="ixv-11487" unitRef="usd">21261000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c0" decimals="3" id="ixv-11488" unitRef="pure">-2.746</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c7" decimals="3" id="ixv-11489" unitRef="pure">23.685</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-11490" unitRef="usd">-43000</us-gaap:IncomeTaxExpenseBenefit>
    <txmd:EffectiveIncomeTaxRateDiscontinuedOperations contextRef="c0" decimals="3" id="ixv-11491" unitRef="pure">0.005</txmd:EffectiveIncomeTaxRateDiscontinuedOperations>
    <txmd:EffectiveIncomeTaxRateDiscontinuedOperations contextRef="c7" decimals="3" id="ixv-11492" unitRef="pure">0</txmd:EffectiveIncomeTaxRateDiscontinuedOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-11493">Deferred income taxes result from temporary differences between the amount
of assets and liabilities recognized for financial reporting and tax purposes. The components of the net deferred tax assets as of December
31, 2023 and 2022 are as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred income tax assets (liabilities):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;158,040&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;176,631&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based payment compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,590&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest expense limitation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,547&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,707&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Gain on sale of ANNOVERA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,401&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,624&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrual for sales returns and coupons&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;288&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;186&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;186&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;256&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,062&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred income tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178,255&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(200,428&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(178,255&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;200,428&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred income tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="-3" id="ixv-11494" unitRef="usd">158040000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="-3" id="ixv-11495" unitRef="usd">176631000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c3" decimals="-3" id="ixv-11496" unitRef="usd">3339000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c4" decimals="-3" id="ixv-11497" unitRef="usd">8590000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="c3" decimals="-3" id="ixv-11498" unitRef="usd">19547000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="c4" decimals="-3" id="ixv-11499" unitRef="usd">19707000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <txmd:DeferredTaxAssetGainOnSaleOfIntellectualProperty contextRef="c3" decimals="-3" id="ixv-11500" unitRef="usd">-3401000</txmd:DeferredTaxAssetGainOnSaleOfIntellectualProperty>
    <txmd:DeferredTaxAssetGainOnSaleOfIntellectualProperty contextRef="c4" decimals="-3" id="ixv-11501" unitRef="usd">-3624000</txmd:DeferredTaxAssetGainOnSaleOfIntellectualProperty>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c3" decimals="-3" id="ixv-11502" unitRef="usd">288000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c3" decimals="-3" id="ixv-11503" unitRef="usd">186000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c4" decimals="-3" id="ixv-11504" unitRef="usd">186000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther contextRef="c3" decimals="-3" id="ixv-11505" unitRef="usd">256000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c4" decimals="-3" id="ixv-11506" unitRef="usd">-1062000</us-gaap:DeferredTaxAssetsOther>
    <txmd:DeferredTaxAssetsLiabilitiesGross contextRef="c3" decimals="-3" id="ixv-11507" unitRef="usd">178255000</txmd:DeferredTaxAssetsLiabilitiesGross>
    <txmd:DeferredTaxAssetsLiabilitiesGross contextRef="c4" decimals="-3" id="ixv-11508" unitRef="usd">-200428000</txmd:DeferredTaxAssetsLiabilitiesGross>
    <txmd:DeferredTaxAssetsLiabilitiesNetOfValuationAllowance contextRef="c3" decimals="-3" id="ixv-11509" unitRef="usd">-178255000</txmd:DeferredTaxAssetsLiabilitiesNetOfValuationAllowance>
    <txmd:DeferredTaxAssetsLiabilitiesNetOfValuationAllowance contextRef="c4" decimals="-3" id="ixv-11510" unitRef="usd">200428000</txmd:DeferredTaxAssetsLiabilitiesNetOfValuationAllowance>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0" id="ixv-10557">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;12. Income (loss) per common share&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;The following table sets forth the computation of basic and diluted
income (loss) per common share (each adjusted to account for the Reverse Stock Split) for the periods presented (in thousands, except
per share amounts):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Net income (loss) from continuing operations&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,699&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,074&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Net income (loss) from discontinued operations&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,579&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;110,923&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Net income (loss)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(10,278&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;111,997&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Weighted average common shares for basic income (loss) per common share&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,441&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,028&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Effect of dilutive securities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;338&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Weighted average common shares for diluted income (loss) per common share&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,441&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,366&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Income (loss) per common share, continuing operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Basic&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.74&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.74&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.11&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Income (loss) per common share, discontinued operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Basic&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.25&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12.29&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.25&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11.84&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Since we reported a net loss from continuing operations for 2023, our potentially
dilutive securities are deemed to be anti-dilutive, accordingly, there was no effect of dilutive securities. Therefore, our basic and
diluted loss per common share and our basic and diluted weighted average common shares are the same for 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table sets forth the outstanding securities as of the
periods presented which were not included in the calculation of diluted earnings per common share during 2023 and 2022 (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;172&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;PSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;99&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;101&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;273&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-11511">The following table sets forth the computation of basic and diluted
income (loss) per common share (each adjusted to account for the Reverse Stock Split) for the periods presented (in thousands, except
per share amounts):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Net income (loss) from continuing operations&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(7,699&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,074&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Net income (loss) from discontinued operations&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,579&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;110,923&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Net income (loss)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(10,278&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;111,997&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Weighted average common shares for basic income (loss) per common share&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,441&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,028&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Effect of dilutive securities&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;338&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Weighted average common shares for diluted income (loss) per common share&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,441&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,366&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Income (loss) per common share, continuing operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Basic&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.74&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.12&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.74&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.11&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Income (loss) per common share, discontinued operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Basic&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.25&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12.29&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt"&gt;Diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(0.25&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11.84&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c0" decimals="-3" id="ixv-11512" unitRef="usd">-7699000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c7" decimals="-3" id="ixv-11513" unitRef="usd">1074000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c0" decimals="-3" id="ixv-11514" unitRef="usd">-2579000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c7" decimals="-3" id="ixv-11515" unitRef="usd">110923000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-11516" unitRef="usd">-10278000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-11517" unitRef="usd">111997000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="-3"
      id="ixv-11518"
      unitRef="shares">10441000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="-3"
      id="ixv-11519"
      unitRef="shares">9028000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c7"
      decimals="-3"
      id="ixv-11520"
      unitRef="shares">338000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="-3"
      id="ixv-11521"
      unitRef="shares">10441000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="-3"
      id="ixv-11522"
      unitRef="shares">9366000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c0"
      decimals="2"
      id="ixv-11523"
      unitRef="usdPershares">-0.74</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c7"
      decimals="2"
      id="ixv-11524"
      unitRef="usdPershares">0.12</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c0"
      decimals="2"
      id="ixv-11525"
      unitRef="usdPershares">-0.74</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c7"
      decimals="2"
      id="ixv-11526"
      unitRef="usdPershares">0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c0"
      decimals="2"
      id="ixv-11527"
      unitRef="usdPershares">-0.25</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c7"
      decimals="2"
      id="ixv-11528"
      unitRef="usdPershares">12.29</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c0"
      decimals="2"
      id="ixv-11529"
      unitRef="usdPershares">-0.25</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c7"
      decimals="2"
      id="ixv-11530"
      unitRef="usdPershares">11.84</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-11531">The following table sets forth the outstanding securities as of the
periods presented which were not included in the calculation of diluted earnings per common share during 2023 and 2022 (in thousands):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;172&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;PSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;99&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;101&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;273&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c127"
      decimals="-3"
      id="ixv-11532"
      unitRef="shares">72000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c128"
      decimals="-3"
      id="ixv-11533"
      unitRef="shares">172000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c129"
      decimals="-3"
      id="ixv-11534"
      unitRef="shares">40000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c119"
      decimals="-3"
      id="ixv-11535"
      unitRef="shares">14000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c131"
      decimals="-3"
      id="ixv-11536"
      unitRef="shares">99000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c132"
      decimals="-3"
      id="ixv-11537"
      unitRef="shares">101000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="-3"
      id="ixv-11538"
      unitRef="shares">225000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c7"
      decimals="-3"
      id="ixv-11539"
      unitRef="shares">273000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-10818">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;13. Related parties&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On August 23, 2022, we appointed Mr. Justin Roberts as a director to
fill a newly created vacancy on our Board of Directors. Mr. Roberts was elected to serve as a director at our combined 2022 and 2023 Annual
Meeting held on June 26, 2023. Mr. Roberts will serve until our next Annual Meeting of Stockholders or until his successor is duly elected
or appointed or his earlier death or resignation. As a director of our Company, Mr. Roberts is entitled to receive compensation in the
same manner as our other non-employee directors, described in the section entitled &#x201c;Director Compensation&#x201d; in our Amendment
No. 1 to Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on May 1, 2023, but
he has elected not to receive any compensation for his service as a non-employee director at this time. Mr. Roberts currently serves as
a Partner of Rubric. On July 29, 2022, September 30, 2022, October 28, 2022, and May 1, 2023, we entered into subscription agreements
with Rubric. On December 30, 2022, in accordance with the terms of the Certificate of Designation, we redeemed all 29,000 outstanding
shares of Series A Preferred Stock previously issued to affiliates of Rubric at a purchase price of $1,333 per share. also paid certain
affiliates of Rubric approximately $3.0 million as a make-whole payment pursuant to the subscription agreements previously entered into
between us and Rubric. On June 29, 2023, we issued and sold 312,525 shares of Common Stock to Rubric at a price per share equal to $3.6797
pursuant to the Subscription Agreement and received gross proceeds of $1.15 million, before expenses. On November 15, 2023 Rubric drew
down an additional 877,192 shares of Common Stock at a price per share equal to $2.2761. We received gross proceeds of $2.0 million from
the drawdown, before expenses.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="c133"
      decimals="INF"
      id="ixv-11540"
      unitRef="shares">29000000</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c134"
      decimals="0"
      id="ixv-11541"
      unitRef="usdPershares">1333</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="c133"
      decimals="-5"
      id="ixv-11542"
      unitRef="usd">3000000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="c135"
      decimals="-3"
      id="ixv-11543"
      unitRef="shares">312525000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c135"
      decimals="4"
      id="ixv-11544"
      unitRef="usdPershares">3.6797</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="c136"
      decimals="-4"
      id="ixv-11545"
      unitRef="usd">1150000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c137"
      decimals="-3"
      id="ixv-11546"
      unitRef="shares">877192000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c137"
      decimals="4"
      id="ixv-11547"
      unitRef="usdPershares">2.2761</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="c138"
      decimals="-5"
      id="ixv-11548"
      unitRef="usd">2000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c0" id="ixv-10827">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;14. Business concentrations&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;TherapeuticsMD was previously a women&#x2019;s healthcare company with a
mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause.
In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed
to pharmaceutical organizations that possess commercial capabilities in the relevant territories. As part of the transformation that included
the Mayne License Agreement, historical results of commercial operations for all periods prior to the Closing Date have been reflected
as discontinued operations in our consolidated financial statements. Assets and liabilities associated with the commercial business are
classified as assets and liabilities of discontinued operations in our consolidated balance sheets. Additional disclosures regarding discontinued
operations are provided in Note 2.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;For the year ended December 31, 2023, 100% of license revenue related to
Mayne Pharma and Theramex.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of December 31, 2023, we had a royalty receivable of $3.1 million
relating to the short-term portion of receivable from Mayne Pharma and Theramex and $18.5 million relating to the long-term portion of
royalty receivable which includes royalties recognized from the minimum annual royalty that Mayne Pharma is obligated to pay to us under
the Mayne License Agreement.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <txmd:CustomerLicenseRevenuePercentage
      contextRef="c139"
      decimals="INF"
      id="ixv-11549"
      unitRef="pure">1</txmd:CustomerLicenseRevenuePercentage>
    <txmd:RoyaltyReceivableShortTermPortion
      contextRef="c140"
      decimals="-5"
      id="ixv-11550"
      unitRef="usd">3100000</txmd:RoyaltyReceivableShortTermPortion>
    <txmd:RoyaltyReceivableLongTermPortion
      contextRef="c140"
      decimals="-5"
      id="ixv-11551"
      unitRef="usd">18500000</txmd:RoyaltyReceivableLongTermPortion>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-10841">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;15. Subsequent Events&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Effective March 22, 2024, Tommy G. Thompson resigned as the Company&#x2019;s
Executive Chairman of the Board and was reappointed as the Company&#x2019;s Chairman of the Board.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestrictedCashCurrent
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:RoyaltyReceivableCurrentPortion
      contextRef="c4"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="c4"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c0"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestructuringCharges
      contextRef="c0"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c7"
      decimals="2"
      id="hidden-fact-9"
      unitRef="usdPershares">0.12</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c0"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c7"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c12"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c14"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:AdjustmentsToAdditionalPaidInCapitalLenderWarrants
      contextRef="c12"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:AdjustmentsToAdditionalPaidInCapitalLenderWarrants
      contextRef="c14"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="c12"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="c13"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="c14"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="c7"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c12"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c13"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c14"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c7"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c12"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c14"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="c12"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="c14"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c12"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c13"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c19"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c18"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c20"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c20"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c18"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c19"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:MakeWholePaymentAccretion
      contextRef="c0"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="c0"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="c0"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan
      contextRef="c0"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfDebt
      contextRef="c0"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="c0"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
      contextRef="c0"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities
      contextRef="c0"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities
      contextRef="c0"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="c0"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="c4"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:WarrantsIssuedInRelationToDebtFinancingAgreement
      contextRef="c0"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="c43"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing
      contextRef="c43"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
      contextRef="c43"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:DisposalGroupIncludingDiscontinuedOperationRestructuringCharges
      contextRef="c43"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfBusiness
      contextRef="c43"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:DisposalGroupIncludingDiscontinuedOperationGainOnSale
      contextRef="c43"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c43"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndOtherFinancingCosts
      contextRef="c43"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:DisposalGroupIncludingDiscontinuedOperationExpenseForAccretionOfSeriesAPreferredStock
      contextRef="c43"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="c69"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense
      contextRef="c69"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
      contextRef="c43"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:DisposalGroupIncludingDiscontinuedOperationRentReceivable
      contextRef="c4"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="c4"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:DisposalGroupIncludingDiscontinuedOperationsAccountsPayableCurrent
      contextRef="c3"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c3"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c82"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c83"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c86"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c87"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:AccruedContractTerminationCosts
      contextRef="c3"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:AccruedResearchAndDevelopmentExpenses
      contextRef="c3"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <txmd:AccruedPrepaidRoyalty
      contextRef="c3"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c0"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c7"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList contextRef="c3" id="hidden-fact-75">http://fasb.org/us-gaap/2023#Liabilities</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList contextRef="c4" id="hidden-fact-76">http://fasb.org/us-gaap/2023#Liabilities</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <txmd:WarrantsOutstandingAndExercisableOtherThanOptionsWarrantsAggregateIntrinsicValue
      contextRef="c106"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c11"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c11"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c4"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c4"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c3"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c3"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="c115"
      id="hidden-fact-84"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="c115"
      id="hidden-fact-85"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c115"
      id="hidden-fact-86"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c115"
      id="hidden-fact-87"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="c115"
      id="hidden-fact-88"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c119"
      id="hidden-fact-89"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c119"
      id="hidden-fact-90"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="c119"
      id="hidden-fact-91"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c119"
      id="hidden-fact-92"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c119"
      id="hidden-fact-93"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="c119"
      id="hidden-fact-94"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="c0"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="c4"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c3"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c4"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c3"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c4"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c0"
      id="hidden-fact-101"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c130"
      id="hidden-fact-102"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c105"
      id="hidden-fact-103"
      unitRef="shares"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-11658">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-11659">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-11660">0000025743</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
